<SEC-DOCUMENT>0001731122-22-002062.txt : 20221128
<SEC-HEADER>0001731122-22-002062.hdr.sgml : 20221128
<ACCEPTANCE-DATETIME>20221128170331
ACCESSION NUMBER:		0001731122-22-002062
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221128
DATE AS OF CHANGE:		20221128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		221426387

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>e4251_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:avxl="http://anavex.com/20220930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2022_currency -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_avxl_anavex.com_20220930 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20211001_20220930 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-09-30" id="xdx2ixbrl0091" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-09-30" id="xdx2ixbrl0093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2021-10-01to2022-09-30" id="xdx2ixbrl0151" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:DeferredGrantIncomes" contextRef="From2021-10-01to2022-09-30" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:DeferredGrantIncomes" contextRef="From2019-10-012020-09-30" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-10-01to2022-09-30" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2019-10-012020-09-30" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2019-10-012020-09-30" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012020-09-30" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares" contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0315" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares" contextRef="From2019-10-012020-09-30" id="xdx2ixbrl0316" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-10-012021-09-30" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOffering" contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessSharesIssueCosts" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessSharesIssueCosts" contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2021-10-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-09-30" id="xdx2ixbrl0948" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-09-30" id="xdx2ixbrl0949" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:PermanentDifferencesRelatingToStockBasedCompensation" contextRef="From2019-10-012020-09-30" id="xdx2ixbrl0963" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:PermanentDifferencesRelatingToSection162m" contextRef="From2021-10-01to2022-09-30" id="xdx2ixbrl0965" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:PermanentDifferencesRelatingToSection162m" contextRef="From2019-10-012020-09-30" id="xdx2ixbrl0967" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2021-10-01to2022-09-30" id="xdx2ixbrl0969" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:AdjustmentToTaxAssetsBasedOnSection382" contextRef="From2021-10-01to2022-09-30" id="xdx2ixbrl0973" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:AdjustmentToTaxAssetsBasedOnSection382" contextRef="From2019-10-012020-09-30" id="xdx2ixbrl0975" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2021-10-01to2022-09-30" id="xdx2ixbrl0989" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avxl-20220930.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-10-01to2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_MichaelJFoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_ParkinsonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:ParkinsonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-012017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-06</xbrli:startDate>
        <xbrli:endDate>2019-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_ForeignCountryMember_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_ForeignCountryMember_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 12pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span><b><span style="font-family: Times New Roman, Times, Serif">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt">Washington,
D.C. 20549</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_903_edei--DocumentType_c20211001__20220930_zYhZyaChZNEh"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">(Mark One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Courier New, Courier, Monospace; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><span id="xdx_90A_edei--DocumentAnnualReport_c20211001__20220930_zc25OsoFTkH3"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the fiscal year ended <b><span style="text-decoration: underline"><span id="xdx_90E_edei--DocumentPeriodEndDate_c20211001__20220930_z1Y8QJ5XBfE6"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_908_edei--CurrentFiscalYearEndDate_c20211001__20220930_zukL0KiccFAe"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">September 30</ix:nonNumeric></span>, 2022</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><span id="xdx_90C_edei--DocumentTransitionReport_c20211001__20220930_zdc8TrVXGAkl"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the transition period from ______________ to________________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Commission
file number<b>: <span style="text-decoration: underline"><span id="xdx_902_edei--EntityFileNumber_c20211001__20220930_zI22jwXCNTCd"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityRegistrantName_c20211001__20220930_znGckbt8nytj"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Courier New, Courier, Monospace; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: windowtext 1pt solid; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20211001__20220930_zgTsRw25Zkg5"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></td>
<td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: windowtext 1pt solid; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20211001__20220930_zv5l4EJ22lG9"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
or other jurisdiction of incorporation or organization)</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
Employer Identification No.)</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityAddressAddressLine1_c20211001__20220930_z9yWdJGAawu7"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityAddressAddressLine1">630 5th Avenue</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressAddressLine2_c20211001__20220930_zdevQoHxGaL9"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityAddressAddressLine2">20th Floor</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressCityOrTown_c20211001__20220930_zWLVQ54wzvQg"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20211001__20220930_zXZkIkf7EZPi"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressCountry_c20211001__20220930_zHKSMOXa60Mb"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityAddressCountry">US</ix:nonNumeric></span>A</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityAddressPostalZipCode_c20211001__20220930_zjl0yhwMdtD8"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityAddressPostalZipCode">10111</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
Code)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Registrant&#8217;s
telephone number, including area code <span style="text-decoration: underline">1-<span id="xdx_90A_edei--CityAreaCode_c20211001__20220930_zopK9cVfsWh7"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_90A_edei--LocalPhoneNumber_c20211001__20220930_ztwv8ozhgfXf"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Securities
registered under Section 12(b) of the Act:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Courier New, Courier, Monospace; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock, $0.001 par value</span></td>
<td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AVXL</span></td>
<td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ
Stock Market LLC</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of each class</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
Symbol</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of each exchange on which registered</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(g) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline">None</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of class)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="text-align: justify; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by checkmark
if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityWellKnownSeasonedIssuer_c20211001__20220930_z7dyn99lYgr8"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityWellKnownSeasonedIssuer">Yes</ix:nonNumeric></span>
&#9746;&#160;No &#9744;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="text-align: justify; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by checkmark
if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&#160;<span id="xdx_904_edei--EntityVoluntaryFilers_c20211001__20220930_zgy7LRfZyjv3"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="text-align: justify; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by checkmark
whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityCurrentReportingStatus_c20211001__20220930_zK96Cf8llixj"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
&#9746;&#160;No &#9744;</span></td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 24%"></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityInteractiveDataCurrent_c20211001__20220930_zzUsveAzwp9k"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
&#9746;&#160;&#160;No &#9744;</span></td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="text-align: justify; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by checkmark
whether the registrant is a large accelerated filer, an accelerated filer, a non- accelerated filer, a smaller reporting company, or
an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller
reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 59%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityFilerCategory_c20211001__20220930_zsflVsjvLN2b"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Large accelerated filer</ix:nonNumeric></span> &#9746;</span></td>
<td style="width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company <span id="xdx_905_edei--EntitySmallBusiness_c20211001__20220930_zdgbKyvyFYCf"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt:booleanfalse" name="dei:EntitySmallBusiness">&#9744;</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer &#9744;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20211001__20220930_zi7ZRoEhO0Ok"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#9744;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal controls over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report.</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
<span id="xdx_909_edei--IcfrAuditorAttestationFlag_c20211001__20220930_ztesLLlyOLyb"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt:booleantrue" name="dei:IcfrAuditorAttestationFlag">&#9746;</ix:nonNumeric></span>&#160;&#160;No &#9744;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 24%"></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
</span><span style="font-family: Times New Roman, Times, Serif">&#9744; <span id="xdx_903_edei--EntityShellCompany_c20211001__20220930_zr2rnxfsWkw3"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">State
the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s
most recently completed second fiscal quarter: $<span id="xdx_901_edei--EntityPublicFloat_iI_pn3n3_dm_c20220331_zVjULsXJqN5g"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">921</ix:nonFraction></span> million based on a price of $12.31 per share, being the closing price of the registrant&#8217;s
common stock on March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
the number of shares outstanding of each of the registrant&#8217;s classes of common stock, as of the latest practicable date: <span id="xdx_90D_edei--EntityCommonStockSharesOutstanding_iI_c20221128_zNjLhTvQSMmk"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-11-28" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,961,815</ix:nonFraction></span>
issued and outstanding as of November 28, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">DOCUMENTS
INCORPORATED BY REFERENCE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span style="text-decoration: underline">TABLE OF CONTENTS</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #365F91"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 94%"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</span></a></td>
<td style="text-align: right; width: 6%"><span style="font: 10pt Times New Roman, Times, Serif">6</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1. BUSINESS</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">6</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1A. RISK FACTORS</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">30</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">51</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2. PROPERTIES</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">51</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3. LEGAL PROCEEDINGS</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">51</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4. MINE SAFETY DISCLOSURES</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">51</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">51</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">51</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6 [Reserved]</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">52</span></td></tr>
<tr style="vertical-align: top">
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">ITEM 7 MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</a></span></td>
  <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<br />
  52</span></td>
</tr>
<tr style="vertical-align: top">
<td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">57</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">58</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">82</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9A. CONTROLS AND PROCEDURES</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">82</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9B OTHER INFORMATION</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">82</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">83</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">83</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11. EXECUTIVE COMPENSATION</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">83</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">83</span></td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></a></td>
  <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><br />
  83</span></td>
</tr>
<tr style="vertical-align: top">
<td><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">83</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART IV</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">84</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">84</span></td></tr>
<tr style="vertical-align: top">
<td><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16. FORM 10-K SUMMARY</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">85</span></td></tr>
</table>


<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #365F91">&#160;</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #365F91"></p>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #365F91"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Forward Looking Statements.</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Annual Report on Form 10-K includes forward-looking
statements. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements
regarding our anticipated future clinical and regulatory milestone events, future financial position, business strategy and plans
and objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221;
&#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221;
&#8220;forecast,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;will,&#8221;
&#8220;suggest,&#8221; &#8220;plan&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking
statements. Such forward-looking statements include, without limitation, statements regarding:</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
                                            in our stock price and in the markets in general;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to successfully conduct preclinical studies and clinical trials for our product candidates;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to raise additional capital on favorable terms and the impact of such activities
                                            on our stockholders and stock price;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            impact of the COVID-19 outbreak and its effect on us;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to generate any revenue or to continue as a going concern;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to execute our research and development plan on time and on budget;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our products candidates&#8217; ability to demonstrate efficacy or an acceptable safety profile;</span></td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify">&#160;</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain the support of qualified scientific collaborators;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability, whether alone or with commercial partners, to successfully commercialize any of
                                            our product candidates that may be approved for sale;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to identify and obtain additional product candidates;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our reliance on third parties in non-clinical studies and clinical trials;</span></td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify">&#160;</p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to defend against product liability claims;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to safeguard against security breaches;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain and maintain sufficient intellectual property protection for our product
                                            candidates;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to comply with our intellectual property licensing agreements;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to defend against claims of intellectual property infringement;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to comply with the maintenance requirements of the government patent agencies;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to protect our intellectual property rights throughout the world;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            anticipated start dates, durations and completion dates of our ongoing and future clinical
                                            trials;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the anticipated designs of our future clinical trials;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td style="text-align: justify">our ability to attract and retain qualified employees;</td></tr>
</table>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<p style="margin: 0"></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the impact of Fast Track designation on receipt of actual FDA approval;</span></td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our anticipated future regulatory submissions and our ability to receive regulatory approvals to develop and market our product candidates, including any orphan drug or Fast Track designations; and </span></td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our anticipated future cash position and ability to obtain funding for our operations. </span></td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify"></p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based these forward-looking
statements largely on our current expectations and projections about future events, including the responses we expect from the
U.S. Food and Drug Administration, (&#8220;FDA&#8221;), and other regulatory authorities and financial trends that we believe may
affect our financial condition, results of operations, business strategy, preclinical and clinical trials, and financial needs.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions including, without limitation,
the risks described in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K. These risks are not exhaustive.
Other sections of this Annual Report on Form 10-K include additional factors which could adversely impact our business and financial
performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to
time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our
business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those
contained in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events.
We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and
actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable
laws including the securities laws of the United States, we assume no obligation to update or supplement forward-looking statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Annual Report on Form
10-K, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221;, &#8220;Company&#8221; and &#8220;Anavex&#8221; mean Anavex
Life Sciences Corp., unless the context clearly requires otherwise.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="a_001"></span>PART I</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_002"></span>ITEM 1. BUSINESS
</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Overview and Strategy</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. is a clinical stage
biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous
system (&#8220;CNS&#8221;) diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers,
which we use in the analysis of our clinical trials.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our lead product candidate, ANAVEX<sup>&#174;</sup>2-73,
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked
gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have two core programs and two
seed programs. Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental
diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes key information about our programs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img src="image_001.jpg" alt="" style="height: 231.75pt; width: 468.75pt" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>* = Orphan Drug Designation by the FDA;
Dashed lines indicate planned clinical trials to-date</i></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex has a portfolio of compounds varying
in sigma-1 receptor (SIGMAR1) binding activities. The SIGMAR1 gene encodes the SIGMAR1 protein, which is an intracellular chaperone
protein with important roles in cellular communication. SIGMAR1 is also involved in transcriptional regulation at the nuclear envelope
and restores homeostasis and stimulates recovery of cell function when activated. In order to validate the ability of our compounds
to activate quantitatively the SIGMAR1, we performed, in collaboration with Stanford University, a quantitative Positron Emission
Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73 target engagement or receptor
occupancy with SIGMAR1 in the brain.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="image_002.jpg" alt="" style="height: 312pt; width: 468pt" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Source: Reyes S et al., Sci Rep. 2021 Aug 25;11(1):17150</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cellular Homeostasis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many diseases are possibly directly caused
by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases, such as Rett syndrome or infantile
spasms, the chronic cellular stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases,
such as Alzheimer&#8217;s and Parkinson&#8217;s diseases, chronic cellular stress is possibly caused by age-correlated buildup
of cellular insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (&#8220;RNA&#8221;)
lead to the death of neurons and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy,
a characteristic found in Alzheimer&#8217;s and Parkinson&#8217;s diseases that results from disorders of protein synthesis, trafficking,
folding, processing or degradation in cells. The clearance of macromolecules in the brain is particularly susceptible to imbalances
that result in aggregation and degeneration in nerve cells. For example, Alzheimer&#8217;s disease pathology is characterized by
the presence of amyloid plaques, and neurofibrillary tangles, which are aggregates of hyperphosphorylated Tau protein that are
a marker of other diseases known as tauopathies as well as inflammation of microglia. With the SIGMAR1 activation through SIGMAR1
agonists like ANAVEX<sup>&#174;</sup>2-73, our approach is to restore cellular balance (i.e. homeostasis). Therapies that correct
defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental and neurodegenerative disease progression.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>ANAVEX</i></b><sup>&#174;</sup><b><i>2-73-specific Biomarkers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of some of our clinical trials, we
have incorporated a genomic analysis to better understand potential populations for whom our clinical programs might benefit. In
our clinical trials, a full genomic analysis of Alzheimer&#8217;s disease patients treated with ANAVEX<sup>&#174;</sup>2-73 has
helped us identify actionable genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73
and COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73-specific
biomarker hypothesis. We believe that <i>excluding</i> patients with SIGMAR1 identified biomarker variant (approximately 10%-20%
of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant
improved functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73,
which are considered independent of Alzheimer&#8217;s disease pathology, as well as multiple endpoints and time-points, provides
support for the potential precision medicine clinical development of ANAVEX<sup>&#174;</sup>2-73 by using genetic biomarkers identified
within the trial population itself to target patients who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73 treatment. We
may in the future utilize such an approach in Alzheimer&#8217;s disease as well as indications like Parkinson&#8217;s disease dementia
or Rett syndrome in which ANAVEX<sup>&#174;</sup>2-73 is currently being studied.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Clinical Trials Overview</i></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial, consisting of Part A and Part B, which lasted a total of 57 weeks, for ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s
patients. This open-label, randomized trial in Australia met both primary and secondary endpoints and was designed to assess the
safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic
receptors, which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis
and to reverse the pathological hallmarks observed in Alzheimer&#8217;s disease. In October 2017, we presented positive pharmacokinetic
(&#8220;PK&#8221;) and pharmacodynamic (&#8220;PD&#8221;) data from the Phase 2a clinical trial, which established a concentration-effect
relationship between ANAVEX<sup>&#174;</sup>2-73 and trial measurements. These measures obtained from all patients who participated
in the entire 57 weeks include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally,
the clinical trial appeared to show that ANAVEX<sup>&#174;</sup>2-73 activity was enhanced by its active metabolite (ANAVEX19-144),
which also targets the SIGMAR1 receptor and has a half-life approximately twice as long as the parent molecule.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two consecutive trial extensions for the Phase
2a trial have allowed participants who completed the 52-week Part B of the trial to continue taking ANAVEX<sup>&#174;</sup>2-73,
providing us an opportunity to gather extended safety data for a cumulative time period of five years. In August 2020, patients
completing these Phase 2a trial extensions were granted continued access to treatment with ANAVEX<sup>&#174;</sup>2-73 through the
Australian Government Department of Health &#8211; Therapeutic Goods Administration&#8217;s compassionate use Special Access Scheme.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A larger Phase 2b/3 double-blind, placebo-controlled
trial of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s disease commenced in August 2018. The Phase 2b/3 trial enrolled 509 patients
for 48 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial commenced in Australia;
and during fiscal 2020 additional regions were added in the United Kingdom, The Netherlands, Germany and Canada. Primary and secondary
endpoints will assess safety and both cognitive and functional efficacy, measured through Alzheimer&#8217;s Disease Assessment
Scale &#8211; Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating &#8211; Sum of Boxes for cognition and function (CDR-SB).
In addition to the primary endpoints, the ANAVEX<sup>&#174;</sup>2-73 Phase 2b/3 trial design incorporated pre-specified statistical
analyses related to potential genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a clinical
trial. The trial completed enrollment in June 2021, exceeding the 450 patient enrollment target at 52 sites across Canada, Europe
and Australia.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2019, we initiated a long-term
open label extension study of ANAVEX<sup>&#174;</sup>2-73, entitled the ATTENTION-AD trial, for patients who have completed the
48-week Phase 2b/3 placebo-controlled trial referenced above. This trial extension for an additional two years gives patients
the opportunity to continue their treatment. Upon request by patients, caretakers and investigators, this extension trial was
extended by one additional year.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Rett Syndrome </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease. The data demonstrated dose related and
significant improvements in an array of behavioral and gait paradigms in a mouse model with a MECP2-null mutation that causes neurological
symptoms that mimic Rett syndrome. The study was funded by the International Rett Syndrome Foundation (&#8220;Rettsyndrome.org&#8221;). In January 2017, we were awarded a financial grant
from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter Phase 2 clinical trial of ANAVEX<sup>&#174;</sup>2-73
for the treatment of Rett syndrome. This award was received in quarterly instalments which commenced during fiscal 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase
2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. The clinical
trials are being conducted in a range of patient age demographics and geographic regions, utilizing an oral liquid once-daily formulation
of ANAVEX<sup>&#174;</sup>2-73.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The first Phase 2 trial, (ANAVEX&#174;2-73-RS-001), which took place in the
United States, was completed in December 2020. This trial was a randomized double-blind, placebo-controlled safety, tolerability, PK and
efficacy trial of oral liquid ANAVEX<sup>&#174;</sup>2-73 formulation in 25 adult female patients with Rett syndrome over a 7-week treatment
period including ANAVEX<sup>&#174;</sup>2-73-specific genomic precision medicine biomarkers. The primary endpoint of the trial was safety.
The dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73 was well-tolerated and demonstrated dose-proportional PK. All secondary efficacy endpoints
of the trial showed statistically significant and clinically meaningful response in the Rett Syndrome Behaviour Questionnaire (&#8220;RSBQ&#8221;)
response, when compared to placebo, in the intent to treat (&#8220;ITT&#8221;) cohort (all participants, p = 0.011). 66.7% of ANAVEX<sup>&#174;</sup>2-73
treated subjects showed a statistically significant improvement in RSBQ response as compared to 10% of the subjects on placebo in the
ITT cohort (all participants, p = 0.011). ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained improvement in Clinical Global
Impression Improvement (&#8220;CGI-I&#8221;) response throughout the 7-week clinical trial, when compared to placebo in the ITT cohort
(all participants, p = 0.014). Consistent with previous ANAVEX<sup>&#174;</sup>2-73 clinical trials, patients carrying the common form
of the SIGMAR1 gene treated with ANAVEX<sup>&#174;</sup>2-73 experienced stronger improvements in the prespecified efficacy endpoints.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The second, international
trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the AVATAR trial, commenced in June 2019. This
trial took place in Australia and the United Kingdom using a higher dose than the U.S. based Phase 2 trial for Rett syndrome.
The trial was a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73
in 33 adult patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers.
Based upon the input from the successful U.S. Phase 2 Rett syndrome trial (ANAVEX&#174;2-73-RS-001), we updated the endpoints for
the AVATAR trial (ANAVEX&#174;2-73-RS-002) to appropriately assess the clinically meaningful outcome following International Conference
on Harmonization (ICH) guidelines. These updates were approved by the respective regulatory authorities in the U.K. and in Australia,
respectively, where the AVATAR trial was conducted.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The data from the AVATAR trial was released in February 2022. The clinical
trial met all primary and secondary efficacy and safety endpoints, with consistent improvements in primary efficacy endpoint, RSBQ response
(p = 0.037), and secondary efficacy endpoints, ADAMS (p = 0.010) and CGI-I (p = 0.037) response. Efficacy endpoints demonstrated statistically
significant and clinically meaningful reductions in Rett syndrome symptoms. Convenient once daily oral liquid doses of up to 30 mg of
ANAVEX<sup>&#174;</sup>2-73 were also well tolerated with good medication compliance. All patients who participated in the trial were
eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension protocol.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the third trial
of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the EXCELLENCE trial. This Phase 2/3 trial in pediatric
patients with Rett syndrome includes trial sites in Australia, the United Kingdom, and Canada, and will evaluate the safety and
efficacy of ANAVEX<sup>&#174;</sup>2-73 in approximately 84 pediatric patients, aged 5 to 18, over a 12-week treatment period incorporating
ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. All patients who participate in the trial will be eligible
to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension protocol, which is currently ongoing.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in an animal model of Parkinson&#8217;s disease, which demonstrated significant improvements
on behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation. Additional
data announced in October 2017 indicated that ANAVEX<sup>&#174;</sup>2-73 induced robust neurorestoration in experimental Parkinsonism.
We believe that the encouraging results we have gathered in this preclinical model, coupled with the favorable profile of this
product candidate in the Alzheimer&#8217;s disease trial, support the notion that ANAVEX<sup>&#174;</sup>2-73 has the potential
to treat Parkinson&#8217;s disease dementia.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we completed a double-blind,
randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia
in Spain and Australia, to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease.
The Phase 2 trial enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73
doses, 30 mg and 50 mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 Parkinson&#8217;s disease dementia trial design incorporated
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease trial.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50 mg once daily. The results showed clinically meaningful, dose-dependent, and
statistically significant improvements in the Cognitive Drug Research (&#8220;CDR&#8221;) computerized assessment system analysis.
Treatment with ANAVEX<sup>&#174;</sup>2-73 also resulted in clinically meaningful improvements as measured by the global composite
score of Parkinson&#8217;s disease symptom severity, MDS-Unified Parkinson&#8217;s Disease Rating Scale total score on top of standard
of care including dopaminergic therapy, levodopa and other anti-PD medications after 14 weeks of treatment, suggesting ANAVEX<sup>&#174;</sup>2-73&#8217;s
potential capability of slowing and reversing symptoms that progress in Parkinson&#8217;s disease. In addition, the trial confirmed
the precision medicine approach of targeting SIGMAR1 as a genetic biomarker in response to ANAVEX<sup>&#174;</sup>2-73 may result
in improved clinical outcomes.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2021, we were awarded a research
grant of $1.0 million from&#160;The Michael J. Fox Foundation for Parkinson&#8217;s Research&#160;to develop ANAVEX<sup>&#174;</sup>2-73
for the treatment of Parkinson&#8217;s disease. The award will explore utilization of PET imaging biomarkers to enable measurement
of target engagement and pathway activation of the SIGMAR1 with clinically relevant doses in people with Parkinson&#8217;s disease.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Frontotemporal Dementia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the First-in-Human
Phase 1 clinical trial of ANAVEX<sup>&#174;</sup>3-71. ANAVEX<sup>&#174;</sup>3-71 was previously granted orphan drug designation
for the treatment of Frontotemporal Dementia (&#8220;FTD&#8221;) by the FDA. ANAVEX<sup>&#174;</sup>3-71 is an orally administered small molecule
targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases. In preclinical
studies, ANAVEX<sup>&#174;</sup>3-71 demonstrated disease-modifying activity against the major hallmarks of Alzheimer&#8217;s disease
in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial
dysfunction and neuroinflammation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Phase 1 clinical trial was a prospective
double-blind, randomized, placebo-controlled trial in Australia. A total of 36 healthy male and female subjects were included.
Single escalating doses of ANAVEX<sup>&#174;</sup>3-71 were administered in order to evaluate the safety, tolerability, and PK of
ANAVEX<sup>&#174;</sup>3-71 and the effects of food and gender on its PK in healthy volunteers.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial met its primary and secondary endpoints
of safety, with no serious adverse events (&#8220;SAEs&#8221;) or dose-limiting toxicities observed. ANAVEX<sup>&#174;</sup>3-71
was well tolerated in all cohorts receiving ANAVEX<sup>&#174;</sup>3-71 in single doses ranging from 5 mg to 200 mg daily with no
SAEs and no significant lab abnormalities in any subject. In the trial, ANAVEX<sup>&#174;</sup>3-71 exhibited linear PK. Its pharmacokinetics
was also dose proportional for doses up to 160 mg. Gender had no effect on the PK of the drug and food had no effect on the bioavailability
of ANAVEX<sup>&#174;</sup>3-71. The trial also met the secondary objective of characterizing the effect of ANAVEX<sup>&#174;</sup>3-71
on electrocardiogram (&#8220;ECG&#8221;) parameters. There were no clinically significant ECG parameters throughout the trial.
Participant QTcF measures were normal across all dose groups with no difference between ANAVEX<sup>&#174;</sup>3-71 and placebo.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on these results, and ANAVEX<sup>&#174;</sup>3-71&#8217;s
pre-clinical profile, we intend to advance ANAVEX<sup>&#174;</sup>3-71 into a biomarker-driven clinical development dementia program
for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease, evaluating longitudinal effect of treatment with ANAVEX<sup>&#174;</sup>3-71.
We believe the results of these clinical trials and preclinical study could serve as the basis for advancing into respective registration
studies in the U.S.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 8; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Pipeline</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development pipeline includes
ANAVEX<sup>&#174;</sup>2-73 currently in three different clinical trial indications, and several other compounds in different stages
of clinical and pre-clinical development.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our proprietary SIGMACEPTOR&#8482; Discovery
Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma
receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer&#8217;s
disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate ligands, sigma receptors influence
the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. Multiple
viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular
processes, in order to ensure survival and replication. Hence, it is possible that SIGMAR1 could play a role in modulating the
cellular response to viral infection and ameliorate pathogenesis.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compounds that have been subjects of our research
include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 <i>(blarcamesine)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe ANAVEX<sup>&#174;</sup>2-73 may offer
a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1. ANAVEX<sup>&#174;</sup>2-73
is being developed in an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily
capsule formulation for diseases such as Alzheimer&#8217;s disease.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Rett syndrome, administration of ANAVEX<sup>&#174;</sup>2-73
in liquid form resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET
Rett syndrome disease model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX<sup>&#174;</sup>2-73 was
evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident.
Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<sup>&#174;</sup>2-73
for four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome disease mice. Additionally, chronic
oral dosing daily for 6.5 weeks of ANAVEX<sup>&#174;</sup>2-73 starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett
syndrome disease mouse model assessed the different aspects of muscular coordination, balance, motor learning and muscular strengths,
some of the core deficits observed in Rett syndrome. Administration of ANAVEX<sup>&#174;</sup>2-73 resulted in both significant
and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease model.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2016 and June 2016, the FDA granted
Orphan Drug Designation to ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome and infantile spasms, respectively. In
November 2019, the FDA granted to ANAVEX<sup>&#174;</sup>2-73 the Rare Pediatric Disease (RPD) designation for the treatment of
Rett syndrome. The RPD designation is intended to encourage the development of treatments for rare pediatric diseases.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in February 2020, the FDA granted
Fast Track designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett syndrome. The
FDA Fast Track program is designed to facilitate and expedite the development and review of new drugs to address unmet medical
needs in the treatment of serious and life-threatening conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Parkinson&#8217;s disease, data demonstrates
significant improvements and restoration of function in a disease modifying animal model of Parkinson&#8217;s disease. Significant
improvements were seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints. In October 2020,
we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s
disease dementia, to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease.
The Phase 2 trial enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73
doses, 30 mg and 50 mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 Parkinson&#8217;s disease dementia trial design incorporated
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease trial.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50 mg once daily. The results showed clinically meaningful, dose-dependent, and
statistically significant improvements in the CDR computerized assessment system analysis. We anticipate conducting further clinical
trials of ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia after submitting the results of the trial to the FDA
to obtain regulatory guidance.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Alzheimer&#8217;s disease animal models,
ANAVEX<sup>&#174;</sup>2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic,
anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to SIGMAR1 and moderate affinities to M1-4 type
muscarinic receptors. In addition, ANAVEX<sup>&#174;</sup>2-73 has shown a potential dual mechanism which may impact amyloid, tau
pathology and inflammation. In a transgenic Alzheimer&#8217;s disease animal model Tg2576, ANAVEX<sup>&#174;</sup>2-73 induced a
statistically significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly
increased the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent. It also statistically
alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working
memory and long-term spatial reference memory.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the results of pre-clinical testing,
we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>&#174;</sup>2-73. In this Phase 1
SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown
to have positive effects in mouse models of Alzheimer&#8217;s disease. There were no significant changes in laboratory or ECG parameters.
ANAVEX<sup>&#174;</sup>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed
adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity
and reversible. These side effects are often seen with drugs that target CNS conditions, including Alzheimer&#8217;s disease.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial for ANAVEX<sup>&#174;</sup>2-73, for the treatment of Alzheimer&#8217;s disease. The open-label randomized trial was designed
to assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients with mild-to-moderate Alzheimer&#8217;s
disease. The Phase 2a trial met both primary and secondary objectives of the trial.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2018, we presented
the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a clinical trial. More than 33,000 genes were
analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA and RNA data in patients
treated with ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to ANAVEX<sup>&#174;</sup>2-73,
among them variants related to the SIGMAR1, the target for ANAVEX<sup>&#174;</sup>2-73. Results showed that trial participants with
the common SIGMAR1 wild type gene variant, which is estimated to be about 80% of the population worldwide, demonstrated improved
cognitive (MMSE) and the functional (ADCS-ADL) scores. The results from this evaluation supported the continued evaluation of genomic
information in subsequent clinical trials, since these signatures can now be applied to neurological indications tested in future
clinical trials with ANAVEX<sup>&#174;</sup>2-73 including Alzheimer&#8217;s disease, Parkinson&#8217;s disease dementia and Rett
syndrome.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ANAVEX<sup>&#174;</sup>2-73
data met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled trial. On July 2, 2018, the Human Research
Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled 48-week safety
and efficacy trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of early Alzheimer&#8217;s disease. Clinical trial sites in
Canada, the United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 trial design incorporates inclusion of
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a trial. The Phase 2b/3 trial, which
has completed enrollment, randomized 1:1:1 to either two different ANAVEX<sup>&#174;</sup>2-73 doses or placebo.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe preclinical data from our studies
also supports ANAVEX<sup>&#174;</sup>2-73 as a potential platform drug for other neurodegenerative diseases beyond Alzheimer&#8217;s
disease, Parkinson&#8217;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman
syndrome, multiple sclerosis and, more recently, tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73 demonstrated significant
improvements in all of these indications in the respective preclinical animal models.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a preclinical study sponsored by the Foundation
for Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development of audiogenic seizures. The
results indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced seizures. In a study
sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73 restored
hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed in many
neurodevelopmental and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory synapses.
ANAVEX<sup>&#174;</sup>2-73 normalization of BDNF expression could be a contributing factor for the positive data observed in both
neurodevelopmental and neurodegenerative disorders like Angelman and Fragile X syndromes.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data to-date also
indicates that ANAVEX<sup>&#174;</sup>2-73 has the potential to demonstrate protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data on ANAVEX<sup>&#174;</sup>2-73
related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination in multiple sclerosis disease.
Further, our data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 has the potential to provide protection for oligodendrocytes
(&#8220;OL&#8217;s&#8221;) and oligodendrocyte precursor cells (&#8220;OPC&#8217;s&#8221;), as well as central nervous system neurons
in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, we presented preclinical data
of ANAVEX<sup>&#174;</sup>2-73 in a genetic mouse model of tuberous sclerosis complex (&#8220;TSC&#8221;). TSC is a rare genetic
disorder characterized by the growth of numerous benign tumors in many parts of the body with a high incidence of seizures. The
preclinical data demonstrated that treatment with ANAVEX<sup>&#174;</sup>2-73 significantly increased survival and reduced seizures
in those mice.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>3-71</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>3-71 is a clinical drug
candidate with a novel mechanism of action via SIGMAR1 activation and M1 muscarinic allosteric modulation, which has been shown
to enhance neuroprotection and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71 is a CNS-penetrable potential
disease modifying treatment for cognitive impairments. We believe it is effective in very small doses against the major Alzheimer&#8217;s
hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects
on inflammation and mitochondrial dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive therapeutic advantages in Alzheimer&#8217;s
and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via SIGMAR1 activation
and M1 muscarinic allosteric modulation.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preclinical study examined the response of
ANAVEX<sup>&#174;</sup>3-71 in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit,
amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In April 2016, the FDA granted Orphan Drug Designation
to ANAVEX<sup>&#174;</sup>3-71 for the treatment of FTD.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During pathological conditions ANAVEX<sup>&#174;</sup>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number
of astrocytes. In neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s disease, synaptogenesis is believed
to be impaired. Additional preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71
has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if
impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 11; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the first Phase
1 clinical trial of&#160;ANAVEX<sup>&#174;</sup>3-71. The trial took place in Australia and was a double-blind, randomized, placebo-controlled,
Phase 1 trial to evaluate safety and tolerability, and PK of oral escalating doses of ANAVEX<sup>&#174;</sup>3-71 including effects
of food and gender in healthy volunteers. The trial met its primary and secondary endpoints of safety, respectively with no serious
adverse events (SAEs) or dose-limiting toxicities observed, as more fully described above under <i>Clinical Trials Overview &#8211;
Frontotemporal Dementia</i>.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on these results, and ANAVEX<sup>&#174;</sup>3-71
pre-clinical profile, the Company intends to advance ANAVEX<sup>&#174;</sup>3-71 into a biomarker-driven clinical development dementia
program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease, evaluating longitudinal effect of treatment with
ANAVEX<sup>&#174;</sup>3-71. We believe the results of this clinical trial and preclinical study could serve as a basis for advancing
into respective registration trials in the U.S.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ANAVEX<sup>&#174;</sup>1-41</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1-41 is a sigma-1 agonist.
Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through
the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability. In addition,
in animal models, ANAVEX<sup>&#174;</sup>1-41 prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis
(programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory.
These activities involve both muscarinic and SIGMAR1 systems through a novel mechanism of action.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that
ANAVEX<sup>&#174;</sup>1-41 has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological
conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1066</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1066, a mixed
sigma-1/sigma-2 ligand is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066 was
tested in two preclinical models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic
constriction injury model of neuropathic pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored
the nociceptive threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy
was rapid and remained significant for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by
injection of an inflammatory agent directly into the colon and a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned
the nociceptive threshold to control levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any
effects on normal gastrointestinal transit with ANAVEX<sup>&#174;</sup>1066 and a favorable safety profile in a battery of behavioral
measures.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1037 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is designed for
the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for
SIGMAR1 at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced pre-clinical
studies, this compound revealed antitumor potential. It has also been shown to selectively kill human cancer cells without affecting
normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications highlight
the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors
are highly expressed in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective
apoptosis. In addition, through tumor cell membrane reorganization and interactions with ion channels, we believe our drug candidates
may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original site to other
parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is currently in
the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical
models will be shown in human testing.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 12; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to identify and initiate discussions
with potential strategic and commercial partners to most effectively advance our programs and increase stockholder value. Further,
we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further
our goals.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Target Indications</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are developing compounds with potential
application to two broad categories and several specific indications, including:</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Central Nervous System Diseases</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20.65pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Alzheimer&#8217;s disease &#8211; In 2022, an estimated 6.5 million Americans were suffering from Alzheimer&#8217;s disease. The Alzheimer&#8217;s Association<sup>&#174; </sup>estimates that by 2050, this number is expected to rise to 12.7 million Americans. Medications on the market today treat only the symptoms of Alzheimer&#8217;s disease and do not have the ability to stop its onset or its progression. We believe there is an urgent and unmet need for both a disease modifying cure for Alzheimer&#8217;s disease as well as for better symptomatic treatments.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20.65pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Parkinson&#8217;s disease &#8211; Parkinson&#8217;s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine. Parkinson&#8217;s disease currently is estimated to afflict more than 10 million people worldwide, typically middle-aged and elderly people. The Parkinson&#8217;s disease market is expected to reach to $11.5 billion by 2029, according to GlobalData.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rett syndrome &#8211; Rett
    syndrome is a rare X-linked genetic neurological and developmental disorder that affects the way the brain develops, including protein
    transcription, which is altered and as a result leads to severe disruptions in neuronal homeostasis. It is considered a rare, progressive
    neurodevelopmental disorder and is caused by a single mutation in the MECP2 gene. Because males have a different chromosome combination
    from females, boys who have the genetic MECP2 mutation are affected in devastating ways. Most of them die before birth or in early
    infancy. For females who survive infancy, Rett syndrome leads to severe impairments, affecting nearly every aspect of the child&#8217;s
    life; severe mental retardation, their ability to speak, walk and eat, sleeping problems, seizures and even the ability to breathe
    easily. Rett syndrome affects approximately 1 in every 10,000-15,000 females.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20.65pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Depression &#8211; Depression is a major cause of morbidity worldwide according to the World Health Organization. The global antidepressant drug market is projected to reach $21 Billion by 2030 according to Allied Market Research.&#160;&#160;Pharmaceutical treatment for depression has been historically dominated by blockbuster brands. However, the dominance of the leading brands is waning, largely due to an increase in the number of approvals for antidepressant drugs.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epilepsy &#8211; Epilepsy
    is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient signs and/or
    symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease Control and Prevention,
    in 2015 epilepsy affected 3.4 million Americans. Today, epilepsy is often controlled, but not cured, with medication that is categorized
    as older traditional anti-epileptic drugs and second generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different
    ways, there is a need for drugs used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic
    drugs.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic Pain &#8211;
    We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body.
    Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special
    medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cancer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20.65pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Malignant Melanoma &#8211; Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for a large majority of skin cancer deaths. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to iHealthcareAnalyst, Inc. the worldwide malignant melanoma market is expected to grow to $7.5 billion by 2029.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Prostate Cancer
    &#8211; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive
    system. Cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes.
    Drug therapeutics for prostate cancer are expected to increase to nearly $10.1 billion by the end of 2030 according to Market
    Research Future.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Pancreatic Cancer
    &#8211; Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 62,000 new cases of
    pancreatic cancer will be diagnosed this year and approximately 50,000 patients will die as a result of their cancer, according
    to the American Cancer Society. Sales predictions by Market Data Forecast predict that the market for the global pharmaceutical
    treatment of pancreatic cancer will increase from $2.59 billion in 2022 to $3.73 billion by 2027.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Competition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The drug discovery and development industry
is very competitive, characterized by rapid advancements in technology, where protection of proprietary advancements is essential.
Any product candidates that we may successfully develop and commercialize, may compete with existing therapies, or new therapies
that may become available in the future. Our commercial opportunities could be reduced or eliminated if our competitors develop
and commercialize products that are more effective, have fewer side effects, are more convenient or are less expensive than any
products that we may develop.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe our approach to the treatment of
Alzheimer&#8217;s disease and other CNS diseases differs from our competitors - our platform may offer a disease-modifying approach
in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1. In our preclinical studies, when activated by SIGMAR1
agonists, such as ANAVEX<sup>&#174;</sup>2-73, SIGMAR1 demonstrated reduced cellular stress before and after RNA gene transcription.
Our studies confirm the potential existence of a predictive biomarker of response established through SIGMAR1 mRNA expression that
could be used in future clinical trials. Because of its role in maintaining neuronal homeostasis, we believe sigma receptors show
significant promise as viable targets for therapeutic molecules in an effort to treat Alzheimer&#8217;s disease and other CNS diseases
and disorders, including Parkinson&#8217;s disease and Rett syndrome, by restoring healthy gene expression.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At this time, our competitors are primarily
other biomedical development companies that are aiming to discover and develop compounds to be used in the treatment of Alzheimer&#8217;s
disease and other CNS diseases, and those companies already doing so. We also face competition from academic institutions and government
agencies, both in the United States and abroad.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors may have significantly greater
financial resources, an established presence in the market, expertise in research and development, manufacturing, preclinical and
clinical testing, may be in the process of obtaining regulatory approvals and marketing of approved products. These competitors
also compete with us in recruiting and retaining qualified scientific and technical personnel, establishing clinical trial sites
and patient registration for clinical trials, as well as in acquiring or developing technologies complementary to, or necessary
for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For additional discussion of the risks
related to competition, see Item 1A &#8220;Risk Factors.&#8221;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 14; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patents, Trademarks and Intellectual
Property</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights
to seventeen U.S. patents, nineteen U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug
candidates, methods associated therewith, and to our research programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled
&#8220;ANAVEX<sup>&#174;</sup>2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection&#8221; claims
a composition of matter of ANAVEX<sup>&#174;</sup>2-73 directed to a novel and synergistic neuroprotective compound combined with
donepezil and other cholinesterase inhibitors. This patent is expected to expire in June 2034, absent any patent term extension
for regulatory delays. We own three issued U.S. patents each with claims directed to crystalline forms of ANAVEX<sup>&#174;</sup>2-73.
The first of these three patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73, dosage forms and compositions containing
crystalline ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease using them. This patent is expected
to expire in July 2036, absent any patent term extension for regulatory delays. The second of these three patents claims pharmaceutical
compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease
using the compositions. This patent is expected to expire in June 2037, absent any patent term extension for regulatory delays.
The third of these three patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73,
and methods of treatment for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2037,
absent any patent term extension for regulatory delays. We also own two issued U.S. patents for seizure treatment. The first of
these two patents claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug
combined with either: (i) ANAVEX<sup>&#174;</sup>2-73 and its active metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii) ANAVEX<sup>&#174;</sup>19-144.
The second of these two patents further claims a combination seizure treatment involving administration of an anti-epilepsy drug
combined with (i) ANAVEX<sup>&#174;</sup>19-144, or (ii) ANAVEX 19-144<sup>&#174;</sup> and ANAVEX 2-73<sup>&#174;</sup>. Both patents
are expected to expire in October 2035, absent any patent term extension for regulatory delays. We also own three issued U.S. patents
with claims directed to treating neurodevelopmental disorders. These patents claim methods for treating a neurodevelopmental disorder,
multiple sclerosis, or their related biochemical and functional abnormalitiesby administering ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
and/or ANAVEX<sup>&#174;</sup>1-41 (another sigma receptor ligand similar to ANAVEX<sup>&#174;</sup>2-73), or compositions thereof.
All three patents are expected to expire in January 2037, absent any patent term extension for regulatory delays. In addition,
we own one issued U.S. Patent with claims directed to methods of treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73.
This patent is expected to expire in February 2030, absent any patent term extension for regulatory delays. We also own an issued
U.S. patent that claims crystalline forms of ANAVEX<sup>&#174;</sup>19-144, dosage forms and compositions containing the crystalline
forms of ANAVEX<sup>&#174;</sup>19-144, and methods of treatment for Alzheimer&#8217;s disease. This patent is expected to expire
in July 2036, absent any patent term extension for regulatory delays. Further, we own one issued U.S. Patent with claims directed
to methods of treating cardiac dysfunction with ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in July 2038, absent
any patent term extension for regulatory delays. Additionally, we own one issued U.S. Patent with claims directed to methods of
treating insomnia or anxiety with ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41.
This patent is expected to expire in September 2038, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own two issued U.S. patents
related to ANAVEX<sup>&#174;</sup>1066. The first of these two patents claims methods for treating or preventing pain using (+)
ANAVEX<sup>&#174;</sup>1066 isomer. The second patent claims methods for treating or preventing pain using (-) ANAVEX<sup>&#174;</sup>1066
isomer. Both patents are expected to expire in November 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also have granted or pending applications in Australia, Canada,
China, Europe, Japan, and Hong Kong, which are expected to expire after 2035.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to ANAVEX<sup>&#174;</sup>3-71,
we own exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>&#174;</sup>3-71 compound
and methods of treating various diseases including Alzheimer&#8217;s with the same. These patents are expected to expire in April
2030, and January 2030, respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related
patents or applications that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and
South Africa, which are expected to expire in January 2030.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 15; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own other patent applications
directed to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional protection for
one or more of our product candidates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We regard patents and other intellectual
property rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business
strategy including the selective development, protection, and exploitation of our intellectual property rights. In addition to
filings made with intellectual property authorities, we protect our intellectual property and confidential information by means
of carefully considered processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure
agreements and provisions for the same in contractor&#8217;s agreements. While no agreement offers absolute protection, such agreements
provide some form of recourse in the event of disclosure, or anticipated disclosure.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our intellectual property position,
like that of many biomedical companies, is uncertain and involves complex legal and technical questions for which important legal
principles are unresolved. For more information regarding challenges to our existing or future patents, see &#8220;Risk Factors&#8221;.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Government regulation </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Government authorities in the United
States, at the federal, state and local levels, and other countries extensively regulate, among other things, the research, development,
testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution,
marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the
NDA or ANDA process before it may be legally marketed in the United States. We are subject to various government regulations in
connection with the development of our pipeline.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>U.S. Drug Development and Regulation </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, the FDA regulates drugs
under the Federal Food, Drug, and Cosmetic Act and its implementing regulations (&#8220;FDCA&#8221;). The process of obtaining
regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations
require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at
any time during the product development process, approval process or post approval may subject an applicant to administrative or
judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval,
import refusal, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production
or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.
Any agency or judicial enforcement action could have a material adverse effect on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once a drug candidate is identified for development,
it enters the preclinical testing stage and an Investigational New Drug Application (&#8220;IND&#8221;) may be opened for the regulatory
development of the product. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as
well as other preclinical studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing
information and analytical data, to the FDA as part of the IND to conduct clinical trials. The sponsor must also include a protocol
detailing, among other things, the objectives of the first phase of clinical trials, the parameters to be used in monitoring the
safety of the trial, and the effectiveness criteria to be evaluated should the first phase lend itself to an efficacy evaluation.
Some preclinical testing may continue even after the IND is filed. The IND automatically becomes effective thirty (30) days after
receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. Clinical holds
also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about ongoing or proposed clinical
trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor
that the hold has been lifted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All clinical trials must be conducted under
the supervision of one or more qualified investigators in accordance with FDA good clinical practice (&#8220;GCP&#8221;) requirements,
which include a requirement that all research subjects provide their informed consent in writing for their participation in any
clinical trial. Clinical trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject
selection inclusion and exclusion criteria and the safety and/or effectiveness criteria to be evaluated. Each protocol must be
submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and the investigators for serious
and unexpected adverse events. An Institutional Review Board (&#8220;IRB&#8221;) at each institution participating in the clinical
trial must review and approve each protocol before a clinical trial may commence at the institution and must also approve the information
regarding the trial as well as the informed consent form that must be provided to each trial participant or his or her legal representative,
monitor the study until completed and otherwise comply with all applicable IRB regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Human clinical trials are typically conducted
in three sequential phases that may overlap or be combined in certain cases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 1: The compound is initially introduced
into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if
possible, to gain an early indication of its effectiveness. In most cases, initial Phase 1 clinical trials are conducted with healthy
volunteers. However, where the compound being evaluated is for the treatment of severe or life-threatening diseases, such as cancer,
and especially when the product may be too toxic to ethically administer to healthy volunteers, the initial human testing may be
conducted on patients with the target disease or condition. Sponsors sometimes subdivide their Phase 1 clinical trials into Phase
1a and Phase 1b clinical trials. Phase 1b clinical trials are typically aimed at confirming dosage, PK and safety in a larger number
of patients. Some Phase 1b clinical trials evaluate biomarkers or surrogate markers that may be associated with efficacy in patients
with specific types of diseases or conditions.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 2: This phase involves clinical trials
in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of
the product for specific targeted diseases or conditions and to confirm dosage tolerance and appropriate dosage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 3: Phase 3 clinical trials are undertaken
to further evaluate dosage, clinical efficacy and safety in an expanded patient population, generally at geographically dispersed
clinical trial sites. These clinical trials, often referred to as &#8220;pivotal&#8221; or &#8220;confirmatory&#8221; clinical
trials, are intended to establish the overall risk-benefit ratio of the compound and provide, if appropriate, an adequate basis
for product approval and labeling.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA or the sponsor may suspend a clinical
trial at any time on various grounds, including any finding that the research subjects or patients are being exposed to an unacceptable
health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is
not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected, serious
harm to study subjects. In addition, clinical trials may be overseen by an independent group of qualified experts organized by
the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this board or committee may determine
whether a trial may move forward at designated check points based on access to certain data from the trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 4: Phase 4 or post-approval trials may
also be conducted after a drug receives initial marketing approval. These trials, often referred to as &#8220;Phase 4&#8221; trials,
are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances,
the FDA may mandate the performance of such clinical trials as a condition of approval of continued marketing of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the development of a new drug, sponsors
are given several opportunities to meet with the FDA. These meetings can provide an opportunity for the sponsor to share information
about the progress of the application or clinical trials, for the FDA to provide advice, and for the sponsor and the FDA to reach
agreement on the next phase of development. These meetings may occur prior to the submission of an IND, at the end of Phase 2 clinical
trials, or before an NDA is ultimately submitted. Sponsors typically use the meetings at the end of the Phase 2 trials to discuss
Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the
new drug. Meetings at other times may be made upon request and are subject to approval by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Concurrent with clinical trials, companies
typically complete additional, animal or other non-clinical studies, develop additional information about the chemistry and physicochemical
characteristics of the drug, and finalize a process for manufacturing the product in commercial quantities in accordance with the
FDA&#8217;s current Good Manufacturing Practices (&#8220;cGMP&#8221;) requirements. The manufacturing process must consistently
produce quality batches of the drug and, among other things, the manufacturer must develop methods for testing the identity, strength,
quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must
be conducted to demonstrate the effectiveness of the packaging and that the compound does not undergo unacceptable deterioration
over its shelf life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While the IND is active, progress reports summarizing
the results of ongoing clinical trials and nonclinical studies performed since the last progress report must be submitted on at
least an annual basis to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and
unexpected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs,
findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important, increased incidence
of a serious adverse reaction compared to that listed in the protocol or investigator brochure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are also requirements governing the submission
of certain clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA-regulated
products are required to register and disclose specified clinical trial registration and results information, which is made publicly
available at www.clinicaltrials.gov. Failure to properly report clinical trial results can result in civil monetary penalties.
Disclosure of clinical trial results can often be delayed until the new product or new indication being studied has been approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>U.S. review and approval process </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The results of product development, preclinical
and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted
on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of a New Drug Application
(&#8220;NDA&#8221;). The submission of an NDA is subject to the payment of substantial user fees; a waiver of which may be obtained
under certain limited circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA reviews NDAs to determine, among
other things, whether the product is safe and effective for its intended use and whether it is manufactured in a cGMP-compliant
manner, which will assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug
User Fee Act (&#8220;PDUFA&#8221;), the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard, completed
NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the
NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after the application
is submitted. The FDA conducts a preliminary review of all NDAs within the first sixty days after submission, before accepting
them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional
information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The
resubmitted application also is subject to review before the FDA accepts it for filing.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA may refer an application for a new
drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific
experts, that reviews, evaluates and provides a recommendation as to whether and under what conditions the application should be
approved. The FDA is not bound by the recommendations of such an advisory committee, but it considers advisory committee recommendations
carefully when making decisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before approving an NDA, the FDA will also
inspect the facility where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product
within required specifications. Before approving an NDA, the FDA may also inspect one or more clinical trial sites to assure compliance
with GCP requirements and inspect the clinical trial records.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the FDA evaluates an NDA, it will issue
an approval letter or a Complete Response Letter. A Complete Response Letter indicates that the review cycle of the application
is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific
deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial
or other significant and time-consuming requirements related to clinical trials, nonclinical studies or product manufacturing.
If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the
letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not
satisfy the criteria for approval. An approval letter authorizes commercial marketing of the drug with prescribing information
for specific indications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Pediatric Research Equity Act (&#8220;PREA&#8221;),
requires IND sponsors to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage
form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment
unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the
product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical
trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that
the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness
data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor
that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric
formulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a drug receives FDA approval, the approval
may be limited to specific diseases and dosages, which could restrict the commercial value of the product. In addition, the FDA
may require testing and surveillance programs to monitor the safety of approved products which have been commercialized and may
require a sponsor to conduct post-marketing clinical trials (Phase 4 clinical trials), which are designed to further assess a drug&#8217;s
safety and effectiveness after NDA approval. The FDA may also place other conditions on approval, including a requirement for a
risk evaluation and mitigation strategy (&#8220;REMS&#8221;) to assure the safe use of the drug. If the FDA concludes a REMS is
needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required.
A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution
methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict
the commercial promotion, distribution, prescribing or dispensing of products. Marketing approval may be withdrawn for non-compliance
with REMS or other regulatory requirements, or if problems occur following initial marketing.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Post-approval requirements </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once an approval is granted, the FDA may withdraw
the approval if compliance with regulatory standards is not maintained or if problems occur after the drug reaches the market.
Later discovery of previously unknown problems with a drug may result in restrictions on the drug or even complete withdrawal of
the drug from the market. After approval, some types of changes to the approved drug, such as adding new indications, certain manufacturing
changes and additional labeling claims, are subject to further FDA review and approval. Manufacturers and other entities involved
in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state
agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations
and other laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any drug product manufactured or distributed
by us pursuant to FDA approval will be subject to continuing regulation by the FDA, including, among other things, record-keeping
requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug
sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with
FDA promotion and advertising requirements. FDA strictly regulates labeling, advertising, promotion and other types of information
regarding approved drugs that are placed on the market, and imposes requirements and restrictions on drug manufacturers, such as
those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that
are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific
and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the
failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product for a certain
indication or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with
the applicable governmental requirements at any time during the product development process, approval process or after approval,
may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. The FDA
sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-marketing clinical
trials, enforcement letters, import refusals, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment,
restitution, disgorgement of profits, or civil or criminal penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Expedited development and review programs
</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA has a fast track designation program
that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically,
new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition
and demonstrate the potential to address unmet medical needs for the disease or condition. With regard to a fast track product,
the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor
provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines
that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any product submitted to the FDA for approval,
including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development
and review, such as priority review and accelerated approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A product is eligible for priority review if
it is intended to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared
to currently marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new
drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority
review designations within six months of the filing date, as compared to ten months for review of NDAs under its current PDUFA
review goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, a product may be eligible for
accelerated approval. Drugs intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated
approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical
benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely
to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity,
or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may
require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials.
Drugs receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required
post-marketing trials or if such trials fail to verify the predicted clinical benefit. In addition, the FDA currently requires
as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial
launch of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Food and Drug Administration Safety and
Innovation Act (&#8220;FDASIA&#8221;) established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that
may be eligible to receive breakthrough therapy designation. A sponsor may seek FDA designation of a compound as a &#8220;breakthrough
therapy&#8221; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening
disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over
existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance.
The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be
granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work to
expedite the development and review of such drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fast track designation, priority review and
breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.
However, even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets
the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Orphan drug designation </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Orphan Drug Act, the FDA may grant
orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer
than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no
reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease
or condition will be recovered from sales of the product. Orphan designation must be requested before an NDA is submitted. After
the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are publicly disclosed by
the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a product that has orphan designation subsequently
receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan
product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication
for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity
or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial
incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. However,
competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain
approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan exclusivity also
could block the approval of one of our compounds for seven years if our compound is determined to be contained within the competitor&#8217;s
product for the same indication or disease, or if a competitor obtains approval of the same drug as defined by the FDA. In addition,
if an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled
to orphan exclusivity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Abbreviated New Drug Applications, 505(b)(2)
Applications, and Marketing exclusivity </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In seeking approval for a drug through an NDA,
applicants are required to list with the FDA each patent with claims that cover the applicant&#8217;s drug or an approved method
of use of the drug. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the
FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the &#8220;Orange Book.&#8221; Drugs
listed in the Orange Book can, in turn, be cited by competitors in support of approval of an Abbreviated New Drug Application,
or ANDA, or a 505(b)(2)&#160;application. In this case, the original NDA (the&#160;so-called&#160;pioneer drug) is known as the
&#8220;listed&#8221; drug or &#8220;reference-listed&#8221; drug. An ANDA provides for marketing of a drug that has the same active
ingredient and the same strength, route of administration and dosage form as the listed drug and has been shown through testing
to be bioequivalent to the listed drug or receives a waiver from bioequivalence testing. ANDA applicants are generally not required
to conduct or submit results of preclinical or clinical tests to prove the safety or effectiveness of their drug, other than the
requirement for bioequivalence testing. Drugs approved in this way are considered therapeutically equivalent, and are commonly
referred to as &#8220;generic equivalents&#8221; to the listed drug. These drugs then generally can be substituted by pharmacists
under prescriptions written for the original listed drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A 505(b)(2) application is a type of NDA that
relies, in part, upon data the applicant does not own and to which it does not have a right of reference. Such applications often
are submitted for changes to previously approved drug products, and rely on the FDA&#8217;s prior findings of safety and effectiveness
for a third party&#8217;s NDA to abbreviate the showings the sponsor of the 505(b)(2) application must make to establish that its
product is safe and effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ANDA or 505(b)(2)&#160;applicant is required
to certify to FDA concerning any patents listed for the referenced approved drug in FDA&#8217;s Orange Book. Specifically, for
each listed patent, the applicant must certify that: (1)&#160;the required patent information has not been filed; (2)&#160;the
listed patent has expired; (3)&#160;the listed patent has not expired but will expire on a particular date and approval is sought
after patent expiration; or (4)&#160;the listed patent is invalid, unenforceable or will not be infringed by the new drug. A certification
that the new drug will not infringe the already approved drug&#8217;s listed patents or that such patents are invalid or unenforceable
is called a Paragraph IV certification. If the ANDA or 505(b)(2)&#160;applicant does not include a Paragraph IV certification,
the ANDA or 505(b)(2)&#160;application will not be approved until all of the listed patents claiming the referenced drug have expired,
except for any listed patents that only apply to uses of the drug not being sought by the ANDA or 505(b)(2)&#160;applicant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the ANDA or 505(b)(2)&#160;applicant has
made a Paragraph IV certification, the applicant must also send notice of a Paragraph IV Notice Letter to the NDA and patent holders
once the ANDA or 505(b)(2)&#160;application has been accepted for filing by FDA. The NDA and patent holders may then initiate a
patent infringement lawsuit in response to the notice of the Paragraph IV Notice Letter. The filing of a patent infringement lawsuit
within 45&#160;days of the receipt of notice of a Paragraph IV Notice Letter automatically prevents FDA from approving the ANDA
until the earlier of 30&#160;months, expiration of the patent, settlement of the lawsuit, modification by a court or a decision
in the infringement case that is favorable to the ANDA or 505(b)(2)&#160;applicant. As discussed below, the ANDA or 505(b)(2)&#160;application
also will not be approved until any applicable&#160;non-patent&#160;exclusivity listed in the Orange Book for the reference-listed
drug has expired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Market exclusivity provisions under the FDCA
can delay the submission or approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing
exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a
new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule
or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept
for review an abbreviated new drug application (&#8220;ANDA&#8221;), or an NDA submitted under Section 505(b)(2) (a &#8220;505(b)(2)
NDA&#8221;), submitted by another company for another drug containing the same active moiety, regardless of whether the drug is
intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or
have a legal right of reference to all the data required for approval. However, an application may be submitted after four years
if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator
NDA holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDCA alternatively provides three years
of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability
studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application,
for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification
for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving
ANDAs or 505(b)(2) NDAs for drugs containing the active ingredient for the original indication or condition of use. Five-year and
three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would
be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical
trials necessary to demonstrate safety and effectiveness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pediatric exclusivity is another type of marketing
exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity
attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from
the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition,
orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>United States Patent Term Restoration</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depending upon the timing, duration and specifics
of FDA approval of our future product candidates, some of our United States patents may be eligible for limited patent term extension
under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments.
The Hatch-Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during
the FDA regulatory review process for a drug that has not been previously approved for commercial marketing. Patent-term restoration,
however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date and only
those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. The patent-term
restoration period is generally&#160;one-half&#160;the time between the effective date of an IND and the submission date of an
NDA plus the time between the submission date of an NDA and the approval of that application, except that the review period is
reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug
is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The
U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension
or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent
life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in
the filing of the relevant NDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Foreign Sales</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales outside the United States of potential
drug compounds we develop will also be subject to foreign regulatory requirements governing human clinical trials and marketing
for drugs. The requirements vary widely from country to country, but typically the registration and approval process takes several
years and requires significant resources. In most cases, if the FDA has not approved a potential drug compound for sale in the
United States, the potential drug compound may be exported for sale outside of the United States, only if it has been approved
in any one of the following: the European Union or a country in the European Economic Area (the countries in the European Union
and the European Free Trade Association) if the drug or device is marketed in that country or the drug or device is authorized
for general marketing in the European Economic Area, Canada, Australia, New Zealand, Japan, Israel, Switzerland and South Africa.
There are specific FDA regulations that govern this process.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>U.S. coverage and reimbursement </i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Significant uncertainty exists as to
the coverage and reimbursement status of any compound for which we may seek regulatory approval. Sales in the United States will
depend in part on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government
health programs such as Medicare, Medicaid, CHIP, TRICARE and the Veterans Administration, as well as managed care organizations
and private health insurers. Prices at which we or our customers seek reimbursement for our therapeutic compounds can be subject
to challenge, reduction or denial by payors.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The process for determining whether
a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the
payor will pay for the product. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement
rate will be available. Additionally, in the United States there is no uniform policy among payors for coverage or reimbursement.
Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement
policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ
significantly from payor to payor. If coverage and adequate reimbursement are not available, or are available only at limited levels,
successful commercialization of, and obtaining a satisfactory financial return on, any product we develop may not be possible.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Third-party payors are increasingly challenging
the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety
and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to
conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be
in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our compounds to be medically
necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage
may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return
on our investment in drug development.<span style="font-family: Arial, Helvetica, Sans-Serif; color: black"> </span><span style="color: black">Additionally,
we or our collaborators may develop companion diagnostic tests for use with our product candidates. Companion diagnostic tests
require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or
biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products,
will apply to companion diagnostics.</span></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Fraud and Abuse Laws </i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Federal and state health care laws and
regulations restrict business practices in the biopharmaceutical industry. In the biopharmaceutical industry, there are a number
of federal and state health care regulatory requirements that apply to entities, including, but not limited to, the federal and
state fraud and abuse laws. These laws include, but are not limited to, anti-kickback and self-referral law, civil false claims
act law, criminal false statement law, civil monetary penalty laws, exclusion law, and other civil, criminal, and administrative
laws. Health care laws, regulations, and guidance continuously evolve and are thereby subject to constant change.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Federal Anti-Kickback Statute, 42
U.S.C. &#167; 1320a-7b(b), among other things, prohibits the knowing and willful offer, payment, solicitation or receipt of any
form of remuneration, whether directly or indirectly and overtly or covertly in cash or in kind, in return for, or to induce the
referral of an individual for the:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 20.65pt">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">furnishing or arranging for the furnishing of items or services reimbursable in whole or in part under Medicare, Medicaid or other federal healthcare programs; or</span></td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;purchase, lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering of any item or service reimbursable in whole or in part under Medicare, Medicaid or other federal healthcare programs.</span></td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There are a number of narrow safe harbors
to the Federal Anti-Kickback Statute. Such safe harbors permit certain payments and business practices that, although they would
otherwise potentially implicate the Federal Anti-Kickback Statute, are not treated as an offense under the same if all of the requirements
of the specific applicable safe harbor are met. Actual knowledge of the statute or specific intent to violate it is not required
in order for a person or entity to have committed a violation.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Federal Anti-Kickback Statute applies
to certain arrangements with healthcare providers, product end users and other parties, including marketing arrangements and discounts
and other financial incentives offered in connection with the sales of our products. Regulatory authorities may determine that
certain marketing, pricing, or other activities violate the Federal Anti-Kickback Statute or other applicable laws. Noncompliance
with the Federal Anti-Kickback Statute can result in civil, administrative and/or criminal penalties, restrictions on the ability
to operate in certain jurisdictions, and exclusion from participation in Medicare, Medicaid or other federal healthcare programs.
In addition, non-compliance can result in the need to curtail and/or restructure operations. Any penalties, damages, fines, exclusions,
curtailment or restructuring of operations could adversely affect the ability to operate a business, financial condition, and results
of operations. A violation of the Federal Anti-Kickback Statute can serve as a false or fraudulent claim for purposes of the civil
False Claims Act and the civil monetary penalties statute.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal Health Insurance Portability and Accountability
Act of 1996 (&#8220;HIPAA&#8221;) among other things, enacted numerous provisions that prohibit knowingly and willfully executing, or
attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses,
representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program,
regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly
and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious
or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare
matters. These provisions include 18 U.S.C. &#167;&#167; 286, 287, 669, 1035, 1347, and 1518, all as described further below.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Ethics in Patient Referrals Act,
commonly known as the &#8220;Stark Law,&#8221; 42 U.S.C. &#167; 1395nn, prohibits a physician from making referrals for certain
&#8220;designated health services&#8221; payable by Medicare to an entity in which the physician or an immediate family member
of such physician has an ownership or investment interest or with which the physician has entered into a compensation arrangement,
unless a statutory exception applies. There are a number of exceptions to the Stark Law. Such exceptions permit certain payments
and arrangements that, although they would otherwise potentially implicate the Stark Law, are not treated as a violation under
the same if the requirements of the specific exceptions are met. Violation of the Stark Law could result in denial of payment,
disgorgement of reimbursements received under a noncompliance arrangement, civil penalties, damages and exclusion from Medicare
or other governmental programs. These requirements are highly technical and there can be no guarantee that regulatory authorities
will not determine or assert that arrangements are in violation of the Stark Law and do not otherwise meet applicable Stark Law
exceptions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal false statements statute,
42 U.S.C. &#167; 1320a-7b(a), prohibits knowingly and willfully falsifying, concealing, or omitting a material fact or making any
materially false statement in connection with the delivery of health care benefits, items, or services. Similarly, 18 U.S.C. &#167;
1035 prohibits a person or entity, in any matter involving a health care benefit program, from knowingly or willfully falsifying,
concealing, or covering up by any trick, scheme, or device a material fact; making any materially false, fictitious, or fraudulent
statements or representations; or making or using any materially false writing or document knowing the same to contain any materially
false, fictitious, or fraudulent statement or entry. In addition to criminal penalties, violation of these statutes may result
in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care
programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. &#167; 669 prohibits knowingly
and willfully embezzling, stealing, or otherwise without authority converting to the use of any person or entity other than the
rightful owner, or intentionally misapplying any of the moneys, funds, securities, premiums, credits, property, or other assets
of a health care benefit program. In addition to criminal penalties, violation of this statute may result in collateral administrative
sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The criminal health care fraud statute,
18 U.S.C. &#167; 1347, establishes criminal liability for whoever knowingly and willfully executes, or attempts to execute, a scheme
or artifice to defraud any health care benefit program, or to obtain, by means of false or fraudulent pretenses, representations,
or promises, any of the money or property owned by, or under the custody or control of, any health care benefit program, in connection
with the delivery of or payment for health care benefits, items, or services. In addition to criminal penalties, violation of this
statute may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other
federal health care programs. A person or entity need not have actual knowledge of this law or specific intent to commit a violation
of this law.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. &#167; 1518 establishes criminal
liability for whoever willfully prevents, obstructs, misleads, delays or attempts to prevent, obstruct, mislead, or delay the communication
of information or records relating to a violation of a Federal health care offense to a criminal investigator. In addition to criminal
penalties, violation of this statute may result in collateral administrative sanctions, including exclusion from participation
in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. &#167; 286 establishes criminal
liability for whoever enters into any agreement, combination, or conspiracy to defraud the United States, or any department or
agency thereof, by obtaining or aiding to obtain the payment or allowance of any false, fictitious or fraudulent claim. In addition
to criminal penalties, violation of this statute may result in collateral administrative sanctions, including exclusion from participation
in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. &#167; 287 establishes criminal
liability for whoever knowingly makes or presents a false, fictitious or fraudulent claim to the United States Government, including
any department or agency thereof. In addition to criminal penalties, violation of this statute may result in collateral administrative
sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Federal False Claims Act, 31 U.S.C.
&#167; 3729, et seq., provides, in part, that the federal government&#8212;or a private party on behalf of the government&#8212;may
bring a lawsuit against any person whom it believes has knowingly presented, or caused to be presented, a false or fraudulent claim
for payment, or who has made a false statement or used a false record to get a claim paid or to avoid, decrease or conceal an obligation
to pay money to the federal government or who has knowingly retained an overpayment. Knowledge under the Federal False Claims Act
means actual knowledge, deliberate indifference, or reckless disregard. In addition, amendments in 1986 to the Federal False Claims
Act have made it easier for private parties to bring whistleblower lawsuits against companies.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The civil monetary penalties law, 42
U.S.C. &#167; 1320a-7a, provides, in part, that the federal government may seek civil monetary penalties against any person who
presents or causes to be presented claims to a Federal health care program that the person knows or should know is for an item
or services that was not provided as claimed or is false or fraudulent, or the person has made a false statement or used a false
record to get a claim paid. The federal government may also seek civil monetary penalties for a wide variety of other conduct,
including offering remuneration to influence a Medicare or Medicaid beneficiary&#8217;s selection of providers and violations of
the Federal Anti-Kickback Statute.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Violations of the Federal False Claims
Act and/or the Civil Monetary Penalties Law can result in penalties ranging from $12,537 to $25,076 for each false claim violation
of the Federal False Claims Act and varying amounts based on the type of violation of the Civil Monetary Penalties Law, plus up
to three times the amount of damages that the federal government sustained. In addition, the federal government may also seek exclusion
from participation in all federal health care programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">42 U.S.C. Section 1320a-7 provides that
individuals and entities can be mandatorily or permissively excluded from participation in federal health care programs. The grounds
for mandatory exclusion include, but are not limited to, conviction for a criminal offense related to the delivery of an item or
service reimbursed under a federal or state health care program, and a conviction related to health care fraud. The grounds for
permissive exclusion include, but are not limited to, criminal offenses relating to fraud inside and outside of health care, convictions
related to obstruction of an investigation or audit, and/or failure to disclose certain required information. Exclusion from federal
health care programs&#8212;whether mandatory or permissive&#8212;may mean that our customers may not be able to get reimbursed
by federal and/or state health care programs for use or dispensing of our products .</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>State Fraud and Abuse Provisions</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Many states have also adopted some form
of anti-kickback and anti-referral laws and false claims acts and civil monetary penalties and other fraud and abuse provisions
that apply regardless of payer, in addition to items and services reimbursed under Medicaid and other state programs. A determination
of liability under such laws could result in fines, penalties, and exclusion, as well as restrictions on the ability to operate
in these jurisdictions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Corporate liability can be present as
a result of the illegal activities of employees, representatives, contractors, collaborators, agents, subsidiaries, or affiliates,
even if they were not explicitly authorized. There can be no assurance that all employees, representatives, contractors, collaborators,
agents, subsidiaries or affiliates will comply with the foregoing laws at all times. Violation of the aforementioned and other
laws could result in whistleblower complaints, investigations, sanctions, settlements, prosecution, government oversight and reporting,
other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions
or other administrative remedies, suspension and/or debarment from contracting with certain governments or other persons, the loss
of privileges, reputational harm, contract damages, adverse media coverage and other collateral consequences. In addition, corporate
directors, officers, employees, and other representatives who engage in violations of these and other laws may face imprisonment,
fines, and penalties. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if a
company does not prevail in any possible civil or criminal litigation, business, financial condition, and results of operations
could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s
attention and resources and significant defense costs and other professional fees. Enforcement actions and sanctions could further
harm business, financial condition, and results of operations. Any of the consequences contained in this paragraph and section
could adversely affect the ability to operate the business, financial condition, and the results of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Sunshine Act</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Sunshine Act requires manufacturers of products reimbursed by Medicare, Medicaid or the Children&#8217;s Health Insurance Program
(&#8220;CHIP&#8221;) to collect and annually report detailed data to the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;)
regarding payments or other transfers of value to physicians,<span style="color: black"> certain other health care providers (such
as physicians assistants and nurse practitioners),</span> and teaching hospitals (&#8220;covered recipients&#8221;), as well as
any ownership or investment interest held by physicians and their immediate family members. The reporting data must be accompanied
by an attestation as to the accuracy of the data and failure to timely and accurately submit required information may result in
civil monetary penalties.</span></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Health Insurance Portability and
Accountability Act </i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Besides enacting the program integrity provisions described above, HIPAA, also
created a new set of privacy and security requirements. As amended by the Health Information Technology for Economic and Clinical Health
Act, and implementing regulations thereunder, HIPAA requires certain healthcare providers, health plans and healthcare clearinghouses
who conduct specified electronic healthcare transactions (&#8220;covered entities&#8221;), as well as their independent contractors and
agents who conduct certain activities involving protected health information on their behalf (&#8220;business associates&#8221;) to comply
with enumerated requirements relating to the privacy, security and transmission of protected health information. Failure to comply with
HIPAA can result in corrective action, as well as civil fines and penalties and government oversight. Among other changes, HITECH made
HIPAA security standards directly applicable to business associates, increased the tiered civil and criminal fines and penalties that
may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority
to file actions to enforce HIPAA. Further, the breach notification rule implemented under HITECH requires covered entities to notify affected
individuals, the U.S. Department of Health and Human Services Office of Civil Rights (&#8220;OCR&#8221;), the agency that enforces HIPAA,
and for breaches affecting more than 500 individuals, the media, of any breaches of unsecured protected health information. HIPAA does
not create a private right of action for individuals, though individuals may submit complaints related to HIPAA to OCR.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Legislative Activities Aimed at Controlling
Drug Costs </i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, there have been, and continue to be proposed and enacted
legislation at the federal and state levels designed to, among other things, bring more transparency to drug pricing, review the relationship
between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement
methodologies for drugs. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition
in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on
September 9, 2021, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing High
Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could
pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the Inflation Reduction Act
(&#8220;IRA&#8221;) passed on August 16, 2022. The IRA, among other things, (1) directs HHS to negotiate the price of certain highly-utilized
single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize
price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may
be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on
the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS
to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for
lowering drug costs for Medicare and Medicaid beneficiaries. We expect that additional U.S. federal healthcare reform measures will be
adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services,
which could result in reduced demand for our product candidates or additional pricing pressures.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i></i></p>

<!-- Field: Page; Sequence: 27; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i></i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically, a significant portion
of our operating expenses has related to research and development. See our Consolidated Financial Statements contained elsewhere
in this Annual Report for costs and expenses related to research and development, and other financial information for fiscal years
2022, 2021 and 2020.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Scientific Advisors </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">We are advised
by scientists and physicians with experience relevant to our Company and our product candidates.</span> Our scientific advisors
include clinicians and scientists who are affiliated with a number of highly regarded medical institutions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employees</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have approximately thirty-eight full-time
employees, and we retain several independent contractors on a regular or as-needed basis. We believe that we have good relations with
our employees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Available Information</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">Our internet
website address is </span><span style="text-underline-style: none; color: windowtext">www.anavex.com</span><span style="color: black">.
Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed
or furnished pursuant to section 13(a) or 15(d) of the Exchange Act are available free of charge through our website. We include
our website address in this report only as an inactive textual reference and do not intend it to be an active link to our website.
The contents of our website are not incorporated into this report.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_003"></span>ITEM 1A. RISK
FACTORS</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to other information in
this Annual Report on Form 10-K, the following risk factors should be carefully considered in evaluating our business because such
factors may have a significant impact on our business, operating results, liquidity and financial condition. As a result of the
risk factors set forth below, actual results could differ materially from those projected in any forward-looking statements. Additional
risks and uncertainties not presently known to us, or that we currently consider to be immaterial, may also impact our business,
operating results, liquidity and financial condition. If any such risks occur, our business, operating results, liquidity and financial
condition could be materially affected in an adverse manner. Under such circumstances, the trading price of our securities could
decline, and you may lose all or part of your investment.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Company</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have had a history of losses
and no revenue, which raises a risk regarding our ability to continue as a going concern in the future.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Since inception through September 30,
2022, we have accumulated a deficit of approximately $246 million. We can offer no assurance that we will ever operate profitably
or that we will generate positive cash flow in the future. To date, we have not generated any revenues from our operations. Our
history of losses and no revenues creates a greater risk of our continued ability to continue as a going concern in the future.
As a result, our management expects the business to continue to experience negative cash flows for the foreseeable future and cannot
predict when, if ever, our business might become profitable. We will need to raise additional funds, and such funds may not be
available on commercially acceptable terms, if at all. If we are unable to raise funds on acceptable terms, we may not be able
to execute our business plan, take advantage of future opportunities, or respond to competitive pressures or unanticipated requirements.
This may seriously harm our business, financial condition and results of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are an early clinical stage pharmaceutical
research and development company and may never be able to successfully develop marketable products or generate any revenue. We
have a very limited relevant operating history upon which an evaluation of our performance and prospects can be made. There is
no assurance that our future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease
operations.</i></b></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an early clinical stage company and
have not generated any revenues to date and have no operating history. Moreover, we cannot be certain that our research and development
efforts will be successful or, if successful, that our potential drug compounds will ever be approved for sales to pharmaceutical
companies or generate commercial revenues. We have no relevant operating history upon which an evaluation of our performance and
prospects can be made. We are subject to all of the business risks associated with a new enterprise, including, but not limited
to, risks of unforeseen capital requirements, failure of potential drug compounds either in non-clinical testing or in clinical
trials, failure to establish business relationships and competitive disadvantages against larger and more established companies.
If we fail to become profitable, we may suspend or cease operations.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We will need additional funding
and may be unable to raise additional capital when needed, which would force us to delay, reduce or eliminate our research and
development activities.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have funded our operations primarily
through private placement of our equity securities, grants and our &#8220;at the market offering&#8221; in connection with an Amended
and Restated Sales Agreement, dated May 1, 2020, with Cantor Fitzgerald &amp; Co. and SVB Leerink LLC (the &#8220;Sales Agents&#8221;),
pursuant to which we may offer and sell shares of common stock registered under an effective registration statement from time to
time through the Sales Agents.<span style="font-family: Arial, Helvetica, Sans-Serif"> </span>We will need to raise additional
funding and the current economic conditions may have a negative impact on our ability to raise additional needed capital on terms
that are favorable to our Company or at all. We may not be able to generate significant revenues for several years, if at all.
Until we can generate significant revenues, if ever, we expect to satisfy our future cash needs through equity or debt financing.
We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available,
we may be required to delay, reduce the scope of, or eliminate one or more of our research and development activities.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Business</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Even if we are able to develop
our potential drug compounds, we may not be able to receive regulatory approval, or if approved, we may not be able to generate
significant revenues or successfully commercialize our products, which will adversely affect our financial results and financial
condition and we will have to delay or terminate some or all of our research and development plans which may force us to cease
operations.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of our potential drug compounds are exclusively
focused on SIGMAR1 which has not previously been the subject of any approved drug products and will require extensive additional
research and development, including non-clinical testing and clinical trials, as well as regulatory approvals, before we can market
them. In particular, human therapeutic products are subject to rigorous non-clinical and clinical testing and other approval procedures
of the FDA and similar regulatory authorities in other countries. Various federal statutes and regulations also govern or influence
testing, manufacturing, safety, labeling, storage, and record-keeping related to such products and their marketing. We cannot predict
if or when any of the potential drug compounds we intend to develop will be approved for marketing. There are many reasons that
we may fail in our efforts to develop our potential drug compounds. These include:</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility that non-clinical
    testing or clinical trials may show that our potential drug compounds are ineffective and/or cause harmful side effects;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators may not authorize
    us to commence or continue a clinical trial or may impose a clinical hold or may limit the conduct of a clinical trial through the
    imposition of a partial clinical hold;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of patients
    required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be
    slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or the duration
    of these clinical trials may be longer than we anticipate;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 29; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our third-party contractors,
    including investigators, may fail to meet their contractual obligations to us in a timely manner, or at all, or may fail to comply
    with regulatory requirements;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our potential drug compounds
    may prove to be too expensive to manufacture or administer to patients;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our potential drug compounds
    may fail to receive necessary regulatory approvals from the United States Food and Drug Administration or foreign regulatory authorities
    in a timely manner, or at all;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even if our potential drug
    compounds are approved, we may not be able to produce them in commercial quantities or at reasonable costs;</span></td></tr>
  </table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even if our potential drug
    compounds are approved, they may not achieve commercial acceptance;</span></td></tr>
  </table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory or governmental
    authorities may apply restrictions to any of our potential drug compounds, which could adversely affect their commercial success;
    and</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proprietary rights
    of other parties may prevent us or our potential collaborative partners from marketing our potential drug compounds.</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If we fail to develop our potential
drug compounds, our financial results and financial condition will be adversely affected, we will have to delay or terminate some
or all of our research and development plans and may be forced to cease operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our research and development plans
will require substantial additional future funding which could impact our operations and financial condition. </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">It will take several years before we
can develop potentially marketable products, if at all. Our research and development plans will require substantial additional
capital, arising from costs to:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">conduct research, non-clinical testing and human clinical trials;</span></td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish pilot scale and
    commercial scale manufacturing processes and facilities; and</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish and develop quality
    control, regulatory, marketing, sales, finance and administrative capabilities to support these programs.</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our future operating and capital needs
will depend on many factors, including:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the pace of scientific
    progress in our research and development programs and the magnitude of these programs;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the scope and results of pre-clinical testing and human clinical trials;</span></td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the time and costs involved
    in obtaining regulatory approvals;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the time and costs involved
    in preparing, filing, prosecuting, securing, maintaining and enforcing patents;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing technological
    and market developments;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish
    additional collaborations;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our existing
    collaborations;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of manufacturing
    scale -up; and</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our
    commercialization activities.</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We base our outlook regarding the need
for funds on many uncertain variables. Such uncertainties include the success of our research initiatives, regulatory approvals,
the timing of events outside our direct control such as negotiations with potential strategic partners and other factors. Any of
these uncertain events can significantly change our cash requirements as they determine such one-time events as the receipt or
payment of major milestones and other payments.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Additional funds may be required to
support our operations and if we are unable to obtain them on favorable terms, we may be required to cease or reduce certain further
research and development programs of our drug product platform, sell some or all our intellectual property, merge with another
entity or scale back operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>If we or any companion diagnostic collaborator
of ours are unable to successfully develop and obtain regulatory approval for companion diagnostic tests for our drug candidates,
or experience significant delays in doing so, we may not realize the commercial potential of our drug candidates.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We analyze genomic data from clinical trials
to identify biomarkers, which we use in the analysis of our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Identification of these patients will
require the use and development of companion diagnostics. According to the FDA&#8217;s 2014 guidance document on In Vitro Companion
Diagnostic Devices, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device
could be essential for the safe and effective use of the corresponding therapeutic product, the premarket application for the companion
diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">We do not have experience or capabilities
in developing or commercializing diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical
validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes.
Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic
for a drug candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the
companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for,
manufacturing and commercializing companion diagnostics similar to those we face with respect to our drug candidates, including
issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate
quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for our drug
candidates, or experience delays in doing so, the development of these drug candidates may be adversely affected, these drug candidates
may not obtain marketing approval, and we may not realize the full commercial potential of any of these therapeutics that have
or may obtain marketing approval. We may not be able to enter into arrangements with another diagnostic company to develop and
obtain regulatory approval for of an alternative diagnostic test for use in connection with the development and commercialization
of our drug candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or
commercialization of our therapeutic candidates or therapeutics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Companion diagnostics are subject to
regulation by the FDA and comparable foreign regulatory authorities as medical devices and will likely require separate regulatory
approval prior to commercialization. If we or third parties are unable to successfully develop companion diagnostics for our drug
candidates, or experience delays in doing so:</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                                                                                                                development
                                                                                                                                of
                                                                                                                                these
                                                                                                                                drug
                                                                                                                                candidates
                                                                                                                                may
                                                                                                                                be
                                                                                                                                delayed
                                                                                                                                because
                                                                                                                                it
                                                                                                                                may
                                                                                                                                be
                                                                                                                                difficult
                                                                                                                                to
                                                                                                                                identify
                                                                                                                                patients
                                                                                                                                for
                                                                                                                                enrollment
                                                                                                                                in
                                                                                                                                our
                                                                                                                                clinical
                                                                                                                                trials
                                                                                                                                in
                                                                                                                                a
                                                                                                                                timely
                                                                                                                                manner;</span></td></tr>
</table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">these
                                                                                                                                drug
                                                                                                                                candidates
                                                                                                                                may
                                                                                                                                not
                                                                                                                                receive
                                                                                                                                marketing
                                                                                                                                approval
                                                                                                                                if
                                                                                                                                their
                                                                                                                                safe
                                                                                                                                and
                                                                                                                                effective
                                                                                                                                use
                                                                                                                                depends
                                                                                                                                on
                                                                                                                                a
                                                                                                                                companion
                                                                                                                                diagnostic;
                                                                                                                                and</span></td></tr>
</table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt">&#9679;</td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
                                                                                                                                may
                                                                                                                                not
                                                                                                                                realize
                                                                                                                                the
                                                                                                                                full
                                                                                                                                commercial
                                                                                                                                potential
                                                                                                                                of
                                                                                                                                these
                                                                                                                                drug
                                                                                                                                candidates
                                                                                                                                that
                                                                                                                                receive
                                                                                                                                marketing
                                                                                                                                approval
                                                                                                                                if,
                                                                                                                                among
                                                                                                                                other
                                                                                                                                reasons,
                                                                                                                                we
                                                                                                                                are
                                                                                                                                unable
                                                                                                                                to
                                                                                                                                appropriately
                                                                                                                                identify
                                                                                                                                patients
                                                                                                                                or
                                                                                                                                types
                                                                                                                                of
                                                                                                                                tumors
                                                                                                                                targeted
                                                                                                                                by
                                                                                                                                these
                                                                                                                                drug
                                                                                                                                candidates.</span></td></tr></table>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Even if our drug candidates and any
associated companion diagnostics are approved for marketing, the need for companion diagnostics may slow or limit adoption of our
drug candidates. Our drug candidates may be perceived negatively compared to alternative treatments that do not require the use
of companion diagnostics, either due to the additional cost of the companion diagnostic or the need to complete additional prior
to administering our drug candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of these events were to occur, our business
and growth prospects would be harmed materially.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/104% Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20"><b><i>All but one of our
clinical trials to date have been conducted outside<span style="letter-spacing: 0.05pt"> </span>the United States,<span style="letter-spacing: 0.05pt">
</span>and the FDA<span style="letter-spacing: -0.05pt"> </span>and other<span style="letter-spacing: 0.05pt"> </span>foreign<span style="letter-spacing: 0.05pt">
</span>regulatory<span style="letter-spacing: 0.05pt"> </span>authorities<span style="letter-spacing: 0.1pt"> </span>may not accept<span style="letter-spacing: 0.05pt">
</span>data from<span style="letter-spacing: 0.05pt"> </span>such trials.</i></b></p>

<p style="font: 6pt/6pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/104% Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20">The acceptance<span style="letter-spacing: 0.1pt">
</span>of study<span style="letter-spacing: 0.05pt"> </span>data<span style="letter-spacing: 0.05pt"> </span>from<span style="letter-spacing: 0.05pt">
</span>clinical<span style="letter-spacing: 0.1pt"> </span>trials<span style="letter-spacing: 0.1pt"> </span>conducted<span style="letter-spacing: 0.05pt">
</span>outside<span style="letter-spacing: 0.05pt"> </span>the<span style="letter-spacing: 0.05pt"> </span>United<span style="letter-spacing: 0.05pt">
</span>States<span style="letter-spacing: 0.05pt"> </span>by the FDA<span style="letter-spacing: -0.05pt"> </span>may<span style="letter-spacing: 0.05pt">
</span>be subject<span style="letter-spacing: 0.05pt"> </span>to certain<span style="letter-spacing: 0.1pt"> </span>conditions<span style="letter-spacing: 0.1pt">
</span>or may<span style="letter-spacing: 0.05pt"> </span>not be accepted<span style="letter-spacing: 0.05pt"> </span>at all.<span style="letter-spacing: 0.05pt">
</span>In cases<span style="letter-spacing: 0.05pt"> </span>where data<span style="letter-spacing: 0.05pt"> </span>from<span style="letter-spacing: 0.05pt">
</span>foreign<span style="letter-spacing: 0.05pt"> </span>clinical<span style="letter-spacing: 0.1pt"> </span>trials<span style="letter-spacing: 0.1pt">
</span>are<span style="letter-spacing: 0.05pt"> </span>intended<span style="letter-spacing: 0.05pt"> </span>to serve<span style="letter-spacing: 0.05pt">
</span>as the<span style="letter-spacing: 0.05pt"> </span>sole<span style="letter-spacing: 0.05pt"> </span>basis<span style="letter-spacing: 0.05pt">
</span>for<span style="letter-spacing: 0.05pt"> </span>regulatory<span style="letter-spacing: 0.1pt"> </span>approval in the<span style="letter-spacing: 0.05pt">
</span>United<span style="letter-spacing: 0.05pt"> </span>States,<span style="letter-spacing: 0.05pt"> </span>the<span style="letter-spacing: 0.05pt">
</span>FDA<span style="letter-spacing: -0.05pt"> </span>will<span style="letter-spacing: 0.05pt"> </span>generally<span style="letter-spacing: 0.1pt">
</span>not approve<span style="letter-spacing: 0.05pt"> </span>the<span style="letter-spacing: 0.05pt"> </span>application<span style="letter-spacing: 0.1pt">
</span>on the<span style="letter-spacing: 0.05pt"> </span>basis<span style="letter-spacing: 0.05pt"> </span>of foreign<span style="letter-spacing: 0.05pt">
</span>data<span style="letter-spacing: 0.05pt"> </span>alone<span style="letter-spacing: 0.05pt"> </span>unless (i)<span style="letter-spacing: 0.05pt">
</span>the<span style="letter-spacing: 0.05pt"> </span>data<span style="letter-spacing: 0.05pt"> </span>are<span style="letter-spacing: 0.05pt">
</span>applicable<span style="letter-spacing: 0.1pt"> </span>to the<span style="letter-spacing: 0.05pt"> </span>United<span style="letter-spacing: 0.05pt">
</span>States<span style="letter-spacing: 0.05pt"> </span>population<span style="letter-spacing: 0.05pt"> </span>and United<span style="letter-spacing: 0.05pt">
</span>States<span style="letter-spacing: 0.05pt"> </span>medical<span style="letter-spacing: 0.1pt"> </span>practice;<span style="letter-spacing: 0.1pt">
</span>(ii)<span style="letter-spacing: 0.1pt"> </span>the<span style="letter-spacing: 0.05pt"> </span>trials<span style="letter-spacing: 0.1pt">
</span>were performed<span style="letter-spacing: 0.1pt"> </span>by clinical<span style="letter-spacing: 0.1pt"> </span>investigators<span style="letter-spacing: 0.15pt">
</span>of recognized<span style="letter-spacing: 0.1pt"> </span>competence<span style="letter-spacing: 0.1pt"> </span>and pursuant<span style="letter-spacing: 0.05pt">
</span>to good clinical<span style="letter-spacing: 0.1pt"> </span>practice<span style="letter-spacing: 0.1pt"> </span>regulations;
and (iii)<span style="letter-spacing: 0.1pt"> </span>the<span style="letter-spacing: 0.05pt"> </span>data<span style="letter-spacing: 0.05pt">
</span>may<span style="letter-spacing: 0.05pt"> </span>be considered<span style="letter-spacing: 0.1pt"> </span>valid<span style="letter-spacing: 0.05pt">
</span>without<span style="letter-spacing: 0.05pt"> </span>the<span style="letter-spacing: 0.05pt"> </span>need for<span style="letter-spacing: 0.05pt">
</span>an on-site<span style="letter-spacing: 0.1pt"> </span>inspection<span style="letter-spacing: 0.1pt"> </span>by the<span style="letter-spacing: 0.05pt">
</span>FDA,<span style="letter-spacing: -0.05pt"> </span>or if<span style="letter-spacing: 0.05pt"> </span>the<span style="letter-spacing: 0.05pt">
</span>FDA considers<span style="letter-spacing: 0.1pt"> </span>such inspection<span style="letter-spacing: 0.1pt"> </span>to be
necessary,<span style="letter-spacing: 0.1pt"> </span>the<span style="letter-spacing: 0.05pt"> </span>FDA<span style="letter-spacing: -0.05pt">
</span>is<span style="letter-spacing: 0.05pt"> </span>able<span style="letter-spacing: 0.05pt"> </span>to validate<span style="letter-spacing: 0.1pt">
</span>the<span style="letter-spacing: 0.05pt"> </span>data<span style="letter-spacing: 0.05pt"> </span>through<span style="letter-spacing: 0.05pt">
</span>an on-site<span style="letter-spacing: 0.1pt"> </span>inspection<span style="letter-spacing: 0.1pt"> </span>or other<span style="letter-spacing: 0.05pt">
</span>appropriate<span style="letter-spacing: 0.1pt"> </span>means.<span style="letter-spacing: 0.05pt"> </span>Many foreign<span style="letter-spacing: 0.05pt">
</span>regulatory<span style="letter-spacing: 0.1pt"> </span>bodies<span style="letter-spacing: 0.05pt"> </span>have similar<span style="letter-spacing: 0.1pt">
</span>approval<span style="letter-spacing: 0.05pt"> </span>requirements.<span style="letter-spacing: 0.15pt"> </span>In addition,<span style="letter-spacing: 0.05pt">
</span>such foreign<span style="letter-spacing: 0.05pt"> </span>trials<span style="letter-spacing: 0.1pt"> </span>would be subject<span style="letter-spacing: 0.05pt">
</span>to the<span style="letter-spacing: 0.05pt"> </span>applicable<span style="letter-spacing: 0.1pt"> </span>local<span style="letter-spacing: 0.05pt">
</span>laws of the<span style="letter-spacing: 0.05pt"> </span>foreign<span style="letter-spacing: 0.05pt"> </span>jurisdictions<span style="letter-spacing: 0.15pt">
</span>where the<span style="letter-spacing: 0.05pt"> </span>trials<span style="letter-spacing: 0.1pt"> </span>are conducted.<span style="letter-spacing: 0.05pt">
</span>There<span style="letter-spacing: 0.05pt"> </span>can be no assurance<span style="letter-spacing: 0.1pt"> </span>that<span style="letter-spacing: 0.05pt">
</span>the<span style="letter-spacing: 0.05pt"> </span>FDA<span style="letter-spacing: -0.05pt"> </span>or any other<span style="letter-spacing: 0.05pt">
</span>foreign<span style="letter-spacing: 0.05pt"> </span>regulatory<span style="letter-spacing: 0.1pt"> </span>authority<span style="letter-spacing: 0.1pt">
</span>will<span style="letter-spacing: 0.05pt"> </span>accept<span style="letter-spacing: 0.05pt"> </span>data from<span style="letter-spacing: 0.05pt">
</span>trials<span style="letter-spacing: 0.1pt"> </span>conducted<span style="letter-spacing: 0.05pt"> </span>outside<span style="letter-spacing: 0.05pt">
</span>of the<span style="letter-spacing: 0.05pt"> </span>United<span style="letter-spacing: 0.05pt"> </span>States<span style="letter-spacing: 0.05pt">
</span>or the<span style="letter-spacing: 0.05pt"> </span>applicable<span style="letter-spacing: 0.1pt"> </span>jurisdiction.<span style="letter-spacing: 0.15pt">
</span>If<span style="letter-spacing: 0.05pt"> </span>the<span style="letter-spacing: 0.05pt"> </span>FDA<span style="letter-spacing: -0.05pt">
</span>or any comparable foreign<span style="letter-spacing: 0.05pt"> </span>regulatory<span style="letter-spacing: 0.1pt"> </span>authority<span style="letter-spacing: 0.1pt">
</span>does not accept<span style="letter-spacing: 0.05pt"> </span>such data,<span style="letter-spacing: 0.05pt"> </span>it<span style="letter-spacing: 0.05pt">
</span>would result<span style="letter-spacing: 0.1pt"> </span>in the<span style="letter-spacing: 0.05pt"> </span>need for<span style="letter-spacing: 0.05pt">
</span>additional<span style="letter-spacing: 0.1pt"> </span>trials, which would be costly<span style="letter-spacing: 0.05pt">
</span>and time-consuming<span style="letter-spacing: 0.15pt"> </span>and delay<span style="letter-spacing: 0.05pt"> </span>aspects<span style="letter-spacing: 0.05pt">
</span>of our business<span style="letter-spacing: 0.05pt"> </span>plan,<span style="letter-spacing: 0.05pt"> </span>and which
may<span style="letter-spacing: 0.05pt"> </span>result<span style="letter-spacing: 0.1pt"> </span>in our product candidates<span style="letter-spacing: 0.1pt">
</span>not receiving<span style="letter-spacing: 0.1pt"> </span>approval<span style="letter-spacing: 0.05pt"> </span>or clearance<span style="letter-spacing: 0.1pt">
</span>for<span style="letter-spacing: 0.05pt"> </span>commercialization<span style="letter-spacing: 0.2pt"> </span>in the<span style="letter-spacing: 0.05pt">
</span>applicable<span style="letter-spacing: 0.1pt"> </span>jurisdiction.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have received Fast Track designation
for one of our compounds and may seek such designation or breakthrough therapy and priority review for other compounds in the future.
Fast Track designation or breakthrough therapy designation may not actually lead to a faster FDA review and approval process.</i></b></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For some of our compounds, including
ANAVEX<sup>&#174;</sup>2-73, we hope to benefit from the FDA&#8217;s fast track and priority review programs. In February 2020,
the FDA granted Fast Track designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett
syndrome. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority
review and the ability to submit a rolling application for regulatory review. Fast Track designation applies to both the product
candidate and the specific indication for which it is being studied. If any of our compounds receive Fast Track designation but
do not continue to meet the criteria for Fast Track designation, or if our clinical trials are delayed, suspended or terminated,
or put on clinical hold due to unexpected adverse events or issues with clinical supply, we will not receive the benefits associated
with the Fast Track program. Furthermore, Fast Track designation does not change the standards for approval. The receipt of Fast
Track designation for a compound may not result in a faster development or regulatory review or approval process compared to products
considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if
any product candidate qualifies for Fast Track designation, the FDA may later decide that the product candidates no longer meet
the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Fast Track designation
alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under FDA policies, a compound is eligible
for priority review, or review within a six-month time frame from the time a complete NDA is accepted for filing, if the compound
provides a significant improvement compared to marketed drugs in the treatment, diagnosis or prevention of a disease. The FDA determines
whether a drug qualifies for Priority Review after an NDA for such drug is submitted to the FDA. Therefore, until NDAs are submitted
for our compounds, we cannot be assured that they will be granted Priority Review. Additionally, even if Priority Review is granted
for one of our compounds, the FDA does not always meet its six-month PDUFA goal date for Priority Review and the review process
is often extended by FDA requests for additional information or clarification.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We may seek Breakthrough Therapy designation
for one or more of our current or future compounds. Designation as a Breakthrough Therapy is largely within the discretion of the
FDA. Accordingly, even if we believe that a compound meets the criteria for designation as a Breakthrough Therapy, the FDA may
disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for
a product candidate may not result in a faster development process, review or approval compared to candidate products considered
for approval under&#160;non-expedited&#160;FDA review procedures and does not assure ultimate approval by the FDA. In addition,
even if one or more compounds qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the
conditions for qualification and revoke the designation.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Fast track or breakthrough therapy designation
for our compounds may not actually lead to a faster review process, and a delay in the review process or in the approval of our
compounds will delay revenue from their potential sales and will increase the capital necessary to fund these compound development
programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>We have received orphan drug designation for several
of our compounds, but we may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Orphan Drug Act, the FDA may
grant orphan designation to a drug intended to treat a rare disease or condition or for which there is no reasonable expectation
that the cost of developing and making available in the United States a drug for a disease or condition will be recovered from
sales in the United States for that drug. If a product that has orphan drug designation subsequently receives the first FDA approval
for the indication for which it has such designation, the product is entitled to orphan product exclusivity, which means that the
FDA may not approve any other applications, including a full NDA, to market the same drug or biologic for the same indication for
seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have received orphan drug designation
for several of our compounds, but we may not be able to obtain or maintain orphan drug exclusivity in the United States for hose
compounds. We may not be the first to obtain marketing approval of any compound for which we have obtained orphan drug designation
for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition,
exclusive marketing rights in the United States may be limited if we seek FDA marketing approval for an indication broader than
the orphan designated indication. Additionally, any compound with orphan drug designation may lose such designation if the FDA
later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient
quantities of the product to meet the needs of patients with the rare disease or condition. Even after an orphan drug is approved,
the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the
later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.&#160;In
addition, others may obtain orphan drug exclusivity for products addressing the same diseases or conditions as products we are
developing, thus limiting our ability to compete in the markets addressing such diseases or conditions for a significant period
of time.<b>&#160;</b><span style="color: black; background-color: white">Orphan drug designation neither shortens the development
time or regulatory review time of a drug nor gives the product candidate any advantage in the regulatory review or approval process
or entitles the product candidate to priority review.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to demonstrate efficacy
in our non-clinical studies and clinical trials our future business prospects, financial condition and operating results will be
materially adversely affected.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The success of our research and development
efforts will be greatly dependent upon our ability to demonstrate potential drug compound efficacy in non-clinical studies, as
well as in clinical trials. Non-clinical studies involve testing potential drug compounds in appropriate non-human disease models
to demonstrate efficacy and safety. Regulatory agencies evaluate these data carefully before they will approve clinical testing
in humans. If certain non-clinical data reveals potential safety issues or the results are inconsistent with an expectation of
the potential drug compound&#8217;s efficacy in humans, the regulatory agencies may require additional more rigorous testing before
allowing human clinical trials. This additional testing will increase program expenses and extend timelines. We may decide to suspend
further testing on our potential drug compounds if, in the judgment of our management and advisors, the non-clinical test results
do not support further development.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, success in non-clinical testing
and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results
of later clinical trials will replicate the results of prior clinical trials and non-clinical testing. The clinical trial process
may fail to demonstrate that our potential drug compounds are safe for humans and effective for indicated uses. This failure would
cause us to abandon a drug candidate and may delay development of other potential drug compounds. Any delay in, or termination
of, our non-clinical testing or clinical trials will delay the filing of an IND and NDA with the FDA or the equivalent applications
with pharmaceutical regulatory authorities outside the United States and, ultimately, our ability to commercialize our potential
drug compounds and generate product revenues. In addition, we expect that our early clinical trials will involve small patient
populations. Because of the small sample size, the results of these early clinical trials may not be indicative of future results.
Also, the IND process may be extremely costly and may substantially delay the development of our potential drug compounds. Moreover,
positive results of non-clinical tests will not necessarily indicate positive results in subsequent clinical trials.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Following successful non-clinical testing,
potential drug compounds will need to be tested in a clinical development program to provide data on safety and efficacy prior
to becoming eligible for product approval and licensure by regulatory agencies. From the first human trial through to regulatory
approval can take many years and 10-12 years is not unusual for certain compounds.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of our future clinical development
potential drug compounds become the subject of problems, our ability to sustain our development programs will become critically
compromised. For example, efficacy or safety concerns may arise, whether or not justified, that could lead to the suspension or
termination of our clinical programs. Examples of problems that could arise include, among others:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy or safety concerns
    with the potential drug compounds, even if not justified;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing difficulties
    or concerns;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory proceedings
    subjecting the potential drug compounds to potential recall;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity affecting doctor
    prescription or patient use of the potential drug compounds;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pressure from competitive
    products; or</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of more effective
    treatments.</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Each clinical phase is designed to test
attributes of the drug and problems that might result in the termination of the entire clinical plan can be revealed at any time
throughout the overall clinical program. The failure to demonstrate efficacy in our clinical trials would have a material adverse
effect on our future business prospects, financial condition and operating results.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we do not obtain the support
of qualified scientific collaborators, our revenue, growth and profitability will likely be limited, which would have a material
adverse effect on our business.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We will need to establish relationships
with leading scientists and research institutions. We believe that such relationships are pivotal to establishing products using
our technologies as a standard of care for various indications. Additionally, although in discussion, there is no assurance that
our current research partners will continue to work with us or that we will be able to attract additional research partners. If
we are not able to establish scientific relationships to assist in our research and development, we may not be able to successfully
develop our potential drug compounds. If this happens, our business will be adversely affected.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to develop,
market or generate sales of our products to the extent anticipated. Our business may fail and investors could lose all their investment
in our Company.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Assuming that we are successful in developing
our potential drug compounds and receiving regulatory clearances to market our products, our ability to successfully penetrate
the market and generate sales of those products may be limited by a number of factors, including the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our competitors receive
    regulatory approvals for and begin marketing similar products in the United States, the European Union, Japan and other territories
    before we do, greater awareness of their products as compared to ours will cause our competitive position to suffer;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information from our competitors
    or the academic community indicating that current products or new products are more effective or offer compelling other benefits
    than our future products could impede our market penetration or decrease our future market share; and</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 20.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The pricing and reimbursement
    environment for our future products, as well as pricing and reimbursement decisions by our competitors and by payers, may have an
    effect on our revenues.</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If this happens, our business will be
adversely affected.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>None of our potential drug compounds
may reach the commercial market for a number of reasons and our business may fail.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Successful research and development
of pharmaceutical products is high risk. Most products and development candidates fail to reach the market. Our success depends
on the discovery of new drug compounds that we can commercialize. It is possible that our products may never reach the market for
a number of reasons. They may be found ineffective or may cause harmful side-effects during non-clinical testing or clinical trials
or fail to receive necessary regulatory approvals. We may find that certain products cannot be manufactured at a commercial scale
and, therefore, they may not be economical to produce. Our potential products could also fail to achieve market acceptance or be
precluded from commercialization by proprietary rights of third parties. Our patents, patent applications, trademarks and other
intellectual property may be challenged, and this may delay or prohibit us from effectively commercializing our products. Furthermore,
we do not expect our potential drug compounds to be commercially available for a number of years, if at all. If none of our potential
drug compounds reach the commercial market, our business will likely fail and investors will lose all of their investment in our
Company. If this happens, our business will be adversely affected.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If our competitors succeed in
developing products and technologies faster or that are more effective or with a better profile than our own, or if scientific
developments change our understanding of the potential scope and utility of our potential products, then our technologies and future
products may be rendered undesirable or obsolete.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We face significant competition from
industry participants that are pursuing technologies in similar disease states to those that we are pursuing and are developing
pharmaceutical products that are competitive with our products. Nearly all of our industry competitors have greater capital resources,
larger overall research and development staffs and facilities, and a longer history in drug discovery and development, obtaining
regulatory approval and pharmaceutical product manufacturing and marketing than we do. With these additional resources, our competitors
may be able to respond to the rapid and significant technological changes in the biotechnology and pharmaceutical industries faster
than we can. Our future success will depend in large part on our ability to maintain a competitive position with respect to these
technologies. Rapid technological development, as well as new scientific developments, may result in our products becoming obsolete
before we can recover any of the expenses incurred to develop them. For example, changes in our understanding of the appropriate
population of patients who should be treated with a targeted therapy like we are developing may limit the drug&#8217;s market potential
if it is subsequently demonstrated that only certain subsets of patients should be treated with the targeted therapy.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have advanced our research and development
efforts on the treatment of neurodegenerative and central nervous system, or CNS, disorders, a field that has seen very limited success
in product development.</i></b></p>

<p style="font: 10pt ArialMT,sans-serif; margin: 0; background-color: white; color: #222222">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have advanced our research
and development efforts on addressing neurodegenerative, neurodevelopmental and CNS disorders. Collectively, efforts by pharmaceutical
companies in the field of neurodegenerative,&#160;neurodevelopmental&#160;and CNS disorders have seen very limited successes in product
development. The development of neurodegenerative and CNS therapies presents unique challenges, including an imperfect understanding of
the biology, the presence of the blood brain barrier, or BBB, that can restrict the flow of drugs to the brain, a frequent lack of translatability
of preclinical study results in subsequent clinical trials and dose selection, and the product candidate having an effect that may be
too small to be detected using the outcome measures selected in clinical trials or if the outcomes measured do not reach statistical significance.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our reliance on third parties, such as
university laboratories, contract manufacturing organizations and contract or clinical research organizations, may result in delays
in completing, or a failure to complete, non-clinical testing or clinical trials if they fail to perform under our agreements with
them or non-compliance with regulations.</i></b></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the course of product development, we may
engage university laboratories, other biotechnology companies or contract or clinical manufacturing organizations to manufacture
drug material for us to be used in non-clinical and clinical testing and contract research organizations to conduct and manage
non-clinical studies and clinical trials. If we engage these organizations to help us with our non-clinical and clinical programs,
many important aspects of this process have been and will be out of our direct control. If any of these organizations we may engage
in the future fail to perform their obligations under our agreements with them or fail to perform non-clinical testing and/or clinical
trials in a satisfactory manner, we may face delays in completing our clinical trials, as well as commercialization of any of our
potential drug compounds. Furthermore, any loss or delay in obtaining contracts with such entities may also delay the completion
of our clinical trials, regulatory filings and the potential market approval of our potential drug compounds.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, any of these third parties may
engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. Misconduct
by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that
violate the regulations of any regulatory authorities, including those laws requiring the reporting of true, complete and accurate
information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that
require the reporting of financial information or data accurately. It is not always possible to identify and deter misconduct by
employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming
from a failure to comply with these laws or regulations.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to compete successfully
with respect to partnering, licensing, mergers, acquisitions, joint venture and other collaboration opportunities, we may be limited
in our ability to research and develop our potential drug compounds.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors compete with us to attract
established biotechnology and pharmaceutical companies or organizations for partnering, licensing, mergers, acquisitions, joint
ventures or other collaborations. Collaborations include contracting with academic research institutions for the performance of
specific scientific testing. If our competitors successfully enter into partnering arrangements or license agreements with academic
research institutions, we will then be precluded from pursuing those specific opportunities. Since each of these opportunities
is unique, we may not be able to find a substitute. Other companies have already begun many drug development programs, which may
target diseases that we are also targeting, and have already entered into partnering and licensing arrangements with academic research
institutions, reducing the pool of available opportunities.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Universities and public and private
research institutions also compete with us. While these organizations primarily have educational or basic research objectives,
they may develop proprietary technology and acquire patent applications and patents that we may need for the development of our
potential drug compounds. In some instances, we will attempt to license this proprietary technology, if available. These licenses
may not be available to us on acceptable terms, if at all. If we are unable to compete successfully with respect to acquisitions,
joint venture and other collaboration opportunities, we may be limited in our ability to develop new products.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The use of any of our products
in clinical trials may expose us to liability claims, which may cost us significant amounts of money to defend against or pay out,
causing our business to suffer.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The nature of our business exposes us
to potential liability risks inherent in the testing, manufacturing and marketing of our products. We currently have one drug compound
in clinical trials, however, when any of our products enter clinical trials or become marketed products, they could potentially
harm people or allegedly harm people possibly subjecting us to costly and damaging product liability claims. Some of the patients
who participate in clinical trials are already ill when they enter a trial or may intentionally or unintentionally fail to meet
the exclusion criteria. The waivers we obtain may not be enforceable and may not protect us from liability or the costs of product
liability litigation. Although we intend to obtain product liability insurance, which we believe is adequate, we are subject to
the risk that our insurance will not be sufficient to cover claims. The insurance costs along with the defense or payment of liabilities
above the amount of coverage could cost us significant amounts of money and management distraction from other elements of the business,
causing our business to suffer.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to safeguard
against security breaches with respect to our information systems, our business may be adversely affected.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the course of our business, we gather,
transmit and retain confidential information through our information systems. Although we endeavor to protect confidential information
through the implementation of security technologies, processes and procedures, it is possible that an individual or group could
defeat security measures and access sensitive information about our business and employees. Any misappropriation, loss or other
unauthorized disclosure of confidential information gathered, stored or used by us could have a material impact on the operation
of our business, including damaging our reputation with our employees, third parties and investors. We could also incur significant
costs implementing additional security measures and organizational changes, implementing additional protection technologies, training
employees or engaging consultants. In addition, we could incur increased litigation as a result of any potential cyber-security
breach. We are not aware that we have experienced any material misappropriation, loss or other unauthorized disclosure of confidential
or personally identifiable information as a result of a cyber-security breach or other act, however, a cyber-security breach or
other act and/or disruption to our information technology systems could have a material adverse effect on our business, prospects,
financial condition or results of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Even if we receive regulatory
approval for one or more compounds, we will be subject to continuing regulatory obligations and ongoing regulatory review, which
may result in significant additional expense. Additionally, our compounds, if approved, could be subject to labeling and other
restrictions on marketing or withdrawal from the market, and we may be subject to penalties, if we fail to comply with regulatory
requirements or if we experience unanticipated problems with our compounds, when and if any of them are approved. </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 36; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Following potential approval of any
our compounds, the FDA may impose significant restrictions on a drug&#8217;s indicated uses or marketing or require potentially
costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy
of the drug. The FDA may also require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) as a condition of approval
of one or more of our compounds, which could include requirements for a medication guide, physician communication plans or additional
elements to ensure safe use of the drug. Additional REMS elements may include restricted distribution methods, patient registries
and other risk minimization tools.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if the FDA or a comparable
foreign regulatory authority approves one or more of our compounds, the manufacturing processes, labeling, packaging, distribution,
adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for the approved drug will be subject
to additional and potentially extensive ongoing regulatory requirements. These requirements include submissions of safety and other
post-marketing information and reports, establishment registration, as well as continued compliance with cGMPs and GCP requirements
for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our products, including
adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure
to comply with regulatory requirements, may result in, among other things:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the marketing or manufacturing of our products, withdrawal of the product from the market
                                            or voluntary or mandatory product recalls; </span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
                                            restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds
                                            on clinical trials; </span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on product distribution or use, or requirements to conduct post-marketing studies or clinical
                                            trials; </span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            seizure or detention, or refusal to permit the import or export of our products;</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
                                            or the imposition of civil or criminal penalties; and</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                            by the FDA to approve pending applications or supplements to approved applications filed
                                            by us or suspension or revocation of approvals.</span></td></tr></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The occurrence of any event or penalty
described above may limit our ability to commercialize our compounds and generate revenue, and could require us to expend significant
time and resources in response or generate negative publicity.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of our compounds are approved,
our product labeling, advertising and promotion will also be subject to regulatory requirements and ongoing regulatory review.
The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a drug may not be promoted
for uses that are not approved by the FDA as reflected in the drug&#8217;s approved labeling. If we receive marketing approval
for a compound, physicians may nevertheless lawfully prescribe it to their patients in a manner that is inconsistent with the approved
label. While the FDA recently clarified that mere knowledge that a physician is prescribing an approved drug for off label use
is not sufficient to constitute unlawful off-label promotion, if we are found to have actively promoted such off label uses, we
may become subject to significant liability under the FDCA. The federal government has levied large civil and criminal fines against
companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. Additionally,
promotion for off label uses could result in significant liability under the False Claims Act. The FDA has also requested that
companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA&#8217;s and other regulatory
authorities&#8217; policies are subject to change at any time, and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our compounds. If we are unable to timely adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance post-marketing, we may
lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Finally, we cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative or executive action, either
in the United States or abroad. It is difficult to predict how any such legislative, administrative or executive actions will be
implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these legislative
or executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the
normal course, our business may be negatively impacted.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 37; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The COVID-19 coronavirus could
adversely impact our business, including our clinical trials, and financial condition.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, a novel strain of
coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, the COVID-19 coronavirus has spread to multiple
countries, including the United States, Australia and European and Asia-Pacific countries, including countries in which we have
planned or active clinical trial sites. As the COVID-19 coronavirus continues to spread around the globe, we may experience disruptions
that could potentially impact our business and clinical trials.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The extent to which the COVID-19 coronavirus
may impact our future business operations, including our clinical trials, and financial condition will depend on future developments,
which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the
duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures
or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the
disease.<span style="font-family: Arial, Helvetica, Sans-Serif; color: black"> </span><span style="color: black">Moreover, to the
extent the COVID-19 pandemic adversely affects our business, financial condition and results of operations, it may also have the
effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</span></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We receive&#160;Australian&#160;government
research and development income&#160;tax&#160;incentive refunds. If our research and development expenditures are not deemed to
be eligible for the refund, proposed modifications to the&#160;tax&#160;incentive program are enacted, or the&#160;tax&#160;incentive
program is discontinued by the&#160;Australian&#160;government, it could have a negative effect on our future cash flows and the
funding of future research and development projects.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our subsidiary, Anavex Australia Pty
Ltd., is incorporated in Australia where we are currently engaged in research and development activities for ANAVEX<sup>&#174;</sup>2-73
and ANAVEX<sup>&#174;</sup>3-71. Our subsidiary is eligible to participate in the&#160;Australian&#160;Federal Government&#8217;s
Research and Development&#160;Tax&#160;Incentive program, under which the government provides a cash refund for a portion of eligible
research and development expenditures (currently 43.5% to 48.5% depending on the entity&#8217;s corporate tax rate) by small&#160;Australian&#160;entities,
which are defined as&#160;Australian&#160;entities with less than $20 million (Australian) in revenue.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Research and Development&#160;Tax&#160;Incentive
refund is offered by the&#160;Australian&#160;federal government for eligible research and development purposes based on the filing
of an annual application. As part of this program, our subsidiary applied for and received cash refunds from the&#160;Australian&#160;Taxation
Office, or the ATO, for a percentage of the research and development costs expended by our subsidiary in Australia. Since the fiscal
year ended September 30, 2015, we have been receiving Research and Development&#160;Tax&#160;Incentive refunds related to research
and development expenditures made.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain research and development expenses
incurred outside of Australia are also eligible for the&#160;Australian&#160;research and development&#160;tax&#160;incentive program,
provided we obtain an Advance Overseas Finding from AusIndustry, a division of the Australian Government&#8217;s Department of
Industry, Innovation and Science (&#8220;AusIndustry&#8221;).&#160;To receive an Advance Overseas Finding, the expenses must have
been for eligible research and development activities, as determined by AusIndustry, and the expenditures must have a scientific
link to the&#160;Australian&#160;activities, be unable to be conducted in Australia and the total actual and reasonably anticipated
overseas costs must be expected to be less than the total actual and reasonably anticipated expenditures for activities conducted
within Australia, as determined by AusIndustry at the time of application for an Advance Overseas Finding (&#8220;OSF&#8221;).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">This OSF binds
both AusIndustry and the Commissioner of Taxation for three income years. However, for compliance purposes, specific issue guidance
jointly issued by AusIndustry and the ATO in 2014 provides that an OSF can apply for the duration of the overseas activity provided
the activities are not new or materially different then the activities described in the OSF. Currently, the Company is outside
of the binding three-year period with respect to OSF applicable to some of its programs being claimed in Australia.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 38; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">To the extent that some or all of our
research and development expenditures are deemed to be &#8220;ineligible,&#8221; then our refunds may decrease or be eliminated.
In addition, the&#160;Australian&#160;government may in the future modify the requirements of, reduce the amounts of the refunds
available under, or discontinue the Research and Development&#160;Tax&#160;Incentive program. Any such change to our anticipated
refunds or change to the Research and Development&#160;Tax&#160;Incentive program would have a negative effect on our future cash
flows.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>A variety of risks are associated with
operating our business internationally which could materially adversely affect our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">We are presently
conducting clinical development solely in Australia, </span>United Kingdom, The Netherlands, Germany and Canada<span style="color: black">
and may choose to conduct additional international and U.S. clinical trials in the future. Additionally, while we have not taken
any steps to enter into any non-U.S. markets, we may do so in the future. Accordingly, we are subject to risks related to operating
in foreign countries, including:</span></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">different standards of care in various countries that could complicate
the evaluation of our product candidates;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">different United States and foreign drug import and export rules;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">reduced protection for intellectual property rights in certain countries;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">unexpected changes in tariffs, trade barriers and regulatory requirements;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">economic weakness, including inflation, or political instability in
particular foreign economies and markets;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">compliance with tax, employment, immigration, and labor laws for employees
living or traveling abroad;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">compliance with the FCPA and other anti-corruption and anti-bribery
laws;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">foreign taxes, including withholding of payroll taxes;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">foreign currency fluctuations, which could result in increased operating
expenses and reduced revenue, and other obligations incident to doing business in another country;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">workforce uncertainty in countries where labor unrest is more common
than in the United States;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">production shortages resulting from any events affecting raw material
supply or manufacturing capabilities abroad;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">different payor reimbursement regimes, governmental payors or patient
self-pay systems and price controls;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">potential liability resulting from development work conducted by foreign
partners;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">business interruptions resulting from natural disasters, outbreaks
of contagious diseases, such as COVID-19, or geopolitical actions, including war and terrorism, or systems failure including cybersecurity
breaches; and</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt">&#9679;</td>
    <td style="text-align: justify">compliance with evolving and expansive foreign regulatory requirements,
including data privacy laws (such as the GDPR).</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, in connection with the ongoing
conflict between Russia and Ukraine, the U.S. government and European Union countries have imposed enhanced export controls on
certain products and sanctions on certain industry sectors and parties in Russia. The U.S. government has also indicated it will
consider imposing additional sanctions and other similar measures in the near future. Although we do not currently conduct any
clinical trials in Russia or Ukraine, further escalation of geopolitical tensions could have a broader impact that expands into
other markets where we do business or conduct certain research and development operations, which could adversely affect our business,
our supply chain for our product candidates, our collaborators or our ability to carry out our clinical trials.</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><i>&#160;</i></b></span></p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><i>Our
ability to use our net operating loss (&#8220;NOL&#8221;) carryforwards and certain tax credit carryforwards may be subject to
limitation.</i></b></span></p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, we had $123.4 million
of U.S. federal and $199.0 million of state and local NOL carryforwards. We had approximately $10.6 million of NOL carryforwards
in Australia as of the same period. Our NOL carryforwards are subject to review and possible adjustment by the U.S. and state tax
authorities. In addition, under Sections 382 and 383 of the Code and corresponding provisions of state law, if a corporation undergoes
an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change (by value) in its equity ownership over
a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and research and development credits
to offset its post-change income may be limited. This could limit the amount of NOLs or research and development credit carryforwards
that we can utilize annually to offset future taxable income or tax liabilities. Subsequent ownership changes and changes to the
U.S. tax rules in respect of the utilization of NOLs and research and development credits carried forward may further affect the
limitation in future years. In addition, at the state level, there may be periods during which the use of NOLs is suspended or
otherwise limited, which could accelerate or permanently increase state taxes owed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 39; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted a Section 382 study during the
year ended September 30, 2021 and determined that, during the year ended September 30, 2015, there was a change in ownership which
resulted in $25.8 million of federal NOLs being subject to an annual limitation. During the year ended September 30, 2021, we reduced
our federal NOLs by $12.1 million and our research and development tax credit carryforwards by $0.8 million, which are the amount
of tax assets that will expire unutilized pursuant to the Section 382 study. This resulted in a reduction of $2.5 million of NOLs
and $0.8 million of research and development credits and a corresponding reduction in the valuation allowance of $3.3 million,
which was recorded in the 2021 fiscal year. Subsequent ownership changes in future years could trigger additional limitations of
our NOLs. During the year ended September 30, 2022, we determined that there were no changes in ownership pursuant to Section 382.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are subject to healthcare laws and
regulations which may require substantial compliance efforts and could expose us to criminal sanctions, civil and administrative
penalties, contractual damages, reputational harm and diminished profits and future earnings, among other penalties.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Healthcare providers, physicians and others
will play a primary role in the recommendation and prescription of our products, if approved. Our arrangements with such persons
and third-party payors and our general business operations will expose us to broadly applicable fraud and abuse and other healthcare
laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market,
sell and distribute our drugs, if we obtain marketing approval. Restrictions under applicable U.S. federal, state and foreign healthcare
laws and regulations include, but are not limited to, the following:</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the U.S. federal Anti-Kickback Statute,
    which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing
    remuneration, including any kickback, bribe or rebate, directly or indirectly, in cash or in kind, to induce or reward, or
    in return for, either the referral of an individual for, or the purchase or lease, order or recommendation of, any item, good,
    facility or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">U.S. federal civil and criminal false
    claims laws and civil monetary penalties laws, including the civil False Claims Act, which impose criminal and civil penalties,
    including those from civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly
    presenting, or causing to be presented, claims for payment that are false or fraudulent or making a false statement to avoid,
    decrease, or conceal an obligation to pay money to the federal government;</span></td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Stark Law prohibits a physician from making referrals for certain &#8220;designated
health services&#8221; payable by Medicare to an entity in which the physician or an immediate family member of such physician has an
ownership or investment interest or with which the physician has entered into a compensation arrangement, unless a statutory exception
applies. There are a number of exceptions to the Stark Law. Such exceptions permit certain payments and arrangements that, although they
would otherwise potentially implicate the Stark Law, are not treated as a violation under the same if the requirements of the specific
exceptions are met.</span></td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">HIPAA, which among other things, created additional federal criminal statutes
that impose criminal and civil liability for, such actions as executing or attempting to execute a scheme to defraud any healthcare benefit
program or knowingly and willingly falsifying, concealing or covering up a material fact or making false statements relating to healthcare
matters;</span></td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The privacy and security provisions of HIPAA, which impose certain requirements
on covered entities and their business associates, including mandatory contractual terms, with respect to safeguarding the privacy, security
and transmission of individually identifiable health information;</span></td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">U.S. federal transparency requirements
    under the Physician Payments Sunshine Act, enacted as part of the Affordable Care Act that require applicable manufacturers
    of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s
    Health Insurance Program, with specific exceptions, to track and annually report to CMS payments and other transfers of value
    provided to physicians, certain other healthcare providers (such as physicians assistants and nurse practitioners),and teaching
    hospitals, as well as ownership and investment interests held by physicians or their immediate family members; and</span></td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">analogous state or foreign laws and
    regulations, such as state anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party
    payor, including commercial insurers, state marketing and/or transparency laws applicable to manufacturers that may be broader
    in scope than the federal requirements, state laws that require biopharmaceutical companies to comply with the biopharmaceutical
    industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government
    and state laws governing the privacy and security of health information in certain circumstances, many of which differ from
    each other in significant ways and may not have the same effect as HIPAA, thus complicating compliance efforts.</span></td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ensuring that our business arrangements with
third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities
will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable
fraud and abuse or other healthcare laws and regulations. If our operations were found to be in violation of any of these laws
or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative
penalties, damages, fines, disgorgement, imprisonment, possible exclusion from government funded healthcare programs, such as Medicare
and Medicaid, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations,
any of which could substantially disrupt our operations. If the physicians or other providers or entities with whom we expect to
do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions,
including exclusions from government funded healthcare programs. We may incur significant costs achieving and maintaining compliance
with applicable federal and state privacy, security, and fraud laws. Any action against us for violation of these laws, even if
we successfully defend against it, could cause us to incur significant legal expenses and divert our attention from the operation
of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We expect current and future legislation
affecting the pharmaceutical industry, including drug pricing reform, to impact our business generally, which could adversely affect
our business operations. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, there have been, and continue to be proposed and enacted
legislation at the federal and state levels designed to, among other things, bring more transparency to drug pricing, review the relationship
between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement
methodologies for drugs. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition
in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on
September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform
and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can
take to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source
drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases
that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to
legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical
industry. If any of our products are subject to such negotiation, we may lose a significant amount of the revenues expected during the
full life cycle of these products. Further, the Biden administration released an additional executive order on October 14, 2022, directing
HHS to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models
for lowering drug costs for Medicare and Medicaid beneficiaries. We&#160;expect that additional U.S. federal healthcare reform measures
will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products
and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The coverage and reimbursement status
of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates,
if approved, could limit our ability to market those products and decrease our ability to generate product revenue.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Significant uncertainty exists as to the coverage
and reimbursement status of any compound for which we may seek regulatory approval. Sales in the United States will depend in part
on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health
programs such as Medicare, Medicaid, CHIP, TRICARE and the Veterans Administration, as well as managed care organizations and private
health insurers. Prices at which we or our customers seek reimbursement for our therapeutic compounds can be subject to challenge,
reduction or denial by payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The process for determining whether a payor
will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will
pay for the product. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate
will be available. Additionally, in the United States there is no uniform policy among payors for coverage or reimbursement. Third-party
payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies,
but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly
from payor to payor. If coverage and adequate reimbursement are not available, or are available only at limited levels, successful
commercialization of, and obtaining a satisfactory financial return on, any product we develop may not be possible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">Third-party payors are
increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition
to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we
may need to conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would
be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our compounds to be medically
necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may
not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our
investment in drug development. </span>Additionally, we or our collaborators may develop companion diagnostic tests for use with our
product candidates. Companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement
for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to
pharmaceutical or biological products, will apply to companion diagnostics. <span style="color: black">Our inability to promptly obtain
coverage and adequate reimbursement from third-party payors for the product candidates, and for us or our collaborators to obtain coverage
and adequate reimbursement for related companion diagnostic tests that may be developed, could have a material and adverse effect on
our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Common Stock</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>A decline in the price of our
common stock could affect our ability to raise further working capital and adversely impact our operations and would severely dilute
existing or future investors if we were to raise funds at lower prices.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A prolonged decline in the price of
our common stock could result in a reduction in our ability to raise capital. Because our operations have been financed through
the sale of equity securities, a decline in the price of our common stock could be especially detrimental to our continued operations.
Any reduction in our ability to raise equity capital in the future would force us to reallocate funds from other planned uses and
would have a significant negative effect on our business plans and operations, including our ability to develop new products and
continue our current operations. If our stock price declines, there can be no assurance that we can raise additional capital or
generate funds from operations sufficient to meet our obligations. We believe the following factors could cause the market price
of our common stock to continue to fluctuate widely and could cause our common stock to trade at a price below the price at which
you purchase your shares of common stock:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations
    in our quarterly operating results;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of new services,
    products, acquisitions or strategic relationships by us or our competitors;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in accounting treatments
    or principles;</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in earnings estimates
    by securities analysts and in analyst recommendations; and</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: top">
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general political, economic,
    regulatory and market conditions.</span></td></tr>
  </table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The market price for our common stock
may also be affected by our ability to meet or exceed expectations of analysts or investors. Any failure to meet these expectations,
even if minor, could materially adversely affect the market price of our common stock.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we issue additional shares
of common stock in the future, it will result in the dilution of our existing stockholders and may cause the share price of our
common stock to fall.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have 200,000,000 shares of common
stock authorized for issuance and we also have 10,000,000 shares of preferred stock authorized. Our Board of Directors has the
authority to issue additional shares of preferred and common stock up to the authorized capital stated in the articles of incorporation.
Our Board of Directors may choose to issue some or all such shares of common stock to acquire one or more businesses or to provide
additional financing in the future. The issuance of any such shares of common stock will result in a reduction of the book value
or market price of the outstanding shares of our common stock. If we do issue any such additional shares of common stock, such
issuance also will cause a reduction in the proportionate ownership and voting power of all other stockholders. Further, any such
issuance may result in a change of control of our corporation. In the event we do issue or sell additional shares of common or
preferred stock, it may result in stockholder dilution and may cause our share price to fall.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our stock price has been volatile and
may be volatile in the future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our stock price has been volatile at certain
times historically, and may be volatile in the future. We may incur rapid and substantial increases or decreases in our stock price
in the foreseeable future that are do not coincide in timing with the disclosure of news or developments by us. The stock market
in general, and the market for biotechnology and pharmaceutical companies in particular, has experienced extreme volatility that
has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced
by many factors, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">announcements of new data, clinical trial results or those of companies that are perceived to be similar to us;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">announcements related to any delays in any preclinical or clinical trials related to our products;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">announcements related to our products&#8217; ability to demonstrate efficacy or an acceptable safety profile of our product candidates or similar announcements by companies that are perceived to be similar to us;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">our ability to meet or exceed expectations of analysts or investors;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">news that the number of patients required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or the duration of these clinical trials may be longer than we anticipate;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">actions taken by regulatory agencies with respect to our product candidates or the progress of our clinical trials, including with respect to any fast track or orphan drug designations;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partners or our competitors;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">grants awarded to us or companies that are perceived to be similar to us from outside entities;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">trading volume of our common stock;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">developments concerning our collaborations or partners;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">the impact of the COVID-19 outbreak and its effect on us;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">the perception of the biotechnology or pharmaceutical industries by the public, legislatures, regulators and the investment community;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">developments or disputes concerning intellectual property rights;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">significant lawsuits, including patent or stockholder litigation;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">our ability or inability to raise additional capital and the terms on which we raise it;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">sales of our common stock by us or our stockholders;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">declines in the market prices of stocks generally or of companies that are perceived to be similar to us; and</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt; line-height: 115%">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; line-height: 115%">general economic, industry and market conditions.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 42; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, companies trading in the stock
market in general, and The Nasdaq Capital Market in particular, have experienced extreme price and volume fluctuations that have
often been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors
may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods
of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if
instituted against us, could result in substantial costs and diversion of management&#8217;s attention and resources, which could
materially and adversely affect our business, financial condition, results of operations and growth prospects. There can be no
guarantee that our stock price will remain at current prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our common stock may become the target
of a &#8220;short squeeze.&#8221;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities of certain companies have experienced
significant and extreme volatility in stock price due to short sellers of shares of common stock, known as a &#8220;short squeeze.&#8221;
These short squeezes have caused extreme volatility in those companies and in the market and have led to the price per share of
those companies to trade at a significantly inflated rate that is disconnected from the underlying value of the company. Many investors
who have purchased shares in those companies at an inflated rate face the risk of losing a significant portion of their original
investment as the price per share has declined steadily as interest in those stocks have abated. There can be no assurance that
we will not, in the future be, a target of a short squeeze, and you may lose a significant portion or all of your investment if
you purchase our shares at a rate that is significantly disconnected from our underlying value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><b><i>If we fail to maintain
an effective system of internal control over financial reporting, we may not be able to accurately report our financial results
or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm
our business and the trading price of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">Pursuant to Section 404
of the Sarbanes-Oxley Act, our management is required to report upon the effectiveness of our internal control over financial reporting.
We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial
reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to
accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal
control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material
weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy
and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions
or investigations by the Nasdaq Stock Market, the SEC or other regulatory authorities. Failure to remedy any material weakness
in our internal control over financial reporting, or to implement or maintain other effective control systems required of public
companies, could also restrict our future access to the capital markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><b><i>Our disclosure
controls and procedures may not prevent or detect all errors or acts of fraud.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">We are subject to the
periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that
information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management,
and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe
that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can
provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations
include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or
mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement
causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the
individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly,
because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Intellectual
Property </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to obtain and
maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection
obtained is not sufficiently broad, our competitors could develop and commercialize product candidates similar or identical to
ours, and our ability to successfully commercialize our product candidates that we may pursue may be impaired. </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success depends in large part on
our ability to obtain and maintain protection of our intellectual property, particularly patents, in the United States and other
countries with respect to our product candidates and technology. We seek to protect our proprietary position by filing patent applications
in the United States and abroad related to our product candidates or by in-licensing intellectual property. U.S. patents related
to ANAVEX<sup>&#174;</sup>2-73 are directed to a dosage form comprising certain doses of ANAVEX<sup>&#174;</sup>2-73 and donepezil,
and the coverage is limited to the United States only. We may not be able to obtain patent protection for ANAVEX<sup>&#174;</sup>2-73
as a single drug or in other jurisdictions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The patent position of biotechnology and pharmaceutical
companies generally is highly uncertain, involves complex legal, technological and factual questions and has in recent years been
the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the
laws of the United States, or vice versa. Further, we may not be aware of all third-party intellectual property rights potentially
relating to our product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries,
and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or,
in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in
our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result,
the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future
patent applications may not result in patents being issued that protect our product candidates, in whole or in part, or which effectively
prevent others from commercializing competitive product candidates. Even if our patent applications issue as patents, they may
not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise
provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative
product candidates in a non-infringing manner.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, we may be subject to a third-party
preissuance submission of prior art to the United States Patent and Trademark Office, or the USPTO, or become involved in opposition,
derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or
the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of,
or invalidate, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without
payment to us, or result in our inability to manufacture or commercialize drugs without infringing on third-party patent rights.
In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless
of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product
candidates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the issuance of a patent
is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or
patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent
claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from
using or commercializing similar or identical product candidates, or limit the duration of the patent protection of our product
candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents
protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio
may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to seventeen
U.S. patents, nineteen U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates,
methods associated therewith, and to our research programs. Neither patents nor patent applications ensure the protection of our
intellectual property for a number of reasons, including the following:</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="width: 5%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; width: 5%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors may interfere with our patenting process in a variety of ways. Competitors may claim that Anavex is not entitled to an issued patent for a variety of legal reasons. Competitors may also claim that we are infringing their patents and restrict our freedom to operate. If a court or, in some circumstances, a board of a national patent authority, agrees, we would lose some or all of our patent protection. As a company, we have no meaningful experience with competitors interfering with our patents or patent applications.</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because of the time, money and effort involved in obtaining and enforcing patents, our management may spend less time and resources on developing potential drug compounds than they otherwise would, which could increase our operating expenses and delay product programs.</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of a patent may not provide significant practical protection. If we receive a patent of narrow scope, then it may be possible for competitors to design products that do not infringe our patent(s).</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex is seeking patent protection for a number of indications, combination products and drug regimens. The lack of patent protection in global markets for a specific end product or indication may inhibit our ability to advance our compounds and may make Anavex less attractive to potential partners.</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defending a patent lawsuit takes significant time and can be very expensive.</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a court decides that an Anavex compound, its method of manufacture or use, infringes on the competitor&#8217;s patent, we may have to pay substantial damages for infringement.</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A court may prohibit us from making, selling or licensing the potential drug compound unless the patent holder grants a license. A patent holder is not required to grant a license. If a license is available, we may have to pay substantial royalties or grant cross licenses to our patents, and the license terms may be unacceptable.</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redesigning our potential drug compounds so that they do not infringe on other patents may not be possible or could require substantial funds and time.</span></td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">It is also unclear whether our trade
secrets are adequately protected. While we use reasonable efforts to protect our trade secrets, our employees or consultants may
unintentionally or willfully disclose our information to competitors. Enforcing a claim that someone illegally obtained and is
using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition,
courts outside the United States are sometimes less willing to protect trade secrets. Our competitors may independently develop
equivalent knowledge, methods and know-how.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We may also support and collaborate
in research conducted by government organizations, hospitals, universities or other educational institutions. These research partners
may be unable or unwilling to grant us exclusive rights to technology or products derived from these collaborations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">If we do
not obtain required intellectual property licenses or rights, we could encounter delays in our product development efforts while
we attempt to design around other patents or even be prohibited from developing, manufacturing or selling potential drug compounds
requiring these rights or licenses. There is also a risk that legal disputes may arise as to the rights to technology or potential
drug compounds developed in collaboration with other parties, all with attendant risk, distraction, expense, and lack of predictability.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patent terms may be inadequate to protect
our competitive position on our product candidates for an adequate amount of time.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patents have a limited lifespan. In the United
States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S.
non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited.
Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from
competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory
review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.
As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing
products similar or identical to ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depending upon the timing, duration and specifics
of FDA marketing approval of product candidates that we identify, one of the U.S. patents covering such product candidate or the
use thereof may be eligible for up to five years of patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act allows
a maximum of one patent to be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory
review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of
product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing
it may be extended. Patent term extension also may be available in certain foreign countries upon regulatory approval of our product
candidates. Nevertheless, we may not be granted patent term extension either in the United States or in any foreign country because
of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within
applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements.
Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental
authority could be less than we request. If we are unable to obtain patent term extension or restoration, or the term of any such
extension is less than we request, the period during which we will have the right to exclusively market our product may be shortened
and our competitors may obtain approval of competing products following our patent expiration sooner, and our revenue could be
reduced, possibly materially.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Also, there are detailed rules and requirements
regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations,
or the Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy
the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline
to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved
and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to
provide advance notice to us of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic
version of such product candidate.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to comply with our
obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions
to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 45; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are party to an exclusive license
agreement with Life Science Research Israel Ltd., with respect to certain in-licensed intellectual property related to our ANAVEX<sup>&#174;</sup>3-71
product candidate, and we may need to obtain additional licenses from others in the future. Our license agreement with Life Science
Research Israel Ltd. imposes, and we expect that future license agreements will impose, various development, diligence, commercialization,
and other obligations on us. In spite of our efforts, our licensors might conclude that we have materially breached our obligations
under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to
develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or
if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to
seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization
of ANAVEX<sup>&#174;</sup>3-71<b><i> </i></b>or other product candidates covered by any such future licenses. Any of the foregoing
could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, disputes may arise regarding
intellectual property subject to a licensing agreement, including:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 4%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 4%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject
    to the licensing agreement;</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 4%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 4%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 4%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors
    and us and our partners; and</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; width: 4%; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                    priority of invention of patented technology.</span></p>
        <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
        <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the agreements under which
we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements
may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could
narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe
to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on
our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that
we have licensed prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may
be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect
on our business, financial conditions, results of operations, and prospects.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If we do not obtain required intellectual
property licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other
patents or even be prohibited from developing, manufacturing or selling potential drug compounds requiring these rights or licenses.
There is also a risk that legal disputes may arise as to the rights to technology or potential drug compounds developed in collaboration
with other parties, all with attendant risk, distraction, expense, and lack of predictability.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Third-party claims of intellectual
property infringement may prevent or delay our development and commercialization efforts.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success will also depend in part on our
ability to commercialize our compounds without infringing the proprietary rights of others. However, our research, development
and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property
rights owned or controlled by third parties.<span style="font-family: Arial, Helvetica, Sans-Serif"> </span>We have not conducted
extensive freedom of use patent searches and no assurance can be given that patents do not exist or could be issued which would
have an adverse effect on our ability to market our technology or maintain our competitive position with respect to our technology.
Because patent applications can take many years to issue, there may be currently pending patent applications which may later result
in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim
that use of our technologies infringes upon these patents. If our compounds or other subject matter are claimed under other United
States patents or other international patents or are otherwise protected by third party proprietary rights, we may be subject to
infringement actions. In such event, we may challenge the validity of such patents or other proprietary rights or we may be required
to obtain licenses from such companies in order to develop, manufacture or market our technology. There can be no assurances that
we would be successful in a challenge or be able to obtain such licenses or that such licenses, if available, could be obtained
on commercially reasonable terms. Furthermore, the failure to succeed in a challenge, develop a commercially viable alternative
or obtain needed licenses could be materially adverse. Adverse consequences include delays in marketing some or all of our potential
drug compounds based on our drug technology or the inability to proceed with the development, manufacture or sale of potential
drug compounds requiring such licenses. If we defend ourselves against charges of patent infringement or to protect our proprietary
rights against third parties, substantial costs will be incurred regardless of whether we are successful. Such proceedings are
typically protracted with no certainty of success. An adverse outcome could subject us to significant liabilities to third parties
and force us to curtail or cease the research and development of our technology.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 46; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties making claims against us may
obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize ANAVEX<sup>&#174;</sup>2-73
or our other product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense
and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement
against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement,
pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require
substantial time and monetary expenditure. Additionally, parties making claims against us may be able to sustain the costs of complex
patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk
that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the
initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise
have a material adverse effect on our business, results of operations, financial condition and prospects.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to protect the
confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would
be harmed.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">While we use reasonable efforts to protect
our trade secrets, our employees or consultants may unintentionally or willfully disclose our information to competitors. Enforcing
a claim that someone illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming,
and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.
Our competitors may independently develop equivalent knowledge, methods and know-how.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We seek to protect our confidential
proprietary information, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants,
scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. However,
we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade
secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access
to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties
may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain
adequate remedies for such breaches. We also seek to preserve the integrity and confidentiality of our confidential proprietary
information by maintaining physical security of our premises and physical and electronic security of our information technology
systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information
were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from
using that technology or information to compete with us, which could harm our competitive position.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be subject to claims that our
employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or
that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As is common in the biotechnology and pharmaceutical
industry, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies,
including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors
do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees,
consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade
secrets or other proprietary information, of any of our employee&#8217;s former employer or other third parties. Litigation may
be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we
may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Although we are not currently involved
in any litigation, we may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could
be expensive, time consuming and unsuccessful and could harm our business.</i></b></p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 47; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Competitors may infringe our patents
or other intellectual property. Although we are not currently involved in any litigation, if we were to initiate legal proceedings
against a third party to enforce a patent covering ANAVEX<sup>&#174;</sup>2-73 or our other product candidates, the defendant could
counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United
States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could
be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description
or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of
the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following
legal assertions of invalidity and unenforceability is unpredictable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Interference or derivation proceedings
provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with
respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or
to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer
us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access
to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may
result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation
could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our
research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring
ANAVEX<sup>&#174;</sup>2-73 or our other product candidates to market.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be subject to claims challenging
the inventorship of our patents and other intellectual property.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We or our licensors may be subject to
claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade
secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes
arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation
may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of
our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership
of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of
the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Obtaining and maintaining our
patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed
by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Periodic maintenance fees, renewal fees,
annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various
governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications.
We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these
fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number
of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable
law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late
fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant
jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse
effect on our business.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 48; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to protect
our intellectual property rights throughout the world.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Filing, prosecuting and defending patents
on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property
rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws
of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United
States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United
States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors
may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also
export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United
States. These products may compete with our products and our patents or other intellectual property rights may not be effective
or sufficient to prevent them from competing.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in patent law could diminish
the value of our patents and patent applications in general, thereby impairing our ability to protect our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Changes in either the patent laws or interpretation
of the patent laws in the United States and other countries could increase the uncertainties and costs surrounding the prosecution
of patent applications and the enforcement or defense of issued patents. After March 2013, under the Leahy-Smith America Invents
Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in
which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled
to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party
that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention
of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time
from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential
for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)
file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor&#8217;s
patents or patent applications. The America Invents Act also includes a number of significant changes that affect the way patent
applications will be prosecuted and also may affect patent litigation. Therefore, the America Invents Act and its implementation
could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the
enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business,
financial condition, results of operations, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the patent positions of companies
in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have
narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain
situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once
obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing
patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability
to protect and enforce our intellectual property in the future.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk factors disclosed in this Annual
Report on Form 10-K could materially and adversely affect our business, financial condition and results of operations. The risks
described herein are not the only risks we face. Our operations could also be affected by additional factors that are not presently
known to us or by factors that we currently consider immaterial to our business.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_004"></span>ITEM 1B. UNRESOLVED
STAFF COMMENTS </span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_005"></span>ITEM 2. PROPERTIES</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not own any real property. We
maintain a corporate head office at 630 5th Avenue, 20th Floor, New York, NY, USA. Our lease costs for this office are approximately
$9,500 per month. We believe our offices are suitable and adequate to operate our business currently, as they provide us with sufficient
space to conduct our operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_006"></span>ITEM 3. LEGAL
PROCEEDINGS</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We know of
no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our Company
or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our directors,
officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse party or
has a material interest adverse to our or our subsidiary&#8217;s interest.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_007"></span>ITEM 4. MINE
SAFETY DISCLOSURES</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="a_008"></span>PART II</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_009"></span>ITEM 5. MARKET
FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Market information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is quoted on the Nasdaq
Global Select Stock Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;AVXL.&#8221;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 49; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Holders of Common Stock </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of <span style="color: black">November
28, 2022</span>, there were approximately 49 stockholders of record, and 77,961,815 shares of our common stock were issued and
outstanding. Most of our stockholders hold their shares in street name.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Dividends </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not paid any cash dividends
on our common stock and have no intention of paying any dividends on the shares of our common stock. Our current policy is to retain
earnings, if any, for use in our operations and in the development of our business. Our future dividend policy will be determined
from time to time by our Board of Directors.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recent Sales of Unregistered Securities
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the beginning of our fiscal year
ended September 30, 2022, we have not sold any equity securities that were not registered under the Securities Act of 1933 that
were not previously reported in a quarterly report on Form 10-Q or in a current report on Form 8-K.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Repurchases of Equity Securities by Our
Company and Affiliated Purchasers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_010"></span>ITEM 6 [Reserved]</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_011"></span>ITEM 7 MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION </span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following discussion should be read
in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this report. Past operating
results are not necessarily indicative of results that may occur in future periods. This discussion contains forward-looking statements,
which involve a number of risks and uncertainties. See <b><i>Forward Looking Statements</i></b> included elsewhere in this report.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This section discusses year over year comparisons
for the fiscal years ended September 30, 2022 and 2021. Discussion of year over year comparisons between the fiscal years ended September
30, 2021 and 2020 have been excluded from this Form 10-K and can be found in &#8220;<i>Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations</i>&#8221; in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended September
30, 2021.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">We
are in the development stage and have not earned any revenues since our inception in 2004. We do not anticipate earning any revenues
until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Our operating costs consist primarily
of research and development activities including the cost of clinical trials and clinical supplies as well as clinical drug manufacturing
and formulation. Research and development expenses also include personnel related costs such as salaries and wages, and third-party
contract research organization (CRO) expenses in support of these clinical trials. Personnel costs include salaries and wages,
benefits, and non-cash stock-based compensation charges associated with options and other equity awards granted to employees and
consultants who are directly engaged in support of our research and development activities.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">General and administrative expenses
consist of personnel costs, expenses for outside professional services and expenses associated with operating as a public company.
Personnel costs consist of salaries and wages, benefits and stock-based compensation for general and administrative personnel.
Outside professional services and public company expenses, include expenses related to compliance and reporting, additional
insurance expenses, audit and SOX compliance, expenses associated with patent research, applications and filings, investor and
stockholder relations activities and other administrative expenses and professional services.</p>

<!-- Field: Page; Sequence: 50; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><b>Year ended September 30, 2022</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><b></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">During fiscal 2022, we advanced our business and clinical trials
through the following events:</p>



<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    January 2022, we reported positive top-line results from the placebo-controlled Phase 1 clinical trial (ANAVEX&#174;3-71-001) in
    development for the treatment of neurodegenerative diseases including Frontotemporal Dementia (FTD), for which ANAVEX&#174;3-71 has
    been granted Orphan Drug Designation by the FDA. The trial achieved primary and secondary safety endpoints.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    February 2022, we reported positive top-line results from the second randomized, placebo-controlled AVATAR Phase 3 clinical trial
    (ANAVEX&#174;2-73-RS-002) for the treatment of adult patients with Rett syndrome. The trial met its primary and secondary efficacy
    and safety endpoints, with consistent and clinically meaningful improvements in all efficacy measures.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    April 2022, we completed the last patient visit in the 48-week open label extension of the Parkinson&#8217;s Disease Dementia Phase
    2 clinical trial.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    June 2022, the last patient last visit in the randomized, placebo-controlled Phase 2b/3 clinical trial ANAVEX&#174;2-73-AD-004 for
    the treatment of early Alzheimer&#8217;s disease occurred. We expect to present top line data at the upcoming Clinical Trial on Alzheimer&#8217;s
    Disease (CTAD) Congress 2022 in San Francisco, CA.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
    fiscal 2022, we made significant progress in the randomized, placebo-controlled EXCELLENCE Phase 2/3 clinical trial ANAVEX&#174;2-73-RS-003
    for the treatment of pediatric patients with Rett syndrome with expansion of enrollment into clinical sites across Canada and the
    United Kingdom.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><b><i></i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">Our operating expenses for fiscal 2022 increased to $51.0 million, from $42.0
million in fiscal 2021. The increase is attributable to an increase in research and development expenses of $4.9 million in 2022 to $37.9
million, as described below.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following table summarizes our research and development
expenses for the years ended September 30, 2022, and 2021 (in thousands):</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 62%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs of external service providers</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,102</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,243</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel costs</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,012</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,987</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,250</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,660</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License fees</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other common costs</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total research and development costs</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,916</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,984</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
</table>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal 2022, external service
providers costs by product candidate were as follows (in thousands):</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>2-73</span></td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">15,510</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>3-71</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,251</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All other product candidates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">298</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other external service provider costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">43</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total external service provider costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">18,102</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
decrease in external service provider costs from fiscal 2021 to fiscal 2022 is related to a decrease in clinical trial expenditures over
the comparable period, associated with the completion of the enrollment and recruitment activities for our Phase 2b/3 trial in Alzheimer</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s
disease, and manufacturing activities in the comparable period associated with the Rett syndrome program. This decrease was offset by
an increase in personnel costs and non-cash stock-based compensation associated with an expanding team directly engaged in support of
ongoing research and development activities.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">General and administrative expenses for
fiscal 2022 increased to $13.1 million, from $9.0 million in fiscal 2021, most significantly related to an increase in personnel and
an increase in associated non-cash stock option compensation charges.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
fiscal 2022, we utilized cash and cash equivalents of $24.2 million to fund our operations, compared to $30.4 million during fiscal 2021.
Our cash position decreased to $149.2 million at September 30, 2022, a decrease of $2.9 million over the prior year. Cash for operations
was generated through the issuance of shares of common stock under the financing arrangements described below.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 51; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We will continue to see an increase in our research and development expenditures as we advance our ANAVEX<sup>&#174;</sup>2-73
clinical trials, including planned advancement of ANAVEX<sup>&#174;</sup>2-73 for Parkinson&#8217;s disease program, planned initiation
of a Fragile X clinical program, ongoing extension studies of our current clinical programs, continued advancement of our other
pipeline compounds such as ANAVEX<sup>&#174;</sup>3-71, and as we continue to add additional staffing to manage and support these
clinical initiatives.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other income </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Net other income for the year ended September
30, 2022 was $3.4 million as compared to $4.4 million for fiscal 2021. The primary reason for the decrease in other income was due to
a decrease in research and development incentive income and an increased foreign exchange loss associated with incentive and other receivables
denominated in Australian dollars, and related impact from the fluctuation of the Australian dollar against the US dollar during the
year. The decrease was offset by an increase in interest income.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">During fiscal 2022, we recorded $3.3 million
in research and development incentive income, consisting of the Australian research and development incentive credit administered through
the Australian Tax Office, in connection with fiscal 2022 eligible expenditures. In comparison, research and development incentive income
for fiscal 2021 was $4.5 million in connection with fiscal 2021 eligible expenditures and fiscal 2020 expenditures for which an overseas
finding ruling was obtained during fiscal 2021. We expect to continue to receive support from the Australian government for various clinical
trials being conducted within Australia.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><b><i>Net loss</i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><b><i></i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss for fiscal 2022 was $48.0 million,
or $0.62 per share, compared to a net loss of approximately $37.9 million, or $0.54 per share for fiscal 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liquidity and Capital Resources </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Working Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Assets</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152,704,603</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">161,616,490</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Liabilities</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,213,561</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,798,386</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working Capital</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">142,491,042</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,818,104</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">At September 30, 2022, we had $149.2 million
in cash and cash equivalents, a decrease of $2.9 million, from $152.1 million at September 30, 2021. The decrease in cash and cash equivalents
during the year is a result of cash utilized in operations, partially offset by cash provided by financing activities, as described below.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="color: black">We intend to
continue to use our capital resources to advance our clinical trials for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71, and
to perform work necessary to prepare for future development of our pipeline compounds</span>.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash Flows</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2021</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left; text-indent: -10pt; padding-left: 10pt">Cash flows used in operating activities</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(24,237,864</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(30,383,674</td><td style="width: 1%; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash flows provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,287,980</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,242,401</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,949,884</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">122,858,727</td><td style="text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash flow used in operating activities</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">There was a decrease in cash used in operating
activities of $6.1 million during fiscal 2022 primarily due to the collection of incentive and tax receivables.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 52; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash flow provided by financing activities</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Cash provided by financing activities
<span style="color: black">in fiscal 2022 </span>was $21.3 million, net of financing costs, primarily attributable to cash received from
the issuance of common shares at various market prices under the Sales Agreement.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Cash provided by financing activities <span style="color: black">in
fiscal 2021 </span>was $153.2 million, net of financing costs, primarily attributable to cash received from the issuance of common shares
at various market prices under the 2019 Purchase Agreement, the Sales Agreement <span style="color: black">and a direct registered offering.&#160;</span></p>



<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="color: black">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other Financings</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><b>Purchase Agreement</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On June 7, 2019, we
entered into a Purchase Agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln
Park&#8221;), as amended on July 1, 2020, pursuant to which Lincoln Park committed to purchase up to $50.0 million of our common
stock. Concurrently with the execution of the 2019 Purchase Agreement in 2019, we issued 324,383 shares of our common stock to
Lincoln Park as a fee for its commitment to purchase shares of our common stock under the 2019 Purchase Agreement and became obligated
to issue up to 162,191 shares pro rata, when and if Lincoln Park purchased, at our discretion, the $50.0 million aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal year 2021, the Company
issued to Lincoln Park an aggregate of 4,086,209 shares of common stock under the 2019 Purchase Agreement, including 4,007,996
shares of common stock for an aggregate purchase price of $24.1 million and 78,213 commitment shares. As of<span style="color: black">
September 30, 2022 and 2021, no shares of our common stock remain available for purchase by Lincoln Park under the 2019 Purchase
Agreement.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Controlled Equity Offering Sales
Agreement</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2020, we entered into an Amended
and Restated Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and SVB Leerink LLC (the &#8220;Sales
Agents&#8221;), pursuant to which we may offer and sell shares of common stock registered under an effective registration statement
from time to time through the Sales Agents (the &#8220;At-the-Market Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on
our instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell shares of common stock
by methods deemed to be an &#8220;at the market offering&#8221;, in negotiated transactions at market prices prevailing at the
time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated
transactions, subject to our prior written consent. We are not obligated to make any sales of shares under the Sales Agreement.
We or the Sales Agents may suspend or terminate the At-the-Market Offering upon notice to the other party, subject to certain conditions.
The Sales Agents will act as agents on a commercially reasonable efforts basis consistent with their normal trading and sales practices,
applicable state and federal law, and rules and regulations and the rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have agreed to pay the Sales Agents&#8217; commissions
for their services of 3.0% of the gross proceeds from the sale of shares of common stock pursuant to the Sales Agreement. We have
also agreed to provide the Sales Agents with customary indemnification and contribution rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal 2022, 1,623,813 shares were sold
pursuant to the At-the-Market Offering for gross proceeds of $21.0 million (net proceeds of $20.3 million after deducting offering
expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal 2021, 5,634,576 shares were sold
pursuant to the At-the-Market Offering for gross proceeds of $79.1 million (net proceeds of $76.7 million after deducting commissions
and offering expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 53; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Registered Direct Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 24, 2021, the Company completed a registered
direct offering off of the Company&#8217;s shelf registration statement on Form S-3 filed with the SEC on July 3, 2019. The Company
issued 2,380,953 common shares at $21.00 per share for gross proceeds of $50.0 million (net proceeds of $46.9 million after deducting
offering fees and expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Off-Balance Sheet Arrangements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have no off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-transform: uppercase"><b>Application
of Critical Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States.
Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities,
revenue and expenses. These estimates and assumptions are affected by management</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s
application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with
the following aspects of our financial statements is critical to an understanding of our financial statements.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We base our assumptions and estimates
on historical experience and other sources that we believe to be reasonable at the time. Actual results may vary from our estimates due
to changes in circumstances, politics, global economics, general business conditions and other factors. Our significant estimates are
related to the valuation of warrants and options.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">There are accounting policies that we
believe are significant to the presentation of our financial statements. The most significant of these accounting policies relates to
the accounting for our research and development expenses and stock-based compensation expense.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and Development Expenses</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed
as incurred. These expenses are comprised of the costs of the Company&#8217;s proprietary research and development efforts, including
preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and stock based compensation expense,
contract services including external research and development expenses incurred under arrangements with third parties such as contract
research organizations (&#8220;CROs&#8221;), facilities costs, overhead costs and other related expenses. Milestone payments made
by the Company to third parties are expensed when the specific milestone has been achieved. Manufacturing costs are expensed as
incurred in accordance with Accounting Standard Codification (&#8220;ASC&#8221;) 730, Research and Development, as these materials
have no alternative future use outside of their intended use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nonrefundable advance payments for goods or
services that will be used or rendered for future research and development activities are deferred and amortized over the period
that the goods are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes
estimates of costs incurred in relation to external CROs, and clinical site costs. The Company analyzes the progress of clinical
trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount
expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining
the accrued balance and expense in any accounting period. The Company reviews and accrues CRO expenses and clinical trial study
expenses based on work performed and relies upon estimates of those costs applicable to the stage of completion of a study. Accrued
CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which
the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements
are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven and depend on factors
such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial
or similar conditions. The objective of our policy is to record expenses in our financial statements based on actual services received
and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree
of completion of the event or events specified in the specific clinical trial contract.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 54; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In addition, we incur expenses in respect
of the acquisition of intellectual property relating to patents and trademarks. The probability of success and length of time to develop
commercial applications of the drugs subject to the acquired patents and trademarks is difficult to determine and numerous risks and
uncertainties exist with respect to the timely completion of the development projects. There is no assurance the acquired patents and
trademarks will ever be successfully commercialized. Due to these risks and uncertainties, we expense the acquisition of patents and
trademarks.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based Compensation</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">We account for all stock-based payments and awards under the
fair value-based method.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The fair value of all share purchase options
and warrants are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards
expected to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Compensation costs for stock-based payments
with graded vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested
awards as they occur.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have granted share purchase option
awards that vest upon achievement of certain performance criteria, or milestone-based awards. We estimate an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when we conclude that achieving the performance criteria is probable. We periodically review and update as appropriate our estimates
of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement of the performance
criteria.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">We use the Black-Scholes option valuation model to calculate the fair value
of share purchase options and warrants at the date of the grant. This model requires the input of subjective assumptions, including the
expected price volatility, and expected life of each&#160;award. These assumptions consist of estimates of future market conditions, which
are inherently uncertain, and therefore, are subject to management&#8217;s judgment. Changes in these assumptions can materially affect
the fair value estimates.</p>
<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.6pt; text-indent: -21.6pt"><b>RECENT ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.6pt; text-indent: -21.6pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">For a discussion of recent accounting
pronouncements and their possible effect on our results, see Note 2 to our Consolidated Financial Statements found elsewhere in this
Annual Report.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_012"></span>ITEM 7A QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Interest Rate Risk</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
invest our excess cash in investment-grade, interest-bearing securities. The primary objective of our investment policy is to preserve
principal and liquidity. To achieve this objective, our investment policy allows for investments in domestic money market certificates,
certificates of deposit, money market funds, commercial papers, bonds or commercial papers, and establishes diversification and credit
quality requirements and limits investments by maturity and issuer. At September 30, 2022 and 2021, the majority of our excess cash was
held in a JP Morgan Chase Prime Money Market Fund. The average amount invested at any given time throughout the year ended September
30, 2022 was $132.7 million (high: $133.2 million; low: $132.2 million) and the average rate of return was 0.74%. A hypothetical 100
basis point change in interest rates during any of the periods presented would not have a material impact on the fair market value of
our cash and cash equivalents as of September 30, 2022 and 2021. To date, we have not experienced a loss of principal on any of our investments
and as of September 30, 2022 we did not have any allowance for credit losses from our cash and cash equivalents.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 55; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Foreign Exchange Risk</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">We face foreign exchange risk as a result of entering into
transactions denominated in currencies other than U.S. dollars and as a result of the existence of sales and tax incentive receivables
denominated in other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, we do not utilize any
forward exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made.
Volatile market conditions and supply chain shortages may result in significant changes in exchange rates, and in particular a change
in foreign currencies values relative to the U.S. dollar may affect our operating expenses as expressed in U.S. dollars. An adverse movement
in foreign exchange rates could have a material effect on payments made to foreign suppliers.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">For the year ended September 30, 2022,
a majority of our expenses were denominated in U.S. dollars. A hypothetical 10% change in foreign exchange rates applied to foreign currency
transactions for the year ended September 30, 2022 would not have had a material impact on our consolidated financial statements.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">At
September 30, 2022, we held net assets of $6.4 million (AUD $9.9 million) denominated in Australian dollars.</span> <span style="font-family: Times New Roman, Times, Serif">A
hypothetical 10% change in foreign exchange rates at September 30, 2022 would result in a change in reported net assets of +/-
$0.6 million.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Inflation Risk</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Inflation generally may affect us by
increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material impact on our results
of operations during the periods presented.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_013"></span>ITEM 8. FINANCIAL
STATEMENTS AND SUPPLEMENTARY DATA</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"></span></p>

<!-- Field: Page; Sequence: 56; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p><p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p><p style="margin: 0"></p>



<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ANAVEX LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSOLIDATED FINANCIAL STATEMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 57; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;<b>&#160;</b></p>



<p style="margin: 0"></p>



<p style="margin: 0"></p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 10pt/107% Arial, Helvetica, Sans-Serif; text-align: center; width: 100%"><span style="font: 10pt Times New Roman, Times, Serif"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></td></tr>
</table>
<p style="font: 9pt/normal Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 9pt/normal Arial, Helvetica, Sans-Serif; margin: 0">&#160;&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Board of Directors and Shareholders</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Opinion on internal control over financial reporting</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #3A215E"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the internal control over financial reporting
of Anavex Life Sciences Corp. (a Nevada corporation) and subsidiaries (the &#8220;Company&#8221;) as of September 30, 2022, based
on criteria established in the 2013 <i>Internal Control&#8212;Integrated Framework</i> issued by the Committee of Sponsoring Organizations
of the Treadway Commission (&#8220;COSO&#8221;). In our opinion, the Company maintained, in all material respects, effective internal
control over financial reporting as of September 30, 2022, based on criteria established in the 2013 <i>Internal Control&#8212;Integrated
Framework</i> issued by COSO.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We also have audited, in accordance with the standards of
the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated financial statements of the
Company as of and for the year ended September 30, 2022, and our report dated November 28, 2022 expressed an unqualified opinion<span style="color: blue">
</span>on those financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Basis for opinion</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s management is responsible for maintaining
effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial
reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility
is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting
firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audit in accordance with the standards of
the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal
control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal
control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating
effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in
the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 58; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Definition and limitations of internal control over financial
reporting</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A company&#8217;s internal control over financial reporting
is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control
over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations
of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">/s/ GRANT THORNTON LLP&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Hartford, Connecticut</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">November 28, 2022</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 59; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 10pt/107% Arial, Helvetica, Sans-Serif; text-align: center; width: 100%"><span style="font: 10pt Times New Roman, Times, Serif"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></td></tr>
</table>
<p style="font: 9pt/normal Arial, Helvetica, Sans-Serif; margin: 0">&#160;<span style="background-color: white"><b>&#160;</b></span><br /></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Board of Directors and Shareholders</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Opinion on the financial statements </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated<span style="color: blue">
</span>balance sheet of Anavex Life Sciences Corp. (a Nevada corporation) and subsidiaries (the &#8220;Company&#8221;) as of September
30, 2022, the related consolidated<span style="color: blue"> </span>statements of operations and comprehensive loss, changes in
stockholders&#8217; equity, and cash flows for the year ended September 30, 2022, and the related notes (collectively referred
to as the &#8220;financial statements&#8221;). In our opinion, the<span style="color: blue"> </span>consolidated financial statements
present fairly, in all material respects, the financial position of the Company<span style="color: blue"> </span>as of September
30, 2022, and the results of its<span style="color: blue"> </span>operations and its<span style="color: blue"> </span>cash flows
for the year ended September 30, 2022, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We also have audited, in accordance with the standards of
the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over
financial reporting as of September 30, 2022, based on criteria established in the 2013 <i>Internal Control - Integrated Framework</i>
issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;), and our report dated November
28, 2022 expressed an unqualified opinion.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Basis for opinion </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility of the
Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audit in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 60; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Critical audit matters</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: blue"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Critical audit matters are matters<span style="color: blue">
</span>arising from the current period audit of the financial statements that were communicated or required to be communicated
to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved
our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">/s/ <span id="xdx_90F_edei--AuditorName_c20211001__20220930_z3BnY67CNO25"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:AuditorName">GRANT THORNTON LLP</ix:nonNumeric></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: red">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We have served as the Company&#8217;s auditor since 2022.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="xdx_908_edei--AuditorLocation_c20211001__20220930_zzwTwPOVP4se"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:AuditorLocation">Hartford, Connecticut</ix:nonNumeric></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">November 28, 2022</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #4F2D7F"><span id="xdx_901_edei--AuditorFirmId_c20211001__20220930_zGX636tREDXe" style="display: none"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="dei:AuditorFirmId">248</ix:nonNumeric></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 61; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Report of Independent Registered
Public Accounting Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: fuchsia"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shareholders and Board of Directors</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: fuchsia"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: fuchsia"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">New York, New York</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm; color: fuchsia">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><b>Opinion on the
Consolidated Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm; color: fuchsia"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">We have audited the accompanying consolidated balance sheet of Anavex Life
Sciences Corp. (the &#8220;Company&#8221;) as of September 30, 2021, the related consolidated statements of operations and comprehensive
loss, stockholders&#8217; equity, and cash flows for each of the two years in the period ended September 30, 2021, and the related notes
(collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements
present fairly, in all material respects, the financial position of the Company at September 30, 2021, and the results of its operations
and its cash flows for each of the two years in the period ended September 30, 2021<b>,</b> in conformity with accounting principles generally
accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm; color: fuchsia">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also have audited, in accordance with the standards
of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over financial
reporting as of September 30, 2021, based on criteria established in <i>Internal Control &#8211; Integrated Framework <span>(2013)</span></i>
issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) and our report dated November 24,
2021 expressed an unqualified opinion thereon.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm; color: fuchsia"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">These consolidated
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of
the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm; color: fuchsia">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the consolidated financial statements are free of material misstatement, whether due to error or fraud.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: fuchsia">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. <span>We believe
that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: fuchsia">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><b>Critical Audit
Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm; color: fuchsia"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Critical audit matters are matters arising from the
current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee
and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially
challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ BDO USA, LLP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We served as the Company&#8217;s auditor from 2013 to 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">New York, New York</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: fuchsia">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">November 24, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 62; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX
                            LIFE SCIENCES CORP.</b></span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
    BALANCE SHEETS</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    at September 30, 2022 and 2021</span></p></td></tr>
  </table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_306_111_ze13jhnuTJhg" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20220930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20210930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsAbstract_iB_zN2N3Dctu60l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrentAbstract_i01B_znoPwepVtYye" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzrvI_zr1GvNnKs746" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,157,861</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,107,745</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxesReceivable_i02I_maCzrvI_z17EfeECcxX" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
    and tax receivables</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,192,580</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,136,831</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzrvI_zAbc0g6LdeZd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">354,162</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">371,914</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_i01TI_mtCzrvI_zhvjqAk3rQf3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Assets</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,704,603</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,616,490</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z81xDZPOvE85" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
    and Stockholders' Equity</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zP2pLwgJJWTh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableCurrent_i02I_maCzVyU_zd1NjbBSxCPl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,824,777</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,739,781</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzVyU_z91DmivIsqHh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    liabilities (Note 3)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,944,953</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,614,774</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredRentCredit_i02I_maCzVyU_z0IhOKf9JxI9" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    grant income (Note 4)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredRentCredit" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,831</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredRentCredit" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,831</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--Liabilities_i02TI_mtCzVyU_maCzp89_zgxTVPTDhgCk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Liabilities</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,213,561</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,798,386</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_z4HgmKY75Yx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
    and Contingencies - Note 6</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
    stock</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_c20220930_pdd" title="Preferred stock, authorized"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_c20210930_pdd" title="Preferred stock, authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span>
    preferred stock, par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_c20220930_pdd" title="Preferred stock, par value (in dollars per share)"><span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210930_pdd" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--PreferredStockValue_i01I_pp0p0_maCzDEE_maCzmkV_c20220930_za5pl0ToGqY5" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0091">&#8212;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--PreferredStockValue_i01I_pp0p0_maCzmkV_c20210930_zJUNa8lY5Bv1" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0093">&#8212;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20220930_pdd" title="Common shares, authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20210930_pdd" title="Common shares, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span>
    common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20220930_pdd" title="Common shares, par value (in dollars per share)"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20210930_pdd" title="Common shares, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
    and outstanding:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20220930_pdd" title="Common shares, issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20220930_pdd" title="Common shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,815</ix:nonFraction></ix:nonFraction></span></span>
    common shares (2021 - <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20210930_pdd" title="Common shares, issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20210930_pdd" title="Common shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,918,465</ix:nonFraction></ix:nonFraction></span></span>)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--CommonStockValue_i01I_pp0p0_maCzDEE_maCzmkV_c20220930_zwPbtMf22627" title="Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding:77,942,815 common shares (2021 - 75,918,465)" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,944</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--CommonStockValue_i01I_pp0p0_maCzmkV_c20210930_zbHEV4RknpFd" title="Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding:77,942,568 common shares (September 30, 2021 - 75,918,465)" style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,920</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_maCzmkV_zjvsUvJOIGt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,976,881</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,328,048</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzmkV_zKmUkbyJdP8b" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">245,563,783</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">197,585,864</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquity_i01TI_mtCzmkV_maCzp89_z9N8AzgAQxK4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders' Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,491,042</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,818,104</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzp89_zTLMxnWiNNA2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Liabilities and Stockholders' Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,704,603</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,616,490</ix:nonFraction></span></td><td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 63; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX
                            LIFE SCIENCES CORP.</b></span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the years ended September 30, 2022, 2021 and 2020</span></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_113_zuG0RW3zsSk9" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20211001_20220930" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_492_20201001_20210930" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_497_20191001__20200930_z4oYuJtJLr3h" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr id="xdx_400_eus-gaap--OperatingExpensesAbstract_iB_zZBX8SrD1oil" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzu5q_z0Y8NBlCKUD7" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,070,068</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,017,511</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,856,609</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzu5q_z30zM1TxVEPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,915,747</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,983,674</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,231,623</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--OperatingExpenses_i01NT_di_mtCzu5q_msOILzgk0_zbcEjSsKe0vl" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating expenses</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,985,815</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,001,185</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">31,088,232</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"></td></tr>
<tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_i01T_mtOILzgk0_maCzpqV_zCV2uwYnpIn7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
loss&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,985,815</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,001,185</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">31,088,232</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zqUyGufCrXr3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income (expenses)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_ecustom--NonOperatingIncomeFromGrants_i01_maCzoHp_zak0aD1nKCf8" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant income</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0151">&#8212;</span></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,100</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,888</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCzoHp_zPoICmkWMJ19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development incentive income</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,323,011</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,547,099</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,375,025</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--InterestIncomeExpenseNet_i01_maCzoHp_ztgHQ3d8f3V5" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest income, net</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">946,988</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,261</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,973</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCzoHp_z5T953YhNSSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign exchange (loss) gain, net</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">903,611</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">267,344</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,540</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzoHp_maCzpqV_zEIp6qoX4KCl" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total other income, net</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,366,388</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,360,116</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,830,426</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtCzpqV_maCzjDD_maNLACLzYer_ztHcBhYtroSl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss before provision for income taxes</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,619,427</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,641,069</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,257,806</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_di_msCzjDD_msNLACLzYer_zLb2FUo5uyuj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expense, current</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,492</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,565</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,664</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_ecustom--NetLossAndComprehensiveLoss_iT_mtNLACLzYer_zS12bCYL4i97" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss and comprehensive loss</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:NetLossAndComprehensiveLoss" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,977,919</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:NetLossAndComprehensiveLoss" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,908,634</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:NetLossAndComprehensiveLoss" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,280,470</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_ecustom--EarningPerShareBasicAndDilutedAbstract_iB_zV7ZdDoqTDRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Loss per share</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_ecustom--NetLossPerShareBasicAndDiluted_i01_zS1T3Rk8fjU2" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.62</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.54</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.45</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_z55V7lCijfUf" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average number of shares outstanding</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_i01_zD9cFHEvAL2i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">76,909,993</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">69,802,960</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">58,194,894</ix:nonFraction></span></td>
<td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 64; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 100%"><p style="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX
                            LIFE SCIENCES CORP.</b></span></p>
    <p style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
    STATEMENTS OF CASH FLOWS</span></p>
    <p style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the years ended September 30, 2022 and 2021</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><br />
</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_112_zpu3rMLqc0zf" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td style="font: bold 9pt Times New Roman, Times, Serif">&#160;</td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td id="xdx_499_20211001__20220930_zZPLe8t2Tjpa" style="font: bold 9pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif">&#160;</td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left">&#160;</td>
<td id="xdx_492_20201001__20210930_zqvc5wwiWFoi" style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right">&#160;</td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left">&#160;</td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif">&#160;</td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left">&#160;</td>
<td id="xdx_49B_20191001__20200930_z1InAQBDrBFe" style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right">&#160;</td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zPrIezvwuZ63" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash Flows used in Operating Activities</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLoss_i01_maCz6hr_zFZ7bPRTLg21" style="vertical-align: bottom; background-color: White">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,977,919</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,908,634</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,280,470</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_400_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zf4FYjdYZ3rj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments to reconcile net loss to net cash used in operations:</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i02_maCz6hr_z4vUWQW7WM12" style="vertical-align: bottom; background-color: White">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,379,242</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,231,403</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,876,906</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zPAYmqx47Kec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in working capital balances related to operations:</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCz6hr_zlW0K4TT0vh3" style="vertical-align: bottom; background-color: White">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive and tax receivables</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,944,251</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,287,491</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,206,595</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCz6hr_zkYa0bRDKAAe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and deposits</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,387</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,290</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,159</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCz6hr_zVOruYqVGLu8" style="vertical-align: bottom; background-color: White">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">915,004</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,727</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">465,722</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCz6hr_zLYGxvk31A06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">330,179</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,298,200</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,800,232</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_ecustom--DeferredGrantIncomes_i02N_di_msCz6hr_zGO3bAhO5Wte" style="vertical-align: bottom; background-color: White">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred grant income</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#8212;</span></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:DeferredGrantIncomes" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">443,831</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0237">&#8212;</span></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtCz6hr_maCzWH1_zcZfRTvsML5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in operating activities</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,237,864</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,383,674</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,287,046</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zoxFfedRU7ob" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash Flows provided by Financing Activities</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCztWi_zKyVYy7PwSQi" style="vertical-align: bottom; background-color: White">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common shares</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,984,667</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,218,762</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,754,198</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_msCztWi_zVUqG3tbXAu5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share issue costs</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">706,877</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,550,921</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,764</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40C_eus-gaap--ProceedsFromWarrantExercises_i01_maCztWi_zoExdMlo7bXl" style="vertical-align: bottom; background-color: White">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from exercise of warrants</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0255">&#8212;</span></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,500</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0257">&#8212;</span></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCztWi_zWq8w5Fxunc4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from exercise of stock options</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,010,190</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,108,060</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCztWi_maCzWH1_zTPwAbJuzvQc" style="vertical-align: bottom; background-color: White">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash provided by financing activities</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,287,980</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,242,401</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,350,434</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzWH1_zldaI1y9rnn4" style="vertical-align: bottom; background-color: White">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase (decrease) in cash and cash equivalents during the period</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,949,884</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,858,727</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,063,388</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--Cash_iS_zjOda00vVNDd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents, beginning of period</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,107,745</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,249,018</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,185,630</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--Cash_iE_zcQtFvQPOrW8" style="vertical-align: bottom; background-color: White">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents, end of period</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,157,861</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,107,745</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,249,018</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--SupplementalCashFlowInformationRelatedText_iB_zOPaoM2uJUVb" style="vertical-align: bottom; background-color: White">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental Cash Flow Information</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--CashPaidForStateAndLocalMinimumIncomeTaxes_i01_zzaU3JlAnlL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid for state and local minimum income taxes</span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,903</ix:nonFraction></span></td>
<td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,531</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 9pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: 9pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,664</ix:nonFraction></span></td>
<td style="font: 9pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Consolidated Financial Statements</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 65; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX
                            LIFE SCIENCES CORP.</b></span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
    STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the years ended September 30, 2022, 2021 and 2020</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_114_zXJd212FJO56" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td style="font-size: 10pt">&#160;</td>
<td style="font-size: 10pt; text-align: left">&#160;</td>
<td style="font-size: 10pt; text-align: right">&#160;</td>
<td style="font-size: 10pt; text-align: left">&#160;</td>
<td style="font-size: 10pt">&#160;</td>
<td style="font-size: 10pt; text-align: left">&#160;</td>
<td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zTb6tbe4CvZe" style="font-size: 10pt; text-align: right">&#160;</td>
<td style="font-size: 10pt; text-align: left">&#160;</td>
<td style="font-size: 10pt">&#160;</td>
<td style="font-size: 10pt; text-align: left">&#160;</td>
<td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zvuPieVnDFva" style="font-size: 10pt; text-align: right">&#160;</td>
<td style="font-size: 10pt; text-align: left">&#160;</td>
<td style="font-size: 10pt">&#160;</td>
<td style="font-size: 10pt; text-align: left">&#160;</td>
<td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zNBv9mU8lGod" style="font-size: 10pt; text-align: right">&#160;</td>
<td style="font-size: 10pt; text-align: left">&#160;</td>
<td style="font-size: 10pt">&#160;</td>
<td style="font-size: 10pt; text-align: left">&#160;</td>
<td id="xdx_4B1_z9qfIWmH45G6" style="font-size: 10pt; text-align: right">&#160;</td>
<td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</span></td>
<td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="padding-bottom: 1pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="padding-bottom: 1pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid-in</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par Value</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td></tr>
<tr id="xdx_434_c20191001__20200930_eus-gaap--StockholdersEquity_iS_z0xVxESibjEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 35%; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, September 30, 2019</span></td>
<td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmgCsqhuMISj" title="Balance at beginning, shares" style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,650,521</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,652</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,633,807</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">133,396,760</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,289,699</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zKSgAPLd7CY5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued under 2019 purchase agreement</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--StockRepurchasedDuringPeriodValue_znHtjEyasJm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase shares</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_985_eus-gaap--StockRepurchasedDuringPeriodShares_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWML6zYdUAJf" title="Purchase shares (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,564,584</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,565</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,246,733</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,254,298</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_zGhmW5ESFKq7" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitment shares</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98F_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zf0K5MtC3JL6" title="Commitment shares (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,943</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptionInShares_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued pursuant to cashless exercise of stock options</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98F_ecustom--SharesIssuedPursuantToCashlessExerciseOptionInShares_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5RWEA1royw2" title="Shares issued pursuant to cashless exercise of options (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOptionInShares" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">721</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--SharesIssuedUnderSalesAgreement_z6JOKERgYjfb" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued under Sales Agreement</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_984_ecustom--SharesIssuedUnderSalesAgreementInShares_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwYAN2UX3eOh" title="Shares issued under Sales Agreement (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementInShares" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,760,429</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,760</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,498,140</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,499,900</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_ecustom--LessShareIssueCosts_zVULeReI0DGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: share issue costs</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">403,764</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">403,764</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,876,906</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,876,906</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,280,470</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,280,470</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_436_c20201001__20210930_eus-gaap--StockholdersEquity_iS_z1oCWtStGaSg" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, September 30, 2020</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9a90fbeBTH8" title="Balance at beginning, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,045,198</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,047</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,851,752</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">159,677,230</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,236,569</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued under 2019 purchase agreement</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--StockRepurchasedDuringPeriodValue_zIvTxjoacHCd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase shares</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_eus-gaap--StockRepurchasedDuringPeriodShares_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbmJVwAsfL8b" title="Purchase shares (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,007,996</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,008</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,107,190</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,111,198</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitment shares</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98C_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYw6talt81L3" title="Commitment shares (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,213</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_iP3custom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_zkH6C1cIP6H8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued pursuant to exercise of stock options</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98A_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsInShares_iP3custom--SharesIssuedPursuantToExerciseOfStockOptions_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcv9FfT9JjI6" title="Shares issued pursuant to exercise of stock options (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,421,529</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,421</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,106,639</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,108,060</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--SharesIssuedUnderSalesAgreement_zZfsCsbFUKC9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued under Sales Agreement</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_986_ecustom--SharesIssuedUnderSalesAgreementInShares_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsDFN8yotfPd" title="Shares issued under Sales Agreement (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementInShares" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,634,576</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,635</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,101,915</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,107,550</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--LessShareIssueCosts_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: share issue costs</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,437,523</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,437,523</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_404_ecustom--SharesIssuedPursuantToRegisteredDirectOffering_iP3custom--LessShareIssueCosts_zYcJlZT59qCc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued pursuant to registered direct offering</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98C_ecustom--SharesIssuedPursuantToRegisteredDirectOfferingInShares_iP3custom--SharesIssuedPursuantToRegisteredDirectOffering_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsldMKQVDD4c" title="Shares issued pursuant to registered direct offering (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingInShares" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,380,953</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOffering" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,381</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOffering" contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,997,632</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOffering" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,013</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--LessSharesIssueCosts_iP3custom--SharesIssuedPursuantToRegisteredDirectOfferingInShares_zBn9WJHZxQLc" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: share issue costs</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessSharesIssueCosts" contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,097,032</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessSharesIssueCosts" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,097,032</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_401_ecustom--SharesIssuedPusuantToExerciseOfWarrants_iP3custom--LessSharesIssueCosts_z6QKkWStJ6t" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued pusuant to exercise of warrants</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_987_ecustom--SharesIssuedPusuantToExerciseOfWarrantsInShares_iP3custom--SharesIssuedPusuantToExerciseOfWarrants_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z06JasljWAV9" title="Shares issued pusuant to exercise of warrants (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrantsInShares" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,150</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,500</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zBK9oRT3VpFk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,231,403</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,231,403</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--NetIncomeLoss_zLEbaQxRJ3Q2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8212;</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,908,634</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,908,634</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_435_c20211001__20220930_eus-gaap--StockholdersEquity_iS_zJfvJzghCv3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, September 30, 2021</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJUbu4ES7tgc" title="Balance at beginning, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,918,465</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,920</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,328,048</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">197,585,864</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,818,104</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued pursuant to exercise of stock options</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_987_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsInShares_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zotXUL374UW8" title="Shares issued pursuant to exercise of stock options (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares" contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,537</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,009,789</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,010,190</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--SharesIssuedUnderSalesAgreement_zS0FrMHBNSGg" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued under Sales Agreement</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_ecustom--SharesIssuedUnderSalesAgreementInShares_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNiXPlWtLKyk" title="Shares issued under Sales Agreement (in shares)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementInShares" contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,623,813</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,623</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2021-10-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,983,044</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreement" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,984,667</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_ecustom--LessShareIssueCosts_zz2T86PYFml5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: share issue costs</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">723,242</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">723,242</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zzPsxYnqxuPb" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0442">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,379,242</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0444">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,379,242</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--NetIncomeLoss_zkbIs3x0dkC3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8212;</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#8212;</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,977,919</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,977,919</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_439_c20211001__20220930_eus-gaap--StockholdersEquity_iE_zqJZeNqDH3j5" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, September 30, 2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDmBqDSio9W9" title="Balance at ending, shares" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,815</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,944</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,976,881</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">245,563,783</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,491,042</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Consolidated Financial Statements</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<!-- Field: Page; Sequence: 66; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 1</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zF7GK65rrkwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 &#9;<span id="xdx_826_zTGyf9kqqwe9">Business Description and Basis of Presentation</span>
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment
of neurodegenerative and neurodevelopmental diseases. The Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73 is being developed
to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases, including rare diseases,
such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein
2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><i>Basis of Presentation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and the instructions to Form
10-K and have been prepared under the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sale or generate commercial revenues. To date, we have not
generated any revenues from our operations. The Company expects the business to continue to experience negative cash flows for the foreseeable
future and cannot predict when, if ever, its business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
is uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The
actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#8217;s research and development programs and the level of
financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future
clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement
(as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if available,
that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on a timely basis,
if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Coronavirus Disease 2019 (COVID-19)</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The recent global outbreak of COVID-19 did not have
a material impact on the Company&#8217;s result of operations or financial condition for the year ended September 30, 2022. However,
the future course of the pandemic could have adverse effects in the U.S and global economies and thus negatively impact our business
and financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_z67hzn4v1sKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 2&#9;<span id="xdx_82F_zNxE6e33dQI4">Summary of Significant Accounting Policies</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_849_eus-gaap--UseOfEstimates_z8gKMmY1HLRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zWG3EmOoh2sk">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the
basis for making judgments about the book values of assets and liabilities and the accrual of costs and expenses that are not readily
apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23B_zoYwhAI9Az2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 67; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zUhBV7AlnAg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zAizb6WqZ886" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zNXgJ7SLBxzi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 2</span></p></ix:exclude>


<ix:exclude><p id="xdx_234_z2jL3uDi2pJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zJ2MdZ71Dy5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zIuhEHzP31n6">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly owned subsidiaries, Anavex Australia Pty Limited. (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6tEegO9VsS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_z0JMPFdEJVJc">Cash and equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#8217;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains its investments at one large well known financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20220930_zInmgKI67LC4" title="Federal Deposit Insurance Corporation"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>, under current regulations. At September 30, 2022 and 2021, substantially
all of the Company&#8217;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zr6NvoPtLvGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_z8Kq4tFCNR84">Research and Development Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#8217;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and stock-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#8220;CROs&#8221;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#8220;ASC&#8221;) 730, Research and Development, as these materials have no alternative future use outside of their intended use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the studies including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are
made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.
The Company&#8217;s historical accrual estimates have not been materially different from actual costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_235_zCmJ2z0zYEM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 68; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zacJO7ZLXPvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zxLDoSwWfmGl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z0N08yuoiWJ1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 3</span></p></ix:exclude>


<ix:exclude><p id="xdx_23B_zyS3oOQ3rg9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:RevenueRecognitionIncentives"><p id="xdx_849_eus-gaap--RevenueRecognitionIncentives_zsVE6ZiohaM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zTbyIPlIwXve">Research and Development Incentive Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is eligible to obtain certain research
and development tax credits, including the Australian research and development tax incentive credit (the &#8220;Australia R&amp;D credit&#8221;)
through a program administered through the Australian Tax Office (the &#8220;ATO&#8221;) and AusIndustry, a division of the Australian
Government&#8217;s Department of Industry, Innovation and Science (&#8220;AusIndustry&#8221;), which provides for a cash refund based
on a percentage of eligible research and development activities undertaken in Australia by the Company&#8217;s wholly owned subsidiary,
Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;D credit program to receive the cash refund for certain
research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by AusIndustry
pursuant to an advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Australia R&amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, Income Taxes (&#8220;ASC 740&#8221;), since the incentives are
not linked to the Company&#8217;s taxable income and can be realized regardless of whether the Company has generated taxable income in
the respective jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to the Australia R&amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 <i>Accounting for Government Grants and Disclosure of Government Assistance</i> (&#8220;IAS 20&#8221;). The Company
recognizes the Research and Development Incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;D credit
Program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#8217;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zyGAkxtLqYfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zwn8BSjXghg8">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_237_zSfRMEWNqUkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 69; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_z8A73GsVFV1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zwWmn959pyld" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zGUnEWjavRI4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 4</span></p></ix:exclude>


<ix:exclude><p id="xdx_23D_zsaRqYNe114b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, diluted loss per share excludes
<span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220930_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,329,616</ix:nonFraction></span> potentially dilutive common shares (2021 &#8211; diluted loss per share excludes <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930_zIjvlIpEANY8" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,540,903</ix:nonFraction></span> potentially dilutive common shares;
2020 &#8211; diluted loss per share excludes <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20191001__20200930_zXI5VTYcTPKf" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,576,266</ix:nonFraction></span> potentially dilutive common shares) related to outstanding options and warrants,
as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zSS2UperrY14" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zc95zI2r0ta8">Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The book value of the Company&#8217;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#8217;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zJYZsysB1fQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86B_zcmI4X4oLBB1">Foreign Currency Translation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zAaQa43BTZQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_869_zkULV6MVVQV1">Segment and Geographic Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating segments are defined as components of an
enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making
group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as
one operating segment, which is the business of developing novel therapies for the management of CNS diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="avxl:GrantIncomePolicyTextBlock"><p id="xdx_843_ecustom--GrantIncomePolicyTextBlock_ziGpSNcmT4Pc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zrBFYtQohVki">Grant Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statement of operations
in the period they are earned and when the related research and development costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zCmmKHc71zg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z1zXqEoNhwOj">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_zhITyK99j7i2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 70; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zvtn7RBR6zK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_z3BK8Tn9a8f9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zzEC04ix2Vk7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 5</span></p></ix:exclude>


<ix:exclude><p id="xdx_232_zVL934UV0mp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC
740 regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements
when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are
initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon
ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts. Application requires
numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions
and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional
information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic
adjustments may have a material impact on the consolidated statements of operations. At September 30, 2022 the Company did <span id="xdx_905_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20220930_zFBUlap6tPSl" title="Uncertain tax positions"><ix:nonFraction name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="AsOf2022-09-30" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span>t
have any uncertain tax positions.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes interest and penalties
related to current income tax expense on the interest income, net line, in the accompanying consolidated statement of operations.
Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets. There were <span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20211001__20220930_z9D7qWr5ILXe" title="Interest and penalties"><span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20201001__20210930_zc3co7wNJLWg" title="Interest and penalties"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="From2021-10-01to2022-09-30" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="From2020-10-012021-09-30" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>
interest and penalties related to current income tax expense during the years ended September 30, 2022, 2021 and 2020.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock"><p id="xdx_84C_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zWB35jw4KtT" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zcoUScD6bzFe">Stock-based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for all stock-based payments
and awards under the fair value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of all share purchase options and warrants
are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected to
vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation costs for stock-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option valuation
model to calculate the fair value of share purchase options and warrants at the date of the grant. This model requires the input of subjective
assumptions, including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury
yield curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted
are expected to be outstanding using the simplified method. The Company&#8217;s historical share option exercise experience does not provide
a reasonable basis for estimating the expected term. Expected volatility is based on the average of the daily share price changes over
the expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not
paid any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions
consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment.
Changes in these assumptions can materially affect the fair value estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price of options or warrants may be paid
in cash or, if approved by the Company&#8217;s compensation committee in advance, &#8220;net settled&#8221; in shares of the Company&#8217;s
common stock. In a net settlement of an option or warrant, the Company does not receive payment of the exercise price from the holder
but reduces the number of shares of common stock issued upon the exercise of the stock option or warrant by the smallest number of whole
shares that have an aggregate fair market value equal to or over the aggregate exercise price for the option shares covered by the option
or warrant exercised. Shares issued pursuant to the exercise of options and warrants are issued from the Company&#8217;s treasury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_235_zMLESGgiOr2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 71; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zHTrvYluHtd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zjrt6GQ5zqwa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zW9Nm2v9A306" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 6</span></p></ix:exclude>


<ix:exclude><p id="xdx_23F_zCxnDJgecpbj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zaRnwuPwOpr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zge762DQGdy1">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - &#9;quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active &#9;&#9;markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - &#9;assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2022 and 2021, the Company did not
have any Level 2 or Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zkvzJbYcbfqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_zwDAbvay2cOh">Recently Adopted Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective October 1, 2021, the Company adopted Accounting
Standards Update (&#8220;ASU&#8221;) 2019-12, &#8220;Simplifying the Accounting for Income Taxes (ASC 740)&#8221;, which is intended to
simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740
and clarifying and amending existing guidance to improve consistent application. There was no material impact on the Company&#8217;s operations,
financial condition, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2021, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued ASU&#160;2021-10, &#8220;Government Assistance (Topic 832): Disclosures by Business Entities about Government
Assistance&#8221; (&#8220;ASU&#160;2021-10&#8221;). ASU&#160;2021-10&#160;increases the transparency of government assistance including
the disclosure of (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance
on an entity&#8217;s financial statements. ASU&#160;2021-10&#160;is effective for fiscal years beginning after December 15, 2021, with
early adoption permitted. Upon implementation, the Company may use either a prospective or retrospective method of adoption when adopting
the ASU. The adoption of ASU 2021-10 will impact the disclosures related to the research and development incentive income that the Company
receives from the ATO for its clinical trials in Australia. The Company currently plans to adopt the provisions of this ASU on October
1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="avxl:AccuredLiabilitiesTextBlock"><p id="xdx_801_ecustom--AccuredLiabilitiesTextBlock_z3o5phRPO5A4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 3&#9;<span id="xdx_828_zfXvANdGyVfa">Accrued Liabilities</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consist of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zdAM0DDAypG6" summary="xdx: Disclosure - Accrued Liabilities (Details)" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zZ9g3MhxkYHd" style="display: none">Schedule of components of accrued liabilities</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_497_20220930_zCsJnLHVGyn1" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20210930_zH7qnVnSgIg" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td></tr>
<tr id="xdx_402_ecustom--ClinicalSiteCostsAndPatientVisits_iI_pp0p0_maALCzi8D_zKCvwFUb29Yb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued clinical site and patient visits costs</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:ClinicalSiteCostsAndPatientVisits" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,031,105</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:ClinicalSiteCostsAndPatientVisits" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,035,800</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCzi8D_z59IhkWemSt2" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued compensation and benefits</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,297,337</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,201,903</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_ecustom--FixedContractAccruals_iI_pp0p0_maALCzi8D_z82jvbG5jm9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed contract accruals</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">417,414</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">649,649</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzi8D_zj7ZweeM9CA8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other accrued liabilities</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,199,097</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,727,422</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzi8D_zkbmpaxQjJBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; font-size: 10pt; text-indent: -10pt"><span style="color: rgb(204,238,255); font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accrued liabilities</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,944,953</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,614,774</ix:nonFraction></span><span style="font-family: Symbol; font-size: 10pt"></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Symbol">&#160;</span></td></tr>
</table></ix:nonNumeric>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.3pt"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.3pt">&#160;</p>

<ix:exclude><p id="xdx_23A_z0SDHSmDPja4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.3pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 72; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zYYXct7BNrmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.3pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_z8IAwoq2w5Cj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zkB5ntPXjTp2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 7</span></p></ix:exclude>


<ix:exclude><p id="xdx_233_zn44fgvf3e7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.3pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.3pt"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_80B_ecustom--OtherIncomeDisclosureTextBlock_zU3cSb79ifBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 4&#9;<span id="xdx_826_zJZEI4e9LGY5">Other Income</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the year ended September
30, 2022, the Company received $<span id="xdx_905_ecustom--GrantIncome_pp0p0_c20211001__20220930_z2u92HMuICM4" title="Grant income"><ix:nonFraction name="avxl:GrantIncome" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> (2021: $<span id="xdx_906_ecustom--GrantIncome_pp0p0_c20201001__20210930_zPN81FvQohqg" title="Grant income"><ix:nonFraction name="avxl:GrantIncome" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">497,931</ix:nonFraction></span>; 2020: $<span id="xdx_90F_ecustom--GrantIncome_pp0p0_c20191001__20200930_zku1wbrapr6i" title="Grant income"><ix:nonFraction name="avxl:GrantIncome" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>) of a $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_pp0p0" title="Research and development incentive income"><span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-09-30_custom_MichaelJFoxMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-09-30_custom_ParkinsonMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">995,862</ix:nonFraction></ix:nonFraction></span></span> research grant awarded during the year ended September 30,
2021, by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant will be used to fund a clinical trial of the Company&#8217;s
lead compound, ANAVEX<sup>&#174;</sup>2-73 related to Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income is
being deferred when received and amortized to other income as the related research and development expenditures are incurred. During
the year ended September 30, 2022, the Company recognized $Nil <span id="xdx_90B_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20211001__20220930_zs56r1Fw9Vr4" title="Grant income" style="display: none"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> (2021: $<span id="xdx_902_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20201001__20210930_z4xGVkmSgWOf" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,100</ix:nonFraction></span>; 2020: $Nil <span id="xdx_905_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20191001__20200930_zpOtF977WMD2" title="Grant income" style="display: none"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>) of this grant on its statements of
operations within grant income. At September 30, 2022 an amount of $<span id="xdx_905_ecustom--DeferredGrantIncome_iI_pp0p0_c20220930_zHSY1Kqy6NPc" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,831</ix:nonFraction></span> (2021: $<span id="xdx_90F_ecustom--DeferredGrantIncome_iI_pp0p0_c20210930_zlZsniCllbk3" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,831</ix:nonFraction></span>) of this grant is recorded as deferred
grant income, representing the amount of this grant which has not yet been amortized to other income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the year ended September
30, 2017, the Company was awarded grant funding in the amount of $<span id="xdx_90A_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20161001__20170930_zRusqhsKmkb4" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2016-10-012017-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">597,886</ix:nonFraction></span>. The grant was received in equal quarterly installments over
a period of two years ending during the year ended September 30, 2020, in exchange for a commitment to complete clinical testing for a
therapeutic drug candidate for the treatment of Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income was deferred
when received and amortized to other income as the related research and development expenditures were incurred. During the year ended
September 30, 2020, the Company recognized $<span id="xdx_901_ecustom--NonOperatingsIncomeFromGrant_pp0p0_c20191001__20200930_zLTqt7UR3fJf" title="Grant income"><ix:nonFraction name="avxl:NonOperatingsIncomeFromGrant" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,888</ix:nonFraction></span> of this grant on its statement of operations as a component of other income. At September
30, 2020, the Company had recognized the full amount of grant funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents income earned by the Company&#8217;s Australian subsidiary, of the Australian research and development tax
incentive credit (the &#8220;tax incentive credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the year ended September
30, 2022, the Company recorded research and development incentive income of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20220930_zptCGi3Wu2o8" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,323,011</ix:nonFraction></span> (AUD <span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220930__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-012022-09-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,468,246</ix:nonFraction></span>) (2021: $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930_zENzyy82PQGf" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,547,099</ix:nonFraction></span> (AUD <span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930__srt--CurrencyAxis__currency--AUD_zju0evbwj6P7" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-09-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,068,993</ix:nonFraction></span>);
2020: $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20191001__20200930_zu5JJvjaShHi" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,375,025</ix:nonFraction></span> (AUD <span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20191001__20200930__srt--CurrencyAxis__currency--AUD_zCsdgTDf7xQg" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2019-10-012020-09-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,392,266</ix:nonFraction></span>)) in respect of the tax incentive credit for eligible research and development expenses incurred during
the year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company evaluates its
eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant data available. Although
the Company believes that it complies with all the relevant conditions of the program, as a matter of course, the Company may be subject
to pre-issue review or audit by the ATO and, the ATO may have different interpretations of certain eligibility requirements. Currently,
the Company&#8217;s tax incentive claims from 2018 to 2022 are open to potential review or audit by the ATO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="avxl:EquityOfferingAgreementsTextBlock"><p id="xdx_80D_ecustom--EquityOfferingAgreementsTextBlock_zcZ20XPeqUm" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 5&#9;<span id="xdx_820_zV2n9mdJ9cu8">Equity Offerings</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board of Directors&#160;(the &#8220;Board&#8221;)&#160;has
the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number
of shares constituting any series or the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Registered Direct Offering</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 22, 2021, the Company and Deep Track Capital
entered into a securities purchase agreement pursuant to which the Company sold to Deep Track Capital an aggregate of 2,380,953 shares
of common stock at $21 per share in a registered direct offering, for gross proceeds of $50,000,013. Net proceeds of the offering were
$46,902,981 after deducting offering fees and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23D_zr0ymPKDOX6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 73; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_ztbgZJSfpAz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zX6DHOqfW5oj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zbYIKdoocqMh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 8</span></p></ix:exclude>


<ix:exclude><p id="xdx_231_zKCKdaWsKbk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on the Company&#8217;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company
or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales
Agents will act as agents on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has agreed to pay the Sales Agents
commissions for their services of up to <span id="xdx_908_ecustom--PercentageOfGrossProceedsFromSales_dp_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zjzDU1V5j2fd" title="Percentage of gross proceeds from sales"><ix:nonFraction name="avxl:PercentageOfGrossProceedsFromSales" contextRef="From2021-10-012022-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>%
of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed to provide the Sales
Agents with customary indemnification and contribution rights. During the year ended September 30, 2022, <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-10-012022-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,623,813</ix:nonFraction></span>
shares were sold pursuant to the Offering for gross proceeds of $<span id="xdx_90E_ecustom--GrossProceedsFromIssuancePublicOffering_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from Issuance Public Offering"><ix:nonFraction name="avxl:GrossProceedsFromIssuancePublicOffering" contextRef="From2021-10-012022-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,984,667</ix:nonFraction></span>
(net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceeds from Issuance Public Offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-10-012022-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,261,425</ix:nonFraction></span>
after deducting offering expenses) (2021: <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,634,576</ix:nonFraction></span>
shares were sold for gross proceeds of $<span id="xdx_90C_ecustom--GrossProceedsFromIssuancePublicOffering_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from Issuance Public Offering"><ix:nonFraction name="avxl:GrossProceedsFromIssuancePublicOffering" contextRef="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">79,107,550</ix:nonFraction></span>,
net proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceeds from Issuance Public Offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,670,027</ix:nonFraction></span>;
2020: <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zrSONM0rgtk4" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,760,429</ix:nonFraction></span>
shares were sold for gross proceeds of $<span id="xdx_901_ecustom--GrossProceedsFromIssuancePublicOffering_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zFBrcYjWPI8k" title="Gross proceeds from Issuance Public Offering"><ix:nonFraction name="avxl:GrossProceedsFromIssuancePublicOffering" contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,499,900</ix:nonFraction></span>,
net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zkxflyK1y5Ye" title="Proceeds from Issuance Public Offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,096,136</ix:nonFraction></span>).
At September 30, 2022, an amount of $<span id="xdx_90B_ecustom--SalesOfAgreementAmount_c20220930_pp0p0" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142,407,882</ix:nonFraction></span>
(2021: $<span id="xdx_90A_ecustom--SalesOfAgreementAmount_c20210930_pp0p0" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">163,392,550</ix:nonFraction></span>)
was registered pursuant to an effective registration statement and available to be sold under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 7, 2019, the Company entered into a $50,000,000
purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), as amended
on July 1, 2020, pursuant to which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase,
up to $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Value of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> in value of its shares of common stock from time to time over a three-year period until July 1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2019 Purchase
Agreement, the Company issued to Lincoln Park <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">324,383</ix:nonFraction></span> shares of common stock as a commitment fee during the year ended September 30, 2019
and agreed to issue up to <span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:NumberOfSharesObligatedToPurchaseProrataBasic" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,191</ix:nonFraction></span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span>
aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, the Company
did not issue any shares to Lincoln Park under the 2019 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2021, the Company
issued to Lincoln Park an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zv73hCO6Jap9" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,086,209</ix:nonFraction></span> (2020: <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zs5ERxvfL3Xc" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,633,527</ix:nonFraction></span>) shares of common stock under the 2019 Purchase Agreement, including
<span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zB4Lseqfa8A2" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,007,996</ix:nonFraction></span> (2020: <span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zIXAwXdBBgvl" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,564,584</ix:nonFraction></span>) shares of common stock for an aggregate purchase price of $<span id="xdx_90B_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zMvbCtQkjOKk" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,111,198</ix:nonFraction></span> (2020: $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEfYfoeymscg" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,254,298</ix:nonFraction></span>) and <span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zQDyDlyELEhf" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,213</ix:nonFraction></span> (2020:
<span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zyEtCT6Ix1Zb" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,943</ix:nonFraction></span>) commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2022 and 2021, <span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_do_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgFGX2CFruQ1" title="Amount of shares remain available"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span> shares remained
available for issuance under the 2019 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_809_eus-gaap--CommitmentsDisclosureTextBlock_zEUxRjYnMXo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 6&#9;<span id="xdx_82C_zHFA39oBUbW2">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Lease</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">During
the year ended September 30, 2022, the Company incurred office lease expense of $<span id="xdx_909_eus-gaap--LeaseAndRentalExpense_c20211001__20220930_pp0p0" title="Operating Leases, Rent Expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,865</ix:nonFraction></span> (2021: $<span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20201001__20210930_pp0p0" title="Operating Leases, Rent Expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">130,784</ix:nonFraction></span>; 2020: $<span id="xdx_904_eus-gaap--LeaseAndRentalExpense_pp0p0_c20191001__20200930_zU59dp2F0LJ2" title="Operating Leases, Rent Expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">233,423</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<ix:exclude><p id="xdx_23C_zFp48rFgezv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 74; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zlPW390C3RB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"></p><ix:exclude><p id="xdx_23C_zD0KT5fbdEcj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
                                            Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zGA3xUIKh7y" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 9</span></p></ix:exclude>


<ix:exclude><p id="xdx_23A_ztfdLw4pO2Gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the
Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing
employees. During the year ended September 30, 2022, the Company made $<span id="xdx_90C_eus-gaap--PensionContributions_c20211001__20220930_pp0p0" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">158,112</ix:nonFraction></span> (2021: $<span id="xdx_90A_eus-gaap--PensionContributions_c20201001__20210930_pp0p0" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">128,856</ix:nonFraction></span>; 2020: $<span id="xdx_909_eus-gaap--PensionContributions_pp0p0_c20191001__20200930_zOosKtYuwNic" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">98,058</ix:nonFraction></span>) in matching contributions
under the 401(k) plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the warrant activity
during the years ended September 30, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zrqYgJE63aq5" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_za46SsaCHP49" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td>
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price ($)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 0%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt 0pt 0pt 10pt; width: 35%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, September 30, 2021</span></td>
<td style="padding: 0pt 0pt 0pt 10pt; width: 1%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z7c7dsHrZL8i" title="Share Purchase Warrants Balance, at beginning" style="width: 25%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,000</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8KDPG7kevJf" title="Weighted Average Exercise Price Balance, at beginning" style="width: 25%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.69</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zbeBtxvzaGg6" title="Share Purchase Warrants Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2021-10-012022-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" contextRef="From2021-10-012022-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, September 30, 2022</span></td>
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zuQr9LLe9DB6" title="Share Purchase Warrants Balance, at ending" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zvXWeia4T0N2" title="Weighted Average Exercise Price Balance, at ending" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.72</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center"></p>

</ix:nonNumeric><p id="xdx_8AB_z8bGCEAnMthj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 30, 2022, the Company had share purchase
warrants outstanding as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zwOtrbAziuLf" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><span id="xdx_8BD_zcRVkusmwtE2" style="display: none">Schedule of share purchase warrants outstanding</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiry Date</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 0%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number" style="width: 35%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-09-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Exercise Price" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zLnV2zUuBYb8" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2022-09-30_custom_PurchaseWarrants1Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 6, 2024</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-09-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_z6UNquRzlyx5" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2022-09-30_custom_PurchaseWarrants2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 21, 2026</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930_pdd" title="Number" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center; text-indent: -0.8pt"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AA_zYSWPinQIxEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center; text-indent: -0.8pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>2015 Stock Option Plan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s board of
directors approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted
stock awards to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_230_zbco7zDRs0p7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 75; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zCLYf6aJJjAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zr7vj6Y76dWi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zp7u3Gul4k3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 10</span></p></ix:exclude>


<ix:exclude><p id="xdx_236_zNfGk2LF7Qsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>2019 Stock Option Plan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zzWOxS5qgCP" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">406,453</ix:nonFraction></span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>2022 Stock Option Plan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> additional shares of Common Stock will be available for issuance under the 2022 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. At September
30, 2022, <span id="xdx_90F_ecustom--OptionIssued_c20211001__20220930_pdd" title="Option issued"><ix:nonFraction name="avxl:OptionIssued" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,058,000</ix:nonFraction></span> options had been issued under the 2022 Plan and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-09-30_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,363,453</ix:nonFraction></span> options were available for issue under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock option
activity during the year ended September 30, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zxj8vJ2mgkUj" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BD_zxDXwkvCac17" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average Grant</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date Fair Value</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1px solid; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1px solid; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intrinsic value
    ($)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 0%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 0pt 10pt; width: 24%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
                                            September 30, 2021</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPzYUjBpavfa" title="Options Outstanding at beginning" style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,330,903</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2NpkNzhLGgl" title="Weighted Average Exercise Price Outstanding at beginning" style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.74</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 15%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxko9TbKfx9a" title="Aggregate intrinsic value Outstanding at beginning" style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,132,451</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Options Granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,358,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.13</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.07</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1155kjkYbq1" title="Options Forfeited" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">118,750</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.86</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Grant Date Fair Value Forfeited" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.23</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdEigvjic9H1" title="Options Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,537</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Grant Date Fair Value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Aggregate intrinsic value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,201,015</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
                                            September 30, 2022</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znyDJZ5oimhh" title="Options Outstanding at ending" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,169,616</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFjA3B56xNq9" title="Weighted Average Exercise Price Outstanding at ending" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.61</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxkf1hOMxhv3" title="Aggregate intrinsic value Outstanding at ending" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,267,309</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable,
                                            September 30, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Options Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,777,113</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.40</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Aggregate intrinsic value Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,173,997</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_8A4_z3NTfV2vEe1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23D_zAtJPtTTmzXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 76; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_z1yBVkMCWtZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zYyJmMM2nHja" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zkAT8nrYdJo" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 11</span></p></ix:exclude>


<ix:exclude><p id="xdx_235_zF03ReTa5XI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at September 30, 2022 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zyZBDTTcl3Mh" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><span id="xdx_8B3_zwaH8kPgNzea" style="display: none">Summarizes information about stock options</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="7" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted</span></td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="7" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="7" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of exercise
prices</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contractual life</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">exercise</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in years)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price ($)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vested options</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price ($)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Range of exercise prices, lower range limit" style="width: 11%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.92</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Range of exercise prices, upper range limit" style="width: 11%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.96</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zNXxIiez54p" title="Number of outstanding options" style="width: 11%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,903,762</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 11%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zUWDCjO2Vsv9" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.12</ix:nonNumeric></span></span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Weighted average exercise price" style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.30</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Number of vested options" style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,883,345</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Weighted average exercise price" style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.30</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Number of outstanding options" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,078,800</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zAZpr64athib" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.34</ix:nonNumeric></span></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.30</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Number of vested options" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,063,800</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.29</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.04</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.98</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Number of outstanding options" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,957,054</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zdl65uiwL7Ul" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.07</ix:nonNumeric></span></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.28</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Number of vested options" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,365,387</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.31</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.20</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.01</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Number of outstanding options" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,698,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zUVWbwYyTdDg" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.58</ix:nonNumeric></span></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Number of vested options" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">109,581</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.40</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.22</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.58</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Number of outstanding options" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,532,000</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_znKOmouiD8R" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.44</ix:nonNumeric></span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.23</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Number of vested options" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">355,000</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.66</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Number of outstanding options" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,169,616</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Number of vested options" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,777,113</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



</ix:nonNumeric><p id="xdx_8AF_zBzjJBYZBh0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average per share fair value of options
vested during the year ended September 30, 2022 was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930_z6N5VgaNTOxg" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.69</ix:nonFraction></span> (2021: $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930_pdd" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.54</ix:nonFraction></span>, 2020: $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930_zh2nDHPUCdda" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.55</ix:nonFraction></span>). At September 30, 2022, the weighted average contractual
life of options outstanding was <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zC7JTH074Ukk" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.4</ix:nonNumeric></span> years (2021: <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zaEsZSlAor45" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2020-10-012021-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.8</ix:nonNumeric></span> years) and for options exercisable was <span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zhqdiAHZ5y49" title="Options exercisable"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.1</ix:nonNumeric></span> years (2021: <span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zpLPnSSSeGej" title="Options exercisable"><ix:nonNumeric contextRef="From2020-10-012021-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.5</ix:nonNumeric></span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at September 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9;The Company recognized stock-based compensation
expense of $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,379,242</ix:nonFraction></span> during the year ended September 30, 2022 (2021: $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210930_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,231,403</ix:nonFraction></span>; 2020: $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930_zU3Qc5vKLyVl" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,876,906</ix:nonFraction></span>) in connection with the issuance and
vesting &#9;of stock options and warrants in exchange for services. These amounts have been included in general and &#9;administrative
expenses and research and development expenses on the Company&#8217;s consolidated statements of &#9;operations as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zRsv1hPuGVY1" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zVL7LQlGNg7d" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,129,412</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEdoL2xos1Xl" title="Total share based compensation" style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,571,335</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ziQTxjhxUGJg" title="Total share based compensation" style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012020-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,210,789</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,249,830</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zS5vl9HDS9Pj" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,660,068</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zr97YiLgSPx4" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012020-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,666,117</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,379,242</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930_zzMufGfKjIcc" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,231,403</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930_z1XcI0m56cNj" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,876,906</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



</ix:nonNumeric><p id="xdx_8A2_z1aNr2eyavRd" style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20220930_pp0p0" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,032,000</ix:nonFraction></span> in stock-based
compensation is expected to be recorded over the remaining term &#9;of such options and warrants through fiscal 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option and
warrant award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zeaKNUmKwXb6" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B9_zNFFdnXS3Ma4" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220930_zeZpDHresJzh" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.11</ix:nonFraction></span></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20210930_zXhtykYhwUSj" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.73</ix:nonFraction></span></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20191001__20200930_z3dmWdOI0ns9" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.57</ix:nonFraction></span></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of options (years)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220930_z6aEovXTPwa6" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.57</ix:nonNumeric></span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210930_zAkG3Sccvdl" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2020-10-012021-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.74</ix:nonNumeric></span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200930_zL0wY6kX2d2j" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2019-10-012020-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.53</ix:nonNumeric></span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annualized volatility</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220930_zhztPPc8Mdk9" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84.17</ix:nonFraction></span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20210930_zQmgc3QlShK7" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">93.43</ix:nonFraction></span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20191001__20200930_zNuF8kSdMzs1" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.99</ix:nonFraction></span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend rate</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220930_zKqoqQv2xAHf" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20210930_zuCGmjCDBG03" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20191001__20200930_zRRaloMMiN2g" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
</table>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AC_zhPIVcNeZJQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the years ended September 30, 2022, 2021 and 2020 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zuuSmKjYsNnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 77; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zXXmQ0aZVQ4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zRndvfTWcebg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zKQWGZszdd6g" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 12</span></p></ix:exclude>


<ix:exclude><p id="xdx_23E_zuDPKBptvPfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_ziIqbRNtNcaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7&#9; &#9;<span id="xdx_82B_zVa8z1O31jAd">Income Taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s U.S. and foreign loss before income
taxes are set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zx5dvH0NFZnj" summary="xdx: Disclosure - Income Taxes (Details)" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"><span id="xdx_8B1_zHT4EuIsczU9" style="display: none">Schedule of Income before Income Tax, Domestic and Foreign</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20211001__20220930_zMKYknPhq378" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20201001__20210930_zfxrFFPCwnc4" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_497_20191001__20200930_zGhw73ioTF9l" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,001,893</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,850,926</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,096,148</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,617,534</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,790,143</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,161,658</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,619,427</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,641,069</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,257,806</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>



<p style="font: 10pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

</ix:nonNumeric><p id="xdx_8AF_zmSqGbBUck62" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of net deferred income tax assets as of September 30, 2022
and 2021 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zjMfQmQsT4Kb" summary="xdx: Disclosure - Income Taxes (Details 1)" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zI9P67rFLgNc"><span id="xdx_8B6_zAX90pApmdX1" style="display: none">Schedule of deferred tax asset and liabilities</span></span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20220930_zbByw7DrQqFg" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_497_20210930_zx5QfwiHm1x4" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
</tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 62%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryforwards</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,208,000</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,982,000</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development tax credit carryforwards</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,182,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,577,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,373,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,453,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_40D_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unpaid charges</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:DeferredTaxAssetsUnpaidCharges" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">894,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:DeferredTaxAssetsUnpaidCharges" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible asset costs</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">388,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">323,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign exchange and other</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8KqZpS1dx02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance of deferred tax assets</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,089,000</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,486,000</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
</tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0948">&#8212;</span></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0949">&#8212;</span></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
</table>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A7_zBJOu8iSi81g" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of income tax expense at the statutory
federal income tax rate and income taxes as reflected in the consolidated financial statements for the years ended September 30, 2022
and 2021 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zr0kxcDJW9E5" summary="xdx: Disclosure - Income Taxes (Details 2)" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_zFSOKYViXamk" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20211001__20220930_zmPaFeGlxVAg" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49B_20201001__20210930_z7JqXnu6yzNl" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20191001__20200930_ztqOVCwmuym" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax benefit at statutory federal rate</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,000,000</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,934,000</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,519,000</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign income taxed at other rates</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">170,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">353,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">723,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40A_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent differences relating to stock based compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:PermanentDifferencesRelatingToStockBasedCompensation" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">714,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:PermanentDifferencesRelatingToStockBasedCompensation" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,379,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0963">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--PermanentDifferencesRelatingToSection162m_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent differences relating to Section 162(m)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0965">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:PermanentDifferencesRelatingToSection162m" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">816,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0967">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other permanent differences</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0969">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">741,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_ecustom--AdjustmentToTaxAssetsBasedOnSection382_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment to tax assets based on Section 382</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:AdjustmentToTaxAssetsBasedOnSection382" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,330,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development credits, net</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">232,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,042,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,267,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State and local taxes</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,975,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,022,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,911,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_404_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_zzfQV4aVbjg6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment to true up to prior years' tax provision</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_zckaICNVDz7b" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of change in statutory tax rates</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,000</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--TaxesExcludingIncomeAndExciseTaxes_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State minimum and excise taxes</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:TaxesExcludingIncomeAndExciseTaxes" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,492</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:TaxesExcludingIncomeAndExciseTaxes" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,565</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:TaxesExcludingIncomeAndExciseTaxes" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,664</ix:nonFraction></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation allowances</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,603,000</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,495,000</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,442,000</ix:nonFraction></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expense</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,492</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,565</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,664</ix:nonFraction></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A5_z1WET1ZcRca6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, the Company had U.S. federal
net operating loss carryforwards of approximately $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20220930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z8vBX27flW33" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-09-30_custom_FederalMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">123.4</ix:nonFraction></span> million (2021: $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zetJd9cR1BI4" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-09-30_custom_FederalMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">101.6</ix:nonFraction></span> million) of which <span id="xdx_908_ecustom--OperatingLossCarryforwardsDescription_c20211001__20220930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember" title="Operating loss carryforwards description"><ix:nonNumeric contextRef="From2021-10-012022-09-30_custom_FederalMember" name="avxl:OperatingLossCarryforwardsDescription">$37.7 million will begin to expire in
2025 and $85.7 million can be carried forward indefinitely</ix:nonNumeric></span>, state and local net operating loss carryforwards of approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20220930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zrw2NUpRciRf" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-09-30_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">199.0</ix:nonFraction></span> million
(2021: $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zIg7ytUWaNm1" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-09-30_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">177.7</ix:nonFraction></span> million) which will begin to expire in <span id="xdx_90A_ecustom--OperatingLossCarryForwardsExpirationYear_c20211001__20220930" title="Operating loss carry forwards expiration year"><ix:nonNumeric contextRef="From2021-10-01to2022-09-30" name="avxl:OperatingLossCarryForwardsExpirationYear">2036</ix:nonNumeric></span>, and Research and Development tax credits of $<span id="xdx_90B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pp0n3_dm_c20211001__20220930_zKD2NjpyaC17" title="Research and Development tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">2.2</ix:nonFraction></span> million (2021: $<span id="xdx_90F_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pp0n3_dm_c20201001__20210930_z9IBoLQSFtMd" title="Research and Development tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million)
which will begin to expire in 2029. The Company had approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20220930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zNYH13afw2ii" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-09-30_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">10.6</ix:nonFraction></span> million (approximately AU$ <span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_c20220930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_zLjYRvafTY6f" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-09-30_us-gaap_ForeignCountryMember_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">14.9</ix:nonFraction></span> million) (2021: $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_c20210930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zxXCgppp4vi2" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-09-30_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">7.9</ix:nonFraction></span> million (approximately
AU$ <span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_zLOAe0ZkUhz3" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-09-30_us-gaap_ForeignCountryMember_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">11.2</ix:nonFraction></span> million)) of net operating loss carryforwards in Australia, which have an indefinite life, available to offset future taxable
income in those jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates its valuation allowance
requirements based on available evidence. When circumstances change, and this causes a change in management&#8217;s judgment about
the recoverability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income.
Because management of the Company does not currently believe that it is more likely than not that the Company will receive the
benefit of these assets, a full valuation allowance has been established at September 30, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zPJdmlZQSLQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 78; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zXhoD9zpxGP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_z6QVuEiRfEZa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_238_z13Moaem4mG6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 218pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements <br />
September 30, 2022 Page 13</span></p></ix:exclude>


<ix:exclude><p id="xdx_233_zU8i6Ce11Bdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files income tax returns in the U.S. federal
jurisdiction and various state and local and foreign jurisdictions. The Company&#8217;s tax returns are subject to tax examinations by
U.S. federal and state tax authorities, or examinations by foreign tax authorities until the respective statutes of limitation expire.
The Company is subject to tax examinations by tax authorities for all taxation years commencing on or after 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the provisions of the Internal Revenue Code,
the net operating loss (&#8220;NOL&#8221;) carryforwards are subject to review and possible adjustment by the Internal Revenue Service
and state tax authorities. Under Section 382 of the Internal Revenue Code, NOL and tax credit carryforwards may become subject to an annual
limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over a three-year period,
as well as similar state tax provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company conducted a Section 382 study during
the year ended September 30, 2021 and determined that, during the year ended September 30, 2015, there was a change in ownership
which resulted in $25.8 million of federal NOLs being subject to an annual limitation of $439,914. During the year ended September 30, 2021,
the Company reduced its federal NOLs by $12.1 million and its Research and Development tax credit carryforwards by $0.8 million,
which are the amount of tax assets that will expire unutilized pursuant to the Section 382 study. This resulted in a reduction of
$2.5 million of NOLs and $0.8 million of research and development credits and a corresponding reduction in the valuation allowance
of $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0n3_dm_c20211001__20220930_zKyNQSpELoTk" title="Decrease in vaution allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-10-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3.3</ix:nonFraction> </span>million,
which was recorded in the 2021 fiscal year. Subsequent ownership changes in future years could trigger additional limitations of the
Company&#8217;s NOLs<span style="background-color: white">. During the year ended September 30, 2022 the Company determined that
there were no changes in ownership pursuant to Section 382.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, the Company did not provide
any foreign withholding taxes related to its foreign subsidiaries&#8217; undistributed earnings, as such earnings have been retained and
are intended to be indefinitely reinvested to fund ongoing operations of the foreign subsidiaries. It is not practicable to estimate the
amount of taxes that would be payable upon remittance of these earnings, because such tax, if any, is dependent upon circumstances existing
if and when remittance occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_81B_zYU2SFZ3aedi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>





<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 79; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_014"></span>ITEM 9. CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS </span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Not Applicable</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_015"></span>ITEM 9A. CONTROLS
AND PROCEDURES</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Disclosure Controls and Procedures</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain disclosure controls and procedures
that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports filed
under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules
and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our chief
executive officer and our principal financial officer, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We carried out an evaluation, under the supervision
and with the participation of our management, including our principal executive and principal financial officer, of the effectiveness
of the design and operation of our disclosure controls and procedures, as defined in&#160;Rule&#160;13(a)-15(e) under the Exchange
Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls
and procedures were effective as of September 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Management&#8217;s Annual Report on Internal
Control over Financial Reporting </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Exchange
Act. Under the supervision and with the participation of our management, including our Principal Executive Officer and Principal
Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criteria
established in the framework in&#160;Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (&#8220;COSO&#8221;).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on this evaluation, our management
concluded that our internal controls over financial reporting were effective as of September 30, 2022.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The effectiveness of our internal control over
financial reporting as of September 30, 2022, has been audited by Grant Thornton LLP, an independent registered public accounting
firm, as stated in their report which appears in this Annual Report on Form 10-K.</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in Internal Control over Financial
Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended September 30,
2022, there were no changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant
to Rules 13a 15(d) or 15d 15(d) of the Exchange Act that materially affected, or are reasonably likely to materially affect, our
internal controls over financial reporting.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_016"></span>ITEM 9B OTHER
INFORMATION</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 80; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="a_017"></span>PART III</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_018"></span>ITEM 10 DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
information required by this Item will be set forth in the section headed </span>&#8220;<span style="font-family: Times New Roman, Times, Serif">&#8212;Election
of Directors</span>&#8221; <span style="font-family: Times New Roman, Times, Serif">and </span>&#8220;<span style="font-family: Times New Roman, Times, Serif">Information
Regarding the Board of Directors and Corporate Governance</span>&#8221; <span style="font-family: Times New Roman, Times, Serif">in our
definitive Proxy Statement for our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after our year ended
September 30, 2022 (our </span>&#8220;<span style="font-family: Times New Roman, Times, Serif">Proxy Statement</span>&#8221;<span style="font-family: Times New Roman, Times, Serif">)
and is incorporated in this report by reference.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_019"></span>ITEM 11. EXECUTIVE
COMPENSATION</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
information required by this Item will be set forth in the section headed </span>&#8220;<span style="font-family: Times New Roman, Times, Serif">Executive
Compensation</span>&#8221; <span style="font-family: Times New Roman, Times, Serif">in our Proxy Statement and is incorporated in this
report by reference.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal"><span id="a_020"></span>ITEM 12. SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
information required by this Item will be set forth in the section headed </span>&#8220;<span style="font-family: Times New Roman, Times, Serif">Security
Ownership of Certain Beneficial Owners and Management</span>&#8221; <span style="font-family: Times New Roman, Times, Serif">in our Proxy
Statement and is incorporated in this report by reference.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">Information
regarding our equity compensation plans will be set forth in the section headed </span>&#8220;<span style="font-family: Times New Roman, Times, Serif">Executive
Compensation</span>&#8221; <span style="font-family: Times New Roman, Times, Serif">in our Proxy Statement and is incorporated in this
report by reference.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_021"></span>ITEM 13. CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
information required by this Item will be set forth in the section headed </span>&#8220;<span style="font-family: Times New Roman, Times, Serif">Transactions
With Related Persons</span>&#8221; <span style="font-family: Times New Roman, Times, Serif">in our Proxy Statement and is incorporated
in this report by reference.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_022"></span>ITEM 14. PRINCIPAL
ACCOUNTING FEES AND SERVICES </span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
information required by this Item will be set forth in the section headed </span>&#8220;<span style="font-family: Times New Roman, Times, Serif">&#8212;Ratification
of Selection of Independent Registered Public Accounting Firm</span>&#8221; <span style="font-family: Times New Roman, Times, Serif">in
our Proxy Statement and is incorporated in this report by reference.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 81; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt">&#160;</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="a_023"></span>PART IV</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_024"></span>ITEM 15. EXHIBITS,
FINANCIAL STATEMENT SCHEDULES</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-transform: uppercase"><b></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Articles of Incorporation and Bylaws</b></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation, as amended (incorporated by reference to our Annual Report on Form 10-K filed on November 24, 2021)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(4)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Instruments Defining the Rights of Security Holders</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Registrant&#8217;s Securities*</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(10)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material Contracts</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&#94;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577415003756/s102397_ex10-91.htm">2015 Omnibus Incentive Plan (incorporated by reference to our Annual Report on Form 10-K filed on December 29, 2015)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&#94;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419002242/s115994_def14a.htm">2019 Omnibus Incentive Plan (incorporated by reference to our Proxy Statement, dated February 11, 2019, as filed on February 11, 2019)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&#94;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112222001056/e3822_ex5-1.htm">2022 Omnibus Incentive Plan (incorporated by reference to our Registration Statement on Form S-8, as filed on June 10, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&#94;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000106299314004769/exhibit31-1.htm">Employment Agreement, dated as of July 5, 2013, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Quarterly Report on Form 10-Q filed on August 13, 2014)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&#94;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006259/s103666_ex10-1.htm">First
    Amendment to Employment Agreement, dated as of July 5, 2016, by and between the Company and Christopher Missling, PhD
    (incorporated by reference to our Current Reporton Form 8-K filed on July 7, 2016)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&#94;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006410/s103735_ex10-1.htm">Amended and Restated First Amendment to Employment Agreement, dated as of July 18, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 22, 2016)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&#94;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex10-1.htm">Second Amendment to Employment Agreement, dated as of May 3, 2019 by and between the Company and Christopher Missling, PhD (incorporated by reference to our Quarterly Report on Form 10-Q filed on May 9, 2019)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8&#94;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112222000700/e3692_ex10-1.htm">Third Amendment to Employment Agreement, dated April 7, 2022 by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on April 8, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9&#94;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/s108360_ex10-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Employment Agreement by and between the Company and withSandra Boenisch (incorporated by reference to our Annual Report on Form 10-K filed on December 11, 2017)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10&#94;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112220000103/e1699_10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Amended and Restated Employment Agreement between the Company and Sandra Boenisch, dated February 4, 2020 (incorporated by reference to our Quarterly Report on Form 10-Q filed on February 6, 2020)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11&#94;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112220000103/e1699_10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 2 to Amended and Restated Employment Agreement between the Company and Sandra Boenisch, dated February 28, 2022 (incorporated by reference to our Current Report on Form 8-K filed on March 4, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112220000432/e1889_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Sales Agreement, dated May 1, 2020, by and among the Company, Cantor Fitzgerald &amp; Co. and SVB Leerink LLC (incorporated by reference to our Current Report on Form 8-K filed on May 1, 2020)</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 82; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-transform: uppercase"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-transform: uppercase"><b></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
<td style="width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(14)</b></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code of Ethics</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416008914/s104917_ex14-1.htm">Code of Ethics Adopted on September 13, 2016 (incorporated by reference to our Annual Report on Form 10-K filed on December 14, 2016)</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(21)</b></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiaries</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/0001314052/000173112221002062/e3306_ex21-1.htm">Subsidiaries of the Registrant</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(23)</b></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consent</b></span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
<td><a href="e4251_ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Grant Thornton LLP Independent Registered Public Accounting Firm</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td>23.2*</td>
<td><a href="e4251_ex23-2.htm">Consent of BDO USA LLP Independent Registered Public Accounting Firm</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(31)</b></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 302 Certifications</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
<td><a href="e4251_ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 302 Certification of Christopher Missling, PhD.</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
<td><a href="e4251_ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 302 Certification of Sandra Boenisch</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(32)</b></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 906 Certifications</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
<td><a href="e4251_ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 906 Certification of Christopher Missling, PhD and Sandra Boenisch</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(101)</b></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>XBRL</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL INSTANCE DOCUMENT</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION SCHEMA</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-transform: uppercase"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>


<p style="margin: 0"></p>


<p style="margin: 0"></p>


<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">* Filed herewith.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">&#94; Denotes a management contract or compensatory plan or arrangement.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_025"></span>ITEM 16. FORM
10-K SUMMARY</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Not Applicable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 83; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Pursuant
to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date: November 28, 2022</b></span></td>
<td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX LIFE SCIENCES CORP.</b></span></td></tr>
<tr style="vertical-align: top">
<td style="width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
<td style="border-bottom: Black 1px solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Christopher Missling, PhD</i></span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (Principal Executive</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer)</span></td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">&#160;</span></p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt; background-color: white"></span></p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt; background-color: white"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signatures</b></span></td>
    <td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 47%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title(s)</b></span></td>
    <td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christopher Missling, PhD</i></span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (Principal Executive Officer)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Sandra
    Boenisch</i></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer and Treasurer (Principal
    Accounting Officer)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Athanasios
    Skarpelos</i></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Athanasios Skarpelos</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Claus
    van der Velden, PhD</i></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claus van der Velden, PhD</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Steffen
    Thomas, PhD</i></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steffen Thomas, PhD</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Peter
    Donhauser, D.O.</i></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Donhauser, D.O.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Jiong
    Ma, PhD</i></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiong Ma, PhD</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">86</span><span style="font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt; background-color: white"></span></p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>



<p style="margin: 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>e4251_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DESCRIPTION OF THE REGISTRANT&rsquo;S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp (the &ldquo;<U>Company</U>&rdquo;) has one class
of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: the Company&rsquo;s common stock, par value
$0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Description of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following summary description sets forth some of the general terms
and provisions of the Common Stock. Because this is a summary description, it does not contain all of the information that may be important
to you. For a more detailed description of the Company&rsquo;s Common Stock, you should refer to the provisions of the Company&rsquo;s
Articles of Incorporation, as amended (the &ldquo;Charter&rdquo;) and the Company&rsquo;s Bylaws (the &ldquo;Bylaws&rdquo;), each of which
is an exhibit to the Annual Report on Form 10-K to which this description is an exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Authorized Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are authorized to issue 200,000,000 shares of Common
Stock with a par value of $0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The outstanding shares of our Common Stock are fully paid and non-assessable.
The holders of Common Stock are entitled to one vote per share for the election of directors and with respect to all other matters submitted
to a vote of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Liquidation, Dissolution or Similar Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon liquidation, dissolution or winding up of the
corporation, the holders of Common Stock are entitled to share ratably in all net assets available for distribution to stockholders after
payment to creditors. The Common Stock is not convertible or redeemable and has no preemptive, subscription or conversion rights. There
are no conversion, redemption, sinking fund or similar provisions regarding the Common Stock. Each outstanding share of Common Stock is
entitled to one vote on all matters submitted to a vote of stockholders. There are no cumulative voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Dividend Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each stockholder is entitled to receive the dividends
as may be declared by our board of directors out of funds legally available for dividends and, in the event of liquidation, to share pro
rata in any distribution of our assets after payment of liabilities. Our board of directors is not obligated to declare a dividend. Any
future dividends will be subject to the discretion of our board of directors and will depend upon, among other things, future earnings,
the operating and financial condition of our Company, its capital requirements, general business conditions and other pertinent factors.
It is not anticipated that dividends will be paid in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Nevada Anti-Takeover Law and Charter and Bylaws Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nevada Revised Statutes sections 78.378 to 78.3793
provide state regulation over the acquisition of a controlling interest in certain Nevada corporations unless the articles of incorporation
or bylaws of the corporation provide that the provisions of these sections do not apply. The statute creates a number of restrictions
on the ability of a person or entity to acquire control of a Nevada company by setting down certain rules of conduct and voting restrictions
in any acquisition attempt, among other things. Our bylaws provide that these sections do not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no provisions in our articles of incorporation
or our bylaws that would delay, defer or prevent a change in control of our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Indemnification Of Directors And Executive Officers And Limitation On
Liability.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Bylaws provide that any person who was or is a
party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative, by reason of the fact that such person is or was a director, officer, employee or agent of the Company
(or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise) shall be indemnified and held harmless by the Company to the fullest extent permitted by Nevada law
against expenses including attorneys&rsquo; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by
such person in connection with such proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Bylaws also provide that the expenses of officers
and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the Company as they are incurred and
in advance of the final disposition of the action, suit or proceeding upon receipt of an undertaking by or on behalf of the director or
officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled to be indemnified
by the Company. Such right of indemnification shall be a contract right which may be enforced in any manner desired by such person. Such
right of indemnification shall not be exclusive of any other right which such directors, officers or representatives may have or hereafter
acquire and, without limiting the generality of such statement, they shall be entitled to their respective rights of indemnification under
any bylaw, agreement, vote of stockholders, provision of law or otherwise, as well as their rights under the Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Bylaws provide that the Board of Directors may
cause the Company to purchase and maintain insurance on behalf of any person who is or was a director or officer of the Company, or is
or was serving at the request of the Company as a director or officer of another Company, or as its representative in a partnership, joint
venture, trust or other enterprise against any liability asserted against such person and incurred in any such capacity or arising out
of such status, whether or not the Company would have the power to indemnify such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nevada Revised Statutes 78.751 and 78.7502 have provisions
that provide for discretionary and mandatory indemnification of officers, directors, employees, and agents of a corporation. Under these
provisions, such persons may be indemnified by a corporation against expenses, including attorney&rsquo;s fees, judgment, fines and amounts
paid in settlement, actually and reasonably incurred by him in connection with the action, suit or proceeding, if he acted in good faith
and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation and with respect to any
criminal action or proceeding had no reasonable cause to believe his conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the extent that a director, officer, employee or
agent has been successful on the merits or otherwise in defense of any action, suit or proceeding, or in defense of any claim, issue or
matter, the Nevada Revised Statues provide that he must be indemnified by the Company against expenses, including attorney&rsquo;s fees,
actually and reasonably incurred by him in connection with the defense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 78.7502 of the Nevada Revised Statues also
provides that any discretionary indemnification, unless ordered by a court or advanced by the Company, may be made only as authorized
in the specific case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The determination must be made:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By the stockholders;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By the Company&rsquo;s Board of Directors by majority vote of a quorum consisting of directors who were not parties to that act, suit or proceeding;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a majority vote of a quorum consisting of directors who were not parties to the act, suit or proceeding cannot be obtained, by independent legal counsel in a written opinion; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a quorum consisting of directors who were not parties to the act, suit or proceeding cannot be obtained, by independent legal counsel in a written opinion.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>e4251_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We have
issued our reports dated November 28, 2022, with respect to the consolidated financial statements and internal control over financial
reporting included in the Annual Report of Anavex Life Sciences Corp. on Form 10-K for the year ended September 30, 2022. We consent
to the incorporation by reference of said reports in the Registration Statements of Anavex Life Sciences Corp. on Forms S-3</FONT>
<FONT STYLE="font-size: 10pt">(No. 333-218292, and No. 333-259788) and Forms S-8 (No. 333-219934, No. 333-255166 and No. 333-265537)</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">/s/ GRANT THORNTON LLP</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Hartford, CT</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">November 28, 2022</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>e4251_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 23.2</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Consent of Independent Registered Public
Accounting Firm</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hereby consent to the incorporation by reference
in the Registration Statements on Form S-3 (No. 333-218292 and No. 333-259788) and Form S-8 (No. 333-219934, No. 333-255166 and
No. 333-265537) of Anavex Life Sciences Corp. and subsidiaries of our reports dated November 24, 2021, relating to the consolidated
financial statements and the effectiveness of Anavex Life Science Corp.&rsquo;s internal control over financial reporting, which
appear in this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/<I>s/ BDO USA, LLP</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">November 28, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; text-indent: 0cm"></P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>e4251_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 31.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Christopher Missling, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Annual Report on Form 10-K of Anavex Life Sciences Corp.;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top; width: 93%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 40%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
                       November 28, 2022 &nbsp;</FONT></P>
                       <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD>
<TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Christopher Missling</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
Missling, PhD </FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer, President,<BR>
 Secretary<BR> (Principal Executive Officer)</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>e4251_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Sandra Boenisch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual Report on Form 10-K of Anavex Life Sciences Corp.;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the financial statements, and other financial information included in this
                                            report, fairly present in all material respects the financial condition, results of operations
                                            and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and
                                            maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
                                            and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
                                            Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 93%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant, including its consolidated subsidiaries, is made known to us by others within
                                            those entities, particularly during the period in which this report is being prepared;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                    such internal control over financial reporting, or caused such internal control over financial reporting
                                    to be designed under our supervision, to provide reasonable assurance regarding the reliability of
                                    financial reporting and the preparation of financial statements for external purposes in accordance
                                    with generally accepted accounting principles;<BR>
</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this
                                    report our conclusions about the effectiveness of the disclosure controls and procedures, as of the
                                    end of the period covered by this report based on such evaluation; and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                    in this report any change in the registrant&rsquo;s internal control over financial reporting that
                                    occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth
                                    fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely
                                    to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                    significant deficiencies and material weaknesses in the design or operation of internal control over
                                    financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability
                                    to record, process, summarize and report financial information; and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                    fraud, whether or not material, that involves management or other employees who have a significant
                                    role in the registrant&rsquo;s internal control over financial reporting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
                           November 28, 2022</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sandra Boenisch</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra
    Boenisch, CPA, CGA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Financial Officer, Treasurer<BR>
    (Principal Financial and Accounting <BR>
Officer)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>e4251_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 32.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Annual Report of Anavex Life
Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-K for the fiscal year ending September 30, 2022 as filed with the Securities and
Exchange Commission (the &ldquo;Report&rdquo;), the undersigned, in the capacities and on the date indicated below, hereby certify, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
<TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company. &nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: November 28, 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Christopher Missling</I></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Executive Officer, President, Secretary (Principal Executive Officer)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>/s/ Sandra Boenisch&#9;</I></P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 169.65pt">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer, Treasurer<BR>
(Principal Financial and Accounting<BR>
 Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin: 0; text-align: justify">The foregoing certification is being furnished solely to accompany the
Report pursuant to 18 U.S.C. &sect; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless
of any general incorporation language in such filing. A signed original of this written statement required by Section 906, or other document
authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written
statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>avxl-20220930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8KlZs7xRiXgen8uCandcSaeFOcPtxJFzmZkhv2p2fTma3ysomAR/8SJnx7VGkegJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:avxl="http://anavex.com/20220930" elementFormDefault="qualified" targetNamespace="http://anavex.com/20220930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" id="ConsolidatedStatementsOfChangesInStockholdersEquity">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" id="BusinessDescriptionAndBasisOfPresentation">
	  <link:definition>00000007 - Disclosure - Business Description and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilities" id="AccruedLiabilities">
	  <link:definition>00000009 - Disclosure - Accrued Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000010 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferings" id="EquityOfferings">
	  <link:definition>00000011 - Disclosure - Equity Offerings</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000012 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000013 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000014 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
	  <link:definition>00000015 - Disclosure - Accrued Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000016 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000017 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000018 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" id="AccruedLiabilitiesDetails">
	  <link:definition>00000019 - Disclosure - Accrued Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000020 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" id="EquityOfferingsDetailsNarrative">
	  <link:definition>00000021 - Disclosure - Equity Offerings (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000022 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000023 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
	  <link:definition>00000024 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
	  <link:definition>00000025 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
	  <link:definition>00000026 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" id="CommitmentsAndContingenciesDetails5">
	  <link:definition>00000027 - Disclosure - Commitments and Contingencies (Details 5)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000028 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000029 - Disclosure - Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000030 - Disclosure - Income Taxes (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
	  <link:definition>00000031 - Disclosure - Income Taxes (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000032 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="avxl_MichaelJFoxMember" name="MichaelJFoxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ParkinsonMember" name="ParkinsonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2022Member" name="StockOptionPlan2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrantsMember" name="PurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice1Member" name="OptionPrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice2Member" name="OptionPrice2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice3Member" name="OptionPrice3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice4Member" name="OptionPrice4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice5Member" name="OptionPrice5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FederalMember" name="FederalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrants" name="NonOperatingIncomeFromGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NetLossAndComprehensiveLoss" name="NetLossAndComprehensiveLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EarningPerShareBasicAndDilutedAbstract" name="EarningPerShareBasicAndDilutedAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NetLossPerShareBasicAndDiluted" name="NetLossPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncomes" name="DeferredGrantIncomes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" name="CashPaidForStateAndLocalMinimumIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptions" name="SharesIssuedPursuantToExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" name="SharesIssuedPursuantToExerciseOfStockOptionsInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionInShares" name="SharesIssuedPursuantToCashlessExerciseOfOptionInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOptionInShares" name="SharesIssuedPursuantToCashlessExerciseOptionInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnderSalesAgreement" name="SharesIssuedUnderSalesAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnderSalesAgreementInShares" name="SharesIssuedUnderSalesAgreementInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LessShareIssueCosts" name="LessShareIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToRegisteredDirectOffering" name="SharesIssuedPursuantToRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToRegisteredDirectOfferingInShares" name="SharesIssuedPursuantToRegisteredDirectOfferingInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LessSharesIssueCosts" name="LessSharesIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPusuantToExerciseOfWarrants" name="SharesIssuedPusuantToExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPusuantToExerciseOfWarrantsInShares" name="SharesIssuedPusuantToExerciseOfWarrantsInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureAccruedLiabilitiesAbstract" name="DisclosureAccruedLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccuredLiabilitiesTextBlock" name="AccuredLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingsAbstract" name="DisclosureEquityOfferingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingAgreementsTextBlock" name="EquityOfferingAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrantIncomePolicyTextBlock" name="GrantIncomePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ClinicalSiteCostsAndPatientVisits" name="ClinicalSiteCostsAndPatientVisits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FixedContractAccruals" name="FixedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrantIncome" name="GrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncome" name="DeferredGrantIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingsIncomeFromGrant" name="NonOperatingsIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrossProceedsFromIssuancePublicOffering" name="GrossProceedsFromIssuancePublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SalesOfAgreementAmount" name="SalesOfAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues4" name="StockIssuedDuringPeriodSharesNewIssues4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues3" name="StockIssuedDuringPeriodValueNewIssues3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues3" name="StockIssuedDuringPeriodSharesNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues4" name="StockIssuedDuringPeriodValueNewIssues4" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionIssued" name="OptionIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredTaxAssetsUnpaidCharges" name="DeferredTaxAssetsUnpaidCharges" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PermanentDifferencesRelatingToStockBasedCompensation" name="PermanentDifferencesRelatingToStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PermanentDifferencesRelatingToSection162m" name="PermanentDifferencesRelatingToSection162m" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AdjustmentToTaxAssetsBasedOnSection382" name="AdjustmentToTaxAssetsBasedOnSection382" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" name="IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OperatingLossCarryforwardsDescription" name="OperatingLossCarryforwardsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OperatingLossCarryForwardsExpirationYear" name="OperatingLossCarryForwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>avxl-20220930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20220930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:href="avxl-20220930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20220930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20220930.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="avxl-20220930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20220930.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20220930.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="avxl-20220930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20220930.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20220930.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20220930.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20220930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxes" xlink:href="avxl-20220930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avxl-20220930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20220930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesTables" xlink:href="avxl-20220930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="avxl-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20220930.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20220930.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20220930.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails" xlink:href="avxl-20220930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails1" xlink:href="avxl-20220930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails2" xlink:href="avxl-20220930.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:href="avxl-20220930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaapDeferredRentCredit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRentCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NetLossAndComprehensiveLoss" xlink:label="loc_avxlNetLossAndComprehensiveLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_avxlNetLossAndComprehensiveLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_avxlNetLossAndComprehensiveLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DeferredGrantIncomes" xlink:label="loc_avxlDeferredGrantIncomes" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlDeferredGrantIncomes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000009 - Disclosure - Accrued Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000010 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000014 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000015 - Disclosure - Accrued Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000016 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="00000017 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000019 - Disclosure - Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ClinicalSiteCostsAndPatientVisits" xlink:label="loc_avxlClinicalSiteCostsAndPatientVisits" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_avxlClinicalSiteCostsAndPatientVisits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_FixedContractAccruals" xlink:label="loc_avxlFixedContractAccruals" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_avxlFixedContractAccruals" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000020 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000021 - Disclosure - Equity Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="00000027 - Disclosure - Commitments and Contingencies (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000028 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="00000029 - Disclosure - Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="00000030 - Disclosure - Income Taxes (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails2" xlink:title="00000031 - Disclosure - Income Taxes (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000032 - Disclosure - Income Taxes (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>avxl-20220930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20220930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:href="avxl-20220930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20220930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20220930.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="avxl-20220930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20220930.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20220930.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="avxl-20220930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20220930.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20220930.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20220930.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20220930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxes" xlink:href="avxl-20220930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avxl-20220930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20220930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesTables" xlink:href="avxl-20220930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="avxl-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20220930.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20220930.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20220930.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails" xlink:href="avxl-20220930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails1" xlink:href="avxl-20220930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails2" xlink:href="avxl-20220930.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:href="avxl-20220930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsInShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsInShares_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptionInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionInShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionInShares_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOptionInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOptionInShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOptionInShares_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedUnderSalesAgreement" xlink:label="loc_avxlSharesIssuedUnderSalesAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreement_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedUnderSalesAgreementInShares" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementInShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementInShares_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_LessShareIssueCosts" xlink:label="loc_avxlLessShareIssueCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlLessShareIssueCosts_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOffering" xlink:label="loc_avxlSharesIssuedPursuantToRegisteredDirectOffering_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToRegisteredDirectOffering_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingInShares" xlink:label="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingInShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingInShares_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_LessSharesIssueCosts" xlink:label="loc_avxlLessSharesIssueCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlLessSharesIssueCosts_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPusuantToExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPusuantToExerciseOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPusuantToExerciseOfWarrants_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPusuantToExerciseOfWarrantsInShares" xlink:label="loc_avxlSharesIssuedPusuantToExerciseOfWarrantsInShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPusuantToExerciseOfWarrantsInShares_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000009 - Disclosure - Accrued Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000010 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000014 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000015 - Disclosure - Accrued Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000016 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="00000017 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000019 - Disclosure - Accrued Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000020 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_MichaelJFoxMember" xlink:label="loc_avxlMichaelJFoxMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ParkinsonMember" xlink:label="loc_avxlParkinsonMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlParkinsonMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="loc_currencyAUD_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_GrantIncome" xlink:label="loc_avxlGrantIncome_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlGrantIncome_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlDeferredGrantIncome_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NonOperatingsIncomeFromGrant" xlink:label="loc_avxlNonOperatingsIncomeFromGrant_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingsIncomeFromGrant_120" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000021 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_GrossProceedsFromIssuancePublicOffering" xlink:label="loc_avxlGrossProceedsFromIssuancePublicOffering_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromIssuancePublicOffering_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4_90" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="00000027 - Disclosure - Commitments and Contingencies (Details 5)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000028 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPensionContributions_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="00000029 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="00000030 - Disclosure - Income Taxes (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails2" xlink:title="00000031 - Disclosure - Income Taxes (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000032 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_FederalMember" xlink:label="loc_avxlFederalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_avxlFederalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="loc_currencyAUD_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OperatingLossCarryforwardsDescription" xlink:label="loc_avxlOperatingLossCarryforwardsDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_avxlOperatingLossCarryforwardsDescription_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OperatingLossCarryForwardsExpirationYear" xlink:label="loc_avxlOperatingLossCarryForwardsExpirationYear_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_avxlOperatingLossCarryForwardsExpirationYear_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_120" xlink:type="arc" order="4" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>avxl-20220930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_MichaelJFoxMember" xlink:label="avxl_MichaelJFoxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MichaelJFoxMember" xlink:to="avxl_MichaelJFoxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MichaelJFoxMember_lbl" xml:lang="en-US">Michael J Fox [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ParkinsonMember" xlink:label="avxl_ParkinsonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ParkinsonMember" xlink:to="avxl_ParkinsonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ParkinsonMember_lbl" xml:lang="en-US">Parkinson [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald And Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">2019 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">2015 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">2019 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockOptionPlan2022Member" xlink:label="avxl_StockOptionPlan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2022Member" xlink:to="avxl_StockOptionPlan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2022Member_lbl" xml:lang="en-US">Stock Option Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PurchaseWarrantsMember" xlink:label="avxl_PurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrantsMember_lbl" xml:lang="en-US">Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Purchase Warrants 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice1Member" xlink:label="avxl_OptionPrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice1Member" xlink:to="avxl_OptionPrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice1Member_lbl" xml:lang="en-US">Option Price 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice2Member" xlink:label="avxl_OptionPrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice2Member" xlink:to="avxl_OptionPrice2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice2Member_lbl" xml:lang="en-US">Option Price 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice3Member" xlink:label="avxl_OptionPrice3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice3Member" xlink:to="avxl_OptionPrice3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice3Member_lbl" xml:lang="en-US">Option Price 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice4Member" xlink:label="avxl_OptionPrice4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice4Member" xlink:to="avxl_OptionPrice4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice4Member_lbl" xml:lang="en-US">Option Price 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice5Member" xlink:label="avxl_OptionPrice5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice5Member" xlink:to="avxl_OptionPrice5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice5Member_lbl" xml:lang="en-US">Option Price 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_FederalMember" xlink:label="avxl_FederalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FederalMember" xlink:to="avxl_FederalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FederalMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities (Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US">Deferred grant income (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 6</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding:77,942,568 common shares (September 30, 2021 - 75,918,465)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common shares, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="avxl_NonOperatingIncomeFromGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrants" xlink:to="avxl_NonOperatingIncomeFromGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrants_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange (loss) gain, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NetLossAndComprehensiveLoss" xlink:label="avxl_NetLossAndComprehensiveLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NetLossAndComprehensiveLoss" xlink:to="avxl_NetLossAndComprehensiveLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="avxl_NetLossAndComprehensiveLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_EarningPerShareBasicAndDilutedAbstract" xlink:label="avxl_EarningPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EarningPerShareBasicAndDilutedAbstract" xlink:to="avxl_EarningPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EarningPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NetLossPerShareBasicAndDiluted" xlink:label="avxl_NetLossPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NetLossPerShareBasicAndDiluted" xlink:to="avxl_NetLossPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NetLossPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DeferredGrantIncomes" xlink:label="avxl_DeferredGrantIncomes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncomes" xlink:to="avxl_DeferredGrantIncomes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avxl_DeferredGrantIncomes_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationRelatedText" xlink:to="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:to="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xml:lang="en-US">Cash paid for state and local minimum income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance at beginning, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Shares issued under 2019 purchase agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Purchase shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_lbl" xml:lang="en-US">Commitment shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptionInShares" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionInShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionInShares_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOptionInShares" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOptionInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOptionInShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOptionInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOptionInShares_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of options (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedUnderSalesAgreement" xlink:label="avxl_SharesIssuedUnderSalesAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnderSalesAgreement" xlink:to="avxl_SharesIssuedUnderSalesAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnderSalesAgreement_lbl" xml:lang="en-US">Shares issued under Sales Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedUnderSalesAgreementInShares" xlink:label="avxl_SharesIssuedUnderSalesAgreementInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnderSalesAgreementInShares" xlink:to="avxl_SharesIssuedUnderSalesAgreementInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnderSalesAgreementInShares_lbl" xml:lang="en-US">Shares issued under Sales Agreement (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_LessShareIssueCosts" xlink:label="avxl_LessShareIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LessShareIssueCosts" xlink:to="avxl_LessShareIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LessShareIssueCosts_lbl" xml:lang="en-US">Less: share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOffering" xlink:label="avxl_SharesIssuedPursuantToRegisteredDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToRegisteredDirectOffering" xlink:to="avxl_SharesIssuedPursuantToRegisteredDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToRegisteredDirectOffering_lbl" xml:lang="en-US">Shares issued pursuant to registered direct offering</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingInShares" xlink:label="avxl_SharesIssuedPursuantToRegisteredDirectOfferingInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToRegisteredDirectOfferingInShares" xlink:to="avxl_SharesIssuedPursuantToRegisteredDirectOfferingInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToRegisteredDirectOfferingInShares_lbl" xml:lang="en-US">Shares issued pursuant to registered direct offering (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_LessSharesIssueCosts" xlink:label="avxl_LessSharesIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LessSharesIssueCosts" xlink:to="avxl_LessSharesIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_LessSharesIssueCosts_lbl" xml:lang="en-US">Less: share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPusuantToExerciseOfWarrants" xlink:label="avxl_SharesIssuedPusuantToExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPusuantToExerciseOfWarrants" xlink:to="avxl_SharesIssuedPusuantToExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPusuantToExerciseOfWarrants_lbl" xml:lang="en-US">Shares issued pusuant to exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPusuantToExerciseOfWarrantsInShares" xlink:label="avxl_SharesIssuedPusuantToExerciseOfWarrantsInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPusuantToExerciseOfWarrantsInShares" xlink:to="avxl_SharesIssuedPusuantToExerciseOfWarrantsInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPusuantToExerciseOfWarrantsInShares_lbl" xml:lang="en-US">Shares issued pusuant to exercise of warrants (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance at ending, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="avxl_DisclosureAccruedLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureAccruedLiabilitiesAbstract" xlink:to="avxl_DisclosureAccruedLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_AccuredLiabilitiesTextBlock" xlink:label="avxl_AccuredLiabilitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccuredLiabilitiesTextBlock" xlink:to="avxl_AccuredLiabilitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_AccuredLiabilitiesTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="avxl_DisclosureEquityOfferingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingsAbstract" xlink:to="avxl_DisclosureEquityOfferingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingsAbstract_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="avxl_EquityOfferingAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingAgreementsTextBlock_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionIncentives" xlink:label="us-gaap_RevenueRecognitionIncentives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionIncentives" xlink:to="us-gaap_RevenueRecognitionIncentives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionIncentives_lbl" xml:lang="en-US">Research and Development Incentive Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment and Geographic Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_GrantIncomePolicyTextBlock" xlink:label="avxl_GrantIncomePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrantIncomePolicyTextBlock" xlink:to="avxl_GrantIncomePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US">Grant Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of components of accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of exercisable share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summarizes information about stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax asset and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal Deposit Insurance Corporation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US">Uncertain tax positions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Interest and penalties</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ClinicalSiteCostsAndPatientVisits" xlink:label="avxl_ClinicalSiteCostsAndPatientVisits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalSiteCostsAndPatientVisits" xlink:to="avxl_ClinicalSiteCostsAndPatientVisits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ClinicalSiteCostsAndPatientVisits_lbl" xml:lang="en-US">Accrued clinical site and patient visits costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_FixedContractAccruals" xlink:label="avxl_FixedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FixedContractAccruals" xlink:to="avxl_FixedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FixedContractAccruals_lbl" xml:lang="en-US">Fixed contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">All other accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_GrantIncome" xlink:label="avxl_GrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrantIncome" xlink:to="avxl_GrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_GrantIncome_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DeferredGrantIncome" xlink:label="avxl_DeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NonOperatingsIncomeFromGrant" xlink:label="avxl_NonOperatingsIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingsIncomeFromGrant" xlink:to="avxl_NonOperatingsIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_NonOperatingsIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_GrossProceedsFromIssuancePublicOffering" xlink:label="avxl_GrossProceedsFromIssuancePublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrossProceedsFromIssuancePublicOffering" xlink:to="avxl_GrossProceedsFromIssuancePublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrossProceedsFromIssuancePublicOffering_lbl" xml:lang="en-US">Gross proceeds from Issuance Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SalesOfAgreementAmount" xlink:label="avxl_SalesOfAgreementAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SalesOfAgreementAmount" xlink:to="avxl_SalesOfAgreementAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SalesOfAgreementAmount_lbl" xml:lang="en-US">Sales of agreement amount</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Value of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Share issued for offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Share Purchase Warrants Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, lower range limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, upper range limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of outstanding options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions" xlink:label="us-gaap_PensionContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionContributions" xlink:to="us-gaap_PensionContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionContributions_lbl" xml:lang="en-US">Contribution amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionIssued" xlink:label="avxl_OptionIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionIssued" xlink:to="avxl_OptionIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionIssued_lbl" xml:lang="en-US">Option issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of options vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average contractual life of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">United States</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DeferredTaxAssetsUnpaidCharges" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredTaxAssetsUnpaidCharges" xlink:to="avxl_DeferredTaxAssetsUnpaidCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges_lbl" xml:lang="en-US">Unpaid charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible asset costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xml:lang="en-US">Foreign exchange and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax benefit at statutory federal rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign income taxed at other rates</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PermanentDifferencesRelatingToStockBasedCompensation" xlink:label="avxl_PermanentDifferencesRelatingToStockBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PermanentDifferencesRelatingToStockBasedCompensation" xlink:to="avxl_PermanentDifferencesRelatingToStockBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PermanentDifferencesRelatingToStockBasedCompensation_lbl" xml:lang="en-US">Permanent differences relating to stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PermanentDifferencesRelatingToSection162m" xlink:label="avxl_PermanentDifferencesRelatingToSection162m" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PermanentDifferencesRelatingToSection162m" xlink:to="avxl_PermanentDifferencesRelatingToSection162m_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PermanentDifferencesRelatingToSection162m_lbl" xml:lang="en-US">Permanent differences relating to Section 162(m)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_AdjustmentToTaxAssetsBasedOnSection382" xlink:label="avxl_AdjustmentToTaxAssetsBasedOnSection382" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AdjustmentToTaxAssetsBasedOnSection382" xlink:to="avxl_AdjustmentToTaxAssetsBasedOnSection382_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AdjustmentToTaxAssetsBasedOnSection382_lbl" xml:lang="en-US">Adjustment to tax assets based on Section 382</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" xlink:label="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" xlink:to="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_lbl" xml:lang="en-US">Research and development credits, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State and local taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Adjustment to true up to prior years' tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Effect of change in statutory tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:label="us-gaap_TaxesExcludingIncomeAndExciseTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:to="us-gaap_TaxesExcludingIncomeAndExciseTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesExcludingIncomeAndExciseTaxes_lbl" xml:lang="en-US">State minimum and excise taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OperatingLossCarryforwardsDescription" xlink:label="avxl_OperatingLossCarryforwardsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OperatingLossCarryforwardsDescription" xlink:to="avxl_OperatingLossCarryforwardsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OperatingLossCarryforwardsDescription_lbl" xml:lang="en-US">Operating loss carryforwards description</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OperatingLossCarryForwardsExpirationYear" xlink:label="avxl_OperatingLossCarryForwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OperatingLossCarryForwardsExpirationYear" xlink:to="avxl_OperatingLossCarryForwardsExpirationYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OperatingLossCarryForwardsExpirationYear_lbl" xml:lang="en-US">Operating loss carry forwards expiration year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and Development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Decrease in vaution allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PercentageOfGrossProceedsFromSales_doc" xml:lang="en-US">Represents information related to percentage of gross proceeds from sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ValueOfSharesObligatedToPurchase_doc" xml:lang="en-US">Information related to value of shares obligated to purchase initially.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreement1Member_doc" xml:lang="en-US">Represents the information pertaining to purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Information related to type of legal entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xml:lang="en-US">Information related to number of shares obligated to purchase prorata basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrantsMember_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredTaxAssetsUnpaidCharges" xlink:to="avxl_DeferredTaxAssetsUnpaidCharges_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges_doc" xml:lang="en-US">It represents as a deferred tax assets unpaid charges.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NetLossAndComprehensiveLoss" xlink:to="avxl_NetLossAndComprehensiveLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NetLossAndComprehensiveLoss_2_lbl" xml:lang="en-US">NetLossAndComprehensiveLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncomes" xlink:to="avxl_DeferredGrantIncomes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncomes_2_lbl" xml:lang="en-US">DeferredGrantIncomes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LessSharesIssueCosts" xlink:to="avxl_LessSharesIssueCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LessSharesIssueCosts_2_lbl" xml:lang="en-US">LessSharesIssueCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccuredLiabilitiesTextBlock" xlink:to="avxl_AccuredLiabilitiesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccuredLiabilitiesTextBlock_2_lbl" xml:lang="en-US">AccuredLiabilitiesTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingAgreementsTextBlock_2_lbl" xml:lang="en-US">EquityOfferingAgreementsTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrantIncome" xlink:to="avxl_GrantIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrantIncome_2_lbl" xml:lang="en-US">GrantIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_2_lbl" xml:lang="en-US">NonOperatingIncomeFromGrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingsIncomeFromGrant" xlink:to="avxl_NonOperatingsIncomeFromGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingsIncomeFromGrant_2_lbl" xml:lang="en-US">NonOperatingsIncomeFromGrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>avxl-20220930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20220930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:href="avxl-20220930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20220930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20220930.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="avxl-20220930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20220930.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20220930.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="avxl-20220930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20220930.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20220930.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20220930.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20220930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxes" xlink:href="avxl-20220930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avxl-20220930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20220930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesTables" xlink:href="avxl-20220930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="avxl-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20220930.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20220930.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20220930.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20220930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails" xlink:href="avxl-20220930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails1" xlink:href="avxl-20220930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails2" xlink:href="avxl-20220930.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:href="avxl-20220930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaapDeferredRentCredit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRentCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NetLossAndComprehensiveLoss" xlink:label="loc_avxlNetLossAndComprehensiveLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_avxlNetLossAndComprehensiveLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_EarningPerShareBasicAndDilutedAbstract" xlink:label="loc_avxlEarningPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_avxlEarningPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NetLossPerShareBasicAndDiluted" xlink:label="loc_avxlNetLossPerShareBasicAndDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlEarningPerShareBasicAndDilutedAbstract" xlink:to="loc_avxlNetLossPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_avxlWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_avxlWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DeferredGrantIncomes" xlink:label="loc_avxlDeferredGrantIncomes" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_avxlDeferredGrantIncomes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="loc_us-gaapSupplementalCashFlowInformationRelatedText" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:to="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsInShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptionInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionInShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOptionInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOptionInShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOptionInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedUnderSalesAgreement" xlink:label="loc_avxlSharesIssuedUnderSalesAgreement" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedUnderSalesAgreementInShares" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementInShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_LessShareIssueCosts" xlink:label="loc_avxlLessShareIssueCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlLessShareIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOffering" xlink:label="loc_avxlSharesIssuedPursuantToRegisteredDirectOffering" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToRegisteredDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingInShares" xlink:label="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingInShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_LessSharesIssueCosts" xlink:label="loc_avxlLessSharesIssueCosts" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlLessSharesIssueCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPusuantToExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPusuantToExerciseOfWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPusuantToExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SharesIssuedPusuantToExerciseOfWarrantsInShares" xlink:label="loc_avxlSharesIssuedPusuantToExerciseOfWarrantsInShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPusuantToExerciseOfWarrantsInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000009 - Disclosure - Accrued Liabilities">
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="loc_avxlDisclosureAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_AccuredLiabilitiesTextBlock" xlink:label="loc_avxlAccuredLiabilitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlAccuredLiabilitiesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000010 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings">
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="loc_avxlEquityOfferingAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_avxlEquityOfferingAgreementsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000014 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionIncentives" xlink:label="loc_us-gaapRevenueRecognitionIncentives" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionIncentives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_GrantIncomePolicyTextBlock" xlink:label="loc_avxlGrantIncomePolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_avxlGrantIncomePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="loc_us-gaapShareBasedCompensationForfeituresPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationForfeituresPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000015 - Disclosure - Accrued Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="loc_avxlDisclosureAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000016 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="00000017 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000019 - Disclosure - Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="loc_avxlDisclosureAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ClinicalSiteCostsAndPatientVisits" xlink:label="loc_avxlClinicalSiteCostsAndPatientVisits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlClinicalSiteCostsAndPatientVisits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_FixedContractAccruals" xlink:label="loc_avxlFixedContractAccruals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlFixedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000020 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_MichaelJFoxMember" xlink:label="loc_avxlMichaelJFoxMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ParkinsonMember" xlink:label="loc_avxlParkinsonMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlParkinsonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_GrantIncome" xlink:label="loc_avxlGrantIncome" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlGrantIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlDeferredGrantIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NonOperatingsIncomeFromGrant" xlink:label="loc_avxlNonOperatingsIncomeFromGrant" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingsIncomeFromGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000021 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_GrossProceedsFromIssuancePublicOffering" xlink:label="loc_avxlGrossProceedsFromIssuancePublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromIssuancePublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="00000027 - Disclosure - Commitments and Contingencies (Details 5)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000028 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPensionContributions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="00000029 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="00000030 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_DeferredTaxAssetsUnpaidCharges" xlink:label="loc_avxlDeferredTaxAssetsUnpaidCharges" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlDeferredTaxAssetsUnpaidCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="loc_us-gaapDeferredTaxAssetsUnrealizedCurrencyLosses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails2" xlink:title="00000031 - Disclosure - Income Taxes (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PermanentDifferencesRelatingToStockBasedCompensation" xlink:label="loc_avxlPermanentDifferencesRelatingToStockBasedCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlPermanentDifferencesRelatingToStockBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_PermanentDifferencesRelatingToSection162m" xlink:label="loc_avxlPermanentDifferencesRelatingToSection162m" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlPermanentDifferencesRelatingToSection162m" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_AdjustmentToTaxAssetsBasedOnSection382" xlink:label="loc_avxlAdjustmentToTaxAssetsBasedOnSection382" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlAdjustmentToTaxAssetsBasedOnSection382" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" xlink:label="loc_avxlIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:label="loc_us-gaapTaxesExcludingIncomeAndExciseTaxes" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapTaxesExcludingIncomeAndExciseTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000032 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_FederalMember" xlink:label="loc_avxlFederalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_avxlFederalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OperatingLossCarryforwardsDescription" xlink:label="loc_avxlOperatingLossCarryforwardsDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_avxlOperatingLossCarryforwardsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220930.xsd#avxl_OperatingLossCarryForwardsExpirationYear" xlink:label="loc_avxlOperatingLossCarryForwardsExpirationYear" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_avxlOperatingLossCarryForwardsExpirationYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /B!](# 2(  A$! Q$!_\0
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MM_M&GWEO=P9*^;;RK(N1U&0<59H **** "BBB@ HHHH **** "BBB@ HHHH
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M\# 1<*% &0!G@YK0\0^$++6-+$%FEOI][%-%<6UW';J3%(CA@<#&1Q@C/0T
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M=MYGDQ#"^;*TK8SGEG)8_B: . ^($&MV8MM:OM0MKWP_8W\-Q)IL4!AD8>8
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MK_\ D_'_ (5T%% '/_VOXB_Z%?\ \GX_\*/[7\1?]"O_ .5"/_"N@HH Y_\
MM?Q%_P!"O_Y4(_\ "C^U_$7_ $*__D_'_A7044 <_P#VOXB_Z%?_ ,GX_P#"
MC^U_$7_0K_\ E0C_ ,*Z"B@#G_[7\1?]"O\ ^5"/_"C^U_$7_0K_ /D_'_A7
M044 <_\ VOXB_P"A7_\ )^/_  H_M?Q%_P!"O_Y4(_\ "N@HH Y_^U_$7_0K
M_P#E0C_PH_M?Q%_T*_\ Y/Q_X5T%% '/_P!K^(O^A7_\GX_\*/[7\1?]"O\
M^5"/_"N@HH Y_P#M?Q%_T*__ )4(_P#"C^U_$7_0K_\ D_'_ (5T%% '/_VO
MXB_Z%?\ \GX_\*/[7\1?]"O_ .5"/_"N@HH Y_\ M?Q%_P!"O_Y4(_\ "C^U
M_$7_ $*__D_'_A7044 <_P#VOXB_Z%?_ ,GX_P#"C^U_$7_0K_\ E0C_ ,*Z
M"B@#G_[7\1?]"O\ ^5"/_"C^U_$7_0K_ /D_'_A7044 <_\ VOXB_P"A7_\
M)^/_  H_M?Q%_P!"O_Y4(_\ "N@HH Y_^U_$7_0K_P#E0C_PH_M?Q%_T*_\
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MK_\ D_'_ (5T%% '/_VOXB_Z%?\ \GX_\*/[7\1?]"O_ .5"/_"N@HH Y_\
MM?Q%_P!"O_Y4(_\ "C^U_$7_ $*__D_'_A7044 <_P#VOXB_Z%?_ ,GX_P#"
MC^U_$7_0K_\ E0C_ ,*Z"B@#G_[7\1?]"O\ ^5"/_"C^U_$7_0K_ /D_'_A7
M044 <_\ VOXB_P"A7_\ )^/_  H_M?Q%_P!"O_Y4(_\ "N@HH Y_^U_$7_0K
M_P#E0C_PH_M?Q%_T*_\ Y/Q_X5T%% '/_P!K^(O^A7_\GX_\*/[7\1?]"O\
M^5"/_"N@HH Y_P#M?Q%_T*__ )4(_P#"C^U_$7_0K_\ D_'_ (5T%% '/_VO
MXB_Z%?\ \GX_\*/[7\1?]"O_ .5"/_"N@HH Y_\ M?Q%_P!"O_Y4(_\ "C^U
M_$7_ $*__D_'_A7044 <_P#VOXB_Z%?_ ,GX_P#"C^U_$7_0K_\ E0C_ ,*Z
M"B@#G_[7\1?]"O\ ^5"/_"C^U_$7_0K_ /D_'_A7044 <_\ VOXB_P"A7_\
M)^/_  H_M?Q%_P!"O_Y4(_\ "N@HH Y_^U_$7_0K_P#E0C_PH_M?Q%_T*_\
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MK_\ D_'_ (5T%% '/_VOXB_Z%?\ \GX_\*/[7\1?]"O_ .5"/_"N@HH Y_\
MM?Q%_P!"O_Y4(_\ "C^U_$7_ $*__D_'_A7044 <_P#VOXB_Z%?_ ,GX_P#"
MC^U_$7_0K_\ E0C_ ,*Z"B@#G_[7\1?]"O\ ^5"/_"C^U_$7_0K_ /D_'_A7
M044 <_\ VOXB_P"A7_\ )^/_  H_M?Q%_P!"O_Y4(_\ "N@HH Y_^U_$7_0K
M_P#E0C_PH_M?Q%_T*_\ Y/Q_X5T%% '/_P!K^(O^A7_\GX_\*/[7\1?]"O\
M^5"/_"N@HH Y_P#M?Q%_T*__ )4(_P#"C^U_$7_0K_\ D_'_ (5T%% '/_VO
MXB_Z%?\ \GX_\*/[7\1?]"O_ .5"/_"N@HH Y_\ M?Q%_P!"O_Y4(_\ "C^U
M_$7_ $*__D_'_A7044 <_P#VOXB_Z%?_ ,GX_P#"C^U_$7_0K_\ E0C_ ,*Z
M"B@#G_[7\1?]"O\ ^5"/_"C^U_$7_0K_ /D_'_A7044 <_\ VOXB_P"A7_\
M)^/_  H_M?Q%_P!"O_Y4(_\ "N@HH Y_^U_$7_0K_P#E0C_PH_M?Q%_T*_\
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MK_\ D_'_ (5T%% '/_VOXB_Z%?\ \GX_\*/[7\1?]"O_ .5"/_"N@HH Y_\
MM?Q%_P!"O_Y4(_\ "C^U_$7_ $*__D_'_A7044 <_P#VOXB_Z%?_ ,GX_P#"
MC^U_$7_0K_\ E0C_ ,*Z"B@#G_[7\1?]"O\ ^5"/_"C^U_$7_0K_ /D_'_A7
M044 <_\ VOXB_P"A7_\ )^/_  H_M?Q%_P!"O_Y4(_\ "N@HH Y_^U_$7_0K
M_P#E0C_PH_M?Q%_T*_\ Y/Q_X5T%% '/_P!K^(O^A7_\GX_\*/[7\1?]"O\
M^5"/_"N@HH Y_P#M?Q%_T*__ )4(_P#"C^U_$7_0K_\ D_'_ (5T%% '/_VO
MXB_Z%?\ \GX_\*/[7\1?]"O_ .5"/_"N@HH Y_\ M?Q%_P!"O_Y4(_\ "C^U
M_$7_ $*__D_'_A7044 <_P#VOXB_Z%?_ ,GX_P#"C^U_$7_0K_\ E0C_ ,*Z
M"B@#G_[7\1?]"O\ ^5"/_"C^U_$7_0K_ /D_'_A7044 <_\ VOXB_P"A7_\
M)^/_  H_M?Q%_P!"O_Y4(_\ "N@HH Y_^U_$7_0K_P#E0C_PH_M?Q%_T*_\
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MK_\ D_'_ (5T%% '/_VOXB_Z%?\ \GX_\*/[7\1?]"O_ .5"/_"N@HH Y_\
MM?Q%_P!"O_Y4(_\ "C^U_$7_ $*__D_'_A7044 <_P#VOXB_Z%?_ ,GX_P#"
MC^U_$7_0K_\ E0C_ ,*Z"B@#G_[7\1?]"O\ ^5"/_"C^U_$7_0K_ /D_'_A7
M044 <_\ VOXB_P"A7_\ )^/_  H_M?Q%_P!"O_Y4(_\ "N@HH Y_^U_$7_0K
M_P#E0C_PH_M?Q%_T*_\ Y/Q_X5T%% '/_P!K^(O^A7_\GX_\*/[7\1?]"O\
M^5"/_"N@HH Y_P#M?Q%_T*__ )4(_P#"C^U_$7_0K_\ D_'_ (5T%% '/_VO
MXB_Z%?\ \GX_\*/[7\1?]"O_ .5"/_"N@HH Y_\ M?Q%_P!"O_Y4(_\ "C^U
M_$7_ $*__D_'_A7044 <_P#VOXB_Z%?_ ,GX_P#"C^U_$7_0K_\ E0C_ ,*Z
M"B@#G_[7\1?]"O\ ^5"/_"C^U_$7_0K_ /D_'_A7044 <_\ VOXB_P"A7_\
M)^/_  H_M?Q%_P!"O_Y4(_\ "N@HH Y_^U_$7_0K_P#E0C_PH_M?Q%_T*_\
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M_P#LJ/\ A"?^HA_Y!_\ LJ.?,OY5^'^8<N"[_G_D6_\ A,M._P">-U_WRO\
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M(/<5QU\/.C*TCIHUHU5=#Z***P-@HHHH **** "BBB@ HHHH **** "BBB@
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MN7.DF))<MV9^H:;-IS0+*R-YT0E7:3P#V/O2OIDT>D1ZD63R9)3$%!.[//\
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MU_R*VIM*%_KUD;A=RVMFCR)W8Y.!^8/^32'3]6N['6#<P@3W13RDW@@ 'I^
MJ'6;2U]2E3U>AP5%.EC>&5XI!AT8JP]".M-KK.<****8!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %=AX,\9R:'*ME>LSZ<YX/4PD]Q[>H_$>_
M'T5G4IQJ1Y9%PG*$N:)](12QSQ)+$ZO&X#*RG((/<4^O-OAC=ZN_G6Q0OI29
M^=SCRW]%]<]QVZ_7TFOG:]+V4W"]SVZ53VD%*P4445B:!1110 4444 %%%%
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M\\$$<L;=&4H 1^5>=Q66I^&_BOX4\'7I:2TTK4WFT^9NKP3%2!T[%#^)8=J
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MYF,=I86<1=MJX6-%'8#^0KQ&S\5Z)\0/%\>N>)]8M-/T+3)<Z;I4TH#S./\
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M7;N'TJ*BBM$0%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M([S<VZ*QC/[V7'7_ &5]_P"7\_:K.SM]/M([6UB6*&,855[5Y^,QBI^Y#?\
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MEU&>(S16Y/S.@ZD?D?R-7Z "BBB@ HHHH **** "BBB@#)\3?\B]=?\  /\
MT,5SW@W_ )"\O_7 _P#H2UT/B;_D7KK_ (!_Z&*YWP;_ ,A>7_K@?_0EKQ\3
M_O\ 3]%^;/2H?[I/^NQW%%%%>P>:%%%% !1110 4444 %%%% !1110 4444
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MC:';2017VHW8D??NOKN&X8<8P"Q) XZ4+"M_:C]X/$+^5_<>MT5X0? 'C\$
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M6NN:C.K*Z_:;B423C=GD2$9R,\>G%"P%5]@>-I>9Z_17@/\ 8FI_]#MXM_\
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MQ5QQQE*3L>Z45F>']?T_Q/HL&JZ9,9+:8=&&&1AP58=F!X(_I6G7(=04444
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M0QQ0KT1% 4?A1RS[A[3#K['X_B_/MT\M->-LI/#VAWLEUH'ART%G$-MYJ%G
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M^RJO\OXK_,GZ_2?VOP9TZZ9?(\Y# JV=O-!TV_\ +CY'!'&:YC_A:G_4%_\
M)K_["C_A:G_4%_\ )K_["I_LBK_+^*_S'_:-/^;\&=4FGWJW1D9L#&!@T+I]
M[\X#=??K7+?\+4_Z@O\ Y-?_ &% ^*?_ %!?_)K_ .PH_LBK_+^*_P Q_P!H
MT_YOP9TT>EWJ$%I2 /X0>#4LVG7LP&R3RO7:>M<I_P +3_Z@W_DU_P#84?\
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M)2T@%HHHH 6EI*6@ I:2EH 6E%)2BD 4M)2T  I:054U35+71[%[R\?;&O
M&6=CT51W)]*3:2NQI-NR%U35+71[![R\DVQKP !EG8]%4=R?2NB\ ^$-1.H)
MXJ\1>9!>E&6QTX.0MI&PY+_WI&'7/3Z_=U]$\&Z7,=+UO4+-Y-0A3SH%G!'V
M=G /*=-X]3R#TKL*\?%8EU'RQV_,];#8=4US2W"BBBN(ZPHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P K^YFM163_ ,)-I'_/W_Y#?_"C_A)M(_Y^_P#R&_\ A1]:H?SK[T'L*O\
M*_N9K45D_P#"3:1_S]_^0W_PH_X2;2/^?O\ \AO_ (4?6J'\Z^]!["K_ "O[
MF:U%9/\ PDVD?\_?_D-_\*/^$FTC_G[_ /(;_P"%'UJA_.OO0>PJ_P K^YFM
M163_ ,)-I'_/W_Y#?_"C_A)M(_Y^_P#R&_\ A1]:H?SK[T'L*O\ *_N9K45D
M_P#"3:1_S]_^0W_PH_X2;2/^?O\ \AO_ (4?6J'\Z^]!["K_ "O[F:U%9/\
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MR,\?+V[UA?\ "B=#_P"AC\4?^!R?_&Z]!_X2+1/^@SI__@4G^-'_  D6B?\
M09T__P "D_QH;K/>_P"()4EV.4T3X1>'M'>9I;K5=3\P  7]WN"8S]W8%ZY[
MYZ50O?@CH-W>S7"ZWXBMEE<L(8+U0D>>RY0G'U)KNO\ A(M$_P"@SI__ (%)
M_C2?\)%H?_09T_\ \"D_QHO6M;7\0M2O?0XBP^">@V5]#<OK/B&[6-MQ@N+U
M3&_LP5 <?0BK>M?"'P]K$T4D5YJ^FB-2I2QN]JO[G>&YKK?^$BT3_H,Z?_X%
M)_C1_P )%HG_ $&=/_\  I/\:+UK6U_$+4KWT//_ /A1.A_]#'XH_P# Y/\
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M/#+'++J6I&1@P>^NBS)[#8%XKI_^$BT3_H,Z?_X%)_C2?\)%H?\ T&=/_P#
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M;U%2A7R;V\#)SCG"JISQZ]Z[#_A(M$_Z#.G_ /@4G^-)_P )%H?_ $&=/_\
M I/\:$ZRU5_Q!JD^QQFJ?!G0M2U&6[CU?7[%9,8M[2\"QI@ <!E)YQD\]2:@
MM_@AHD%S%,?$'B681N&,<E\I5\'.#A <'H>:[O\ X2+1/^@SI_\ X%)_C1_P
MD6B?]!G3_P#P*3_&B];?7\0M2\CF-;^%/A_64A6*XU/3/*))-A=E2^<?>WAN
MF.V.M8__  HO1?\ H9?%/_@<G_QNN_\ ^$BT3_H,Z?\ ^!2?XTG_  D6A_\
M09T__P "D_QH;K/5W_$$J2VL<]+\+O#TFA#3 ]^D@C5/MR73?:.,?-G[N3CG
MY>]87_"C-%_Z&7Q3_P"!Z?\ QNN__P"$BT3_ *#.G_\ @4G^-'_"1:)_T&=/
M_P# I/\ &ANL][_B"5);6.:T3X5^']&AECEFU+4S(P8/?W19D]AM"\5D2_ _
M199GD'B+Q/&&8ML2^3:N>P^3I7>?\)%HG_09T_\ \"D_QI/^$BT/_H,Z?_X%
M)_C1>LU;7\0M2WT.0TCX/:%I5^+J35-<U!0I7R+V\#1G/?"JIR/K1J_P>T+5
M;\W4>J:[IZE0OD65X%C&.^&5CD_6NP_X2+1/^@SI_P#X%)_C1_PD6B?]!G3_
M /P*3_&B]:UM?Q"U*]]#@D^!VBJZM_PDGBAL'.#?)@_^0ZV=;^%F@:S#%'%/
MJ6F&-BQ>PNBK/['<&XKI/^$BT3_H,Z?_ .!2?XTG_"1:'_T&=/\ _ I/\:+U
MDK:_B%J6^AP/_"C=&_Z&;Q5_X'I_\;K>B^&&@1Z"=,,FH/(8V3[<UT?M'.?F
MS]W(SQ\O:NA_X2+1/^@SI_\ X%)_C1_PD6B?]!G3_P#P*3_&A.LMK_B#5)[V
M.!_X4;HW_0S>*O\ P/3_ .-UKZ%\*M!T7S_-N]5U/S=N/[0NRWEXS]W:%QG/
M.<]!73_\)%HG_09T_P#\"D_QI/\ A(M#_P"@SI__ (%)_C0G66JO^(-4GO8X
M:X^">BSW,LP\0^)H1(Y81QWRA4R<X&4)P/K5C2_@YHFF:C%=OK.OWRQYS;W=
MZ&B?((^8*H/&<CGJ!79?\)%HG_09T_\ \"D_QH_X2+1/^@SI_P#X%)_C1>MO
MK^(6I;:')ZU\(]#UB\2XCU+6M-58PGDV-YM1N2=Q#*QSSCKV%9O_  H[1_\
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M%,(D<N(XM04(F3G"@H>!T%=M_P )%HG_ $&=/_\  I/\:3_A(M#_ .@SI_\
MX%)_C1>M:VOXA:EOH<EI/PDTK2]3AO7UWQ%?+'NS;WE\'B?((^8!0>,Y'/4"
MI]=^%FDZW>I<IJVN::%C$?DZ?>;$;!)W$,K'/..O0"NG_P"$BT3_ *#.G_\
M@4G^-'_"1:)_T&=/_P# I/\ &B]:UM?Q"U*]]#A?^%*:9_T-?BW_ ,&*_P#Q
MNN@USX>:/K=DELEQJ.FE9!)YVGW121L C:2VX8YSTZ@5M?\ "1:)_P!!G3__
M  *3_&D_X2+0_P#H,Z?_ .!2?XT7K+O^(6I/L<-_PI73/^AL\7?^#%?_ (W6
M]9_#O2+30)-*-UJ=P[HZ?;IKHFX7=GD, !D9XX[#K6Y_PD6B?]!G3_\ P*3_
M !H_X2+1/^@SI_\ X%)_C0G66U_Q!JD]['"_\*5TW_H;/%W_ (,5_P#C=;&@
M?#/2=">=GU+6-4\T !=1N_,$>,_=VA<9SS]*Z+_A(M$_Z#.G_P#@4G^-)_PD
M6A_]!G3_ /P*3_&A>V6JO^(-4GO8XZ_^#^F7U_/=+XC\3VPE<N(+>_"QQY[*
M"A( ^M.T[X1:9I^H07;>(O$MV(FW&"YOPT;^S ("1^-=A_PD6B?]!G3_ /P*
M3_&C_A(M$_Z#.G_^!2?XT?O=]?Q#]UY'-:[\,-*URZCG35=;TP(FSR]/O/+1
MN2<D,K<\_I65_P *6TW_ *&WQ=_X,5_^(KNO^$BT3_H,Z?\ ^!2?XTG_  D6
MA_\ 09T__P "D_QH?MGO?\02I+:QCZI\/M)U+2%T];G4;)EV_P"E6ER5F./5
MCD<]^*H:#\*=$T368-4EO]7U:XM\FW&J7(F6%C_&H"CYN.O]<&NH_P"$BT3_
M *#.G_\ @4G^-._M[1_L\UQ_:UAY,"[Y9/M*;8U]6.< ?6E)U6O>N.*II^[8
MT**Y_P#X3OP?_P!#7H?_ (,8?_BJOZ9K^C:TTBZ5J]A?M$ 9!:W*2E >F=I.
M.AK(T-&BL.?QGX5M;B6WN/$NC0SQ.4DCDOXE9&!P006R"#VI]GXN\-:C=QVE
MEXATFYN9#A(8+V-W8XSPH;)XH V:*S-2\1Z'HTR0ZIK.G6,KKO5+JZ2)F7.,
M@,1D<52_X3OP?_T->A_^#&'_ .*H Z"BJ=_JVFZ5:+=ZCJ%I9VS$*LUQ,L:$
MGH-S$#FLO_A._"'_ $->A_\ @QA_^*H Z"BJ=GJVFZC8M?6.H6ES9KG-Q!,K
MQC'7Y@<<5E_\)WX/_P"AKT/_ ,&,/_Q5 '045FZ9XAT36I)(]*UC3[YXQN=;
M6Y24J/4A2<57NO&'ABPNI+6\\1Z1;W$1VR137T:.A]""V10!M45B6WC+PO>7
M,=M:^)-'GN)6"1Q17T3,['H  V2:LZGXAT319$CU76-/L'D&Y%NKE(BP]0&(
MS0!I45S_ /PG?@__ *&O0_\ P8P__%5J7.K:;9:<-1NM0M(+$A6%S+,JQ$-]
MT[B<<Y&.>: +E%<__P )WX/_ .AKT/\ \&,/_P 56GI^L:9JUJ]UINHV=Y;H
MQ1YK:=9$5@ 2"5) ."#^- %VBN?_ .$[\'_]#7H?_@QA_P#BJN:;XET'6;AK
M?2];TV^G5"[1VMTDK!<@9(4DXR0,^XH U**Q[[Q9X;TR\DL[_P 0:5:74>-\
M,]Y'&ZY (RI.1D$'\:C@\9^%;JXBM[?Q+HTT\KA(XX[^)F=B<  !LDD\8H W
M**S]3UW1]$\K^UM5L;#SL^7]KN$BWXQG&XC.,CIZBL__ (3OPA_T->A_^#&'
M_P"*H Z"BJ;ZMIL>EC5'U"T73R@?[6TRB+:>AWYQ@Y'.:R_^$[\'_P#0UZ'_
M .#&'_XJ@#H**I:;K&F:S"\VEZC9WT2-L9[6=955NN"5)P>:S6\<^$48JWBG
M1 P."#J$60?^^J -^BLG3_%/A[5KH6NFZ[I=Y<$%A%;7<<CD#J<*2:2_\5>'
M=+NVM-0U_2[2Y4 M#<7D<;@$9&5)!Z4 :]%4=,UK2M:CDDTK4[.^2,[7:UG6
M4*?0E2<5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MYG6_#4^H:@UU;RQ+O W+(2.0,<8![ 5TU%8UZ$*\>6>QI2JRI2YHG#_\(;J/
M_/:U_P"^F_\ B:/^$-U'_GM:_P#?3?\ Q-=Q17)_9>'[/[SI^OUCA_\ A#=1
M_P">UK_WTW_Q-'_"&ZC_ ,]K7_OIO_B:[BBC^R\/V?WA]?K'#_\ "&ZC_P ]
MK7_OIO\ XFC_ (0W4?\ GM:_]]-_\37<44?V7A^S^\/K]8X?_A#=1_Y[6O\
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M4?\ GM:_]]-_\31_PANH_P#/:U_[Z;_XFNXHH_LO#]G]X?7ZQP__  ANH_\
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M.'D5E")V-+^TZ_?\$-8"EV_,XL_"H9 &M9S_ -.O_P!G0?A5@D?VUD_]>O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M::W<P'3+"8KM^>6+<QRH/)JGX<_Y!&O?]>W]&IDGBVYE<O)I^G.YZLT))/\
MX]6?#K$\ OQ''"JWH*R*%("@Y^[SQUI*F^3EMV!R7->YT^C,-=2PNB1]NL)
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MKULC'VW_ ,A)_A6-54XR2=Q3:>P4445H0%%%% !1110 4444 %%%% !1110
M5IZ):W4]\LENQC6,_-)VQZ>]1Z7I<NIS[5RL2_??T]OK7:P6T5I L,*A47]?
M>L:E1+1%QC?4&J)JE:HFK!%LB:HFJ5JB:J0F1-435*U1-5HED35$U2M4352)
M(FJ)JE:HFJT(B:HVJ1JC:J0B-JB-2M41ZU2$**>*8*>* '"GBF"GBD \4\4P
M4\4 /%/%,%/%(!XIXI@IXI#'BGBF"GBD \4\4P4\4ACQ3Q3!5EO!&K^)UM81
M<K8Z-*3]LE4D3R(,?)'Q@!N06/Z]#C6JQI1YF:4J;J2Y46?A]J^HZKXEN!I4
M"MH$ 9+R\<D++-CY5B_O$<9/3'X9]2JKINFV>D:=!I^GVT=O:6Z!(HHQ@*/\
M\YZD\U:KP:M1U).3/;ITU3CRH****S+"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \.U[0=8F\1:G+%I-\\;W<K
M*ZV[D,"YP0<<BL__ (1W7/\ H#:A_P" K_X5] T5Z4<RDDERG"\#%N]SY^_X
M1W6_^@-J'_@*_P#A1_PCNM_] ;4/_ 5_\*^@:*?]IS_E%]0CW/G[_A'=;_Z
MVH?^ K_X4?\ ".ZY_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^
M K_X4?\ ".ZW_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X
M4?\ ".ZY_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X4?\
M".ZW_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X4?\ ".ZY
M_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X4?\ ".ZW_P!
M;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X4?\ ".ZY_P! ;4/_
M  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X4?\ ".ZW_P! ;4/_  %?
M_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X4?\ ".ZY_P! ;4/_  %?_"OH
M&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X4?\ ".ZW_P! ;4/_  %?_"OH&BC^
MTY_RA]0CW/G[_A'=;_Z VH?^ K_X4?\ ".ZY_P! ;4/_  %?_"OH&BC^TY_R
MA]0CW/G[_A'=;_Z VH?^ K_X4?\ ".ZW_P! ;4/_  %?_"OH&BC^TY_RA]0C
MW/G[_A'=;_Z VH?^ K_X4?\ ".ZY_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[
M_A'=;_Z VH?^ K_X4?\ ".ZW_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=
M;_Z VH?^ K_X4?\ ".ZY_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z
MVH?^ K_X4?\ ".ZW_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^
M K_X4?\ ".ZY_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X
M4?\ ".ZW_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X4?\
M".ZY_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X4?\ ".ZW
M_P! ;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X4?\ ".ZY_P!
M;4/_  %?_"OH&BC^TY_RA]0CW/G[_A'=;_Z VH?^ K_X5J:%%XE\/7SW=IH=
MV\CQF,B6TD(P2#VQSP*]MHI2S&4E9Q5AK!*+NI'F?_"6^-O^A</_ ( S?_%4
MH\7>-O\ H7/_ "2F_P#BJ]+HK#ZS#_GVC7V$_P"=GF?_  EOC?=G_A'F_P#
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M>-_^A<_\D9O_ (JD/B_QN?\ F7?_ "2F_P#BJ]+HH^L4_P#GV@]A/^=GFO\
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M)KQ&BC^S:7=_A_D'UZIV7]?,]N_X3_PQ_P!!/_R!)_\ $T?\)_X8_P"@G_Y
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M ?$__0,_\CQ__%4?\(#XG_Z!G_D>/_XJCZIA/Y_Q0?6,1_)^#/2O^$_\,?\
M03_\@2?_ !-'_"?^&/\ H)_^0)?_ (FO-?\ A /$_P#T#/\ R/'_ /%5'<^"
M/$5I:RW,^G[(8D,CMYT9PH&2<!O2CZIA7]O\4'UG$?R?@ST[_A/_  Q_T$__
M "!)_P#$T?\ "?\ AC_H)_\ D"7_ .)KQ&BM?[-I=W^'^1G]>J=E_7S/;O\
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M$:*/[-I=W^'^0?7JG9?U\SV[_A/_  Q_T$__ "!)_P#$T?\ "?\ AC_H)_\
MD"7_ .)KQ&BC^S:7=_A_D'UZIV7]?,]N_P"$_P##'_03_P#($G_Q-'_"?^&/
M^@G_ .0)?_B:\1HH_LVEW?X?Y!]>J=E_7S/;O^$_\,?]!/\ \@2?_$T?\)_X
M8_Z"?_D"7_XFO$:*/[-I=W^'^0?7JG9?U\SV[_A/_#'_ $$__($G_P 31_PG
M_AC_ *"?_D"7_P")KQ&BC^S:7=_A_D'UZIV7]?,]N_X3_P ,?]!/_P @2?\
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MB2XM)HD/\3H0*/[.H]W^'^0?7JO9'LG_  G_ (8_Z"?_ ) D_P#B:/\ A/\
MPQ_T$_\ R!+_ /$UXDJECA02?0"D(P<&C^S:7=_A_D'UZIV7]?,]N_X3_P ,
M?]!/_P @2?\ Q-'_  G_ (8_Z"?_ ) E_P#B:\1I=K?W3^5']FTN[_#_ "#Z
M]4[+^OF>V_\ "?\ AC_H)_\ D"3_ .)H_P"$_P##'_03_P#($O\ \37B.,=:
M5E9<;E(STR.M']FTN[_#_(/KU3LOZ^9[;_PG_AC_ *"?_D"3_P")H_X3_P ,
M?]!/_P @2_\ Q->(T $] 31_9M+N_P /\@^O5.R_KYGMW_"?^&/^@G_Y D_^
M)H_X3_PQ_P!!/_R!+_\ $UXC2A68$A20.N!TH_LVEW?X?Y!]>J=E_7S/;?\
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M] :'KEGK^GK=VC>TD9^]&WH:TZ\_^'GA>\L,ZM=O)#YR;8[<'&Y3_$P_D*]
MKYO$0A"HXP=T>Y1E*4$Y*S"BBBL34**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSZ5<O/;JA=D,9W@D8/\ ^JMG_A /$_\ T#/_ "/%_P#%4?\ " >)_P#H&?\
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M;NGVA/\ &HQXDT]G+-JFF_+TS<)_C7FG_" >)_\ H&?^1X__ (JC_A /$_\
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M\(!XG_Z!G_D>+_XJJ6%PZ=_:+[T)XBLU;D_,YJBNE_X0#Q/_ - S_P CQ_\
MQ5'_  @'B?\ Z!G_ )'B_P#BJ]'ZQ2_F7WHX/8U/Y7]QS5%=+_P@'B?_ *!G
M_D>+_P"*H_X0#Q/_ - S_P CQ?\ Q5'UBE_,OO0>QJ?RO[CFJ*Z7_A /$_\
MT#/_ "/'_P#%4?\ " >)_P#H&?\ D>+_ .*H^L4OYE]Z#V-3^5_<<U172_\
M" >)_P#H&?\ D>+_ .*H_P"$ \3_ /0,_P#(\7_Q5'UBE_,OO0>QJ?RO[CFJ
M*Z7_ (0#Q/\ ] S_ ,CQ_P#Q5'_" >)_^@9_Y'B_^*H^L4OYE]Z#V-3^5_<<
MU172_P#" >)_^@9_Y'B_^*H_X0#Q/_T#/_(\7_Q5'UBE_,OO0>QJ?RO[CFJ*
MZ7_A /$__0,_\CQ__%4?\(!XG_Z!G_D>+_XJCZQ2_F7WH/8U/Y7]QS5%=+_P
M@'B?_H&?^1XO_BJ/^$ \3_\ 0,_\CQ?_ !5'UBE_,OO0>QJ?RO[CFJ*Z7_A
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M_P"*H^L4OYE]Z#V-3^5_<<U172_\(!XG_P"@9_Y'B_\ BJ/^$ \3_P#0,_\
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M^XYZ6XGG5%FFDD$8VH'8G:/0>E/M[VZM PMKF:'=][RY"N?KBM[_ (0#Q/\
M] S_ ,CQ_P#Q5'_" >)_^@9_Y'B_^*I>WH[<R^]![*K_ "O[C$DU._EV^9?7
M+[&#+NE8[2.XYZU7DD>:1I)'9W8Y9F.23]:Z/_A /$__ $#/_(\7_P 51_P@
M'B?_ *!G_D>+_P"*H5:BMI+[T'LJO\K^XYZ:XFN"IFFDD*KM7>Q.!Z#/:HZZ
M7_A /$__ $#/_(\?_P 51_P@'B?_ *!G_D>+_P"*I^WH_P R^]![&I_*_N,.
M'4;ZVC\N"\N(H^NU)64?D#23W]Y=($N+N>90<A9)"P!]>36[_P (!XG_ .@9
M_P"1XO\ XJC_ (0#Q/\ ] S_ ,CQ?_%4O;4=^9?>@]E5_E?W'-5(\\TD*1/*
M[1QYV(6)"YZX':NA_P"$ \3_ /0,_P#(\?\ \51_P@'B?_H&?^1XO_BJ?MZ/
M\R^]![&I_*_N.<BEDAD$D4C1N.C*<$?C4]QJ%Y=($N+N:5!SM>0D5N?\(!XG
M_P"@9_Y'B_\ BJ/^$ \3_P#0,_\ (\7_ ,52]O1WYE]Z#V57^5_<<U4@GF6!
MH%E<1,<M&&.TGU(KH?\ A /$_P#T#/\ R/'_ /%4?\(!XG_Z!G_D>+_XJG[>
MC_,OO0>QJ?RO[CGDGFCCDCCE=8Y,;U5B V/4=ZF35+^.+RDO;A8P,!1*0 /S
MK;_X0#Q/_P! S_R/%_\ %4?\(!XG_P"@9_Y'B_\ BJ3K47]I?>@]E5_E?W'-
M'DY-.1WB</&S(ZG(93@@UT?_  @'B?\ Z!G_ )'C_P#BJ/\ A /$_P#T#/\
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M3_R:_P#L*/\ A;/_ %!/_)K_ .PH^HXC^7\5_F'UNCW_ #/2J*\U_P"%L_\
M4$_\FO\ ["C_ (6S_P!03_R:_P#L*/J.(_E_%!];H]_S/2J*\U_X6S_U!/\
MR:_^PH_X6S_U!/\ R:_^PH^HXC^7\5_F'UNCW_,]*HKS7_A;/_4$_P#)K_["
MC_A;/_4$_P#)K_["CZCB/Y?Q0?6Z/?\ ,]*HKS7_ (6S_P!03_R:_P#L*/\
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M3_R:_P#L*/\ A;/_ %!/_)K_ .PH^HXC^7\5_F'UNCW_ #/2J*\U_P"%L_\
M4$_\FO\ ["C_ (6S_P!03_R:_P#L*/J.(_E_%!];H]_S/2J*\U_X6S_U!/\
MR:_^PH_X6S_U!/\ R:_^PH^HXC^7\5_F'UNCW_,]*HKS7_A;/_4$_P#)K_["
MC_A;/_4$_P#)K_["CZCB/Y?Q0?6Z/?\ ,]*HKS7_ (6S_P!03_R:_P#L*/\
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M3_R:_P#L*/\ A;/_ %!/_)K_ .PH^HXC^7\5_F'UNCW_ #/2J*\U_P"%L_\
M4$_\FO\ ["C_ (6S_P!03_R:_P#L*/J.(_E_%!];H]_S/2J*\U_X6S_U!/\
MR:_^PH_X6S_U!/\ R:_^PH^HXC^7\5_F'UNCW_,]*HKS7_A;/_4$_P#)K_["
MC_A;/_4$_P#)K_["CZCB/Y?Q0?6Z/?\ ,]*HKS7_ (6S_P!03_R:_P#L*/\
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M3_R:_P#L*/\ A;/_ %!/_)K_ .PH^HXC^7\5_F'UNCW_ #/2J*\U_P"%L_\
M4$_\FO\ ["C_ (6S_P!03_R:_P#L*/J.(_E_%!];H]_S/2J*\U_X6S_U!/\
MR:_^PH_X6S_U!/\ R:_^PH^HXC^7\5_F'UNCW_,]*HKS7_A;/_4$_P#)K_["
MC_A;/_4$_P#)K_["CZCB/Y?Q0?6Z/?\ ,]*HKS7_ (6S_P!03_R:_P#L*/\
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M:)I6C@3?(P SA1W-.L+M;_3[:\2*6);B)91',NUT# '##L1GD5QMSI^O>%_
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M0$T5UFCSWMMX1DDT]&:?[5C"1[SC [4WQ"&GT&QN[Z!8M2>0J1MVLR<\D?\
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MT%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% %B\L;BP>-+F/8TB"11D'*GZ?2C[#<&P-]Y?^C[_+
MW9'WOIUK9\7?\?=A_P!>:?S-(O\ R(K?]?G]*R4WRI]S1Q5VCGP"3@#)K8'A
M;63!YOV,XQG:6&['TS^E9UE.+6_M[AEW+%*KE?7!S74:C8W.IW4FL:+?F8D
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M*!:7GAZ_8J-N\#@UV%S;Q>+/"\T(A, G4@"3JIK%E^)/AZ;_ %EC?M]8D_\
MBZ='\3= B38EGJ"KZ"-/_BZ\[ZO7_E9W_6:7\Q9T_P %1Z-X.NM'M)!YDZG+
MMR,D5#+X-G^R6<MK)''=Q6?V61@,*X[FF2_$_16C*K:ZADCO&G_Q=53\1]+V
M@"+4 ?\ <3_XJAX?$?RL7UFE_,3P>%]3ATZ"PC%J!'*K>8T?. >1FK1\*79_
MMU&DCVWTZ21%1@J%'>LY_B/I;*!Y6H9'^RO_ ,52#XBZ4&&8]1QW^5/_ (JD
M\-7?V6/ZS2_F-G^PK^.T52ZL0,#CI5/7='N!I>GV\LF^Y60GS!5)_B+I+-Q'
MJ6W_ '4_^*IMQ\0=&N%B#6]^2AR"43_XJLW@:W\I/MZ7\QU<.DNE[!,&0*B+
M\H'.<5GW/AJZFNXKA)H\PS^:!CK6,?B/I>\$07W'^PO_ ,51_P +&TLR%C%J
M R.@1/\ XJE]1K?RA[:C_,:USH.I:AJWVV:5%5%P!BKLVEWD6HP7UNR86 Q,
MI'.3WK!3XE:2$96AU Y&!\B?_%5 /B'I65S'J. .RI_\51]1K?RL/;T?YC;M
M/#EY%JBWLDB%B<G Z5IV^ERQ:G?W!88G^Z/PKDG^(FEL3A-1]OE3_P"*H'Q%
MTKS%8QZC@#D;4_\ BJ/J-;^5A[>C_,:MOX:N[9[6Y1XF>%F)!&0<TM]H>HW%
MK,H,*O+T 7C\168GQ'TE<#RM1VC_ &$_^*H/Q'TK/RPZA^*)_P#%4XX*LG?E
M'[>C_,6_^$7O;SQ!8ZB[Q(MN%#(5Y.!VK,ELKJ"\M+-$611J9N"4'0'UJROQ
M)TH'/D7Y_P" )_\ %5#!\0-%BG,K6MZ6)S_JT_\ BJU^JUOY0^L4OYCA_$7_
M ",VJ_\ 7Y-_Z&:S:MZK=)?:Q>WD081SW$DJAAR S$C/OS52O?@K12/%D[R8
M44459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 =3<1V?B*RLY5OX+:[@B$4D<[;00.X_7\ZK:K/:66B
M0Z1:W"W,GF>;-*GW<XZ#_/:N?HK)4[=="W/R-5].L(AIS-J2LMP,S[!DP].H
MS[_I6OINFVFD:BE^VMVK019.(V^9QZ8'_P!>N3HIR@VK7!22=[&LT-KJ;:I?
MO=I;L',D4+8R^23CK_*LZTB2>[ABDD6-'<*SL<!1GDU%15)6TN2W<ZO5?%5Q
M;W[V^G- ;2(!$.P,#@=CZ4V]O[?5+72=1EFA6[BG$<R9 .W.=V/3C]:Y:BLU
M1BK6+]HWN=!JNJ?9?&,M_:2+*JLG*-E6&P C/YBM+6YM,U.;2(H;F%;=I&:0
M;P-@."<^AZUQM%'LEH^P>T>OF=3J7B^\349DLFA^S(VV,E <@<9SZ56\074&
MJ:?I^HB6/[45,4\88;LCH<=AU_,5S]%-4HQLUT$ZC=[G9PZS:+X;6\,J#4HH
M#:JNX;CDC!QU/&#GZUD^$;F"UUU9+B5(D\MAN=@!GZFL*BCV2LUW'[1W3[&W
M/H$,4$D@UG3G**6VK,"6QV'O5@WL6B:#%#8W"-?7>))I(VSY:CHOU_\ KUSE
M%/D;^)W%S6V1OZ]+::E:6VJPR1+<R8CN( WS;@/O8]./Y5@44548\JL3)W=S
M8\.V5A=WS-J%S%%#$ VR1POF'TR>U:.NVOV]I+I]8TXI$A\JWCE!P!_"!W-<
MM14N#<N:Y2DK6L7H]:U.*)8H[Z=44!5 <\#TJ_X;EM;*2ZU*XDC#V\9\F)FP
M7<\<#_/6L*BG*"::[B4FG<G1ENKY6NI2JRR9EDQDC)Y.*Z&RT>TL-1AO?[<L
MS;PL'RK_ #MCG&/?I7+T42BWHG8%)+H:M[K=P=6N[FQFD@CF?.%.,@< G_/>
MK_AO4RVLS7&H78R;9D#S/CN#CG\:YNBDZ<7&PU-IW-[PW>0XN],O)5CM;J,X
M9S@*XZ'G@?\ UA4=KHMI>6:/'JUM'< D213':!SU![C&*Q:*'!W;3L'-I9HZ
M76=32UM]/M+*^,\]H&W7*'UXP#W&/Z52T_Q!=Q:I:SWES+-%$^2K-G (()QZ
MX)K'HH5.-K,'-WN=8--TV/6?[4.K6ILQ)YX0-\^<YV[?K^--MM7MM5DU:TNY
MA;QWK!XG?HI7IG\E_*N5HJ?97W8_:=D=/$MKX?TR]S>P7-Y<IY2+ VX(#U)/
M^>E1^&;2"&\MM2FU&SB5&;,3RA7Z$=#7.44_9Z-7W%SZK38UM>LXX+V2XCO;
M:X6>5W"PR!BHSGG'UK)HHJXJRL2W=W"BBBJ$%%%% !1110 444JJSL%4%F)P
M !DDT "JSN%52S,<  9)->M>"?!*Z4J:EJ2!KYAF.,\B$?\ Q7\J/!/@E=*5
M-2U*,-?$9CC/(A'_ ,5_*NXKQL9C.;]W3VZL]/"X7E]^>X4445YAWA1110!@
M^(_&&D>%S;QWTDLEW<G%O9VL1EGEQUVHO./?I6=I?Q&T?4-7@TF[M-4T>_N,
M_9X=5M# 9B.RDY!//3-9OAJ--0^,'C.^N1OGL([2SM=W6*-HR[8]-S<T[XS6
M\;?#:^OQ\EUI\L-U:S#[T<@D4 @_0D?C0!W]%>=^.M0\2R>*O".CZ!J(TYM4
M2Z%R[1A]BJL9W 'JR@MCW/-0^+CXE\+:#X?LM*\02W>HWFN16PNK]%.4='^5
M]H&5! /'/% 'I585EXC^V>,=5\/_ &79]@MX9_/\S._S-W&W'&-OJ<YKD=3/
MB3P+J6AW]QXEN=9L;Z_CL;Z"ZAC4*TG DCV@;0"/N\]:J7&G:UJGQEU^VTO5
M_P"R[8V%J;N>*,-.1\VU4W A<Y.3C/ Q0!ZM17$^"=0U:/Q#XC\,ZMJ#:B=*
M>"2WNY$"R/%*A8*VT $J5QGO7*^*M0N] L=0O9/BE'_;UJKS1Z<! D3%>1%Y
M7+9(& 2<YH ]@HKS7Q3X@\0W<'@=M O(;&YUILR>:F^,!H=W([[<D@=R!FIX
M'U[PIX]T'2[SQ!<ZQI^M).CB[B16AFC3?N4J!\I'&WM0!Z'7#'XIZ3Y]TL>C
M^(9X+:X>WENH--:2$.APWS*37<UPGPJ_Y >M?]AV]_\ 1E '3Z#XBTGQ-IJZ
MAH]['=6Y.TE>"C?W64\J?8UJ5YWID$>D_'75+2R7R[;4M%2_N8TX7SUF\L-C
MU(S]<DUG> X?%OBF(ZQJ/BBX@L[74)8[>V@B3]^B2G=YI(Y!^X ,8 S0!ZK1
M7(^#-5OM2U7Q9%>7#2QV>KO!;J0/W<81#M&/<FL*'Q=JUCX3\?ZJTANI]*U6
MZAM%=1B-%6/:..H!8F@#TNBO%];3Q-IMCX5U"#Q[?W3:W>V]M/&B0@$2C)>$
M;> /0YZ]J]FC0I$B,[.54 NV,M[G% &#)XE+>.X?#-M;"4K9->7<Y?'DKN"H
MH&.2QSZ<#-7-,U^SU75-5T^W$HFTR589RZ@ LRAAMYY&#7*> R;WQKX\U.0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_4;_ /)7_P"SKTJBCZ]B/YOP0?5*/;\SS7_A4W_4;_\ )7_[.C_A4W_4;_\
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M_4;_ /)7_P"SKTJBCZ]B/YOP0?5*/;\SS7_A4W_4;_\ )7_[.C_A4W_4;_\
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M_4;_ /)7_P"SKTJBCZ]B/YOP0?5*/;\SS7_A4W_4;_\ )7_[.C_A4W_4;_\
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M_4;_ /)7_P"SKTJBCZ]B/YOP0?5*/;\SS7_A4W_4;_\ )7_[.C_A4W_4;_\
M)7_[.O2J*/KV(_F_!?Y!]4H]OS/-?^%3?]1O_P E?_LZ/^%3?]1O_P E?_LZ
M]*HH^O8C^;\$'U2CV_,\U_X5-_U&_P#R5_\ LZ/^%3?]1O\ \E?_ +.O2J*/
MKV(_F_!?Y!]4H]OS/-?^%3?]1O\ \E?_ +.C_A4W_4;_ /)7_P"SKTJBCZ]B
M/YOP0?5*/;\SS7_A4W_4;_\ )7_[.C_A4W_4;_\ )7_[.O2J*/KV(_F_!?Y!
M]4H]OS/-?^%3?]1O_P E?_LZ/^%3?]1O_P E?_LZ]*HH^O8C^;\$'U2CV_,\
MU_X5-_U&_P#R5_\ LZ/^%3?]1O\ \E?_ +.O2J*/KV(_F_!?Y!]4H]OS/-?^
M%3?]1O\ \E?_ +.C_A4W_4;_ /)7_P"SKTJBCZ]B/YOP0?5*/;\SS7_A4W_4
M;_\ )7_[.C_A4W_4;_\ )7_[.O2J*/KV(_F_!?Y!]4H]OS/-?^%3?]1O_P E
M?_LZ/^%3?]1O_P E?_LZ]*HH^O8C^;\$'U2CV_,\U_X5-_U&_P#R5_\ LZ/^
M%3?]1O\ \E?_ +.O2J*/KV(_F_!?Y!]4H]OS/-?^%3?]1O\ \E?_ +.C_A4W
M_4;_ /)7_P"SKTJBCZ]B/YOP0?5*/;\SS7_A4W_4;_\ )7_[.C_A4W_4;_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFL+H*!DDPMQ^E5H89;B410QO)(>BHN2?PI?5J'\J#ZQ6[G:?\+2UO_GUT_\
M[]O_ /%T?\+2UO\ Y]=/_P"_;_\ Q=<H^D:DB%VL+E549),38 _*E72-2=0R
MV%R589!$3<C\J/JV'[(/;UN[.J_X6EK?_/KI_P#W[?\ ^+H_X6EK?_/KI_\
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MM+6_^?73_P#OV_\ \77$44?5*/\ *A?6*O\ ,=O_ ,+2UO\ Y]=/_P"_;_\
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M_P#XNC_A:6M_\^NG_P#?M_\ XNN(HH^J4?Y4+ZQ5_F.W_P"%I:W_ ,^NG_\
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M_A:6M_\ /KI__?M__BZ/^%I:W_SZZ?\ ]^W_ /BZXBBCZI1_E']8J_S';_\
M"TM;_P"?73_^_;__ !='_"TM;_Y]=/\ ^_;_ /Q=<111]4H_RH7UBK_,=O\
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M[JI(7/J>U+#;3W <PPR2!!N?8I.T>IH^JT/Y4'UBKW.R_P"%I:W_ ,^NG_\
M?M__ (NC_A:6M_\ /KI__?M__BZXVWMI[J3R[>&25\9VHI)QZ\59_L75/^@?
M=?\ ?IO\*3PV'6\4'MZSZLZG_A:6M_\ /KI__?M__BZ/^%I:W_SZZ?\ ]^W_
M /BZXR:":WE,4T3QR#JC*01^%+/;3VLGEW$,D3XSM=2#C\:?U6A_*@^L5>YV
M7_"TM;_Y]=/_ ._;_P#Q='_"TM;_ .?73_\ OV__ ,77(V^GWMU&9+>TFE0'
M&Y(R1G\*BF@FMY#'/$\3C^%U*G\C1]5H;<J#ZQ6[G9_\+2UO_GUT_P#[]O\
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MMYK:4Q3Q/%(/X74@U& 6( &2> !3^JT/Y4+ZQ5_F.W_X6EK?_/KI_P#W[?\
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M_P#?M_\ XNN(HH^J4?Y4+ZQ5_F.W_P"%I:W_ ,^NG_\ ?M__ (NC_A:6M_\
M/KI__?M__BZXBBCZI1_E']8J_P QV_\ PM+6_P#GUT__ +]O_P#%T?\ "TM;
M_P"?73_^_;__ !=<111]4H_RH7UBK_,=O_PM+6_^?73_ /OV_P#\71_PM+6_
M^?73_P#OV_\ \77$44?5*/\ */ZQ5_F/6?"GQ &KW?V+5$AM[AS^Y>/(1O\
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M;6EXB_Y&;5?^OR;_ -#-9M?3T_@1\]/XF%%%%62%%%% !1110 4444 %%%%
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M,&F:DT<9#6\@\R%@<Y4U,(INSZ[>@Y.VJ^9WNKW<=O:RS7#B.)0ZA&(/GY3
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M(YD/]!Z"M>OFL1*$JC=-61[E&,XP2F]0HHHK$U"BBB@ HHHH **** "BBB@
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M *!G_D>7_P"*H_X0#PQ_T#/_ "/)_P#%4?VE2[/\/\P^HU.Z_KY'B-%>W?\
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M'E_^*H_X0#PQ_P! S_R/)_\ %4?VE2[/\/\ ,/J-3NOZ^1XC17MW_" >&/\
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M,_\ (\G_ ,51_:5+L_P_S#ZC4[K^OD>(T5[=_P (!X8_Z!G_ )'E_P#BJ/\
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M?]!G3_\ P*3_ !H_X2+1/^@SI_\ X%)_C7S]11_9D/Y@^OR['T#_ ,)%H?\
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MZAE(96&00<@BEKS#O"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:FI_85K_ ,)=_96^7[/C.<C=]S=UQZ^U4==TDZ1J!A5B\#C=$Y[C\.XKHO\
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MYXP*XV5D>9VC38A8E4SG:.PSWI46VKNX5+)V1M66E:?%HR:GJDD_ERR%(HX
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MW-SH^IVMS<6L\TKFXB$,FXA^I^@Z#\37.Z5K8LK9[*[MDNK*0Y:-N"I]0?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?/WB+_D9M6_Z_)O\ T,UFUT6O
M:#K$WB+4Y8M)OGC>[E976W<A@7."#CD5G_\ ".ZW_P! ;4/_  %?_"OIJ=2'
M(M3P9PES/0S:=$_E2I)C.U@V/I6A_P ([K?_ $!M0_\  5_\*/\ A'=;_P"@
M-J'_ ("O_A5^TAW)Y)=BQ_PD'_%2_P!K_9NV/*\S_9V]<?CTK/MK^6TU);V'
MB17+8['/4?2K'_".ZW_T!M0_\!7_ ,*/^$=UO_H#:A_X"O\ X5*=-=5V*M/L
M6+OQ ;K7X-4-L%\K;^ZWYSCWQ[^E9E[<_;+Z>YV;/-D9]N<XR<XS5O\ X1W6
M_P#H#:A_X"O_ (4?\([K?_0&U#_P%?\ PH3IQV8-3>Z$U#5?MME96B0B&*U3
M;@-G>W=O\^M&FZJ;"UO;9X1-%=1[""V-I['I[TO_  CNM_\ 0&U#_P !7_PH
M_P"$=UO_ * VH?\ @*_^%%Z=K706G>]AM]JGVW3K"T\G9]D5EW;L[LX[8XZ5
M8C\03#P_)I4D0<'A)"V"HSG&,<U#_P ([K?_ $!M0_\  5_\*/\ A'=;_P"@
M-J'_ ("O_A2O2M:Z"T^PFBZJ='OC<B'S<QE-N['7_P#556RN?L=]!<[-_E2!
M]N<9P>F:M_\ ".ZW_P! ;4/_  %?_"C_ (1W6_\ H#:A_P" K_X4^:GJ[K47
M+/L6+/Q!]EURYU(VH<3AE,6_& 2#UQ[>E,O-4TRXM9(H-%2"5ONR"<G;SZ8J
M+_A'=;_Z VH?^ K_ .%'_".ZW_T!M0_\!7_PI?NKWO\ B.T[6M^!I77B6POI
M!+=Z(DLH4+N-P1T_X#6#>30SW4DL%N+>)C\L0;=MX]:N?\([K?\ T!M0_P#
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M+_7&O)K41VZ06UJP,<"'CKW-$VNR/XC_ +7CB\MMRGR]V> H4C..X'IWJ/\
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M VH?^ K_ .%'M(=PY)=C-HK2_P"$=UO_ * VH?\ @*_^%'_".ZW_ - ;4/\
MP%?_  H]I#N')+L9M%:7_".ZW_T!M0_\!7_PH_X1W6_^@-J'_@*_^%'M(=PY
M)=C-HK2_X1W6_P#H#:A_X"O_ (4?\([K?_0&U#_P%?\ PH]I#N')+L9M%:7_
M  CNM_\ 0&U#_P !7_PH_P"$=UO_ * VH?\ @*_^%'M(=PY)=C-HK2_X1W6_
M^@-J'_@*_P#A1_PCNM_] ;4/_ 5_\*/:0[AR2[&;16E_PCNM_P#0&U#_ ,!7
M_P */^$=UO\ Z VH?^ K_P"%'M(=PY)=C-HK2_X1W6_^@-J'_@*_^%'_  CN
MM_\ 0&U#_P !7_PH]I#N')+L9M%:7_".ZW_T!M0_\!7_ ,*/^$=UO_H#:A_X
M"O\ X4>TAW#DEV,VBM+_ (1W6_\ H#:A_P" K_X4?\([K?\ T!M0_P# 5_\
M"CVD.X<DNQFTJJSL%52S,<  9)-:/_".ZW_T!M0_\!7_ ,*])\$^"5TI4U+4
MD#7Q&8XSR(1_\5_*L:V)A2CS7N:4J$ZDK6#P3X)72E34M2C#7S#,<9Y$(_\
MBOY5W%%%>!5JRJRYI'LTZ<:<>6(4445F6%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#&C^S)_P P?7X]CZ!HKY^_X2+6_P#H,ZA_X%/_ (T?\)%KG_09U#_P*?\
MQH_LR?\ ,'U^/8^@:*^?O^$BUO\ Z#.H?^!3_P"-'_"1:W_T&=0_\"G_ ,:/
M[,G_ #!]?CV/H&BOG[_A(M;_ .@SJ'_@4_\ C1_PD6N?]!G4/_ I_P#&C^S)
M_P P?7X]CZ!HKY^_X2+6_P#H,ZA_X%/_ (T?\)%K?_09U#_P*?\ QH_LR?\
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MOZMKNO:QIR64FO:A:JK!O-LY!#(<#&"ZC)'/-"RZMY \=2\SW"BOG'[#J_\
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M$:1_:HI EP=N.?, SDXY/?)]:2R^MY \;2\SV2BOGS^R-4_Z'7Q;_P"#5O\
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MYBH<%]XZC<#@8]N/QSUKP_\ X2+6_P#H,ZA_X%/_ (T?\)%K?_08U#_P*?\
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M:0U2_MK2O^@G9?\ @0O^-6)[JWMHA+//%%&3@/(X4'\30IQ>S!Q:Z$E.K/\
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ME/(2.=68_@#3KG5=.LI?*NM0M8),9V2S*IQZX)I<T;7N'++:Q=I:S!X@T4D
M:O8$GH!<I_C5NZO;2Q17N[J&W1C@--($!/IS1S1>MPY7M8LTM9G_  D.B?\
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M_P"!2?XT.45NQJ+>R-2EJO#>VEQ:FZANH9+< DRI("@ Z\CCBJG_  D>A?\
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M /($?_Q-'_"?^)_^@G_Y B_^)KT_J&(_F7WO_(X/K='^7\$>N?\ ".Z)_P!
M;3__  %3_"C_ (1W1/\ H#:?_P" J?X5Y'_PG_B?_H)_^0(O_B:/^$_\3_\
M03_\@1?_ !-'U'$?S?B_\@^MT?Y?P1ZY_P ([HG_ $!M/_\  5/\*/\ A'=#
M_P"@-I__ ("I_A7D?_"?^)_^@G_Y C_^)H_X3_Q/_P!!/_R!%_\ $T?4<1_-
M^+_R#ZW1_E_!'KG_  CNB?\ 0&T__P !4_PH_P"$=T3_ * VG_\ @*G^%>1_
M\)_XG_Z"?_D"+_XFC_A/_$__ $$__($7_P 31]1Q'\WXO_(/K='^7\$>N?\
M".Z)_P! ;3__  %3_"C_ (1W0_\ H#:?_P" J?X5Y'_PG_B?_H)_^0(__B:/
M^$_\3_\ 03_\@1?_ !-'U'$?S?B_\@^MT?Y?P1ZY_P ([HG_ $!M/_\  5/\
M*/\ A'=$_P"@-I__ ("I_A7D?_"?^)_^@G_Y B_^)H_X3_Q/_P!!/_R!%_\
M$T?4<1_-^+_R#ZW1_E_!'KG_  CNB?\ 0&T__P !4_PH_P"$=T/_ * VG_\
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M1]1Q'\WXO_(/K='^7\$>N?\ ".Z)_P! ;3__  %3_"C_ (1W1/\ H#:?_P"
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M*/\ A'=#_P"@-I__ ("I_A7D?_"?^)_^@G_Y C_^)H_X3_Q/_P!!/_R!%_\
M$T?4<1_-^+_R#ZW1_E_!'KG_  CNB?\ 0&T__P !4_PH_P"$=T3_ * VG_\
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M1]1Q'\WXO_(/K='^7\$>N?\ ".Z)_P! ;3__  %3_"C_ (1W0_\ H#:?_P"
MJ?X5Y'_PG_B?_H)_^0(__B:/^$_\3_\ 03_\@1?_ !-'U'$?S?B_\@^MT?Y?
MP1ZY_P ([HG_ $!M/_\  5/\*/\ A'=$_P"@-I__ ("I_A7D?_"?^)_^@G_Y
M B_^)H_X3_Q/_P!!/_R!%_\ $T?4<1_-^+_R#ZW1_E_!'KG_  CNB?\ 0&T_
M_P !4_PH_P"$=T/_ * VG_\ @*G^%>1_\)_XG_Z"?_D"/_XFC_A/_$__ $$_
M_($7_P 31]1Q'\WXO_(/K='^7\$>N?\ ".Z)_P! ;3__  %3_"C_ (1W1/\
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M>&M!UFX6XU31--OIU0(LEU:I*P7). 6!.,DG'N:I_P#"">$/^A4T/_P70_\
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MZ'U!"Y%;5% &;J?A[1-:D235='T^_>,;4:ZMDE*CT!8'%4?^$$\(?]"IH?\
MX+H?_B:Z"B@"E=:/IE]IZ:?=Z=:7%D@4+;30*\:A?NX4C QV]*S/^$$\'_\
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MH?\ XFN@HH IVVDZ;9:<=.M=/M(+$AE-M%"JQ$-]X;0,<Y.?7-9?_"">#_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:^&['RX\274@_?3$<L?0>@K=KPL7BW5?+'X?S/6PV&5-<TMPHHHKA.L****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P "D_QI?^$BT3_H,Z?_ .!2?XT>TQ'=_B')1[+\#,_X0#PQ_P! S_R/)_\
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M .!2?XT>TQ'=_B')1[+\#,_X0#PQ_P! S_R/)_\ %4?\(!X8_P"@9_Y'E_\
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MXT?\)%HG_09T_P#\"D_QH]IB.[_$.2CV7X&9_P (!X8_Z!G_ )'D_P#BJ/\
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M_P "D_QI?^$BT3_H,Z?_ .!2?XT>TQ'=_B')1[+\#,_X0#PQ_P! S_R/)_\
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M .!2?XT>TQ'=_B')1[+\#,_X0#PQ_P! S_R/)_\ %4?\(!X8_P"@9_Y'E_\
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MXT?\)%HG_09T_P#\"D_QH]IB.[_$.2CV7X&9_P (!X8_Z!G_ )'D_P#BJ/\
MA /#'_0,_P#(\O\ \56E_P )%HG_ $&=/_\  I/\:7_A(M$_Z#.G_P#@4G^-
M'M,1W?XAR4>R_ S/^$ \,?\ 0,_\CR?_ !5'_" >&/\ H&?^1Y?_ (JM/_A(
MM$_Z#.G_ /@4G^-'_"1:)_T&=/\ _ I/\:/:8CN_Q#DH]E^!F?\ " >&/^@9
M_P"1Y/\ XJM/2O#^EZ)YG]G6BPF3&]MS,3^+$G%)_P )%HG_ $&=/_\  I/\
M:OPS17$*S02I+$XRKHP96'L14SG6:M-NWG<J,*=[Q2)****Q- HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ/:LO41I@:/^S3<E<'?Y^/PQBFIINR!QLBE16MX>TRWU6^EBN6D6..%I/W9
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MMW=<=L^].,^;8'&PVBBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]P>UJ7OS/[S#LO">BZ;?07MG:-#<P.)(I%GDRK#H1\U7M=TZW\3/ ^M&:]:
M$1&6=_E!QG&#["KAI#1[&G:W*ON%[6I>_,_O.</@?P[_ - [_P CR?\ Q5;M
M\C:EHJZ/>3W,VG*J*+=KA]H"XVCKVP*D-(::HTUM%?<#JU']I_><Z?!'AW_H
M'?\ D:3_ .*K;TB(^']/EL-)FN;2UE<R/%'<. S$ $]?0 ?A4II#35&FMHK[
M@=6H]Y/[SGCX*\/?] __ ,C2?_%5HZ+I-IX<O'O-'6:SN'C,3213N"4)!(Z^
MH'Y5>-(:%0I+:*^X'6J/[3^\R]4\/Z;K6HRZAJ4,ES>38\R:2>0LV %&?F]
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M-<U*;4=3MGN;R;;YDKSR9; "CHWH /PK6I12]C3M;E7W#]K4O?F?WF%9^#-
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M3-W=[C****V("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!X]XWT75;OQA?SVVF7DT+>7MDC@9E.(U'! ]:Y__A'=;_Z VH?^ K_X
M5] T5Z,,QE"*CR['%/!1E)RON?/W_".ZW_T!M0_\!7_PH_X1W6_^@-J'_@*_
M^%?0-%5_:<_Y2?J$>Y\_?\([K?\ T!M0_P# 5_\ "C_A'=;_ .@-J'_@*_\
MA7T#11_:<_Y0^H1[GS]_PCNM_P#0&U#_ ,!7_P */^$=UO\ Z VH?^ K_P"%
M?0-%']IS_E#ZA'N?/W_".ZW_ - ;4/\ P%?_  H_X1W6_P#H#:A_X"O_ (5]
M T4?VG/^4/J$>Y\_?\([K?\ T!M0_P# 5_\ "C_A'=;_ .@-J'_@*_\ A7T#
M11_:<_Y0^H1[GS]_PCNM_P#0&U#_ ,!7_P */^$=UO\ Z VH?^ K_P"%?0-%
M']IS_E#ZA'N?/W_".ZW_ - ;4/\ P%?_  H_X1W6_P#H#:A_X"O_ (5] T4?
MVG/^4/J$>Y\_?\([K?\ T!M0_P# 5_\ "C_A'=;_ .@-J'_@*_\ A7T#11_:
M<_Y0^H1[GS]_PCNM_P#0&U#_ ,!7_P */^$=UO\ Z VH?^ K_P"%?0-%']IS
M_E#ZA'N?/W_".ZW_ - ;4/\ P%?_  H_X1W6_P#H#:A_X"O_ (5] T4?VG/^
M4/J$>Y\_?\([K?\ T!M0_P# 5_\ "C_A'=;_ .@-J'_@*_\ A7T#11_:<_Y0
M^H1[GS]_PCNM_P#0&U#_ ,!7_P */^$=UO\ Z VH?^ K_P"%?0-%']IS_E#Z
MA'N?/W_".ZW_ - ;4/\ P%?_  H_X1W6_P#H#:A_X"O_ (5] T4?VG/^4/J$
M>Y\_?\([K?\ T!M0_P# 5_\ "C_A'=;_ .@-J'_@*_\ A7T#11_:<_Y0^H1[
MGS]_PCNM_P#0&U#_ ,!7_P */^$=UO\ Z VH?^ K_P"%?0-%']IS_E#ZA'N?
M/W_".ZW_ - ;4/\ P%?_  H_X1W6_P#H#:A_X"O_ (5] T4?VG/^4/J$>Y\_
M?\([K?\ T!M0_P# 5_\ "C_A'=;_ .@-J'_@*_\ A7T#11_:<_Y0^H1[GS]_
MPCNM_P#0&U#_ ,!7_P */^$=UO\ Z VH?^ K_P"%?0-%']IS_E#ZA'N?/W_"
M.ZW_ - ;4/\ P%?_  H_X1W6_P#H#:A_X"O_ (5] T4?VG/^4/J$>Y\_?\([
MK?\ T!M0_P# 5_\ "C_A'=;_ .@-J'_@*_\ A7T#11_:<_Y0^H1[GS]_PCNM
M_P#0&U#_ ,!7_P */^$=UO\ Z VH?^ K_P"%?0-%']IS_E#ZA'N?/W_".ZW_
M - ;4/\ P%?_  H_X1W6_P#H#:A_X"O_ (5] T4?VG/^4/J$>Y\_?\([K?\
MT!M0_P# 5_\ "C_A'=;_ .@-J'_@*_\ A7T#11_:<_Y0^H1[GS]_PCNM_P#0
M&U#_ ,!7_P */^$=UO\ Z VH?^ K_P"%?0-%']IS_E#ZA'N?/W_".ZW_ - ;
M4/\ P%?_  H_X1W6_P#H#:A_X"O_ (5] T4?VG/^4/J$>Y\_?\([K?\ T!M0
M_P# 5_\ "C_A'=;_ .@-J'_@*_\ A7T#11_:<_Y0^H1[GS]_PCNM_P#0&U#_
M ,!7_P */^$=UO\ Z VH?^ K_P"%?0-%']IS_E#ZA'N?/W_".ZW_ - ;4/\
MP%?_  H_X1W6_P#H#:A_X"O_ (5] T4?VG/^4/J$>Y\_?\([K?\ T!M0_P#
M5_\ "C_A'=;_ .@-J'_@*_\ A7T#11_:<_Y0^H1[GS]_PCNM_P#0&U#_ ,!7
M_P */^$=UO\ Z VH?^ K_P"%?0-%']IS_E#ZA'N?/W_".ZW_ - ;4/\ P%?_
M  H_X1W6_P#H#:A_X"O_ (5] T4?VG/^4/J$>Y\_?\([K?\ T!M0_P# 5_\
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M1Q@GN,/@\?2J:>%_B$SJ&\%[03@L=4@./?K7T'10\?B/YOP0?4Z/;\SQ;6_
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M\([\0_\ H2/_ "K6_P#C6[J_@?Q58:?%/I^G6VIW#.%:WCNUB* @DMN< '!
M'![U[)10L?7[_@@^IT>Q\_\ _"/?$/\ Z$?_ ,JUO_C6]8^!_%%QHK7=S86U
MI>A7(L7N@[$C.!O4%>>._&>:]BHH6/KKK^"!X.CV/ /[ ^(?_0C_ /E6M_\
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MS_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\
MU'M<_P# S_ZU=!10!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044
M<_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10!S__  BO_4>US_P,
M_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<
M_P# S_ZU=!10!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\
M\(K_ -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10!S__  BO_4>US_P,_P#K
M4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<_P#
MS_ZU=!10!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_
M -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10!S__  BO_4>US_P,_P#K4?\
M"*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU
M=!10!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[
M7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10!S__  BO_4>US_P,_P#K4?\ "*_]
M1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10
M!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\
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MS_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\
MU'M<_P# S_ZU=!10!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044
M<_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10!S__  BO_4>US_P,
M_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<
M_P# S_ZU=!10!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\
M\(K_ -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10!S__  BO_4>US_P,_P#K
M4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<_P#
MS_ZU=!10!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_
M -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10!S__  BO_4>US_P,_P#K4?\
M"*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU
M=!10!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[
M7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10!S__  BO_4>US_P,_P#K4?\ "*_]
M1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10
M!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\
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MS_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\
MU'M<_P# S_ZU=!10!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044
M<_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10!S__  BO_4>US_P,
M_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<
M_P# S_ZU=!10!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\
M\(K_ -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10!S__  BO_4>US_P,_P#K
M4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_ -1[7/\ P,_^M1_PBO\ U'M<_P#
MS_ZU=!10!S__  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_ .M7044 <_\ \(K_
M -1[7/\ P,_^M1_PBO\ U'M<_P# S_ZU=!10!S__  BO_4>US_P,_P#K4?\
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MRB+:>AWYQ@Y'.: ,O_A%?^H]KG_@9_\ 6H_X17_J/:Y_X&?_ %J/^$[\'_\
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MI!J%I+IX1G-VDRM$%7.X[P<8&#DYXP: ,O\ X17_ *CVN?\ @9_]:C_A%?\
MJ/:Y_P"!G_UJ/^$[\'_]#7H?_@QA_P#BJOZ9K^C:TTBZ5J]A?M$ 9!:W*2E
M>F=I..AH H?\(K_U'M<_\#/_ *U'_"*_]1[7/_ S_P"M4MSXR\+V=S);77B3
M1X+B)BDD4M]$K(PZ@@MD&G6?B[PUJ-W':6/B'2;FYD.$A@O8W=CC/"ALGB@"
M#_A%?^H]KG_@9_\ 6H_X17_J/:Y_X&?_ %JNZEXCT/1IDAU36=.L977>J75T
MD3,O3(#$9%4O^$[\'_\ 0UZ'_P"#&'_XJ@ _X17_ *CVN?\ @9_]:C_A%?\
MJ/:Y_P"!G_UJT[W6-,TVR2]O]1M+6T<@)//.J1L2,C#$X.169_PG?@__ *&O
M0_\ P8P__%4 '_"*_P#4>US_ ,#/_K4?\(K_ -1[7/\ P,_^M6I9ZMINHV+7
MUEJ%I<V:YS<03*\8QU^8'''>LO\ X3OP?_T->A_^#&'_ .*H /\ A%?^H]KG
M_@9_]:C_ (17_J/:Y_X&?_6J]IOB'1-:D>/2M8T^_>,;G6UN4E*CU(4G%5[O
MQAX8L;J2UO/$>D6]Q$=LD4U]&CH?0@MD4 0_\(K_ -1[7/\ P,_^M1_PBO\
MU'M<_P# S_ZU2VWC+PO>7,=M:^)-'GGE8)'%%?1,SL>@ #9)JUJ>OZ-HK1KJ
MNKV%@TH)C%U<I$7 ZXW$9ZB@"A_PBO\ U'M<_P# S_ZU'_"*_P#4>US_ ,#/
M_K4?\)WX/_Z&O0__  8Q?_%5J7.K:;9:<-1NM0M(+$A6%S+,JQ$-]T[B<<Y&
M/7- &7_PBO\ U'M<_P# S_ZU'_"*_P#4>US_ ,#/_K4?\)WX/_Z&O0__  8P
M_P#Q5:>GZQIFK6KW6FZC9WENC%'FMIUD16 !()4D X(/XT 9G_"*_P#4>US_
M ,#/_K4?\(K_ -1[7/\ P,_^M1_PG?@__H:]#_\ !C%_\55S3?$N@ZS<-;Z7
MK>FWTZH7:.UNDE8*"!DA23C) S[B@"G_ ,(K_P!1[7/_  ,_^M1_PBO_ %'M
M<_\  S_ZU6+[Q9X;TR\DL[_Q!I5I=1XWPSWD<;KD C*DY&00?QJ*'QKX4N)D
MAA\3Z+)+(P1$2_B+,QX  #<F@!G_  BO_4>US_P,_P#K4?\ "*_]1[7/_ S_
M .M6AJ>NZ/HGE?VMJMC8>=GR_M5PD6_&,XW$9QD?F*S_ /A._!__ $->A_\
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MUS_P,_\ K4?\(K_U'M<_\#/_ *U=!10!S_\ PBO_ %'M<_\  S_ZU'_"*_\
M4>US_P #/_K5T%% '/\ _"*_]1[7/_ S_P"M1_PBO_4>US_P,_\ K5T%% '/
M_P#"*_\ 4>US_P #/_K4?\(K_P!1[7/_  ,_^M7044 <_P#\(K_U'M<_\#/_
M *U'_"*_]1[7/_ S_P"M7044 <__ ,(K_P!1[7/_  ,_^M1_PBO_ %'M<_\
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M\#/_ *U=!10!S_\ PBO_ %'M<_\  S_ZU'_"*_\ 4>US_P #/_K5T%% '/\
M_"*_]1[7/_ S_P"M1_PBO_4>US_P,_\ K5T%% '/_P#"*_\ 4>US_P #/_K5
M:T_0OL%T)_[5U2YP"/+N;C>GUQBM:B@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "N!^+O_(J6O_7\G_H$E=]7 _%W_D5+7_K^3_T"
M2ML-_%B95_X;/%Z*VO#>CP:U>2V\LLL;A08RD99<Y_B(Z#\O\=CQAX=LM,C>
M\A+QF1U$<4<9\M1C!RW8YY_I7M.:4N4\GE=KG&T5U":3H5IHEA>ZE)?>9=!C
MB$K@8/N/I4&GZ9I&K>(X;.T>[%FT9+&0J'W $\<8QT_6CG0<ISU%=9!H.B:P
M+B#2+J[6]B0N([@#:X'T'KC\^E9NAZ''J,=Q>7EQ]FT^V \V0#))]![_ /UN
M.:.=!RLQ:*ZJUTSPUJ\QL[&ZO;>Z8'RFN I5SZ<?_6JMX>\.QZAKMUIVH-)%
M]GC9F\M@#D,!U(/'-'.NH<K.>HK6N=$>R\21Z7<%MCS(@<<%D8@ C\/UJ]=:
M=H&F:Q?65])?E8F41&+:>"H)SD>]/F0<K.;HKL-0TGPOIJVQGDU(BXB$J;2A
MX/KQ5&PT.P_LY]6U.YFAL&D*6Z(!YDO7\!T_0]*7.K7'RLYVBNICT/1]:MI_
M[$GN5O(5+_9[@#YP/3'^-0:/9^';XVMK.^H"\E(5MNT)N/IQTHYT+E.=HKHM
M8M/#MC]JMH'U WD1*+OVE-P/?CI5[5-&\-:-<1VUW+J+2M&),QE,<_A[4<Z#
ME./HKH]"T;3-;\0W%K%)<K9)$9$+%0YQM'/&.I-9>M:8VD:M/9DEE0Y1C_$I
MY!IJ2;L%G:Y0HKJ=&\+0WWAVYU.ZDE1@KM J$ ':.IR.>>/PJ#1='TR?0KS5
M-2DN0D$H3; 1GG'J/4TN=!RLYVBN@U/1+'^QQJVD7,LMLK^7*DP&Y&_ #U'Y
MU,NB:5I5C!/KEQ<?:+A=Z6UN!N5?5L__ %OQHYT'*SF:*Z*_T/3YM'?5=%N)
M9(8B!/#,!O3/?CMT_P :EMM'T2'PY9ZGJ4MZ&N7=<0E<#!([CT%'.K!RLYBB
MMK7]%@TU+2ZLKAI[*[4M&7&&&.Q_.KWAWPM%K&E7%S-*T<A8QVP! #.%SSD<
MCZ>AHYU:X<KO8Y>BK>FVBW6KVMI-N59)EC?'!&3@_C3M7M([#5[JUB+&.*0J
MI;KCWJKZV%;2Y2HI5&Y@/4XKK]1T?POIE^;*ZN=120 $N-K*,_AFDY6&E<X^
MBMC6=!;2KBW*3K/:70#0SJ.H]QZ\UK:GI?A?2;UK2YDU,RJ 24*$<C/I2YT'
M*SD:*Z3P]H>G:WK%W#YERMI&I:(Y4/C.!G@BL;5+!]+U.XLI.3$^ ?4=0?Q&
M*:DF[!9VN5**ZNP\*13^%+C5KF25)A&\L**1C:H[\=\57TK2=)?P])JFIR78
M"S^4! 5] >X]Z7.@Y6<Y16KJ*:*WDKI;7A=FP_VC;C'MBM/Q3X6CT6*&YLY)
M9+=CLD\P@E&[= .#_GK1SK1!RLY>BM_^R-/@T+2M3NGN=MS*ZS",C@ D#;D>
MPK0M])\+W.F75^DFI>3;%0X)3/)P,<4.:#E9R%%=1INCZ)K&JR06<EZ(([5I
M29"H;>" .W3!K$TC3VU35K:R4D>:^&(ZA>I/Y T^9!8I45N>*-$BT6^B%J[R
M6L\8>-V(.3W&1U['\:PZ:=U=":L[!16_K=E;:9HVEVWDK]MF3[1-(?O '[J_
M3_"M'4]&\-:-<1VUW+J+2M&LF8RI'/X>U3SH?*<?1716<'A:XF6%GU,/)+M3
M[F,$X7/'TJ?6M-\-Z5<7-D9-1-W$OR\J5W%<C/'3D4<^MK!RZ7.6HKK)M'\.
MZ?9V#W\VH"6Z@64F(J0,@9[5GZUH,5C:0ZC877VK3YCM5R,,A]"/PH4TP<68
M=%;_ (@LK;[!INJ64*Q0W46V1%'"R+P?Z_E6!5)W0FK!1113 **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (6/X3_Z"O\ Y+R__$T?\+'\)_\ 05_\EY?_ (FN!_X5%K__ #^:;_W]D_\
MB*/^%1:__P _FF?]_)/_ (BCV.&_F_K[@]KB/Y?Z^\[[_A8_A/\ Z"O_ )+R
M_P#Q-'_"Q_"?_05_\EY?_B:X'_A46O\ _/YIO_?R3_XBC_A46O\ _/YIG_?R
M3_XBCV.&_F_K[@]KB/Y3OO\ A8_A/_H*_P#DO+_\31_PL?PG_P!!7_R7E_\
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M;_W]D_\ B*/^%1:__P _FF?]_)/_ (BCV.&_F_K[@]KB/Y?Z^\[[_A8_A/\
MZ"O_ )+R_P#Q-'_"Q_"?_05_\EY?_B:X'_A46O\ _/YIO_?R3_XBC_A46O\
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MPZ57+9IH5[Z,L>%_W?AWQ%))Q$UN$!/0MAL?S'YU?AGTN#P-I!U6TDN83+(
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M&!]\'_)K+JHIJZ9,FF=-X\9CXD*D8"PH%'MS_P#7K<\57&@Q:G"NIV-S//\
M9U(:*3 VY.!U^M8GBEO[2T[2M:4[O,B\B;V=?\?F_*LS7M9.N7R7)@$.R)8]
MN[=G&>>@]:B,;I>13=KD-JT+:[ UNC)";E3&K')"[N 36AXU_P"1NOO^V?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O OB/\ \C[J?_;+_P!%)7OM>!?$
M?_D?M3_[9?\ HI*[<#_$?I_D<F,^!>I[1X9_Y%/1_P#KQ@_] %:M97AG_D5-
M'_Z\8/\ T 5JUR3^)G3'X4%%%%24%%%% !1110 4444 %%%% !1110 4444
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M>N@TCP[X@U;3VO$T&_ME5BOE7B"&0X&<A&.2.>*]XHH6,J('A:9\VBYUD?\
M,F>*O_!6]:FAV6N:W>O;1^&=:LRD9D\R^M?(0X(& S'!//3T!]*]^HIK&50>
M$IGSYJ/]LZ7J$UF_A/Q%<-$0#+:V)EC;C/RL#@]:2SN-7N[V"U'@_P 31&:1
M8Q)-IS(B9.,LQ. !W)Z"OH2BCZ[5#ZI3/$-=L-:T#[/YGAW5KWSMV/[/@%QL
MQC[VT_+G/&>N#Z5DC5=5'_,E>+/_  5-_C7T+10\;5$L'3/&IM.UFW\/#6#H
M.I.A1'^RQQ!KGYB!CRLYR,\CL :QH9?$NM31Z=I7A;6K*ZG;:+O4[)H8(%[N
MQ.<X'0=_?H??J*)8VJU8%A*:,OP[HPT#0;33/M4MVT"8>XFQOE8\ECC_ #C'
M)ZUJ445R-WW.I*P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5X%\1_P#D?=3_ .V7_HI*]]KP+XC_ /(^ZG_V
MR_\ 125VX'^(_3_(Y,9\"]3VCPS_ ,BIH_\ UXP?^@"M6LKPS_R*FC_]>,'_
M * *U:Y)_$SIC\*"BBBI*"BBB@ HHHH **** ([BXAM+:6XN94A@B4O))(P5
M44#)))Z "H[&_M-3LH[RPN8;FVE!*30N'5L'!P1[@C\*\^^,=_/+H6G>%K%\
M7WB"\2U7KQ&""[<=LE0?8FJ?PDD?P[K'B3P%<R,S:9<FXLR[99H'QS^J'ZN:
M /2(]7TR759=+CU"U?4(EWR6JS*947CDKG('(_,>M/N=3L+.ZM;6ZO;>"XNF
M*V\4D@5I2.H4'DXR.GK7SQXGAU6Q^+/BCQ5HY+7&@RV]Q+#_ ,](60+(/ICK
M[$GM77>,M8L_$'C'X4ZM82;[:ZN9I$/<?ZG(/N#D'W!H ]=N[RVL+26[O+B*
MWMXEW22RN%51ZDGI38+ZTN;!;Z"ZAEM'3S%G1P4*]=V[ICWKSGXNSR:N=!\$
M6KL)M;O%-P5P2MO&0S$CZX/_   TSX/7$EC9:YX)U [Y]#NWC3<N \#DD$#N
M,[C]&% 'I%AJ-EJME'>:?=PW5K)G9-"X=6P<'!'N"*9)JNGPZI#IDE];I?S(
M9([9I0)'49R0O4C@_D?2O-?A2S>&_$WBCP),QQ97/VRR#,23 ^/Y Q_BQIG@
MX?\ "5_$OQ9XN?Y[2Q!TNP/!7Y1\[+^6?^VAH [<^/?" )!\4:/D?]/L?^-:
M$7B'1I[BTMX=6LI)KR,RVT:3J6F09^9!GYAP>GH?2OG_ .'.M_#&Q\(Q0^*;
M>T?4Q-(6:6Q>4[<\?,%(KTGQ_P"$(=5\':?JOA9$M;_156\TPP)L!C&&* 8[
MC! (ZC'<T =]?ZKI^E+"VH7UO:K-((HC/($WN>BC/4^U<_XG^(WACPC>1V6J
MZ@1>.-PMX8VD<+ZD*./QK@/!US=?%WQC;>*-2MO)T?0T5+:U)RKW9 +M] <'
M\$]ZX'XL:+<V?CC4/[2C-O'=W$MU!J4D1=)4,2A(L@'E2I7VW9Z8- 'TKH7B
M'2O$NE+J6D7D=U:,2N]<@J1U# X*GV-5H/&7ABYU!;"#Q!IDEVS;%B2Z0EF_
MNCGD^W6O._A!X<FO/#&NR:AI\]CI6L006\=J[%68+!Y<LHZ$;R2<]\5Q_CJ]
M^&=QX:AT'P=9V\FM-<QQV\T4#1LAW8)>60#<#R.21SGM0!](5FZIX@T;0S$-
M6U6RL3+GRQ<SK'OQC.,GG&1^=6[*.:&PMHKF3S)TB59'_O, ,G\35+5_#FBZ
M^8CJVEVEZ8<^69X@Q3.,XSZX'Y4 58/&_A2ZN([>#Q)I,LTK!(XTO(RS,3@
M#/))K5O]1LM*LWN]0NX+2V3&Z6>0(H].37CC>&=$UKXVV>FZ-I5I::=X=C%U
M>O;Q!?,G)!1"1UP=O'LXJ]\9?!<-[H.M>)KW4KV<VMN@L[(OMAMVW*&; ZD_
MYSQ@ ]:@GBNK>.XMY4EAE0/'(C JZD9!!'4$5)6#X'_Y)_X;_P"P7:_^BEK>
MH **** "BBB@ HHHH **** .5^(__(A:G_VR_P#1J5P/PB_Y&NZ_Z\7_ /0X
MZ[[XC_\ (A:G_P!LO_1J5P/PB_Y&NZ_Z\7_]#CKOH_[M+^NQQU?]XB>T4445
MP'8%%%% !1110 4444 %%%% !1110 5S'CKQ'>>&-$AO;*."25[E8B)E)&"K
M'L1S\HKIZX'XN_\ (J6O_7\G_H$E:T(J51)F=9M0;1RO_"W=?_Y\]-_[]R?_
M !='_"W=?_Y\],_[]2?_ !=<58Z?=ZG<BWLX6EE(S@<8'J2>!5O4O#NJ:3")
MKNVVQ$XWJP89]\=*];V%&]K(\WVU7>YU7_"W=?\ ^?/3?^_4G_Q='_"W=?\
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M>U/ZO1VL'MZG<[?_ (6[K_\ SYZ;_P!^I/\ XNC_ (6[K_\ SYZ;_P!^Y/\
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MNO\ _/GIO_?J3_XNC_A;NO\ _/GIO_?N3_XNN!HH^K4OY0]O4[G??\+=U_\
MY\]-_P"_<G_Q='_"W=?_ .?/3/\ OU)_\77 T4?5J7\H>WJ=SOO^%NZ__P ^
M>F_]^I/_ (NC_A;NO_\ /GIO_?N3_P"+K@:*/JU+^4/;U.YWW_"W=?\ ^?/3
M?^_<G_Q='_"W=?\ ^?/3/^_4G_Q=<#11]6I?RA[>IW.^_P"%NZ__ ,^>F_\
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M-%'U:E_*'MZG<[[_ (6[K_\ SYZ;_P!^I/\ XNC_ (6[K_\ SYZ;_P!^Y/\
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M>+-1MHX]/OK72I%?<TL-H)"PQ]W$A(]^.>*Y-:D6FL/2["]O4[E\>+OB&?\
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M>&C8=48=F'I_0@UY5>BZ4K,]*C656-T:E%%%8FH4444 %%%% !1110 4444
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MPT7Q!X7T[2M.N'DN],T^VCND,;*%8(%."1@\J:[RBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9?\ HI*[<#_$?I_D<F,^!>I[1X9_Y%31_P#KQ@_] %:M97AG_D5-'_Z\8/\
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M;:?S_/0LG1MN0 <_-BNL\*?\*WUMK^W\-6VE3LT/EW216VTM&QZ'(&02/T%
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M -_8_P#XBC_A46@?\_FI?]_8_P#XBCZ[2#ZK4/%Z*]H_X5%H'_/YJ7_?R/\
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M -_8_P#XBC_A46@?\_FI?]_8_P#XBCZ[2#ZK4/%Z*]H_X5%H'_/YJ7_?R/\
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M -_8_P#XBC_A46@?\_FI?]_8_P#XBCZ[2#ZK4/%Z*]H_X5%H'_/YJ7_?R/\
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M -_8_P#XBC_A46@?\_FI?]_8_P#XBCZ[2#ZK4/%Z*]H_X5%H'_/YJ7_?R/\
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M$2,;4VR87&/W@P^>!DYR>^<FCZUY!]6\SYC:HFZU]$?\*2^'G_0O?^3MQ_\
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ML;.\NA=W-O D4EQMV^85 &[&3UQ5^@#QK5[JS\5_%'X<WTEK'-:7^GS3&&9
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MS3?_  +C_P :/^$FT#_H.:;_ .!<?^-?-U%=_P!0CW.+ZY+L?2/_  D^@?\
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MN2['TC_PDV@?]!S3?_ N/_&C_A)M _Z#FF_^!<?^-?-U%'U"/</KDNQ](_\
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M+C_QH_X2;0/^@YIO_@7'_C7S=11]0CW#ZY+L?2/_  D^@?\ 0<TW_P "X_\
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MVM7^(?A'0[1+F^U^S$3.(QY#&=LD$_=C#$#@\XQ^=?.[5$U'U7S']9\CW/\
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M&'_R2N/_ (W7%+4HIO+UTE^ ECN\3U"7QQX9A\/C7'UB :>8UE\P9+;3C!V
M;^XXQFL[1OBIX)U_4XM-T[78Y+N8XCCDAEBWGT!=0"?09R:X1:KZCIEKJUB]
MI=INC;D$'#(PZ,I[$42R_320+':ZH]THKCO"7B2V@TC3]+UC6%DU/(@26Y94
M>Z;G&/5L8'J?<FNQKSYPE!\LMSNC)37-$****DH**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP+XC_ /(^ZG_VR_\
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M.:/<U:*RO^$FT#_H.:;_ .!<?^-'_"3Z!_T'--_\"X_\:.278.:/<U:*RO\
MA)M _P"@YIO_ (%Q_P"-'_"3:!_T'-,_\"X_\:.278.:/<U:*RO^$FT#_H.:
M;_X%Q_XT?\)/H'_0<TW_ ,"X_P#&CDEV#FCW,KXC_P#(A:G_ -LO_1J5P/PB
M_P"1KNO^O%__ $..NO\ 'VNZ1>>"=0M[75;&>9_+VQQ7",QQ(I. #GH#7(?"
M+_D:[K_KQ?\ ]#CKNI)K#2O_ %L<E1IUXV/:****\\[0HHHH **** "BBB@
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MY44]"P%=EJ__  C.DZHUC-HLC*H4F2.=L\C/ )KCH/\ CXC_ -X?SK>\;?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !5>^T4?7JG9?U\P^IP[L\"_X5QXL_Z!7_DQ%_\ %4?\*X\6?] K_P F(O\
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ME_X"2?X4O_",Z_\ ] /4_P#P$D_PHO"][A:=K6(-0U:XU*WLX9EC"VD0BCV
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M6T':9;'BRZ2^2\BL=/BE2-HU\N$@?-CGKUX_4U@$EB2222<DFM3_ (1G7_\
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MWU9W8ATBNUB*#U)D !_"L(^&_B&?^9(_\JMO_C0Z]/N'L*CZ%9JA:NI/P_\
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M2705P3C(W, O'/?G'%-8FEW$\/4['.BI!3QX7^(8_P"9*_\ *K;_ .-;^D>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6'/XE\
MBXEA_L369/+<KOCM<JV#C(.>16Y10!S_ /PE7_4!US_P#_\ KT?\)5_U =<_
M\ __ *]=!5:[U&QL-OVR\M[?=]WSI53/TR::3>B$VEN9'_"5?]0'7/\ P#_^
MO1_PE7_4!US_ , __KU>_P"$BT3_ *#.G_\ @4G^-'_"1:)_T&=/_P# I/\
M&J]G/L+GCW*/_"5?]0'7/_ /_P"O1_PE7_4!US_P#_\ KU>_X2+1/^@SI_\
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MB?\ 09T__P "D_QH]G/L'/'N4?\ A*O^H#KG_@'_ /7H_P"$J_Z@.N?^ ?\
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M?\)%HG_09T__ ,"D_P :/^$BT3_H,Z?_ .!2?XT>SGV#GCW*/_"5?]0'7/\
MP#_^O1_PE7_4!US_ , __KU>_P"$BT3_ *#.G_\ @4G^-6K6^M+Y"]I=07"C
MJT,@<#\J3A):M I1>S,?_A*O^H#KG_@'_P#7H_X2K_J ZY_X!_\ UZZ"BI*.
M?_X2K_J ZY_X!_\ UZ/^$J_Z@.N?^ ?_ ->N@HH Y_\ X2K_ *@.N?\ @'_]
M>C_A*O\ J ZY_P" ?_UZZ"B@#G_^$J_Z@.N?^ ?_ ->C_A*O^H#KG_@'_P#7
MKH** .?_ .$J_P"H#KG_ (!__7H_X2K_ *@.N?\ @'_]>N@HH Y__A*O^H#K
MG_@'_P#7H_X2K_J ZY_X!_\ UZZ"B@#G_P#A*O\ J ZY_P" ?_UZ/^$J_P"H
M#KG_ (!__7KH*RM?U^U\.V*7=W',\;RB("$ G)!/<CC@U48N3LMQ2DHJ[*G_
M  E7_4!US_P#_P#KT?\ "5?]0'7/_ /_ .O61_PM+1/^?74/^_:?_%T?\+2T
M3_GUU#_OVG_Q=;?5*W\IC]9I?S&O_P )5_U =<_\ _\ Z]'_  E7_4!US_P#
M_P#KUD?\+2T3_GUU#_OVG_Q='_"TM$_Y]=0_[]I_\71]4K?RC^LTOYC7_P"$
MJ_Z@.N?^ ?\ ]>C_ (2K_J ZY_X!_P#UZR/^%I:)_P ^NH?]^T_^+H_X6EHG
M_/KJ'_?M/_BZ/JE;^47UFE_,:_\ PE7_ % =<_\  /\ ^O1_PE7_ % =<_\
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M^NH?]^T_^+H_X6EHG_/KJ'_?M/\ XNCZI6_E%]9I?S&O_P )5_U =<_\ _\
MZ]'_  E7_4!US_P#_P#KUD?\+2T3_GUU#_OVG_Q='_"TM$_Y]=0_[]I_\71]
M4K?RC^LTOYC7_P"$J_Z@.N?^ ?\ ]>C_ (2K_J ZY_X!_P#UZR/^%I:)_P ^
MNH?]^T_^+H_X6EHG_/KJ'_?M/_BZ/JE;^47UFE_,:_\ PE7_ % =<_\  /\
M^O1_PE7_ % =<_\  /\ ^O61_P +2T3_ )]=0_[]I_\ %T?\+2T3_GUU#_OV
MG_Q='U2M_*/ZS2_F-?\ X2K_ *@.N?\ @'_]>C_A*O\ J ZY_P" ?_UZR/\
MA:6B?\^NH?\ ?M/_ (NC_A:6B?\ /KJ'_?M/_BZ/JE;^47UFE_,:_P#PE7_4
M!US_ , __KT?\)5_U =<_P# /_Z]9'_"TM$_Y]=0_P"_:?\ Q='_  M+1/\
MGUU#_OVG_P 71]4K?RC^LTOYC7_X2K_J ZY_X!__ %Z/^$J_Z@.N?^ ?_P!>
MLC_A:6B?\^NH?]^T_P#BZ/\ A:6B?\^NH?\ ?M/_ (NCZI6_E%]9I?S&O_PE
M7_4!US_P#_\ KT?\)5_U =<_\ __ *]9'_"TM$_Y]=0_[]I_\71_PM+1/^?7
M4/\ OVG_ ,71]4K?RC^LTOYC7_X2K_J ZY_X!_\ UZ/^$J_Z@.N?^ ?_ ->L
MC_A:6B?\^NH?]^T_^+H_X6EHG_/KJ'_?M/\ XNCZI6_E%]9I?S&O_P )5_U
M=<_\ _\ Z]'_  E7_4!US_P#_P#KUD?\+2T3_GUU#_OVG_Q='_"TM$_Y]=0_
M[]I_\71]4K?RC^LTOYC7_P"$J_Z@.N?^ ?\ ]>C_ (2K_J ZY_X!_P#UZR/^
M%I:)_P ^NH?]^T_^+H_X6EHG_/KJ'_?M/_BZ/JE;^47UFE_,:_\ PE7_ % =
M<_\  /\ ^O1_PE7_ % =<_\  /\ ^O61_P +2T3_ )]=0_[]I_\ %T?\+2T3
M_GUU#_OVG_Q='U2M_*/ZS2_F-?\ X2K_ *@.N?\ @'_]>C_A*O\ J ZY_P"
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MZ/\ A*O^H#KG_@'_ /7KH** .?\ ^$J_Z@.N?^ ?_P!>C_A*O^H#KG_@'_\
M7KH** .?_P"$J_Z@.N?^ ?\ ]>C_ (2K_J ZY_X!_P#UZZ"B@#G_ /A*O^H#
MKG_@'_\ 7H_X2K_J ZY_X!__ %ZZ"B@#G_\ A*O^H#KG_@'_ /7H_P"$J_Z@
M.N?^ ?\ ]>N@HH Y_P#X2K_J ZY_X!__ %Z/^$J_Z@.N?^ ?_P!>N@HH Y__
M (2K_J ZY_X!_P#UZ/\ A*O^H#KG_@'_ /7KH** .?\ ^$J_Z@.N?^ ?_P!>
MC_A*O^H#KG_@'_\ 7KH** .?_P"$J_Z@.N?^ ?\ ]>C_ (2K_J ZY_X!_P#U
MZZ"B@#G_ /A*O^H#KG_@'_\ 7H_X2K_J ZY_X!__ %ZZ"B@#G_\ A*O^H#KG
M_@'_ /7H_P"$J_Z@.N?^ ?\ ]>N@HH Y_P#X2K_J ZY_X!__ %Z/^$J_Z@.N
M?^ ?_P!>N@HH Y__ (2K_J ZY_X!_P#UZ/\ A*O^H#KG_@'_ /7KH** .?\
M^$J_Z@.N?^ ?_P!>C_A*O^H#KG_@'_\ 7KH** .?_P"$J_Z@.N?^ ?\ ]>C_
M (2K_J ZY_X!_P#UZZ"B@#G_ /A*O^H#KG_@'_\ 7H_X2K_J ZY_X!__ %ZZ
M"B@#G_\ A*O^H#KG_@'_ /7H_P"$J_Z@.N?^ ?\ ]>N@HH Y_P#X2K_J ZY_
MX!__ %Z/^$J_Z@.N?^ ?_P!>N@HH Y__ (2K_J ZY_X!_P#UZ/\ A*O^H#KG
M_@'_ /7KH** .?\ ^$J_Z@.N?^ ?_P!>C_A*O^H#KG_@'_\ 7KH** .?_P"$
MJ_Z@.N?^ ?\ ]>C_ (2K_J ZY_X!_P#UZZ"B@#G_ /A*O^H#KG_@'_\ 7H_X
M2K_J ZY_X!__ %ZZ"B@#G_\ A*O^H#KG_@'_ /7H_P"$J_Z@.N?^ ?\ ]>N@
MHH Y_P#X2K_J ZY_X!__ %Z/^$J_Z@.N?^ ?_P!>N@HH Y__ (2K_J ZY_X!
M_P#UZ/\ A*O^H#KG_@'_ /7KH** .?\ ^$J_Z@.N?^ ?_P!>C_A*O^H#KG_@
M'_\ 7KH** .?_P"$J_Z@.N?^ ?\ ]>C_ (2K_J ZY_X!_P#UZZ"B@#G_ /A*
MO^H#KG_@'_\ 7H_X2K_J ZY_X!__ %ZZ"B@#G_\ A*O^H#KG_@'_ /7H_P"$
MJ_Z@.N?^ ?\ ]>N@HH Y_P#X2K_J ZY_X!__ %Z/^$J_Z@.N?^ ?_P!>N@HH
M Y__ (2K_J ZY_X!_P#UZ/\ A*O^H#KG_@'_ /7KH** .?\ ^$J_Z@.N?^ ?
M_P!>C_A*O^H#KG_@'_\ 7KH** .?_P"$J_Z@.N?^ ?\ ]>C_ (2K_J ZY_X!
M_P#UZZ"B@#G_ /A*O^H#KG_@'_\ 7H_X2K_J ZY_X!__ %ZZ"B@#G_\ A*O^
MH#KG_@'_ /7H_P"$J_Z@.N?^ ?\ ]>N@HH Y_P#X2K_J ZY_X!__ %Z/^$J_
MZ@.N?^ ?_P!>N@HH Y__ (2K_J ZY_X!_P#UZ/\ A*O^H#KG_@'_ /7KH**
M.?\ ^$J_Z@.N?^ ?_P!>C_A*O^H#KG_@'_\ 7KH** .?_P"$J_Z@.N?^ ?\
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M^1X__BJ/^$ \3_\ 0,_\CQ__ !5>W44?VE5[+\?\P^HT^[_KY'B/_" >)_\
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M\CQ__%5[=11_:57LOQ_S#ZC3[O\ KY'B/_" >)_^@9_Y'C_^*H_X0#Q/_P!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZEI]M?6DGF6US$LT3X(W(P!!P>1P15B@ HHHH **** "BBB@ HHHH YKQ_\
M\B3J/_;/_P!&+7$?"W_D9KG_ *\V_P#0TKM_'_\ R).H_P#;/_T8M<1\+?\
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M $$__($?_P 31_PG_B?_ *"?_D"/_P")HY<9W7]?(.;#=F:7_"K=;_Y^M/\
M^_C_ /Q%'_"K=;_Y^M/_ ._C_P#Q%9O_  G_ (G_ .@G_P"0(_\ XFC_ (3_
M ,3_ /03_P#($7_Q-'+C.Z_KY!S8;LS2_P"%6ZW_ ,_6G_\ ?Q__ (BC_A5N
MM_\ /UI__?Q__B*S?^$_\3_]!/\ \@1__$T?\)_XG_Z"?_D"/_XFCEQG=?U\
M@YL-V9I?\*MUO_GZT_\ [^/_ /$4?\*MUO\ Y^M/_P"_C_\ Q%9O_"?^)_\
MH)_^0(__ (FC_A/_ !/_ -!/_P @1?\ Q-'+C.Z_KY!S8;LS2_X5;K?_ #]:
M?_W\?_XBC_A5NM_\_6G_ /?Q_P#XBLW_ (3_ ,3_ /03_P#($?\ \31_PG_B
M?_H)_P#D"/\ ^)HY<9W7]?(.;#=F:7_"K=;_ .?K3_\ OX__ ,11_P *MUO_
M )^M/_[^/_\ $5F_\)_XG_Z"?_D"/_XFC_A/_$__ $$__($7_P 31RXSNOZ^
M0<V&[,TO^%6ZW_S]:?\ ]_'_ /B*/^%6ZW_S]:?_ -_'_P#B*S?^$_\ $_\
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M\)_XG_Z"?_D"/_XFCEQG=?U\@YL-V9I?\*MUO_GZT_\ [^/_ /$4?\*MUO\
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MNM_\_6G_ /?Q_P#XBLW_ (3_ ,3_ /03_P#($?\ \31_PG_B?_H)_P#D"/\
M^)HY<9W7]?(.;#=F:7_"K=;_ .?K3_\ OX__ ,11_P *MUO_ )^M/_[^/_\
M$5F_\)_XG_Z"?_D"/_XFC_A/_$__ $$__($7_P 31RXSNOZ^0<V&[,TO^%6Z
MW_S]:?\ ]_'_ /B*/^%6ZW_S]:?_ -_'_P#B*S?^$_\ $_\ T$__ "!'_P#$
MT?\ "?\ B?\ Z"?_ ) C_P#B:.7&=U_7R#FPW9FE_P *MUO_ )^M/_[^/_\
M$4?\*MUO_GZT_P#[^/\ _$5F_P#"?^)_^@G_ .0(_P#XFC_A/_$__03_ /($
M7_Q-'+C.Z_KY!S8;LS2_X5;K?_/UI_\ W\?_ .(H_P"%6ZW_ ,_6G_\ ?Q__
M (BLW_A/_$__ $$__($?_P 31_PG_B?_ *"?_D"/_P")HY<9W7]?(.;#=F:7
M_"K=;_Y^M/\ ^_C_ /Q%'_"K=;_Y^M/_ ._C_P#Q%9O_  G_ (G_ .@G_P"0
M(_\ XFC_ (3_ ,3_ /03_P#($7_Q-'+C.Z_KY!S8;LS2_P"%6ZW_ ,_6G_\
M?Q__ (BI;?X6:J;B,7-Y9K!N^<QLS-CV!4#-9'_"?^)_^@G_ .0(_P#XFI[/
MXB>((+N.2YNEN85/SQ-$B[A]0 12<<9;=?U\AJ6%OLSUW3M.M=*L8[.SB$<,
M8X ZD^I/<U:JCI.K6FM:>EY9R;HVX(/WD/<$=C5ZO$ES<SYMSUHVLN78****
MD84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2_*,[6/#8[XZ5PEU\/=8T#XS:)_9EE<S>&S?F^A,49,5J6V^8K$#"_<7&>H
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ME)246_P$DFKV.=Z&DHHK<R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#7\/>(;OP[J N+<[HFP)82?ED']#Z&O;M)U:TUK3T
MO+.3=&W!!^\A[@CL:^>JU_#WB&[\.Z@+BW.Z)L"6$GY9!_0^AKAQ>$59<T?B
M_,Z\-B73?*]CWRBJVGWL>HZ?!>1*ZQS('4.NU@#ZBK->$TT[,]=.ZN@HHHI#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O$?'_\
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M'_"K=$_Y^M0_[^)_\17D=%'U:M_S]_#_ ((>WI?\^_Q/7/\ A5NB?\_6H?\
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M_6H?]_$_^(H_X5;HG_/UJ'_?Q/\ XBO(Z*/JU;_G[^'_  0]O2_Y]_B>N?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\_\ _".ZW_T!M0_\!7_PH_X1W6_^@-J'_@*_^%']GP_Y^?U]X?79?R?U]Q]
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M\_\ _".ZW_T!M0_\!7_PH_X1W6_^@-J'_@*_^%']GP_Y^?U]X?79?R?U]Q]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^/\ PKH*X/Q/-(^M31,Y*1A0JYX&5!_K6U"C[67+>QC7J^RCS6N;G]K^(O\
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M*/[7\1?]"O\ ^3\?^%<K_9>H?\^-S_WY;_"C^R]0_P"?&Y_[\M_A1]2C_/\
MU]X?7)?R?U]QU7]K^(O^A7_\GX_\*/[7\1?]"O\ ^3\?^%<K_9>H?\^-S_WY
M;_"C^R]0_P"?&Y_[\M_A1]2C_/\ U]X?7)?R?U]QU7]K^(O^A7_\GX_\*/[7
M\1?]"O\ ^3\?^%<K_9>H?\^-S_WY;_"C^R]0_P"?&Y_[\M_A1]2C_/\ U]X?
M7)?R?U]QU7]K^(O^A7_\GX_\*/[7\1?]"O\ ^3\?^%<K_9>H?\^-S_WY;_"C
M^R]0_P"?&Y_[\M_A1]2C_/\ U]X?7)?R?U]QU7]K^(O^A7_\GX_\*/[7\1?]
M"O\ ^3\?^%<K_9>H?\^-S_WY;_"C^R]0_P"?&Y_[\M_A1]2C_/\ U]X?7)?R
M?U]QU7]K^(O^A7_\GX_\*/[7\1?]"O\ ^3\?^%<K_9>H?\^-S_WY;_"C^R]0
M_P"?&Y_[\M_A1]2C_/\ U]X?7)?R?U]QU7]K^(O^A7_\GX_\*/[7\1?]"O\
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M_P#R?C_PH_M?Q%_T*_\ Y/Q_X5T%% '/_P!K^(O^A7_\GX_\*/[7\1?]"O\
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MA5W<<_\ UJIRW%Y/?6J7BD%7!4,FW@D?X4*HVWY#=-)(SL$=125U4L]\=8:
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M]5->;7H.#NMCT*-;G5GN6J***YS<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY_XD_P"0_<_\ _\ 017H%>?^)/\ D/W7_ /_ $$5VX#^(_3_ "./'?PUZG:Z
M7_R";/\ ZX)_Z"*MU4TO_D$V?_7!/_015NN2?Q,ZH?"@HHHJ2@HHHH ****
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M'A807D"3QB03 [64,,X;T-5+GPY_PB_[-][82)MN7L3<7.1@^8Y#$'W PO\
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M ,<;_"C^W-._Y^/_ !QO\*[/;U?Y#D]C3_F.6^P7G_/I/_W[-'V"\_Y])_\
MOV?\*ZG^W-._Y^/_ !QO\*/[<T[_ )^/_'&_PH]O5_D#V-/^8Y;[!>?\^D__
M '[/^%'V"\_Y])_^_9_PKJ?[<T[_ )^/_'&_PH_MS3O^?C_QQO\ "CV]7^0/
M8T_YCEOL%Y_SZ3_]^S1]@O/^?2?_ +]G_"NI_MS3O^?C_P <;_"C^W-._P"?
MC_QQO\*/;U?Y ]C3_F.6^P7G_/I/_P!^S_A1]@O/^?2?_OV?\*ZG^W-._P"?
MC_QQO\*/[<T[_GX_\<;_  H]O5_D#V-/^8Y;[!>?\^D__?LT?8+S_GTG_P"_
M9_PKJ?[<T[_GX_\ '&_PH_MS3O\ GX_\<;_"CV]7^0/8T_YCEOL%Y_SZ3_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@"Z_X!_Z&*Y_PA_R%I?^N!_]"6N^C_NTOZ['#6_WF/\ 7<[6BBBN [@HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,NI-2=T;5EYR:(7L1FX\W]Y@9..W]/UK0@@\UUOWMS%=;"/+R!O..M<O%-+
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M1V<@8RQR<4U2M)2$ZEXN(RBBBMC(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "NKT&6ZDL\3C,0XC8]2/\*R](T@W;"><$0#H/[_ /\ 6KJ0 JA5  '
M [5PXJK%^XCLPU.2]YBT445Q'8%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7 >)0?[?N??;_P"@BN_JE>:38W\@DN;<.X&
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M_P (WI/_ #Z?^1'_ ,:/^$;TG_GT_P#(C_XT>VPW\O\ 7WA['$_S?U]QS_\
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M +Y;_P"*H_X2_4/^>-M_WRW_ ,570?\ "-Z3_P ^G_D1_P#&C_A&])_Y]/\
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M7ZA_SQMO^^6_^*H_X2_4/^>-M_WRW_Q5=!_PC>D_\^G_ )$?_&C_ (1O2?\
MGT_\B/\ XT>VPW\O]?>'L<3_ #?U]QS_ /PE^H?\\;;_ +Y;_P"*H_X2_4/^
M>-M_WRW_ ,570?\ "-Z3_P ^G_D1_P#&C_A&])_Y]/\ R(_^-'ML-_+_ %]X
M>QQ/\W]?<<__ ,)?J'_/&V_[Y;_XJC_A+]0_YXVW_?+?_%5T'_"-Z3_SZ?\
MD1_\:/\ A&])_P"?3_R(_P#C1[;#?R_U]X>QQ/\ -_7W'/\ _"7ZA_SQMO\
MOEO_ (JC_A+]0_YXVW_?+?\ Q5=!_P (WI/_ #Z?^1'_ ,:/^$;TG_GT_P#(
MC_XT>VPW\O\ 7WA['$_S?U]QS_\ PE^H?\\;;_OEO_BJ/^$OU#_GC;?]\M_\
M570?\(WI/_/I_P"1'_QH_P"$;TG_ )]/_(C_ .-'ML-_+_7WA['$_P W]?<<
M_P#\)?J'_/&V_P"^6_\ BJ/^$OU#_GC;?]\M_P#%5T'_  C>D_\ /I_Y$?\
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MNI_X1NS_ .>L_P#WT/\ "C_A&[/_ )Z3_P#?0_PH^M4P^K5#EJ*ZG_A&[/\
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M[/\ YZ3_ /?0_P */^$;L_\ GK/_ -]#_"CZU3#ZM4.6HKJ?^$;L_P#GK/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /2!6\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT5&+1VO!#*&'4@]&'452_P"&@?!A) BU7(Z_Z*/_ (JO39+*TEE,LEK"\C
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M .2A&1@>IR!CU- &O17C ^+WB^^TJ?Q!I?@=I/#\.YC/),=S(O5A@=!@Y(!
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M-;3C[KC#HPZJP[$?_JR.:NQ164]D5A2"2TG4Y" %)%(P>G!!%>':5J(^"GQ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF H[5[%X+OO&FIIJ">--#L-/0!!;BWD#B4'=O# ._3Y?3KWKI_L-G_SZP?\
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M^T:E<0^3&F]4X8A6.6('"ECUH \.T#QS*?B=KWC(>'M3U>*8M:V9M8B5C08
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M@LA^\T;PPI>3^ZTP(R/KOV@CN$->UUY]\(O!=YX1\,3R:O'LUG4)S-=9<.5
M)"J6!(/=NO\ $:ZKQ38ZKJ7AF_L]$U#[!J<D>+>Y/16!!P>#@$ C(&1G(Z4
M<'JOP%\+ZK>WUZ]]JZ7%W-).Q$ZE59F+'@KDC)[G/O67\+M0U;PKX[U+X;:E
M<I>6EI&9K.95P5!P^/H0^2#G![U8AU[XTZ?']CG\,:9J$JC:MUYBJ']R X'Z
M+6I\.O FM:;X@U+Q=XLN8I=<U!=@ABP5A3C()'!/"@ < #J<\ 'I=%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 45Y/KGQ]\.:)KE[I3:=J5P]G,
MT$DD:H%+J<-C+9QD&L__ (:1\.?] ;5?_(?_ ,50![117B__  TCX<_Z VJ_
M^0__ (JC_AI'PY_T!M5_\A__ !5 'M%%>+_\-(^'/^@-JO\ Y#_^*H_X:1\.
M?] ;5?\ R'_\50![117B_P#PTCX<_P"@-JO_ )#_ /BJ/^&D?#G_ $!M5_\
M(?\ \50![117B_\ PTCX<_Z VJ_^0_\ XJC_ (:1\.?] ;5?_(?_ ,50![11
M7B__  TCX<_Z VJ_^0__ (JC_AI'PY_T!M5_\A__ !5 'M%%>+_\-(^'/^@-
MJO\ Y#_^*H_X:1\.?] ;5?\ R'_\50![117B_P#PTCX<_P"@-JO_ )#_ /BJ
M/^&D?#G_ $!M5_\ (?\ \50![117B_\ PTCX<_Z VJ_^0_\ XJC_ (:1\.?]
M ;5?_(?_ ,50![117B__  TCX<_Z VJ_^0__ (JC_AI'PY_T!M5_\A__ !5
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MTCX<_P"@-JO_ )#_ /BJ/^&D?#G_ $!M5_\ (?\ \50![117B_\ PTCX<_Z
MVJ_^0_\ XJC_ (:1\.?] ;5?_(?_ ,50![117B__  TCX<_Z VJ_^0__ (JC
M_AI'PY_T!M5_\A__ !5 'M%%>+_\-(^'/^@-JO\ Y#_^*H_X:1\.?] ;5?\
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M5?\ R'_\50![117B_P#PTCX<_P"@-JO_ )#_ /BJ/^&D?#G_ $!M5_\ (?\
M\50![117B_\ PTCX<_Z VJ_^0_\ XJC_ (:1\.?] ;5?_(?_ ,50![117B__
M  TCX<_Z VJ_^0__ (JC_AI'PY_T!M5_\A__ !5 'M%%>+_\-(^'/^@-JO\
MY#_^*H_X:1\.?] ;5?\ R'_\50![117B_P#PTCX<_P"@-JO_ )#_ /BJ/^&D
M?#G_ $!M5_\ (?\ \50![117B_\ PTCX<_Z VJ_^0_\ XJC_ (:1\.?] ;5?
M_(?_ ,50![117B__  TCX<_Z VJ_^0__ (JC_AI'PY_T!M5_\A__ !5 'M%%
M>+_\-(^'/^@-JO\ Y#_^*H_X:1\.?] ;5?\ R'_\50![117B_P#PTCX<_P"@
M-JO_ )#_ /BJ/^&D?#G_ $!M5_\ (?\ \50![117B_\ PTCX<_Z VJ_^0_\
MXJC_ (:1\.?] ;5?_(?_ ,50![117B__  TCX<_Z VJ_^0__ (JC_AI'PY_T
M!M5_\A__ !5 'M%%>+_\-(^'/^@-JO\ Y#_^*H_X:1\.?] ;5?\ R'_\50![
M117B_P#PTCX<_P"@-JO_ )#_ /BJ/^&D?#G_ $!M5_\ (?\ \50![117B_\
MPTCX<_Z VJ_^0_\ XJC_ (:1\.?] ;5?_(?_ ,50![117B__  TCX<_Z VJ_
M^0__ (JC_AI'PY_T!M5_\A__ !5 'M%%>+_\-(^'/^@-JO\ Y#_^*H_X:1\.
M?] ;5?\ R'_\50![117B_P#PTCX<_P"@-JO_ )#_ /BJ/^&D?#G_ $!M5_\
M(?\ \50![117B_\ PTCX<_Z VJ_^0_\ XJC_ (:1\.?] ;5?_(?_ ,50![11
M7B__  TCX<_Z VJ_^0__ (JC_AI'PY_T!M5_\A__ !5 'M%%>+_\-(^'/^@-
MJO\ Y#_^*H_X:1\.?] ;5?\ R'_\50![117B_P#PTCX<_P"@-JO_ )#_ /BJ
M/^&D?#G_ $!M5_\ (?\ \50![117B_\ PTCX<_Z VJ_^0_\ XJC_ (:1\.?]
M ;5?_(?_ ,50![117B__  TCX<_Z VJ_^0__ (JC_AI'PY_T!M5_\A__ !5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_1K5A4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !10*7%.P"44M
M%'*P$HI:*+ )12XI<4U!@-HIVVC;5>SD*XVBG8HQ2=-H=QM%+BC%38!**6BB
MP"44M%'* E%+1Q18!****0!1110 4444 %%%% !1110 4444 %%%% !1110
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M,I5G0-)+[25[UV4.E[$^[7T-.E&FK3/G,;F'++E3.-ET0[>%K'O=&90?DKU
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MOFJ_&F%H5'",=$>'"OF6)3G".AXP/"30]C^56(=""<-7IL]KL)#H/RK.N;-
M<JHYKW<MXDH8M7BCSZF.KQER5-&<8FC*.U2?V.I%=)Y*@\XJ:&%6.,"O5EF/
M*N:QD\7/>YPMWH!DX _2LT^"996R%/Y5ZTEI$N"5&:MQVC,/D0 ?2O"QO%>'
MP_Q+4WH8_$R]VDKGB\W@B:-#\I_*N7U31)+1CP>*^CIH-N1(HKS3QA;1J[X
M[UUY5FM#-(OE5K'?A,RK^V]G51Y"R\D5&15Z]3;.V.F:I$5EBJ7++0^JA*ZN
M-HHHK@9H(:*#14 %%%% !1110 4444 %%%% !1110 4444 %%%% !12T4 %*
M*3%*,5J@"EQ0 :LV]I)<.%1"3712HRJ/0B4DE=D*J3TKJ/#FBO=3*=N<XJ;2
MO"5Q.ZLT38KU#PWX<CL8@TD>&%>GS4L%3=6HSP\RS.G3@XP=V6='T1;>%=P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ?@YRQ.$4I[GO9+B)?"V<F:::D=2#@BHS7F5X.+/JD[C:*4TVN)LI"TE%%2
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MSG%6KJ)%C.0,U^+5\ZK+$W@^IK1RKFH>T9YSXE\.17$+R*.>O2O'=9TTV<Y
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M44Z29":2EQ25X<XGHH::*4TE<[W&%%%%( HHHH **** "BBB@ HHHH ****
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M?4U][5?[B#\C[7)6^34HFFFG&FUX=1GT*&FDI325Q2W*"BBBD 4444 %%%%
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M2J),EHZG1IMDB8/>O5?#MTS*HSQBO&]$R9D';->T^"].EU*9;> J)/++#<<
MX[5ZE>T\+),^7S:BY/EBKMG2XI*L7=I<6<GEW$31M[CK]#WJM7YU7:IR:/E'
M"47RR5F+GFGJ,TU5R:G5.*^?QV*OLST,+0;U8PK41&#5HCBJ[]:PP.(?/J;8
MNBE$CF^[G%0+=,#M(JT,$8--\E,YK[FAB*3I^_J>0FEHR&2Y"1L0.U<#XJN]
MROSSQ7=7\82W+#TKROQ5<[7<9]*^ER2E3C3E.)ZF5TU.K='!7[;K@FJ1J:=]
M\A-0&LL7+FD??4U:*0AHHHK@9H!I*4TE2P"D-+0:AC$HHHJ0"BBB@ HHHH *
M*** "BBB@!YI*=28KJE$D%ZUN^'VVW:_[PK# YK3TF7R[A><<BO1P&DC#$J]
M-H]T\-2;H$_W:Z1NM<)X6U%=B#=_#7<(XD7(->9G]*7M.=+0_.L93<*KN*:L
M6\>\U7[U=M6"FOSO-IRV.O+(1E-<QHPV^%I7BJS X*TYUS7R[F^8^YCAH.FN
M4QKB/ K/88-;-TF!61)PU>OE]1\UCY?-J*BQHI&(ZGM1534)Q;VK,3C@U]+@
M,#+$8B*/#<[KD1P'CV[7;(H;TKR*4Y<GU-=EXPU'SKF1=Q/-<8W)%?HN,M"E
M&DNA]QE-#V5!7(^].%)BG"O,A&YZEQK=J;3G[4VL:JM-C04445F,**** "BB
MB@ HHHH **** "BBB@ I124HJH[@.HHHK80#@U+&V'!J*GKS71AVU(E[';>&
M[@!U&>U>LZ2[-$N*\;\.#]XASVKV+1'7REY]*]7'7EA+GQF=12EH7[B(M&<U
MD-9;G^[6_-(NPBJ2,-V:\?!8JI3INQX=.<DB&VLG0@XK6C4K& :8DR 5*&##
MBN#&UJE9WD9SDY/43I4=PI>/BI#2,=J$FO-PTW&JK$G.W,)#DD5%'A6J]>,"
MQQZU2"_-7W>'J.=/WCO@[QU)9F_<\5P_B(L5;\:[29ML?-<3K\RMN /K770C
MRP9W9>OWAY[>9\XYJFU7KX@S&J1KQ\8M3[6E\*&49I33:\MHU"BBBI #24II
M*B6XPHHHI %%%% !1110 4444 %%%% !1B@4M-( HHHJD HI1UI*5:N*8BS:
MG$R?6O1?#K$JOTKSB [95/O7H7AJ=,*">U?2Y?*T=3R,T5X';(/DJ*2(.>:M
MQX>,$8IA7YJZ(U??9\BI:BVEL 016W"I1*HV;*I&:UEVLO%>!F5>4IV9RUI-
MO4KLY%5IY3C(JW,NT9-49&4\5GA5&33L3 PKZ1S4-D6WG-:D\2/V%01P[&R!
M@5]-3J05/E/0C-<EBX9<1?A7$>)KG(?Z"NFN[E8HB2V*\^\0WRR%L-Z5G&$:
M<7)G9EU%RJ7.2NGW3,?>JQ-2.V6)]ZBKY_%5.:1]G!604E%%<+;*"BBB@!*]
M9_9X_P"2D3?]@Z7_ -#2O)J]9_9X_P"2D3?]@Z7_ -#2LQGU-1110 4444 %
M%%% 'P[XV_Y'WQ%_V%+G_P!&M6%6[XV_Y'WQ%_V%+G_T:U85 !1110 4444
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MH_:19DF%O)1&4G&3E0">@_*MBT^,GCRSLEM4UQG5%V))+!')(H_WF4D_4YH
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MX:BLK:EWSQCD5#+-NSZ4UU*CFJK.*QHX:#E>),8)B2)NJNZ!:D:8 =:I7-R
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MJPJW?&W_ "/OB+_L*7/_ *-:L*@ HHHH **** "BBB@ HHHH **** "BBB@
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MZTE%'M)]V.PNX^M&3244N>3Z@&:***5V 4444@"BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>J?L^_\E-'
M_7E+_-:\KKU3]GW_ )*:/^O*7^:T ?5=%%% !1110 4444 ?#?C+_D>/$'_8
M2N/_ $8U8E;?C+_D>/$'_82N/_1C5B4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7JG[/O_)31
M_P!>4O\ -:\KKU3]GW_DIH_Z\I?YK0!]5T444 %%%% !1110!\-^,O\ D>/$
M'_82N/\ T8U8E;?C+_D>/$'_ &$KC_T8U8E !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9+I^KRH':TMK-K@6^>1O8'KCMQ^(YK6F\*>'- \8^ O$NBW<[:)JU[&Z179
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M"%2_!>UNSIWC6[56^QKHLL;MC@R$$J/K@-^= 'DU%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 :?A[^QQKUJ=?^T'2E8M<+;?ZQ@%)"CZG
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MFT1OD@J#D[@".O'TKCZ]7^.4%Q;7WA6"\S]IBT2))L]=X)#?KFO** "BBB@
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M"BDD$Y8\_,?3Z4GA#Q7=^#->36;"UM+BZCC9$%TC,J;A@L-K*<XR.O<UA44
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MI"K>:'P!@'=C'RCM^-8%% &]H_BV_P!$\.ZUHEM#;/;:NJ+</(K%U"$D;2&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>J?L^_\ )31_UY2_S6O*Z]4_9]_Y*:/^O*7^:T ?5=%%% !1110 4444 ?#?
MC+_D>/$'_82N/_1C5B5M^,O^1X\0?]A*X_\ 1C5B4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7JG[/O\ R4T?]>4O\UKRNO5/V??^2FC_ *\I?YK0!]5T444 %%%% !1110!\
M-^,O^1X\0?\ 82N/_1C5B5M^,O\ D>/$'_82N/\ T8U8E !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/_@N_P#MM'_#,R_]#:?_  7?_;: /GZBOH'_ (9F7_H;3_X+O_MM'_#,R_\
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M .VT?\,S+_T-I_\ !=_]MH ^?J*^@?\ AF9?^AM/_@N_^VT?\,S+_P!#:?\
MP7?_ &V@#Y^HKZ!_X9F7_H;3_P""[_[;1_PS,O\ T-I_\%W_ -MH ^?J*^@?
M^&9E_P"AM/\ X+O_ +;1_P ,S+_T-I_\%W_VV@#Y^HKZ!_X9F7_H;3_X+O\
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MPS,O_0VG_P %W_VV@#Y^HKZ!_P"&9E_Z&T_^"[_[;1_PS,O_ $-I_P#!=_\
M;: /GZBOH'_AF9?^AM/_ (+O_MM'_#,R_P#0VG_P7?\ VV@#Y^HKZ!_X9F7_
M *&T_P#@N_\ MM'_  S,O_0VG_P7?_;: /GZBOH'_AF9?^AM/_@N_P#MM'_#
M,R_]#:?_  7?_;: /GZBOH'_ (9F7_H;3_X+O_MM'_#,R_\ 0VG_ ,%W_P!M
MH ^?J*^@?^&9E_Z&T_\ @N_^VT?\,S+_ -#:?_!=_P#;: /GZBOH'_AF9?\
MH;3_ ."[_P"VT?\ #,R_]#:?_!=_]MH ^?J*^@?^&9E_Z&T_^"[_ .VT?\,S
M+_T-I_\ !=_]MH ^?J*^@?\ AF9?^AM/_@N_^VT?\,S+_P!#:?\ P7?_ &V@
M#Y^HKZ!_X9F7_H;3_P""[_[;1_PS,O\ T-I_\%W_ -MH ^?J*^@?^&9E_P"A
MM/\ X+O_ +;1_P ,S+_T-I_\%W_VV@#Y^HKZ!_X9F7_H;3_X+O\ [;1_PS,O
M_0VG_P %W_VV@#Y^HKZ!_P"&9E_Z&T_^"[_[;1_PS,O_ $-I_P#!=_\ ;: /
MGZBOH'_AF9?^AM/_ (+O_MM'_#,R_P#0VG_P7?\ VV@#Y^HKZ!_X9F7_ *&T
M_P#@N_\ MM'_  S,O_0VG_P7?_;: /GZBOH'_AF9?^AM/_@N_P#MM'_#,R_]
M#:?_  7?_;: /GZBOH'_ (9F7_H;3_X+O_MM'_#,R_\ 0VG_ ,%W_P!MH ^?
MJ*^@?^&9E_Z&T_\ @N_^VT?\,S+_ -#:?_!=_P#;: /GZBOH'_AF9?\ H;3_
M ."[_P"VT?\ #,R_]#:?_!=_]MH ^?J*^@?^&9E_Z&T_^"[_ .VT?\,S+_T-
MI_\ !=_]MH ^?J*^@?\ AF9?^AM/_@N_^VT?\,S+_P!#:?\ P7?_ &V@#Y^H
MKZ!_X9F7_H;3_P""[_[;1_PS,O\ T-I_\%W_ -MH ^?J*^@?^&9E_P"AM/\
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M_P"VT?\ #,R_]#:?_!=_]MH ^?J*^@?^&9E_Z&T_^"[_ .VT?\,S+_T-I_\
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUZ)0 445&]Q#&Q5Y5##J": )**A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\
M\]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z
M/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__
M #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/S
MH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH
M?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__
M #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/S
MH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_
M //9/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_
M.@":BH?M=O\ \]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*
MA^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_
M //9/SH^UV__ #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_
M.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O
M_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__ #V3
M\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/SH FH
MJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O
M_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__ #V3
M\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV
M_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9
M/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__ #V3\Z5;F%V"K*A)Z &@
M"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBL'Q!XIM?#VI:)93V\TKZM=BUC:/&$..IR1QTXZ^F: -Z
MBBB@ HHHH **** *&N?\B_J7_7K+_P"@&O/-#TN;6OV<HM.MD+W$^DN(D'\3
MC)4?B0*]0DC26-HY$5T8%65AD$'J"*CM+2VL+6.UL[>*WMXAMCBA0(B#T '
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M2T4 )M7^Z/RHVK_='Y4M% ";5_NC\J-J_P!T?E2T4 )M7^Z/RHVK_='Y4M%
M";5_NC\J-J_W1^5+10 FU?[H_*H(%7S;C@??]/858J"#_77'^_\ T% $VU?[
MH_*C:O\ ='Y4M% ";5_NC\J-J_W1^5+10 FU?[H_*C:O]T?E2T4 )M7^Z/RH
MVK_='Y4M% ";5_NC\J-J_P!T?E2T4 )M7^Z/RHVK_='Y4M% ";5_NC\J@@5?
M-N.!]_T]A5BH(/\ 77'^_P#T% $VU?[H_*C:O]T?E2T4 )M7^Z/RHVK_ '1^
M5+10 FU?[H_*C:O]T?E2T4 )M7^Z/RHVK_='Y4M% ";5_NC\J-J_W1^5+10
MFU?[H_*C:O\ ='Y4M% ";5_NC\J@M%4Q-P/OMV]ZL5!:?ZEO]]OYT 3;5_NC
M\J-J_P!T?E2T4 )M7^Z/RHVK_='Y4M% ";5_NC\J-J_W1^5+10 FU?[H_*C:
MO]T?E2T4 )M7^Z/RHVK_ '1^5+10 FU?[H_*C:O]T?E2T4 )M7^Z/RJ"T53$
MW ^^W;WJQ4%I_J6_WV_G0!-M7^Z/RHVK_='Y4M% ";5_NC\J-J_W1^5+10 F
MU?[H_*C:O]T?E2T4 )M7^Z/RHVK_ '1^5+10 FU?[H_*C:O]T?E2T4 )M7^Z
M/RHVK_='Y4M% #65=A^4=/2HK55-I%P/NCM4S?</TJ*T_P"/2+_=% $NU?[H
M_*C:O]T?E2T4 )M7^Z/RHVK_ '1^5+10 FU?[H_*C:O]T?E2T4 )M7^Z/RHV
MK_='Y4M% ";5_NC\J-J_W1^5+10 FU?[H_*C:O\ ='Y4M% #)%7RV^4=#VIE
MLJ_98N!]P=O:I)/]6_T-,M?^/6+_ '!_*@"3:O\ ='Y4;5'8?E2T4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %<A\1/#%AXFT!$U36I-*LK23SY)E** 1T)+=,'H1S77UYS\5/LAN_"
MB:T0/#S:G_IY<XCW;#Y0?MMW=<\4 <7I\GAF[O(]/M?C/XA,S,$023NJDGH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M444 %%%% !4$'^NN/]_^@J>H(/\ 77'^_P#T% $]%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<%\2[?6E.A:MX=TJ6_U73KMI(PI78$9"KJX)'#
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M<?\ =D_[]F@">BH/M<?]V3_OV:/M<?\ =D_[]F@">BH/M<?]V3_OV:/M<?\
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M<?\ =D_[]F@">BH/M<?]V3_OV:/M<?\ =D_[]F@">BH/M<?]V3_OV:/M<?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7.>,?$Z>&M-@"6$FHW]],+:SL8R
M 9W(Z$G@*!DDFNCKCO'NCZM<MH^NZ%!'=:EHMRTZVDC[1<1LI1U#'@-@\$T
M<;I>LZE:0>(-1/@'0_[:T6YA$L-C&BR>6R;V(DYRP&.GOP:]4T/6+7Q!H=EJ
MUD6-M=Q+*FX8(SV/N#P?I7CVE^(_%\>M>*'T[P'K"7VM31M ;N/RX8"(@A+N
M0 <$9XZUZIX.T$^&/"&EZ*T@D>T@".Z]"YY;'MDF@#<HHHH **** "BBB@ H
MHHH **** "J=M_R$K[ZI_P"@U<JG;?\ (2OOJG_H- %RBBB@ HHHH **** "
MBBB@ HHHH **** "H(/]=<?[_P#05/4$'^NN/]_^@H GHHHH **** "BBB@
MHHHH **** "BBB@ KG?#G_(:\2?]?R_^BDKHJYWPY_R&O$G_ %_+_P"BDH Z
M*BBB@ HHHH ***CDN((O]9-&G^\P%)M+5C2;V)**I/K&FQ_>OK?\) ?Y5%_;
M^F?PW)?_ '(V;^0K)XFBMYK[T6J-1[1?W&E16;_;=N?]7;WDG^Y;/_A1_:Y/
MW=,U _\ ;$#^9I?6J/25_P 1^PJ=C2HK-_M.Z;[FDW1_WF0?UH^W:B>FCO\
M\"N$']:/K,//_P !E_D'L9>7WK_,TJ@M/]2W^^W\ZJ?;-5/324'UNA_A4-M<
M:KY1V:?!C>W6X]_]VE]9AV?_ (#+_(/8R[K[U_F;%%9OG:P?^7.T'UG/_P 3
M1YFM?\^UD/K,W_Q-/ZQ'L_N8>Q?=?>C2HK-WZU_SQL/^_K__ !-&[6_^>6G_
M /?Q_P#XFCZPOY7]S#V3[K[S2HK-W:W_ ,\M/_[^/_\ $T;];_YXV'_?U_\
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MXO9DN,ET)**0$'H0:6J)$;[A^E16G_'I%_NBI6^X?I45I_QZ1?[HH FHHHH
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M<@=:H_M/[R)+:WC_ -7!&O\ NH!4M%%;));&;;>X4444Q!1110 5!:?ZEO\
M?;^=3U!:?ZEO]]OYT 3T444 %%%% !1110 4444 %%%% !1110 5!:?ZEO\
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MQX>^(.M>$A>7-SIBVD5_9+<RF1X S%70,>2N>1GI^9J3X;?\A/QO_P!C#/\
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M)S2:KJ]M\2?$>@:=X?\ ,NM*TS4$U&_U 1LL(,8.R)2<;BQ/..@P?6M'7O\
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M0 5!:?ZEO]]OYU/4%I_J6_WV_G0!/1110 4444 %%%% !1110 4444 %%%%
M!4%I_J6_WV_G4]06G^I;_?;^= $]%%% !1110 4444 %%%% !1110 4444 (
MWW#]*BM/^/2+_=%2M]P_2HK3_CTB_P!T4 34444 %%%% !1110 4444 %%%%
M !1110!BZQ+KNZ:&PL+.6W:,CS);@HV2.> I_G5#PW'XAL-/TZPGL;'[+%&J
M-,MRQ;:!UV[>OXUT\G^K?Z&F6O\ QZQ?[@_E0!+1110 4444 %%%% !1110
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MFIZ59ZA&C(EU DRJW4!E# '\Z\_\8Z1;:Q\&A>WDER9[313-&4N'0,QA!.\
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M,JNI5E#*>H(R#2@ # X% 'F$FJP?#[XEZ[=ZT'@T37U@F@OA&S1Q31J5:-R
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M,-Q[UW%-"(K,P50S=2!R: .#^&O_ "$/&_\ V,=Q_P"@I1<?\E[LO^Q=D_\
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M4 %%%% !1110 C?</TJ*T_X](O\ =%2M]P_2HK3_ (](O]T4 34444 %%%%
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MB;2]/\6:M>37/B.YN)+G/VYP8@)&"H(PV-@51P1T- 'J]%%% !1110 4444
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MQ)9I;6S?\N=H-Y2/_>/WF]\#C%==?+]L^/VEPSC='8Z#)=0 ]%D>7RV(]]M
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M6Z<#VH NT5!ONO\ GE'_ -]G_"C?=?\ /*/_ +[/^% $]%0;[K_GE'_WV?\
M"C?=?\\H_P#OL_X4 3T5!ONO^>4?_?9_PHWW7_/*/_OL_P"% $]%0;[K_GE'
M_P!]G_"C?=?\\H_^^S_A0!/14&^Z_P">4?\ WV?\*-]U_P \H_\ OL_X4 3T
M5!ONO^>4?_?9_P *-]U_SRC_ .^S_A0!/4%I_J6_WV_G1ONO^>4?_?9_PJ&V
M:X$1VQH1O;JWO]* +M%0;[K_ )Y1_P#?9_PHWW7_ #RC_P"^S_A0!/14&^Z_
MYY1_]]G_  HWW7_/*/\ [[/^% $]%0;[K_GE'_WV?\*-]U_SRC_[[/\ A0!/
M14&^Z_YY1_\ ?9_PHWW7_/*/_OL_X4 3T5!ONO\ GE'_ -]G_"C?=?\ /*/_
M +[/^% $]%0;[K_GE'_WV?\ "C?=?\\H_P#OL_X4 3U!:?ZEO]]OYT;[K_GE
M'_WV?\*AMFN!$=L:$;VZM[_2@"[14&^Z_P">4?\ WV?\*-]U_P \H_\ OL_X
M4 3T5!ONO^>4?_?9_P *-]U_SRC_ .^S_A0!/14&^Z_YY1_]]G_"C?=?\\H_
M^^S_ (4 3T5!ONO^>4?_ 'V?\*-]U_SRC_[[/^% $]%0;[K_ )Y1_P#?9_PH
MWW7_ #RC_P"^S_A0!/14&^Z_YY1_]]G_  HWW7_/*/\ [[/^% $S?</TJ*T_
MX](O]T4UGN=I_=1]/[Y_PJ.V:X%M'MCC*[1@E_\ ZU %RBH-]U_SRC_[[/\
MA1ONO^>4?_?9_P * )Z*@WW7_/*/_OL_X4;[K_GE'_WV?\* )Z*@WW7_ #RC
M_P"^S_A1ONO^>4?_ 'V?\* )Z*@WW7_/*/\ [[/^%&^Z_P">4?\ WV?\* )Z
M*@WW7_/*/_OL_P"%&^Z_YY1_]]G_  H GHJ#?=?\\H_^^S_A1ONO^>4?_?9_
MPH ED_U;_0TRU_X]8O\ <'\JC=KGRVS%'C!_C_\ K4VW:X%O'MCC(VC!+_\
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MH\N:*(=7*2*Y ]\ X]ZO:!XI3Q+#<+'I&KV+11@O]OLVA&XY^5<_>(QSCU%
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M5I_QZ1?[HJ5ON'Z5%:?\>D7^Z* )J*** "BBB@ HHHH **** "BBB@ HHHH
M;)_JW^AIEK_QZQ?[@_E3Y/\ 5O\ 0TRU_P"/6+_<'\J ):*** "BBB@ HHHH
M **** "BBB@ HHHH *YG4?#EU>?$'1?$"2PBUL+6>&1&)WL7QC'&,<<\UTU%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'N: .Q\0ZQ#X?\.ZCJ\^#'9V[RX/\1 X7\3@?C7!ZMKOB?0O@,VNW6H$Z_\
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M0 4444 %%%% !4%I_J6_WV_G4]06G^I;_?;^= $]%%% !1110 4444 %%%%
M!1110 4444 (WW#]*BM/^/2+_=%2M]P_2HK3_CTB_P!T4 34444 %%%% !11
M10 4444 %%%% !1110 V3_5O]#3+7_CUB_W!_*GR?ZM_H:9:_P#'K%_N#^5
M$M%%% !1110 4444 %%%% !1110 4C,%4L<X SP,G\J6B@#S7P1X0L]=M-2\
M1^*_#]O+J.K7TDZ1:C:!I+>$?)&F'&1PN?H13_'G@'38O"TNH>%]"LK36].E
MCO;5K*T5)':-LE?E&3D9X[G%>CT4 >?>*H[W6M1\ :A!IUV%&H)<3H86W6ZM
M&3^\&/EQG!SCFNF\6^'+?Q7X:O-(G;895S#*.L4HY1Q]#C\,BMNB@#R_X3V_
MB"+4/%5[XDTZ>UO)IX%=FC(69HXRK.G'S XSQQS4W@CPA9Z[::EXC\5^'[>7
M4=6OI)TBU&T#26\(^2-,.,CA<_0BO2J* /./'G@'38O"TNH>%]"LK36].ECO
M;5K*T5)':-LE?E&3D9X[G%=3JNGQ^,? \]E<026XU.R_U<R%7A9ER-P/(*MC
MCU%;U% 'EWPOLM=U+5)]?\2V%Q:7=E8PZ1;)<(59@GS2R8/7<VWD>AK<^+>G
MWFJ?"_6K/3[6:ZNI%B*0PH7=L2H3@#D\ FNUHH X5?B7&$ /@[QEP/\ H#/_
M (T[QCJVLZGX9T^P\/Z?J$%[KI$)FFMV4V$1'[QY?[C ' !.<].17<44 <9K
MG@"SNOA_#X=TK_19M/5)=-G!PT4Z<J^?4G.3_M&M;P?K%]K?AFUN]4T^XL-1
M ,=S!/$4(D7@E0>JGJ"/7VK=HH *I:O?R:7H]Y?16<][)!$TB6UNNZ24@<*H
M]35VB@#QGPQXBGMM3N/$?B/PIXMN_$%R"@,6C2&*SASQ%%D]/4]2?U]0\/Z\
MOB"RDN5TS5-/V2>7Y>HVI@=N <@'J.>OL:UJ* "N2^(\^JKX1FL-$MIYM0U.
M1;&-XHRPA$G#2,1]U0N?F/0D5UM% %#1-(MM!T.RTFT&(+2%8DXY.!U/N3R?
MK6'K?C&[\/ZPUO=>&=6N=.**T5_I\7V@9[AT'S+@]^<UU=% 'F5])J'Q$\3>
M'_LVB:CI^C:1>KJ$UWJ,!@:5T'R)&A^8@D\GI_7TVBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *YGQKX@MM TZVW:7_:NH7<XM[&Q &992/4
M@A0 ,D]JZ:N.\>Z/JURVCZ[H4$=UJ6BW+3K:2/M%Q&RE'4,> V#P30!RUGXI
MU_\ LSQ#+=>#-*FU#1KF)9;*UQGRF3>QW'.6 QT'X&O2- U2RUO0+'4].7;9
MW,*R1KM"[0>Q Z$'(/TKR'2_$?B^/6O%#Z=X#UA+[6IHV@-W'Y<,!$00EW(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,>%OB5X2TO[%IT7@LEV,D]Q,]TTL[GJ[MCDUT>N>&M?O+K0O$>GSZ=%XET^
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M_G4]06G^I;_?;^= $]%%% !1110 4444 %%%% !1110 4444 (WW#]*BM/\
MCTB_W14K?</TJ*T_X](O]T4 34444 %%%% !1110 4444 %%%% !1110 V3_
M %;_ $-,M?\ CUB_W!_*GR?ZM_H:9:_\>L7^X/Y4 2T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $)"@DD
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MQ*,":Y'TF- %VBJ7]FQ_\][K_O\ -1_9L?\ SWNO^_S4 7:*I?V;'_SWNO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM:M:M:7NMW[WGV9_O0Q=$5O]K&2?K7;4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7$*3*K=0& (!_.K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7S[LCK@]5C!/_ V]4J;P1X@L='^#=AJU[./LEA;.C.ISN$;M& /4G: /4D4
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MEF!8J%(7;N_BSD 'H-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR222<#TK>HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380377562512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">630 5th Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">20th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 921,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,961,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Hartford, Connecticut<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380380607552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 149,157,861<span></span>
</td>
<td class="nump">$ 152,107,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">3,192,580<span></span>
</td>
<td class="nump">9,136,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">354,162<span></span>
</td>
<td class="nump">371,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">152,704,603<span></span>
</td>
<td class="nump">161,616,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,824,777<span></span>
</td>
<td class="nump">4,739,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities (Note 3)</a></td>
<td class="nump">5,944,953<span></span>
</td>
<td class="nump">5,614,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred grant income (Note 4)</a></td>
<td class="nump">443,831<span></span>
</td>
<td class="nump">443,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">10,213,561<span></span>
</td>
<td class="nump">10,798,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding:77,942,568 common shares (September 30, 2021 - 75,918,465)</a></td>
<td class="nump">77,944<span></span>
</td>
<td class="nump">75,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">387,976,881<span></span>
</td>
<td class="nump">348,328,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(245,563,783)<span></span>
</td>
<td class="num">(197,585,864)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">142,491,042<span></span>
</td>
<td class="nump">150,818,104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 152,704,603<span></span>
</td>
<td class="nump">$ 161,616,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380380687664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">77,942,815<span></span>
</td>
<td class="nump">75,918,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="nump">77,942,815<span></span>
</td>
<td class="nump">75,918,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380377797136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 13,070,068<span></span>
</td>
<td class="nump">$ 9,017,511<span></span>
</td>
<td class="nump">$ 5,856,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">37,915,747<span></span>
</td>
<td class="nump">32,983,674<span></span>
</td>
<td class="nump">25,231,623<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">50,985,815<span></span>
</td>
<td class="nump">42,001,185<span></span>
</td>
<td class="nump">31,088,232<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss&#160;</a></td>
<td class="num">(50,985,815)<span></span>
</td>
<td class="num">(42,001,185)<span></span>
</td>
<td class="num">(31,088,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrants', window );">Grant income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">54,100<span></span>
</td>
<td class="nump">149,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">3,323,011<span></span>
</td>
<td class="nump">4,547,099<span></span>
</td>
<td class="nump">4,375,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">946,988<span></span>
</td>
<td class="nump">26,261<span></span>
</td>
<td class="nump">179,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (loss) gain, net</a></td>
<td class="num">(903,611)<span></span>
</td>
<td class="num">(267,344)<span></span>
</td>
<td class="nump">125,540<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">3,366,388<span></span>
</td>
<td class="nump">4,360,116<span></span>
</td>
<td class="nump">4,830,426<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(47,619,427)<span></span>
</td>
<td class="num">(37,641,069)<span></span>
</td>
<td class="num">(26,257,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="num">(358,492)<span></span>
</td>
<td class="num">(267,565)<span></span>
</td>
<td class="num">(22,664)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NetLossAndComprehensiveLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (47,977,919)<span></span>
</td>
<td class="num">$ (37,908,634)<span></span>
</td>
<td class="num">$ (26,280,470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_EarningPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NetLossPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">$ 76,909,993<span></span>
</td>
<td class="nump">$ 69,802,960<span></span>
</td>
<td class="nump">$ 58,194,894<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EarningPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EarningPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NetLossAndComprehensiveLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NetLossAndComprehensiveLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NetLossPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NetLossPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380374333952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (47,977,919)<span></span>
</td>
<td class="num">$ (37,908,634)<span></span>
</td>
<td class="num">$ (26,280,470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">18,379,242<span></span>
</td>
<td class="nump">8,231,403<span></span>
</td>
<td class="nump">4,876,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">5,944,251<span></span>
</td>
<td class="num">(4,287,491)<span></span>
</td>
<td class="num">(2,206,595)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="nump">1,387<span></span>
</td>
<td class="nump">88,290<span></span>
</td>
<td class="nump">57,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(915,004)<span></span>
</td>
<td class="nump">750,727<span></span>
</td>
<td class="nump">465,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">330,179<span></span>
</td>
<td class="nump">2,298,200<span></span>
</td>
<td class="nump">1,800,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredGrantIncomes', window );">Deferred grant income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">443,831<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(24,237,864)<span></span>
</td>
<td class="num">(30,383,674)<span></span>
</td>
<td class="num">(21,287,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">20,984,667<span></span>
</td>
<td class="nump">153,218,762<span></span>
</td>
<td class="nump">28,754,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issue costs</a></td>
<td class="num">(706,877)<span></span>
</td>
<td class="num">(5,550,921)<span></span>
</td>
<td class="num">(403,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,466,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,010,190<span></span>
</td>
<td class="nump">4,108,060<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">21,287,980<span></span>
</td>
<td class="nump">153,242,401<span></span>
</td>
<td class="nump">28,350,434<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents during the period</a></td>
<td class="num">(2,949,884)<span></span>
</td>
<td class="nump">122,858,727<span></span>
</td>
<td class="nump">7,063,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">152,107,745<span></span>
</td>
<td class="nump">29,249,018<span></span>
</td>
<td class="nump">22,185,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">149,157,861<span></span>
</td>
<td class="nump">152,107,745<span></span>
</td>
<td class="nump">29,249,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes', window );">Cash paid for state and local minimum income taxes</a></td>
<td class="nump">$ 326,903<span></span>
</td>
<td class="nump">$ 139,531<span></span>
</td>
<td class="nump">$ 22,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashPaidForStateAndLocalMinimumIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncomes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncomes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380373980704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 52,652<span></span>
</td>
<td class="nump">$ 153,633,807<span></span>
</td>
<td class="num">$ (133,396,760)<span></span>
</td>
<td class="nump">$ 20,289,699<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning, shares at Sep. 30, 2019</a></td>
<td class="nump">52,650,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase shares</a></td>
<td class="nump">$ 7,565<span></span>
</td>
<td class="nump">21,246,733<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,254,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares (in shares)</a></td>
<td class="nump">7,564,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">Commitment shares</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="num">$ (69)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1', window );">Commitment shares (in shares)</a></td>
<td class="nump">68,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptionInShares', window );">Shares issued pursuant to cashless exercise of stock options</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOptionInShares', window );">Shares issued pursuant to cashless exercise of options (in shares)</a></td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreement', window );">Shares issued under Sales Agreement</a></td>
<td class="nump">$ 1,760<span></span>
</td>
<td class="nump">$ 7,498,140<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,499,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreementInShares', window );">Shares issued under Sales Agreement (in shares)</a></td>
<td class="nump">1,760,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LessShareIssueCosts', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(403,764)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(403,764)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,876,906<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,876,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(26,280,470)<span></span>
</td>
<td class="num">(26,280,470)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 62,047<span></span>
</td>
<td class="nump">186,851,752<span></span>
</td>
<td class="num">(159,677,230)<span></span>
</td>
<td class="nump">27,236,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending, shares at Sep. 30, 2020</a></td>
<td class="nump">62,045,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase shares</a></td>
<td class="nump">$ 4,008<span></span>
</td>
<td class="nump">24,107,190<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,111,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares (in shares)</a></td>
<td class="nump">4,007,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">Commitment shares</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1', window );">Commitment shares (in shares)</a></td>
<td class="nump">78,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="nump">$ 1,421<span></span>
</td>
<td class="nump">4,106,639<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,108,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares', window );">Shares issued pursuant to exercise of stock options (in shares)</a></td>
<td class="nump">1,421,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreement', window );">Shares issued under Sales Agreement</a></td>
<td class="nump">$ 5,635<span></span>
</td>
<td class="nump">79,101,915<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">79,107,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreementInShares', window );">Shares issued under Sales Agreement (in shares)</a></td>
<td class="nump">5,634,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LessShareIssueCosts', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,437,523)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,437,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToRegisteredDirectOffering', window );">Shares issued pursuant to registered direct offering</a></td>
<td class="nump">$ 2,381<span></span>
</td>
<td class="nump">49,997,632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingInShares', window );">Shares issued pursuant to registered direct offering (in shares)</a></td>
<td class="nump">2,380,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LessSharesIssueCosts', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,097,032)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,097,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPusuantToExerciseOfWarrants', window );">Shares issued pusuant to exercise of warrants</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">1,466,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,466,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPusuantToExerciseOfWarrantsInShares', window );">Shares issued pusuant to exercise of warrants (in shares)</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,231,403<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,231,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(37,908,634)<span></span>
</td>
<td class="num">(37,908,634)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 75,920<span></span>
</td>
<td class="nump">348,328,048<span></span>
</td>
<td class="num">(197,585,864)<span></span>
</td>
<td class="nump">150,818,104<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending, shares at Sep. 30, 2021</a></td>
<td class="nump">75,918,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">1,009,789<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,010,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares', window );">Shares issued pursuant to exercise of stock options (in shares)</a></td>
<td class="nump">400,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreement', window );">Shares issued under Sales Agreement</a></td>
<td class="nump">$ 1,623<span></span>
</td>
<td class="nump">20,983,044<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,984,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreementInShares', window );">Shares issued under Sales Agreement (in shares)</a></td>
<td class="nump">1,623,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LessShareIssueCosts', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(723,242)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(723,242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,379,242<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,379,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(47,977,919)<span></span>
</td>
<td class="num">(47,977,919)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 77,944<span></span>
</td>
<td class="nump">$ 387,976,881<span></span>
</td>
<td class="num">$ (245,563,783)<span></span>
</td>
<td class="nump">$ 142,491,042<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending, shares at Sep. 30, 2022</a></td>
<td class="nump">77,942,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LessShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LessShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LessSharesIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LessSharesIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptionInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfOptionInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOptionInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOptionInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToRegisteredDirectOfferingInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPusuantToExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPusuantToExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPusuantToExerciseOfWarrantsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPusuantToExerciseOfWarrantsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUnderSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUnderSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUnderSalesAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUnderSalesAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380380002256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description and Basis of Presentation</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zF7GK65rrkwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 	<span id="xdx_826_zTGyf9kqqwe9">Business Description and Basis of Presentation</span>
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment
of neurodegenerative and neurodevelopmental diseases. The Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73 is being developed
to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases, including rare diseases,
such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein
2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><i>Basis of Presentation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and the instructions to Form
10-K and have been prepared under the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sale or generate commercial revenues. To date, we have not
generated any revenues from our operations. The Company expects the business to continue to experience negative cash flows for the foreseeable
future and cannot predict when, if ever, its business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
is uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The
actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#8217;s research and development programs and the level of
financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future
clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement
(as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if available,
that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on a timely basis,
if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Coronavirus Disease 2019 (COVID-19)</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The recent global outbreak of COVID-19 did not have
a material impact on the Company&#8217;s result of operations or financial condition for the year ended September 30, 2022. However,
the future course of the pandemic could have adverse effects in the U.S and global economies and thus negatively impact our business
and financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380380515360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_z67hzn4v1sKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 2	<span id="xdx_82F_zNxE6e33dQI4">Summary of Significant Accounting Policies</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p id="xdx_849_eus-gaap--UseOfEstimates_z8gKMmY1HLRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zWG3EmOoh2sk">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the
basis for making judgments about the book values of assets and liabilities and the accrual of costs and expenses that are not readily
apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zJ2MdZ71Dy5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zIuhEHzP31n6">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly owned subsidiaries, Anavex Australia Pty Limited. (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6tEegO9VsS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_z0JMPFdEJVJc">Cash and equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#8217;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains its investments at one large well known financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20220930_zInmgKI67LC4" title="Federal Deposit Insurance Corporation">250,000</span>, under current regulations. At September 30, 2022 and 2021, substantially
all of the Company&#8217;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zr6NvoPtLvGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_z8Kq4tFCNR84">Research and Development Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#8217;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and stock-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#8220;CROs&#8221;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#8220;ASC&#8221;) 730, Research and Development, as these materials have no alternative future use outside of their intended use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the studies including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are
made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.
The Company&#8217;s historical accrual estimates have not been materially different from actual costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--RevenueRecognitionIncentives_zsVE6ZiohaM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zTbyIPlIwXve">Research and Development Incentive Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is eligible to obtain certain research
and development tax credits, including the Australian research and development tax incentive credit (the &#8220;Australia R&amp;D credit&#8221;)
through a program administered through the Australian Tax Office (the &#8220;ATO&#8221;) and AusIndustry, a division of the Australian
Government&#8217;s Department of Industry, Innovation and Science (&#8220;AusIndustry&#8221;), which provides for a cash refund based
on a percentage of eligible research and development activities undertaken in Australia by the Company&#8217;s wholly owned subsidiary,
Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;D credit program to receive the cash refund for certain
research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by AusIndustry
pursuant to an advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Australia R&amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, Income Taxes (&#8220;ASC 740&#8221;), since the incentives are
not linked to the Company&#8217;s taxable income and can be realized regardless of whether the Company has generated taxable income in
the respective jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to the Australia R&amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 <i>Accounting for Government Grants and Disclosure of Government Assistance</i> (&#8220;IAS 20&#8221;). The Company
recognizes the Research and Development Incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;D credit
Program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#8217;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zyGAkxtLqYfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zwn8BSjXghg8">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, diluted loss per share excludes
<span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220930_pdd" title="Loss per share for potentially dilutive common shares">13,329,616</span> potentially dilutive common shares (2021 &#8211; diluted loss per share excludes <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930_zIjvlIpEANY8" title="Loss per share for potentially dilutive common shares">11,540,903</span> potentially dilutive common shares;
2020 &#8211; diluted loss per share excludes <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20191001__20200930_zXI5VTYcTPKf" title="Loss per share for potentially dilutive common shares">10,576,266</span> potentially dilutive common shares) related to outstanding options and warrants,
as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zSS2UperrY14" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zc95zI2r0ta8">Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The book value of the Company&#8217;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#8217;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zJYZsysB1fQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86B_zcmI4X4oLBB1">Foreign Currency Translation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zAaQa43BTZQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_869_zkULV6MVVQV1">Segment and Geographic Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating segments are defined as components of an
enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making
group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as
one operating segment, which is the business of developing novel therapies for the management of CNS diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_843_ecustom--GrantIncomePolicyTextBlock_ziGpSNcmT4Pc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zrBFYtQohVki">Grant Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statement of operations
in the period they are earned and when the related research and development costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zCmmKHc71zg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z1zXqEoNhwOj">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC
740 regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements
when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are
initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon
ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts. Application requires
numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions
and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional
information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic
adjustments may have a material impact on the consolidated statements of operations. At September 30, 2022 the Company did <span id="xdx_905_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20220930_zFBUlap6tPSl" title="Uncertain tax positions">no</span>t
have any uncertain tax positions.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes interest and penalties
related to current income tax expense on the interest income, net line, in the accompanying consolidated statement of operations.
Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets. There were <span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20211001__20220930_z9D7qWr5ILXe" title="Interest and penalties"><span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20201001__20210930_zc3co7wNJLWg" title="Interest and penalties">no</span></span>
interest and penalties related to current income tax expense during the years ended September 30, 2022, 2021 and 2020.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zWB35jw4KtT" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zcoUScD6bzFe">Stock-based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for all stock-based payments
and awards under the fair value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of all share purchase options and warrants
are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected to
vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation costs for stock-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option valuation
model to calculate the fair value of share purchase options and warrants at the date of the grant. This model requires the input of subjective
assumptions, including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury
yield curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted
are expected to be outstanding using the simplified method. The Company&#8217;s historical share option exercise experience does not provide
a reasonable basis for estimating the expected term. Expected volatility is based on the average of the daily share price changes over
the expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not
paid any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions
consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment.
Changes in these assumptions can materially affect the fair value estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price of options or warrants may be paid
in cash or, if approved by the Company&#8217;s compensation committee in advance, &#8220;net settled&#8221; in shares of the Company&#8217;s
common stock. In a net settlement of an option or warrant, the Company does not receive payment of the exercise price from the holder
but reduces the number of shares of common stock issued upon the exercise of the stock option or warrant by the smallest number of whole
shares that have an aggregate fair market value equal to or over the aggregate exercise price for the option shares covered by the option
or warrant exercised. Shares issued pursuant to the exercise of options and warrants are issued from the Company&#8217;s treasury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zaRnwuPwOpr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zge762DQGdy1">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2022 and 2021, the Company did not
have any Level 2 or Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zkvzJbYcbfqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_zwDAbvay2cOh">Recently Adopted Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective October 1, 2021, the Company adopted Accounting
Standards Update (&#8220;ASU&#8221;) 2019-12, &#8220;Simplifying the Accounting for Income Taxes (ASC 740)&#8221;, which is intended to
simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740
and clarifying and amending existing guidance to improve consistent application. There was no material impact on the Company&#8217;s operations,
financial condition, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2021, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued ASU&#160;2021-10, &#8220;Government Assistance (Topic 832): Disclosures by Business Entities about Government
Assistance&#8221; (&#8220;ASU&#160;2021-10&#8221;). ASU&#160;2021-10&#160;increases the transparency of government assistance including
the disclosure of (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance
on an entity&#8217;s financial statements. ASU&#160;2021-10&#160;is effective for fiscal years beginning after December 15, 2021, with
early adoption permitted. Upon implementation, the Company may use either a prospective or retrospective method of adoption when adopting
the ASU. The adoption of ASU 2021-10 will impact the disclosures related to the research and development incentive income that the Company
receives from the ATO for its clinical trials in Australia. The Company currently plans to adopt the provisions of this ASU on October
1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380377559344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureAccruedLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AccuredLiabilitiesTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p id="xdx_801_ecustom--AccuredLiabilitiesTextBlock_z3o5phRPO5A4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 3	<span id="xdx_828_zfXvANdGyVfa">Accrued Liabilities</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consist of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zdAM0DDAypG6" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zZ9g3MhxkYHd" style="display: none">Schedule of components of accrued liabilities</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_497_20220930_zCsJnLHVGyn1" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20210930_zH7qnVnSgIg" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td></tr>
<tr id="xdx_402_ecustom--ClinicalSiteCostsAndPatientVisits_iI_pp0p0_maALCzi8D_zKCvwFUb29Yb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued clinical site and patient visits costs</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,031,105</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,035,800</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCzi8D_z59IhkWemSt2" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued compensation and benefits</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,297,337</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,201,903</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_ecustom--FixedContractAccruals_iI_pp0p0_maALCzi8D_z82jvbG5jm9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed contract accruals</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">417,414</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">649,649</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzi8D_zj7ZweeM9CA8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other accrued liabilities</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,199,097</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,727,422</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzi8D_zkbmpaxQjJBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; font-size: 10pt; text-indent: -10pt"><span style="color: rgb(204,238,255); font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accrued liabilities</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,944,953</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,614,774</span><span style="font-family: Symbol; font-size: 10pt"/></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Symbol">&#160;</span></td></tr>
</table>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.3pt"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.3pt">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.3pt"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccuredLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccuredLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380381781232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_80B_ecustom--OtherIncomeDisclosureTextBlock_zU3cSb79ifBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 4	<span id="xdx_826_zJZEI4e9LGY5">Other Income</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the year ended September
30, 2022, the Company received $<span id="xdx_905_ecustom--GrantIncome_pp0p0_c20211001__20220930_z2u92HMuICM4" title="Grant income">0</span> (2021: $<span id="xdx_906_ecustom--GrantIncome_pp0p0_c20201001__20210930_zPN81FvQohqg" title="Grant income">497,931</span>; 2020: $<span id="xdx_90F_ecustom--GrantIncome_pp0p0_c20191001__20200930_zku1wbrapr6i" title="Grant income">0</span>) of a $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_pp0p0" title="Research and development incentive income"><span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_pp0p0" title="Research and development incentive income">995,862</span></span> research grant awarded during the year ended September 30,
2021, by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant will be used to fund a clinical trial of the Company&#8217;s
lead compound, ANAVEX<sup>&#174;</sup>2-73 related to Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income is
being deferred when received and amortized to other income as the related research and development expenditures are incurred. During
the year ended September 30, 2022, the Company recognized $Nil <span id="xdx_90B_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20211001__20220930_zs56r1Fw9Vr4" style="display: none" title="Grant income">0</span> (2021: $<span id="xdx_902_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20201001__20210930_z4xGVkmSgWOf" title="Grant income">54,100</span>; 2020: $Nil <span id="xdx_905_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20191001__20200930_zpOtF977WMD2" style="display: none" title="Grant income">0</span>) of this grant on its statements of
operations within grant income. At September 30, 2022 an amount of $<span id="xdx_905_ecustom--DeferredGrantIncome_iI_pp0p0_c20220930_zHSY1Kqy6NPc" title="Deferred grant income">443,831</span> (2021: $<span id="xdx_90F_ecustom--DeferredGrantIncome_iI_pp0p0_c20210930_zlZsniCllbk3" title="Deferred grant income">443,831</span>) of this grant is recorded as deferred
grant income, representing the amount of this grant which has not yet been amortized to other income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the year ended September
30, 2017, the Company was awarded grant funding in the amount of $<span id="xdx_90A_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20161001__20170930_zRusqhsKmkb4" title="Grant income">597,886</span>. The grant was received in equal quarterly installments over
a period of two years ending during the year ended September 30, 2020, in exchange for a commitment to complete clinical testing for a
therapeutic drug candidate for the treatment of Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income was deferred
when received and amortized to other income as the related research and development expenditures were incurred. During the year ended
September 30, 2020, the Company recognized $<span id="xdx_901_ecustom--NonOperatingsIncomeFromGrant_pp0p0_c20191001__20200930_zLTqt7UR3fJf" title="Grant income">149,888</span> of this grant on its statement of operations as a component of other income. At September
30, 2020, the Company had recognized the full amount of grant funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents income earned by the Company&#8217;s Australian subsidiary, of the Australian research and development tax
incentive credit (the &#8220;tax incentive credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the year ended September
30, 2022, the Company recorded research and development incentive income of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20220930_zptCGi3Wu2o8" title="Research and development incentive income">3,323,011</span> (AUD <span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220930__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">4,468,246</span>) (2021: $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930_zENzyy82PQGf" title="Research and development incentive income">4,547,099</span> (AUD <span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930__srt--CurrencyAxis__currency--AUD_zju0evbwj6P7" title="Research and development incentive income">6,068,993</span>);
2020: $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20191001__20200930_zu5JJvjaShHi" title="Research and development incentive income">4,375,025</span> (AUD <span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20191001__20200930__srt--CurrencyAxis__currency--AUD_zCsdgTDf7xQg" title="Research and development incentive income">6,392,266</span>)) in respect of the tax incentive credit for eligible research and development expenses incurred during
the year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company evaluates its
eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant data available. Although
the Company believes that it complies with all the relevant conditions of the program, as a matter of course, the Company may be subject
to pre-issue review or audit by the ATO and, the ATO may have different interpretations of certain eligibility requirements. Currently,
the Company&#8217;s tax incentive claims from 2018 to 2022 are open to potential review or audit by the ATO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380383400560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingsAbstract', window );"><strong>Equity Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_EquityOfferingAgreementsTextBlock', window );">Equity Offerings</a></td>
<td class="text"><p id="xdx_80D_ecustom--EquityOfferingAgreementsTextBlock_zcZ20XPeqUm" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 5	<span id="xdx_820_zV2n9mdJ9cu8">Equity Offerings</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board of Directors&#160;(the &#8220;Board&#8221;)&#160;has
the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number
of shares constituting any series or the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Registered Direct Offering</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 22, 2021, the Company and Deep Track Capital
entered into a securities purchase agreement pursuant to which the Company sold to Deep Track Capital an aggregate of 2,380,953 shares
of common stock at $21 per share in a registered direct offering, for gross proceeds of $50,000,013. Net proceeds of the offering were
$46,902,981 after deducting offering fees and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on the Company&#8217;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company
or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales
Agents will act as agents on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has agreed to pay the Sales Agents
commissions for their services of up to <span id="xdx_908_ecustom--PercentageOfGrossProceedsFromSales_dp_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zjzDU1V5j2fd" title="Percentage of gross proceeds from sales">3.0</span>%
of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed to provide the Sales
Agents with customary indemnification and contribution rights. During the year ended September 30, 2022, <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold">1,623,813</span>
shares were sold pursuant to the Offering for gross proceeds of $<span id="xdx_90E_ecustom--GrossProceedsFromIssuancePublicOffering_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from Issuance Public Offering">20,984,667</span>
(net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceeds from Issuance Public Offering">20,261,425</span>
after deducting offering expenses) (2021: <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold">5,634,576</span>
shares were sold for gross proceeds of $<span id="xdx_90C_ecustom--GrossProceedsFromIssuancePublicOffering_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from Issuance Public Offering">79,107,550</span>,
net proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceeds from Issuance Public Offering">76,670,027</span>;
2020: <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zrSONM0rgtk4" title="Number of common stock sold">1,760,429</span>
shares were sold for gross proceeds of $<span id="xdx_901_ecustom--GrossProceedsFromIssuancePublicOffering_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zFBrcYjWPI8k" title="Gross proceeds from Issuance Public Offering">7,499,900</span>,
net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zkxflyK1y5Ye" title="Proceeds from Issuance Public Offering">7,096,136</span>).
At September 30, 2022, an amount of $<span id="xdx_90B_ecustom--SalesOfAgreementAmount_c20220930_pp0p0" title="Sales of agreement amount">142,407,882</span>
(2021: $<span id="xdx_90A_ecustom--SalesOfAgreementAmount_c20210930_pp0p0" title="Sales of agreement amount">163,392,550</span>)
was registered pursuant to an effective registration statement and available to be sold under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 7, 2019, the Company entered into a $50,000,000
purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), as amended
on July 1, 2020, pursuant to which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase,
up to $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Value of shares obligated to purchase">50,000,000</span> in value of its shares of common stock from time to time over a three-year period until July 1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2019 Purchase
Agreement, the Company issued to Lincoln Park <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares">324,383</span> shares of common stock as a commitment fee during the year ended September 30, 2019
and agreed to issue up to <span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Pro rata basic number of shares obligated to purchase">162,191</span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity">50,000,000</span>
aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, the Company
did not issue any shares to Lincoln Park under the 2019 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2021, the Company
issued to Lincoln Park an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zv73hCO6Jap9" title="Share issued for offering, shares">4,086,209</span> (2020: <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zs5ERxvfL3Xc" title="Share issued for offering, shares">7,633,527</span>) shares of common stock under the 2019 Purchase Agreement, including
<span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zB4Lseqfa8A2" title="Number of shares issued for aggregate purchase price">4,007,996</span> (2020: <span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zIXAwXdBBgvl" title="Number of shares issued for aggregate purchase price">7,564,584</span>) shares of common stock for an aggregate purchase price of $<span id="xdx_90B_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zMvbCtQkjOKk" title="Number of shares issued for aggregate purchase price, value">24,111,198</span> (2020: $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEfYfoeymscg" title="Number of shares issued for aggregate purchase price, value">21,254,298</span>) and <span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zQDyDlyELEhf" title="Number of shares issued for commitment">78,213</span> (2020:
<span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zyEtCT6Ix1Zb" title="Number of shares issued for commitment">68,943</span>) commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2022 and 2021, <span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_do_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgFGX2CFruQ1" title="Amount of shares remain available">no</span> shares remained
available for issuance under the 2019 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380386952240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_809_eus-gaap--CommitmentsDisclosureTextBlock_zEUxRjYnMXo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 6	<span id="xdx_82C_zHFA39oBUbW2">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Lease</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">During
the year ended September 30, 2022, the Company incurred office lease expense of $<span id="xdx_909_eus-gaap--LeaseAndRentalExpense_c20211001__20220930_pp0p0" title="Operating Leases, Rent Expense">72,865</span> (2021: $<span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20201001__20210930_pp0p0" title="Operating Leases, Rent Expense">130,784</span>; 2020: $<span id="xdx_904_eus-gaap--LeaseAndRentalExpense_pp0p0_c20191001__20200930_zU59dp2F0LJ2" title="Operating Leases, Rent Expense">233,423</span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"/>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the
Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing
employees. During the year ended September 30, 2022, the Company made $<span id="xdx_90C_eus-gaap--PensionContributions_c20211001__20220930_pp0p0" title="Contribution amount">158,112</span> (2021: $<span id="xdx_90A_eus-gaap--PensionContributions_c20201001__20210930_pp0p0" title="Contribution amount">128,856</span>; 2020: $<span id="xdx_909_eus-gaap--PensionContributions_pp0p0_c20191001__20200930_zOosKtYuwNic" title="Contribution amount">98,058</span>) in matching contributions
under the 401(k) plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the warrant activity
during the years ended September 30, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zrqYgJE63aq5" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_za46SsaCHP49" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td>
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price ($)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 0%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt 0pt 0pt 10pt; width: 35%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, September 30, 2021</span></td>
<td style="padding: 0pt 0pt 0pt 10pt; width: 1%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z7c7dsHrZL8i" style="width: 25%; text-align: right" title="Share Purchase Warrants Balance, at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">210,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8KDPG7kevJf" style="width: 25%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.69</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zbeBtxvzaGg6" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.00</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, September 30, 2022</span></td>
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zuQr9LLe9DB6" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zvXWeia4T0N2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.72</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center"/>

<p id="xdx_8AB_z8bGCEAnMthj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 30, 2022, the Company had share purchase
warrants outstanding as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zwOtrbAziuLf" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><span id="xdx_8BD_zcRVkusmwtE2" style="display: none">Schedule of share purchase warrants outstanding</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiry Date</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 0%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 35%; text-align: right" title="Number"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 12%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zLnV2zUuBYb8" title="Expiry Date">May 6, 2024</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.00</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_z6UNquRzlyx5" title="Expiry Date">April 21, 2026</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160,000</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center; text-indent: -0.8pt"><span style="font-size: 10pt"/></p>

<p id="xdx_8AA_zYSWPinQIxEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center; text-indent: -0.8pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>2015 Stock Option Plan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s board of
directors approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted
stock awards to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>2019 Stock Option Plan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance">6,000,000</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zzWOxS5qgCP" title="Option granted">406,453</span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>2022 Stock Option Plan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Additional shares of common stock available for issuance">10,000,000</span> additional shares of Common Stock will be available for issuance under the 2022 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. At September
30, 2022, <span id="xdx_90F_ecustom--OptionIssued_c20211001__20220930_pdd" title="Option issued">2,058,000</span> options had been issued under the 2022 Plan and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant">8,363,453</span> options were available for issue under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock option
activity during the year ended September 30, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zxj8vJ2mgkUj" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BD_zxDXwkvCac17" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average Grant</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date Fair Value</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1px solid; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1px solid; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intrinsic value
    ($)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 0%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 0pt 10pt; width: 24%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
                                            September 30, 2021</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPzYUjBpavfa" style="width: 15%; text-align: right" title="Options Outstanding at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,330,903</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2NpkNzhLGgl" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.74</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 15%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxko9TbKfx9a" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140,132,451</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,358,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.07</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1155kjkYbq1" style="text-align: right" title="Options Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(118,750</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.86</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdEigvjic9H1" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(400,537</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.52</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.88</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,201,015</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
                                            September 30, 2022</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znyDJZ5oimhh" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,169,616</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFjA3B56xNq9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.61</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxkf1hOMxhv3" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Outstanding at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,267,309</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable,
                                            September 30, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,777,113</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.40</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,173,997</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt; text-align: justify"/>

<p id="xdx_8A4_z3NTfV2vEe1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at September 30, 2022 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zyZBDTTcl3Mh" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><span id="xdx_8B3_zwaH8kPgNzea" style="display: none">Summarizes information about stock options</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="7" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted</span></td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="7" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="7" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of exercise
prices</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contractual life</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">exercise</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in years)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price ($)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vested options</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price ($)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit"><span style="font: 10pt Times New Roman, Times, Serif">0.92</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"><span style="font: 10pt Times New Roman, Times, Serif">2.96</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zNXxIiez54p" style="width: 11%; text-align: right" title="Number of outstanding options"><span style="font: 10pt Times New Roman, Times, Serif">3,903,762</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 11%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zUWDCjO2Vsv9" title="Weighted average remaining contractual life (in years)">5.12</span></span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">2.30</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options"><span style="font: 10pt Times New Roman, Times, Serif">3,883,345</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">2.30</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font: 10pt Times New Roman, Times, Serif">3.15</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font: 10pt Times New Roman, Times, Serif">4.80</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"><span style="font: 10pt Times New Roman, Times, Serif">2,078,800</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zAZpr64athib" title="Weighted average remaining contractual life (in years)">5.34</span></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">3.30</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"><span style="font: 10pt Times New Roman, Times, Serif">2,063,800</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">3.29</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font: 10pt Times New Roman, Times, Serif">5.04</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font: 10pt Times New Roman, Times, Serif">8.98</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"><span style="font: 10pt Times New Roman, Times, Serif">3,957,054</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zdl65uiwL7Ul" title="Weighted average remaining contractual life (in years)">6.07</span></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">6.28</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"><span style="font: 10pt Times New Roman, Times, Serif">2,365,387</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">6.31</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font: 10pt Times New Roman, Times, Serif">9.20</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font: 10pt Times New Roman, Times, Serif">13.01</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"><span style="font: 10pt Times New Roman, Times, Serif">1,698,000</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zUVWbwYyTdDg" title="Weighted average remaining contractual life (in years)">9.58</span></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">10.50</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"><span style="font: 10pt Times New Roman, Times, Serif">109,581</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">12.40</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font: 10pt Times New Roman, Times, Serif">13.22</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font: 10pt Times New Roman, Times, Serif">24.58</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"><span style="font: 10pt Times New Roman, Times, Serif">1,532,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_znKOmouiD8R" title="Weighted average remaining contractual life (in years)">8.44</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">18.23</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"><span style="font: 10pt Times New Roman, Times, Serif">355,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">18.66</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"><span style="font: 10pt Times New Roman, Times, Serif">13,169,616</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"><span style="font: 10pt Times New Roman, Times, Serif">8,777,113</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<p id="xdx_8AF_zBzjJBYZBh0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average per share fair value of options
vested during the year ended September 30, 2022 was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930_z6N5VgaNTOxg" title="Weighted average grant date fair value of options vested">4.69</span> (2021: $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930_pdd" title="Weighted average grant date fair value of options vested">2.54</span>, 2020: $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930_zh2nDHPUCdda" title="Weighted average grant date fair value of options vested">2.55</span>). At September 30, 2022, the weighted average contractual
life of options outstanding was <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zC7JTH074Ukk" title="Weighted average contractual life of options outstanding">6.4</span> years (2021: <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zaEsZSlAor45" title="Weighted average contractual life of options outstanding">6.8</span> years) and for options exercisable was <span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zhqdiAHZ5y49" title="Options exercisable">5.1</span> years (2021: <span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zpLPnSSSeGej" title="Options exercisable">5.5</span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at September 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">	The Company recognized stock-based compensation
expense of $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930_pp0p0" title="Share based compensation">18,379,242</span> during the year ended September 30, 2022 (2021: $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210930_pp0p0" title="Share based compensation">8,231,403</span>; 2020: $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930_zU3Qc5vKLyVl" title="Share based compensation">4,876,906</span>) in connection with the issuance and
vesting 	of stock options and warrants in exchange for services. These amounts have been included in general and 	administrative
expenses and research and development expenses on the Company&#8217;s consolidated statements of 	operations as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zRsv1hPuGVY1" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zVL7LQlGNg7d" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 11%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,129,412</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEdoL2xos1Xl" style="width: 11%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,571,335</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ziQTxjhxUGJg" style="width: 11%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,210,789</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,249,830</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zS5vl9HDS9Pj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,660,068</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zr97YiLgSPx4" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,666,117</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,379,242</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930_zzMufGfKjIcc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,231,403</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930_z1XcI0m56cNj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,876,906</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<p id="xdx_8A2_z1aNr2eyavRd" style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20220930_pp0p0" title="Remaining stock based compensation">19,032,000</span> in stock-based
compensation is expected to be recorded over the remaining term 	of such options and warrants through fiscal 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option and
warrant award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zeaKNUmKwXb6" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B9_zNFFdnXS3Ma4" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220930_zeZpDHresJzh" title="Risk-free interest rate">3.11</span></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20210930_zXhtykYhwUSj" title="Risk-free interest rate">0.73</span></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20191001__20200930_z3dmWdOI0ns9" title="Risk-free interest rate">1.57</span></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of options (years)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220930_z6aEovXTPwa6" title="Expected life of options (years)">5.57</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210930_zAkG3Sccvdl" title="Expected life of options (years)">5.74</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200930_zL0wY6kX2d2j" title="Expected life of options (years)">5.53</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annualized volatility</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220930_zhztPPc8Mdk9" title="Annualized volatility">84.17</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20210930_zQmgc3QlShK7" title="Annualized volatility">93.43</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20191001__20200930_zNuF8kSdMzs1" title="Annualized volatility">95.99</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend rate</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220930_zKqoqQv2xAHf" title="Dividend rate">0.00</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20210930_zuCGmjCDBG03" title="Dividend rate">0.00</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20191001__20200930_zRRaloMMiN2g" title="Dividend rate">0.00</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
</table>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"/></p>

<p id="xdx_8AC_zhPIVcNeZJQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the years ended September 30, 2022, 2021 and 2020 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380383370976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_ziIqbRNtNcaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7	 	<span id="xdx_82B_zVa8z1O31jAd">Income Taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s U.S. and foreign loss before income
taxes are set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zx5dvH0NFZnj" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"><span id="xdx_8B1_zHT4EuIsczU9" style="display: none">Schedule of Income before Income Tax, Domestic and Foreign</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20211001__20220930_zMKYknPhq378" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20201001__20210930_zfxrFFPCwnc4" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_497_20191001__20200930_zGhw73ioTF9l" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(40,001,893</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28,850,926</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,096,148</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,617,534</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,790,143</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,161,658</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(47,619,427</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(37,641,069</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26,257,806</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>



<p style="font: 10pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"/></p>

<p id="xdx_8AF_zmSqGbBUck62" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of net deferred income tax assets as of September 30, 2022
and 2021 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zjMfQmQsT4Kb" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zI9P67rFLgNc"><span id="xdx_8B6_zAX90pApmdX1" style="display: none">Schedule of deferred tax asset and liabilities</span></span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20220930_zbByw7DrQqFg" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_497_20210930_zx5QfwiHm1x4" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
</tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 62%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryforwards</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,208,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,982,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development tax credit carryforwards</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,182,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,577,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,373,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,453,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_40D_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unpaid charges</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">894,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible asset costs</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">388,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">323,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign exchange and other</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8KqZpS1dx02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance of deferred tax assets</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(63,089,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(47,486,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
</tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0948">&#8212;</span></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0949">&#8212;</span></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
</table>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"/></p>

<p id="xdx_8A7_zBJOu8iSi81g" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of income tax expense at the statutory
federal income tax rate and income taxes as reflected in the consolidated financial statements for the years ended September 30, 2022
and 2021 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zr0kxcDJW9E5" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_zFSOKYViXamk" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20211001__20220930_zmPaFeGlxVAg" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49B_20201001__20210930_z7JqXnu6yzNl" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20191001__20200930_ztqOVCwmuym" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax benefit at statutory federal rate</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,000,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,934,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,519,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign income taxed at other rates</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(170,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(353,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(723,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40A_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent differences relating to stock based compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(714,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,379,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0963">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--PermanentDifferencesRelatingToSection162m_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent differences relating to Section 162(m)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0965">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">816,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0967">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other permanent differences</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0969">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">741,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_ecustom--AdjustmentToTaxAssetsBasedOnSection382_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment to tax assets based on Section 382</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,330,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development credits, net</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">232,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,042,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,267,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State and local taxes</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,975,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,022,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,911,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_404_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_zzfQV4aVbjg6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment to true up to prior years' tax provision</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">373,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_zckaICNVDz7b" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of change in statutory tax rates</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">216,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--TaxesExcludingIncomeAndExciseTaxes_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State minimum and excise taxes</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">358,492</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">267,565</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,664</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation allowances</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,603,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,495,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,442,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expense</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">358,492</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">267,565</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,664</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"/></p>

<p id="xdx_8A5_z1WET1ZcRca6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, the Company had U.S. federal
net operating loss carryforwards of approximately $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20220930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z8vBX27flW33" title="Operating loss carryforwards">123.4</span> million (2021: $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zetJd9cR1BI4" title="Operating loss carryforwards">101.6</span> million) of which <span id="xdx_908_ecustom--OperatingLossCarryforwardsDescription_c20211001__20220930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember" title="Operating loss carryforwards description">$37.7 million will begin to expire in
2025 and $85.7 million can be carried forward indefinitely</span>, state and local net operating loss carryforwards of approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20220930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zrw2NUpRciRf" title="Operating loss carryforwards">199.0</span> million
(2021: $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zIg7ytUWaNm1" title="Operating loss carryforwards">177.7</span> million) which will begin to expire in <span id="xdx_90A_ecustom--OperatingLossCarryForwardsExpirationYear_c20211001__20220930" title="Operating loss carry forwards expiration year">2036</span>, and Research and Development tax credits of $<span id="xdx_90B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pp0n3_dm_c20211001__20220930_zKD2NjpyaC17" title="Research and Development tax credits">2.2</span> million (2021: $<span id="xdx_90F_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pp0n3_dm_c20201001__20210930_z9IBoLQSFtMd" title="Research and Development tax credits">1.6</span> million)
which will begin to expire in 2029. The Company had approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20220930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zNYH13afw2ii" title="Operating loss carryforwards">10.6</span> million (approximately AU$ <span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_c20220930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_zLjYRvafTY6f" title="Operating loss carryforwards">14.9</span> million) (2021: $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_c20210930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zxXCgppp4vi2" title="Operating loss carryforwards">7.9</span> million (approximately
AU$ <span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_zLOAe0ZkUhz3" title="Operating loss carryforwards">11.2</span> million)) of net operating loss carryforwards in Australia, which have an indefinite life, available to offset future taxable
income in those jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates its valuation allowance
requirements based on available evidence. When circumstances change, and this causes a change in management&#8217;s judgment about
the recoverability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income.
Because management of the Company does not currently believe that it is more likely than not that the Company will receive the
benefit of these assets, a full valuation allowance has been established at September 30, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files income tax returns in the U.S. federal
jurisdiction and various state and local and foreign jurisdictions. The Company&#8217;s tax returns are subject to tax examinations by
U.S. federal and state tax authorities, or examinations by foreign tax authorities until the respective statutes of limitation expire.
The Company is subject to tax examinations by tax authorities for all taxation years commencing on or after 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the provisions of the Internal Revenue Code,
the net operating loss (&#8220;NOL&#8221;) carryforwards are subject to review and possible adjustment by the Internal Revenue Service
and state tax authorities. Under Section 382 of the Internal Revenue Code, NOL and tax credit carryforwards may become subject to an annual
limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over a three-year period,
as well as similar state tax provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company conducted a Section 382 study during
the year ended September 30, 2021 and determined that, during the year ended September 30, 2015, there was a change in ownership
which resulted in $25.8 million of federal NOLs being subject to an annual limitation of $439,914. During the year ended September 30, 2021,
the Company reduced its federal NOLs by $12.1 million and its Research and Development tax credit carryforwards by $0.8 million,
which are the amount of tax assets that will expire unutilized pursuant to the Section 382 study. This resulted in a reduction of
$2.5 million of NOLs and $0.8 million of research and development credits and a corresponding reduction in the valuation allowance
of $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0n3_dm_c20211001__20220930_zKyNQSpELoTk" title="Decrease in vaution allowance">3.3 </span>million,
which was recorded in the 2021 fiscal year. Subsequent ownership changes in future years could trigger additional limitations of the
Company&#8217;s NOLs<span style="background-color: white">. During the year ended September 30, 2022 the Company determined that
there were no changes in ownership pursuant to Section 382.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, the Company did not provide
any foreign withholding taxes related to its foreign subsidiaries&#8217; undistributed earnings, as such earnings have been retained and
are intended to be indefinitely reinvested to fund ongoing operations of the foreign subsidiaries. It is not practicable to estimate the
amount of taxes that would be payable upon remittance of these earnings, because such tax, if any, is dependent upon circumstances existing
if and when remittance occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380374341280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_849_eus-gaap--UseOfEstimates_z8gKMmY1HLRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zWG3EmOoh2sk">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the
basis for making judgments about the book values of assets and liabilities and the accrual of costs and expenses that are not readily
apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zJ2MdZ71Dy5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zIuhEHzP31n6">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly owned subsidiaries, Anavex Australia Pty Limited. (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and equivalents</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6tEegO9VsS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_z0JMPFdEJVJc">Cash and equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#8217;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains its investments at one large well known financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20220930_zInmgKI67LC4" title="Federal Deposit Insurance Corporation">250,000</span>, under current regulations. At September 30, 2022 and 2021, substantially
all of the Company&#8217;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zr6NvoPtLvGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_z8Kq4tFCNR84">Research and Development Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#8217;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and stock-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#8220;CROs&#8221;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#8220;ASC&#8221;) 730, Research and Development, as these materials have no alternative future use outside of their intended use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the studies including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are
made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.
The Company&#8217;s historical accrual estimates have not been materially different from actual costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionIncentives', window );">Research and Development Incentive Income</a></td>
<td class="text"><p id="xdx_849_eus-gaap--RevenueRecognitionIncentives_zsVE6ZiohaM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zTbyIPlIwXve">Research and Development Incentive Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is eligible to obtain certain research
and development tax credits, including the Australian research and development tax incentive credit (the &#8220;Australia R&amp;D credit&#8221;)
through a program administered through the Australian Tax Office (the &#8220;ATO&#8221;) and AusIndustry, a division of the Australian
Government&#8217;s Department of Industry, Innovation and Science (&#8220;AusIndustry&#8221;), which provides for a cash refund based
on a percentage of eligible research and development activities undertaken in Australia by the Company&#8217;s wholly owned subsidiary,
Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;D credit program to receive the cash refund for certain
research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by AusIndustry
pursuant to an advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Australia R&amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, Income Taxes (&#8220;ASC 740&#8221;), since the incentives are
not linked to the Company&#8217;s taxable income and can be realized regardless of whether the Company has generated taxable income in
the respective jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to the Australia R&amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 <i>Accounting for Government Grants and Disclosure of Government Assistance</i> (&#8220;IAS 20&#8221;). The Company
recognizes the Research and Development Incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;D credit
Program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#8217;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zyGAkxtLqYfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zwn8BSjXghg8">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, diluted loss per share excludes
<span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220930_pdd" title="Loss per share for potentially dilutive common shares">13,329,616</span> potentially dilutive common shares (2021 &#8211; diluted loss per share excludes <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930_zIjvlIpEANY8" title="Loss per share for potentially dilutive common shares">11,540,903</span> potentially dilutive common shares;
2020 &#8211; diluted loss per share excludes <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20191001__20200930_zXI5VTYcTPKf" title="Loss per share for potentially dilutive common shares">10,576,266</span> potentially dilutive common shares) related to outstanding options and warrants,
as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zSS2UperrY14" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zc95zI2r0ta8">Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The book value of the Company&#8217;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#8217;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zJYZsysB1fQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86B_zcmI4X4oLBB1">Foreign Currency Translation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographic Reporting</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zAaQa43BTZQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_869_zkULV6MVVQV1">Segment and Geographic Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating segments are defined as components of an
enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making
group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as
one operating segment, which is the business of developing novel therapies for the management of CNS diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_GrantIncomePolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p id="xdx_843_ecustom--GrantIncomePolicyTextBlock_ziGpSNcmT4Pc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zrBFYtQohVki">Grant Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statement of operations
in the period they are earned and when the related research and development costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zCmmKHc71zg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z1zXqEoNhwOj">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC
740 regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements
when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are
initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon
ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts. Application requires
numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions
and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional
information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic
adjustments may have a material impact on the consolidated statements of operations. At September 30, 2022 the Company did <span id="xdx_905_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20220930_zFBUlap6tPSl" title="Uncertain tax positions">no</span>t
have any uncertain tax positions.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes interest and penalties
related to current income tax expense on the interest income, net line, in the accompanying consolidated statement of operations.
Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets. There were <span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20211001__20220930_z9D7qWr5ILXe" title="Interest and penalties"><span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20201001__20210930_zc3co7wNJLWg" title="Interest and penalties">no</span></span>
interest and penalties related to current income tax expense during the years ended September 30, 2022, 2021 and 2020.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zWB35jw4KtT" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zcoUScD6bzFe">Stock-based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for all stock-based payments
and awards under the fair value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of all share purchase options and warrants
are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected to
vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation costs for stock-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option valuation
model to calculate the fair value of share purchase options and warrants at the date of the grant. This model requires the input of subjective
assumptions, including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury
yield curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted
are expected to be outstanding using the simplified method. The Company&#8217;s historical share option exercise experience does not provide
a reasonable basis for estimating the expected term. Expected volatility is based on the average of the daily share price changes over
the expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not
paid any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions
consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment.
Changes in these assumptions can materially affect the fair value estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price of options or warrants may be paid
in cash or, if approved by the Company&#8217;s compensation committee in advance, &#8220;net settled&#8221; in shares of the Company&#8217;s
common stock. In a net settlement of an option or warrant, the Company does not receive payment of the exercise price from the holder
but reduces the number of shares of common stock issued upon the exercise of the stock option or warrant by the smallest number of whole
shares that have an aggregate fair market value equal to or over the aggregate exercise price for the option shares covered by the option
or warrant exercised. Shares issued pursuant to the exercise of options and warrants are issued from the Company&#8217;s treasury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zaRnwuPwOpr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zge762DQGdy1">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2022 and 2021, the Company did not
have any Level 2 or Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zkvzJbYcbfqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_zwDAbvay2cOh">Recently Adopted Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective October 1, 2021, the Company adopted Accounting
Standards Update (&#8220;ASU&#8221;) 2019-12, &#8220;Simplifying the Accounting for Income Taxes (ASC 740)&#8221;, which is intended to
simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740
and clarifying and amending existing guidance to improve consistent application. There was no material impact on the Company&#8217;s operations,
financial condition, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2021, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued ASU&#160;2021-10, &#8220;Government Assistance (Topic 832): Disclosures by Business Entities about Government
Assistance&#8221; (&#8220;ASU&#160;2021-10&#8221;). ASU&#160;2021-10&#160;increases the transparency of government assistance including
the disclosure of (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance
on an entity&#8217;s financial statements. ASU&#160;2021-10&#160;is effective for fiscal years beginning after December 15, 2021, with
early adoption permitted. Upon implementation, the Company may use either a prospective or retrospective method of adoption when adopting
the ASU. The adoption of ASU 2021-10 will impact the disclosures related to the research and development incentive income that the Company
receives from the ATO for its clinical trials in Australia. The Company currently plans to adopt the provisions of this ASU on October
1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrantIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrantIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for sales incentives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1D<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=SL116886442-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4549-113899<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (m)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380379905088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureAccruedLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of components of accrued liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zdAM0DDAypG6" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zZ9g3MhxkYHd" style="display: none">Schedule of components of accrued liabilities</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_497_20220930_zCsJnLHVGyn1" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20210930_zH7qnVnSgIg" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td></tr>
<tr id="xdx_402_ecustom--ClinicalSiteCostsAndPatientVisits_iI_pp0p0_maALCzi8D_zKCvwFUb29Yb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued clinical site and patient visits costs</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,031,105</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,035,800</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCzi8D_z59IhkWemSt2" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued compensation and benefits</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,297,337</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,201,903</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_ecustom--FixedContractAccruals_iI_pp0p0_maALCzi8D_z82jvbG5jm9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed contract accruals</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">417,414</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">649,649</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzi8D_zj7ZweeM9CA8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other accrued liabilities</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,199,097</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,727,422</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzi8D_zkbmpaxQjJBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; font-size: 10pt; text-indent: -10pt"><span style="color: rgb(204,238,255); font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accrued liabilities</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,944,953</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,614,774</span><span style="font-family: Symbol; font-size: 10pt"/></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Symbol">&#160;</span></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380377935008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of exercisable share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zrqYgJE63aq5" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_za46SsaCHP49" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td>
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price ($)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 0%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt 0pt 0pt 10pt; width: 35%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, September 30, 2021</span></td>
<td style="padding: 0pt 0pt 0pt 10pt; width: 1%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z7c7dsHrZL8i" style="width: 25%; text-align: right" title="Share Purchase Warrants Balance, at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">210,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8KDPG7kevJf" style="width: 25%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.69</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zbeBtxvzaGg6" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.00</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, September 30, 2022</span></td>
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zuQr9LLe9DB6" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zvXWeia4T0N2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.72</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center"/>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zwOtrbAziuLf" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><span id="xdx_8BD_zcRVkusmwtE2" style="display: none">Schedule of share purchase warrants outstanding</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiry Date</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 0%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 35%; text-align: right" title="Number"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 12%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zLnV2zUuBYb8" title="Expiry Date">May 6, 2024</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.00</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_z6UNquRzlyx5" title="Expiry Date">April 21, 2026</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160,000</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center; text-indent: -0.8pt"><span style="font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zxj8vJ2mgkUj" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BD_zxDXwkvCac17" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average Grant</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date Fair Value</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1px solid; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1px solid; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intrinsic value
    ($)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 0%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 0pt 10pt; width: 24%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
                                            September 30, 2021</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPzYUjBpavfa" style="width: 15%; text-align: right" title="Options Outstanding at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,330,903</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2NpkNzhLGgl" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.74</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 15%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxko9TbKfx9a" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140,132,451</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,358,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.07</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1155kjkYbq1" style="text-align: right" title="Options Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(118,750</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.86</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdEigvjic9H1" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(400,537</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.52</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.88</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,201,015</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
                                            September 30, 2022</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znyDJZ5oimhh" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,169,616</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFjA3B56xNq9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.61</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxkf1hOMxhv3" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Outstanding at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,267,309</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable,
                                            September 30, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,777,113</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.40</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,173,997</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt; text-align: justify"/>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarizes information about stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zyZBDTTcl3Mh" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><span id="xdx_8B3_zwaH8kPgNzea" style="display: none">Summarizes information about stock options</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="7" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted</span></td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="7" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="7" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td>
<td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of exercise
prices</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contractual life</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">exercise</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in years)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price ($)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vested options</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price ($)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit"><span style="font: 10pt Times New Roman, Times, Serif">0.92</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"><span style="font: 10pt Times New Roman, Times, Serif">2.96</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zNXxIiez54p" style="width: 11%; text-align: right" title="Number of outstanding options"><span style="font: 10pt Times New Roman, Times, Serif">3,903,762</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 11%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zUWDCjO2Vsv9" title="Weighted average remaining contractual life (in years)">5.12</span></span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">2.30</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options"><span style="font: 10pt Times New Roman, Times, Serif">3,883,345</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">2.30</span></td>
<td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font: 10pt Times New Roman, Times, Serif">3.15</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font: 10pt Times New Roman, Times, Serif">4.80</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"><span style="font: 10pt Times New Roman, Times, Serif">2,078,800</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zAZpr64athib" title="Weighted average remaining contractual life (in years)">5.34</span></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">3.30</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"><span style="font: 10pt Times New Roman, Times, Serif">2,063,800</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">3.29</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font: 10pt Times New Roman, Times, Serif">5.04</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font: 10pt Times New Roman, Times, Serif">8.98</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"><span style="font: 10pt Times New Roman, Times, Serif">3,957,054</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zdl65uiwL7Ul" title="Weighted average remaining contractual life (in years)">6.07</span></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">6.28</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"><span style="font: 10pt Times New Roman, Times, Serif">2,365,387</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">6.31</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font: 10pt Times New Roman, Times, Serif">9.20</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font: 10pt Times New Roman, Times, Serif">13.01</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"><span style="font: 10pt Times New Roman, Times, Serif">1,698,000</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zUVWbwYyTdDg" title="Weighted average remaining contractual life (in years)">9.58</span></span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">10.50</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"><span style="font: 10pt Times New Roman, Times, Serif">109,581</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">12.40</span></td>
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
<td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font: 10pt Times New Roman, Times, Serif">13.22</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;$</span></td>
<td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font: 10pt Times New Roman, Times, Serif">24.58</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"><span style="font: 10pt Times New Roman, Times, Serif">1,532,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_znKOmouiD8R" title="Weighted average remaining contractual life (in years)">8.44</span></span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">18.23</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"><span style="font: 10pt Times New Roman, Times, Serif">355,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">18.66</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"><span style="font: 10pt Times New Roman, Times, Serif">13,169,616</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"><span style="font: 10pt Times New Roman, Times, Serif">8,777,113</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zRsv1hPuGVY1" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zVL7LQlGNg7d" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 11%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,129,412</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEdoL2xos1Xl" style="width: 11%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,571,335</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ziQTxjhxUGJg" style="width: 11%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,210,789</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,249,830</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zS5vl9HDS9Pj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,660,068</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zr97YiLgSPx4" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,666,117</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,379,242</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930_zzMufGfKjIcc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,231,403</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930_z1XcI0m56cNj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,876,906</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zeaKNUmKwXb6" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B9_zNFFdnXS3Ma4" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220930_zeZpDHresJzh" title="Risk-free interest rate">3.11</span></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20210930_zXhtykYhwUSj" title="Risk-free interest rate">0.73</span></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20191001__20200930_z3dmWdOI0ns9" title="Risk-free interest rate">1.57</span></span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of options (years)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220930_z6aEovXTPwa6" title="Expected life of options (years)">5.57</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210930_zAkG3Sccvdl" title="Expected life of options (years)">5.74</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200930_zL0wY6kX2d2j" title="Expected life of options (years)">5.53</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annualized volatility</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220930_zhztPPc8Mdk9" title="Annualized volatility">84.17</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20210930_zQmgc3QlShK7" title="Annualized volatility">93.43</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20191001__20200930_zNuF8kSdMzs1" title="Annualized volatility">95.99</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend rate</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220930_zKqoqQv2xAHf" title="Dividend rate">0.00</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20210930_zuCGmjCDBG03" title="Dividend rate">0.00</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20191001__20200930_zRRaloMMiN2g" title="Dividend rate">0.00</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
</table>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"/></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380380476800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zx5dvH0NFZnj" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"><span id="xdx_8B1_zHT4EuIsczU9" style="display: none">Schedule of Income before Income Tax, Domestic and Foreign</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20211001__20220930_zMKYknPhq378" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20201001__20210930_zfxrFFPCwnc4" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_497_20191001__20200930_zGhw73ioTF9l" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(40,001,893</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28,850,926</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,096,148</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,617,534</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,790,143</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,161,658</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(47,619,427</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(37,641,069</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26,257,806</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>



<p style="font: 10pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"/></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax asset and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zjMfQmQsT4Kb" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zI9P67rFLgNc"><span id="xdx_8B6_zAX90pApmdX1" style="display: none">Schedule of deferred tax asset and liabilities</span></span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_494_20220930_zbByw7DrQqFg" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_497_20210930_zx5QfwiHm1x4" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
</tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 62%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryforwards</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,208,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,982,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development tax credit carryforwards</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,182,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,577,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,373,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,453,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_40D_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unpaid charges</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">894,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible asset costs</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">388,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">323,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign exchange and other</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
<tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8KqZpS1dx02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance of deferred tax assets</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(63,089,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(47,486,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
</tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0948">&#8212;</span></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0949">&#8212;</span></span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
</tr>
</table>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zr0kxcDJW9E5" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_zFSOKYViXamk" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49D_20211001__20220930_zmPaFeGlxVAg" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49B_20201001__20210930_z7JqXnu6yzNl" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49E_20191001__20200930_ztqOVCwmuym" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
<tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax benefit at statutory federal rate</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,000,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,934,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,519,000</span></td>
<td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign income taxed at other rates</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(170,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(353,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(723,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40A_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent differences relating to stock based compensation</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(714,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,379,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0963">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--PermanentDifferencesRelatingToSection162m_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent differences relating to Section 162(m)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0965">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">816,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0967">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other permanent differences</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0969">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">741,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_ecustom--AdjustmentToTaxAssetsBasedOnSection382_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment to tax assets based on Section 382</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,330,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development credits, net</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">232,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,042,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,267,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State and local taxes</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,975,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,022,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,911,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_404_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_zzfQV4aVbjg6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment to true up to prior years' tax provision</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">373,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_zckaICNVDz7b" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of change in statutory tax rates</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">216,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,000</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--TaxesExcludingIncomeAndExciseTaxes_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State minimum and excise taxes</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">358,492</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">267,565</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,664</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation allowances</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,603,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,495,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,442,000</span></td>
<td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expense</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">358,492</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">267,565</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,664</span></td>
<td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"/></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380373845680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal Deposit Insurance Corporation</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">13,329,616<span></span>
</td>
<td class="nump">11,540,903<span></span>
</td>
<td class="nump">10,576,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest and penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380377646368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureAccruedLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ClinicalSiteCostsAndPatientVisits', window );">Accrued clinical site and patient visits costs</a></td>
<td class="nump">$ 2,031,105<span></span>
</td>
<td class="nump">$ 2,035,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,297,337<span></span>
</td>
<td class="nump">1,201,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_FixedContractAccruals', window );">Fixed contract accruals</a></td>
<td class="nump">417,414<span></span>
</td>
<td class="nump">649,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">All other accrued liabilities</a></td>
<td class="nump">2,199,097<span></span>
</td>
<td class="nump">1,727,422<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 5,944,953<span></span>
</td>
<td class="nump">$ 5,614,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ClinicalSiteCostsAndPatientVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ClinicalSiteCostsAndPatientVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FixedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FixedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380374079968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_GrantIncome', window );">Grant income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 497,931<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">3,323,011<span></span>
</td>
<td class="nump">4,547,099<span></span>
</td>
<td class="nump">4,375,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 597,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="nump">443,831<span></span>
</td>
<td class="nump">443,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingsIncomeFromGrant', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 4,468,246<span></span>
</td>
<td class="nump">6,068,993<span></span>
</td>
<td class="nump">$ 6,392,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember', window );">Michael J Fox [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">995,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember', window );">Parkinson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 995,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingsIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingsIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380377609680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SalesOfAgreementAmount', window );">Sales of agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,407,882<span></span>
</td>
<td class="nump">$ 163,392,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald And Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,623,813<span></span>
</td>
<td class="nump">5,634,576<span></span>
</td>
<td class="nump">1,760,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_GrossProceedsFromIssuancePublicOffering', window );">Gross proceeds from Issuance Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,984,667<span></span>
</td>
<td class="nump">$ 79,107,550<span></span>
</td>
<td class="nump">$ 7,499,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,261,425<span></span>
</td>
<td class="nump">$ 76,670,027<span></span>
</td>
<td class="nump">$ 7,096,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Value of shares obligated to purchase</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="nump">324,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,086,209<span></span>
</td>
<td class="nump">7,633,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">162,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,007,996<span></span>
</td>
<td class="nump">7,564,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,111,198<span></span>
</td>
<td class="nump">$ 21,254,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,213<span></span>
</td>
<td class="nump">68,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues4', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrossProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrossProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information related to number of shares obligated to purchase prorata basic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information related to percentage of gross proceeds from sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SalesOfAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SalesOfAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information related to value of shares obligated to purchase initially.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380374488560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Purchase Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at beginning | shares</a></td>
<td class="nump">210,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at beginning | $ / shares</a></td>
<td class="nump">$ 5.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Share Purchase Warrants Forfeited | shares</a></td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at ending | shares</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at ending | $ / shares</a></td>
<td class="nump">$ 3.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380374351392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Purchase Warrants 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Apr. 21,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380374338784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning | shares</a></td>
<td class="nump">11,330,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at beginning</a></td>
<td class="nump">$ 5.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at beginning | $</a></td>
<td class="nump">$ 140,132,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted | shares</a></td>
<td class="nump">2,358,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 10.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="nump">$ 7.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited | shares</a></td>
<td class="num">(118,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">$ 6.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value Forfeited</a></td>
<td class="nump">$ 5.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised | shares</a></td>
<td class="num">(400,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value Exercised</a></td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value Exercised | $</a></td>
<td class="nump">$ 4,201,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at ending | shares</a></td>
<td class="nump">13,169,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at ending</a></td>
<td class="nump">$ 6.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at ending | $</a></td>
<td class="nump">$ 62,267,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable at ending | shares</a></td>
<td class="nump">8,777,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable at ending</a></td>
<td class="nump">$ 4.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value Exercisable at ending | $</a></td>
<td class="nump">$ 55,173,997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380378013968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">13,169,616<span></span>
</td>
<td class="nump">11,330,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.61<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">8,777,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">3,903,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">5 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">3,883,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">2,078,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">5 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,063,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 8.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">3,957,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,365,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 13.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">9 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">109,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 12.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">13.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 24.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,532,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">8 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 18.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380378558576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 18,379,242<span></span>
</td>
<td class="nump">$ 8,231,403<span></span>
</td>
<td class="nump">$ 4,876,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">7,129,412<span></span>
</td>
<td class="nump">3,571,335<span></span>
</td>
<td class="nump">2,210,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 11,249,830<span></span>
</td>
<td class="nump">$ 4,660,068<span></span>
</td>
<td class="nump">$ 2,666,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380380648784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 5)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.11%<span></span>
</td>
<td class="nump">0.73%<span></span>
</td>
<td class="nump">1.57%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 6 months 25 days<span></span>
</td>
<td class="text">5 years 8 months 26 days<span></span>
</td>
<td class="text">5 years 6 months 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">84.17%<span></span>
</td>
<td class="nump">93.43%<span></span>
</td>
<td class="nump">95.99%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380374370624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="nump">$ 72,865<span></span>
</td>
<td class="nump">$ 130,784<span></span>
</td>
<td class="nump">$ 233,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution amount</a></td>
<td class="nump">$ 158,112<span></span>
</td>
<td class="nump">$ 128,856<span></span>
</td>
<td class="nump">$ 98,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OptionIssued', window );">Option issued</a></td>
<td class="nump">2,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options vested</a></td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="nump">$ 2.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life of options outstanding</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 18,379,242<span></span>
</td>
<td class="nump">$ 8,231,403<span></span>
</td>
<td class="nump">$ 4,876,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 19,032,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member', window );">Stock Option Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="nump">406,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">8,363,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OptionIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OptionIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380374078560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (40,001,893)<span></span>
</td>
<td class="num">$ (28,850,926)<span></span>
</td>
<td class="num">$ (18,096,148)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(7,617,534)<span></span>
</td>
<td class="num">(8,790,143)<span></span>
</td>
<td class="num">(8,161,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total</a></td>
<td class="num">$ (47,619,427)<span></span>
</td>
<td class="num">$ (37,641,069)<span></span>
</td>
<td class="num">$ (26,257,806)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380378546384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 46,208,000<span></span>
</td>
<td class="nump">$ 34,982,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">2,182,000<span></span>
</td>
<td class="nump">1,577,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">13,373,000<span></span>
</td>
<td class="nump">10,453,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredTaxAssetsUnpaidCharges', window );">Unpaid charges</a></td>
<td class="nump">894,000<span></span>
</td>
<td class="nump">89,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible asset costs</a></td>
<td class="nump">388,000<span></span>
</td>
<td class="nump">323,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Foreign exchange and other</a></td>
<td class="nump">44,000<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance of deferred tax assets</a></td>
<td class="num">(63,089,000)<span></span>
</td>
<td class="num">(47,486,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredTaxAssetsUnpaidCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents as a deferred tax assets unpaid charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredTaxAssetsUnpaidCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380377722912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at statutory federal rate</a></td>
<td class="num">$ (10,000,000)<span></span>
</td>
<td class="num">$ (7,934,000)<span></span>
</td>
<td class="num">$ (5,519,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income taxed at other rates</a></td>
<td class="num">(170,000)<span></span>
</td>
<td class="num">(353,000)<span></span>
</td>
<td class="num">(723,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PermanentDifferencesRelatingToStockBasedCompensation', window );">Permanent differences relating to stock based compensation</a></td>
<td class="num">(714,000)<span></span>
</td>
<td class="num">(4,379,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PermanentDifferencesRelatingToSection162m', window );">Permanent differences relating to Section 162(m)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">816,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other permanent differences</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">741,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AdjustmentToTaxAssetsBasedOnSection382', window );">Adjustment to tax assets based on Section 382</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,330,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet', window );">Research and development credits, net</a></td>
<td class="nump">232,000<span></span>
</td>
<td class="nump">1,042,000<span></span>
</td>
<td class="nump">1,267,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes</a></td>
<td class="num">(4,975,000)<span></span>
</td>
<td class="num">(7,022,000)<span></span>
</td>
<td class="num">(2,911,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Adjustment to true up to prior years' tax provision</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="nump">373,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Effect of change in statutory tax rates</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">216,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesExcludingIncomeAndExciseTaxes', window );">State minimum and excise taxes</a></td>
<td class="nump">358,492<span></span>
</td>
<td class="nump">267,565<span></span>
</td>
<td class="nump">22,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowances</a></td>
<td class="nump">15,603,000<span></span>
</td>
<td class="nump">13,495,000<span></span>
</td>
<td class="nump">7,442,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 358,492<span></span>
</td>
<td class="nump">$ 267,565<span></span>
</td>
<td class="nump">$ 22,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AdjustmentToTaxAssetsBasedOnSection382">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AdjustmentToTaxAssetsBasedOnSection382</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PermanentDifferencesRelatingToSection162m">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PermanentDifferencesRelatingToSection162m</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PermanentDifferencesRelatingToStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PermanentDifferencesRelatingToStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesExcludingIncomeAndExciseTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>All taxes not related to income of the entity or excise or sales taxes levied on the revenue of the entity that are not reported elsewhere. These taxes could include production, real estate, personal property, and pump tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesExcludingIncomeAndExciseTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380374093520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OperatingLossCarryForwardsExpirationYear', window );">Operating loss carry forwards expiration year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and Development tax credits</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease in vaution allowance</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=avxl_FederalMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 123,400,000<span></span>
</td>
<td class="nump">101,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OperatingLossCarryforwardsDescription', window );">Operating loss carryforwards description</a></td>
<td class="text">$37.7 million will begin to expire in
2025 and $85.7 million can be carried forward indefinitely<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 199,000,000.0<span></span>
</td>
<td class="nump">177,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">10,600,000<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member] | Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OperatingLossCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OperatingLossCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OperatingLossCarryforwardsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OperatingLossCarryforwardsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=avxl_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=avxl_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>e4251_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20220930"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20220930.xsd" xlink:type="simple"/>
    <context id="From2021-10-01to2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-11-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-11-28</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_MichaelJFoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_ParkinsonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:ParkinsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2016-10-012017-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-06</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_PurchaseWarrants2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_ForeignCountryMember_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_ForeignCountryMember_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-10-01to2022-09-30">0001314052</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-10-01to2022-09-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2021-10-01to2022-09-30">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-10-01to2022-09-30">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0091"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2021-10-01to2022-09-30"
      id="xdx2ixbrl0151"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:DeferredGrantIncomes
      contextRef="From2021-10-01to2022-09-30"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:DeferredGrantIncomes
      contextRef="From2019-10-012020-09-30"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-10-01to2022-09-30"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2019-10-012020-09-30"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2019-10-012020-09-30"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012020-09-30"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares
      contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0315"
      unitRef="Shares"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares
      contextRef="From2019-10-012020-09-30"
      id="xdx2ixbrl0316"
      unitRef="Shares"
      xsi:nil="true"/>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-012021-09-30"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToRegisteredDirectOffering
      contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessSharesIssueCosts
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessSharesIssueCosts
      contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPusuantToExerciseOfWarrants
      contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2021-10-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0948"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0949"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:PermanentDifferencesRelatingToStockBasedCompensation
      contextRef="From2019-10-012020-09-30"
      id="xdx2ixbrl0963"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:PermanentDifferencesRelatingToSection162m
      contextRef="From2021-10-01to2022-09-30"
      id="xdx2ixbrl0965"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:PermanentDifferencesRelatingToSection162m
      contextRef="From2019-10-012020-09-30"
      id="xdx2ixbrl0967"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2021-10-01to2022-09-30"
      id="xdx2ixbrl0969"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:AdjustmentToTaxAssetsBasedOnSection382
      contextRef="From2021-10-01to2022-09-30"
      id="xdx2ixbrl0973"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:AdjustmentToTaxAssetsBasedOnSection382
      contextRef="From2019-10-012020-09-30"
      id="xdx2ixbrl0975"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2021-10-01to2022-09-30"
      id="xdx2ixbrl0989"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-10-01to2022-09-30">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2021-10-01to2022-09-30">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-10-01to2022-09-30">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-10-01to2022-09-30">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2021-10-01to2022-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-10-01to2022-09-30">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-10-01to2022-09-30">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-10-01to2022-09-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-10-01to2022-09-30">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-10-01to2022-09-30">630 5th Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-10-01to2022-09-30">20th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-10-01to2022-09-30">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-10-01to2022-09-30">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2021-10-01to2022-09-30">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2021-10-01to2022-09-30">10111</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-10-01to2022-09-30">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-10-01to2022-09-30">689-3939</dei:LocalPhoneNumber>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2021-10-01to2022-09-30">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2021-10-01to2022-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2021-10-01to2022-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-10-01to2022-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-10-01to2022-09-30">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-10-01to2022-09-30">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-10-01to2022-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2021-10-01to2022-09-30">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2021-10-01to2022-09-30">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">921000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-11-28" decimals="INF" unitRef="Shares">77961815</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="From2021-10-01to2022-09-30">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2021-10-01to2022-09-30">Hartford, Connecticut</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2021-10-01to2022-09-30">248</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">149157861</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">152107745</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3192580</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">9136831</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">354162</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">371914</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">152704603</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">161616490</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3824777</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">4739781</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">5944953</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">5614774</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRentCredit contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">443831</us-gaap:DeferredRentCredit>
    <us-gaap:DeferredRentCredit contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">443831</us-gaap:DeferredRentCredit>
    <us-gaap:Liabilities contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">10213561</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">10798386</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">77942815</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">77942815</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">75918465</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">75918465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">77944</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">75920</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">387976881</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">348328048</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">-245563783</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-197585864</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142491042</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">150818104</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">152704603</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">161616490</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">13070068</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">9017511</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">5856609</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">37915747</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">32983674</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">25231623</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-50985815</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-42001185</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-31088232</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-50985815</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-42001185</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-31088232</us-gaap:OperatingIncomeLoss>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">54100</avxl:NonOperatingIncomeFromGrants>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">149888</avxl:NonOperatingIncomeFromGrants>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">3323011</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">4547099</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">4375025</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">946988</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">26261</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">179973</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-903611</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-267344</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">125540</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">3366388</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">4360116</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">4830426</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-47619427</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-37641069</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-26257806</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">358492</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">267565</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">22664</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <avxl:NetLossAndComprehensiveLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-47977919</avxl:NetLossAndComprehensiveLoss>
    <avxl:NetLossAndComprehensiveLoss
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-37908634</avxl:NetLossAndComprehensiveLoss>
    <avxl:NetLossAndComprehensiveLoss
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-26280470</avxl:NetLossAndComprehensiveLoss>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.62</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2020-10-012021-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.54</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2019-10-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.45</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      unitRef="USDPShares">76909993</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2020-10-012021-09-30"
      decimals="INF"
      unitRef="USDPShares">69802960</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2019-10-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">58194894</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-47977919</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-37908634</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-26280470</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">18379242</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">8231403</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">4876906</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-5944251</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">4287491</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">2206595</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-1387</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-88290</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-57159</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-915004</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">750727</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">465722</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">330179</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">2298200</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">1800232</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <avxl:DeferredGrantIncomes
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-443831</avxl:DeferredGrantIncomes>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-24237864</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-30383674</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-21287046</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">20984667</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">153218762</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">28754198</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">706877</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">5550921</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">403764</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">1466500</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">1010190</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">4108060</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">21287980</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">153242401</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">28350434</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-2949884</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">122858727</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">7063388</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:Cash contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">152107745</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">29249018</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">22185630</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">149157861</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">152107745</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">29249018</us-gaap:Cash>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">326903</avxl:CashPaidForStateAndLocalMinimumIncomeTaxes>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">139531</avxl:CashPaidForStateAndLocalMinimumIncomeTaxes>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">22664</avxl:CashPaidForStateAndLocalMinimumIncomeTaxes>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">52650521</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">52652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">153633807</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-133396760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">20289699</us-gaap:StockholdersEquity>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7564584</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7565</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">21246733</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">21254298</us-gaap:StockRepurchasedDuringPeriodValue>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">68943</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">69</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-69</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:SharesIssuedPursuantToCashlessExerciseOptionInShares
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">721</avxl:SharesIssuedPursuantToCashlessExerciseOptionInShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1</avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="INF"
      unitRef="Shares">-1</avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares>
    <avxl:SharesIssuedUnderSalesAgreementInShares
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1760429</avxl:SharesIssuedUnderSalesAgreementInShares>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1760</avxl:SharesIssuedUnderSalesAgreement>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">7498140</avxl:SharesIssuedUnderSalesAgreement>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">7499900</avxl:SharesIssuedUnderSalesAgreement>
    <avxl:LessShareIssueCosts
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-403764</avxl:LessShareIssueCosts>
    <avxl:LessShareIssueCosts
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-403764</avxl:LessShareIssueCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4876906</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">4876906</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-26280470</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-26280470</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">62045198</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">62047</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">186851752</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-159677230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">27236569</us-gaap:StockholdersEquity>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4007996</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4008</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">24107190</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">24111198</us-gaap:StockRepurchasedDuringPeriodValue>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">78213</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">78</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-78</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1421529</avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1421</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4106639</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">4108060</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedUnderSalesAgreementInShares
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5634576</avxl:SharesIssuedUnderSalesAgreementInShares>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5635</avxl:SharesIssuedUnderSalesAgreement>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">79101915</avxl:SharesIssuedUnderSalesAgreement>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">79107550</avxl:SharesIssuedUnderSalesAgreement>
    <avxl:LessShareIssueCosts
      contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-2437523</avxl:LessShareIssueCosts>
    <avxl:LessShareIssueCosts
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-2437523</avxl:LessShareIssueCosts>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingInShares
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2380953</avxl:SharesIssuedPursuantToRegisteredDirectOfferingInShares>
    <avxl:SharesIssuedPursuantToRegisteredDirectOffering
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2381</avxl:SharesIssuedPursuantToRegisteredDirectOffering>
    <avxl:SharesIssuedPursuantToRegisteredDirectOffering
      contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">49997632</avxl:SharesIssuedPursuantToRegisteredDirectOffering>
    <avxl:SharesIssuedPursuantToRegisteredDirectOffering
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">50000013</avxl:SharesIssuedPursuantToRegisteredDirectOffering>
    <avxl:LessSharesIssueCosts
      contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-3097032</avxl:LessSharesIssueCosts>
    <avxl:LessSharesIssueCosts
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-3097032</avxl:LessSharesIssueCosts>
    <avxl:SharesIssuedPusuantToExerciseOfWarrantsInShares
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">350000</avxl:SharesIssuedPusuantToExerciseOfWarrantsInShares>
    <avxl:SharesIssuedPusuantToExerciseOfWarrants
      contextRef="From2020-10-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">350</avxl:SharesIssuedPusuantToExerciseOfWarrants>
    <avxl:SharesIssuedPusuantToExerciseOfWarrants
      contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1466150</avxl:SharesIssuedPusuantToExerciseOfWarrants>
    <avxl:SharesIssuedPusuantToExerciseOfWarrants
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">1466500</avxl:SharesIssuedPusuantToExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8231403</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">8231403</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-37908634</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-37908634</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75918465</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">348328048</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-197585864</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">150818104</us-gaap:StockholdersEquity>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares
      contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">400537</avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">401</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1009789</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">1010190</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedUnderSalesAgreementInShares
      contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1623813</avxl:SharesIssuedUnderSalesAgreementInShares>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2021-10-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1623</avxl:SharesIssuedUnderSalesAgreement>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2021-10-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">20983044</avxl:SharesIssuedUnderSalesAgreement>
    <avxl:SharesIssuedUnderSalesAgreement
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">20984667</avxl:SharesIssuedUnderSalesAgreement>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-723242</avxl:LessShareIssueCosts>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-723242</avxl:LessShareIssueCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18379242</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">18379242</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-47977919</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-47977919</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77942815</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77944</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">387976881</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-245563783</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142491042</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zF7GK65rrkwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Note 1 	&lt;span id="xdx_826_zTGyf9kqqwe9"&gt;Business Description and Basis of Presentation&lt;/span&gt;
&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Anavex Life Sciences Corp. (&#x201c;Anavex&#x201d; or
the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#x201c;CNS&#x201d;) diseases with high unmet need. Anavex analyzes genomic data
from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment
of neurodegenerative and neurodevelopmental diseases. The Company&#x2019;s lead compound ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 is being developed
to treat Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease and potentially other central nervous system diseases, including rare diseases,
such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein
2 (&#x201c;MECP2&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and the instructions to Form
10-K and have been prepared under the accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the Company&#x2019;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sale or generate commercial revenues. To date, we have not
generated any revenues from our operations. The Company expects the business to continue to experience negative cash flows for the foreseeable
future and cannot predict when, if ever, its business might become profitable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
is uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The
actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development programs and the level of
financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future
clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the Sales Agreement
(as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if available,
that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on a timely basis,
if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Coronavirus Disease 2019 (COVID-19)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The recent global outbreak of COVID-19 did not have
a material impact on the Company&#x2019;s result of operations or financial condition for the year ended September 30, 2022. However,
the future course of the pandemic could have adverse effects in the U.S and global economies and thus negatively impact our business
and financial results.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_z67hzn4v1sKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 2	&lt;span id="xdx_82F_zNxE6e33dQI4"&gt;Summary of Significant Accounting Policies&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--UseOfEstimates_z8gKMmY1HLRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zWG3EmOoh2sk"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the
basis for making judgments about the book values of assets and liabilities and the accrual of costs and expenses that are not readily
apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zJ2MdZ71Dy5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zIuhEHzP31n6"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly owned subsidiaries, Anavex Australia Pty Limited. (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6tEegO9VsS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z0JMPFdEJVJc"&gt;Cash and equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span&gt;The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#x2019;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains its investments at one large well known financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20220930_zInmgKI67LC4" title="Federal Deposit Insurance Corporation"&gt;250,000&lt;/span&gt;, under current regulations. At September 30, 2022 and 2021, substantially
all of the Company&#x2019;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zr6NvoPtLvGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_z8Kq4tFCNR84"&gt;Research and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#x2019;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and stock-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#x201c;CROs&#x201d;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#x201c;ASC&#x201d;) 730, Research and Development, as these materials have no alternative future use outside of their intended use.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the studies including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are
made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates.
The Company&#x2019;s historical accrual estimates have not been materially different from actual costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--RevenueRecognitionIncentives_zsVE6ZiohaM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zTbyIPlIwXve"&gt;Research and Development Incentive Income&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is eligible to obtain certain research
and development tax credits, including the Australian research and development tax incentive credit (the &#x201c;Australia R&amp;amp;D credit&#x201d;)
through a program administered through the Australian Tax Office (the &#x201c;ATO&#x201d;) and AusIndustry, a division of the Australian
Government&#x2019;s Department of Industry, Innovation and Science (&#x201c;AusIndustry&#x201d;), which provides for a cash refund based
on a percentage of eligible research and development activities undertaken in Australia by the Company&#x2019;s wholly owned subsidiary,
Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;amp;D credit program to receive the cash refund for certain
research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by AusIndustry
pursuant to an advanced overseas finding application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Australia R&amp;amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, Income Taxes (&#x201c;ASC 740&#x201d;), since the incentives are
not linked to the Company&#x2019;s taxable income and can be realized regardless of whether the Company has generated taxable income in
the respective jurisdictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With respect to the Australia R&amp;amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 &lt;i&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/i&gt; (&#x201c;IAS 20&#x201d;). The Company
recognizes the Research and Development Incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;amp;D credit
Program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#x2019;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zyGAkxtLqYfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zwn8BSjXghg8"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2022, diluted loss per share excludes
&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220930_pdd" title="Loss per share for potentially dilutive common shares"&gt;13,329,616&lt;/span&gt; potentially dilutive common shares (2021 &#x2013; diluted loss per share excludes &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930_zIjvlIpEANY8" title="Loss per share for potentially dilutive common shares"&gt;11,540,903&lt;/span&gt; potentially dilutive common shares;
2020 &#x2013; diluted loss per share excludes &lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20191001__20200930_zXI5VTYcTPKf" title="Loss per share for potentially dilutive common shares"&gt;10,576,266&lt;/span&gt; potentially dilutive common shares) related to outstanding options and warrants,
as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zSS2UperrY14" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zc95zI2r0ta8"&gt;Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The book value of the Company&#x2019;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#x2019;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zJYZsysB1fQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zcmI4X4oLBB1"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zAaQa43BTZQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zkULV6MVVQV1"&gt;Segment and Geographic Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating segments are defined as components of an
enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making
group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as
one operating segment, which is the business of developing novel therapies for the management of CNS diseases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--GrantIncomePolicyTextBlock_ziGpSNcmT4Pc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zrBFYtQohVki"&gt;Grant Income&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statement of operations
in the period they are earned and when the related research and development costs are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zCmmKHc71zg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z1zXqEoNhwOj"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the provisions of ASC
740 regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements
when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are
initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon
ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts. Application requires
numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions
and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional
information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic
adjustments may have a material impact on the consolidated statements of operations. At September 30, 2022 the Company did &lt;span id="xdx_905_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20220930_zFBUlap6tPSl" title="Uncertain tax positions"&gt;no&lt;/span&gt;t
have any uncertain tax positions.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes interest and penalties
related to current income tax expense on the interest income, net line, in the accompanying consolidated statement of operations.
Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets. There were &lt;span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20211001__20220930_z9D7qWr5ILXe" title="Interest and penalties"&gt;&lt;span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20201001__20210930_zc3co7wNJLWg" title="Interest and penalties"&gt;no&lt;/span&gt;&lt;/span&gt;
interest and penalties related to current income tax expense during the years ended September 30, 2022, 2021 and 2020.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zWB35jw4KtT" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zcoUScD6bzFe"&gt;Stock-based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for all stock-based payments
and awards under the fair value method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of all share purchase options and warrants
are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected to
vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Compensation costs for stock-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the Black-Scholes option valuation
model to calculate the fair value of share purchase options and warrants at the date of the grant. This model requires the input of subjective
assumptions, including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury
yield curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted
are expected to be outstanding using the simplified method. The Company&#x2019;s historical share option exercise experience does not provide
a reasonable basis for estimating the expected term. Expected volatility is based on the average of the daily share price changes over
the expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not
paid any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions
consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#x2019;s judgment.
Changes in these assumptions can materially affect the fair value estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The purchase price of options or warrants may be paid
in cash or, if approved by the Company&#x2019;s compensation committee in advance, &#x201c;net settled&#x201d; in shares of the Company&#x2019;s
common stock. In a net settlement of an option or warrant, the Company does not receive payment of the exercise price from the holder
but reduces the number of shares of common stock issued upon the exercise of the stock option or warrant by the smallest number of whole
shares that have an aggregate fair market value equal to or over the aggregate exercise price for the option shares covered by the option
or warrant exercised. Shares issued pursuant to the exercise of options and warrants are issued from the Company&#x2019;s treasury.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zaRnwuPwOpr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zge762DQGdy1"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2022 and 2021, the Company did not
have any Level 2 or Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zkvzJbYcbfqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zwDAbvay2cOh"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective October 1, 2021, the Company adopted Accounting
Standards Update (&#x201c;ASU&#x201d;) 2019-12, &#x201c;Simplifying the Accounting for Income Taxes (ASC 740)&#x201d;, which is intended to
simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740
and clarifying and amending existing guidance to improve consistent application. There was no material impact on the Company&#x2019;s operations,
financial condition, or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2021, the Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) issued ASU&#160;2021-10, &#x201c;Government Assistance (Topic 832): Disclosures by Business Entities about Government
Assistance&#x201d; (&#x201c;ASU&#160;2021-10&#x201d;). ASU&#160;2021-10&#160;increases the transparency of government assistance including
the disclosure of (1) the types of assistance, (2) an entity&#x2019;s accounting for the assistance, and (3) the effect of the assistance
on an entity&#x2019;s financial statements. ASU&#160;2021-10&#160;is effective for fiscal years beginning after December 15, 2021, with
early adoption permitted. Upon implementation, the Company may use either a prospective or retrospective method of adoption when adopting
the ASU. The adoption of ASU 2021-10 will impact the disclosures related to the research and development incentive income that the Company
receives from the ATO for its clinical trials in Australia. The Company currently plans to adopt the provisions of this ASU on October
1, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_849_eus-gaap--UseOfEstimates_z8gKMmY1HLRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zWG3EmOoh2sk"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the
basis for making judgments about the book values of assets and liabilities and the accrual of costs and expenses that are not readily
apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zJ2MdZ71Dy5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zIuhEHzP31n6"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly owned subsidiaries, Anavex Australia Pty Limited. (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6tEegO9VsS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z0JMPFdEJVJc"&gt;Cash and equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span&gt;The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#x2019;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains its investments at one large well known financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20220930_zInmgKI67LC4" title="Federal Deposit Insurance Corporation"&gt;250,000&lt;/span&gt;, under current regulations. At September 30, 2022 and 2021, substantially
all of the Company&#x2019;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zr6NvoPtLvGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_z8Kq4tFCNR84"&gt;Research and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#x2019;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and stock-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#x201c;CROs&#x201d;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#x201c;ASC&#x201d;) 730, Research and Development, as these materials have no alternative future use outside of their intended use.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the studies including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are
made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates.
The Company&#x2019;s historical accrual estimates have not been materially different from actual costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionIncentives contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_849_eus-gaap--RevenueRecognitionIncentives_zsVE6ZiohaM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zTbyIPlIwXve"&gt;Research and Development Incentive Income&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is eligible to obtain certain research
and development tax credits, including the Australian research and development tax incentive credit (the &#x201c;Australia R&amp;amp;D credit&#x201d;)
through a program administered through the Australian Tax Office (the &#x201c;ATO&#x201d;) and AusIndustry, a division of the Australian
Government&#x2019;s Department of Industry, Innovation and Science (&#x201c;AusIndustry&#x201d;), which provides for a cash refund based
on a percentage of eligible research and development activities undertaken in Australia by the Company&#x2019;s wholly owned subsidiary,
Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;amp;D credit program to receive the cash refund for certain
research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by AusIndustry
pursuant to an advanced overseas finding application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Australia R&amp;amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, Income Taxes (&#x201c;ASC 740&#x201d;), since the incentives are
not linked to the Company&#x2019;s taxable income and can be realized regardless of whether the Company has generated taxable income in
the respective jurisdictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With respect to the Australia R&amp;amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 &lt;i&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/i&gt; (&#x201c;IAS 20&#x201d;). The Company
recognizes the Research and Development Incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;amp;D credit
Program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#x2019;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionIncentives>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zyGAkxtLqYfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zwn8BSjXghg8"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2022, diluted loss per share excludes
&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220930_pdd" title="Loss per share for potentially dilutive common shares"&gt;13,329,616&lt;/span&gt; potentially dilutive common shares (2021 &#x2013; diluted loss per share excludes &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930_zIjvlIpEANY8" title="Loss per share for potentially dilutive common shares"&gt;11,540,903&lt;/span&gt; potentially dilutive common shares;
2020 &#x2013; diluted loss per share excludes &lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20191001__20200930_zXI5VTYcTPKf" title="Loss per share for potentially dilutive common shares"&gt;10,576,266&lt;/span&gt; potentially dilutive common shares) related to outstanding options and warrants,
as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      unitRef="Shares">13329616</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-10-012021-09-30"
      decimals="INF"
      unitRef="Shares">11540903</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-10-012020-09-30"
      decimals="INF"
      unitRef="Shares">10576266</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zSS2UperrY14" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zc95zI2r0ta8"&gt;Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The book value of the Company&#x2019;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#x2019;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zJYZsysB1fQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zcmI4X4oLBB1"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zAaQa43BTZQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zkULV6MVVQV1"&gt;Segment and Geographic Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating segments are defined as components of an
enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making
group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as
one operating segment, which is the business of developing novel therapies for the management of CNS diseases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <avxl:GrantIncomePolicyTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_843_ecustom--GrantIncomePolicyTextBlock_ziGpSNcmT4Pc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zrBFYtQohVki"&gt;Grant Income&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statement of operations
in the period they are earned and when the related research and development costs are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:GrantIncomePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zCmmKHc71zg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z1zXqEoNhwOj"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the provisions of ASC
740 regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements
when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are
initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon
ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts. Application requires
numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions
and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional
information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic
adjustments may have a material impact on the consolidated statements of operations. At September 30, 2022 the Company did &lt;span id="xdx_905_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20220930_zFBUlap6tPSl" title="Uncertain tax positions"&gt;no&lt;/span&gt;t
have any uncertain tax positions.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes interest and penalties
related to current income tax expense on the interest income, net line, in the accompanying consolidated statement of operations.
Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets. There were &lt;span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20211001__20220930_z9D7qWr5ILXe" title="Interest and penalties"&gt;&lt;span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_do_c20201001__20210930_zc3co7wNJLWg" title="Interest and penalties"&gt;no&lt;/span&gt;&lt;/span&gt;
interest and penalties related to current income tax expense during the years ended September 30, 2022, 2021 and 2020.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zWB35jw4KtT" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zcoUScD6bzFe"&gt;Stock-based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for all stock-based payments
and awards under the fair value method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of all share purchase options and warrants
are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected to
vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Compensation costs for stock-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the Black-Scholes option valuation
model to calculate the fair value of share purchase options and warrants at the date of the grant. This model requires the input of subjective
assumptions, including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury
yield curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted
are expected to be outstanding using the simplified method. The Company&#x2019;s historical share option exercise experience does not provide
a reasonable basis for estimating the expected term. Expected volatility is based on the average of the daily share price changes over
the expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not
paid any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions
consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#x2019;s judgment.
Changes in these assumptions can materially affect the fair value estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The purchase price of options or warrants may be paid
in cash or, if approved by the Company&#x2019;s compensation committee in advance, &#x201c;net settled&#x201d; in shares of the Company&#x2019;s
common stock. In a net settlement of an option or warrant, the Company does not receive payment of the exercise price from the holder
but reduces the number of shares of common stock issued upon the exercise of the stock option or warrant by the smallest number of whole
shares that have an aggregate fair market value equal to or over the aggregate exercise price for the option shares covered by the option
or warrant exercised. Shares issued pursuant to the exercise of options and warrants are issued from the Company&#x2019;s treasury.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

</us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zaRnwuPwOpr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zge762DQGdy1"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2022 and 2021, the Company did not
have any Level 2 or Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zkvzJbYcbfqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zwDAbvay2cOh"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective October 1, 2021, the Company adopted Accounting
Standards Update (&#x201c;ASU&#x201d;) 2019-12, &#x201c;Simplifying the Accounting for Income Taxes (ASC 740)&#x201d;, which is intended to
simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740
and clarifying and amending existing guidance to improve consistent application. There was no material impact on the Company&#x2019;s operations,
financial condition, or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2021, the Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) issued ASU&#160;2021-10, &#x201c;Government Assistance (Topic 832): Disclosures by Business Entities about Government
Assistance&#x201d; (&#x201c;ASU&#160;2021-10&#x201d;). ASU&#160;2021-10&#160;increases the transparency of government assistance including
the disclosure of (1) the types of assistance, (2) an entity&#x2019;s accounting for the assistance, and (3) the effect of the assistance
on an entity&#x2019;s financial statements. ASU&#160;2021-10&#160;is effective for fiscal years beginning after December 15, 2021, with
early adoption permitted. Upon implementation, the Company may use either a prospective or retrospective method of adoption when adopting
the ASU. The adoption of ASU 2021-10 will impact the disclosures related to the research and development incentive income that the Company
receives from the ATO for its clinical trials in Australia. The Company currently plans to adopt the provisions of this ASU on October
1, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:AccuredLiabilitiesTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_801_ecustom--AccuredLiabilitiesTextBlock_z3o5phRPO5A4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 3	&lt;span id="xdx_828_zfXvANdGyVfa"&gt;Accrued Liabilities&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The principal components of accrued liabilities consist of:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zdAM0DDAypG6" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zZ9g3MhxkYHd" style="display: none"&gt;Schedule of components of accrued liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20220930_zCsJnLHVGyn1" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20210930_zH7qnVnSgIg" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--ClinicalSiteCostsAndPatientVisits_iI_pp0p0_maALCzi8D_zKCvwFUb29Yb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued clinical site and patient visits costs&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,031,105&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,035,800&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCzi8D_z59IhkWemSt2" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,297,337&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,201,903&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--FixedContractAccruals_iI_pp0p0_maALCzi8D_z82jvbG5jm9k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fixed contract accruals&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;417,414&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;649,649&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzi8D_zj7ZweeM9CA8" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All other accrued liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,199,097&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,727,422&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzi8D_zkbmpaxQjJBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 2.5pt 10pt; font-size: 10pt; text-indent: -10pt"&gt;&lt;span style="color: rgb(204,238,255); font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,944,953&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,614,774&lt;/span&gt;&lt;span style="font-family: Symbol; font-size: 10pt"/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Symbol"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.3pt"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.3pt"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 21.3pt"/&gt;

</avxl:AccuredLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2021-10-01to2022-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zdAM0DDAypG6" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zZ9g3MhxkYHd" style="display: none"&gt;Schedule of components of accrued liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20220930_zCsJnLHVGyn1" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20210930_zH7qnVnSgIg" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--ClinicalSiteCostsAndPatientVisits_iI_pp0p0_maALCzi8D_zKCvwFUb29Yb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued clinical site and patient visits costs&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,031,105&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,035,800&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCzi8D_z59IhkWemSt2" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,297,337&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,201,903&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--FixedContractAccruals_iI_pp0p0_maALCzi8D_z82jvbG5jm9k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fixed contract accruals&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;417,414&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;649,649&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzi8D_zj7ZweeM9CA8" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All other accrued liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,199,097&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,727,422&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzi8D_zkbmpaxQjJBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 2.5pt 10pt; font-size: 10pt; text-indent: -10pt"&gt;&lt;span style="color: rgb(204,238,255); font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,944,953&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,614,774&lt;/span&gt;&lt;span style="font-family: Symbol; font-size: 10pt"/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Symbol"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avxl:ClinicalSiteCostsAndPatientVisits contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">2031105</avxl:ClinicalSiteCostsAndPatientVisits>
    <avxl:ClinicalSiteCostsAndPatientVisits contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2035800</avxl:ClinicalSiteCostsAndPatientVisits>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">1297337</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1201903</us-gaap:AccruedBonusesCurrent>
    <avxl:FixedContractAccruals contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">417414</avxl:FixedContractAccruals>
    <avxl:FixedContractAccruals contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">649649</avxl:FixedContractAccruals>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">2199097</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1727422</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">5944953</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">5614774</us-gaap:AccruedLiabilitiesCurrent>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_80B_ecustom--OtherIncomeDisclosureTextBlock_zU3cSb79ifBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 4	&lt;span id="xdx_826_zJZEI4e9LGY5"&gt;Other Income&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Grant income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;During the year ended September
30, 2022, the Company received $&lt;span id="xdx_905_ecustom--GrantIncome_pp0p0_c20211001__20220930_z2u92HMuICM4" title="Grant income"&gt;0&lt;/span&gt; (2021: $&lt;span id="xdx_906_ecustom--GrantIncome_pp0p0_c20201001__20210930_zPN81FvQohqg" title="Grant income"&gt;497,931&lt;/span&gt;; 2020: $&lt;span id="xdx_90F_ecustom--GrantIncome_pp0p0_c20191001__20200930_zku1wbrapr6i" title="Grant income"&gt;0&lt;/span&gt;) of a $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_pp0p0" title="Research and development incentive income"&gt;&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_pp0p0" title="Research and development incentive income"&gt;995,862&lt;/span&gt;&lt;/span&gt; research grant awarded during the year ended September 30,
2021, by the Michael J. Fox Foundation for Parkinson&#x2019;s Research. The grant will be used to fund a clinical trial of the Company&#x2019;s
lead compound, ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 related to Parkinson&#x2019;s disease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The grant income is
being deferred when received and amortized to other income as the related research and development expenditures are incurred. During
the year ended September 30, 2022, the Company recognized $Nil &lt;span id="xdx_90B_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20211001__20220930_zs56r1Fw9Vr4" style="display: none" title="Grant income"&gt;0&lt;/span&gt; (2021: $&lt;span id="xdx_902_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20201001__20210930_z4xGVkmSgWOf" title="Grant income"&gt;54,100&lt;/span&gt;; 2020: $Nil &lt;span id="xdx_905_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20191001__20200930_zpOtF977WMD2" style="display: none" title="Grant income"&gt;0&lt;/span&gt;) of this grant on its statements of
operations within grant income. At September 30, 2022 an amount of $&lt;span id="xdx_905_ecustom--DeferredGrantIncome_iI_pp0p0_c20220930_zHSY1Kqy6NPc" title="Deferred grant income"&gt;443,831&lt;/span&gt; (2021: $&lt;span id="xdx_90F_ecustom--DeferredGrantIncome_iI_pp0p0_c20210930_zlZsniCllbk3" title="Deferred grant income"&gt;443,831&lt;/span&gt;) of this grant is recorded as deferred
grant income, representing the amount of this grant which has not yet been amortized to other income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;During the year ended September
30, 2017, the Company was awarded grant funding in the amount of $&lt;span id="xdx_90A_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20161001__20170930_zRusqhsKmkb4" title="Grant income"&gt;597,886&lt;/span&gt;. The grant was received in equal quarterly installments over
a period of two years ending during the year ended September 30, 2020, in exchange for a commitment to complete clinical testing for a
therapeutic drug candidate for the treatment of Rett syndrome.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The grant income was deferred
when received and amortized to other income as the related research and development expenditures were incurred. During the year ended
September 30, 2020, the Company recognized $&lt;span id="xdx_901_ecustom--NonOperatingsIncomeFromGrant_pp0p0_c20191001__20200930_zLTqt7UR3fJf" title="Grant income"&gt;149,888&lt;/span&gt; of this grant on its statement of operations as a component of other income. At September
30, 2020, the Company had recognized the full amount of grant funding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Research and development
incentive income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Research and development
incentive income represents income earned by the Company&#x2019;s Australian subsidiary, of the Australian research and development tax
incentive credit (the &#x201c;tax incentive credit&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;During the year ended September
30, 2022, the Company recorded research and development incentive income of $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20220930_zptCGi3Wu2o8" title="Research and development incentive income"&gt;3,323,011&lt;/span&gt; (AUD &lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220930__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;4,468,246&lt;/span&gt;) (2021: $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930_zENzyy82PQGf" title="Research and development incentive income"&gt;4,547,099&lt;/span&gt; (AUD &lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930__srt--CurrencyAxis__currency--AUD_zju0evbwj6P7" title="Research and development incentive income"&gt;6,068,993&lt;/span&gt;);
2020: $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20191001__20200930_zu5JJvjaShHi" title="Research and development incentive income"&gt;4,375,025&lt;/span&gt; (AUD &lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20191001__20200930__srt--CurrencyAxis__currency--AUD_zCsdgTDf7xQg" title="Research and development incentive income"&gt;6,392,266&lt;/span&gt;)) in respect of the tax incentive credit for eligible research and development expenses incurred during
the year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company evaluates its
eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant data available. Although
the Company believes that it complies with all the relevant conditions of the program, as a matter of course, the Company may be subject
to pre-issue review or audit by the ATO and, the ATO may have different interpretations of certain eligibility requirements. Currently,
the Company&#x2019;s tax incentive claims from 2018 to 2022 are open to potential review or audit by the ATO.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <avxl:GrantIncome
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">0</avxl:GrantIncome>
    <avxl:GrantIncome
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">497931</avxl:GrantIncome>
    <avxl:GrantIncome
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">0</avxl:GrantIncome>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-09-30_custom_MichaelJFoxMember"
      decimals="0"
      unitRef="USD">995862</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-09-30_custom_ParkinsonMember"
      decimals="0"
      unitRef="USD">995862</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">54100</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:DeferredGrantIncome contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">443831</avxl:DeferredGrantIncome>
    <avxl:DeferredGrantIncome contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">443831</avxl:DeferredGrantIncome>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2016-10-012017-09-30"
      decimals="0"
      unitRef="USD">597886</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingsIncomeFromGrant
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">149888</avxl:NonOperatingsIncomeFromGrant>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">3323011</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-012022-09-30_currency_AUD"
      decimals="0"
      unitRef="USD">4468246</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">4547099</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-09-30_currency_AUD"
      decimals="0"
      unitRef="USD">6068993</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">4375025</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2019-10-012020-09-30_currency_AUD"
      decimals="0"
      unitRef="USD">6392266</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:EquityOfferingAgreementsTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_80D_ecustom--EquityOfferingAgreementsTextBlock_zcZ20XPeqUm" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 5	&lt;span id="xdx_820_zV2n9mdJ9cu8"&gt;Equity Offerings&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Tahoma, Helvetica, Sans-Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s Board of Directors&#160;(the &#x201c;Board&#x201d;)&#160;has
the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number
of shares constituting any series or the designation of the series.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Registered Direct Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 22, 2021, the Company and Deep Track Capital
entered into a securities purchase agreement pursuant to which the Company sold to Deep Track Capital an aggregate of 2,380,953 shares
of common stock at $21 per share in a registered direct offering, for gross proceeds of $50,000,013. Net proceeds of the offering were
$46,902,981 after deducting offering fees and expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sales Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald&#160;&amp;amp;
Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;), pursuant to which the Company may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#x201c;Offering&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon delivery of a placement notice based on the Company&#x2019;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#x201c;at the market offering&#x201d; offering, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company
or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales
Agents will act as agents on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has agreed to pay the Sales Agents
commissions for their services of up to &lt;span id="xdx_908_ecustom--PercentageOfGrossProceedsFromSales_dp_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zjzDU1V5j2fd" title="Percentage of gross proceeds from sales"&gt;3.0&lt;/span&gt;%
of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed to provide the Sales
Agents with customary indemnification and contribution rights. During the year ended September 30, 2022, &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold"&gt;1,623,813&lt;/span&gt;
shares were sold pursuant to the Offering for gross proceeds of $&lt;span id="xdx_90E_ecustom--GrossProceedsFromIssuancePublicOffering_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from Issuance Public Offering"&gt;20,984,667&lt;/span&gt;
(net proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211001__20220930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceeds from Issuance Public Offering"&gt;20,261,425&lt;/span&gt;
after deducting offering expenses) (2021: &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold"&gt;5,634,576&lt;/span&gt;
shares were sold for gross proceeds of $&lt;span id="xdx_90C_ecustom--GrossProceedsFromIssuancePublicOffering_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from Issuance Public Offering"&gt;79,107,550&lt;/span&gt;,
net proceeds of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceeds from Issuance Public Offering"&gt;76,670,027&lt;/span&gt;;
2020: &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zrSONM0rgtk4" title="Number of common stock sold"&gt;1,760,429&lt;/span&gt;
shares were sold for gross proceeds of $&lt;span id="xdx_901_ecustom--GrossProceedsFromIssuancePublicOffering_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zFBrcYjWPI8k" title="Gross proceeds from Issuance Public Offering"&gt;7,499,900&lt;/span&gt;,
net proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zkxflyK1y5Ye" title="Proceeds from Issuance Public Offering"&gt;7,096,136&lt;/span&gt;).
At September 30, 2022, an amount of $&lt;span id="xdx_90B_ecustom--SalesOfAgreementAmount_c20220930_pp0p0" title="Sales of agreement amount"&gt;142,407,882&lt;/span&gt;
(2021: $&lt;span id="xdx_90A_ecustom--SalesOfAgreementAmount_c20210930_pp0p0" title="Sales of agreement amount"&gt;163,392,550&lt;/span&gt;)
was registered pursuant to an effective registration statement and available to be sold under the Sales Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2019 Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 7, 2019, the Company entered into a $50,000,000
purchase agreement (the &#x201c;2019 Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;), as amended
on July 1, 2020, pursuant to which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase,
up to $&lt;span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Value of shares obligated to purchase"&gt;50,000,000&lt;/span&gt; in value of its shares of common stock from time to time over a three-year period until July 1, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In consideration for entering into the 2019 Purchase
Agreement, the Company issued to Lincoln Park &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"&gt;324,383&lt;/span&gt; shares of common stock as a commitment fee during the year ended September 30, 2019
and agreed to issue up to &lt;span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Pro rata basic number of shares obligated to purchase"&gt;162,191&lt;/span&gt; shares pro rata, when and if, Lincoln Park purchased, at the Company&#x2019;s discretion, the $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity"&gt;50,000,000&lt;/span&gt;
aggregate commitment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2022, the Company
did not issue any shares to Lincoln Park under the 2019 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2021, the Company
issued to Lincoln Park an aggregate of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zv73hCO6Jap9" title="Share issued for offering, shares"&gt;4,086,209&lt;/span&gt; (2020: &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zs5ERxvfL3Xc" title="Share issued for offering, shares"&gt;7,633,527&lt;/span&gt;) shares of common stock under the 2019 Purchase Agreement, including
&lt;span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zB4Lseqfa8A2" title="Number of shares issued for aggregate purchase price"&gt;4,007,996&lt;/span&gt; (2020: &lt;span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zIXAwXdBBgvl" title="Number of shares issued for aggregate purchase price"&gt;7,564,584&lt;/span&gt;) shares of common stock for an aggregate purchase price of $&lt;span id="xdx_90B_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zMvbCtQkjOKk" title="Number of shares issued for aggregate purchase price, value"&gt;24,111,198&lt;/span&gt; (2020: $&lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEfYfoeymscg" title="Number of shares issued for aggregate purchase price, value"&gt;21,254,298&lt;/span&gt;) and &lt;span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zQDyDlyELEhf" title="Number of shares issued for commitment"&gt;78,213&lt;/span&gt; (2020:
&lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zyEtCT6Ix1Zb" title="Number of shares issued for commitment"&gt;68,943&lt;/span&gt;) commitment shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2022 and 2021, &lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_do_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgFGX2CFruQ1" title="Amount of shares remain available"&gt;no&lt;/span&gt; shares remained
available for issuance under the 2019 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:EquityOfferingAgreementsTextBlock>
    <avxl:PercentageOfGrossProceedsFromSales
      contextRef="From2021-10-012022-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Pure">0.030</avxl:PercentageOfGrossProceedsFromSales>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-10-012022-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">1623813</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <avxl:GrossProceedsFromIssuancePublicOffering
      contextRef="From2021-10-012022-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">20984667</avxl:GrossProceedsFromIssuancePublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-10-012022-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">20261425</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">5634576</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <avxl:GrossProceedsFromIssuancePublicOffering
      contextRef="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">79107550</avxl:GrossProceedsFromIssuancePublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">76670027</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">1760429</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <avxl:GrossProceedsFromIssuancePublicOffering
      contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">7499900</avxl:GrossProceedsFromIssuancePublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">7096136</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <avxl:SalesOfAgreementAmount contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142407882</avxl:SalesOfAgreementAmount>
    <avxl:SalesOfAgreementAmount contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">163392550</avxl:SalesOfAgreementAmount>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">324383</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">162191</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">4086209</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">7633527</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">4007996</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">7564584</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">24111198</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">21254298</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">78213</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">68943</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">0</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_809_eus-gaap--CommitmentsDisclosureTextBlock_zEUxRjYnMXo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 6	&lt;span id="xdx_82C_zHFA39oBUbW2"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;During
the year ended September 30, 2022, the Company incurred office lease expense of $&lt;span id="xdx_909_eus-gaap--LeaseAndRentalExpense_c20211001__20220930_pp0p0" title="Operating Leases, Rent Expense"&gt;72,865&lt;/span&gt; (2021: $&lt;span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20201001__20210930_pp0p0" title="Operating Leases, Rent Expense"&gt;130,784&lt;/span&gt;; 2020: $&lt;span id="xdx_904_eus-gaap--LeaseAndRentalExpense_pp0p0_c20191001__20200930_zU59dp2F0LJ2" title="Operating Leases, Rent Expense"&gt;233,423&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"/&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Employee 401(k) Benefit Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the
Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing
employees. During the year ended September 30, 2022, the Company made $&lt;span id="xdx_90C_eus-gaap--PensionContributions_c20211001__20220930_pp0p0" title="Contribution amount"&gt;158,112&lt;/span&gt; (2021: $&lt;span id="xdx_90A_eus-gaap--PensionContributions_c20201001__20210930_pp0p0" title="Contribution amount"&gt;128,856&lt;/span&gt;; 2020: $&lt;span id="xdx_909_eus-gaap--PensionContributions_pp0p0_c20191001__20200930_zOosKtYuwNic" title="Contribution amount"&gt;98,058&lt;/span&gt;) in matching contributions
under the 401(k) plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&#x2019;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Share Purchase Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the warrant activity
during the years ended September 30, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zrqYgJE63aq5" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_za46SsaCHP49" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="3" style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Price ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 0%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 35%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, September 30, 2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 1%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z7c7dsHrZL8i" style="width: 25%; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;210,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8KDPG7kevJf" style="width: 25%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.69&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zbeBtxvzaGg6" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(50,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.00&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, September 30, 2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zuQr9LLe9DB6" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;160,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zvXWeia4T0N2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.72&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center"/&gt;

&lt;p id="xdx_8AB_z8bGCEAnMthj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 30, 2022, the Company had share purchase
warrants outstanding as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zwOtrbAziuLf" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left"&gt;&lt;span id="xdx_8BD_zcRVkusmwtE2" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expiry Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="width: 0%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 35%; text-align: right" title="Number"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;150,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 12%; text-align: right" title="Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.17&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 40%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zLnV2zUuBYb8" title="Expiry Date"&gt;May 6, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.00&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_z6UNquRzlyx5" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;160,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center; text-indent: -0.8pt"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_8AA_zYSWPinQIxEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center; text-indent: -0.8pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock&#x2013;based Compensation
Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;2015 Stock Option Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 18, 2015, the Company&#x2019;s board of
directors approved a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;), which provided for the grant of stock options and restricted
stock awards to directors, officers, employees and consultants of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;2019 Stock Option Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2022, &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zzWOxS5qgCP" title="Option granted"&gt;406,453&lt;/span&gt;
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;2022 Stock Option Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#x201c;2022 Plan&#x201d;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Additional shares of common stock available for issuance"&gt;10,000,000&lt;/span&gt; additional shares of Common Stock will be available for issuance under the 2022 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#x2019;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. At September
30, 2022, &lt;span id="xdx_90F_ecustom--OptionIssued_c20211001__20220930_pdd" title="Option issued"&gt;2,058,000&lt;/span&gt; options had been issued under the 2022 Plan and &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"&gt;8,363,453&lt;/span&gt; options were available for issue under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock option
activity during the year ended September 30, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zxj8vJ2mgkUj" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BD_zxDXwkvCac17" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Average Grant&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1px solid; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;($)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1px solid; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;($)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;intrinsic value
    ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 0%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 24%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
                                            September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPzYUjBpavfa" style="width: 15%; text-align: right" title="Options Outstanding at beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,330,903&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2NpkNzhLGgl" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.74&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxko9TbKfx9a" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;140,132,451&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,358,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.07&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1155kjkYbq1" style="text-align: right" title="Options Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(118,750&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.86&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdEigvjic9H1" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(400,537&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.52&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,201,015&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
                                            September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znyDJZ5oimhh" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13,169,616&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFjA3B56xNq9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxkf1hOMxhv3" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;62,267,309&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable,
                                            September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,777,113&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;55,173,997&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt; text-align: justify"/&gt;

&lt;p id="xdx_8A4_z3NTfV2vEe1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock options
at September 30, 2022 by a range of exercise prices:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zyZBDTTcl3Mh" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_zwaH8kPgNzea" style="display: none"&gt;Summarizes information about stock options&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="7" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="7" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;average&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="7" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;remaining&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;average&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Range of exercise
prices&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;contractual life&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;exercise&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;exercise&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;options&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(in years)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;price ($)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;vested options&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;price ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;0.92&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.96&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zNXxIiez54p" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,903,762&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zUWDCjO2Vsv9" title="Weighted average remaining contractual life (in years)"&gt;5.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.30&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,883,345&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.30&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.15&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.80&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,078,800&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zAZpr64athib" title="Weighted average remaining contractual life (in years)"&gt;5.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.30&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,063,800&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.29&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.04&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;8.98&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,957,054&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zdl65uiwL7Ul" title="Weighted average remaining contractual life (in years)"&gt;6.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.28&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,365,387&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.31&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9.20&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;13.01&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,698,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zUVWbwYyTdDg" title="Weighted average remaining contractual life (in years)"&gt;9.58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10.50&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;109,581&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12.40&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;13.22&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;24.58&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,532,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_znKOmouiD8R" title="Weighted average remaining contractual life (in years)"&gt;8.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;18.23&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;355,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;18.66&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;13,169,616&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;8,777,113&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8AF_zBzjJBYZBh0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average per share fair value of options
vested during the year ended September 30, 2022 was $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930_z6N5VgaNTOxg" title="Weighted average grant date fair value of options vested"&gt;4.69&lt;/span&gt; (2021: $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930_pdd" title="Weighted average grant date fair value of options vested"&gt;2.54&lt;/span&gt;, 2020: $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930_zh2nDHPUCdda" title="Weighted average grant date fair value of options vested"&gt;2.55&lt;/span&gt;). At September 30, 2022, the weighted average contractual
life of options outstanding was &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zC7JTH074Ukk" title="Weighted average contractual life of options outstanding"&gt;6.4&lt;/span&gt; years (2021: &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zaEsZSlAor45" title="Weighted average contractual life of options outstanding"&gt;6.8&lt;/span&gt; years) and for options exercisable was &lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zhqdiAHZ5y49" title="Options exercisable"&gt;5.1&lt;/span&gt; years (2021: &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zpLPnSSSeGej" title="Options exercisable"&gt;5.5&lt;/span&gt; years).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#x2019;s stock for the options
that were in-the-money at September 30, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;	The Company recognized stock-based compensation
expense of $&lt;span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930_pp0p0" title="Share based compensation"&gt;18,379,242&lt;/span&gt; during the year ended September 30, 2022 (2021: $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210930_pp0p0" title="Share based compensation"&gt;8,231,403&lt;/span&gt;; 2020: $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930_zU3Qc5vKLyVl" title="Share based compensation"&gt;4,876,906&lt;/span&gt;) in connection with the issuance and
vesting 	of stock options and warrants in exchange for services. These amounts have been included in general and 	administrative
expenses and research and development expenses on the Company&#x2019;s consolidated statements of 	operations as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zRsv1hPuGVY1" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zVL7LQlGNg7d" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 11%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,129,412&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEdoL2xos1Xl" style="width: 11%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,571,335&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ziQTxjhxUGJg" style="width: 11%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,210,789&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,249,830&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zS5vl9HDS9Pj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,660,068&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zr97YiLgSPx4" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,666,117&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18,379,242&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930_zzMufGfKjIcc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,231,403&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930_z1XcI0m56cNj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,876,906&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8A2_z1aNr2eyavRd" style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An amount of approximately $&lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20220930_pp0p0" title="Remaining stock based compensation"&gt;19,032,000&lt;/span&gt; in stock-based
compensation is expected to be recorded over the remaining term 	of such options and warrants through fiscal 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of each option and
warrant award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zeaKNUmKwXb6" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zNFFdnXS3Ma4" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220930_zeZpDHresJzh" title="Risk-free interest rate"&gt;3.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20210930_zXhtykYhwUSj" title="Risk-free interest rate"&gt;0.73&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20191001__20200930_z3dmWdOI0ns9" title="Risk-free interest rate"&gt;1.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life of options (years)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220930_z6aEovXTPwa6" title="Expected life of options (years)"&gt;5.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210930_zAkG3Sccvdl" title="Expected life of options (years)"&gt;5.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200930_zL0wY6kX2d2j" title="Expected life of options (years)"&gt;5.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220930_zhztPPc8Mdk9" title="Annualized volatility"&gt;84.17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20210930_zQmgc3QlShK7" title="Annualized volatility"&gt;93.43&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20191001__20200930_zNuF8kSdMzs1" title="Annualized volatility"&gt;95.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220930_zKqoqQv2xAHf" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20210930_zuCGmjCDBG03" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20191001__20200930_zRRaloMMiN2g" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_8AC_zhPIVcNeZJQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of stock compensation charges recognized
during the years ended September 30, 2022, 2021 and 2020 was determined with reference to the quoted market price of the Company&#x2019;s
shares on the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">72865</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">130784</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">233423</us-gaap:LeaseAndRentalExpense>
    <us-gaap:PensionContributions
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">158112</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">128856</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">98058</us-gaap:PensionContributions>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2021-10-01to2022-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zrqYgJE63aq5" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_za46SsaCHP49" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="3" style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="3" style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Price ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 0%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 35%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, September 30, 2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 1%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z7c7dsHrZL8i" style="width: 25%; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;210,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8KDPG7kevJf" style="width: 25%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.69&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zbeBtxvzaGg6" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(50,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.00&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, September 30, 2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zuQr9LLe9DB6" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;160,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zvXWeia4T0N2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.72&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center"/&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">210000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">5.69</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2021-10-012022-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited
      contextRef="From2021-10-012022-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">12.00</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.72</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2021-10-01to2022-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zwOtrbAziuLf" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left"&gt;&lt;span id="xdx_8BD_zcRVkusmwtE2" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expiry Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="width: 0%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 35%; text-align: right" title="Number"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;150,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 12%; text-align: right" title="Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.17&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 40%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zLnV2zUuBYb8" title="Expiry Date"&gt;May 6, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.00&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_z6UNquRzlyx5" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220930_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;160,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: center; text-indent: -0.8pt"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-09-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="USDPShares">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2022-09-30_custom_PurchaseWarrants1Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-09-30_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2022-09-30_custom_PurchaseWarrants2Member">2026-04-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">406453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <avxl:OptionIssued
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      unitRef="Shares">2058000</avxl:OptionIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-09-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">8363453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2021-10-01to2022-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zxj8vJ2mgkUj" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BD_zxDXwkvCac17" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Average Grant&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1px solid; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;($)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1px solid; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;($)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;intrinsic value
    ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 0%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 24%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
                                            September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPzYUjBpavfa" style="width: 15%; text-align: right" title="Options Outstanding at beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,330,903&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2NpkNzhLGgl" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.74&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxko9TbKfx9a" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;140,132,451&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,358,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.07&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1155kjkYbq1" style="text-align: right" title="Options Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(118,750&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.86&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdEigvjic9H1" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(400,537&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.52&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,201,015&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
                                            September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znyDJZ5oimhh" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13,169,616&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFjA3B56xNq9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxkf1hOMxhv3" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;62,267,309&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable,
                                            September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,777,113&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;55,173,997&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt; text-align: justify"/&gt;

</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">11330903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">140132451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">2358000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">10.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">7.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">118750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.23</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">400537</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.88</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">4201015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">13169616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">62267309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">8777113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">55173997</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-10-01to2022-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zyZBDTTcl3Mh" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_zwaH8kPgNzea" style="display: none"&gt;Summarizes information about stock options&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="7" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="7" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;average&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="7" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;remaining&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;average&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Range of exercise
prices&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;contractual life&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;exercise&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;exercise&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;options&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(in years)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;price ($)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;vested options&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;price ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;0.92&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.96&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zNXxIiez54p" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,903,762&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zUWDCjO2Vsv9" title="Weighted average remaining contractual life (in years)"&gt;5.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.30&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,883,345&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.30&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.15&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.80&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,078,800&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zAZpr64athib" title="Weighted average remaining contractual life (in years)"&gt;5.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.30&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,063,800&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.29&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.04&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;8.98&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,957,054&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zdl65uiwL7Ul" title="Weighted average remaining contractual life (in years)"&gt;6.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.28&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,365,387&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.31&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9.20&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;13.01&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,698,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zUVWbwYyTdDg" title="Weighted average remaining contractual life (in years)"&gt;9.58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10.50&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;109,581&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12.40&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;13.22&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;24.58&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,532,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_znKOmouiD8R" title="Weighted average remaining contractual life (in years)"&gt;8.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;18.23&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;355,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;18.66&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;13,169,616&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;8,777,113&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.96</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="Shares">3903762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">P5Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="Shares">3883345</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">4.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="Shares">2078800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">P5Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="Shares">2063800</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">5.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">8.98</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="Shares">3957054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">6.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="Shares">2365387</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">6.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">9.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">13.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="Shares">1698000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">P9Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">10.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="Shares">109581</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">12.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">13.22</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">24.58</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="Shares">1532000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">P8Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">18.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="Shares">355000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">18.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">13169616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">8777113</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      unitRef="USDPShares">4.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-10-012021-09-30"
      decimals="INF"
      unitRef="USDPShares">2.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-10-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">2.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-01to2022-09-30">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-10-012021-09-30">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-01to2022-09-30">P5Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2020-10-012021-09-30">P5Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">18379242</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">8231403</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">4876906</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2021-10-01to2022-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zRsv1hPuGVY1" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zVL7LQlGNg7d" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 11%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,129,412&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEdoL2xos1Xl" style="width: 11%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,571,335&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ziQTxjhxUGJg" style="width: 11%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,210,789&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,249,830&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zS5vl9HDS9Pj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,660,068&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zr97YiLgSPx4" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,666,117&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18,379,242&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20201001__20210930_zzMufGfKjIcc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,231,403&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200930_z1XcI0m56cNj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,876,906&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">7129412</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">3571335</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012020-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">2210789</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">11249830</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">4660068</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012020-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2666117</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">18379242</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">8231403</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">4876906</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">19032000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-10-01to2022-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zeaKNUmKwXb6" style="font: 9.5pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zNFFdnXS3Ma4" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220930_zeZpDHresJzh" title="Risk-free interest rate"&gt;3.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20210930_zXhtykYhwUSj" title="Risk-free interest rate"&gt;0.73&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20191001__20200930_z3dmWdOI0ns9" title="Risk-free interest rate"&gt;1.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life of options (years)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220930_z6aEovXTPwa6" title="Expected life of options (years)"&gt;5.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210930_zAkG3Sccvdl" title="Expected life of options (years)"&gt;5.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200930_zL0wY6kX2d2j" title="Expected life of options (years)"&gt;5.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220930_zhztPPc8Mdk9" title="Annualized volatility"&gt;84.17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20210930_zQmgc3QlShK7" title="Annualized volatility"&gt;93.43&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20191001__20200930_zNuF8kSdMzs1" title="Annualized volatility"&gt;95.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220930_zKqoqQv2xAHf" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20210930_zuCGmjCDBG03" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20191001__20200930_zRRaloMMiN2g" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      unitRef="Pure">0.0311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-10-012021-09-30"
      decimals="INF"
      unitRef="Pure">0.0073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-10-012020-09-30"
      decimals="INF"
      unitRef="Pure">0.0157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-10-01to2022-09-30">P5Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-10-012021-09-30">P5Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-10-012020-09-30">P5Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      unitRef="Pure">0.8417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-10-012021-09-30"
      decimals="INF"
      unitRef="Pure">0.9343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-10-012020-09-30"
      decimals="INF"
      unitRef="Pure">0.9599</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-10-012021-09-30"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-10-012020-09-30"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-10-01to2022-09-30">&lt;p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_ziIqbRNtNcaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 7	 	&lt;span id="xdx_82B_zVa8z1O31jAd"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s U.S. and foreign loss before income
taxes are set forth below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zx5dvH0NFZnj" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zHT4EuIsczU9" style="display: none"&gt;Schedule of Income before Income Tax, Domestic and Foreign&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20211001__20220930_zMKYknPhq378" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20201001__20210930_zfxrFFPCwnc4" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20191001__20200930_zGhw73ioTF9l" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;United States&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(40,001,893&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(28,850,926&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(18,096,148&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,617,534&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8,790,143&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8,161,658&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(47,619,427&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(37,641,069&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(26,257,806&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p id="xdx_8AF_zmSqGbBUck62" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The components of net deferred income tax assets as of September 30, 2022
and 2021 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zjMfQmQsT4Kb" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zI9P67rFLgNc"&gt;&lt;span id="xdx_8B6_zAX90pApmdX1" style="display: none"&gt;Schedule of deferred tax asset and liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20220930_zbByw7DrQqFg" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20210930_zx5QfwiHm1x4" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 62%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;46,208,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34,982,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,182,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,577,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13,373,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,453,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unpaid charges&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;894,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;89,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible asset costs&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;388,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;323,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;44,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;62,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8KqZpS1dx02" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuation allowance of deferred tax assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(63,089,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(47,486,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0949"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_8A7_zBJOu8iSi81g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation of income tax expense at the statutory
federal income tax rate and income taxes as reflected in the consolidated financial statements for the years ended September 30, 2022
and 2021 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zr0kxcDJW9E5" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zFSOKYViXamk" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20211001__20220930_zmPaFeGlxVAg" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49B_20201001__20210930_z7JqXnu6yzNl" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20191001__20200930_ztqOVCwmuym" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income tax benefit at statutory federal rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(10,000,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,934,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5,519,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign income taxed at other rates&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(170,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(353,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(723,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Permanent differences relating to stock based compensation&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(714,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,379,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--PermanentDifferencesRelatingToSection162m_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Permanent differences relating to Section 162(m)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;816,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0967"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0969"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;741,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;35,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--AdjustmentToTaxAssetsBasedOnSection382_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustment to tax assets based on Section 382&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,330,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development credits, net&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;232,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,042,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,267,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State and local taxes&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,975,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,022,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,911,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_zzfQV4aVbjg6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustment to true up to prior years' tax provision&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;24,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;48,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;373,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_zckaICNVDz7b" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effect of change in statutory tax rates&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0989"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;216,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;36,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--TaxesExcludingIncomeAndExciseTaxes_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State minimum and excise taxes&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;358,492&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;267,565&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,664&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change in valuation allowances&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15,603,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13,495,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,442,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;358,492&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;267,565&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,664&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_8A5_z1WET1ZcRca6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2022, the Company had U.S. federal
net operating loss carryforwards of approximately $&lt;span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20220930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z8vBX27flW33" title="Operating loss carryforwards"&gt;123.4&lt;/span&gt; million (2021: $&lt;span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zetJd9cR1BI4" title="Operating loss carryforwards"&gt;101.6&lt;/span&gt; million) of which &lt;span id="xdx_908_ecustom--OperatingLossCarryforwardsDescription_c20211001__20220930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember" title="Operating loss carryforwards description"&gt;$37.7 million will begin to expire in
2025 and $85.7 million can be carried forward indefinitely&lt;/span&gt;, state and local net operating loss carryforwards of approximately $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20220930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zrw2NUpRciRf" title="Operating loss carryforwards"&gt;199.0&lt;/span&gt; million
(2021: $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zIg7ytUWaNm1" title="Operating loss carryforwards"&gt;177.7&lt;/span&gt; million) which will begin to expire in &lt;span id="xdx_90A_ecustom--OperatingLossCarryForwardsExpirationYear_c20211001__20220930" title="Operating loss carry forwards expiration year"&gt;2036&lt;/span&gt;, and Research and Development tax credits of $&lt;span id="xdx_90B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pp0n3_dm_c20211001__20220930_zKD2NjpyaC17" title="Research and Development tax credits"&gt;2.2&lt;/span&gt; million (2021: $&lt;span id="xdx_90F_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pp0n3_dm_c20201001__20210930_z9IBoLQSFtMd" title="Research and Development tax credits"&gt;1.6&lt;/span&gt; million)
which will begin to expire in 2029. The Company had approximately $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20220930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zNYH13afw2ii" title="Operating loss carryforwards"&gt;10.6&lt;/span&gt; million (approximately AU$ &lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_c20220930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_zLjYRvafTY6f" title="Operating loss carryforwards"&gt;14.9&lt;/span&gt; million) (2021: $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_c20210930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zxXCgppp4vi2" title="Operating loss carryforwards"&gt;7.9&lt;/span&gt; million (approximately
AU$ &lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_zLOAe0ZkUhz3" title="Operating loss carryforwards"&gt;11.2&lt;/span&gt; million)) of net operating loss carryforwards in Australia, which have an indefinite life, available to offset future taxable
income in those jurisdictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates its valuation allowance
requirements based on available evidence. When circumstances change, and this causes a change in management&#x2019;s judgment about
the recoverability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income.
Because management of the Company does not currently believe that it is more likely than not that the Company will receive the
benefit of these assets, a full valuation allowance has been established at September 30, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company files income tax returns in the U.S. federal
jurisdiction and various state and local and foreign jurisdictions. The Company&#x2019;s tax returns are subject to tax examinations by
U.S. federal and state tax authorities, or examinations by foreign tax authorities until the respective statutes of limitation expire.
The Company is subject to tax examinations by tax authorities for all taxation years commencing on or after 2018.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the provisions of the Internal Revenue Code,
the net operating loss (&#x201c;NOL&#x201d;) carryforwards are subject to review and possible adjustment by the Internal Revenue Service
and state tax authorities. Under Section 382 of the Internal Revenue Code, NOL and tax credit carryforwards may become subject to an annual
limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over a three-year period,
as well as similar state tax provisions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company conducted a Section 382 study during
the year ended September 30, 2021 and determined that, during the year ended September 30, 2015, there was a change in ownership
which resulted in $25.8 million of federal NOLs being subject to an annual limitation of $439,914. During the year ended September 30, 2021,
the Company reduced its federal NOLs by $12.1 million and its Research and Development tax credit carryforwards by $0.8 million,
which are the amount of tax assets that will expire unutilized pursuant to the Section 382 study. This resulted in a reduction of
$2.5 million of NOLs and $0.8 million of research and development credits and a corresponding reduction in the valuation allowance
of $&lt;span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0n3_dm_c20211001__20220930_zKyNQSpELoTk" title="Decrease in vaution allowance"&gt;3.3 &lt;/span&gt;million,
which was recorded in the 2021 fiscal year. Subsequent ownership changes in future years could trigger additional limitations of the
Company&#x2019;s NOLs&lt;span style="background-color: white"&gt;. During the year ended September 30, 2022 the Company determined that
there were no changes in ownership pursuant to Section 382.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2022, the Company did not provide
any foreign withholding taxes related to its foreign subsidiaries&#x2019; undistributed earnings, as such earnings have been retained and
are intended to be indefinitely reinvested to fund ongoing operations of the foreign subsidiaries. It is not practicable to estimate the
amount of taxes that would be payable upon remittance of these earnings, because such tax, if any, is dependent upon circumstances existing
if and when remittance occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2021-10-01to2022-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zx5dvH0NFZnj" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zHT4EuIsczU9" style="display: none"&gt;Schedule of Income before Income Tax, Domestic and Foreign&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20211001__20220930_zMKYknPhq378" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20201001__20210930_zfxrFFPCwnc4" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20191001__20200930_zGhw73ioTF9l" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;United States&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(40,001,893&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(28,850,926&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(18,096,148&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,617,534&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8,790,143&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8,161,658&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(47,619,427&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(37,641,069&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(26,257,806&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Trebuchet MS, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-40001893</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-28850926</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-18096148</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-7617534</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-8790143</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-8161658</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-47619427</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-37641069</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-26257806</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2021-10-01to2022-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zjMfQmQsT4Kb" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zI9P67rFLgNc"&gt;&lt;span id="xdx_8B6_zAX90pApmdX1" style="display: none"&gt;Schedule of deferred tax asset and liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20220930_zbByw7DrQqFg" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20210930_zx5QfwiHm1x4" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 62%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;46,208,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34,982,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,182,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,577,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13,373,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,453,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unpaid charges&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;894,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;89,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible asset costs&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;388,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;323,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;44,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;62,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8KqZpS1dx02" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuation allowance of deferred tax assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(63,089,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(47,486,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0949"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">46208000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">34982000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">2182000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1577000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">13373000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">10453000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <avxl:DeferredTaxAssetsUnpaidCharges contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">894000</avxl:DeferredTaxAssetsUnpaidCharges>
    <avxl:DeferredTaxAssetsUnpaidCharges contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">89000</avxl:DeferredTaxAssetsUnpaidCharges>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">388000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">323000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">44000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">62000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">63089000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">47486000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2021-10-01to2022-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zr0kxcDJW9E5" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zFSOKYViXamk" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20211001__20220930_zmPaFeGlxVAg" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49B_20201001__20210930_z7JqXnu6yzNl" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20191001__20200930_ztqOVCwmuym" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; font-size: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income tax benefit at statutory federal rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(10,000,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,934,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5,519,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign income taxed at other rates&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(170,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(353,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(723,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Permanent differences relating to stock based compensation&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(714,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,379,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--PermanentDifferencesRelatingToSection162m_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Permanent differences relating to Section 162(m)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;816,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0967"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0969"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;741,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;35,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--AdjustmentToTaxAssetsBasedOnSection382_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustment to tax assets based on Section 382&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,330,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development credits, net&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;232,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,042,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,267,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State and local taxes&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,975,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,022,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,911,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_zzfQV4aVbjg6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustment to true up to prior years' tax provision&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;24,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;48,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;373,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_zckaICNVDz7b" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effect of change in statutory tax rates&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0989"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;216,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;36,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--TaxesExcludingIncomeAndExciseTaxes_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State minimum and excise taxes&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;358,492&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;267,565&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,664&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change in valuation allowances&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15,603,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13,495,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,442,000&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;358,492&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;267,565&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,664&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-10000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-7934000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-5519000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-170000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-353000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-723000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <avxl:PermanentDifferencesRelatingToStockBasedCompensation
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-714000</avxl:PermanentDifferencesRelatingToStockBasedCompensation>
    <avxl:PermanentDifferencesRelatingToStockBasedCompensation
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-4379000</avxl:PermanentDifferencesRelatingToStockBasedCompensation>
    <avxl:PermanentDifferencesRelatingToSection162m
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">816000</avxl:PermanentDifferencesRelatingToSection162m>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">741000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">35000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <avxl:AdjustmentToTaxAssetsBasedOnSection382
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">3330000</avxl:AdjustmentToTaxAssetsBasedOnSection382>
    <avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">232000</avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet>
    <avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">1042000</avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet>
    <avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">1267000</avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">-4975000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">-7022000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">-2911000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">24000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">48000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">373000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">216000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">36000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:TaxesExcludingIncomeAndExciseTaxes
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">358492</us-gaap:TaxesExcludingIncomeAndExciseTaxes>
    <us-gaap:TaxesExcludingIncomeAndExciseTaxes
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">267565</us-gaap:TaxesExcludingIncomeAndExciseTaxes>
    <us-gaap:TaxesExcludingIncomeAndExciseTaxes
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">22664</us-gaap:TaxesExcludingIncomeAndExciseTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">15603000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">13495000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">7442000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">358492</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">267565</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2019-10-012020-09-30"
      decimals="0"
      unitRef="USD">22664</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-09-30_custom_FederalMember"
      decimals="0"
      unitRef="USD">123400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-09-30_custom_FederalMember"
      decimals="0"
      unitRef="USD">101600000</us-gaap:OperatingLossCarryforwards>
    <avxl:OperatingLossCarryforwardsDescription contextRef="From2021-10-012022-09-30_custom_FederalMember">$37.7 million will begin to expire in
2025 and $85.7 million can be carried forward indefinitely</avxl:OperatingLossCarryforwardsDescription>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-09-30_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      unitRef="USD">199000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-09-30_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      unitRef="USD">177700000</us-gaap:OperatingLossCarryforwards>
    <avxl:OperatingLossCarryForwardsExpirationYear contextRef="From2021-10-01to2022-09-30">2036</avxl:OperatingLossCarryForwardsExpirationYear>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">2200000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">1600000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-09-30_us-gaap_ForeignCountryMember"
      decimals="0"
      unitRef="USD">10600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-09-30_us-gaap_ForeignCountryMember_currency_AUD"
      decimals="0"
      unitRef="USD">14900</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-09-30_us-gaap_ForeignCountryMember"
      decimals="0"
      unitRef="USD">7900</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-09-30_us-gaap_ForeignCountryMember_currency_AUD"
      decimals="0"
      unitRef="USD">11200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      unitRef="USD">3300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MLZD7)O^B?7IOM]M"=A1RZF?!X@U\-TC_XM<,Q+L X[(BP,@"C \!>M43S"S
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MK>U.3SC=)M7.SY1SZB>'&X(=PN(;Q.\K2OGA)'Y 7F$__ ]02P,$%     @
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MC"(37P9\)["6&V-DG,PXOS>3RW1@.4804$B48<#ZL8(14&J(M(S?-:?5'&F
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M]_5#!D_#FF41)3+-(Y6B3+Y<#J[(14"Q"2@0/R+YFA_<(R/E6:E?YN%V<3G
MID4REG-M*$*X;.6-C&/#!.WXIR(=U-\T@8?W._;/A7@0\QSF\D;%/Z.%7ET.
M_ %:R)=P$^M']?I55H)<PS=7<5[\HM<2Z\$7YYM<JZ0*AN<D2LMK^%8EXB"
M\(X 6@709H#3$<"J /;> *<*<(K,E%**/ 2A#L>C3+VBS*"!S=P4R2RB07Z4
MFGZ?Z0S^C2!.CV^F][/IM]O@ZFD2H-D37.XF]T\S-/V,I@^3QZNG6P"@J_L
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M]WIHKQXPUV"=4ZC+\U68+F&.F^+U$2UA2]$MCK;+C<",MSO, J3<8TYS^;$
M"75=!W?HV]LLTNM$=NO/017K5L4LPY!SUNZS-M!A'(8K;ZJR 'V&'<H[9.T=
M$.FW0/>P8S0=A9XE[ TE6F=J&Q5[-7C<E6L=OMD7VHK\>&'Q.!$.;1H(&Y1Y
M'$H+;TTZ"Q3&LNOYN$OOWAN1?G-T6RO:.8@SV#UE68<_(FT[\XFYOB-H4YX%
M" /4Y<T%U@JDG#L=RO;^B/0;I+HG3>4$D5#F5V;;#173O+:JXRT'"MTG/+"
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M-,8M3%VK(")![ 9$\$[IX$%(%VDJU[:8KOA/.T%.+8.[?,8DP+A5]:<.PRC
M$6TA3AQV?AA$E/:@V=-MY#DT:@U+M\CY75[T:H1ME/WQ/0^3J-WO'':4Q@RV
M#VU 74/",*9>'R*Z0T0'$25B+I0"2 O%*P-U"RJQ>Y(&X[B7/'+5H6V@@\GQ
M/>:U%]D1!CSD9"<.R:!4JL6,J[U#,>>#VG ;][ P^-2+6-A)98>IAX&&,&IK
M'6=4 H4)^SW=BNQD&_%?*H172M[GL%E =S_155Y!KWI>#)-!5?A?.]11HR7'
MBG;([$Y'DD'M-+G6>FW[/9)SJVY*V&[K)5<]/ ;=0H!CYH=ANY@[+$G@40+B
MA;;SQA&418%/8M:3-COE1IZ1;A8)R@&B '#:W9Q(5V.=1#AD40>3PS ( AS3
M3DUP6(*VB_:6UR&BG6XC@Y(%6J],A<@TFBM90@,6*LUU/7D/7-G2Z(;X&SK(
M712C[K3"[ ?=3O#_1SQD:*>ZR+#LZF=(6R$/1;(6LDZ:NH*)8/AKBY"IP] G
MF.&P0\/@N_X&#3N)1H8U6M,<]NOEO*F7SS2(KLJJ*WG,.DPXI!VL<Y_ZN+,H
M'$&9%V#?ZUD5=*?>Z+!Z ZFM!&S0T*M,;*Y>VWY8X[?:M+X0/]8@OHMZRYRM
ME67!+ 6"GIG+S,4"=>@]&OLQ8^TNZ; DE+* =36?PQ2*C>>QGF)'=Z*/#HN^
M:1_:-^A.+/*JLHAA&0P =LBW@!(<17[01NR0A+#-C3%A;< N\4A8$'H]1R!T
M)PKIL"@<0"S@Z3#6KKPCL(,*0 .U]ULN4S<MB<.T0\LAV)W:H\-JKP9;;[OF
M4D$M@[UYC;V0*>S:R[S*RW6Y%<9VM^E>V=M!]D^D/!K&[7.'J<..>''04;\.
M.TK#3I\;[QU"ET(MZL-\C>H]U^9PMWG:_&!P41^3MYY?DM-D<^R_"[/Y%>(C
M5Y#D&A5B#B'QVPC>26T.]C<W1J[JH^X[:8PLZ\NEX)E0U@"^GTMIGF[L ,W/
M*Y-?4$L#!!0    ( #J(?%7!F_ZJQP@  *$[   8    >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&ULK5MK<]NZ$?TK&+73WLY$$5X$R=3VC"/Q-IF;V&[DM-/I
M] ,MP18GDJA+4G;NOR](,:+P($PH\ =+E!9GEP<K<,^"O'C)BV_EBO,*?-^L
MM^7E:%55NW>32;E8\4U:OLUW?"N^><R+35J)P^)I4NX*GBZ;09OU!$/()ILT
MVXZN+IK/[HJKBWQ?K;,MORM N=]LTN*/]WR=OUR.T.C'!U^RIU55?S"YNMBE
M3WS.JZ^[NT(<38XHRVS#MV66;T'!'R]'U^A=0DD]H+'X5\9?RI/WH#Z5ASS_
M5A]\7%Z.8!T17_-%54.DXN693_EZ72.).'YO04='G_7 T_<_T']M3EZ<S$-:
M\FF^_G>VK%:7HV@$EOPQW:^K+_G+!]Z>4%#C+?)UV?P'+P=;%H_ 8E]6^:8=
M+"+89-O#:_J])>)D ,8] W [ "L#".L90-H!1/40]@R@[0"J#$"T9T#0#FA.
M?7(X]X:X65JE5Q=%_@**VEJ@U6\:]IO1@J]L6R?*O"K$MYD85UU-;V_FMY\^
MSJ[ODQF8WXN7S\G-_1S<_@JF'ZYO_I',P<<;\<7M]+</MY]FR9?Y7T'RSZ\?
M[_\#QN#K? 9^^?/?+B:5B*3&FRQ:K^\/7G&?UWRS$5DRK_+%-_#?SWSSP(O_
M&6"F=ICKY3*KTRU=@[LT6XZS+9BFNZP2QQ;0F1WT"Z_$[XLO09(6VVS[5-JP
M$CO6?2YBD8=-Q 0=9PD?9PDW.+0'YSU_RK9U,.)'L4ZW"_X&/*?K/0=I!>9\
M]Q80^ 9@B&+35!R@@P:Z7C>>KP+, GPQ>3YE6K=" 6&$1#"4+6>ZY1@10F(6
M,BB;)KHIACB*61P?#24^R)$/8N?CP$)]^@\_J'D#RE5:\'(0)P=XIG " XP4
M6JQQU*OXNW*7+OCE2"S3)2^>^>CJ+W]"#/[=E'@^P1)/8!+_],@_M?)_MR\6
M*[$\MY2;&*;:U(<!"Q1VJ38-&&'*0D*4G+.&8SY98"+-Z#"@.([,"1D<"0E<
M" &_B*7H\-:X.@9:&((<&D14X<?JU#7[?((EGL DLMF1;&8EN[YZ9)6H5BI+
M_C$M_UBLL*N;C%6;F342A\3[>1R)JO!(5>A&U6N9&6J9R:*8*C_'J=6I:U[Z
M!$L\@4ED1T>R(RO9\P/#65GN1?FPVQ?E/A7$5SE8I.5JS<L2\.^\6&1BG<@?
M0=E4/_FNKF",*1QI<Z%>G72+L6(RLX;LD, _CR-Q&A\YC7URVK+Y6I;'^OJK
M7?FM<;GFN$^PQ!.8-!\(=H(!.LS(?KOD!9BG8B; ]5/!>;W6& 4!U M,K6"<
M&JQ"&D>(*H8S>Y .>6WV&,<0FBL"=**LT,\2]5J>MAZ80IJH5U3>K*&X9JM7
MM,07FCP-G71"=NWT2:P1[PXD'^8"+/*R,BZX=J3A235M@:2%F4(2,JJFL2>/
MR0"/,G^=U$)VK=6D<=.,60KF-CN^+=-ZD342>(8H,1.H"S0:A2R&3"70D\=D
M@$>9P$XK(;M8NN$56.>E.>,\"9NI+Z 9TB72&#,<01JJZGZ0J4Q:IZ>075 E
MV^6K[0X,C90&>N6/14CJBJEK,!2Q*$"AVAJ9&4S'*(A9&&*B<:+;8F'& M;3
M\D"=ZD%VV7/2]. -.ST=CQY:F%[9"UH"=")]6V;.T"J6:XE/M,07FCP%G9I"
M=CDUH._1(IRF'X50XUC769@B&*)8*W3.4#3F!<[H4OSU]3Y0IWN07?@X=C^0
M+EL$16$<,Y6E,T2')1-]HB6^T&3*.UF$[+IH4 ^DQ9!J6RT3=2TT5HUF]F!<
MDO#G@>0&>B=;L%VV.'="6CQ))$88J:T0NUO7'/6*EOA"DRGO!!!V$4"GVMVI
M#=)ZD90CU>0ZUJ626% 9(VI'SQZT0RZ;/4:0]10_^&2WQRY9SB#NU6S6]4%-
M8J I27MHSOGL$RWQA29/2Z>$\  EY-[Y:%&E#3A&U*T0K.N/,$80Q2A0$]B7
MY.EQ&09!7P9WF@?;-8^'W@?6U86@C0:A6B780W'.6)]HB2\T>1HZ%87M*LJA
M]V%'<E"BV*"6,"5"5JF;>KY<)D-<R@QVH@O;15?_4ESPIZRL>"$^7F8%7U1B
M37[DA=!E1GKUS29,(NTBIHNTNA<9,J)J4GO8+MSI+@-8_Z$^[CJUA.UJZ1SN
M7ET5#"J&1# .M+K,ZQZ55[3$%YH\+YU<PW:YYK(J>-H^FF+#5A6!<0CUS/:U
M8S7$I<Q@I[ZPVZZ4L3Y[28M"?&SF55=F)% W0[ NS1!E#*F&,WNT+I29/09]
MFR&DDU_$9=?H%<9>6P2(+LU(LVBI-^]XU69>T1)?:/)\=-J,#-!F [OZ=BB'
M18#HBBG"!%&H5@:^/"8#/,H$=AJ-V#6:K:MO'^I"F">@&3%L#Y$PAI&HJ)4.
M]B!3F;23V_;L"FI05Q\9*=5%5!C$6/O%ZY*&T(C4>Q)J3\M@.D9Q&$1!I&[3
M)09;L0I'*$*PCY-.*A&[5!K<UC?SHJLDP0N*J':OG3T,Y\70JTSRA29/02>3
MB%TF>6I4$7WGB4+MAE+#OA,454FD]JGL,;NL@2:/=6>A[Z+>B2-RKC@ZNT]%
M# H(PH"HVW?VR)RSV>LFE2\T>58ZV45<9-?@-A71-ZX04S7[E!CT%XPC JEZ
M:X,]2I?\-;L4=6G8D\"=$B(N=^R=U:8BAKOT6"WM->:\;F9Y14M\H<G3T,DI
M8I=3#H+4CN126IGVO3#!5-6COCPF SS*-^-WXHH.$%<#BWD[E .!5!=A*!*%
MHLZ@+Y?)$)<RA9T>HG8]9"OG[4-=*/,$-*.ZK!G3, [#&"EE1#+(5":MTT#4
MKH$&E?/82*G^9)"(2+V&3 UF)!+!LTAMG<X,IF-,@X"1,"(J)X:'G2BFL:CF
M^Q*IDSAT\*-)]G+>S(MA2T;P@B-U%VAJ#\/U<N(5+?&%=IB"R<G3C?7#JY_3
MXBD3E>2:/PIX^#84\U@<G@<]'%3YKGG@\2&OJGS3O%WQ5%S;:P/Q_6.>5S\.
MZF<HCT_E7OT?4$L#!!0    ( #J(?%7?(D(IP0<  +D1   8    >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&ULK5C;CMM&$GWG5S04(+ !13>/X\1S 31C9V/L
MVAY$L7>!Q3ZTR*;8<;.;Z<O,*%^_IZI)2A[,3++ OD@BV55==>J<ZJ+.;IW_
M$AJEHKAKC0WGDR;&[O5\'LI&M3+,7*<LGM3.MS+BTN_FH?-*5FS4FOEJL?A^
MWDIM)Q=G?._:7YRY%(VVZMJ+D-I6^OVE,N[V?+*<##=^T;LFTHWYQ5DG=VJC
MXJ?NVN-J/GJI=*MLT,X*K^KSR7KY^O*$UO."SUK=AJ/?@C+9.O>%+MY5YY,%
M!:2,*B-YD/BZ45?*&'*$,'[O?4[&+<GP^/?@_2?.';EL95!7SOQ35[$YG_PP
M$96J93+Q%W?[L^KS>4G^2F<"?XK;?NUB(LH4HFM[8T30:IN_Y5V/PU\Q6/4&
M*XX[;\11OI%17IQY=RL\K88W^L&ILC6"TY:*LHD>3S7LXL5E"K@3@GBC0NEU
MEZ&RE;B400?A:G'M55 V2GIR-H_8DRSG9>__,OM?/>)_N1+OG8U-$&]MI:JO
M'<P1[!CQ:HCX<O6DQXWJ9N+%8BI6B]7J"7\O1@1>L+\7C_C[Z'?2ZC\XOZFX
M<C8XHRLY G&</^'QD[;2EEH:L<%-!8+&(/Z]WH;H0;'_/ 11#N#DX0!(=J]#
M)TMU/NEH+W^C)A???K/\?G'Z1'HG8WHG3WG_/Q3X2?\/1__!1266XG_;^[!\
M;>6-NA/_T+42FU(K6ZJ RG@4_MFWW_RP6BU.\Q*^6)X*YXO8*-$_NW)M)^V^
M?_A<8"LI2@2N2U0M1#0;L=6N:R1D7:H4^7Z9K82R.RRHA+:"?%;J!IVKHS)3
MP)6N:^5QH5'[BE9XV;&+(+;[0G:=V6N[$\"BU-RY6E7I$GF)Z$0)0X^]+&!R
M*8BP#V#0F-35A\T8=*6#0K<)Z >Q$0V:BTBV19>V2E6S 2)II=G_@54[95VK
M2P'BRJ+VKCU..%4:2["_KBCR>D_IHP=_43Y,Q6VCRT9(KT0*E)(3N6F*#F5A
M=L=&1L1A#-IPJ=!%&9FCW,56657K*'!*Y&<X(")A5@ SJY)WE4*(,* FS!SH
M[X[H(M(AYYGX%3Z.RKA\=1J$P9G#57()YNL/Z\]O_X62+U^=G#Y"*'@)"B:#
MI)%=/:HW'-3; $NDH&R!LG5 HA)=\B%)U!QP4$(^&4!(<7NU2X;]\X;T<*/*
MY'74_8JW=V4C[8XS:'5@%@PEWKR]&DM,:\E<6_2.5&:7V(^.FV*Y^.[OO&(,
M3HS!(7^5<99E"31B9IQ&8IW)9 #2QNSIN>KB@<V?K*8K[EP<_KI5'BP9X_LT
MV\S$W];KZR'*&63X>]*5CGNQ!@/ZE.\7IX/B210HHD^[L4RA(%[UFX^,/-94
MEN, 1>]6E-):%Y$V)..C9 ?@H$:QJ,#2$V-A<^Q)U6!?#)FHL P)R8=0)P3M
MIX6NC^Y,#_X>BSS[@7]/SB!L[VZ(0&!XD$;!9X]S)(JUP)%IY6%A$W/8D1H5
M!*9R$9%1,9A4@M(<%@M6K$M>8-KRF5Q?B4"HNPZ2# S2=NB3U%$<53]Q=Z$U
MGKLEQ+7+2BME:$2-T2N,VL0W(%1R:U11IYA\AK^''"1#OX+<&X7C$* 1 E-&
M:MRWI5$'J"!M!0,'Y9.WF7B/?K1C4>&IT3#MFP>7/WEJG#RF$6%+V<'.%)T+
MFN5Z*%Q=:VK[K+Z61M.'*'?/#\ $3WTOZ:W:NYY35MU%@3FDS7.(K&,O'JK.
M&%Y0Q9\W"B9S"(DZ,%4'N1.A^& @\AS3$7@R?UV(9C\=&1YU2T'3)69D0I#-
M1VU$CSU#@6Z6;,_]O)?$OFV7FT3J""[NV\>J:63@$;7B<JF O5CG%+;';J@>
M>H*ZD2;U%*PP2^XSYMO?J.<3I;AY\:8%)IJ$H&1+7>8Q[1/O+!H$F-2KY@;S
M/<#@VTB6PY7"IG8+Z.&EAE_G QI#:1(OV:9(^A &\,1\"N73-^B=G19'J%7)
MC[-83]][X$W9%+79^;XX#T7]:!]A0]F&L62&'L)-<> $C*%6&DODC=0FL__7
M>Z7@!KW5AEHG\I'5;YCGN32]RJEK&] D#$#Q3D,-G3TFS)AM<2_;F?A()S$1
MV7(+\:1.RL_((R0WDDZ&-2!A+A?/$"#>7D")BK2*H1)-EN>VE\\90,(U4]@Z
M)I^7U%E8+[*J6+((HL<$$0[R'1&AK3'D4"?AJ85R\MQ3QB6H;.[#PUYN2XS/
MV1^ZJJ%6*0,V9+?*MTC[W5=UI2F/"#1LG!WE&CP4+3,2V)(BMC0]\ E!)>=X
M$1$YY*BI^XW9H7N6&=4* ._I& @EG0>5NT4EJ2/BELPGY9/G%;^0\M0PH^$6
M\=UH#[S>Y"D([S?+'\6SJX^?W[WY;OGC<Z87S5\PW1FW13:0]!:X?*&MAG48
MHBH&@HZ<0@KJ ,03H0$3!-ZSZ@$UX#V6'!U.($KD0'ETQPSC>)#LD1?&9:KK
MAJ8,5O?P9C83/[M;/CMX-!^4"H(BM5Z2B*!2-+7BMNDG'5G!!DMPFO.!-PPN
MLPT#V&>.HX?F736(-(7QR$,]AU0AAN',*FC=5_I%N@#^H3>L^='K- BXXS\-
M@N!)*[]9CW?'_R76^77\L#S_J?%>^AW&.PB[ANEB]NKE).MSN(BNXY?SK8MX
MU>>?#>9<Y6D!GM<.DNPO:(/QWYJ+_P)02P,$%     @ .HA\50E/QGU:&P
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MIZ>*ADR2=Z0B6Z#(NI55LI?^]I?O+LZ_?9;9*ZWJ^0GWN>=S2QPY9CL2U47
M0Z"MZ.^<DU,R-8-^C_F9O1GZH9ML"J$5\32! FG3&-I:<0&.#MF[C@R]WC2B
M_"MZB/Q6)19*NB'?5::_D3Z..*JR&2K'6Z[GC:E=ML6M^VQ_J6^<O2YKD>;*
M=Q2PP#W,^F[EH4%_UQ+Q,"Q"7=5DHS M??MR0.@A4[#O^BW16M?,]P.H]>+L
MV>Y3_.?S9P]GIN#CAEW#4>[(N[ $HRDWQ9VP&=]-:[YV!&[HQ=?KQ<\S^]6$
M]+492R>DS!6YYZJPO_35_-^@A'^_Z_PMW!$^OVU[G-R9%7)S>]DT1(.,Y312
M)!'(LY2RSV!@431\2.V*&*%-)PNB\TUXJ6 %7A5!O" ""1T_WLG<]V#?:V(,
M'H9.4;_R 5Z1_$,OVRZ''6:[(IQ'N]C41*J:Q8,'"G0H^AH>A%Q*&5?D4TI6
M##M%6.,(T#DR?X%&Z03%8+.AP[HB5TA48+U,*&?[9U[?R/H3'I-#B-+ "^^^
M'NV7EG<XX]TG0O[1D&?3/]_09HE^2XB&N(]8Q-Y_XT/=BTLIBZ[;PN.Q8V-O
MM;LJN:7.?];3?%/4G3Y;#:PMR!]6%!)/:9?7HBZ*,VH=I(O@2OQE-V8D=S.J
MP6Z 1<A/-91OB#_.=43JKRC4D6<II[+F$LXFG^PH[R']S,BI0TV^,V2>:]>Q
MQ]@4Y(B"G Y:C0)+32 ]D*^#ZQ32,3"6M%$4D?X@UP:A%>V," .&S*R/8BRV
MHY+8O5",=!WKQB2;ED#9X%$Z/O0_B:XY'3(8$HB.8K<D\Z3<R'YJR3]EKH_>
MZNM^ +-3\E.BO..DW$71?HK:2F8EIV?&L(HR.I@9Q1;WN73PLHXLE4,+T1I@
MLR+O/ +,P#:]' A"DA-(<<J\DA?M2UWM#5Z'%V"WZQ5P/GCU\LW50SML8&=_
MM1=/SF9G9V?V?8Z-7F;8Z*<87M_?BYZ8)PW%@"@X5]!W-3<225*8E@.YWG0U
MGE1_)S3TPXXQ$U[V]+3K@;F/8CAW0Z:M*(X.-&-)0FF$ZQD+A9[^1IHVZ2\]
M8BVKOAT ALAXZ!V%@FZ]:?R6O%(@1]I%#+)PK;NIU0J/8CN5=,;8#HF31?I0
MERZ,O!E$_ZZ5V'U$H!$CBR8U5)!S*=JE'@=.#,B)=A6=L([!4AA +(RKIQ5\
MMRS:^D^% S&(7KU_&\; 29J(J$M5 9R[(J>>02Z!41%H1T;G]M>:H$2/ [0I
MML+@NB#?N@.DV,'E+$]LYV[E6L,.<.-*. 9*\R-9B@.6@UE1KH!6*93]NK]]
M1VUQFE6)\K*L[9J ;5407U>^2A[))+!Q?1759+]%SGWLR,RPI+CI".DD#A,P
M)3?,^\Y9AJ*U 3GBT"-"Z0FH.X[O*!+@V[G]S;>=@W=E0$YPD_E/2H937WK/
M3C<9F^'P!] '/#_P8<.FM1((\<X(%P^;()>(ZK1%*<5AS+M&QO8GJ-XJ@)'<
M3<(N/C-+1MYLX.<=X0/?:=X@QI..!AXC D@?\!C!P=\Y4265M9P7A, \<2:9
M)U_3I DY<)XPQ53!Y#; B^.H$O5T$'$.)#Z-3H/@IKP^M_]: 4-I%DC&PO"[
MHM!4E#$N2W[B)KG+;&+Y!.":[9^T-^32EJ3VY/+4/67.BQ7*N(<T!O_2N%@P
M0"(MGN[6L^XD3]6-B>?>59'U?XR)ET3?F$5TSO#Y! AP0!HD=Q1-14E 4O?4
MM>RS)2W?3=HOI[D4':RFBBG3L<QHY(<CQ=[763X;T[]1 CU5O3B%+"N+*93F
M?9HGJ3[>D$%5A#!(G=/M81L)D^H$R4)NJ ?&PY%L4#T%*<0DPD1;]3AB4="=
MIV/9C\60CO0+=*0XC5Y;J-U"C>2K2U@!HQK7+LD?P2 ($X"0'D4[PBBDLXTZ
MIF0[53<L0WY@\$>.%0VC4.%GRHZR70?65%W2?LF*8@52,&@'6A85 PK5GX3)
MH042!-*I483Y3)LC;E3U%)>'")P$Y';+S&;NA90!ED4U=/R)&WC($&'+UPM'
M7F:B;'%[#HZ)?)]J^69HA"55)IS7W+Y,B)N.VA%!Q4I&/9I=/5:>K7"-KH%(
M28"QCG*K ],M6 WW!"C-B)8$- #EI+B 8XDLE8/&&&V/0K8WJ8[U1NI8N8,D
M)9,S7L:\S"\@I%5A4R@PNZ$ 52W!Y1.(!6%3"MT>CR1X?2RO*<!_@+=C=$V9
M_ON_%>O-LY?Z4 RY%,W(%)=$V;+O+-9),1S.XM<[#'V@==_"P-UTM0]O4RSG
M?'T(;]H*KR&!1U)2A\QH1X+F-2)/"YF2AWJ):FX?@]-(YTW;^MLQJ]$BR%B\
M&-=,\$O3Z@VR_\I)8"\DEY#XST7!RH DO"X46BP9-J1-_9IHS@>HIU#9PL>-
MNI\"M23AX4+-=F9V"S#S_<(-V1OA'S_R-Q8\CNUYVF&R3PUMDB1D>H!FU&C-
MOP&A2< ]#C/LE56#^DF5CD'U)(6AY.*4L_A;)3MNI]E0%!F*-J$7P6N"E(C5
M@'22CT_FSB4^?%$E4.=M43< @J;/U"JE(&PN^V,LV[:(5,62D,82Q918@2=!
M&T0= FJM_>O%V?P,$+N!H69'IQ)$+6"M7B]()D:?>85^<JQ%+XD[U*:YQ,MU
M8 0[Q?.FI#0=@5HX%9.?%%J)"0D=6Q2[^E4ZV5,W@J09]<QC?J#QG.>A'C\0
M$10')O'>()W0G%P1,;[-!)K"<AM*"OIL)]=7]H/?4&[R[3=GL^1FB\]NS*OP
M#'T[GNU0QZ V59E!Z"#(^4F:%H<.(,G *M6^!,,\VB*ITW,@0Y.$4I=&,24E
M49RCY6J%M!)8>FE3Y"1KR;DTC$.[O]/^AZJ6HB+AWP-1_IBUQ@R(9-.8KOJ7
M$+8<:DG Q!5P2XL]W;1=LT1]@_L1].F4#L -VA0#J1%"0H$' '8LD<3-9")F
M(=#;+SGY?'-Y?7&6)WYX>'3L]K4LS&&U#F7C48;A&N_XS&4@J^9&R!1.[GF7
ML1RL]5MQ1A1(O-82KV,*A&#UX/7UAX?<UM&(G!(D#0KL;,2RZ317OD-A*"!H
MQ3(>:V8KK364;2<;N<^AV>>0X0FH--I'BUY7SP'Q2&BH)B=P79/G0&MNKWRN
M6/J?7-:\K, XR_?/R\/RF:/RL2\6+T$&4(>CK+&3)OK*VZ%L(J8.*6/C_F0J
MT0HM4TOH*,7Z8@C*&HM0 -2&Q<;$,A63.<D<41C#/I)];">FQB?LE3F4XD76
M;-'$R_ H ^WQ"W*CI=ID,^")7] _)&]LKU?8,'E CO.C!V@N/N1O 7A)WX$?
MJ@,[5GY_L34 .AR(6D*GTU='/X[JO=) R8NP #<&%"O<\9P'8"Q2<L(BE#4L
M:%E.O,>5Q9>BP(+ELMBBX<1$J?XM >S_@P!A6(/9!^</N8H:Y3G]C^29V0<7
M#R45@%P,W*7S'@T/35PNGB$9D2D!OTD-''/'93XR0/@[H=RC)SMT6Y&"D@TZ
MWI+R/WA\="TIU6T\4$Q,C?6AO(?PBCP@H9:-#V[,*V5'#%3;1%N37:#322EC
M(2XO8]LFMADBW;^J9#><">FI236"C#YW&XYSLG!E@0*:5,U4[CLN/  :T/*G
M<6GVDYC9<)O>\9[&R9E97&&7NG(6S/GCV>.+O\^>GC^UY^>S)Q3T_W[VV)Z?
MS9Y\^W1V\?2I?94:!&]:<JS#.K74QA;WL?KVM+F@[\X,=ZT"!ZCHGW9:=OG(
MP@$G,QO#X:;82ND0*M^O4N7]*%7EV)0R7VY*L>?-F)_;CZU $9C?'>R;0 [J
M>N+!Q[F5I 1"4RV7Y&+U,$M8 9#((7ND/L1(R(9NN ]*7GVF[1T4X[H(FC6=
MI_]PE%?K"NZPQOD4T.EO[54D]0%]U28UQ-'@XC"*6E):[F:777S\>$T!N:'0
M.#>_^E9Z%X1ZUX$2E-9K(Y;KT4 ?O&JB",OK=65^B&1.]+@21W:Y0A/ =EP&
MHUP$SHXS"IVKD.AA99 1$87#?.O;T_64G9W%[B6.TGST7IC3N./1A9+;<U+:
M]0O*1[0\E3I 2:]10I/K0+.J_P,[FF!DS6^6%,:78/&2.W+$&4ZVFQJ#26\W
MRC+[-K8=J9;3RMU20G["R7FIFSZE](4LH20!I^5H8.Y45,M*XP<,R8Q#$P?'
M'HX-*.RA-XP;I+1[:HOD^Y;K6 Q\[9!2;HA_^SZ5<M_*O C]*[A8-.ZTH"6U
M*H1?,J$X,-8:AR/([3P&TJ*0("-NB"*!--I#<S(RBVW*LUA^R8WC51J6T>!)
MXRL(L90\<DT&%?X.FQ/_<BKS169)F=]F)L7L4E#!RM\Q2&P *#D#UMD?:1+'
MQH+6L)D_.C73+;S%X"OW=+-9&KPN3DR^2FE)$0P:57Y7C;&TH^XA/<^]=*Y8
M,(JA!*/AS*G8U&[,8K(Y/PSJ_'8-M;J"RX"<K<045#Y$6^7.@"=G^:<<);:\
M<=A /)?A%$G.MGCGV$X0XR+E<<VG+[1XYUM)=K3\SJ5WM#[#38W#KME3ZDFP
MVUV.F=/80"QT[(TW0FHD)F;:L?=W_\S>F!GP 12$OM^KRK2@YW<"M=,TTW1@
MRDS/.J_ H*#H6B6<'&+,#;[ +B/8Y!8G98/<Y&Z\#&OTTC&08F2(A0<N.;#4
M)@V")J<\F9W;1I"(@SI-=]5$>JP-AQEK<L>)S Z-.#)6G0 )[B<F=4<#UDXC
M5Y%)%&+;:5>I[^K%T$><3ON 285N>W0([N 06IRX,=F\*3<G."3>.U18=WG1
M PPNY%R]/"RMW95VS:B<.[58S;7<>S.,Q3AB22JIZ>IFTT@#?+?\PL)M'0)\
M%E60OQ_626PA1,H+%_NB$KJ(7^3(\Z\W+$.&I64D5MO48,:&")<6IO8S:3"@
M\<&8/]D!%[ L3Z4H,CBZE2;S0VN"#:3N3^@D<:T2.)!95TJINQTH8!8<H(8-
M3V 4C"ZR<))7 3GCN09DG;*%6MS(/<]XD-]C6^6IH;C14MR2(:'09S4$MAZ9
M$9%03T(L"8KT?+A(@"=G_Q4%HL<7#LI-4 6LFZ'1 H7L'_L.'?*8"K&5%)*W
M9] Y)=KO9<HRDI*B$R<?16$V3@I3-C06G]-$N4D]O[')*B,N()1"=A;+YT?F
M!AFBQ"'CNYWF>=:'QD=$T,E6F)C-Q(F;61H:S9S+SN[MO,+E85A, 5A&DO">
M]G59;SA(2!^7LG@8LA;1M(Q7-&8'K4B;#"&1RYJI]&Q;)\=/@@3:U%BF^ATE
M; D,7\GN7"=N(R$C1.(4S5:";3%."=>D<>3X]P6TG1%@$K(_D/Y.\I>J1IJP
M,W^?SG%,MYA]PNU%PXW@K#06Q]%'!Y$0OK*::,@C,Z[=X/[%[,M5L2.A>FXN
M-:D]S"!1YIF%68S J4IW*!D^I-))0I4ZUIP D;:NLUFPJWP6+%?CI#;-J"I[
M*\[RL.47=^2#0]8IRT";!&,Y=5,LQR2Y;)%&9@^59LRD^1R'=^HN#8X,7'H-
MV62'I'9QS"=%G0PR1Y $T3 QK!ZH2RUPD2@+6.:6L_:(QPHI@:51+U6+\C'3
MIA;QV"%:>RF[T4:B)L;(83R[7/X]15.;0'1?-//IE@@2 Z.']"\++='?KTS4
MP@ZHX>XK,C14"D]AN=+DFHL=V.,S@9SX\+E6;*3JIG_>N!H0B4_LP!.I+AJ"
MD8!S-,%D (_#<6CS(PV.1R K(5('Z.)1BM7X?$MCFXYW?W=CA.J4E_Q^ MP3
M[D"EX4>U$"-28_&=K"NM)PEA 1"-1:8(/JA7Q801Q[[Q"!1A]#315H]Q$5$&
MV;Q4^"1>CXPI\-]GK@XZQ-/LY(F3"- Y21MYE&13B5*TS$:I,@(0^7PSF5,[
MPFN(4UW$:(B7?K[,Z-R^R_ZJY^_@_L><ZS"57,0AJ/Y?- 6=G.MRY?GNB!A:
M2N'-VE=(8WVJX[H#J>=7N*J8L^;WSMC8P18#1*PS28+J=C/T4I+DD2$"]2:[
M,+4[NS+ZL@X:O_6H!#5QBCQ]V^ 6"W**9)5'%,-W]#[$0GU5X"9$K-N;;>V:
M"@'R-A:S8GHT^D545E72>'[5Y.OPZ?0&%R4ZKG%]V'NM<WQ346X^3*<QHW+5
M4Y@#R4/>SAA[#H&-$HG])/#<,Z0GVZJ\I^Y&=A6M\DXJNMKP,T5^V6R\-9;A
MPST5S7DLG3]F6U9G6)5AA'9P8C^#=T/-CK=;"HN!W84YL$B^Q8GMU$+,G39;
M2Y-U##T<U[YS_X(G)_H&T<L*$H-Z^"I%*W<*LB96IO)FJZ@4A>0X02?V+LT3
M(3.&N%K'LC7V\BF*\#,[*[$!P8:?.RI-YN-%D50/FF6W@NIVY?2V1<H<9S'G
M%E8%C&6C?0>Z O'.X-Q<Z5X)TU-.>1@BOY,W7G+-?$Y^!6^5>1ZQA:S_AB)F
M]$ *]+$IAB%%P!R]X,EL^N=06Z><HH[UNNY[Y[)BURR.HP$ :[ZNXR)X*O89
M#S:-3&X,,M)J1S(QK)-:]"2.,DT')I)9QRZW6DE<-IU@T5+JT$D3U2P&O%D-
MI?J_L5DZ<C\Q6[Z8HVGZA'X:A,93>TRG9NV:-AA!;%P(PVEHDQ==C.*2*;79
MY!-;@=JK&@-N%_$ 9(9LQQ=VQ58_K7SI8K':HKS)ER9C.E+!H(2\HN+G V*[
M6CC:3M5WCPY2QS@SMZ\@KDQ>_"I%"SGXK\;#@,G?L:8O/&B?1426VP-HI)J%
MRZJY@&]QGA5-8W@K2($V"N:\BZQP^*! ".#I-2+Y,#5/Y-HILF_:%8]D#0<"
MDXRH/,3+9#ZO2/K.C'1QA& =/ 4\Z?_$2J'2X LF6"H#$^M1(]HNNCQ<W$O7
M!\?"3\^69!1O=ME%=PF9A>6[C*<-*K^Y[R&PU:$NO!6JI $N1/V9HY8@ES3@
M"&7!C( "GI',NOA<K_$^QZU!36<!Z*@5&J;(?8JZE4=M]NC0[CVL(WU\&9,%
M$%3Z)=9DZB\8K2U^;W]AX<_MJ?UC\ E;!?M@:&/N\U!2;T9GLE5Z,[%"-YMG
M_65/T+C;W9)^)VBRD:AER*5_;L0<WNUGRMX%L;>O+NE+<*E.I9BI$$:%X+Q1
MAIZ.\)@D4R,,LQT]3 7=I[=KAW4T9TWBXA5W646"*L?P4SH/?$AUH3N]M2N6
M %0V"LR-.GR=-]/U#FK'=S)WWGC&ZXA6'I/RCC"[1]3L$YW8'J:]:L0LL-3Z
M\08N#RMOQSO##!8R9M5U[O6S#F_+L=(7R-,_SG>B(A?!>J.19)N,AHA&%1Q9
MYKTK!?9<5N3):3/RGP7I?.L!A\0=_\0P!9;RMNP]V#J?'6"FV"-DXDVU8#]R
M<ID-G7Y,@^T79^=_/SV_2"CC6K#\-LWM3PO\TR%6;30]5&I9^S+=3.N]T?1@
MFWY;H@@R-G?\1SCRQ@$VG\ZFYT0VEB!P#3;^8HEL<;P-L1E_KH">2_.W1NYL
M$0<BF]Q.<Y+*I"Y0&CI%+W_-R,TJP.6NY,XD-HI[#,B/%5QWH^]8C)R9L;&1
MP#$741@]WL!+,F+[C7A@:QSW?!PC.G O,9@7'@61N-FO+J]?I-U6=$ &P.1.
MS\_2QA\>6WT@"OSN\<7#[[,Y5]Z4%[$]_9-.V>I/=HR4S$@I0M;,!B,+D;MY
MSE<JVX5Q?(-_I$.&:?)6\<CM>'.64[G)6*Z.[ME^NTD_(Z+OR1P>8 @/Q:;=
MVC%*=1OII7RH;F]N3Y_B2QA[A _UM':D#TJ2KX#B%B8)0\]+[V_AEG7+M_"*
M&[2-7I([81LY?Q)] RJ4QO'OX;!K .[98,*DY]]V^ AHC7/)BQ?[M]R0T@ %
M4$[*77@DXJD!RE=$^^P/60<Y+L;%,_FD^T'RZ:^IQ&>XI3@*S8TZ/4#3#9SX
M"JWM'6ZA[_T\SRX:,(I2LQ^1N/SP5KP.TN?IS>_)S9>=+E;ZI8!-4X@?8L$.
M]$U[P#)(2C*K%S?BQ2_F]M!O7#W*?IML[;HE_P(;WY5L>_F9LO37]"-OE_+;
M9N/C\@MQOQ;=$M--C;NA5\_FWSXYL9W\ZII\Z/V&?^ELX?O>K_F?N,GM.CQ
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M_UI2OXJ&#6A]H8G&;L )#AWP[!]02P,$%     @ .HA\5<0;#-=>!P  E!$
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M+(4\[*3'8:--&!:C6"71#,-"+P&A\[),Q"Y:F@O>\"<*8WCD!FGNID&*5=)
MI*$;IC,W\O-Q#:*W1Z="N]D,F[E(Q%X,$IJXP2QR\WSV=]'3.;(_QE&1$U+
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M^UGJE?155W?04]\HCL"X#5*=>WTS'^*?LFJ]-Y(2+>OBD0Q;<3Z#;N\&H08
MR1<S?\=)/B5S)KB?TA>CJ]>87H6I"Y3*6X:]$4+4'64('B/-@)4%[%MGFOM@
MK4I4L1J?15%]:(=GBL&%64:#CK'':F#0FDJ7DIZM=8U -721=K5ET**&?/(>
M);="$8$_"5!M'\7GK^NUXO$ZZG5Q1;Y>'47^L-/?'R);J5JM 2]D8<B Z#/
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MK9VNA,>?W773W7.BXJ:O]%8[GWW?QU$P3B.J_K33WUBD?01UI.=>K5],4 <
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M'<#W:V-<?T,&AO^GN/P_4$L#!!0    ( #J(?%5U''FL<!P  #M7   9
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M&2\6*$,TDACL2V5<>@AI$[%T-PW+3K(2NC'NW)O"L?[O$&8+4' Q8VL2/I_
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M@'Y?-@2G] ,F\._+??Z_4$L#!!0    ( #J(?%52AD69H0(   $&   9
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M6CL<&:U9X8P&XP/P?*.U.S@^P3#U\S]02P,$%     @ .HA\55VAB$H !@
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M=!PF37M/;1=-6=F[X4W9X$W3_ESBU5X;$L#O\[)L^@49&/Y8</8W4$L#!!0
M   ( #J(?%5*-4R[#@4  )H,   9    >&PO=V]R:W-H965T<R]S:&5E=#$W
M+GAM;+5737/;-A"]ZU=@%$^JS* 1"'XGMF;L))WFD-9C)>FATP-$0A(:$F
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M90ZO-ATFX;"QJO/3YTI9F&7]<@M_'KAV!O!\K90=-B[ ^'=D\0]02P,$%
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M(=M4GM.LPY^W^.@ OH/ 6UJ+%0=IG9-\"#"5G>U[C)Y[_ H9$?_<U.< AF<
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M$0:JX;CC@J'C!A=A9WD#5E!-A40PVA/!+D]BA6)U8X$TVNX8'$4E1U&8H_H
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MA/E%V\9V0BR4K(5D90M6'I1YU?S3^U:('0#VGP&0%D#V =XS +<%N"\%>"W
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M2.TMA>"1$L:!#_)ZC\*^)/21FY3O.*3Q$Q**GD.*K4@OG$7CEMOQ$>N* _I
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MDEDAJP_3ZAM1KO7QTJP4HLSUY8J2A#)E(-\ORE(\W:@&VB/-Z;]02P,$%
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MMRZ;FY">/^XNZX4!&?GGR>I<W[&&H\-%W$DU#H^Z0#/6W U)\-W1ZN+,HV7
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MX7TOZ#6E;/5Z9<K=*N6N-:9'1&0R7!*61F0&:YR&&<XV333;DE!"Q+5JRK1
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M_'?7><8DTU1LF[:U?\BK_&K'S>GS+SR[/RO[CH,FDXO#]]B<N(=N,GT+)M_
M=B?9X7ML;D4'9S)NSN^M2\+.%:&-1G 5&Y(?<+$3FZ319,&%X;+IS7F>,_GD
MIF#E#9W8R_R.OAV?LX(NA+EMP2'9M+^SG"_*K!UU#0O1C-JTO\'TNFE[#[2Y
MN,S9DN7CIJMG$]>,;,-F;3Y V$>NW">,8!R/A1' L#R8 XSC65B>_VD^?70^
M'L.\]8-('^7T48YGA9"Q^V)YPIS,?L(SS;(D25-L1<?CH(,QMFYI"C]A-<P;
M,+ \D.G/UAK?;;Q"GJ\#;$^?JQ!LIG@E8C/%UQJ0\+H!(\O"NXWE 0:V"UCM
M0/YP'JBI,"=)8%<Q;]@;C"-9AB%0B^$:35-D=5+XAO<'>TN2),O""&!A!TF"
M(? VX@CF #Q@2)*X<W#O/(K7YU2\^0_7Z!%02P,$%     @ .HA\59>*NQS
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MDN,!) <?H01!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M
M(:M (:M (:M (:M (:M (:M (6N*0M84A:SI?Y+U0^OE7__Q:M>DEJHY^+/N
MM^+L"U!+ 0(4 Q0    ( #J(?%4'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ .HA\567CCY/N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ .HA\59E<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  ZB'Q5GTUM3RL'  !M+P  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ .HA\59WF->24!   RP\  !@              ("!;@\  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( #J(?%5OFP^FT0(  *,(
M   8              " @3@4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "  ZB'Q5Y,,!Y64%  "Q%0  &               @($_%P
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ .HA\5<(.JF%(
M!@  :AD  !@              ("!VAP  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( #J(?%7!F_ZJQP@  *$[   8              "
M@5@C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  ZB'Q5
MWR)"*<$'  "Y$0  &               @(%5+   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ .HA\50E/QGU:&P  !D\  !@
M     ("!3#0  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M #J(?%7.G=XGM (  #4&   8              " @=Q/  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "  ZB'Q5@&6:ZG0$   -"P  &0
M            @('&4@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( #J(?%7$&PS77@<  )01   9              " @7%7  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ .HA\56?%2TJ1"P
MB1T  !D              ("!!E\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "  ZB'Q5""_%=^\)  "S&   &0              @('.
M:@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( #J(?%5U
M''FL<!P  #M7   9              " @?1T  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ .HA\55*&19FA @   08  !D
M     ("!FY$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #J(?%7(!9PN4 0  !(:   9              "
M@26F  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ .HA\
M54@OO;"N!0  :A\  !D              ("!K*H  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "  ZB'Q5R(PHDNP"   ]"   &0
M        @(&1L   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( #J(?%5/^MQAZ0(  &8*   9              " @;2S  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ .HA\56*6"P(W!   M0\
M !D              ("!U+8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "  ZB'Q5P=F4<B,'  #N-   &0              @(%"NP
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( #J(?%7DR6$Q
M3 ,  (L-   9              " @9S"  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ .HA\51\\T43X @  80D  !D
M ("!'\8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  Z
MB'Q5<UYH588%  #>'   &0              @(%.R0  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( #J(?%5WX?7*P (   4(   9
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M;',O+G)E;'-02P$"% ,4    "  ZB'Q5S9+_E0X#  #>%0  #P
M    @ $1XP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ .HA\58H3@V1C
M 0  MQ,  !H              ( !3.8  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ .HA\554IDH^) 0  7A0  !,
M ( !Y^<  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "@ * #/"@  H>D
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>79</ContextCount>
  <ElementCount>232</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>27</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business Description and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</Role>
      <ShortName>Business Description and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Equity Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferings</Role>
      <ShortName>Equity Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilities</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxes</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Equity Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingsDetailsNarrative</Role>
      <ShortName>Equity Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferings</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Commitments and Contingencies (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails5</Role>
      <ShortName>Commitments and Contingencies (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="e4251_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="e4251_10k.htm">e4251_10k.htm</File>
    <File>avxl-20220930.xsd</File>
    <File>avxl-20220930_cal.xml</File>
    <File>avxl-20220930_def.xml</File>
    <File>avxl-20220930_lab.xml</File>
    <File>avxl-20220930_pre.xml</File>
    <File>e4251_ex23-1.htm</File>
    <File>e4251_ex23-2.htm</File>
    <File>e4251_ex31-1.htm</File>
    <File>e4251_ex31-2.htm</File>
    <File>e4251_ex32-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="391">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="35">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>53
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "e4251_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 10,
   "contextCount": 79,
   "dts": {
    "calculationLink": {
     "local": [
      "avxl-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "e4251_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "avxl-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 345,
   "entityCount": 1,
   "hidden": {
    "http://anavex.com/20220930": 29,
    "http://fasb.org/us-gaap/2022": 23,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 56
   },
   "keyCustom": 53,
   "keyStandard": 179,
   "memberCustom": 18,
   "memberStandard": 9,
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://anavex.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Other Income",
     "role": "http://anavex.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Equity Offerings",
     "role": "http://anavex.com/role/EquityOfferings",
     "shortName": "Equity Offerings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Commitments and Contingencies",
     "role": "http://anavex.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Income Taxes",
     "role": "http://anavex.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://anavex.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Income Taxes (Tables)",
     "role": "http://anavex.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "role": "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:ClinicalSiteCostsAndPatientVisits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Accrued Liabilities (Details)",
     "role": "http://anavex.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:ClinicalSiteCostsAndPatientVisits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://anavex.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:GrantIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Other Income (Details Narrative)",
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "shortName": "Other Income (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:GrantIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:SalesOfAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Equity Offerings (Details Narrative)",
     "role": "http://anavex.com/role/EquityOfferingsDetailsNarrative",
     "shortName": "Equity Offerings (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:SalesOfAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2021-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2021-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Commitments and Contingencies (Details 1)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
     "shortName": "Commitments and Contingencies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Commitments and Contingencies (Details 2)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
     "shortName": "Commitments and Contingencies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_StockOptionMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Commitments and Contingencies (Details 3)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
     "shortName": "Commitments and Contingencies (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-012022-09-30_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Commitments and Contingencies (Details 4)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
     "shortName": "Commitments and Contingencies (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Commitments and Contingencies (Details 5)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails5",
     "shortName": "Commitments and Contingencies (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Income Taxes (Details)",
     "role": "http://anavex.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Income Taxes (Details 1)",
     "role": "http://anavex.com/role/IncomeTaxesDetails1",
     "shortName": "Income Taxes (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Income Taxes (Details 2)",
     "role": "http://anavex.com/role/IncomeTaxesDetails2",
     "shortName": "Income Taxes (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OperatingLossCarryForwardsExpirationYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Income Taxes (Details Narrative)",
     "role": "http://anavex.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income Taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OperatingLossCarryForwardsExpirationYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://anavex.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Business Description and Basis of Presentation",
     "role": "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation",
     "shortName": "Business Description and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://anavex.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:AccuredLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Accrued Liabilities",
     "role": "http://anavex.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4251_10k.htm",
      "contextRef": "From2021-10-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:AccuredLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 27,
   "tag": {
    "avxl_AccuredLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AccuredLiabilitiesTextBlock",
        "verboseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccuredLiabilitiesTextBlock",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_AdjustmentToTaxAssetsBasedOnSection382": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to tax assets based on Section 382"
       }
      }
     },
     "localname": "AdjustmentToTaxAssetsBasedOnSection382",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to cantor fitzgerald and co.",
        "label": "Cantor Fitzgerald And Co [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoMember",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CashPaidForStateAndLocalMinimumIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for state and local minimum income taxes"
       }
      }
     },
     "localname": "CashPaidForStateAndLocalMinimumIncomeTaxes",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ClinicalSiteCostsAndPatientVisits": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical site and patient visits costs"
       }
      }
     },
     "localname": "ClinicalSiteCostsAndPatientVisits",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares"
       }
      }
     },
     "localname": "CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares (in shares)"
       }
      }
     },
     "localname": "CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_DeferredGrantIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant income"
       }
      }
     },
     "localname": "DeferredGrantIncome",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_DeferredGrantIncomes": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredGrantIncomes",
        "negatedLabel": "Deferred grant income"
       }
      }
     },
     "localname": "DeferredGrantIncomes",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_DeferredTaxAssetsUnpaidCharges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a deferred tax assets unpaid charges.",
        "label": "Unpaid charges"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnpaidCharges",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_DisclosureAccruedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities"
       }
      }
     },
     "localname": "DisclosureAccruedLiabilitiesAbstract",
     "nsuri": "http://anavex.com/20220930",
     "xbrltype": "stringItemType"
    },
    "avxl_DisclosureEquityOfferingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings"
       }
      }
     },
     "localname": "DisclosureEquityOfferingsAbstract",
     "nsuri": "http://anavex.com/20220930",
     "xbrltype": "stringItemType"
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "localname": "DisclosureOtherIncomeAbstract",
     "nsuri": "http://anavex.com/20220930",
     "xbrltype": "stringItemType"
    },
    "avxl_EarningPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "localname": "EarningPerShareBasicAndDilutedAbstract",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "avxl_EquityOfferingAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityOfferingAgreementsTextBlock",
        "verboseLabel": "Equity Offerings"
       }
      }
     },
     "localname": "EquityOfferingAgreementsTextBlock",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_EquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to equity offering sales agreement.",
        "label": "Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "EquityOfferingSalesAgreementMember",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_FederalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]"
       }
      }
     },
     "localname": "FederalMember",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_FixedContractAccruals": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed contract accruals"
       }
      }
     },
     "localname": "FixedContractAccruals",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_GrantIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantIncome",
        "verboseLabel": "Grant income"
       }
      }
     },
     "localname": "GrantIncome",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_GrantIncomePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Income"
       }
      }
     },
     "localname": "GrantIncomePolicyTextBlock",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_GrossProceedsFromIssuancePublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from Issuance Public Offering"
       }
      }
     },
     "localname": "GrossProceedsFromIssuancePublicOffering",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LessShareIssueCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: share issue costs"
       }
      }
     },
     "localname": "LessShareIssueCosts",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LessSharesIssueCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LessSharesIssueCosts",
        "verboseLabel": "Less: share issue costs"
       }
      }
     },
     "localname": "LessSharesIssueCosts",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of legal entity.",
        "label": "Lincoln Park Capital Fund, LLC [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_MichaelJFoxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael J Fox [Member]"
       }
      }
     },
     "localname": "MichaelJFoxMember",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_NetLossAndComprehensiveLoss": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NetLossAndComprehensiveLoss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetLossAndComprehensiveLoss",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NetLossPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "NetLossPerShareBasicAndDiluted",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NonOperatingIncomeFromGrant",
        "verboseLabel": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrant",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NonOperatingIncomeFromGrants": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrants",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NonOperatingsIncomeFromGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NonOperatingsIncomeFromGrant",
        "verboseLabel": "Grant income"
       }
      }
     },
     "localname": "NonOperatingsIncomeFromGrant",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NumberOfSharesObligatedToPurchaseProrataBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to number of shares obligated to purchase prorata basic.",
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "localname": "NumberOfSharesObligatedToPurchaseProrataBasic",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OperatingLossCarryForwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carry forwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsExpirationYear",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "avxl_OperatingLossCarryforwardsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards description"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsDescription",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "avxl_OptionIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option issued"
       }
      }
     },
     "localname": "OptionIssued",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OptionPrice1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 1 [Member]"
       }
      }
     },
     "localname": "OptionPrice1Member",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 2 [Member]"
       }
      }
     },
     "localname": "OptionPrice2Member",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 3 [Member]"
       }
      }
     },
     "localname": "OptionPrice3Member",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 4 [Member]"
       }
      }
     },
     "localname": "OptionPrice4Member",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 5 [Member]"
       }
      }
     },
     "localname": "OptionPrice5Member",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomeDisclosureTextBlock",
        "verboseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeDisclosureTextBlock",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ParkinsonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parkinson [Member]"
       }
      }
     },
     "localname": "ParkinsonMember",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PercentageOfGrossProceedsFromSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to percentage of gross proceeds from sales.",
        "label": "Percentage of gross proceeds from sales"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsFromSales",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "avxl_PermanentDifferencesRelatingToSection162m": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences relating to Section 162(m)"
       }
      }
     },
     "localname": "PermanentDifferencesRelatingToSection162m",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_PermanentDifferencesRelatingToStockBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences relating to stock based compensation"
       }
      }
     },
     "localname": "PermanentDifferencesRelatingToStockBasedCompensation",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_PurchaseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to purchase agreement.",
        "label": "2019 Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreement1Member",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 1 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants1Member",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 2 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants2Member",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Purchase Warrants [Member]"
       }
      }
     },
     "localname": "PurchaseWarrantsMember",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SalesOfAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales of agreement amount"
       }
      }
     },
     "localname": "SalesOfAgreementAmount",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price Balance, at ending",
        "periodStartLabel": "Weighted Average Exercise Price Balance, at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfOptionInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of stock options"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOfOptionInShares",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOptionInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of options (in shares)"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOptionInShares",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options"
       }
      }
     },
     "localname": "SharesIssuedPursuantToExerciseOfStockOptions",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptionsInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options (in shares)"
       }
      }
     },
     "localname": "SharesIssuedPursuantToExerciseOfStockOptionsInShares",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedPursuantToRegisteredDirectOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to registered direct offering"
       }
      }
     },
     "localname": "SharesIssuedPursuantToRegisteredDirectOffering",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToRegisteredDirectOfferingInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to registered direct offering (in shares)"
       }
      }
     },
     "localname": "SharesIssuedPursuantToRegisteredDirectOfferingInShares",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedPusuantToExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pusuant to exercise of warrants"
       }
      }
     },
     "localname": "SharesIssuedPusuantToExerciseOfWarrants",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPusuantToExerciseOfWarrantsInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pusuant to exercise of warrants (in shares)"
       }
      }
     },
     "localname": "SharesIssuedPusuantToExerciseOfWarrantsInShares",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedUnderSalesAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Sales Agreement"
       }
      }
     },
     "localname": "SharesIssuedUnderSalesAgreement",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedUnderSalesAgreementInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Sales Agreement (in shares)"
       }
      }
     },
     "localname": "SharesIssuedUnderSalesAgreementInShares",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued for commitment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues3",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues4": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued for aggregate purchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues4",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues3": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Number of shares issued for aggregate purchase price, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues3",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues4": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Amount of shares remain available"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues4",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockOptionPlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of plan.",
        "label": "2015 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2015Member",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2019 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2019Member",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2022 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2022Member",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to value of shares obligated to purchase initially.",
        "label": "Value of shares obligated to purchase"
       }
      }
     },
     "localname": "ValueOfSharesObligatedToPurchase",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
     "nsuri": "http://anavex.com/20220930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r286",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r286",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r286",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r286",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r286",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r236"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued liabilities (Note 3)",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails",
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r164",
      "r165",
      "r166",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r122",
      "r167",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Share based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total share based compensation",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Loss per share for potentially dilutive common shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r5",
      "r44",
      "r72",
      "r80",
      "r84",
      "r88",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r204",
      "r207",
      "r215",
      "r234",
      "r236",
      "r252",
      "r260"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r148",
      "r149",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r4",
      "r236",
      "r272",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r4",
      "r40"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r34",
      "r220"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash and cash equivalents during the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Federal Deposit Insurance Corporation"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r18",
      "r255",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - Note 6"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Maximum number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r49",
      "r50",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r236"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding:77,942,568 common shares (September 30, 2021 - 75,918,465)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r45",
      "r189",
      "r195",
      "r197"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "avxl_NetLossAndComprehensiveLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense, current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r38",
      "r45",
      "r190",
      "r195",
      "r196",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Income tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized.",
        "label": "Deferred grant income (Note 4)"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Intangible asset costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r187",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r187",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r187",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": {
     "auth_ref": [
      "r187",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.",
        "label": "Foreign exchange and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance of deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and Diluted Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Remaining stock based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r24",
      "r25",
      "r26",
      "r49",
      "r50",
      "r51",
      "r53",
      "r58",
      "r60",
      "r64",
      "r89",
      "r112",
      "r113",
      "r164",
      "r165",
      "r166",
      "r192",
      "r193",
      "r210",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r230",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange (loss) gain, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r46",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r27",
      "r72",
      "r79",
      "r82",
      "r83",
      "r85",
      "r251",
      "r256",
      "r259",
      "r266"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "avxl_NetLossAndComprehensiveLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r46",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r72",
      "r79",
      "r82",
      "r83",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r47",
      "r176",
      "r179",
      "r184",
      "r194",
      "r199",
      "r200",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Interest and penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r23",
      "r173",
      "r174",
      "r179",
      "r180",
      "r183",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowances"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r172",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effect of change in statutory tax rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Foreign income taxed at other rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Income tax benefit at statutory federal rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.",
        "label": "Research and Development tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Other permanent differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).",
        "label": "Adjustment to true up to prior years' tax provision"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State and local taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r8",
      "r254",
      "r264"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in working capital balances related to operations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r44",
      "r81",
      "r88",
      "r100",
      "r101",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r205",
      "r207",
      "r208",
      "r215",
      "r234",
      "r235"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r44",
      "r88",
      "r215",
      "r236",
      "r253",
      "r262"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as current.",
        "label": "Uncertain tax positions"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r34",
      "r36",
      "r39"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r21",
      "r22",
      "r26",
      "r28",
      "r39",
      "r44",
      "r52",
      "r54",
      "r55",
      "r56",
      "r57",
      "r59",
      "r60",
      "r61",
      "r72",
      "r79",
      "r82",
      "r83",
      "r85",
      "r88",
      "r100",
      "r101",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r211",
      "r215",
      "r257",
      "r265"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows",
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r72",
      "r79",
      "r82",
      "r83",
      "r85"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Business Description and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "All other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Share issue costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Contribution amount"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r148",
      "r149",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r148",
      "r149",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r6",
      "r236"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Public Offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Issuance of common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r163"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r115",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r115",
      "r231",
      "r233",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r170",
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "verboseLabel": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r169",
      "r237",
      "r274"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r113",
      "r236",
      "r261",
      "r270",
      "r271"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r49",
      "r50",
      "r51",
      "r53",
      "r58",
      "r60",
      "r89",
      "r164",
      "r165",
      "r166",
      "r192",
      "r193",
      "r210",
      "r267",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionIncentives": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for sales incentives.",
        "label": "Research and Development Incentive Income"
       }
      }
     },
     "localname": "RevenueRecognitionIncentives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Number of common stock sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of components of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of deferred tax asset and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of general and administrative expenses and research and development expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r121",
      "r123",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r148",
      "r149",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r128",
      "r144",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Summarizes information about stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of outstanding stock purchase options"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r114",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of exercisable share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment and Geographic Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Share Purchase Warrants Balance, at ending",
        "periodStartLabel": "Share Purchase Warrants Balance, at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weighted average grant date fair value of options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Annualized volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "negatedLabel": "Share Purchase Warrants Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Additional shares of common stock available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Aggregate intrinsic value Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted Average Grant Date Fair Value Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value Outstanding at ending",
        "periodStartLabel": "Aggregate intrinsic value Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Number of outstanding options",
        "periodEndLabel": "Options Outstanding at ending",
        "periodStartLabel": "Options Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Weighted average exercise price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding at ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r148",
      "r149",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r123",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.",
        "label": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationForfeituresPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, lower range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, upper range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value Exercisable at ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life (in years)",
        "verboseLabel": "Weighted average contractual life of options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Number of vested options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at ending, shares",
        "periodStartLabel": "Balance at beginning, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r42",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r20",
      "r24",
      "r25",
      "r26",
      "r49",
      "r50",
      "r51",
      "r53",
      "r58",
      "r60",
      "r64",
      "r89",
      "r112",
      "r113",
      "r164",
      "r165",
      "r166",
      "r192",
      "r193",
      "r210",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r230",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r64",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Share issued for offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r112",
      "r113",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r20",
      "r112",
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Shares issued under 2019 purchase agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r6",
      "r7",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Purchase shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r6",
      "r7",
      "r112",
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Purchase shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r11",
      "r12",
      "r44",
      "r87",
      "r88",
      "r215",
      "r236"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets",
      "http://anavex.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationRelatedText": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional textual information about cash receipts or disbursements in the period required to be supplementally disclosed.",
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationRelatedText",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesExcludingIncomeAndExciseTaxes": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All taxes not related to income of the entity or excise or sales taxes levied on the revenue of the entity that are not reported elsewhere. These taxes could include production, real estate, personal property, and pump tax.",
        "label": "State minimum and excise taxes"
       }
      }
     },
     "localname": "TaxesExcludingIncomeAndExciseTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Decrease in vaution allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Expiry Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(m)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r275": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r276": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r277": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r278": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r279": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r280": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r281": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r282": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r283": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r284": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r285": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r286": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r287": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r288": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r289": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r290": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r291": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r292": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r293": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r294": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001731122-22-002062-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-22-002062-xbrl.zip
M4$L#!!0    ( #J(?%7X#P6ZG@P  $B    1    879X;"TR,#(R,#DS,"YX
M<V3M75MW&CD2?MX]9_]#+R^;?< 8L#.QQYX]!$-"!@-K2.;R,D?N+D";1LU(
MW3:>7[^2^D)?U0VVQ\K@/#@@596JZI-*);747/QGL[*-.Z ,.^2RUCPZKAE
M3,?"9'%9^SRM=Z;=P:!F_.>'?_S=X/\N_EFO&WT,MG5N7#EF?4#FSO?&"*W@
MW/@ !"AR'?J]\079GBAQ^M@&:G2=U=H&%WB%W]*Y<7K4;-\:]7H%N5^ 6 []
M?#.(Y"Y==\W.&XW[^_LCXMRA>X=^94>FLZHF<.HBUV.1M./-<?"O&OLU9F;$
M_.Y'^U?VW>8&_[P \L[K(F*94P3]L3EQ-Y_Z?ZQ^_;J\:ZU;\]D*M1^8L^K<
M--Y-/Y'-=U\^?(7%)[_)"V8N884,#@9AES5A7V#>??O(H8M&Z_BXV?CY>CB5
M=#6?\'QC8_(UC[QY=G;6D+4A:89R<TOM4'2[(:IO$8-(,J_%"GI,F(N(F:"W
MW(@A3GS:\"L3I#B7]*U/BD-2"U)T#,RCA7/7X!6<OM4*"3U67R"TCHCGB-U*
MH4%%@IA1-TO("]-$=?=A#2R7U*]*,%@N33$DO,:K&Z):\!S7CYOU5C/D1'<;
M.V)"!-W!1O1E*?WXK"U&I TK(&[?H:LKF"//Y@;\[B$;SS%8-<-%= &NZ)QL
MC4Q0R@K[-R+$X<. C\6@1)2MUYCW<U[PMPO1(<ZI8\.,*VV(#WP YDD658VN
MPT-(S<#69<W_*&1PB5**!7-,L&PJ&&=-HRY&E2>,XA\ERT4C31P3X3&PQN0'
M^7E-@7$^J?N0%P2, 4D!DXELT[-WX]FJDLL2%(0^VLMKA#DVMI +UGMDB_$T
M70*X+/1D4;7:NRWN4A'B('3O>#0=#P=7G5GORGC?&79&W9XQ_=CKS::O3M]Z
M=8(HMW )+N9ZER"0I%7#T:X.A_$F(?C?!PY/Y#4VGH_7(K?@[;(.L40^06$)
MA.$[&#HL9\#LP*N&[T0%WW3&_[ONC3ATX[XQGO1N.K,!)S ZHRM.>3VYZ7WL
MC::#+SUC.)X>^G"+8])%;-FWG?L2Z+9D:I1.JZ/4[4P_&OWA^*=7.&)^7B*R
M #8@4]<QORX=V^*)>N]W#[L/)0 I&-60O=T!LH^=T8?>U!B,>,6X^^/'\?"J
M=S/]E]'[[^?![)<#Q/&]QS !QJZ F12O14L\MKU'#'-,)C$S??2JDZLQ^TXD
M;GSY8SO,H\"_A(*-F&2#KX$,*=MPYD9<^@$"-?56*T0?QO,I7A">KYN(N!W3
M=#SB\B7VA \I$T,0!"O2JB%ZEX8HD"JPB,DUMH*-4/(!PL.]0#VPAAC=8ILW
M%$*14ZYV^UG:[8$$(R;B /T[YKDL'1#^'7S'Q@N4'FT>ISTJ60V?]P!=Z4^J
MX_D<*!^T03]-%ZI=VDR[U&<W(OX#="M?#ZRP*[,9N3J0(1'(-BJK"-3N;J7=
M'1,E)\F$L /TO3^69V@3^CI>H/9M.^U;G]60O ?HRFJYPS[Y1K6\HWFR?]YA
MO D_'>*.1S;5F*%;NS@1"6K5:)Q62$>,-[ZH0W2Z(JC'O5].IH;A[4XSP"$#
M$HO\<0"RQ6J'9Q:H\6GAD/U;+=9?@8NPS4:(B@W3.]AEGLCPJI%ZQ#K5>!.T
M942-'2*DV:DA<$O1S!%6JX&ILI*-$#A$O\>6L/GC146@]'U+N>9][?9YZ^!\
M",J(U#"4KI-?H2C+HA*AJ *=&I#=5M(''9W*?=VL"DJS!)7,&KP:*D;S%9<\
M=[>JXM(JP26S%*^(2^L5ESQWMZOBTB[!);,HKXA+^Q67/'>?5,7EI 2775?I
M(2XGK[CDN?NT*BZG);AD%O,5<3E]Q27/W:D4>1<&-4Z9I7Q%G XZ=X[M;"5R
MY9QRM?<SZ_7DEM<!I\)95S:+?%R2ZK8S"_-<)Q]F9IOU9JO(S269:SNS\,YW
M\T$FJEEOI@*ZBD#M]LSR.M_M?\5X+?Z(BR\W,#?DA9ES<4OCLL:PN+)4"\J6
M%.:7-7%1HQ[>I/B-FW:T6=DAB1"MN# C(4Q[(V@X%(&HF9&2N=##A3AKH&(7
MMA$J'PIPL2O8XT?N#-$.GUH:3V&RC6YW-9FS@/V,M@Z%_"<UDO>^78U,==AG
M,K6[;>5)#>9#9U>#DZ/MF>R]BAJ)FQO<56IL+RL%W],7FBZXX0YU#9*Y%Z6Z
MSN9?Q!LZIA2E8!'?ZB%?7135FZUZNWFT8=96TUV4V+IA-R5"OCV4*+A4E]<^
M*R(7'V1GJMIHP>4\9:.Y/ VP71:6[*U"_"K?(W208G92HOQ^8)$Z99SR.]NK
M$\B'K?1AEXX09PF_[.2(I#2/4KY0W$V#.$_T;;\>L;T(6JTSA/1^1Q!W0_=M
M=H^>F&V\L!L&=TAEIBCB_V_7V%PBL#_UG<TUK&[%_4VAWV4MKP+;MC@Z<5ES
MJ2?BM+@>?,[C-W:LF9QF+(\&]PW\:2>Z#GMN.2N$R<"%E:#DEGFWC$=X3U!_
MH(ZWOJSYXC G42D\0?0K#[@.2:J;+=9!V>0#R"FR@746%"154O]*E#J8U$7$
M=6@?NW\L@"+;DKM&25O4)#H8,?$H[]T,(A<W4[VIN%X']7DB9#HV$7V^B];8
M17;?(]9PV$U:44ZF@S'RRMA8WAF:V(BTCING23,4!(BW29'IA@9H:M!9F4%G
M>B/2:I48$"/0P8!P^/XDMBJ(R_('=Z961]4+ E.V6D?E6VKE]>HT07^FV(24
MTW-K-%.Y5:BRMEYN%ZK<UE7EDT*53W15^;10Y5.M5.Z#)9+%I+;I0AT4'3DD
M>)4$6?@[Y'WJK#[(B!;J74*S@QE^W:W_VI'+FDG!PFYHG5^Y<@BXB#X\@6TW
MP #Q(,TS]BNX ]M9BWIN ?^+[R"\PND;69586VM'X(I7?^2_2B0 4DFBK64]
M1(DXE ]TND04Q#5\4\"$;<\%JQ-DS=':LR+UX[-MGX)+$>/BR0 L4#R%83'5
M(Z+*.A#Z!,;\!'BQ%/Z^XX%C 2-/Q+SQ7(IG8\\5>\SBA7P%5N[/KH?Y5S '
MRD>%#))^[(A&84&=ML-/O*]F@K#5=ZA\MPEWM]C#LZ\QP2MOE;CP&FZ9[,"Q
MO]T6W#ZGV=&!'[_7#1CSP/(_?R9\)G>!KL2K1M*[*ZW(#8^1H&]WR+5*OCI2
M:513[99J O:-T7Y#3["9$-.8*\@\/H1G3F\#U,0,>(#:[B5$HV%''FV!W\6.
M ?&I]_%!C%=/N$5XLX&QK?J^YM6,KL#]C9C]&*-U-EE&H>1#BSSK\LETG<Y*
M-%?!J"9_:>2&O%OY:9M0MNNP[<(UO^H;"[ WL,",SXG DUP*IAL^55,/. 77
M7\3^:H&G K<V'9@I>C#[%KMP9IH/]\KS,5.1?^L6JWMK%;:7[J;;P[396_CI
M/9AJM-KMP'!EN<J)%]/ QGUO\]PTM$Q-\HC-!S<4\Z10Q:[M%V.42Z0=./$W
M$$2J9_ II=(.HM2U_F*8"@FU@RJI:90T9D=3%4)- (OMULEWMCQDC%%2:&*%
M^*T-R[,AV$I-/\..[:S*UPIE;'P$OR8>Z-J8B!?13SFA3*<ZQ)KP=CG1%\SP
M-C>I0EAJDW^8VOVSDY(^WH"\_BC"@IR"D1T95E2IJS&Q<94SU'3.#14/3BL\
M6]79LIQG&(K'&QIWKKC_606,<FBT!6G"5Q/BSM2"AVO.R-B$.B: Q83V<C\G
M.LM4A?)Q3]:$_"<)!BGMQ!)*>'/BW?(Y-[TY4IU<VWT[X?WQ/,J-.BMQ&R&:
MCXMJ=1UO\C%/]""78[ 0O[XP<\),(C2L IVNB*4>5F=UY_V1*X;DL^LHQNS(
M]-*[ ?*!C;]]<>51_[P%;]M7?P3WLDJ\SB1VQK82N::&R?X8*=HNL2M+K>TD
M40V9,H-SR+\)(,LZ:)9:7R"#XT @#W<!85*+CEB8+23I^X<MR00]R.GB'E'+
M7X0/^'Q /?\7<,0>RFR)2/! -K:J2YW+"3<LY0G,Q-;F"RM2??I[QD- S^<(
ME?5]A\X!Q\Y2O;P:>IS)*O4#*W)$8&Y@DB?B$_'C0X$'V&X#XAD:_HNX/++K
MSW7XSLWJX>[@5(6<Q9)'Y*.REYZ5P]V!&=IT& .7?29KA*WN4OS>:^:(9"&5
MKLL;WEM6B/"B*RR6EL#;9#=@RZV#F2.3C$R_C"W"]^'5=1E48@Z80F+S;6M5
MT?X$@ZY&=ZS_>4R>;9PY4>>5J(U)8$'[771 M#*UKN9&)WEOP'2(B6TLM1@Y
MQ ++XP9PI7L;T5LA_WY%5P['$40;&D\J4=M</=I.%$?YNXC2A[E#Q?P3_S7#
M;02O1OS23_VR>O8#/3E@V&_Z%XY8L5V%]'^>:1<-_RT5_./_ 5!+ P04
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M$_PF.T!N@THKKSL.)^7KN1+RZK6=> Y)198T$]U16$F9;+Y5$J='Y@3 F5/
MUX57FJ%*4EG=P39?CG2&5=(A_6YM7(>DLMH&\YUS74@Y4^#$PKH#;<9=\MC
MG4:U2NU(IF(X4Y$C7E)W:%76(HUDE83HF!!I@#*V)C#?&[ N7E$'6P'H&<.?
M@JWNP*LLEKHCJB3?5&:8&#'[V&;RG@T,ZNNE]"\Q84"A1M8XJ6*K)M^5?OG4
M'5$E^0+3 EAC%1E<\RUU#UFJW")"IFX!RE-,XPR["+^\_6YI-#\WDM*R9T[9
M)N__#.5OV^KY6_0A5-_/9TE!'[ /-,3O*HO?[ E>OO9'P&W\@,:3_K3S-( "
MJ#/J0<FODVG_L3^:#;[WT7 \TY3 ]EBS%R^[DY$J22BJ)U#NGA&P0*:.N:2,
M"F=W1\7#E<X@UU!WF$Q5(Q(W%#U0I=%M2@0!)#(9WR,;8O&5[#.YDN68Z8[[
MJH(IL:^27'MBNR1], 1F1(9@X<KTI3B#B#CI(L8%J6M39,09#U/*[3P9)@=Q
MB-_?EN](9!%G/X 87VS,$F^-2IML$]U-)]?5?@/*IW+RGIVB07*  3SP&P:&
M\";VB!B*MKIC;2%5"OFC2H%WP!QB$^&$&(Y(QM(]W4)WOD59L5PFU=/I@=L
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M9JRP)!!)'YHC:>* TUM1$<.FND-:3"*(O-,ZR..GGS:B]!6G#[$4?7F-M9%
M(9FR3K8:X+!"!KO'7P'VRKI-!-CS9MZ9SI!MYEL!HE)JM8<3"#RH_K(>DW+J
M+]!?,FJWF@ZQ7E'6_P'0<LDZI_=8#]89IBY$04I)M=4- 0956]9-46BZN$$+
MB[)%/]N-6P09;IC74VBB@!I1FY 2LH!<5>R;* :MU.2>UUB7N!,;RBIV2&SZ
M.Q4?RVCK!K-MQ*!VI;H($ONK/W@RA0,J7+"VVAP4$0*D1:I3 ,14:,3*;:43
M-(F-467= !5$H?QC3?VLN%L,A&9X O"+F[Q(<>10+W+\!OE':6B&R*-E(-_?
M?X,,O/#YR3FMDOUD=:VG3@6 !]6-!9]=(==/DHMF&B3-(U9,>2Z3:$'%1_P-
MOQ]L"<(>\U-*3D'Q"XQBF02_\IPAB_+ [35![$/8GA9I4-,=4_.:U/"]%F]4
M3J9$P;N-8B)]V!8I:(QCCS2GO;:GO38H1YR,:Y!BT$^WH0<5M5A-.1C3;DB*
M@AL<;H/S:FAA%3FHH!N38L@&V\C\6EJDFJR$GOR;DV)(A]M((RUXO6RK#3FP
MTZY7BL$\VH;IU]""*DWV^<R^/S@NW_>U7\*_I.7LY=Z_%)/E1& PT'[Q6Y"8
M9BAZ&U,,^_M"=BY="OC6IACJQ&08-7OI('>\IRDFR0YSH/9+\ AM\XP:.\3V
MO1@QJ42FQPU\::!%+GV*PAYF3IRIZFYD^7[.]8/,S\AA?[C7MNZ\@DZLDI/+
M>L'J#<7Q&4MDKFVV>T_"I*\X:5Y29[%FE,GY+$3M=@Q@&=4IGR5Z@VR>A7VM
M$_?EEC!)=,,+[?C\$OTE.V6T2!O-Y8^6HF\[=:2HLA3*88A"S,MG3"O;3)9I
M"97#G*F;;[H;.2IGFDH@4$[.*7 N\,TRECJR_W:!G\&<.%XP46Z>AJ0&CUZ&
MP>,\N*!2*PXA8N!^6@[%3J9*MTK-CU56:!I82)W'U4X"E+B1,89]>AU?V(?Y
MV9H0MK^$)G%6)%ZBG5-T0@QPD*]"]Q09[Q;X\< ('NGK/_STJO_PF_G(M@-X
M?','C?!A\=32-4_ D$*Q %2Y$VS]RE=R@BU/4 V7-A3GZ/MY%B??S^<?:A[^
M12Q\6]<!3$BW'RJ>1[_P _CX6<76'!HI,1\TE)U?:M>="A[2:X/K=HH8D.7(
M,<_1([+Q ^^K(QX8L?#Z+_?O$K;DO<77B-QCLKK Q'-[T>AQ-[^+X-7KEK;D
MK_ Q[;(#>1JH>H<.]-$K[ 1W$?)P/F[+%TPQGFD#?3:C1KNX$Q*FZG4:0 ,3
M +%!VLP?,E-*MD_MH!#@M"_/ZFEQL]^NTCX"\J4!=X=-A,^(OALC=J"3&V^@
MSJ'.&;:9N6$?0V3:X*>YC"H#^#GJL4K0G7:76)5/:?J(J )IA,^1JGN6,H=-
M,DP./).JFBOE#ZYN6=O3^X@HV6=40'$%?%V5,X=%!%?N>"HIN9XN;.[U@44;
M:N9@*YL7O)M(ZAUP-46ODIX[^290ZQ%9?.T8S\7-/.#)K]C07:QE.QPN*EM-
M/HCDI3C9!V] \::2%"J@(U,DB(632F;#T!5N(LL?*=D?KP,D^S"_1 O='CML
M<P4=TK%2B4(=7KNDB5O+>1[,D0\%/#QB1>(E:EY59&@, PCK.:2K2J-*3N2%
MM5[KO'RF.ZSHA>7^:X&(;IM>X'KFP)]1H^Z9&#)7+(RV)L<RVZ.S<<[A\1]!
M2N/%VC$O+\\R-9U3J_:95D#=(I#!F;1BI5^SR8KGWBW8)/2%8$JO"380,BGW
ML7J++6AIDUMQ?MK,(D>FNZB Y,H=L7)HP;5S5VNN0?8ADI@^<2(:R/ T%FBE
MBQ905@TU;5 2!LGQ\%?37:_O;,O(N=M'L'87>2TJOM15=)GNG89[P@G1[5SN
M@S:$F^BB 93204V'P-ZL,KW?[+E'*YYD!W3B],)=I"Q'6H%SX2K(\6[0"(?_
M*3.1!8]ROL6AIP2@*:]:5PD3DAM<_BKVT@Q?BBOTY/U4_)496_6[R'EQ!4#D
M5WP[6WS=EF*);"I@(NO\GA(#"K4ITD87V2VG!(CALC?$25D\38F_R,][751^
MW2X27TQXB/"J[YX3&F2.H8636.TNLEE4?(C/JN^HSW@_TP;143$ZMRJ_,3;3
MI ==$U7?5B]D8 7IW*[]QOA,%1\DM.H+[$5LK.!HNU7YC=&9)CW(9L355%]\
M<\;]35E7[0R+7506N72GF>T>[U:?MR_3C!#]^>6UR+7^XGD>GG1B)D@'7FRY
M8]M-1S3GRD A(80#F7=^A#+QR]49$QBU7!$?R@<K^Y#9 [*#E+>**1#@4Q5!
M.$O.JL^8Y ^CH-2ODCDF3Q:ZTE<H[SX7.4]K)JHYG=F4]PU+TJY*(<_MMR(E
M8ZX:MK1:([A"3V1XU;Y0U&Z\<$,1U%([>4I<;U+H]LTJD$9\A^3$H6P)XZG.
MRVN_7>I.\!Y&MK-[1-1%IN_2EK"&+PJAJ;N:Y*U9:]4<9+LRWL,H1:CIVJ4N
MVQZSG?$?R%HLF7BC1T3T!0K?'W)-+ ,Z8VX<5W?,5QUU=F<\]E+[O=M$MO5S
M@<D]LEQ^21F;O<;/#Q;Q&I7A5BF!HCMFW93RP%U&6P;FK&X:B)YZ$9'<<40(
M57>L5Q5E@ML8-3WT@W07?>(E'6(N>FW0.^E[)WWOI.^=]+V3OG?2]T[ZWDG?
M3BOJG?2*.>G%[M;8*OW&W/0#>7YZ09:&A5@:2KM-2&F:HF)7'IW7W$8JV"C_
M\-SNOI<'&5[H/_\JXM24=IY2$$%W7!]-**[JTY06&&[!0Y?:6'D;AR[JJ%.Y
M75LXLS"I;CCVZ!'2-]U=$WX%B>YF&*EH"YTSIT*""QQ4J.3:'::[=A.O,19T
M[0Y[UV[OVNU=N[UKMW?M]J[=WK7;NW;;:46]:[<NUVXU%ZWX^[:\&\P313OL
M^\T2N7W33LY^O4;'8>\A+*>ASKD"&_?Y]<X]^7KK\D@Y<5QBL26)X=TA4(N=
MQA_96V8A30DX%MMEB]X;^>C$\6^R\.Y2E6>%*0_K[4]01^"B7UG+ Q?0J9)*
MFK^K _'V++5BW4$67/9F5\7&SBWYO1_Y@=2%;A')LWM!(&_/DB7H#[+FYBZ[
MW5$)D=2O4!/R+#;E8;U5"NH(LKRR-^TVOQ)(D;2AY4!!)&_/9F4H$#+HLA<+
METTKK4XVNE-^?]4XNF.ES:D/LM&R=R'+O=L^<N) 0V&R9O/";77'I'93 606
M9:]4;GXNWMA^PS-Q(1S=,\?ZU9<5S*34-"PJFMQ)N!B*[AAH4\H#S;.UQT )
M)=QB5[?K.A$2>7IWK+9NI8'6VMJ#HD!T'E<I.[PC\:C>#H4T!!J=NIXA<3F;
MB>\0!- ;Z YZ \VVL1=+>:+=Y4M_ER]]?&X8Y%BJE&=VTSCEJ0JTQXBO1Z7L
ML<V[=^+98R<EL\>.^NRQ/GNLSQ[KL\?Z[+$T ^BSQ_KL,3G:[;/'^NRQ/GNL
MSQ[K4/:8?WPZ6KM+3*Q_(?,[V_:0B$!< 4Q3,9_ #5=A]EI#RL,ZNV*12(WR
MB1!"4B9E+#=A[?BP9E8],JVC,CO,8TC]I5-[#%'EA5.KC;76:UD#/!Q"]HVL
MR8)*+:FJ&1YPGKQ53V?YK&3?P)HL.$\;T3I)2U1@D!=YQ!R)$A,45.MX128Q
M48$A8H[E$7,L2DQ0</[^K1 3%1@BYKT\8DY$B0D*SC^\%6*B D/$?.C&END2
M/R'B_V6M++>F)>O64^>#M'64"OZ@:@,QJM069)?=V$!]?WAHP"RWGMJ;97%M
MM<3#V9+[L=Z( >ZL(C7=FCO$.L$7+=T@3B#[GL<!$=UPU[I]B\AJF&.7]8+I
MJ.4VH430]=2!$57MV]^Z:<-U*0YT-;1U3/X1>>%]<.B7=]A9\=,Z:I%2M 29
M7VLO>@%>K-)XKL5NN#IJT@WK$_0FJAD*?YP>"O^^9"C\<4.A\)>8TABDA*DD
M>U]6G6;&J02BG#ATJ+PR0>7YM&SUX&P-*!_Y/7%8UT,S5W<]!5WRAW"M9\9F
M959J+,8JAPDL+H)R?BD ;5[D2$ZU9H*11#0OQ)6ZX4$RZ%(Y9*=B2A4-8?Z"
M'+:$LMFR9&2NF-JI2QCH1\277@Y%>6'-0M4;BLL1ZV&XG#S*C:8WB"(&9,F@
MGZ-'9.,'+K0@C0*5YPWM4LJP*"H.V!T;8W%D>^TB,WT/%8@ $RE6GXU%S9!9
M>"%:1!Z!\V"5MGPGZ5N^7TMN^4[^$A&S9E&N^"M.^3"9+M*'DB)MFNT3N_O$
M[CZQ&_*VO;G$[C#[+'L_'R_5V22I-&4HM"P5S:15(Y,Z59GI^E9WHUY.Y2IO
MQ0O34FO&RE:<V/!PD!U7#)9O:HN5G<V;#[GR;92PHD\+*OJTV<R',HH^%<E=
MD*WH87;2#UA^?M(:1<<@@T?GC<VCEX@M"MCVZX:-D[J=ZP=(+3X_[=A!,RRE
M@"^@YDG9GPJ] #?K;NV=<V=,S2FE.\<>**1RBUCNK\".-V2<Z0\6LS4_SH;[
M&<DC,B\PN5CS]S+P>_AU)RO6I'!3G:.]G ; 97;K@IG"4*V1:7H,AO*_9A](
M\!KE/[1S=B9;5^"JMW46F?HR.7GA<O'G]':7KQYPW2\C,]9_EPRPTH\6Z0YS
MJ9*!>X#6]>]X</#H4;=L[E!D$ZUG:Q*G&^")W;&<.A0%&6+[+L<?_W-MN2\3
MA[ID[3F\I^X2D=NE[L0B?YM\,6W5$'M3EZI9J&^T]@;^UJ<]=M+>&] A9-G-
MO;<Q51$E,^<CN1R!GF19>^T WT@/:$:O4*]H[+65-07L=<VF"HB=%932#.?C
MU8.-7Q":(?+([#I=A"OL//IY;%P?U'O?6O3W,TS=*^S^B=P;9."%P_M0]'6M
ML,G4\OC.65Q]6@,--G)^45\@JA\_?:L_;Z(UTX,T3[>#-/V*FE=S$Y,I+<@T
M"7.0BO/H4 BG-J@1Z3 =Z4 ,Z;!&I-F!ND=#,<1-Q^5.'Q!_OK/PPLD9F)=[
M3+P.FQ@$DJ.G4.5FYA486DZ\;&Y%9:)@"U"W-7X+*D?YX-5-IPR6SNZ+2%IJ
MLGQC :VB1*3EQD%B*W36GP0JEN&85J/)7%10U7F\J!O86ATU*@>[5D)?K0&P
M%\CD29.9(8*Q,HTFA&;8.L[ J]Q Y:5$CASSDK5N_VU-+&I:!M=?_JN(,BLV
MF^B9STX!*< .T!AI%Y@@:\'VD6O')2]Y3*65GO_:"GI Z.")3;6<4.)&^&"?
M7KE@'^9G:T*08T!K+U8D7J(MJZT$<' 6KT+;%!GO%OCQP @>Z6L\_/2J\? ;
M[BT-X/'D46CR#HNGEJYY304I% M E;N"JE_Y2JZ:RA-4PXT<Q3GZ?I[%R??S
MVE]!(&+AV[H.8()'F(T%[<*C:1GGRGS0T*MM9'A1?&$@RBI_R1,$XQQ1@UB>
M-QT,012HVR9J"@I5]49$F**+ -'X^<$BWG'(GTB'7YXB5KW]1&7))77UM9,+
MA9]?L:'<ML)S+Q.9:[9_8FO*X/ U_1(= 5]+V:;;9 K5R@PN0IHR$QY@YQ^\
MVC9^XDDXY^@>L=G=Y!M 2I%[MN0'LA-GM.([/-@JBK;40B,H)R+$>22F'SHD
M#K[G__"P'/;-OP%02P,$%     @ .HA\55)8D?!%10  7N\# !4   !A=GAL
M+3(P,C(P.3,P7VQA8BYX;6SM??MSY#:2YN\7<?\#KO?BQHZ0W _9,].>F=VH
MUL.A6;FED]3V[3DN'!2)*G'-(FM(EEKR7W]XD"R2>))% ED]N[&[5A<S@2^!
M#T#BE?CKOSVO$_2$\R+.TK^]>OO-FU<(IV$6Q>GJ;Z\^W1TO[DXO+U^AH@S2
M*$BR%/_M59J]^K=__>__#9'_^>O_.#Y&%S%.HN_1618>7Z;+["_H8[#&WZ,?
M<(KSH,SROZ"?@F1+?\DNX@3GZ#1;;Q)<8O*!9_P]^NZ;MR</Z/C8(MV?<!IE
M^:?;RR;=Q[+<%-^_?OWY\^=OTNPI^)SEOQ7?A-G:+L&[,BBW19/:F^<WU?]P
M];\F<?K;]_3_/00%1J2\TN+[YR+^VRN:;Y7MYY-OLGSU^MV;-V]?_Y\?K^["
M1[P.CN.4EEN(7]5:-!69WMOW[]^_9E]K44'R^2%/ZCQ.7M=PFI3)UU@CWT)2
MQ-\7#-Y5%@8EJW9C-D@I0?]U7(L=TY^.W[X[/GG[S7,1O:H+GY5@GB7X%B\1
M,_/[\F5#J%3$E FOJM\><[R4@TGR_#75?YWB55#BB&;TGF;T]H\THW^I?KX*
M'G#R"E%)P@^E7>\[:55*KUV#O<%YG$7GZ3C4?6U/\$G;R<L]#&CK.S?A/BN#
M9!3XMJ9SV!_QN!+?Z;DO:=+/XW$EW=*<!78I0AY<O/)R3>B/5^2O#D3\7)(!
M#$<U2)J$I@=F.;"!H4J[23T+.^DFM#?/<M%V.C*R-)=!\< 2WA;'JR#8D S>
MO7N-D[*H?SFFO[!"J'[XE8Z->(W3\OP?V[A\H2,W\0'2LE@\QT6=%S/T;Z\L
M=5[W#:':B[RV)LA#0Y%4$J_#C QHF_(XX87/U9=YMK:&4I5?9JGP:_+0Y,,+
MG4!1&-01RW&1;?,0#ZKSME5#2KA"N4Z(%G7B<'K\Z>[5OW)1M)-%OU#I__?7
MU[L<O%",(%IGZ5V9A;_]B-</.%<8+9%S224ES#9]!"$PE%$AZ].$RR$FB'[A
MHOXYLHBBF+JJ07(3Q-%E>AIL8C(":_EBT'')'2OX;1YI%<!PR@9EGU\['425
MR!0)56IPV':+RR!.<70>Y"F9!Q=:FJF$7?)+#[A-++DD&$9IX?6I5 NC6AH2
M@Q(VQR&3FY?[/$B+(*2D+SZ\M+]H?*@A";AEVE##NNRSU0;$R(&0198R,<3D
M)O*Y@J?GA)'NS?N3-XQX])=??XS#QP G?[_(GJ5=EDK(!8'T "E)Y!+>B:"%
MU:_L2@[]'1')R;HC17431OT6IT66JBM;$'%6U0IP347WOL.H9CFH?B4W4C./
M-T5>ML8:\J_=.$/^\>OI-L]Q&LI&$?&SBWI7@:)UWO_FO;X5@(3I4"4RQV2Y
MP.$WJ^SI=5CEP2N[_M>NLNM??EU\.NM9T?WDHI)E8&@%MW_W7KD2,,(\9%N4
M>9#$P1$ZRY(DR OO3N,]2?MZN<B)E[%BJSL:_U AZ](5U,)M>WU20>\<L4$G
M+HX0ICQD>5#&3QBU=%"01IU_7Y>/.$?E8T"FMQVE61U OL9WO5SBG,R'[H($
M%XM5CADDM9-@H^7,;[ WH7$ES"K>R38,IV+IMM9$3!4UNO.X(?7H%.&8=U[D
MCUV?1?[QZQ5>!<EY6L;2F:Q4P@6--- H922?O=-#C:E/!2:%N-B\?<EID!+1
MB[C\?87)0!DMTN@T4W<B6G%GO8<%Z*;;T,AZ)X0E0&%\8AIHIX*(#AF 9I^)
M$IL?@P(W7=);S914*>MN;FJ NYND*@1A\,. KD^.=V_>OD>US@RCAX(;5W$:
M9DE*)\W50O_%-HVNKD[5%#&J.&.*)?B&, 9Y&+RQ RF,/%R+KF/^UFS94,4C
M1%3A++W?$-3T7)]F\M05<3EGDH%K3Y7:W[V310-*6!(C_V*G*>?U2=BN]/6&
M+L#3'$F/]IVZ%]$(.^L_C(";GD,IZ9T&5O D@\UWZ'J=Q@_; EV20DK9[)?Q
M9.8!1X3Z?@A)W@,@R7MKDKR'39+W9H\$"$G>O1M DIVP/Y+T :M)4DL")4D/
M7I\D_"025^#4H"IP_(W%YR"/Z"*BQN'HR3@]>B2#USEJU!;P3A$=*F$)G\H@
M*C2OUU'/F7X.Z )O*3\.I)5T/K.50Q7FM5TQ[Y5OQB;XG?5TMI9VM=)1YV>Q
MT"&(>F.#:9FC)P>3#_I%#I$0;UU30N-(*$6]44+E1"CD8%)"[T"(E #D/;2\
M(>TI4XF<VWL4"IC=NQ,](>]L,2%3;;1Q9Q,.21Z#''\@%([H[0V<%NS:)ONU
M6&S+QRR/?\?1IS3"><^[+CZ\G#_C/(P+?)/'(;ZE&]2ZJSMSY.24J/,558?J
MTV<#I[',9IO0W"IAQ*01$Y_7E:^PTNPTGIM,RMD(K8;8#,ZBB'?RZ''U*[Z>
MS;-JG]U!:\'2^&8R*1^5KO+(1!%PE:[WPSJ5/IT+9J[T$ZM*/_%9Z2?F2C\!
M6NDG]I5^XK#2O[6J]&]]5OJWYDK_%FBE?VM?Z=\ZK'3-;J!,RD>EJ_;_1!%P
ME:[?\>M4^G=P)D^7:9BM<7-CO@YZHYD$:35<3F8LH+<G)1IQ[URRQ]CG%==
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MR*0NFZQ4 ?%L"%X% W=)H%8:1ZT1R^=B'CTT3J.Y9>%O=X\!*<#K;5G0$90
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M;CTD1=_2N$BRSZ:SP7H53T]]*<$KGO@2Y,'TFA8@M4]ZL2=1F!:D ^C$::'
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M(AP2#D"K?#.I]5R2=QK>X@*3LJ1&G>$GG&0;.JDX?Z9GLS&W2U$45IHN*3C
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ME@Y%+$PGB#YB":!6"O[[UX_X<^N^8)ZEY,\0MY8"[$@Z/!F77!UK9)NR0],
MP]R1P,7%<+KFG;R@191MZ&ID^W9H)U7OG+X+'W&T3?#U4KRGR)Z@-WH+ Q)P
MZB<,-JSC(5AK@^'N8,B"5U E0(],T"!=6<I.F9)_!=5EPV2ZRX83$E>,@/4Q
M*W$=;/ ZOXU7C^I[(A.DYX?6(\V6LWQ@8@!)/\X"71NHPDW2IE/%X6V>PFZB
M3V:[L%]S14G=6<CVPRH(C6$[ -KN>L^TW,5-W=/<70#5D0EYI_84Z'6T=D#E
MJ3OWZF6\VRQ)R%R7((X&NB:6J7CLR&U-U'3?IB2\,WL_W#I.M[A;/1#7\'NB
ME^*FI+1T$:==%(NPC)_("#:4Y:,3]D3\/0M"T19&I@JQ>>QGBCQT4?P[#:Z=
M+K-\7853?"#-9]IW%2=L+>?K39*]X#KLL+Q(%@F#P:+;5:?6?L<1#U','EFP
M;T23Y^>G;<U4;/(F-W%F %OB/!;JAK053G$>)&P3.XC6<1K3.WCL("6N3NZR
M;WG[X&74.GB)H9SOE?5G-\$+!;F@HWV[/Z.KOKPLBV*[YK^-'@7WR<3WB+A_
M 9E&Q_$Y &R?$YJE:Y2?,5U%P*1%/I'&N<(HV"6&R(B*EG3K@L559RL( 6F7
M614BE0("U!;YSO4'3%#CW1U.\I^BC,-%&E5GN@8VOI&I^FEM>Q6!O'F-2A)@
M>]K'#ET#JLY+/+"$T>[TQ!&J$V?C6)4\H.9RAI<XSS&9FCZ3#@2S("+CMTH&
MIN:G>8PR6=XL!B4%L#F,P:]K!E&5'BJ#9SJ&8'Y8$>;^ROERB>DT<]<1W 8E
MNQR4A@0M&U0'\G],DI[F4:.-5TR5!J<'L#F,-D+7)II$6\,"HNFB;L+>6P:]
MSGMQ=GEZF=*C*=%B3;?V%66FD'5]05L)MW\A6Q $PSX=.N$ $8[8W/D,;[(B
MIH=\B0Y[>N<TRS=9#H-'B[2,(WI=C7#^#H?;G'7\Y\]ALHUP=$$JD2XN;.M7
M&_HWX[2\FRAMIP\>3%D<G;<1ID@83#N8TAKAS=GZTB3?(Z03VDU6TNN[09*\
MH#I;>CIDG:50'J^J';$7,FOX1&B6ET&<LA/<!;N[7/!K2:JF8J_NLC4,-:I-
M>%M=,)P>"%B((52K,'=Z4RMY)V;C'9T_!^LXY?%K<!HD[!& -+I,Z:/?11W&
M05$X@U/Q<@5DF(G2FR%V28 A[3C<X@42+L7F?YM:?::S1*=$) Z#Y"XN^=OC
M]&DH IPTK9_HVY[2-Y8ME)R=#K(VH#D&9-3PSJ=!,%7/0(25/J(OM'(N<6WT
MQ-2G>3Q^BM>X*-P/6;HML&%<5L@Z?H-+#;?W_)8HZ)U9-NB4A&KM:S(^/> 4
M+^/9'H._B)\QB\I,XXPR$$$B[8X4@LZZ("W0IMN12GDGA!&:&,3BF7&!"_-S
MX$3:>S_"'JH0C[GK.Q23DM.7+JT,Z+Q;J=7P3JU!,(5.)TE0QMX>&7C38/Z^
MWZYRU :[?;"ZS,H@N3(/!1J@_;JYITD"OP%R1D:FE QP?(BZ(?A;$=7Y[HS-
M%H\Y#6\;<;;F*;??3 F Z4#&H-9M*U2IH"H9Q-)I13<OT"\L*?^QS45[=RBO
MR)?+$J]5 1$M=5WR=Y Y;=Y:*8+AZQ"T?9[*N-D)O$\30"R%O>EI#EHC<Q8[
MGWV$I1$\Z]8W*+%#%+CD 6=B& %GY %E%_0NT(I=3:YG"/?9#<[I8?&++&?.
M7=$^\DJW%W"D:!H3Y^$_I/">Q6,./CPR R@-84[CM %GV^>>XR;@[#1-3=%Q
M?LS2ZPVF6\GIBC=[NO?&VKBL>]"*.^M8+4 W':U&%@K?+''.V1&KGKFL#G@9
MAE>IF+NG+-4@=X]7BC+>72\#,(F7Q0_;K>:O]S89BX'=@BCOI5]0P99V#'UA
ML#V# BAH'VTW%3[-$@(CX_=_6N,HW28B5H:*S^W KG:K(--EY&>I9.J"DJ^G
M3)6+]YYT=M/$YPM;^JB5 '/CVO_F;U&7CV1&W%6"LEPS04F95G6FS<+M0U33
M%T[WX:KIT@?3"F<P:H[V-_^B%)D4TCE<L"(=T@]Y5A0W>19B'!5T^+X+$N%=
M&&LM9QZ5O0F-7V56\<[483B%5]D:17;!.6>G32M=1,L.%53;>\].;:ABDWS<
MKA]P7MTO+2Z+8HNCR[35XE0#ZJ DG/I*(XSK>$$#]+WS=0_0??)RO2HV'CO]
MS )F%%FR]ZU>Y=)\KVU1L/06P\WV(8G#ZR69UI*9C7PQVE+5X9+^(&-:R_U6
M>MZ9-@*L./<4.\0Z <130'42WOM(F967]*VP(-'2<X2^R]YQL%GMKM%:V3M;
MQR(6WUEU05959$3J+%PO%ZL<,Y=5>B%**^DNJJ$6ZBYFH53,.UO,V(0#&$'U
M]&Y0BZ. R<]$A>J1+CZF7Q/RK8(21_=9'3=19I!9QQD];.$W1#$IP*",)<H^
M>7ZJPZ?P^V4HJS51F35Q_;P/@,R9Y.[CV9;V<CS.$S?V(_[,/JD6=FR5G4X,
M!AG4F1)8:7KGY"BX0L_&;D;&3)M=D,RJ0>YHHNN0JHVESK1%TIC(4)P'9<!>
MPI1NA@Q+P-W6TQC#=GM10[2],W T9(G?A:@,>F /GZ;-W!1TERGS-J]S/C?G
M(;L'N*E]1=^S!+DAINE!5\L[00=#M9P0D'Z2*K,P'TQ]KBF!5=?^K=2_M55U
M-VD89LQN%F&GYYUL(\"J%^6JCJ\U, <K,O>@G> N%O0FC\.Y3GXH#&'.;&/'
MR8 B$#1]$T]ABHEW/370M)-CG8)U1SPJI-=^;PC[1%7?]%,9,[#?@TU !=@A
M#*3;$W%)UUQ\]G1#QEA!TS?5%*8,Z^E@#[!RK,+%3+9HU^)9CM<TSDKP%,0)
M/8;C?4YA"I;?/D;QX44>)MCN:-S>Z?L.*;U7L0QY:\$Z<>\M9"Z+=!<2F?;Q
M!^'QU?;IFP(]O'0$JXP0RPG,$3AC8:G*ZLIP\&V*A/T_2CRF(,S/% ])%4X#
MF\H4Z7JLH349&M/5=.?9_+4HOJQRF19EOF4]"#N_=_\8I%7\^X]9^H2+$D?<
M=YRZGH;G?Q#M<VRQ3M*,AV;NM+5O^'RE#/+R:HZ&/])X^7Y-O;2.Z@?TT(<@
MH2N31R@@W0->Q6DZXT&%V<J@]0[@S]73% O^,L4Y?[P2W]#%!^F\P#\H=],\
M_[;V9Y"^$4'J*T"52+\#J550I8-J)<2TYNE(_/D1[,X<NWS=+]:++%_BN*0A
M4Q9I=/Z\B7D<[<E]^%$0#L*;V*-P)W$H1N3OII]XS_N)E*V<1[/X$^-MMW4I
MJG3P7.?!Y^LA==UB8Y7;3ML2TA?@0@PJ? <.A!4>[PL+@ IAH,=P9-=10!R_
M#FLV[#;T(O=QS]-Y1J_1QH^9#V/C(_"'U\L>[D0-$(V!E<@^4S4SQV'/T^I7
M35F;YVXK#MDQ4OI3JR3G6>X=G/U!S,]&%NHDP]O O+T[8)X,EI^$^2=HQP/6
M=Z& ^K+:O*W;  /1/U'_,&)1M^L8>.\]:B^<6'E+;6E[0C\&)7WC[>4L*%7M
MW%[=98L<:E2[[=CJ@F'Y0, B'S=Q_H*HA'<R[MM@7?F>!^YD.O$F_;J-<Q\1
M,!C9;V25.&K)?R&;=GN=!G">^X&V4M?^'T1'SWV+GF''_I^A_5^F91ZG11RR
M<_[S5U,_OP-MX_)BFZE5=S/[PMNQU%CANDES>2ZNQ?FUN2^WS;* T\5ERF_E
ML!!@,U6&-*=#:J>:HIJRA4JR 3/-G,\VE;/,-/8_TC)_.U/>RY&:/H=_/"4"
M4.UR^J(=U%ZGR_YPVO'D-@]UD@^FW>]34.PC772[".)\3D]Y, I0[7^>(IYO
MS#9".)Q^8!:[C7T!?P6%JB*JBWA$OB^E2VB=]ZU+;J;JD>9T2$U;4U13-E])
M-E_,N7.CB2K/>[+CY/Y];XGQ/ASPP3! -=69"GE25WP@AL,9A^<Q?*A3[OV&
MR73%4(R_F#H]"#BW2.8J8/OSS%,C\-[&O9H]TM4&-/;KXI2QCU4!U>8K?>D1
M"8$)?ZTUU#H4MC05<([N6 M4?FPCYY_+^W8"31/WZ<4.!'%0/NRH I[4@QV$
MP/O8YM7LH=[K9!W!7-ZK;2',Z+L.A7 XGNNXPIW.;QV6O_>6[='HD3[K 8WS
M0TOM/BN#Q,F1*KNL08WI$Q;FE&O*-OEZ;^4>C+4_<V75H $SS],)>T#WM><W
MTO*,O9>( O]$9\"_;,[-$@S@"V6HSQ/,7S8+%<:./L/\A42@J)H5#4@^ZW4_
M23X'Z :+Q32#S[O+Y$MS< 7+#(O.5/[+;&L>+OA9YWZ@[=*U<V>9]9?8AN=;
M78;8XA_,9?9@+K.N__%65TDS9>B\7<]:<$)3GB4W6*UW3A,'+RQ!;*I"]\;W
MO1?;\C'+X]]Q]"F-<-[:!K\A-A>=_NN6%NA5]AGG_*]X'9>#>M2ILO0_#$];
M>.:Q=YK\8#79>8WL-UHF0%^IPO7HREZO+(Y00O41ZRU00E/XLAKLI\W&=8,5
MLCS8!JLHO-D:;"^_+[/!RHVT;[!;JF_;8 '/T#QMX_A_)W9^V]3/RF:MM<J,
M)P.CO]_#@U7O*-RR5TW)[Z<9<56#L-P&R3W.U^]F\J5'(3FDV=<>13WEM&P$
M#%BMWHOMRI67H%IYR>L$4+A+@8PQ2XR^BE/T@H.\^/KP1QNHF[U?Y,AD9;&1
MF5TGZ.!'K)]:+SI43Q-KHP--GM4AC3FZPIIR4)'E ZM%SF.<VEGD#X_ \A/W
MZ)44$:?];K[M"\K_VH+K"G 0BQWB#A[)_R$K\)R'8B8IC4,;RZ^RHJ .,_%5
M<!K&N+BGABI*6"7LLA7J ;=;AUP2S)BFA=>G$15&'6GT"Y/W_[:[8,=5_;:]
MK>$M!:],$H!KV=1(PV54'Z(-JZ@.8DK^J;5(6+HXDG?MM)]."U5G9:OLDG+#
M#&K3STX3#!4'P>W3DMWR0 751,RC1V%+USLK1_L93<"R15%LU]SIN(V+WRYR
M3 \?8%()Y:WZ/10'^1Z$.SVT&"?QF&TS!=,"75DJ[-P1T>,ED:7G8Y@PRL&\
M_S)F"4%6'LT, >?KR8^L661X$ M8U@4WR3*6,3=8+7-.$R7/,#$9OI=!MT&K
MX^1?F?<T#F]$K:W]*4M(,DE<OK@:4U4Y'^RHJB_*V<95>;:PVJ\36X6SIVFZ
M#1)ZV 8]-?)?9NL]BY_B"*>1Z[;;S??@6ZZL&&=OM^U,O^Q6*[&TWV9K$1A>
M\!4FYM'7'(EU0:)?0%'(.EVBT\'MK,[)!,%P3X=.O.J'"5/H*12F51PAJH4J
M)>\$NB$H2 M@9VSBARUK#0JKY:(NZ:,#VV:/3 X,>33@^MQIRZ!@G6U3_\?9
M26^[SE)V+O@TV,2$_WS[_187.'_"T4667VQI %(:G#%(E3O-(])Q2;719K9Y
M.#@1,"0=B[S/X!^#YWB]7:.T.841LI3Y:G"!\BH]M,QRM&0IHKA*TCO51[L8
M]<&4113%5*4NO=WA^JF=&IL<#\+YM2^Z2=Q><W9@FN3\-@K3TT:A;JZM]DN[
M!A0\!7'"+DC2]GOX#5?Z7LU,QU/ZF1Q$\]06T'Q/)1U^(]29)8\.@E;Y) \9
M*<+0\DQX!.V>L9+OS@*XRF UT57;'[U30H5(49LQDSG<KK%[V'91=_S$$62<
MGFO04F9W$-VE9:%-ZLHH\O+>7AP9V&]^3/J8'SMI9XA:.:*'%]26JW)%+-LC
MM#M"SK-&BX[;PW(_W(9]_H]M7+Y<ID69;^F/Q77YB//[QR#MG*/U]C;E]/@.
MHNN8JUHFZ6NF!G?XG=-,)6(\?LZ<1!31^#5+&N2<AZYIG0G@MUY\7G/\Y[R@
MZ_:*KNUU"D^%8*2Q<$.WQ>#6)7\8HZQ0B/WU%,O0&:V;*%49SW+AWP,Z_^?9
MO%6)N=]Q#@W6Z JF/%1!6?$N84_#YNS7"L -3@-Q2R=Y$.\6G*\W2?:"\1W.
MGPAQY=9]S%+NI;'AMF#7)=K?3[.B_)B5_X'+6QQFJY0VDO83=XHR=92WR[[>
M:7&VVY63C,'TTRZM%>X;-%%;^!83P$9]F1(XF%ZVNR#LY/?MM@1Q==2'V/8!
M+[,<<[G[X!D79^2/HHQ#18'OE:++!CB!Z>UFM4=R8!K+_C;TF\"GE+ZIB^Y*
M,B#ZCU,QPKX+\L]XE4Y78$V"P+G>,WQ/JE>I'3+3NR;TB5Y]/42*_QBG9+9"
M5_SXI;A%&G53X0N"/V(RJR%?Z$C)E@6G*]KQ"( WHGV+=L]6-S;[0VZF>]HL
MO?#MO56?X27.<QP1"Q=%@<NB.8K- BL$>?Y"BH$YKXJ2')2"RU8UPK1VJQB@
M#H;5PS$+D<!PB;+F-'Y"8V6$;35XA+U,;_(LQ 4[=DO*_9&TRS/\A)-L0YN?
M;4D9D_%*74LCM?PUI &7Q'; Q3DR%T9!&J%H)X[*X!F%)/VXA$YM\D?]6[6X
MU]F52J,/.,7+N"SDBP]T<<&VC"?)RFL3F;"PM,UH@GR@+2S/:*.P"$W7JXZG
M7Z]2'. 4+/N4;H(X.B6P5T+\52L-9X<\[: WQS[UXMX[=WN,XD(/E4$A%X+7
M2?^09='G.$G8=* DR..'!/-/MLU-FX373M7".&UGJ='W3LD]0/<YNA-# 94C
M75M1 N3JIS3'/);"Z99\2,,7.B]0!J(>H.^5I2:SM!15*</EIP&Q8@$1X6?2
MA](79*A#G-&3=_ (2H_U<1\C2;+/FINQ5II>2:DV14M'4<T-$=]S(J;LF3_M
M.]SVD/M,; 114$O2,VQ1E2";F;'^$V#7^1%;SZ68J%?NM<!JR4;DX'9S.W"R
M12J(I&D6B^EF?AK&2<S8WOQ<S:6JR=.BO, 1SH.$[F%N"9J7G;XZ -#$>;C?
MYIBX>,2-C(DR -,PYK!*=&"I#&M+#SP=^IIK42>!ECQ-&/%\% 52^3D=<\_B
M)>DF<%K&P<#B-:<&H.G8FFS12$Q)06\.EOA5SG'<- !ZX+[D_C&C^][#BF)I
MZ@;GZR EX&J4(8T<DK"-E_N,K9,)"VNR195QZ3A;QMK'S&9Q:TPBW@F[+_(^
M59ND4+1+"^558JC,9CL,.([!.*1YO_WCN_6(@FDK0^&J:) M07>:!\%* >YP
M*E9I()+(5VO_P785@P:[?[B(_G-K<_#(0AN 2Z RR<(%Z*MZY^HXO,*5%3:4
M;V24G:ECW&&ZSYKI+.OFK].J89S\N7\_;9"FLRYQF"E-?VBGYIU@P[&*X9]J
M9=KK[=8BJE&8](!U3TC2F(ENBN;Q,4LC'&U)[@\)KB:)\A,4I^PTA+C"-7GJ
MSF@[?9$TU)XN:1CTG]P>ZX,X_!!.<812[#\TB*(8V/T"8N\5R31I'08=-E*I
M4P'@,9A,M/ <5$EX9_A^N,7#*S2$!*4QY6#"5@O KCK?Y'&6_P=I>:-9*T\!
M &-UIEFP5:8.G:D:S :7)-]BM-W0/S<T#?ZD^Q^8J[+)LZ>X@'-;4+#ZE&U8
M7Z;G:<#>>QFS,Z)* P"/]>99,%F> '0N:U$+[_B0R5I8LJ"J_/1"G+;V)2B+
M)UFDW9O!K$6>/X?)EL9@X9:S9W5I0 9=YVNCZ)*K]H:T"6K6 L-*:ZCRX7\=
MIRQ:-W4#,-.![0?4K6W\69LI$@;4VXX\J;-_JF!:P&2F"&\Q-%WTDWC4QW\+
MJ0U3;)T;#J8HM7P<]3&8(#OUHU !PTH[G)J3"QC(<S'J2W>Z=^:-6BYI9FE"
MFV8&%3 TL\.I>:&(O1_>U@/S*KW:M"O#\_16FC (*)AB1\(K<"_7VV,=1L8K
M0(_9#[Y-#N7R^+"[X@=P-7SP3?#K&6^!*Y];4&$\PT68QQO5&2A+18</- PP
MI/5R@X66=T(-ACJ$6"C:J3LCV465.?$W8Q[\@RZTVIFMTO5(-;TY&K;)%:$2
M3HO6AG.H(1UNDF"KX]Y'S;VW9(?-^X>D"V =9W@Q6"SCV"?JO3U,;8EVO_Y,
M&CC#_U*.N"357[6J5[,6[$E011D.3\9E QAK9)OO0], 0^^1P(6GJ#&A;%!4
MBY+;[I*DX]#5]=G;D#Z)O,+7RQ]R,AJQX#8X8B'$[H)$$MO!K/)KE(7.:HWD
MQ9[OT%U)L,,K=CT;^MAI6A:DNLCPO.:#,CM83*_Z9?089Y4TW1)<T<3I-C9+
M'=%21@5-_QL?-<OCOUW3TZ7$TV!V+E8Y9N]&_(CI\TA"S9I58-6L-=[A-8M9
MTJ16>=J\'E%0I^ZE1D^#E Q=%W'Y^XI>?XO(^'F:*:I2(PNK#LU AU=>R-)$
MRR91YCR$F9=:8V\#U4^@73\D,;O2?I_=D*)\#+IO E@IP*H_2[3B1HFTYIJW
MD.K7:^L$66];)4FJ/::7Z)(7+Q5:6]9T-6\5;5 E"*L"#2@UK:]\Q)T62$;#
ML@H$WZXMOYWF%;U+F:0W05X_BWZQ3:.KJU-%I1GD8=6='5C+MD=QTJ:7X%60
M('I/M?33P+JO1DKZ%.+ Y4$9? B*;HSZX=JPJG,,=,O*39L',;4]ZX9G0.^+
MQ*&7RF>74/GKO&=;ZGKQU_=XD7S$G]FGXENAVBWU8%7X,-!"X)&F3E/\N;IN
MR]\L1A%+C?70&Y8DI+ID+L/PJNRI'41-RC'+(A%QKZ==AW&*DAAOV6'3H'AD
M#]<6_'F7@K^^%S]LZ[Z;5'358Z,F-?IC+T5ZS! 71X@HDA]1FI4DCW7,4SF2
M)__P@IYP&F5YP=SH9;:EKWWYF=1:%?/).$:='""C3OZ+44[&&VM*]?4.@E,*
MT <WWM1NTL\!?2*U+ SSLJX8K)K28A2.@N-P2]^"(.4?E&@5/V$^.7O,$M*N
MV)\Y?6>QX^K5?F#31Z0H",,LCU@@O,]Q^<@42YROB[KMQ\UCR4=H6VSI%!QM
M-W3J5SV_3N0"5&QP&"]C&KJ&K87[:=>S/0NM?E6W\^*EV&/X1@2+X5"*PW("
M52C>JT3!#C$=V-IR=:L(*.QZ27G7AHHJKA-IM:GLZ63TN?_F<O7.*9VG$0.\
MM*MI X&#8J055H$N)6%)LR06D/^5!8-$VT[<<'^>SNY]WG=OWGZG&""5DK#J
MRP1SX+K7A@B[KIAZ>UD=Q+R*].T_.HD"D'#?E_/]%]*8@FU2HBNJK3WZ.V.Q
M7L7!0YS$92R_)MCZ#*B 9:CZI=R2\52TK/%Q![/@([*LA$6I7[\%4] :<-*'
M0BK1/R NC!8EG]'2ZQ:T([D):'1'_U1?I)%=[9AT8#8*/51-2V&+#5S<4R4U
M!S^KDW#ZX_NU$*!J4&-3GW&M17V7^>YY1&VI[\0@EKL$G;KDJ]N(7U%Q;=3#
M&8O_8Y9F7? 5'V25H!0&5!5FC,*Z64NCJ9-*R5>UC'AQ]/RYS(,L)S/3(']A
M-[J(86Q9-TL25AC\)5)9Q<Z8'2!JN+!2<>.8MW%^YG"7,=KEC!Y8UC7_6.9'
MJ)L9JG/S1$K^@$PYX#:Y7@,0-2R!"B$,N%JKUNKA%'U5Z;KN0?A)!5Q2PK'#
M>NM-CA\)I/A)&%Q-L@ JR!JBY-D/E8Z/&NFM=/:.DNP6%=G9$7KS(D[H7IQ0
M6R/3@5*3^\+OU_+(]/R-ZNQZ07W-X#)M#36W.,3QDRI@@J4J@'H>BU@R<O*[
M&%_5*7Q--\': R3:)0.F1F]R3)>2-5ZT20=T'2J@6E9>I5T/DF J;1&&=">T
MN E>[!M@3PETM:FP6M9;K8XJ?9\[6S_0#7?>"ZCWL]I" "K&C$V\B28*^UHB
MP.5I4#S>T/B?$8X^O'PJ:-RE9AUC$9;QDW(1WUX;0#WM 5KV[!Q- ]6)T-WG
MKV@ZI$%]C7:K0+NT/-5OM7E?$+>I/G]$SYC0=[FE-:J3!U2'5C"%MTHJ);KA
MR-10K8=.3:_TNF^"%W%*H(UM@A)M0-4W O3 )M@DY;\)4I3T_^CNQU.04 ;>
MXJ+,8QKREGX@4Y?N#RU)?DBP/^8W,4O/JY=\:=A<'A]7NE+C% $@GGDR7%A)
M(@D?<;:VTC]"NZP1%Z&;9+T?NQH<$Y)X<D>H089J:(AB0QR<1_*K*/GK"2BB
M-'!DU>=KI[^_UB'=Z.\+ 2I8-39AFY])'J&6K)<[B[@H.!1V(%MPE)1" +H]
M,S9AAUXB[*/4R1QT2R9$K0,#]_BY_) 0)TTH?(TLE#JP@2@<WE+K^*@1=K"7
MSTW/XB),LH*@4U>*7AQ*O5BBE+X;IU3S'V"DN3ZN:35&#2AU9 ]4>"#"I.EU
MO_\^>+[)DCA\D=:1219 [5A#5&R3$PWBP#(=]$OU7ZJ,F+;K8ZJ,:ZT%.*'!
MM+X!*'PEI'YAMV0\T5T>8JYUN82>D<B#L+S/R'2&'@N_R'+6Q1;MVRCG09YV
M]TAGR0! W<YKEW50OU9&1ZC.BIVMY9FQ*ZL\._J]=0V'Y^CE+$26]H[GT=,_
MK V(9R'4L@!(8 U1<L)-I>.[1HHA5=(7AE@G2HRZ2NDK^5Q*F.7.'S'V"1<E
MCO@)#>42A8O,H2U].+59NJ1RS-+O=MB+[KW)MEP%!#$D1_5UBQ88/@3PBY,5
M'G:6D2,B?S),_W7M& 0B #=^@!6$M(WX1'9HPP$;VIB?V2\ XHTN<5QN<W9/
M:!>-7;IOZ3)_ *Z$5[-G&!<(G&..1S)$'*$6)G[S:X?JT/@NMN9+&DTG+>*0
MQ>:9E-RFS+X$]\;:QAEHVS@LK=R/4),_C[9TH QMM;G+E&\4S\%-239?0O]J
M8=V<?&QWF/0L+<O9Y_5R5:2J5N"'HO9CY#P;G HD&HT'/R=+ZMP <&3/=O83
MFRUR?P6SM[\S^E-E(#V&;#O1@H$($G=A%,2<[8!#K#U+!I(N5-.?FT9"@1ZA
M&BJJL#9-"/F<? G1CL@?]6_5]8E.W:51=>&PD%<N/;<A:Q-SY .(Z;.:ISJT
MSRZ"\NR.V-_-ARK+WN8()6F=[1%2M@*:-Q0VVCV#;O,X.&"N:-!:57VCCQ::
M1X3:/UV1O\C/]4_D_]%0=>27_P]02P,$%     @ .HA\52N_MH+2*P  ;/0"
M !4   !A=GAL+3(P,C(P.3,P7W!R92YX;6SM?5MSXSB2]?M&['_0UA>Q,?M0
M%]M5/5,]T]^&;,O5VG%97LO5O;,O'30)R=BF2"U(N>S^]0N E,0;P 1O"55I
M'J;+-@!FGI.X)1*)O_W[\\H?/1$6T3#XZ=7)FW>O1B1P0X\&RY]>?9F_'L\O
MIM-7HRAV L_QPX#\]"H(7_W[___G?QKQ__WM7UZ_'EU1XGL_CBY#]_4T6(1_
M'=TX*_+CZ!,)"'/BD/UU](OC;\1OPBOJ$S:Z"%=KG\2$_R'Y\(^C#V].SAY&
MKU\#VOV%!%[(OMQ-=^T^QO$Z^O'MVZ]?O[X)PB?G:\A^C]ZXX0K6X#QVXDVT
M:^W=\[OT?TGUO_DT^/U'\7\/3D1&'*\@^O$YHC^]$M]-/_OU[$W(EF]/W[T[
M>?M?GZ_G[B-9.:]I('!SR:MM+=%*5;V3CQ\_OI5_W18ME7Q^8/[V&V=OM^+L
M6N9_I9KR&4DB^F,DQ;L.72>6M-=^9J0L(7YZO2WV6OSJ]<GIZ[.3-\^1]VH+
MOD20A3ZY(XN1^"]G;_=5)W">R+.@ZZWXT]N+D)LCEU-6>F1D\=,KY^G9YVV?
MGK[[>/9.M/S_<H7BES4WRX@*JWHU>MOPJT$4^M1S8N*=.[[ :OY(2!S52U)3
ML5?I;AU&@OB1Q-1U_,:B5K;2M=RBFY$5_TXT6\S68FC@MA>- T\,!XP\DB"B
M3^0ZC(P@-V^U3[TNG.CQR@^_-E:AU$"OTCXZP9)$TV >A^[OCZ'O\>%X\K\;
M&K\TEK^^R2XT.M]$-"!1=$DBE]&UX)Q3?NY$E,MPRTC$I9&64*>'<4-=2#_?
MK%8.>YDMYG09T 7O=$$\=MUP$\1\VKWEN+J4U)J062M=R,U;9QOB75/G@?HT
M!LBHKM&%/#,^9+$I7ZVL2)T@%46[D""Q[-EB01C'O!8.1?%N^OAJ16/9"^7@
M)XV K^0 ) &J=B%A@OZ]\UPO4471X?I=M_UOF'YX[SSX37ICOE[/=@@3$MQ
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M293 I@XFT)6'$H&R(:Y7%.-L)63JX^]< 2BV*/O>"E5PP+Q.GU;3 KHO!,X
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M()>>#RI$#F2MG(:&#6+O2MO80"/L+.)^LE@0L1C>&_"=$\M@1#Z%^51R8&X
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M>9I,EPWM]-3P;;)6>=&.CY,UBH95/'&1L?GSE^IW"\!!L*T_84<4P!#/V!B
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M^?"I>#ZU/;<:K\2.0&T0YBUA[UF;\]\4-:.SH?0OXO]$&DG^F_\#4$L#!!0
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M\'TZ/#T$$D,AQM\3I66ZKU1BQ]I8M<7>Y+&*=195RAW!7-WK? 0;-;W9M(]
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MJ;ZH6.,JE+>+9CCJ^##\;VJJHTX_5%['^OM@XK>;-$HI)XRX5S=\DGJ^FPY
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MQM^DLZ9-)++MPR:DD:KSY)IK^5DL<230 L7)8O5OSJ!A_SCC4E#2%56[@FT
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M8N90](CE0RBXN;Q=#+&-YHC,/]BR^A-G0[_%:&65]UG:+Z/6317[#X/]SD;
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MY+KH8MV4R;J0^W:Y2,*'V42LK811H8JJ-@5$?K3FKPTW_9J6IM8N=PF=/V&
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MB_O_\D9*DTO%S5E2D"^'[^@[Q?WY.9VDE82%O%.L3B<\#9Z9S*(%5N'U^VF
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M<>7-@&,KF/GD,7YVO5';&9USS?HB,F! V5*%TLS W Q=>\@.4&ZU0?#_P_X
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M-JXV[B_ML8-1#$@5J&U-"Y:)'[%8UUCB[VF=:(SJ\D/H.T2)11H/->VTR71
MS@S-P,_/!TP"@# ##@V9CWFY-+=N-4N<<-W9Y$UV&OCR(G/@VT>!T4@!B\QW
M,5L+[I/>93&T>@U.)V843V3@&!6;U$J>N4LJP 5?/VI.LMDDLCCRLA[7,[P&
M.G#$I=SFO=9L+\OS$)]4"MF+LT)3 MVV3F'.:BC&EZ66-7?374IMXV?OKRVF
M81FUCOD2PWC.1984I'A@&WA#ZQ5U!:!Y]8RW?7=LLR"'<IA-5:@H@">]&/O5
M<XP"R[Q_,P@+#<[RE>0)M#AI[X"VV[2<(0S]57]"<4?-ZO+LK H+39L>@T'
M]+2?/7WT.;WE=2L7Q&D[#B59A>0C#RG,99:7^&\L(O5ZGSXZFA1Z/%+ 7L(Q
M6<R*<9"/=WISL<#R,^-X\,S_TUJ'K5T90*?<82^DPL8W5-\<QD5.YLX",&$H
M?;,T@6,Z#I"SJ5<POJ=UA!G4<B.[ / R? 7T7-354=>WB7SRXK$EAR&M&+T
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M-XO3GN45"89XJ]92-'86;ML#XW2*5]:$N,E^2.E;T+HH_C(KGNO_R+H_!!K
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MD$MP(D=Z['H3ZT;DP)#G^^W]O-R2$.O)4E%H=M7*F-1<.Q:PGKS B(W,>C_
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MC%O]JN(DU^:BD@5L<:B2,;$1$7SH9M,56/SSWBIAPBB63F8&#61:6F3I# >
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MV&3?B)+4$UF$ZGFX..[2)QL.GA55,:'_GD#U@'8A_16;]G^'8D;/,QS\=['
M[GW5-D68T?:EL^OWT,QX0=+_WM(;.QN<3,D=+\1+;J2M.RIY.H^U-"4'W5[2
M1'"==NN/9%4^I95FMX"=4V2>9%N6\]&J::46\U -MS,Y4/GB;,%R+<46#GA
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M=CS L+[^?O#XZ9-'Q='7H\]&G_>KLULC@" $P.QE%,0X)Q V,;QO:%'ID+.
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M/&Z>/I>\9LE,=A)&)4$"-R8_C4Q5%@<>(<.:?Z^Z:&&:'SJ/ED.S?E#$60G
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MPXR9O6^Q8"YNBB#*I%.IN-PK&B><8,Q&5X+E**,5TUZ'[W48U60?9>P-P-X
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M33OQZ5X[\9YI)S[(/7T#D&W!3O^FD&AM )\,7A8M7;K!MI\$R!*JH@OK<42
M-0<+-2OWPEWA/H80WHF2E_L>4/Z\\C4]K2HK:_X6P_NA6=2$\Y(>8VHI8G=U
M%>@3':GCPX/^X6V]C?], AA#=7>V'I /(5T1@VF!U@*65M&Q),VV)/NU 1*^
M_RM9%H&MY\LAT!_QMB^A9LR2R)W5E EKG?Q\\J\7_^]?VM4"(_SZ"Y!]TM^?
M''W]E!4QS^H%=T>,0A6FY5*DU[K*AGBU@R4OF+XU9R+.QQ Z?!E&S0H2=4\>
M/7FD$N58$_2):KEU;T1AP$O&FU34>A2DXP5B2P[FY0TY?8<'[;J:T&.%X\%K
MDYMF':8M0Y%&(#<=HCB')Y\V?'B)H-BJ4O!5FV2=4.)T:E<V4] @BEN"FWQ$
M;$_T?$;<M#0 +7<I$E>97J)3))*K'&\;.7\S<*,&'7YGJL/(48F3_XF#,'E
M6B\3?T.)2VE,94L3@2&)_MZ$%8JTQR8W8&KZM@ULM*(!:',4%!O+2OJ=YB&(
M7MZ89@D]-GS__HNP:%'9JRW*+60J#S&D"6T7#"KE]BC6DT?WF>C%+KC')5W@
M# JZVGVUJJ")Q.TLJI9E/42XLU.H2[J$*YKQ-6\D5H)*,9PT?^DR@GR4-<$=
M'J3%DIY35S&]69%,GY.',]PVFS%S,SZ#P)F\2Y.LXQE,*FGH6N 1+7A#X(J'
M!_W;KXCOTVFZ(1;& 1+M>ZX2MKDXO3Z?&?VL?\[D3"$P9I"-;-#T'B9\?E68
M?.EB@P7ABTWH")/S,N6O4",( Z@?SGEYVW42[)XM4RRGF=@DX"_KS;!]P#*
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MW1>]')EK:*Y6[C+%6_./"GG\>5V&Y3IWH9*#F^8</X1_%KQ[IZ]!1V9N$@W
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M%#!X0MVSKR*,:3XS/D<WA",H8**5/-O.D!%R>'Q] BS( Y5&$ P?B*J67-(
M* T(/"[TUBO!&]7<"C/;2-L+,LC .-MPBUJTV$!R<%J?>U&*V+1@F%@&@G))
MI/IH&-R'555VD&<%Z&DC@%1@&*O' #%CR2$;PUT=3-0VKF>S8E0W+(@W5$PN
M(W.&@].FOEB>V7*;EDNK0G&%:5:^"S/?:)/3CW?>)WH6E  M>Y_V(A\DX/FW
MD&,_:%.3Q2S;,YICQ2>=E0N#;*%RQD@3>3O Y0C=A4*D08A2+E<*:_JMP\C"
M?13991E7MRC/:U I^+LS.ME:.C#_I[0^5H"RC<\J;C+FMBVT7B@''+<%XW)
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M[)L&B%@N]DOOEN1);LEY$2)()NBJ=LJ:'MO7.:828_+[1?[1HV#V(;0/^_U
MNI@:1)UFZ4\:1]Y\WLG/:%@&D]/2_ZT^0;5;!%&J+B$3D6;[TVI< 6NJ6F^V
M8LCV$)_&V/(BZV6JU,5RI-;SE1#CTG*), O$Z\/O"WS??6.H]-#5C,M@/F=!
ML1ZRNQM<'I?8W"%/5$$" _4R^;.5RT)^-5;,M)ZZOV<5LUW5,\-[]",_FE72
M2J3\C+F]SBK\J@-AM?/A!)90<_EYA=:UP$#$P$H V5S4IJ(7*^3A_@2/F:8<
M/DX]$X(*E.<F1V)[^W\F_#S^(&+U;L,/B+&R_ZJ,(8<M@..6834%(;+"70OB
M.!@_#*.K6NX-A.)C[^Z[I;N3+L#OP&5-7,:B&0H3FAR%T9OZ+Z '!N83A>]Z
MV<5U<;9JNQ5SH>E<@P9&:S)&7=<)>Q!KZ4WGLD)PN A)QUJ7U8*W>2!A"&DQ
M12AU,]OY0B4UYX&H.3Q2NDF8"['RCLF,>-?(?P&$^.!X;:%'8T"W;5X3'G0V
MT^7F8Y(Y^91,1$5%;;RMXGE=&;]H<' VH"$"V>),#!ST L$:G*'D5(]R#U8Q
MXS;E.>(]!6T#[EP/"J./OID@UUUCD K_T;.F#KW]4/N9"A5ALK+B^L 89>>'
M0MVX:L+?UT//I*\L&B=J6]3J],F1KCDS<R*500N>)'4.\/JXB(M-<L@H?3)<
MFN.RPF,ZX37F;(&V(*[YP^(UGSM_SNQ5)CD\.+$)<"BUBB,E(S3$9N:M!AH?
MLTS[>[% "?=7%3B,>T)P*THL6-6L54P3& P^L.AQ/B3O9JME3F@J4U*MG.'Y
MM %)+AR]L:K[&=-W62SQ.JBMIZI%\ ?,'B2'%&FP :L((-? [V@EC^B1^+-&
M^953$N@$<:JN<%/#XU)_F)]=YN346X9-\&QOX)^'"_'!$%.2$@;G\,1-KTG$
MVO3T&R5*6_DUZQ0Y4YW+X8T$"ACS_2_/ 13LUGXO+^@G/'YQ#-W'CGDWV$L?
MNKCY-&K!=,Z?ZK21!K/1G4X E1F]G'+RZD.[.$*(]>N;45?6W4&W,5M;Z*%_
M+/2G_^L!__/QW]$E3-67OC:AH$P/J.2U)6S;&R]L9+\*W]3CQK^I^*(.B\<-
M8R*&,:-P<<1BF0D7EIFRKJ+5EQ<\M%A&JFRW,0#Y_<8HY/FWKA"Y95"G3M<(
MX>D]#KWAM8L;!BT[]A'25*SJRAN:&/YE,"](!_CCI&5EI6](!68FXCUKTQO"
M52>A%7$\;QIOAEK8J7'9^O.OY6;YZU__:M0ZM/DX&B=B(F?SYH)*3Y16U2.9
M5^">,E%QYK-QE]:O>V^\]3"4G \"[83#V$ZC*^C]5%\0OI[CB@"^QK1!-^G'
M_2O3*=+*D_0KT+4 95VCA(P2OT+B8"(4GX:?:U9+,ADMO'])?4.YK?#G;;!T
M!W4#_5IGWYM:,"T!+/Q4[YW)PP?_9>+4SM\%Q__C'R0O:8#FE:1OZCP!$\2E
M]O?\YD%(#B\L]!KP$U0[*#><V*8]\19$TCW*QFX?3--FX<C*/M]WK)B8D=-#
M58^I6L",2-*P8HK(HVMSM\I"BYRW, #^Q:G6.%U/:)DN@@X&+<%"V+/\+7!#
MF3KU.T\"9VG_2/OR4_MW8M4_KS7QA5*\TI/UW1%#^7N_J3Y!"6CKXE<D4!83
MQ</3M$#ZB_ZRG<(0)^1X-747&JJ0!%Q9HG#5B0'-%GNN>Z K/]M^PUM.]D\M
M'*,,0,$OOK]W77$%9O9 _"LS)D'JQAU.W?P,#Q""_^UC-S(YPO]]B.1/9^^N
M(#XMI5E,T\5=X.6E9S&&9Q$42<<\1"R;,*U:G%Z<B482IC'XVABN=GK( ]'V
M\-"6T+5O,"3QV8S]:M.O;S4AA5F0_C4&C99_E']/UHZW/VJYJ!./ U PZ\AN
MUS6<#ATW$T9B.(O,;@[U[V41[V:ZODD9$K>S(.;9;WYEWHCF;)"D#4F2L"!U
M5GC2.!,H(F,A:@Z1/MF>0#BZAY\BR;L(#W<7W9HP:"M;Y/JWVSMU=A;\<[/@
MD6H\V[^9[Y(9<&#0D;@3^X9T,0UWM9#:D"A+:?HOQ@27'/%88=989WTNU*20
M7NOBUW"W_3V1Z>Y<&)E"0H7]4H1E)96'!3QY.X<QTWU?NQ/_^'3AX^"1@_0;
M:R4"\ZM:V>#_B9)@>!!8EE6G?7GG/G2)T@'!2;&-/<PLGW?!(%J8EQ>=/JBY
M]JV#6;9\4XN64W/#))$ZF:RD4Z=*T+S2T'.:WNU'?SB@Y5!:%-MR)8G)<KRR
M&\LLQ\$/*^#R.U!^ _^$?%'FP$1#-D8=>X[3(6*>P==M#S!?6XF:S85$PR35
MZJ:HILP16F(8R>EDS8VQ&/V\-&OGDE)EW]^.01@8[\-!1!YNY@(16VDW+W!_
M2SD"];7G9=Y0 J+YYYDW9W9Z5;^MH6H&9Z*6@WY*> !--4RV,Z%POS^6RLUC
MM= 39"UKS3)(J2\<>F%GE9/P"[R"%?2ID4!:< "\SJ;KO@[GH[WR*,VE/O7.
M$O_14F.BIF6";GG7:C]SKHVUC+2$:)[_]*[!B:3])GX_2=;=__2/QMNQ BL2
M;S2N[]B;SDW%3G:@\[G:H[:YIH%"AV62\1_*:EYU8-^]$N#+7J78WJ%U3\<N
M:6]GK.,9#8Y7U6NR<"7W@*D[</-5X(\;60:)/<B6@:8BX\_A+#2?4+274'ZP
MKH[!#OJ@ :DNM"0Q9OM[6,0LUR25FR" LZWN;MVEA [B6$[W0%&V+8HMXL?#
MK'$RW(9W;R/&@3,PY%'H;V?M>RRF/@'+Q#(MC]SP)-G6.2R.*SPK\V Q?DD_
MXK>2I3RW=:T3<52*7@G&!Q"0OBU;$Y*MGK>NG&*?GJS0S ?Y'-%:W&0N#[+J
M\+ZD A.5(=-*,KU[^0!7%)9F=C>^!D:XO1<1A"\V7LOPDH%125^ O^AJ$OD@
M&Q'8#4";?*+OD@VY%M[ZFQW>^F9XZ^]V>.L=WOJ3.9*_66K2\G)"JZDA0G7.
MT&OX\*0%[OD1A\7OIP(.VTR(^<LM1%6*=AI6M%0("G"?99<>TXVP[IX3D!,0
MJ.:^I>#/GGM"AP)(HTVTISR4P$'#62*H8#<-OL"FS-9E&:OGM;=;"\>9(2%%
M/*"]/^4C-OK"=MA;OG%@\ +%M%.$U4I$,?)%1>+8^1O.&HG14=X5#"U_Y]K%
M!K!3#\VH[SWDPV^ 7S+G;'_OP_CHQ::+;J\U;::]6R<GHR@4H)5]-A&,L0>6
M\M2 UIQ[=]8$1<-Y9?,VF9=5YB]11PX?2\%8Y<(O5$EV+YK:Z73/ )4J3TJL
M6N'&11?A<B3JB9;D#;#:P%=P)T,CO):Z7&HZ+'MPF7H09%%:+9J!^!HD[U'5
MP,O7"?&>*,)="LWK+0 B^;7'W(PD\-B9R1E:):/BM+EP5"F].&7Y8F-Q:5 R
M4"M7D2 9E9OFX-JUYAK#@R/01_SG(Z;F3)"S0$.<N"E''/^@F:UURI^^TBI1
M4#N<EHOR) $H;ZQN'Z<TBTC7K*"M_3T S@)*5:3E-R *;0P%8(TY,WPDF8I2
M9>RTA2/)HL[7DMG*?V7)CX5S2\%SN'<^[J*P$1264& 3C,E%R2,5ED]9^-*L
M&E*$$T<S;(*/^),FRD*6+,Z$'DN8MBXI..[OQ8\ >2HIM,/BR&C7+C0U+-0D
MX[0C)+EZ52L#6V#NBYQRU#3V_FBYE!!0F)Q$G6K9R"1@^<=>FW"UJ"9)O5JP
M/Y)\F^__G"M1WB\F+'Y+'K($=C;B\&BNZ$W 3MFY;(_ 4-6?/N>2F15[1ZXZ
MXG=/G"[A:QG'6+F4+NNJDW1"()#@>>?F%L8K=D?-Q77,Y]TQFVEF,/<M($%T
MLBI;;ZSLC.F<-VQ8;V-B;URWX6O(\HGY<P$,]AL\#(\\U-]Q:R>3/+E-]*W=
M=@-ZD,X,-ZBW :>4?"76"U!:J7FHH&8]DQI#KU)A0IY;WD!N4M ^49[#)C7!
M9FV[<J".Y;@K5'68]K>:<%@4*;IZ9/5XBT?PTQ39P)%"?O,6/P#O:A\/5M.5
M6', )\]DTP, .'-ELOP"@DQK2UA3'5)!6NB(3^]-RFJ9+SX*KEH-1F2@%U47
M =*L*%K%6CO)LNI:7GC;^D+D-:*]#+T#0'FV M88KV'!)H-<N7YZ2R%U(/1-
M^&Z36G=<*+$J%\Y?@9&>K?3=!'A%>-I1KSB:]7&)XQ+[_(@^3PTM$*$P[&$)
MT!>*'0C#KR>-'F,CP6CK5:S6A"G(%M2RM;Z*6$$##!ZU7442 "E6LO+:5Z(.
MQ5;N#B'9F28GKI"D*M9,/?OH)T[68]<>V//M[XGYXX0%GE$0C(5P5$+C=_[U
M58X(7UPOO.0KEEMQS=7&-E-_BTY]&RT]5C3@V2;H/5OO>=2:9V6[Q!G=_G$_
M /N\5:K]:-O5F55W^[8H"?+5+&W9!I<S#(\2KNC]O2&R:%8,@TQVV$9W,1Q]
MJHI_%RZT&@\*.9.III9FYT:[L%0T,.':C8ZA4?3V.#M3<!.W=WW2]#[2NO/*
M7:@G:OW]!N+,'+>XZ[7GI<\^;!4:'2BR(7P>6-6)M7PD8YZ7\'HU1%/;;6AK
MJ42G-(3:%#EM_>:=BVL8N\FE%A'S'LE=_%#+N6(C-DJJ,0$37T**"E%D\T5J
M'[#C(TMM9(0/%CQ]6:<*;:M2W-I"(B6=G,/B[OM1<MN-&UY6U/AV5]2X65'C
M^UU1XPLK:FS9%7=N]S\S+N;$2TNAG-XR*@]]M)RP[<^>'$FB:,%L;'H:]<^)
M,N]>5!I)=K2(YYD=)(8KRW)L29)LZ1_O@"[J0D;=^8>R 2NB>B2_-L+'57ON
M_+%LE!K]U!BR6$T-Y(+H0XAB,*,;E>E@U&!MF)*DL>>GAV]C+HO7R/\\]4-9
ME4%LX]?H'!^S&=-[;5]A.A[<^_'UTU^/^<_[/WXM[F7B>\W"FY"P)7$ZFMGF
M<89T58Z%S(Y+8;Q8.%,H*$Y6%=3"ST[7G3\QE4%F5=N?H83"UQ.]"Q\Q6*X'
M2@ UG6G,5ZHB)W,4W8\"SQB31))=M/')2A'O7(1=<.N%\U[[5#A**A$_.*FD
M"UJZ^L1=9K+-KX)J8<CJ9=/,[Y9OFL5?VLB%M<>7*6S+L)?>>_?+PG]U"'QJ
M7?/8;9>N(7':T@Q]2#Z,@DN(MS)YRU!QE+VV42)H<BYO36&A$KE[PSV2@&19
M">S)7WW1Z*.Q'V'$$D-KB9J)=R/>.L=^:*M'FFLF=8">N\VR1.(-,V,2#8DH
M&73D\1ARMU/(L10<LQUDR];?S$>>G4%^$X.AGG)B?7"/+(3D@^$9_90&9-DB
M6>0:R68=!*+Q,2WZ\.G)3[^^DO#AI\>OLL%R0="OW3!WQAFE4-K,@AX6OY '
M(B.> C86\B9^ @WKNNE9QT))2*CTUD.G\.K$0>\0&6M67SLT)^M1(%DAE0D2
M+0=(M*S35IY63XXMBU7[0=CSLS6>R":LUR0W0C8\D!,O(1#3?0*Y@L^)8_=J
M?MVM]+9T[VZ+^S8C;KU%T>3H]8C;>MW_:(XR\X)Z/6VSWA9+HFTK!FHIJQ=\
MWW D;7'>S%<UL1@RBFG0@>;E1<G9AQP;[+@?FAF7__.0T<R_/)?^;N===O,9
M<IFCFZUT[-8(8?6GW4G3:I53:LJ@HI=P1.B@_9XK6S;:S<G[Y7^Q0G<=Y 'U
M-_CX:3.?WGS[]X[HW>[:[:[/9G>]U[D6NL'3Z$[*=Z,DV \A9>:3)C(WVBB=
M=>[>9"B[?;7;5Y_9O@JXI9NLX\Y5_V0!LV7O8BVA(C?2;-65UO]NK&$25+.X
M*V%USY'<U%O:[8?=?O@T^Z&J_[&J_] QTX:UWH7$Z:0ZKPA_F;05))_GL=8X
M+/VS6_B[A?^I'"R:[ILM>B%!8"88&4_)B6*-"_M:VN71M)2\3A+W(86:?0XL
MQM,;CV*E-^@ .PB(D?-F4O9K& .*.K>]Z6X50]],!+P^"1T.DA4GU@BVB-+&
MG3=08[P*0G8CZ6>O)20C]\_3]KE0:U J%Y(B5(.L.B5X<P)$ICD<#34U$]86
M[EL@3(3=5I#&X?JU0RD+:XV-47YX=ZO<DO6B)'.<@$)&*M-KX/%0%TEJ&X;5
ME/*&-D"A5)@#8+;DHB\'!!WN[UD%4D*S>: <85.PBS<&EHO(\I1CT/_7U"F@
MDT64V''QO-8^ G\Q(M:4+RO@]>7*L!/"G>42.FJB]\RT) :J!,G)+#(4;O#9
MAB_95%J/EN&P8B08"Z*S4 '#&TK*F(FRA;\3V5_FY84J';>ZX8"=%8K(JHWL
MMV2!$N(G>:R*11^_"7S\BKT;0/@V9+!C^S$G?7Y\9 R<72M^]OVZJXQ_=P&M
M=U10O*D],<1N4H&MNC!$I8C,RUTST4^4B<+TLRT=$]]O*M#.1""BY.GQO0/Y
M7EIV"WAU4?, J1@AA";/8"]<"&:R>Q/P9IS8[)I)5G8*"(CM%<+B);/T^$@J
MZ3,W!;%X0H1"UMLYUOI4V:O%G:-),W^.63]KVDHY5F>Q"2<R$L6M*(WQZ !"
M_Y[5H#+F!M&H,#@L^O,VIZX'L".SOMYAXR5UP1 /@?<&9\?;"E<\EJU[-%E&
MS &&'C 'KC-FYW0"$L(%K /5QVL5YHOPL*RE-RMXW'IKP1 H1X*;YG9$4S.5
MJ1<0A^V/N&4)Q^%.G0(ZV=% 1<A!B@B-;$OZR>*LP9GHNEYOD.D]$)^_)H1%
M>?%CJ3I9_BDKDYIL[S!, HNW@OF5LFAD'H/1P@VQY?</M.$N6 P,,)MI>98,
MFW;1O:N$02\O,EM1?MJ<F;^'KM4^3M/FQ80Q+A*\M]X[,-&GNO:QW)UG!".E
MI,BE$!3>/R.RGF9I'V3;EPG5)"P>)L$CKJSUALTJ8P>^4ZO[6:6@8&'.EW8[
MP((D:41]FNJT:>#H6"-H*] )9I &5VIT,/R!USFQH<KN. >PP7CR@2<"9D>0
M#N=Z;3=9"=^TLB>[RI2'!DC)< URDAF%V+3"X0?;RC8<>9;3YH(+@P=7&,(Y
M,2A7#2 1C0SM%5'?R-ED^+N)R60C);^B?2?+O@6)KKR_EW?D.[@@W2!:1U5]
MV.\>A\V]MCE.Q=]-A.B_JB,K_;;;!PJ_ADP')Z>"MNGU(R7,=_(.P%W*U2<-
M5\.-:!8=S-<Z$;=S,'PYR.GO=LCIFR&G?]@AI[](Y/3GLAEO@\3B\<N_/W]R
M</\';QI;[\N=5ZVU):::P]:1N*7Y<)A&&%I*FVU9_QK=O4]\$$UYO@?W[O^
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M*ICDM=W,;RQ==O):D>#K3$\R"+*%'-HHD6O+I7;V]X(*[TCR@TJO-2T7P%V
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MIUPCX>UV-WB]; T6 ;X)FOG3%4EY980I+K"@+,#>Z/\O/Q]$$#G#\"8-RW)
M;B2AA&E4]C3F0X3U)-\>X!HK"3RSG1FWY(A$?D4U\P/ %$Z\">H$CS=U,X<=
M9+"/Y<ATALI5 !]O/O/<G93S(B-(G59PM(6H8,D:H>T?DG+8XF(+2D_([>Y
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M,VD3(U;>PQZL9Y"(AD?ZY-0?& Z-A!;\1&JGE3^%<,'3YL)>CHQI3$*L.<T
MD@$K?E&C*930A:XI=2#LO*H'#C[L8#GYZ(BJ$YMV8_4;_^AZV_N7[E?QUN8H
M-.9WCHP:8DI)Y]X500\J[5V&C^2?8^;-Y-H_>_2J;"#>M@G?Q#4M68*_Z)D,
M3,7+R;*!N;C_R+H^98DS_ZVKW#\UT%RE9?)AS/P+_^&>CRG6)!6SU_-85%!A
M%P8A_GZWU<VYC!%F<NP">08.K]8'* SZEL"]U?[H6313?Z3Y64$G Q#$P2$1
M%WC[G03,X0.)EJ"VWU7KVN($ G[CS&25HL07UX/(N,DTWAZ#'Z<Y6\8V7G&T
M1L5 ]-,G5NE")VU^U^2PDT;"DF"77F3 )6 &MM7ZT+# @,D'3-U"6].V\'])
M&!/FPHPY3B0^]=UREZ_! _+HWHX'Y&8\( ]V/" ['I#;$X-_PRA"#@P-&%(Z
M=V8QA=K8'R+2PLPNZGB:5UW4O/ GJA(3@YQ*6H*)U).$BK>-?CW#R;ODEI>P
M*WK?(O9QC[)3H4>Q*"4A[:')*#RML:3_#8FWE^'3YES<2C/^QU])QXD3E4J4
MN'<5$V !BVYO1D[&H=5@B6.DQI@0C*@)==PZY]ZFS,&Q%_RXG$=>TEQ?F$?U
MU(%YJR#2O5T24,;S7B 8VD:)!H 9/!)RC*0K*:ROWI*21%:_FS] VC3GG_*R
MTE4(^-7-?LM1DAM^_//S5_Y]O'[^^.CUTU!^^SL(/Y!\/<H\R@S\X%\D'37Z
M)$U[4M9*I1;D$,ZI%1ZJ:5+X/+1X$@0P-O&Z;2;^C3<+9'CU+0SM+?B)Y1D]
M]O :._,CTRRM!10C4'$$<A@?J[H:0>/8IO(+YR01(&2#S*J$XDK6(C1Q3CCI
MY%&-G$(2Z7'YX6ME,![>*"[79XB'$-LYO^H(4;&$:GHO']V''&)/2T/"875Q
M16U#J('-H]5KX9:'Q9%\)*0UO*5C[,D ]O+A3AL_>\CK5RQIB4]?;]M.+==D
M\-\-'G58;# \;^YR2=Q5N)NW0Q5C N8LUIHI4**-F>&_,=B^R@C)BR)>P-1%
M9DO'@,T'NV?^L4,T$ZYC-R(_L^"[4G8?Y!GBRZA:8),N.ZDLU^(W![DGP.-L
M!6C]MF35M%U'K:"]_= A! ]M=-61& XQ[%(MD2>1,5HWN;QDF4AO9-,R!K^.
MB;2FG_ VV7C)6## WYH:#D DUY LZ2BI28"TVF :D112Y=;&5E/Q(;W_4X<4
M)TZ'2%:BK?JB<KH.JY/L2625"G5^I'>UX/>%FYX,T*,$OF,$0;!*F_PSJ$QJ
M^DG:)\Q$)X",B5,R_U)-&'YO6,?:X5WA')64>;<\D(14Y=T=EA!FX;,Y]WD(
MDJN8"B%3JBQW(++UJ@ZG<SE9,R<H"9+H#UZQSM,7+U5FJ,+3T)CK.6N,%9RY
M]0OV=OAUX23E883@4N!B*7&YFBH9>QB-C^6%/D=3CC>9GV2,P8E@JQWR^>GT
M1*<*3A8'I"A,G8P!)ZG+K)N]>%OX@11>B,;MZ):*ASX#;($\!D!"-*3I4P@*
MJ=5QR-D6]KAX!JR^-T:4,:9;['<U<  B-D: $R_ 2B?0E^=-*T&CO5\_9#\.
M/^8UXK'L/)%-0;I?K6&TX0E=+5C;3OQXC1QD66M=)G'_2+I<*C&NS*'_J-@W
M-2:8*FR:!%DJB:^$J@[5,J)^\B,L<:LR3G>,U4R28KI0:ZC*D]H_C7>JELYR
M:BC$LF;!46P&-8>L(VRY@"')+HO0S+F0(P8IZ^!F;/^:Y %EX\8'Z)4P_2<L
MO9X8 ^_$J\Y 3#?'%2TU\VVW'>5 /#\?U[GC2&*# #49FG'4.[=;4C!^^5,F
M1GN OYV18(:CQKGUA\.(OB>6Z0%8OG#5#:^D3;LH@=>V(= 5FA.V=\G"2R&-
MNDYCP*P)_=!/)[=C6=EJ$ZSTIRH(R2$-\ZI%'LF0TB0FJ".)7!JVZB1HND]R
MA-XZH)I)E==5][8K7NM[PBOV<_F8(I_>#VXF;Z^34_CB,(5\]".$'2AOFOL?
M2GFT?Z)TZL?@)\$0#5%T(]F@;8E^=2MI0,U-M2FK9;YDI9/=X!.]92C][QT*
M(HZ J?D*H0N3'MIDJL ..1ZP(X7/CM"Y9!PX9.'ZDGN%SW0]FL8O[2T>8>O.
M?2#&<L?@FQ33,/ F8\$DI9*MZN%WJ^_RL/BK$[A2[_T%<(?:'A*GDJT055?@
MPZ2FIR("BKBBYU)>M@B'1N[-)%L+%5?GEFVEH$?=O 8MF:8(F_T]@+FN?E(=
MH2W>K-"E2U2U@SOS9Z!QL;1UQW-'\7OSL@8@9:7 +:-X&"C2UNY$2OG!IO?P
MK// NID(XT2P4N]1S-U!+3&-"ZA3)+ ;23\I$#;'(U)#AQ,NKT+?3T#R:.JI
M;M!;I&U2J?B!3&126K/)1$(FI&[3Z8H+*?<6%\ZIJ8C"W\0'CMV\<HH>#W21
MA02I!J"0A<IP01+,?)J BLM6ED0B 9!D0N;P!J=N;N%%O.K0!7QX FF/I="@
M3CA(+1!KG+<TENQULXIL=6O.M_>M7"?=</&R?[E+UNHS[5]"&\\'[6 ZD.:V
MOUPU4'ZV\\&0/-X':&IZCSM_J ZG/SP$A6LSJ>!?075&=PP0*MGVH<L'N\5[
MVZUWB!$2!/4H]6^'^L#]<WRB3L(/M19VFW.W.3_EYJSK!H7(P!@%QR+D&$/;
MLB8 RHGWH;HJ--%(XN[$![PYG_5XG47:@BMMADE?=EMXMX5W6_@]AI"(5I03
M:JRRV "VJH0.@K4K0PGO]N%N'^[VX<?;AZ'!T/F[(,.KFW"<)D@*L &L.ZWK
M8??*SSU&\ZT<&KL-N]NPNPW['D,P]9@@D3TJ'-N<JLDHH^%@79@=8<PVA=++
M($G!K6U+HS"YI23/FUZZ+:#8TK260  (P0%4@"E/H;;H(T.9_VO)MB32[_Z3
MI<E[1=,8*(2!;F/7[BQ"6WD1:29)+^!?GO;J%HNJ!G^))/BLU(:L7U]LO)],
M',I27PIQ^>)R=JP3/6>5I>K8CY;(VC-GR81JE@OM-8=4VMD1*P[X*\L[B?Q3
M*//P&J?-G(WO1A<2<[F\Z66%*J1O_=N[DP6?W[6-]L&]>Z-[\G\;F>/]/9D'
MY<OXIV)P\/:8J6>IS24 N/M#USH3/G$W+?I7$TFNOS:0 ?8??,*^*63=0<K-
M7BYCZA!"H>%5D]]#TNO)2UR=&1HG>0PK([#M-_0@H15O,I<K0DPYJ$X?[N]M
M&2E7U&G32'^IC+!3%6:_= 0_/)R19U?E1( >3<UOL*/8*C725A1!G'XV$B)@
MJ<M+XV#<(D06QA>DF*7+!M';3STQ2/(3-<U;(Y4+"*RX;4@4L%J"GX+UHWB?
M#7-6R.Z?AE=I8QM\I^E7A:AC?R\N/:PYH6[A?NY5'A66@68[7!;,5QG?W+ET
M()^)I,:,KTHJ;:G-2!H%;:C)$$21,$Z<2IERY/6R;>9Q#N)"*K2O'>?%,IL,
M0H(!=[ED+AI"B;+M1*.8#R5YA&@;<_,7ZD3Z'J.E^PPLW(<Y:5[V2H^P*2PK
MGY-N8^ZDBJEHF?#+?#O=C2:0:TQ%D!K8WUOR9A"=:5J!%8["ZMD^4SG5"K"$
M8HM3K<[0/RVM!/:#5F*2$08Z $"D.^>$=D75[DUI)M Q(<DTE?& 7.8D4JM-
MJVXR;] \H9EFO7/ _VGF6,RF#$#L&T>@_OHH]':H[9L)7FWI)J<U4&L*+=_&
M^:9=+=7$N_;>E%!QXAU$Z1W1#?Z-@5+.)I:'G7_&_3U\4,#M?%FKNHW(HH2>
M!7;,M>1;4YL?[Q9'(8]XI3]M;QDM[>Q !+9U+4QM6A/O2R!M:BQ^F;OD6GVM
M]W=]K3?K:WVXZVO]4OI:/][FTE]6-8C7_8<.OZGJC[^EA^\ZD*)+UT!_C;S?
MFOCCG+8/'IV]R];(Y1_<3%+%Q-./!3!7!Z<.'17^5_>_^;</F@Z[XDZ#%=]I
MN2PA)%?5/"R7K?0!*:ZXU0Y>\7R-.M4.?K8D5.?.V T[Q:63C7"0O/^Z[V!P
MOB]]"9>>51]L!%_,VTT\%'@,4__C6@J%;)UQX86C.R5[^=EW4]J8W0O]3%YH
M^E*TV30'BL;&*FL$4TFW<@*&>YI;[18C1^8\)#V'&55L7^<C&J]W-N$S7T(?
M(/6^>V6W^\H8&X>>\RA:J#2$2>_?;,!T6R0IO%)Q$VLPZ3?B"6G@_)@N7(+*
MA!)(Z\-':\^3TDK_ZL9[)DT80U>1@-?_@)&R2:]MSDB=%\B_^A<EN/K43X%K
M0\-][[K6"3E=*2G8UHO9<Z)_8FB$N]5\RV>8LAB"=Z_&B9'654]\ !K8CQ-I
MJ>T'D6:3A5+1DKKY$DB3(OT+2^ZD6ZJT"_9*>X8UHMVH(JA*Y,5NG7S:T"3C
M'$RPIZ,$>0ICH[4$__M_-)7_+++YJ]8IT;O4EI!6JY9)EG&D:4Z[4.P(91.N
M7O::*-;=LOAXR^*D%8VCB[+5MGT!%]_4[]26I-42K?N!=GWW-F_W;<;&#ZLT
MI,PCNXS#E_8^T1R'8Q9Z.(M!W,SNC=SN&\D*:M3R%:&@G/; >CCLH-N]I5O>
M-Z<NM,P+;./QR[\_?W)P_P<<42RO"# 8E#6A=WAGWS[%>^*!<Y:A<+)Z,[;1
MH.X$CBW5]3I;C>?59!1HXN&?CF(D% 7#$HH<6-%572W7NY?^"4TH, I5=P89
MJ=2<0AES/G?2W0ITDP,938O+[#;I+;^O3%>GO.A6U3++ 2#K([I@*1H+L&_A
M'MB]KT^7DFYZI%!;22;,0%*+'(=A(%V5KU3+W6N\Y6U7SH>QI7D'< KBW+VB
MVS[)A.+%\($IY$QR;'@YB= 57]H?"+NW*3WOWNW'2XQI U/H6@IR9]=O5_J/
MI%GI$Z!^=O?[H/>[TV#/!SNPY\W GH]V8,\=V/.6U"&CYESB.6AJ6%V/T"'*
M8ZD/Z <>_D793<O_+1ZKP_]K^&0.V#]W@XC]R+FMN6@C>XM:R?@NVAH'4/P:
MY6==2E<A^Q5^D('Z.Y6OM^-7FOOU6%;,OO2Y=/X)FE7G72[DCJ[5@LJ$4=E.
MYTGI>W!TH;/IK.R6HX1)#]/63*6W,VEQR+S#4<I2,)F777>@6KDQ8BYZ[1"0
MOJT@M1V%<)-Y.49;6?SRB#JZ U]!5;;/8IFVK*A.L$GE=IJ1$P$/9&N"[$+4
MSQ7Z8]$LS+7%\!IB2W"]*>N:437>F'WWI&TNEJ<)":_H#$26Q?V]DU6)XJ9+
ME,[3SB#M!EQ0M"<JX0;BTR_99L2VL(&&EPEZ-AGK ZNTY&HM3;*T.X5H7^=/
M,_=/=ZB*I'>C->PX[KM$=C-:U+[MV]_+(!+U8/N2]2 :Z:<P8>HL(H792B"X
MI=7S;0T)#;_;+W\!^WMB_+(_ZHC9Y;AM;%+IC<^H;"B).<1O>)UY[+:29SES
MUC@)0MS^E7+JSDRF0T5"_?6BO$O5L4.MJ6MA+0@$[A0IG:]9Y80#:D4 N=/Z
MT!]4]3J")??W+DZU ]NH0*<VNT//2Y&7?#RS4J6%VZI[B]O-FTXU.Y+WK2>5
M#@=:)VUU CGWC&=?FK<W)@SV6Y,#\)N</ZIA]SKFM5OH58:Q:HI V&TA0S#=
M,&4]PEB*I--ZU<TR:-!HR^ 8NI*ZLXDXS=>,N ,@4MVB/AH>6WJZ_15(M)I*
M"\QZ3*P)$2O70O;2\X6QN03PY?X2^-*-[WM<>S H5=>_E?1$Y+V9N]F2K#<I
MWP0H/%)9"7#M%U$8HUO[Y;B0KG^_%&LY;Z6%&U(5*5Z$:T'D1U)5&E4V -0=
M:%&<Z*KU.@@X82?]62M=X+.V7/D%?M2QBQU_'V493!.\DUU<SZ!72]7AWK7)
MZ2QTT2S]9:.-8B5T_GKZ\2'3K0[T990D[W_L_;$7^@HJUJ6P.1\[<0\?W7O$
MHQIC/R[;<>F?YN#EN[E;%T>3I0#NHJ^&O9=JF.@;HFH4F_+[@B^RRZ^Y) [W
M]WZG@:*>$H5?:50,5=U& T71%M-AN/"A;N1[2.W.U F!]<1$;*X>#O3:=#S]
M!NT^EXU)K%S[ 74=!EK]JCZMQAL:C'YO7;$'KO1E":+L3GTXU5QTQAJ!(V15
MVSY#693B?<&-M<<08O)+GZ/JXJNFWDUEKUIT""EVAJKYDLKBNIL2KL-9Y<,G
M$XL#E-CUU35P'LEKW?I2U]=\I>DVCG(%X:C*+0)I3#C_D[4HBN#<G_NAIFNZ
M?VWA8[\R&-0%H(?XR/A? I=^*N[MKZ]DRZ&MPVC7#:"@P3>5,33TEG$</WW,
MH@!M60K=5C881GB)XBA\O.F:..N-7<5&_AO.LM"N!'7T3,I4!I6**LG5Y Q)
M[ N:)[AP2"HDKI?%FF0O@<OC9UIWAW@J)175@GR4IB7DO;Q?_/4^ARABIDBE
M$#98D'SQ<0'!SW8>VL&FBHJ3)=TFU[:-P)O+B6QY.?@^W8GRN^MKTI-T2#(6
MZ?EI;S7@Q/%VGKY3QI<CJ##^[A3)CU>?S5>Q;;I$\Z%K8-36=F*(,^N=<^15
M>,;!T?"/9%=THDS.;4O?AGUTK6G,TV_<&!],'LS"8B4^O[$DK=##H/U]\9P<
MF0CL!/GMZ2@H%T[!P[/PTT@2)?D,!N)_4$E[.A'5PEG:IZ"\QJR*)$OM:JXQ
M%QXQS*;?\ZD< V(KQBGKZ\QDL[F]^Y\9(698($G3%J?-!:58#PBN88$QZF%0
M,*FLJ=E%[4S*'X87Y4:BESCN&HC*C/K"%4S?<3WYZW8Q<$NM!%?=PBTM?></
M4M?V5"DI]Z<GG!.MLV4HCOYC-3V1M0A-,]7[/%B4*I;#$&E6^I-U;=PE_DO,
MJ4]]:"U:D@U."60^A! (O0\P>+)-R32T\ =@^=9[#L_8O%?BSR-=W,9_Q;^X
MR8JVL$';9W18O6E%>@MIL?DZ^.!A&9=L!$]YO$5ZLL6B%;$RC V/) (IT8M_
M*X1/:FDMH2KB7$N([VKV,"Z=ODAI6"4Z6Y.J];L#5DO8 VD(O#]0^24 N)69
M+')[^772L2F$O:CS^<K2@LN+)M!XG;GF3';F&$<3?)?(/X:SI^7BRM8'& <G
MV'34>(2^:'P]@M3;7"CF1>1+;%3XMT=V,UDGFH.QERNFEP9;U@%6B3JF8K+=
M]*-&G->JOSW<U=]N5G_[9E=_^U+J;Y]WRN5]KOWQ)?6>)T#8_;U7AH2]BS2=
M:18KCX!5/E))[#0Z232OAM'"_A]+S9U8T_:0?*7$Q*RA3OPWX_ES^35]L,=1
MP=L38?$X(.\"L$PYZG<WAJA2A,;,-34UZ2%]S8 $PS@1KDLG;L.LEJIO]D@(
MHECU?-V[_I;&7],APR%YAMR3"^1H/IR#YW%XFTM.5H(MO%N[+;D#9>X*R8[0
MXV!+/SVN(!J:3'9<FT6BY!M67I)9VUA-HZ3T/E\KCKK;HBH?,IZ(25>UM#]<
MLZ^;?G'HJ&#LT3GW5@E7EU:,%6%AMX2D\EDC[<#PZ'S8E>"\5=XV>.Y;QEI*
MH7Z85*77=#Y&?NC 7Q5BUMO0_X?%;X?'AS9+=F&J<Q^]./K[T__^CVYUAD7S
MW2/@ _V_'QQ\]U#H$^G#*U=/,6TZ''@(R;@WVXHWM8*@_[,$,Y=>%57RIO:+
MY)_57&/(3([8VP33D-<,1SY%B+0"D60OL:Y+2N>[9\8N&94?1L=RCO>HG73<
M,UK41,X_5OY)?:QO<,4[=')\Q./_#7$>\B9L3_C%<14G9I()2^"_54<>#O\O
MM.)SO3'1V<S/V?^"L/,=NI@ W G7I\5G%D'EWKROVT4HQ"GKBDAA8)!K5[9"
M>:H:HIKQ 9(C!XH0QA*A1?@PVCN8K?*^L)^&(EJ:F.^*]D+:<6Q]=]Y#1Q4Z
MED7W]^QZ&^N?QRYTL J 0LJ$?;A7:[J0^C.S:JDN]64-0OY%$9\B,O$2=8/
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M)\532QEZ>_,4Q B:_&*_+B[TDOR6Q5^;YFW@NAEOW0M7^^E\&) _DIVX=H&
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M8W&=-$Q(3N)D1?&CP'[E5-2T+K;5,T>7JYUV6R2B1J;NH4*G=RF4B,F\ ;!
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M'DQ*# %<)BF8[06[PD?/M=_2C6[9>GU*Q8EAC!9[4E6/8QX:7[=E=]HT-S2
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M:,-^K,QR2X@@03H4\M%A -+*OR7_E#YF+#()F$AX2W%H*_@GYCJ3&_'L&T.
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MVCHNX+@S9HPY2E+4</YM4,#:+5%&\PL8F9O1)5W00S4X@4.F*T=MV%?5UWX
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M9UIE&)E]A:#,P>MC;V(??#UL3LLI- 1\2%:Q9,4 [;5;^H!E74_]X%QJV!9
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MY?GR824:&IA](#7Y0'QCBO\I)?['<-2YSAP^-#70RV4A)6>,FU8857=Q7R-
M+L$7C8^?B^IQQK4DT-0!"T9 ?H/OM8*1[G< .7L<KI8"%+%E5%W"%E]9F$#B
MHB+*_-O(3_&1.:@<4" 68C1/-EL(_2M-3>AAQ%V/#.8!(]:1?E,.JQJ&L5BX
M(!X4T27+?QS:NR.P4!] J7G$?&13=,*X&GM4I1P^:DHK[L2:4$#HJ?%K;/3I
M*C!@]98^PMUVN&L-K'-<^U08$RH;$_&;[=#5L/RB15L[F=W[IMZT]0.(5#&
M2$RW$0.(=@Y%\4JG38X?JE0W,7Z(1\Z:+OA]"R<-U<68F5RZVRN:7 /2J2K%
MG#4CZ&!-=%!5Y:I:E<N-V1W%&Z.#W+N?0@MK4T+PU-"[ADD+2$2SRE:U#JJ*
MK*DEN5*=G"=8M*X504B%)Z1:HRZ7ZH5NGUNGG;HYL3P5+1&<M!W]@VI9 QM&
ME96R& D@B&AEITB1Z[3P?U.=J/,D;W;;,598II#GLPN:;)KYHF9R;>@]D6[U
M_D0A*4W>SBQVG5=0ZA<[@Z<>5D GUJ6J$UGU>6_<WPM3\JR( M<U\ VJM-@4
MOQ"4Z6*50Z3D=J2#RM=QMVB8M6<UM:SIHH^_B-2E!L7QQ5C3D$-9$+=PNBBG
M:'T=5BW@VAM[?R^:V1V[K#RNQ_--3I!OHN5;8?W<1(D<3</-*X)#)"^J&-O?
MPS5GQ(%G#:5[,'$DB\"K7:QO80O01D'&;XR9[ECFG1>N35>L<2&U^40RQFTS
MD5*T7/L8.\=S?U5XH\TW9F.[78I<5<(&+E]]:LE)J5D-D@F9A,0.P(3@?\J
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M:J<#L&EDC/YO9%:7#P(Z="MZA:9W /\Z^,S,=I_._+OD*/C7T4#[940'IYD
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M2S_@:<RE>HP%':G3!I08&F8T/XT<$V40^G:^*C$05"@F6 U!*%4-CPOO^%O
M]3(?GRB0^=XLPG8&3"Z5B%:8F A:^JD1O)Q*P&"?K4Q=(%[EPKL>@L2V3ET^
M=@LJ.@BW++F_!0+HUUCO/?H*ACF@0<ZT'U8_<*!37]OH,_?4=\H=C-7ZCBI
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M6L!O:[A=^AK(S(K83^C8#]!!EZ@Y+PWW9]%FG:PR;BQK@?R-8/4)->RH2?E
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MA5YWQQQAI)5+-J.BR37P(ZI*25@=PNI8,^\5V^"8PW7/S7545;FJ5N5R8\G
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MDYEBF?3._477^SS0M*I66QP,ER)1JMD!IXE8N,089LI:#@73#!D3DMT?KS)
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MVC1J85/^:W6)R@]!K5M(K3/*Y-9+KAGYM#.*ZXI"P].%=()\U^;/UH4_*^@
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M^X$RZS' ]@'&CZB6W1[JY[Y]#Z2(^@E^I3/;9:X!@<G5.VI>;SD),L.P93L
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MH]-[\_C7HS*X.0M-YGM363"%);-@$((ZRLWSGTM-D@KK3M/:LBR8&M8\)F]
M9.)_7/+3PZ)['B_OJW&&3 UI $P!\*=['%.5 PRK0ZQ2*F16V+C=0\L!H190
M0GQ-JM>]JL">JGK%@!?!K8&W*53["2B1LXH#8]GZA[D-R;D*"\\N3[C2PEMZ
M#BDOYN6J6))*406&<X #*<UH9SB>*TE?9MVZ,'[IQ40N/>==ND1+01\'QEGO
MN';YI[*MMY\CMX_Q((:[E\1B(2=6<Y&3P>< QI?='=C8TI<O)W'Y4M6[_!RY
M_-]GQ8>[/\V[Z^^M+;U\J>I=?BZ.R\^)Q7))E$NK$/XGWN7'&]9AEB4T[G'&
MK#V(.&[*T$O>B7>BZ#8VRKA)EF=XT%37[T$SYLJK</0PU_/(++V5[Q$:VW^D
M1(HSHHIFF]7BZ$RV<ZY2^?#55\ZX#;X7+]Y=H+=L5(%KL#2=@D@D@VETQZ6#
M/YHA/8#X?L$AKG+1CY/VE"$IO0,'S62)%]_UA%*BW_ID=V=V[Q,<0>"VOR_<
MFR3&#NZJ%W"(F8AKD"D4.M\WV@.#U=--')9CD<BQH1C:*SBSR%Q$AVNJCEMB
M:8XKTE8'33S.@N:ST&Q5]!\<_*7>*$<+!_H;XS*6K:$M'%*HW''-PFJFBG^E
M#2'F#R(L_<[ZZ/S/7V?H'$BMGZVU<:,#Q(VZ9X7?!>OBX$!"W(AL7V#[%[@=
MOR>FU.J;33I-QB>:B5$T\.O]K:!:AJ'8^[L[/RR3E.'KR*"#T3LP- -WEB--
M-UH4NMXK07MR*83QEQ#I>B_$U9@:&\=HXTK(GJV!FQ]'NFEK;A+,$W L#[?=
M(H%71"M[W>!^QE:;^G:<#$']]M#K&S<N49JXF1$I\;4:!C0CH1-*:3L#X63L
MB(@W<E"@60-+[(?->?+I"9\5V*B7N=3&37K0UFA#$IZKD>P*EZ,_TFD!<T%2
M.(V6MMM$(_-RF?BJ9YV;*H:PH8F.N.4I!N/-7;S*$R[=)802<"7.M%Z444TC
M)_(!H .DEU@;I*8W)6EN-5R;?<-JJ0GOGRY5#OEA+O,\7Q_5E)]*(7]P]_?G
M2HZW*&%1K8^>[B\>2C\>'GX^(&%!=X7O]52#O*0>H@_!VV42 F/]XN#*&T/G
M:*S"WM:\N6H*"= B3LL&=)B[.S@X@%NX8..8L V'#!7!,Z,1WW&!OQ [%+@9
MGU",']+\:18T<@L-/5K<6#S5FTBN/$' UO;^LD=F.>SNM&VKWQ-)Z7^31(X[
MU@M.;S$@%08G(WM3^DPBIW G!EKQCS>(Y$LPQ6R@:R\./Z2/F:Q$;76"8ST5
M:#1H:MS.*219H8 ^-H 4-^G#N68XU&W!:$$7SR;7N;PV;K0*]".^O/6'C;\)
MYJ$,7HW/./^2Y 7/[-S:1%NTNGM[T<_41_II[_:RV;TK7"<1/ KG&R?UD7UP
M\L?]:74>GO0/7_'^WG[%$CDF4R5PZB-)>569[L9USR3*)1 L/!1(1?7R2L$T
M-0R_]]P@D"/J9X1"GR6GI8,Z1M-WO:Q+;."U_=1=OU>10L?;8 Y TBNQG ^T
M&9H^G<?/IL,:$O%P3?:5X># 9CCST2JOC79P*@IT=PGVH-&(_HPV9-(W>THK
M<Z[-V"\9(TU5US?!,YC"08CK3GF=SC3XJ%'4(]##I/O]6[,LC=KK<Y,A74,:
M_7X^MBX[+U>/D WKET:\)T.42=R617K@TAQP4MGGL!H27#V"20_2M^GH,<]Z
M"PQJ&K(T*E!5@FG_E%6Y &,PK%C.>?1+Q+")6B2=*^ \PRVH/*KW)H:3YE2X
M*A,=AB:2@-GKVGJC[[)D-L0.H+FH/8P<N!3:A)_U,D;VL#_B#!?+8_-YZ@PK
MW>8+6&"'>-#7OG 4?EYA_+A=G+F&>Y/!:IJ)FS4A*Q0\D-BX)6G -->XUZ,)
M\^/%-/AX,/K3X>U/2+\.APHK"F=O)I4)%N[,19J'N9#@G(:\L./ZJ'-V-_Q>
MK3Z6=3EM>6'E7)87MEA>F)SEA6TN+RQ?'PU<LWQS<%,:?5_WP)XIC8/R!]\K
M=V95J;1"IT.\@;RP2GTT.C[,%?17^>&I_.;SPHI+YH7)]='#135?N'_(=7M)
MZ)$;R@O;N/*WNX.T/UJUBQ6;H%+G-Z'!I5M!'2_05 -ZG^"4!;XV$ZDKN-<[
M=?-':EN[.YS-VD6,&VE$3]!\"->V0W@2;YZ^RJN:=-!Q%>Q'Z_=P:V %APHX
MIQ=?=XT3]V\ADAK<%RY^]O>/NP\C(QE+(#PQ@2EC)(V"-#]W7*Y&"VMXI'LQ
M<7VC4[21&'*Q"HQ.4,S]RTZ$OM[0 +Q>X 'VOKO3-V@%&-&QL)U)VP\'CT&*
M2KOXAOIT2 /2R=K^H'8&)F;R(WM6&RAL?NR^4/.K'+U1P[L[7JLHOW,F:;\,
M;_)\BYS3,8@ _M@8[+-GHV=?QIJB<NU%X5?P] 5N@S:!\@%*.Z[J;L %,G:#
M8X_@HGS &@7"+.@H^%H1\]1[V*= &H!9?1>PF58JTF))Z- UYE@E#6+ AX*K
ML;V*?\'4B)9,? K0?13648$(J1]ASOUB2#J:]R($!/P6UN)Y2-PSBM>\5- 1
MT*%@99H'9&PP;-18 CXJJ>KJU#3!"V;!G5CV/6,-V.BG1R.17SP-0K7X@1 G
M!_>&TBNYU[>&EPCFO2$(GEFI7O-N8NZI$'N.UH0\KA>DDCN:.74LA&E%Y6VY
MT,D!9XH,?;89/-E^TFQ_?7;9.@07)TE8%@HFG1ZRAPW2O8[+@V.3.'P9Y06,
M*9EX+R%?$7$9G(%(6YQ=]1KA5]S?W:G1?)_P+:)7XT[((G,7>F6X87E"8?0<
M"-%[??9P1'T:J7H.N6-?*EZS7=5,]8QNETY78.0ZGK,]JAZ5GW_9Q;.+WYI'
MN&>A1_WP=7P_E=7W,Y%.W,PWK?++Y?G%K_;L_4SE(PON:*F\\$582_*[G9['
MO#(;#.>+]#\@5L-N29B/A+F24>+/(KW[PZH?<%(\';:3>T,L=QV9!I!>? !:
MWR$W<P/)V9:F@[=U1BI;(.E@P5?51[\.\L7'E\)W]VZ=0VJ;UOUM\ZC4&)UH
M'[[><E-'^&V_QYA!H D0CAQRP&&S)8BZKKP@ZY'O,\.%)HFK_PVD.@7#K1@@
MN'[!FU$9EGQ/IEMX?5;9* S=]F8P]'%#$8>;D4#RX]C0#,\=SZ53L"@FW QI
MEH/-/MOK]DKN@_/D[^X,< XO"YDJI(3>&_Q"KY5N1*3-Y] F;0AD6*2Z +%E
M**G'417?7L)=3?:@@Z;2TUW%V/*KYLF>!GH!S&'(3Z#4AD:\*@$PMG"#X2K<
MI!*RW*!/PAYHFZ0;W;Z F8T0/>(()_5@.Y!&O2BVM'P>"G?8QR,<-4:%K-KC
M;>88X@0'4,?#2,^# /;! %2(7XC.,F+:.S/->()BW0 Q[8U3!7EMT-W!C4@Q
MP1I'LDSW1E%1^MS=(;<&JX\E1'D+DF0M!9(,8)5@BH-#W0@P*@7[>WP6I#B^
M=<-81>0VF',-\1Q:#D;&QGH[HYD1D[O3'=KPW!C+X0KX/&R-I'3AMM4]E8"%
M5CWTT&L@60UX86#J3L1N'3:A!NV4.BK-.7:Z+UQS?Z4,,!0%O+R4T->\'7+I
M.Q1_<&AQ[[;9L:"_$R45+SUP=Z=KJ9 A9WE-1+20]*(Y9!W+2V+#F[W&@8 Y
MV*\+ZP02#'2SUW=)@0MN#J_#6'7LWNS1OF#!/LN^,+0!8P869&,;;/*M]ZD!
MP1D(UZ-KIP., 2&"&.S!YW[_%GW"FL6H"DRP9KUC=G>&$%0#RV3 \LI9 H(O
M7J%<AQZ8<2)*NKKSM->""=<V3C>_FWC,UGJ09D1&.0='9#$84Y[GJQ)<=)XO
M_O,[WSB8MB"'BZE?H4W'N*E)Y'KIYKTF._ZH3D&U-%(G1-NAH=WX?0Y9@U7,
MRWSG[@20]O$L1_PK=W4ZYVC&3AC:28BUU<$70O$/7SO)\G<PXR.9^6.K\-?L
M;=QKL<;+3XPV!M=0S0(>/"EG@S(U;*[I[@[H00+QHN(&CBIF77B"*M=/B8.Z
M,:0N90A5L[$)!/-)$Q_R&E_?T.F\/ZK%88)BOF..:KS:-DP#/,^E.3-LT+67
M_B=R,]UULZ/16=&>&U-DF2UDK\29Q0UT"*DW>Z03Q?9W=P[I?9%M!_>*&\AR
M,[D44J$ZQH#\^5_;SY\]'DJ0F6MD!;G>C)?2( /@%,Y=Q/6)EDW<B5R[[;"*
MQV90A>UV==?5-"XU4V0]X,$!2G-Z:*=5/(>7=NP*K:<DH\T9-N\+T&A2\-_#
ME"QTJY2;^*<*-IGU").U,:1HSM;UN!"!D]?JBC0DV]UI].%1M=^D;-QO/.;O
M/T!X># Z#14&%O &[,&W)G;M=3[K(@0%A<)?"#K"XT:(BLUT*AH"X-IU8S2F
M%$>Q&<:[X])MSL[S'Q@_.!4W=&-T,9:413='/D2JC;]M]AIHATF>H0#@VZ*.
MPR&R-1E]-G)"'Q.8:4@-*]9'/RZ.;T_;^I4MZZE+#9.RU+#%4L/R66K8YE+#
MJO71MSM[\,?H?W/5T"RL#:2&U>JC1]LMG?XLCIY?E#>:&E:HCWY5+[ORH%K+
MYT*3\MY4:EAIR=2PD_KH\-4\.F]KS5[C\>VDAJVS4<H/DN($%S5/<6DNK%G*
MK'?41\J-^=*_?KGJV4GPD? (3[D^:FOEDGST\U0=0HL"T,9(]V]NP^^F*.3$
MMZE@<*!?A4H405H_3Q1/,A\<&L,B95OCJL# J<GFR4'S)K![@0U >3R,<5:X
M2H^/"O@3\.@;],Y/_O@"W81L+ /[6RT("H-I F.<( 6-JLO># *ZE%\7@K,1
MP<:P\13!0&4_*^V@+X&Y5#CSBW-1=?VKIXT :N'%&,1/RE=D*"[6Z'=WJ!\6
M>_LA]N)5:RCH*5O3]@RH&..MV(ZNV5!/-B2O13# :8G,SXN=80Z9Q XV-5F1
M>P'UH_FOZ2JO>E<?D6'N=,P]TN$;X%&EV7KXE;BV5C?)=P7NJWUSXLO$N8%/
M(. 3$&?MK+V1N3L.N+QQMNGG[3;4+_#=2<(>LI2K7Y[[EN=T=(2/?9.%93Z1
M1![BMR3X1KQ@X+AQR3QR@EC05V(<K]PQ+Q)&=8K>$&*CDT7#43;1XZ\+P#("
M\"2ZDI)2G#A+[T$4R!7 - 9\!S@D1X8\1$#8NQA\@_ OO1_V+H%[E7]=D^\=
M9PDZXRPLT*38&DTVA>6(JPR[YO80;\(<DZ[T@BNO&$V"O]4_.J[SAX_YWDN$
MLE1XB3W^Q!=8YRW@0)X2602X)Z#"."\/E@ ?@SD=.OBB *BFQ>0 '?PWI*Y,
M>G$\N*DJ.U%7'8YA6^Z*#$\&IFE3TIBK3E>)B]M+<&7DBT#";G'C0$I>7T8[
M]6==7=N6:8&'G&L*.%UMYM,S%WU5??0T&)TW_C0;K>?U-?B2ZZ.7HUICH SE
MYE4'1LDV262@IEH]X*'<Z*_@(=YP9X9C'*( R7+5="T@'TD,(1IE D3(]H58
M'0Y-W^,P.3>F[]X;QDIZCLJ>D_Z61/.&WK#98(E.<.P?K>?^1-_&]4B!]$N<
M,PG90#1".$1\#FFA, [:(6.%N&S,*?7=P&.1+F+AD#S+IT#F@T;=QY23LAG2
M5-NGXX6\D84D>:R)9"T]'<XE0^B#PYE>K;4WZ Y::W5QZ$.@ 2[<A(*;V<62
MHW%(+JI:8MQU[6=SBTA]]5P77G0,YX3@^$L+--LMY_MGIG")((C9OH^TOL>&
MPRX/6W=W#BQ(3F'8>E*[/?#0E48&, ;#YBEC]= W=-2?\)%@024O?_K,S0;$
MF'7 .OD<T^F$2"NV^BXW-'!WQW\5"UP%2(G;B#]"</(3^(5EM3E^BSAD,K*>
M?7RW$W_W7E8",;S4P&Q#.AM'<(<]$H7R'R1S;L DQM/0/!0<(S6J<W@/\3-K
M)N;BT&^1<<@3;PZKMHN$A$/?#KP-]M%"YT)/DH3KAH;PRL1DVH+"MB,D"S 6
M247&_B ?;G='@\%KA/V!.=Z#IG"N"W&H>PB] >?!^U (<?$\$Z*>8)IJ.NDJ
M ]D&7A\%/)[1Y?[ M:)@B^%,)_(;NQQT5F+3>E_"E8_W CT[J2:D+")XFP%V
M2%.QPCO"^(UB&9L<,_#PS$H-#UOU8FBUNRO"62%%P$#V.9X4"QS+"0RD'BNT
M(TGR",0]0R&\%I\LI+[3!7<!'!4=FLJJW1TBK.1-:F8)=[VJ09*&IE[X:FB$
M1I:3_+974QZJC_)6L=>YN;XJUE:J/<:Z"OC-A3Q8/&/:EERICUJ_![5+]73X
MT%(^?&651=R>6(_P>#OBL>N*[9UW 1??6(>[D+HG/U\E'K]16*@X[E*)9D=3
M^X9VU:+7Q&,.V*$\SLT7._0PH<(73LV_4'VDUG[DCHYJP]XIQ(OZ7020(7XG
M+V.1O1V"6<+'(PVI<8;S:0S#J_O%F:$F&K%N0O/-GJ-]%MA/8_%*=!.NS5Z/
M!"OVN3#N0>*MZ&5*\PDZ#YKJ'O65_^KHKD:>]F*C%)#HLB&T1?\%) FR)$-K
ML;_H)GAY/@M[)'XU1GT'1_71WVH[_Z/S^O3GFS^&"$D#Q&>'GZ$E+E2(T-N@
MV273\=HS@ER5;)X/V 9.,[[E#Y/?9#LM5,M<>=ZA<VY>?'LX'9K2A["7V9!V
M'O*VN=>-9\L%KH+O6_G9?#!OVV?MV'>,@^!S(-DL7)(\7!H+>P:1B\7DH]$K
MCD K.]\8+HUMWD]76,_JB#3A3__W(>_=8FC>BN3GK4R"+LZ- DUD0)H-)(G?
M)D<P'K'";!BF%1U2M?06,>!#*(:IF>HU4MS1QAZ0GNDZ4.G?Z^5ZN7I7J5T<
MCO0*XJ/?#P<O)_<-N?K'[R0\/[>WVXV/<JX@ROF**!>+G^9G_%36%$O_+B8$
M8LG^H.S?4^01=,A B!Z!ES#  ",U19&(2H]0^7>-'(2)Z!"HQ;F+?V9N0![;
M 14%\6TAO,0:&PTS,7WN=A+1(X$@/PPMH8445,MB+B^)4JX874:]H6N;#WDR
MA-T.A%UL@-D,A"V*E5QN"Q V5,H=\Q/0"/,^L$RH"N*:V$R(MF+UK//T2^O>
MNO(2HBU!0R96&<87$( (8XV*)@V:M='\!EG<!BC<&VL7AIC)2B))E*ME,9\O
MST_8&[B;#/'2@GBQ212$>#EIVEC,3=]-J!C)^<;2B?X*W4Y(7P<,0'3D4"E2
MD1\'C=/B8[?ZM%8#:=T"!4/$:W5!7&0()ADUKU-1#$7+9&5(02J+!:F05D+.
M<"X].!>;^"@5JB+Z-ZTX%RH\^-F/5Q#RG@SQ3#-&'LM_7S3M1_6P5DG*&)$V
M9XP8!ALN,T=D9<..WB6<NVOF!(ML;<VZYG3,3]KO)E6K8JZZ@+43@F(;O=D,
MY=\%RL=H9Y5EI)Y!M&R+4#Y4?M8F?7AAHO/.DYVN)SN?&MV>\OKS\?R@M083
M3,9)%--"RM/D:,2B]%7+POC.<J$^:07ABD^U:8(FH%6M/BZ*V4P\8,&-;<:7
MLV[16A2KA8)8+2[@SPE%L%0)UPSEWR#*QR9:BV))*HCE<K3G(_+\M\-NPS+"
M#IH@L9!%IXE;KZ%(,&4WLJ.VO'CR,)-\LK2?#Z>M4'#$E[T\OH$YVPS5ZJ/<
M[=&WV^[1]:,2QTRB"4"LU&9(SMH,+=9FJ)"U&=I<FZ&#^NC/G]]-MWQP:7?C
M&"X=3=0+3:"KG-5>K&?YI7@8VEKF#;09.D&VT$'1=*]_/][U0@=IOJDV0^4E
MVPSEZR.S4&BU!ZV\5HZCJ=PB")J D%O7"'KLZ2 UJGX)0E0]SH$?3)W^7'UT
MGV_>-LI5O740VO]K\9*<0EA)3JD^.O][?%;0JA>G?XH?ON)=C0^?3W$I3D0/
MHDF'Q@L)!I!::G[V_#I:(LW8SKI*NZ=LY"@X?F9\^LSNCC]^AJ]G]'HF_1,R
MJHEA.H8V02GJI@H=Q"3WJ_*W'_VSPQ\%;_ 1?U%3XW'<&DO-,5K*&HI,#10^
MPI*?)Z%2F@65B7%0UY<5Z63PT^H\M^.'RO1Y2<M%QJMEL9J7HB#S!0\M"H',
MR0S(2%4/,CD"F:>^]-*PE9Y=TF.'##0HH)#))8XMGW!UU21(^"YT-[0PMV:J
M1WY9;@T:V)*^U"P6?6?1.0$GEHV9N<,/_#A6;%-30S&MSJV%:X*O%=L=WOE]
MQYR#(?])[55WZG5V9S_T9D?1C/,3Z_4'YACDYKR+N9FWL'ARR%I^B\" _O2D
M(PW.7!D(4[T_L8)A/LY CUB?N.C5"2.U9QV[S=5/6JT6Q4HI+"XU=;2<7Y:/
M1R60Z1](Z*K3A388!KL[I',!;:--;T\XWQ?0!:)_D29 LJ"A3M\[K]==@0&?
M5.B3U=EP8M8KK]6'KB9C!?Z1S=4-32'YU["T*-0N:P_'O__K]'N@!94+X*-#
M/\M[Y3S?FV!R9ZKN0%.+!*O\IVA+27<QF;*T?P^T$8/N0/=*P -5:VDVM'#$
M32(\U8PTG8'A62,"3))T0A]G@SPHK",;0.!A/"J;%D%&?8+'6=T7B.Y(FE%$
MX6&X[LAF2/USJ1L3PSXY6^G2,J]($QNS380VD"Z6X=,T2J=8LJ63E^J#':%1
MLGL;JX&>HC=,V4F:]4YY45A.Z*&%U].'I^YM^]=5:W%M:U&H):"7%@NB%%W+
MXZFE88A87!!XDZIJ[\H]J9;+OWX<R1M"Q/4KM+@W"^%4=$I,8'#W[H[?E@KW
MU='- %^+FN8-C7F]N?33K,XCR@UY:\++,>0&=W^[_2-]?QZ6+J^;WMVP9P,[
MFGH=(:LEG(%<R(N5:#LKDA.<+  A2OK&7\?4#PVC\91? X3BLT2G0V@<276'
MCD<B_:*9,-W=X4\H^O.LF.;E8R/W,M*4CDY.0D+110J39D:+X7>GQLSI;Y+*
M09T!&M\Q[9= &K1/,KMS[#8F,+^V*!LO,38NE0DAW/2=YX[SO?O46,)#M2C#
M+C&&+95CDX'5LEBIE*(H(J#D*XZO04+O0SS2!_T_V\7]R)$R[BJ&0;DYGE.F
ML.%N0 HOEC_&&NNFLTT5+(+Q!%>O3SONQ$XG/&$M%(;X6=!?S=4X@X,.)L7?
MQFJHK?2TOJLW!=7NMV$"EXHC*E[O.1CFX[)93#>:ZPK.T%3M]TB($_;$2X#Y
M)6Y*O&@AML08GH0$NW+1ML0XW4OA=.\LH+]=W#V[Y?N;?.M\1>5W?-%UJ6I2
MH8HHOQ*I+4S7U\C@+$]; Q[L]X;"'_*B+*"X>8&#L0OK*"I_:;@M==\P./X=
M8._OCBQ)8"C*80@3\X(>P^V)8BV10#7_1C9R^DTL.C]F\!-8Z5\T[ N-FJ[H
MM>4T80*FHZNZ8@]%YM#C/HUD\*[RRN^CB3B[[@H?X7':PQ9]0QC_@M?']KW1
M^O*Q5V*MS-^T-4PM/DDLO#+%,]=S#T_U_*^^;%6V,3J2B%<O+^;EO)B3IMCT
MM?NC,#=I@N&Q\9NK.[:[MT=RC9M>\(O\MK>']K>](2_)4[MD+PQ$#E9'YXK!
M'R$62A51+D3:7Y\BG3;2&FATPN-[?#D:#BOR]<_3UC9>9Q*Y#6*Q4!9SU<@:
M[' *32Z '7U[L^ET]-C/:8/&RV/INOPF[C=F<BV).42NU6ID=<^G+SBX&I;,
M4DO^QB>-U'[Q_'SPJ-QVONE;>)])6+T%,5\NBCDYLN=@.+V6-G![<]#KH:.V
M[XY:Y=>?[3=QO['3:[XJBW(I6KSB879(6>YQ\R7"#!'L)M20]JY#I<)T-Y:#
M1[X0[Q5U<OJ!\'=GR?!C'#28,*:X !^8)$?@26;_H0?I4/@@^'NVU;:5+CB8
MT/5H"@)Z0S'P0!*GHVED+B#Z$R2>T%DW>+0FG1B!;\C6# T&;<)W%4$9*+H!
MI1S[0LUP.U:_W2'7PW;90/O2!FQ@(;I[[%[&<]ET%]VY83"?)GFK-S3'81A$
M-RT2MQA"89@=@ING]VU'FQS_T=# K'Y$.(B3_I%MOH<GS* U!CJZ$7!B]P$+
MJ7D.0S042)5AO\!+\)PR56^U-)M0.UH4O<E5O*UY0XLXN-O:<U^WV8R40S9G
M0PR Q)]X'R0-0]&[=+8'HN8*>'])0!:&PB!*@#_T+)A8!.D_T8=)!5$D7!-P
MC.#L#J_@>A!#J+5MC0 ]JBS@R'=1SWRT/FK^E7._K[7G^VX\A0'%L,( I% \
MR&:UJYY7F_W*AZ]D7P+;F+.UQ0',78G0O8N8R*V+8/H6I[C1\SD=A65L#2S7
M&T*&?L6#E P2QU'U 8P(A4E8./P#,\O(+& V, @Q%SI:"/Y"QF6A7XX0/VFZ
MEKWM4\/([5S;+*TAQ6BA=- ZLZO59DU?3W*R>P+OO@N14)-82.#(>YKQ=YAK
MF7S<4>@\::6/5 *;3B,F0KCG88 #&  :HV5J9(@W3%-%F]7(#%?(?-5?B78
MM?_H*.1A7*\(OR":,K0V_(PHT$6"A8;/3!+O0DHN]NZB_5,BA2E!B";[E$R'
M;#D:M58U&.:J\'1(OO F:.]&:\/ 0P ]N4Y/UJ23#%=;[\H4SOL(L<"I'S):
M$Z'(D:;UA#L;:M8/E9[N*@92HDT"(*3O64C9=)#68)/A1KT^,E&08BPH3&.
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MIUS1-Y@X]'%DV(/01,8^!!>PJ4Y>C[$&K'G%P!X#Q=W=H5_F2EF=/L)L[N'
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MGT'P2T1"H3&5:\Z"0H34SY70_WD_E;V6^%&GII_/.%T,/2P]XH@LZM=-8<#
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M9(,10)U\KE#<6W!G-3R\SJ<BT:J\YZU->''S518_TY>^%IB-7 .S[PO,4M?
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M@SV)JX)_K/@=RXZ&=Q%X=[6ZF]>'C_+:R$G3TWZG%=[/.5Z%"V$AW-;LE+1
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MQ/9RI(/_HDF #-*1"/J=](>""P> \D@@,= 5;8H/CD5W_)<YW+GGG+&5*1'
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M1+5.0;R ZA8VK"ID&%..>)C[@L) <U.K+E7=$S%!M334]\V:==#0/9'X'V$
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MZGG=;^1]C.&F?D?2E?\WW<]E(NGD$?/UAJC^F8DNI>-^0V 6W)%\CB;)DD3
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M?+LX]?:PIU1+-[1L94LWNS]02P,$%     @ .HA\5>ZO(W;@ @  _@L  !
M  !E-#(U,5]E>#(S+3(N:'1M[59M;]I #/Z.Q'_P(JU:)=) 4EJ@:20H=(W&
M6@1T6S^&Y *W)G?9W:4O^_5S$MZJE6G3R(=) RDA]F/[\=D.MJ^F'X=.M6)?
M#;I]O$/VL:?N=#AP;*.XH]98JNW>3?\.)M.[X>!<"SE3'6C4$P53&A,)U^01
MQCSV6*T0U&!"! TU-$33T<HN]L2<L@[4-0PQ*I1O=!TN*8F"#HS3B.@C;TY
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MWM/<6R4-/)1NG[D]S/X?4$L#!!0    ( #J(?%4&^<61G0@  #A,   0
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M'<D>CQWBF[_L^4/[QK#_ 5!+ P04    "  ZB'Q5F[0JXD<&  ""&0  $
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M8N$%(@04'1#$C91<0)'B9;.@U#+6QDL.[>84!P1IASI=/8'9^&^*8.-*H!4
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M6CR1F/_ _DV_?#00TJN&!B!"9J??T0!"1PMU,_TB'+3,B/H><R8#VKR+!CZ
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MJ0A?972R8):."6DFF /[Q7]V%*A4#"&$C!0RVR>] O2^3$*\4E#RM*5GN*@
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M!:R3N3KSZ"HX.H@;%$@%^JNDCTJ2UW9\)M*+6L0KN\WC!ZMX:+FEEK EVM
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MI31-@,T<O+;@]3'A#'S1C$0;<)X0"_"2QF1 ]==+WG/SB-V*2/\A$9)/RV@
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MN,+0D=X@?!Q56V+*V@>Y/P$EZ&0^V'9H"'G"LEP8@+]6FL&0D'9B8HD*DZ3
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M@@#"H&6 5OL5Z218X@N&VWK%"P(P(LU3<\)]2_\G)J"+0QR;WZ8_")R.?)%
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M0OQ70&^&"<AI0PP0WCC6AD1(QSE9.JS4*@/QJ8?]5_DKP)>5OIT.8,O,3--
MFA4X"BUS5E57X/X?NSE2XI37\B3N5#Z#."V'*9;W37H]3](NYL,G:!;VSTX=
MBV <"4XC^GK6IIX[ 5K..6Y[R?_%8(WF"B)_SOK64/WYO 0-]N,;R.F F#O]
M0^D[2V]F]))Q+7:LDF_PD3]+I)M,+SRBU]'V56Z]=-N>*4G,<>J5L.%[X;8Z
M./8;%-VJ->?IW07[SA8R!EIA?O#D.")!J]B7#..ZQ +%7F.(@YZE(:YM63SK
MBW?'+D<5 RFKP1^P9\K7^'?);-/>)7Q\4'WXM0TD^\MGBOZ\^5X4]/_/,T7B
MBCO)R"!^R [X'#^_OF*H[%T9KJV,<L0V3RWC'=;7OMXRY8Y#4ZOPD-'1I0\Y
M-5ZP6_4U&3[:U^I+_+YV#-4@YH<S=A03^.YE!7*Q1MT/CG 5H&9=45O,O)QL
MW[EK6B@+-OS6#G5ZQY924?<E,?M+-;;Q_99[U"'Z0U[<<:$!?..UA2UV9\(8
M]\\@IT@-6S7E(%4]=LXG?E X8<7]Y257XQ$4N*\FU\:L;*2LQ-[5+!K*?'-(
MEK_4W%_PU*=L48@YTUN*+&M\Q8%"+,**HKP\HZ [@I^L6/]YI=:C@6W.K.%"
MCJ+Y>FE30UZ,8"VA%;'<+J/SY%T,LI'G0@S[QJ<W($4RL[J:I99?UN!QJ] &
MS2)_@R]R;5'CHN']5&B0L%K.L8$OEY[X,D_FZLW)IKSR)N>(/A)G'&D!O$-D
M;HN,[_!#ZTVI!5DSLG*_QUB-<*%-E"<TYLW2X_9BOJ$8J0"O/&E9JL@VM5T3
M4GR?RB5[\:%9"5^)09EC[\;B98UODXIZD:8]WS1&>#MMG0HYEO@=[PX\GWWW
MM8FL8UFK3G8VY^#3\ZHR=X:WB1'VMZ/L)D5H]Z&1VD"VACQ @X ,'0<=W=PP
MW(F<6-4RYX\IH0-$QIU_@_+.=>S2.449+X;F#RR9#ST/:ZD@W2V-W;IK8LI@
M._.!ZT33KSTFQ3(R,^J\=ZP:CA<AG?Z<<#,86&^,06F,XDZB7T&C#VOL%1D?
M/>Q=JA$7>*%_W<#8.DFK?H(,]80^55(L+:JD7T*&-ZY1P06781/V4$!A$*8Z
M8AXH\JKB@YUYE6E')P$VS:$'JQ*>_@2N=I&]L8N(JCFFI5BM$S)OLO!MG$_\
MG BQ[5!K;H3@Q">F$[-J7DUWXANW-AXH"T=J%O,?WCVK&!@K&X#,91LP[G[B
M4-3E&;%EN'FJ3G'TP<G[06M&W76!1\M52)' M2)JO;F['U1QV<@@15!P9V#O
MNQ!/Q;IAJJ6]0;C\<X\ORU$ QDU%X60491Q]N=>DDUE-E43M2TLXKB.ML_E6
M7K1=;5#:,8*K@[90LVR8S=E 2SF6/&78]O6'C85-FMA30C6WP5B^,GB;HTW*
MS#P]4V#7D+-.67PZFUQ1:*U)R*GPJ8:4HO*2DMZUO5S=UN/=%5L3T^'E:IW1
M5WM9RJX$RC)*?:6%SPDG6ZXQ7*-6#Q]G(FYT-<VRJM%HS\QJ/QK6F^FU<]>G
MF3]$UF@R)J)!=T243C>2OVDTG17$LBOZ'C_968Q.O1M\+##8^0D+I9I^^^:
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MZ;\:^GW=X*_*R+@(R8=_"LFGY87%<R29#0&7 'A@!8(U-?(W>*@8G]4*T)-
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M"-$]0[JC'5YSL9V\;/IUZ>(=3\E1^]X1CZS:[%SE!JFH&>UVD=FH4"5H[:_
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M72_(4D4?\*B_26&EOP:WC4[@HRR4',*]1>SWK92E]:'W<%6"8WBH>PKN1RW
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M^-*RH@#WQ)6[=="G_B7.US:V&#6_E/+GD&)Y-8^)UPT'GR0U.U2J9A*/)A/
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MES)7O*(K"C8LVXVO>F[G5>M^/;A_TYWL4T59^,OL!*BW;5CP/I,\(WL%^=
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MD<".<R[F0HLRYH)3D^^<9J7^%LOOD:.Q('E_E<OO1Q-]YQ,KH,8:%Q&0B0(
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M)<^8Y4YX==C>T6^S5"K:3>S_X28:O5PJ%PX4L(:WZ7'^!S]\<)$+=7Z7"PE
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M@^:M@/]#V\3!/]XT\Z.;: GC^# 7\J]0DP@IG<?)52. K2*U*D7(.M/RWW
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M?X:'WBK]PLQU'K@(Q*ZX&5KZ ?.V9SW O]8 :.;V;>E-%G0JU5V&Y*R(/;G
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MBEV_$*9==;6FZCRO.#\F1]/5IM@DU>*YTP(_X(#\(!]?:3BSSXO;XDY]JH5
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MY(P<^R^D KX6D=@!V9\N;!4/>\#G;!U8%E=PM@R@%P-<* "[N5H\,WI>GG&
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MZ<R6Z\G9T6S[JVIE?OY:,B<SQ8M/B=["^,K1+O]+W\?_\('>-TV) L+CE5!
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ML;G)9=17N02.Z@D*_&<H)ZZ>.S]TSI08B?1O47]B]9B$U'--E.J.4$29#F?
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M(\Q=G6*C6$0Z@]YG9\!"$.;6]D_(I3Y0&O9E:X$[=O-7W=3O#A'.E><IV*
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MLMSG>M1XF%G$;?C&I=NL9-  SS7+(C:VXK%,.P7]EUYJ62-_->-@#GM?E1>
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M&: C))>O\VTX6U]D=6MCZNA-6J2.X02BXA(_B?D*T(0>0_D2L$&7[J![-&/
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M^'94XT*+L"$1)UIPV*I&_3"+55R[AC)'"O7D\V2.LAVR0DNB'#Q3<+/B=_"
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M46QYL4Y@%^M;!;64S[U4.#X#.^L^X6<CU O_7/L$MPN8_BI5%YZFR(T'/<I
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MJ5C85,$BS&@%>HS&9*2M0WH8\'.R= U?!M>I;=R*UBP.^M@X=Z!M_@<@"EM
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MQK*(L;^7AGN.O*-WKO[&V4L=SJR9XK!Y0L(5;%D5FL065/MO..7Z TX;=O^
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M11):)D9%>=19(TT+)N<J*+^F"RZNZ\,JD1S@:PXE;32 <>7ZE*(^:Q]R*X_
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M"Q_%BSI.FH)$&OVS50H,#2;JN7>FRT7CA%]G4:J*I.D-GC]703)JFS#C=$:
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ML0L7JO\IR),R<3B%B:]^NZX(7<;<=>$8C_A2@1OY7E)5+&!'@C;[#EQ%5C2
M9OAD1^ZYDA:"U4F:L=D%QP[*W>VQ^".4NN)=OO[,SNR;*%.XLN#K-<H2OZ6V
M6O&1/;%9ZO 5QS@3)W?06:\@M8 I(WN4&YMHVLZ@ TFJ8?UMO96IW6V8-,K3
MK%)ER8%AW"6^7*0QA>.AOC7%*]H.<?"581'_5B8GGB'OT(C46I>1A?3R][6
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M<\]I[I[%V1"\Z1-2BOWYE&+<*2>##6J+ZY9G".)#B$2UJ@0$:U6? -1&?C8
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MT,3$M7&VPG(MM66%)64?3.]\O=W'2G]].55>,SD2LIWQJC3QE:]>M[JOY[T
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MMBF;>U2S^5<_J0;A"-V/AVW&V.&H6C(@\,>JGPAFUA4*:IVXTY=G&JDV^''
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MO56V;DWJB&UHQ4E&OMN+'>X7[A<>WGEST[DR>9PC3[3!B*W45[YON\9$5T]
M[/5%_6A-][0%NAWK1VZ(YU8%^1+V;T$WRT23KPET428%<2K^OS5WQY&9"443
M2.K_(B-U\ YZ3DE(JV?]#?45@"4$::6$N^CYCYVT2TCI_>(+6;4?D-AB;1TL
MVPCI(>F=2>Q9.-8<#[SZ((D'/LZ_QP,O'0@CH<I611$KW@7AXOKC9GP'UJ#Z
M$?;-\>@\(X(-MX0I.).;[PF8Y^2C%8HI,.06=6A:$+KG[R$S_^_;M/"U8>'D
ML8&DPKIC^[4<E@WS#QGF8A[-PQVU@SK^+LR'WX4!_;Z7@W]Z!Q&&OK\D^_^C
M9'S_+&L\[V]9XY5X &15*;/@XW36W5"[Q171.<JH<_J+P]5(;W(W8H. 8X^2
M*B.LSG/A 7W&*'JG69,1CJ2@K:_?_OU#1=TZ!I56AKF?'&R62ZU%#E8:TRPZ
MT]PMW8,\F;GF7/9AGGL+;K WA7L[>5+_?DR,2&YGCCU$SGOC&[\#MF@_:/#3
MIZ*J7@%Q3NYG7/MYCF*6ERPNDBO,):2#<MTVHU(771W" L0MTD8ZIVJD'T*+
MG*B67Q_ @:BUOHJ<<;Z9EI'I!%S;>),.T4F_V\^%9U'8%>?/%Y KVB<?!:?@
M+'3IG\7?S<Z0-@/V4\0B>^2>>T4I;#A(1(MTGJX6=4T=7^8W3YL8)/)NF6YW
MQBTN+.T/LB[M)M>K&;^NZXW=Z.0S/1QCYNTK49JQD;WXN&>5_*9UK8$OKN"@
M;.O02K8%:S%!'&1B9>?XH:&*7;GSVQ;<B--)<;9G\2D:IE)2V^>4:7MU8G<P
M=4;T]<BP28*$3\Y2-$:KSN^#1FU?UQC"8M-[2^_V;7$N#86!(8T>@1\T--%5
M-X?G)\2K"G,'LY9B&E617 ]L;-9A?62K\8(\4E]OW!UOB>#ER2NN^FZ37-!W
M/KT[D"+.V%YH-B&J^(6R&%9*F7\57<1Z_?8:'A#K=/KJ-D@]F"+ ?6]$ZJF5
M58GWJ!WSM[$=@4%8ES;\</(PR:)C9?T))&XO^(YY<:B:5P>OF0AI<(3DSF5Q
M3]@%2 (%<CPAT8)[(I5FVWESZE[S<\EV,2?"RDL?_AAV85'0S0T8*J652>Q^
M\4S,; OK9_Y=E5'B9D%/[H?;NOJ%$>"@>WRMV+TNI<@?96HI^8[QR$%$>K=5
M]KBQ/H-?48A(VF;=1+=JJD:_P'F:F:[DHI[0XKG0PL/$#XQ;]2L0W(4/JQB[
MU\]X4ZJN:']GZ2@51,JE/EYVZUW67J+LL[8I+5W;1=F8M#[ .&KGS37OJM4X
MD;],L:A4&K?@MM]S7F&M_-(A];G[\EY&.O(P/CUHU23LJ?[E"[;P!+D.WXAT
M<3>OVH%,]^SO2[$N 7[S'TC&[,Q?567<]#V[]YR+N*7@:^6!TLT6\[10HU.K
ME[Z9?%O8W\L,'3UHY;K:%9J'F %3&QO07;9.EN:L/UW_YA:I5)\XC#X1YOEQ
M7%>Q%&-0ZF(I][;SQE-6L?7NLI)G2WME;C;?JHJ<Y>"9Q*RD!;MYB:$Q0<4V
MLCNK$4,/B^!=%D^FGRZ[,J>33J8+*#^ON\*MUMJ2^$-&_"R1870^'CC]-3)+
M(&3D9D@6U7O6^**V;B!V]B,>@!,VS0G0U[)J&SS 2G#\UMEQ/C?:C13.F/NO
MB##5O!W4N:MQ9\1S_MS3VLU-/HH%["'70^CSAMF6/1JR4*:XVX$A\DW1T]"3
M6^UWNN0%$*^VSY[ISVU4>3;BYM<NAO&<?@A-6%]N;=$8_U[%5L#)]-F,V)SQ
M0#-M(F9=^W6FI^=' \)XBSP8C%&"7QM4_[S5]LC-82?[F_[B".S5J@!#U^UQ
M90?6;)!P3/)M)HJ/F='Z8)JEF"U5T^B1T!Q9X^)[M_-#D(W(C=@WEM+*2.;(
M*T6EE>,W@TNG!8FV!*]&>HK5NPB'JJ^H5D;PIR_-=VDR3748.ZP-I;Z(3J K
M_M#PX3UXQNH.MR-E^]?/LJ=$GO/B 4]W;497%'.=#1FDWF;^C1]WGSF9,#?<
MP&PS[ZO%]G"U%A-RB'M&W^D _+VZJ"'$AQ]A!"-2L<EFX\A>_BK=,*)5FYO9
M%B,U0O?$(E8(MS7U$CX8C3N0JOP4Q;V=:;W>#[\1K=[ANN#LF8E)T?&B1XDW
M?J<)875]70\='H>7V344=^JA\^7Z;><*E0SO?>412 OPB_2QEZL5W=I0KG&M
M/&$H\J:5/#@=:J524]7;U3]TK5$PKO,;0EI7)+7+K[]MD.9ZSXGIMVW&#COS
ME2[]+>^GQIE"HW('MUB:F]Q]L*VISV/]%NNJ^(/-N3>!S2GE[%8/M;,3,]'-
M$(ZD$K9_5O7V_^F_1:SX#*NI=N]:8"G[Z06<'A[8R2YFX_-)H9258EKI &[>
M\U80 T2'$LUI7)PA3UI=KK!M%B#VGXGSZRES=P3?H3]*D:?)Z;QJZ9?U+ /B
M??5?YM(G6K[/HDDYJ?Q[+CU-1FRJ96 FT5E-9?62^_WG_+*N9Q+N/75_X,(*
MX0>W7KIL=6Y9SC\4@6;))/E)$WZ_7\+9QQ9N*9/1+%_<)%]RM=]*G?OA'W+I
M"8P_D^^UDR!11[GS/ZM&/V&#1%E>R]3..*H6?91L'_33XQX^[G$;@EYB'9QL
M/"G\JC4D5EKV7QPJE.L/@#Y/1,"Q[BM[A30?/AHHY*)[1U7Z<B7ZJ%\EV.S,
MKV5;VCO[63.VJ3X>E4#/M6BD<S@J?(\7@D2J_PBJ%(\-XLBGV_F??36:WNIU
M<K!$]6)7ID7TBB-U0^+C>4ZJ1XD.6Q<.O\'H=RRY%+6>*AKT\&<J:VJ;O80U
ME*/,#D_4;3[AP7'"T3K,-PGNC@[N@0P>:-:I[3$$&V5^AQGS4V0V5HF=Q5&W
M!H,7J?% Y 482O,8:\UND$2=1B&N]O&.D,M_"BLWE.5L//1%(IU\%<ES_*H:
M'B";;49LDQ$"O]=UZ*R]$0[,H4HG9C^@?WH\@>1/5\'3!M BW$OC?5Y:/$!M
M=" #^BGO;4R<:-'GNF,7Y;!<<!K8-X+G=)W@>\UD3YHGK^R(\JS,@S0"G*&T
MQZ]F$ )>AYEN# ELKLD8J^6^1N7IEO[TT*-QV7Z]^\3QBR!DGAAAMDCF8]\%
MXX&@?,\D>'[_:EW^.T\5IN]3QL>O)A_3H=9&L=K.<GS,SM8O!?]_1L$Z-LB%
M^LH\WTR#9?HX!2+H@QN4;_@9"^/B*T"-*T9P&9D'A@K-S</ECQ//.+(<G;ZY
M^$_#ZBFO6T<E,:WP@'$[ 5S!<,<!1&7-(T!Q;E3FJ97X%Q^4;@IO#(NU0QSY
M&/QK:6.55F 4;+JH=4BG7/G"]EO=0=*8+F=@W:25-,[DY6B)3-KRI26W5SJE
M!Q[#[2RWV\0>^6K735\>P@.+I)FP*3;$M-*1KU)'T*2X*AX@8B,8PFY%XMAF
MQ=/A K.9JLXKSIE69FPN&I<3A%FO28.D$J*>@.DG&H5B&<[?O4NF,^?G+]5J
M_&&D" \<0U4@H+;\1%7Z'14Q#I_DP0,-)N##$R\06%(P5NNI1*[HXNR#&W3>
M#YZ=)*X2:A&99<1H3B)#5@@1#W%_'?*B*C*5$(R9$:*EC\SI>, [ N9W9ZK2
M+WTX0'4@[\ZHU? 5W0[#YA\*U1<E%]+%706L'J"X!V,>#2I868A=^_(N@6]8
MJ/6)."<8+4OP@3%$R\;H,^QH=5@#+\%#^T:A3HC5%, -_E.8H%Y#DOZ2)2<>
M=J?XJ(K ,N*3,@H2V%@7+)L+ ODFU*K3=PTP>=97M+ZV%+>]EP9KX/\C0 SN
M0CP,Y^V&P)U0P%$9,37TKO(_&+JUG:NB=.!P.4*R?J">\[GC,*;OQ>&S%94!
M?37E"(.[,Q./V"Z.JY[4K#O6WQ1"?TU^]C?UM_[2!M@75YT*SQ\W;YEM"SJC
M/45T]4'JRQ;/TSL"=Q-G%)P8V$L]155>24A 'W,VDHHQQ@;\+DW,3VG^CHX'
MCN"3D#7K-/&Y3\Y+:Y?WYZY.OS<Y:T$9).[M(\?DNO(YM69@W>GL62Z%0;[2
M(&U!8)UEUK?;FNS#,40$,L3J'_(FQS(U1AOZ6] /3 3?A%NS/HUR;F?,KM!U
MQSW+M63FJ*XMN*MPOB2WBK%2O[4,-OCQ[\/Y>_=XL*PB>. 0V %C3T9B.:IY
MW#\6[_(-!'UZW,\8M/2A5<2W??XP0.622:!'A*[7M6S!OY EL5Q\^-JU0L[Q
M91V7H3JKRG>=MUE/;M,M JM<,AY:&=<+[J9D Q&F9]C<S\@"1"&7$B9*2/_6
M/,]1\S=@?S-B/'!DQ3+3XR0IJNXSV9U5M$5!9_7E"8:LRST[8CR\I60R4U7%
M=)>+HE!/]=S]MUNS-V45V,MW!(S_0K[4@RI]J9&G!3.=*;5*;3DOT*GR(P*;
MTRP>PPOY1F -W9/1;!$*[&RQ_7^MI!N94M9-L^S?RD A3D+S0<JEJ^I$Q/[W
M[F>)V!)PWBU;$E9;*B.CX9*W]J,0_8K.U&IWET-+T%_.@9AU;(!%=$ZUCLO3
M=&F37='+,P&BYU T8G&8@X'S.EJ>VKIS[OKZSX/+:%!KI"OMF;#_9 VQJ!<=
MTXX>Y,O(-?[+=A%B[L'1AB&57!I_9;7)">($(PO)XM+Y*TO\[:9?4+^@?D']
M@OJ?A0)NUFM>5/A,7&/Y)U^@9!L/G$5WR]?P-TY%U^U+A>GT3P7;RH%OL"V4
M"5S*5R%;BZ'7B"R4V:" OM#-&I_@$&1[^A /=()Q-78E#XOAK66T@\@Q-!UD
MM)TSIRC>B/3"#2'NXN?VPI_G9HH]9%*@Z<H'@KL2OLQ%\[9;SL9LS-J\\-I3
MCI%]:>(K\3,6-;96.V[!2M0CB9;=M['2X"W"@KQ99*=?)L&,NNG%2/MMZ797
M)I6LB'F5UJ,F[\[Y"T7>"E]=6ZEJ"U3+#_U46JPTN;64$4W\>("/ J?-O6(G
MC:P+W.'28QMXD7$G4&LW1]TPIWF(>+[C!&F:>(9ND%V&.UEP8L3 )<WG%C!*
MW\+\ERX<;*=P0]ZF;CO9E8+^6+.,23HGGO.MJ5*?RD;8^EG?TLR>+>%S74!8
M&NNFCWDUI#_QU>36V8&?AXYTJD6<!S=>6-;N(-)_MT.7?$Y^SL:#F8):%DR!
ME8HV51"CNBK[Z/+7;"(R_B%@;@:>H['.3. _E1%;>=ZEGIFK;SIPNXMO4MOE
M"=/5*MT@"G53 -3P">Z/NX+8CP!O9MOA[HAL'P1\RL!0QR9:+JLV$J(7IK-K
M=8]+#EQBJ@[ :])>&^L;+5\.%JB[$60>!.5=@_W0GL2:.RWMD<BF/PG6Y#94
M"45N-6,B'C@Q\8TJF+)<[8(6[K__*K_9:,*,*PD7],&QY'P-G":ZRD69)R $
M/%[Q<50:[5L'FV@4A U<TI%+\P"CNG8P4N[3B\6+=!=MK]4%#M@+T3TH$Q=1
MR_$00=6$3OFW2@>H!SRRDV!8G#78VIS>1?0Q]JPM[5&82+3>'+BD/8T$_1P>
M&$YS#0^@LP8'O:BAM0WC;)^*B_KGS$9ZI%ZP<O+VOS\1XCRU$"M>(S&[R[]J
MOZ8F\$)N>N,G)QRGF?N3TW>:-GB^)W2N=/>AX2MG&@JG]V<N-ZP#:?K$H+O"
M"T>MUB:NF@U/Q2:)6Z6#S]<2]/B68$[)=H1P1]L_'!G0$@N/WQUE4.9Y-HXP
MK]+9XH^;[3P?\LBIU4BT=W?[ #[<7= 4%&Z56HY^C#IQ-C,IN-'"@5Y8\SW/
M]%D64G^B=Y041I("MQ#(JM88G1XIQX\R9F?C!)K*>OC2F1HNMO9YN_VMXWPE
M5X?TLCTX4:4(!T9GB%9I6DA5K#S/A1-QVU>5T\71=/,9\  892NVPWA?O8P0
M:&8>N%EEU(0<T"6E4 \O&Y_!&IL\*OH^JF=YB088;70J\&:-C"&K]K1B@1+/
MT.&!]])X@%,;#V"UP';*3K0%'Q9-<Q5+!G6QW"C/EH@]'1KGZ!A%NMRX&*GX
M@KYS'_,E%E;TB#_7$1HD!&G[&C];/'R"<' GBP^95N=^ >%IA%U>OJ08ZQ]I
MEYJ4P;DUD?*R^^.%=594UE M,>I'[O:G4>A3GBNR#09R&0W!+#M$KUE15+@"
MI?(:PB14[P^&1#.?0OWHVKX]AGY\<\JY<4PAHZ&3;N>* CN2VD4/#9OE%C&/
M5.E9V]%\>BV!H?_U%8(>4G!4N"(E]^!AS=7'W/(E0DCX4:5#/F.<%O?1<$]6
MHUUGLFV8;-=6<VTWR!+O*KR@KA=J&_O,P[BWP*BA&VO8A-P195S,)!&#&O]4
M"L&/Y"S% [/Z&#EO#PWW].*]W;N53I^?D!3'W)-]1$KZ_$3UH3N!434C@3EI
M\5&N8K%OX]$@M(/VM0@JH>_O$0/-BM]#3?<7GR[.N/\TVM5N]BV_Z?GR!PFO
MXK9G8IO5URG.ZQ1(6<ID.H'.09>['\:>!9.E'E927OPAP)%\T:&?ZQ%<1<[2
M!A%0[2FP2CD&%;9)=*4VC2^1I[N?,E4 S$TYONRF\K2$.WA"\A]KIT+J\M!*
MS95FW_% 8;&Y (S?Y?T/HQ0);=Z0?6\S87%Q+A8+$$&^-L2^SI%\^;EJQN;&
MVED86IH4ZD3P*ZPJ;8#?-L3@DN6U"V&QMP9T>5FHMTY__\RV(#8;U!+0"*84
M>)_<-_\M4LI'NVG$UUA&.%!T[;[PF!O%4O_%YAXE>UU(?F+2!-V0AY1YN(6&
MG-FYB-<+U; :*JAHB$F5/>DL&OX N1=0/'EV\=L2Q(!9J]HCPM6";L=9?!A#
M<)Y)%!(7!Q- /39W/EQ@*2U5#IP7?B;>SK;'%HDM@%#_T,E9[EC=SNC53#:E
M^I^L]48=  [T" Y\C&L:--T<RT.O/<_U#?%-D+%5DV0DS)!KQCM$0V D!1[(
ME_LC84BB7=5O;7WWL'!S8M)E?"M5L[OO>JSRXJL1_?<@9!2LG]2 L$,2MKEC
MA!$AU F^3PAUOB+PP$N%H]>H,DFP;V:$;>MSRM$0F4DT+,"?P_]ELSIUTU=[
MP(O\Z82(31T6"D*&FR.V+_<1MO0;X!:XF41]-_,/$%JQ;IDX#S8%P@-&\#\2
M^7]J#GP,C/FKIV^"> ?XWY9>/.Z 5,S]+6R:$P]DD%<0@CG8H1OX&%6#!\[0
M!.(!J7@P'C@1^3.OX1BDN_ N.72/ P\T:.&!ATR.>  @A%/;L&/DCCON(O<E
MG*\(#$?"_O/]]S',7<=51M2Z&@$Z&_=19 %'A =V%H]1RWM8-@C[X:D7A!$F
M4SW*9_P#W.K"L/#L6#(!5>=0TJD;2XP'5GJ.40,;:/EB5<RY)<)"0X4X>J_^
M1[#OW9\<6ROD<!?S,=XK"#0I'AA*_B.1/7E\U(YC%2$>_;* 7Q;P?XH%"%@.
M8GKWSXX82MDG9TNSV(,Y52Y"BLG4W/E!_[+[>3Y!$6&PO[H,+."!O["A18Z/
MY/^K_%Q<QD-K'J)/8EP<OJ"JDUBN '%O5)\+30W(WE+I=%!4Y%S-_ OC&93#
M<A.LS=.)XF#W9_GMXF+5_9U^\,8(#.54-L %NP$?M( =/3CZMR!>>*J7;<)7
M[M2]&_J+";#"BJ.))LP9B<J PX.?5<@A$'8L9AFTMP9&5TIDZN_+[,0:?['Z
M3^9A."'^4R+8 \)0&G>8_EM!]3\*IIF+3<9T\<P+_*5"V_" 7VH2K#LO$0]X
M]?U6O?R8<%G:.#7/9S%;] 0K_U>F:0IKZ.T!+PP1XLLZB]]KL!\7C:!:#H+/
MN!\*^Y?3HQ \;6&.V%K)@$T6_U[N_+A@RU%U;XWU4K$M=?]R@NH='XX_B[6C
M.-D!SNG%F1C_2Q/,.3X:?Y()DVKW@_:7A?RRD%\6\LM"?EG(OV\AF=RXZ^8:
M8W*79%Q/.[>^9[,J\?Q*%^=%Y:E=MOD)T\PS?^<O\2:U=1YVU$?Y2Y&R!$$6
M[@H3_+=_91*59!S$B+_2T\<D[U_\O_A_\?_B_\7_B_\7_W^?_[8)"OS^:OHN
M36G5:X;8/L ]P<KM/RFOG7\)[;,Z(5![[CF5;/:J6 GX2^QN!PI$:+%M+0,/
MC((/:4H6G]8U>R&RA HF&XU2M'&G4=3C.3JW+4:GHTZ^GGAAPBDK56^G&(.C
MI+B$![[QXP'6UJ/TN#RH"TXFGAU7/7U4L-E"2XDW*V4@9F>+RO[.B,HJ"H26
M%%/% Y+=6#CH9U8A"S,['OAHAI.#'R7_V2:E'RCF/T7C@7>X9-4J7*W<:X*'
M1#0#PYR"S4&/7F^ IP$4^) 8O"D&PVJY.U'!++16ZT!;%!E]ZP3O,7P&C/2&
M(G O$?O,X*/,OF.M&8W+@$:TW'E:L8W+=P[J5N:@\./M)_^Y-V5J<KM11ITH
M/' ;$RJQ@=EG9L4#ITD)CMWB4:FAV=]R'5\1-^&![:.34 @WHK36^M4.4W4*
ML; O$K_Z\*L/_ZM]F*8/>"4P?JM%J;,3Q#DA9@<39KC,0DY\J3]H'*W'"J<<
M;Z);M;K7['Z1R1ZFL3]D19!B_Z(3Z, ,#R33E,/]ZC;Y"1'BT ?8HH6AQ(06
MLNAM76Z(>$3JZY G;C^HU(QXE_]I-2,'$%7=G%XI08)F@@J8J]QF)&[ VHIL
M\(!Q,$%%XB\>@T-!&N=4D2FN3%1JQO+0I^7%-??,HW5S\MA"*\X57#RO$W'C
MRIO6FS8,85F-)[VH^Y:'AK0A- &[^H%7Q\_:#@]_O3N[WV=:+K+AMVY6191_
M\QWUVW,T&L.XNC<Y6@JV@_YA9Y]6^-'$9"C3MU.'-B:?R[YIZOO G:%\G69\
M+4T/$162..;E4W7V@Z>1)X4<KM/,0.J@J_#D*F__UD31G9<>"?PEP6HN5J\W
MR??&)(?E%U I6:4?^I1"&[I8_Z_VWC,@JF5+&VY$)2B@DF.C@&11<FZ00Q:0
MG$$%B0*2D]" DC,(2&PE9R1GD)QI,DC..>>&#F]SSC<SQW//O>]\,_?.G7G'
M'_6C>^^]0M6J5>M9:^^J>U:\%[-<]&/.=S]O0LD!GMP][JQY]7,F%;%6C>X]
M3R?@>25#RZ-3K:2R#@\%G3;X8%N'5FMDT(5S=1%\@>7!$X=A/EBF^F%%!3[7
MID>.NT;<S+E_J:9 X(XUNQ9[Z[VG'1'T3].1CFR"KQ&M3[7>H#NDAK-=!A3J
MX)93_;ZYT71,C^=(X1/15Y-;[7;22["@Q.V+,B354&/)]Y$/-ES&WD('(PCS
M2TU+&/S]]TT[+AV]*;EB)1LV.SZ6P@^$QSDFPQP[J4<FI2G\EZ528D!#N8GA
MM92>ML=@J\ZI)4H)N4L?8UMH%J@ I(DVQO=*I'CLO=':_;CQ&+=]E2KW3[)V
MJ(>&+[8?J5M^XATC=?8.+2\K\=U4QKF6,%9YZRW[),[UY7DIM5WH4$WB?4>/
MA6 7;O=(ZM[;[6;J%;7&^_9(Z17ML3C2<1JF8HI L"BC&FS\.D8GTL-,G;(Q
M@I_]-E_H4F2:PVM'(;E('X(,74&I]&)7O^;EAUP0IN/"L&[^Q3'''85!_?P>
M;HN6T-8DX/!)O@Q<.K?#Y1'><IBS<1HPXM(H ]<NKIDJQ]JDC2A:IK@U9+<#
M0\T8TASX((J<0D Y<F0AQ@\;SEKJ;O;R8"7D:[9:57@_+?Z*+J@'%*I^(%+G
M%D*0J_N(WD?#9T7Z#=5-I.&GX_0\ UD'(X=C4PYN0MV2_$'AUQ\Y_54X"< 9
MTOH$:(->NNA UJ4AK?1.S''L)3GI\[>)E"6U[__9R4#_@89E.P^AJ/C8E;FI
MJ-,61A=Q^!($5SHLTOD="H=5U(;?</E>EJG IV(WQF9+Y1^-@_8GX!A7EUX@
MWQ[SWBB-'REQSZZ2T=AZ^N_1^P'TV3_[TZ3_3HVU]1T8[:\KOJ  ;]!N6&>\
M4C, '8P@I:VDD=_1CKJ\2((=R7J,4&X+0U*<H !<X\)"*,"#_FATJ/86??U:
M61Y?2^,AVP;H9(T Z<4J5Y7[[LV6_]4!:-E,?P\!5^O0\CU0_/_D>S5^=[\2
M*64)N3BR0>"Q5J*7#'B@8#BB% 48#-:3;IZ#D1>"M_H:C[F+E B0:Z"MXB9=
MQ"IHW'[\ZKMB_/T__:Z8;C$.'LP[=W+>>($Y;J,GW<8!([%JW#H 'V,5AC >
MI!H%(HG"Z5*#6#<(L+=MN(/K#<4'%1+2L+^\6/Y*U@_Z-BK42"<Q\'#XEX,^
M=X?YGA6J@!$G:-'Y.(_DJYSZQ('!/NO8+%/W#$.+&IJ0-V(OJ<C $&I;Y,UL
MLTF/_OC%+28;@#89%\$G*I]\4(:]P_.<LB2;S,^KA<FA'H::C55U-951NQI>
M<MUWJ&Z;9E%;C'W< ?KR.$FQ-*4U85VWUSLA5DQ8*2'EJN^/?VUETQS-UF^P
MIV2UV6OWS+0(!%EFZ:W1W\U9J&?<%N.++6I<ZP CBPN?!L7)'GM8BWJN=N[O
MK)T&?=?KN4U8]WJ@$\['WT&-7G KCO.$^O"']C>'4B<^Q?_R4&QJXH( >E3X
MZ&.46Y1Y][VH4K 7,T.NU$J6OR/YB\KZX;4@A6]4'0_'0BZ ;N.-*7P'-(&W
MY*)F6LJMZ15]JY:.H&MZ+^@=Z%6>;U3L3C"GYT>.3>I/%=86F)]Q8J?6FXK?
M7\_'Z3CB418&>E:2545A%WQ<63NZR7L1M&9N)].N*,)T:O6.32!ZAMI!)T30
M/RQ_]IIP@'\,^0F&+J1W5(A:3@AT=T["]KVI(VO'8Y''6O/(QDB>?F7I$EU7
M+9$T026*W,R"-P%V)*-$GE9Z,T3J3X6+9>)%3=^F!K%T_=UVCIC9[_![5"?M
ML=+Q:<>(KC^1BNF8)C/\MLNKK5;G63W7L#%.X8WBYG#Q3<LI[AW!<;GBL/[^
M^U1/PK#LW*/<$^;;%D<9>H#!AT*/)TR5C^1?CO$^-Q][_'V*6>OE\UR<KHZQ
M?&5)%ZN*7:@^JQEZ>J7_/3SM_Q/-@.XJB*,N_S6(2QVKKZF31L>?AT(6H%,H
M"B!9X$9N<V"8M1G&YKP_7@1+J5Z8@Y$XH#V(_]4>JAG:#6B#CS2518=N_.!C
M#!WU-M4E4SU1(O2")B[^ ROUD7)*!3J%ZA&;S#N34U+&L4]Q)M.*,*./B6_Z
M%YK/T@_='W7(\[8UY742':K'N7Y'C"["#%,JJ-F_7? ZDB6QY>XFMF- G+TN
MT<OV@>DGE+)-6("UHB]Y%)" XP*@ZC#WUE81RYZJ4]@@[Y,C<MO(B,>B^UMA
M91AYDLIC/,%XF+)5HSQ"WC>2:W:CGN*TRV!Z=W71>G+/".D-EUOALYNTSRN\
M9#-1BU$[3!-8(N]L(FMW^8R'R\HE/GX,)31_LIF@ )UDIV?[<AHC@(66[4$:
MI'52LC+PQ?YQI=8HH]<T_0->$"V4P>O;95;.SO%G/#=6*+2]$;#L72"P1DYB
M#SX@KB8(%Q80F8U\D^"_QQ/0&\OPQ5%;.E/FF[ #OXB(E)B@'"N=WH%HY$)'
M<;A:[:%Q0Y*X%9F44V0_/X8X_[+]<.26'B0$^7B=!F^TL23#;_44)L:93OFT
M+3*"_%.8S-HU+Q'\H&_[X2'<113F6,^')L7NPJN_Q#MU$1KQO^Q<%[]^CTF4
M=W_]X)DHA;XB,X^K\ROL)H\,\5?D7LU)F$T"\#: S: D$4!92Q <<HRGVEJ9
M0E,R0F*EV*>=&:C\M5;F-I^1.6T$-O20AR^@3CW51:55?TOG@T9Q<?/-+F?0
M=O8R$C,(,)&:-S$[M:GC47Z2GO*ZO%>>6\F'CPX@WK3\5E+K+[=(M;RR,_K-
M7^U,BMT6> N\;%*--B1>- 88J@5?91>B?\LND)6WOF-'VUG"&K)N"@60D#O>
M1P%V[9&U5,2-LT8(9Q&[(*:BQWM_ZE?6WIE^UG<)EO8;ZI=1^:7J7O03VA>L
M^-^..@N#JFUH-L\F'_G>Z(> HEGU\E]7L+Z6*V['%OE6D&WO+ME5'6-M: *K
MX(>>J]?,P1'F*,#9P6_;YFML@8].LE" .;0*BZQ\2#1RNP)O:,!'*XT"M%Z5
MAU" *ZB&1G@1:-RV:#FQTNYL.-YY)/!U)CX#!<"MU$4!( 4@)!*$ MR5AK/,
MV" ]RU" 2W3X )<T02\B8#1J0Q-9QD9S3  M@-"P[3JZOZX;PA6HJOJW+F!8
MO)2EW(T_BL*$ OCJ%J  T#$("G#5@P'Y<^=*<+1<XB"X-_HWH32<$7D%.R%(
M,33L#$R+(Y\!&]*NMCB9Q/U!".!^GF,C[&(8!=A#>X@#XL2_4.KJG22TMNC(
M JU\YUWP ;?=DE#1UC+5A'7OT%](DH8DMJY$ 4 Z8 0<C'Q0"OXWG<!P!> ^
MY!R"] '#KH&0#\/T3!T1[]XGXGU/,/Q1"B)P<\$8"K"VA5:I$:U JX;-'Q3Z
M_5A(7HU%3\AN8U&$_<M:+OD?)0C_P[#V_:@.FALW^,=A$+!-'C\YQ'_#9V+^
M1SF4_SBFVHV_URC\WT:!]&H4'G'5(!O$^_RV^SC^\\9E]IMM_32MGZ;UT[1^
MFM9/T_J?85HY5D@2B\S%)_:N)E^M8;UO>B=.;XCU&?]A]%*@BXP!M+5A\HD9
MU;Y*4,)?@JL\Q*ZKV+;KHHW-+\.WH?=D1DBQ?"C?J+0T0/JVD9=@]*:2O49N
M6'2>CJ6.FX%V5PWO_/NSB+/K3CQN=;+V]J)64!W>DI4)-*:/]/VS;.S_UN82
MCC: 9:<1T X$&:QSNODW"ER-JVYK_N!E[2'P5C\0 ="(,3G_H8ZE2:P4FOSV
MUZ,D;OR>!\WK \]5?15V@B:-L&8/IX-?VJ2<Q#Z0,!XTH0!>"7G[G>!FYB5#
MPO.[AQ4'\J<(82K(C"@GI]L\$5Q"71M^9^ZN*)/E^"Q=26/ED,/Z4/^W.P.P
M]'OR>>![:[9+EXMYED "4K0 0<)\BQPXVA:D,G&>DG 6 ^?#)*.WF)\QG0TX
M-;P$H(1FDZ%SK8UD6S5L836%/J=G7W./5IG$ZVWGO).< 6$G ^?AK1H-K >@
MYE 3:,#NHRRV^%6^FW>Z/?WIY@H<:8B'.0J0C\Z'3MU9 W8>W9N6$&I_*G\8
MLF/48M0@J(GCN'^F-2#*90;Y'JO)Y?)F+G']F7(T<8Y5PZMBS%MGI.2;@$U[
M,6KG-@&" $<4X/;Y/1+^D4>2H^L:320'R\@J^Q-QA7-9KG6=K$!A'(?EAA@'
MT[)9.YT9&)6;7=86@\GD.1:2A#1<6+[ );/G>46IS^NRX32&+X\"(_2,C7.^
MB7XH/DZUP8#X0^[4\>6=&_0\K_Y:$YE_0J0R[&HQ@3$5XDL._3PA8G;MK,4;
M!<"&M *)SAG\>C2B+^65R)IA5J'?T)T-W+^9"1<&[D>?-[8A^<$I./2"'N^-
ME[K%.,7., BH>]3 Y&7LYC;<140N)D.+'G)D*U\_Z?XR!(I[\!C/]W@:?O&U
M<*WI"AA_,/U6XQ1"Y#JHB[Q,6M7H 8'V",]?>0F_7W .W2[CN"'Y&N3+4R [
MYDJY0Q++RD*5DAA(%70<'C!+\;[-X,:EFL#7AJ\AAMH*'+L)-]6GU</W]Q^[
MSGNY:][:WVO3@?K4,=*$.L^#"*<5J(8$7-X S:?MIS7%EW2A=UP66R3V5Q/3
M-A->-Q0'EK,&!Y"+]N$6][YQN\G/>-W'4QDNY?4$2=KG>,#:QK'$[B2C7_8I
M:FAHE/)#1*&.2GUI%\T:PEMOK15ZS7*IK;)$.M."M$9_I74\4F]C@#Q#FX:V
M03=[F>DUS93LWK>=HCH>Q_V]C@2-T@4/SE4/$MB]%I72\M!T9J]K/=XI+?1+
MV0(@$;=1@*M_,P3'HH+B48YSH4ZRJ)4&I;NM.:&569H?D.D)<HN/<42#*(5P
M$'[_(.W;*85(432E[G196*_VB@T[TL1H!)D2L\,EN]Q$G\H7D1H[\9YM@AJK
MWL6@=-'#4.4\9F'O7L>\(5%&13S18!>A.;0^. \C[ E<#6-[,K8QS0Q*89%0
M[QO<R1GL:!=)0I-F2UZHVV$@7#D$9Z::!=:\?SY2+BO:E7G+7$/L,+KL*QWM
M#G3-RVTL9] !1+%Q*IA9NM"TQFW()O@!H(#-N/MU9RNH=:SASCI%P4GH:$8?
M,OR4J?>M=&9G,<OK8!(@\_VP744W##$JYY:YVP38\%>"NG+#>BC 2]=*SMA^
M6((DFV?\O#N!SM1Y_?P,<=V310XB!>LC"\CK,/Y9[5MLM)SAD6ZW48#P9PEM
MI>>O70G:V@,V&QAX[VJQM:AR4?<OC)])Z5?1%?6,!\V>EQ?.3:^[%?GFOV,O
MG.VQQWU35U%J3ML_/]&]EOGDY#/^\#?T&JD$YT,!7M0:(HC*Z_5 +0I.FY<M
MIVZ2<_[EH9P*G.W8.KI;1O?DNKT5>P\]=\$4NW^1YL5,^"U7[/\GN>+"N;^%
MX^N%09=)*$!AQPV;LT\H@#Y4+S6(M5>H^<^VJZH*#S(\9)L"CR^BUU0"_?H_
ME 5K'D/: \,8SU6$P]!P/UV8SGJNA8]S2I)[G+=B]FVO.?<G$Z"<L0%-<E8*
MN0W;SK+O*6?/(YPE 2J'@H>"X,#Y"HWJRX<91*]HB\[H.YYY@L)%MI(;2E.:
M=W8*2>\Q&M@15.73,?.9;/<91XVRX\4+,PK3XSA2B]S":W%(-W8[SF9_QV=K
M;T3]O;;,CYDLU[7D;A0.3<HH7S!H:;4%63<,2Q@(ZIZ\;+HP=N8;G,1@74BV
MPYF>=B06/E16J(?[=R=:= CE;/#I/.NA[BZD>DV-K^Y?G!<[2U$3._K(FK&B
M+$RI>JUA:,[7?$LYU4*0-ZASAXB!J!/=M0-/,,.M\4S.*\SI#XB;!82,<+,)
M7I8!M]3)NS5D%)GU8QQ%2/;DL(_>N!A?1K5.?1Q^5)87+&_)/)UWJWR&(E-V
MIVEI6J,@.+Z.,+N#D?EV[F TG#X2;18B6U]\B)%-PWMT'_0,='5(?!ZX18<D
M.7< D^7SF/9F6YXK&47$B=7XG?;W+7_0TPLCM.T%[]G"2X<*0+[IH?% U>&8
MC_-^GWP(5IZ;5=Z;<<D<<YVN*^+5#M4=XT:PS<X]<WS+>$1OP]@)<F=<Z?=P
MZ5/]^/&C+OQZE,6IP*Q?5!#KU8Y'_Y"SX#$-6V;OU^[O?G[$WK^>>$U+%F8,
M'+B@.-UAU"@;*SNN*XUVL&K"VKN_B[UMN98[OG\68 T7RKX5;%_S\%OL/4]M
MK&-1ORI;%TEM>^E%>'\=+\/PNR*C.:;<28]MMS#(C66Y+:I.:HG",<!%4*D!
MH8(0U[CBYCHZGI+XA^ZM_#^I_2%VVAE=%$7']9%3:,!1 ;Y@MQSH 0<A0&JV
M1HU^]>#>$R@^^N[2=!1@/ ET 2A@Z=O?@P<+*B%<6]"1.>Y0(0N$4G!A_W-J
M$ ONWT,\@:*_E5S<@?]:-$O[TZ+9,%JB:NC%]EL-%, U_&3ZI)LIM:ZE[D^K
M@P'G:&#SH*\2X<F!]#J9&K][((^43+2Y@!LB,+;2<.!F%Y]>@7WI.M=3@RXD
M6@3OFB_D4#_4EUHDNRAC)V<_ODYPD"MXFEE3D7O&E&'T30VK$*O 1%D[6WOV
MC+U[L[TCP*9@+ZO4TI4O8">2TN=QBP#5T,S<E/R"E6@7?5^KBI#@CO U18&-
MV>+LS,]1\E_MA1JY[(Y4??:>#G=]#)4:/,4H.TP.\_@*TJET%@TL_%A;5>-.
MV?Q9KD'[]1MGLL)7009]#B_[+Q(G8S->XW^L48S57^!H,$]ZT>F9D@RZKZ*_
M%4Q<&'3*9>(NT]V9(4.U,W_Q_KW>#I$[D[^0H"Q'6='.%IX*UA-_C[,G;T"U
M-@9):Y/!/38$,[-*=HY9JFPAEY*U!]$0N=7UC.U:7BK$0/KM)*JP=K174/F'
M;8=8C]5$@WVI':X^^@H%D+X<^-:",+U40$(KP5FJ?W+E&:AV9VYC?*38V]M
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M<IFH5-"MWJ#YPWLG1R@ G*YF#H%13@"_ =Y/0]Z=L4%Z3?HCKS6>:Y1\$Z]
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MN8"VE*T KO .V/.;<7["YHO8=6^0^ >A&1]U0B(\4OM7.ROC!$.67U9#\:!
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MZAS\<LP^IW,P_7YO?-_0_!(_?P'U0^Q$:$V\1$:-]:1[REQW$L]4VOTC$L:
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M N.7,%(13"IE28!Y%A.7XK^C U#?_P]02P,$%     @ .HA\54+JQGM!"@$
M<'(!  T   !I;6%G95\P,#(N:G!G[+H%5!Q?FSY8! L>""0XP1V"2W""!W</
M%BRXNP9I+$" (,&=0(?@[AX@N$LW$B1 -]K!>OF^^>_.S+<S.SL[NV=FS_G=
M.L\Y5;?JW'K>M][[RJV+7$1N D^4Y97D 104 $!Y. #D"B +/,; P,1 ?XR)
MB8F%]1@;EQ@/%P<'EXSH*0$Q%3D--14Y)>4+!B[F%W0<])24+$*L'"]Y^/GY
M:9A%Q(5YQ;CX^'G_-@@*%A86+@XN*1X>*2\M)2WO?[HANP'"QZC3Z"ZH*'3
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MW-;[I^Q=D3_(]5UC$X4D?%?[6M\# B;>I^::UM>:JNF'.;/T41@)4NE^.B5
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MC8*Z RK$YLPY7X.4>D3$;//%V6?L %14DBU)/,GM1E\D<-^:=T?JN%3U(Y
MHNJA@*B WIE=#\N5.> ;+;L(J&=F#/>&*VXM$*,H7$8W)=]BVKB"?GQT>&Q.
M%:9'=@N3)#\_(K_D5'G]K3,T F^@W;V .CY_1N (?ZP_BV0WJ9S6T;C\4F(F
MO*./P%6*?E4_:9^<9B DFG"D9.^CP>&UE.7//Y-)W!(@4^5?-2CT(L=*+ZBW
MS+2NDP9KZ<,*?0-#^Q]]A\G[TG/G!/F53-6'Q.;2P[GR*A&%EWC/U6H_O^&_
M>4[V.7$\/%A+^-5G^$^/K LC8 RV=:AE]RP)RE)M.1?C(LZIQ /^X;W%@ 3P
M5\\6A,$O$;5(@%$6,GD7^10)R ^994(#OCA/]BUH([Q[*8YTO?\\.Q.6>_\-
M+T61DDM=<[I=O]](?6"2Z/":J=8'(BXA<AX;^9-!7_.#.ZD@!6]J?/D^"+@$
M$Q_6(JSZR!,;.%39EF5,Y+OZUX!+,GKF;V!TA N<HL\??;"B!A%[<BPF6S$Z
M:$C?N$J?)()=)CXI\1G[E7ZM+]?-8%:6 ]:6*GZ?NM03XS@_U%CIM?:7^'<2
MYFH=AV4W>'FWUSU(('@ "-S9?- #S<_ (.C:.X09CJK6=CL%[6J/2NT8+KRG
M&DR."![JEZS72RL]Q#ZR\K&F<&B16=&2P?#?_ YM[4+QE=2=NJ?S[=.<]1R&
MS(!K<--3GLNO"]6BL3!34C_4NUCW++Y/=1>.S[L(?1VLX\RGLWFB:0/G,%W)
MQ*PI8;ZTB7:/FN(["1$"@<\KE:R*AZR\'!T98*NOCUH,B;]-* T+]TQ:+9[I
M=E(@L@?T0[#/*^J/F,3-=LF*&SW<?&GI!&[*&"@O5A"Z>.;WSY!  C\2^,V>
M0-XGUY"WW=9JJ##1W&/>/F2/!*RMK[=>7$='W@HY0;AQ#?;2:ZQ5K/L4^S 4
MF#D6CU+4J:*)4?3[KLM )R[KXCY]Z:U.Y?'?QTD0.77;%MX?J+Y[')E)0U5?
MF<Y)VE7=F!,XQ)9N4#!(VGE-/'G=0MIS.!"$:69%\,%K^%YRU??3$L%O/XY(
MR^W1KH QW<'5XPF%$D#W&T(RH,)1;[DLX59%HM5);:\:.RV&6O1L)NPC,"$R
MJ>QSA(4$&*8D#^^Y[] /YZI"$7V0!/V!7'31X 3GIN>.7I2%]'2E.V28Z#%4
M9R-'4J3^ZMU=&&MVET)/N?*GQUPH6FXTR1BEQ:MF^%6I9_JN.4M3W]8T-M;&
M;.'O9%-O+Z0M.R !BO>_\QN2>JYI%:T,9NL/4X#NR9.[JI^!9'[0[+5G2H&F
MI<OVUS%?TN@:7$<M>R&)5"T3QW<? +^3P8T_9+</'M\"$PG\+ !;@WD1%1 G
MEWZCDXACSSB:^@$+WVF3VK0G\B5%/2(BDEZMJ#/[9ME2Z \N(4IR>^=6'PF\
M?3"X>O9%]O%Z;IQ#P1#*6UDHV>]&>R%O.A9GL?Y7&U=B3IBN-]6SWM<:&,^R
MT?B"9XUF5(A>*;Q-_/")*&'G-:\X/M:O]>*[PBGU\/,A-ARNPGQ*3W0*R6&]
MSCQ(D#-!DG]3S';M2K&Z=>V0NXUZ9KC\2V*J-9T+U+(9+L0,),AV()CX>]T4
M1^>"&]7!Z,@NG87,RPF#L-DPQ$],ERKCWD[RSD:#Y+?/W.7I=5%D?M,#_I;M
MDYMF!1C9L)3CRTMSKOGI S^J868'MBIJ3(EV[ M3^>?-,UR;\>^4:#TU<ZS3
M7NAG!8K"N"KL8=DZL/DVE&\M'2FN$EX?*UM9\$Y31!,SCZ2(?]\S^-X,U':<
M1 32.'@VN,=*%'#-,+T*ZU#8^4A ]O7!M7]W( J4AK<=?)-S"3YS;HEZ^DD)
M-Z$97YULTD,),A82%XP[I1#%X8DG>DIJ.M!P^*9-TS"6^00W/D4>DNOO25(-
M:^N58(2!8P/5*WQSZ(,J]&1]4U@-LQES0D5()UU94.-@/DG\)X#OY$#7^_#=
M*^7.3@N2N^* 3L]WK_P&?4/,>%8I$Y-Z$@*V-N+=?:%XHM#)UPV-+WL8#NM_
M>*>A@IG3Q:QQ47(S=SNI]\RXYQ-; C:KK?>N<<R%HU[U,JS[GP.;'U92CS'4
M\$6-DY[>2B/\H$%$*P-&'Q)K2QU2_43"7];DA"K2ZFP[8^:$"V^5 TW0D#\B
M(=@ABR^1@,@!#8TTWN30"?J F!+'.]Q/7KCX9,.;-_.7'9"@=V=;>='MLBXV
M74H-M3RJ;KLO%C<ZMYQ]:-H[,$-JR*"3.([^28/<V(>->C*F@J.<34_)= .[
M,B=EW'WI\_/Q-D!NQ5TXMS(U!=%+.&^OPQ_?28$EL\>:[]+HGPNI$%RS'=F.
MK.H%5L(/ZPE<\L&J\-U,GZ^(IT8S7^G.G(\Y#>F27$W']U.'?IF90]NX$?(A
MMCB<-/W/4H:"#=\FDNYH-UK1BZ;TT:-(,_CL)\\"LI"-!#URH;!J?L>$IQKW
MRPT-S^!2'R,HBW%I)SS"7ZI3(<:])='%!,H1+MT?!!3)UW=/=VK:HR%%6I6
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M8C&B?:8(3QTAF^#3GL-S-Y7!P[Y795HU<6!'S;:+ \C?!+:G8)IK2U$K^(=
M+&]]PX>#S^1AO1FI-]4OZ>D/N^SHFV7-%LR"8'$]/KF$L/Y3!_CO>2^L'PN&
MKCM2#&SI:!%KK4B L*9J0%"TI@22?2/^5.,&HXS!MZE%G"0,$S,B5(K^A;4M
M?0G@Z@_N-L<Y:&I:  =5E0RL3JOUJY7H9L918V_'Y_Z2N,B M6G,M;-O=:A
M&DO<,]+3DS._[NKV:+@BKI_\>?$+L\,@V@PQ4S9T*?)0ZCL0E2\WF5F6A[BC
MAEUS.CRD/TP-I8@(+;A/')=EALGL\[=1'"0?A(<97-6Q 4I - >&LN^I*0<0
M__\4;JV_PEU.;LW$E(I]$YV88$LXS#CVE)"/(B%;^Q.2;+_I]1233<>:-<B&
M![<.P]3^>3V'Y5"0[\"?\2BAX;R1;U5F:LB+8.-#3+?%\'; DZ A(^@M#:RC
MG0=:<2OK!WUU9'9I)Q:^P#XAO%W+D(,.Z!=H2J$3_Q<@,&4MKZ QVAU.X/;
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MVJBZSB\X=9'\7%S]B.YKF*Z$E@/UF.\[=4A(=^%4>6KB$]L0F2B($BUKM-P
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MNR;O%UZXG:LD)#\,H.=A/?75-1#A--.(6CR"U&O[:\R+]7ZZ$6PPP%W-ST/
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M"XJS\1ZY%<;4&#6(6(P8TX&=Y)X9RWDU++(J]X+_DRY7"X/V=(XW2YI-<T'
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M0 JCVQ 7*L./$$:'$A(QY">U/<-\;D#5-/8W4U3O</O*0#"L=%6#*,T+\^]
MAA4/R6?O6X&=." ^)[Z*@5*.\BT[%NB;3 &SQ;W#Y-!\\[YN1HE;B?<]ZZ;T
MIHPC1AF2TF#CSW^*'R3^C9?Z?T:X@A1#9NF34!>"=D5FQ_&(6:9Z0RNC[VY&
MC7>H?:63H>OG-MPLGF WP3!R>5L]Z<#0<-<H-,[BB?*QMD%2 Q!6]PPVARJ0
M5 SKZQ)>]M2X?(%"/P5(ED&1,(?%;0KSYR@AJ95&X>\/8#=ZZE('(8?1A$EG
M,PM5BXBVHB-B=_G&*#-;J<U;2?5:(PP#4"TZ9HHY\,5LT7AE>AD)F8SDS@A&
MX4%)8?O6Q\$#\^&+L)<:)*'G@T%&:*!^<];7F-/CP1&[LZF1>BH=JOP#1^PQ
MD'QS+57ABF2W&6FUZ(C(O-_C\6L_.L'TV64T27]*MMJD_C/W'YVF]$_Z@W1R
M'-&ZX0E[=1?(XGUNKDIH!9^_%U_&]?ZMN/T $*O^\I^F:_[+0S9WLG#E#WMO
M[H+'HW(HT#'"<:ALIIYD[G^L&P14_:JLIBJ@UVE7^HIH7_?;9_MG@M/K+21-
MC&^>R&E>I+RQYD(:-9OD"8O'=AR#?YJ+#3\RW0HU=K,I"XX0I^KYA?\A'"(J
M*QIZ9H\NG2B:AQF;D#4 4T":4LZI8'@]4\^>*&11ZF! 8%&LOP2@*3A(IN_F
M6YMJ^EF07C';_Z95HN!;=KY&9:IB%$T8^P!_IGB.ZW&H[(;M$>,8D-!D('25
M7PE[VKNCJB]'YLPNA=@Q7MD5"]X].$TU4P7"#4LH/ILI(DUDNR%\%X@N*67*
M.&PR]0A:DP"*0$U1R3_D\/>_Q@ED4E@TA.-. 1+!D$,$+>79=_?0U9B&M.<+
MEO4B:6N$!YMGS='M/T0A80*34KQ5>CEZJ.7G]+5S^:-FT%T]T,\\3.6HD2)&
MF0S;;E;'K61-"*J,BT; ZB/VS-V0(T)-_?TD!>7C90%U6"A\(%8VXSPN?W!V
MJ?L5_P2SX$?*\_SV;D]R#45ZJL[N'NVY2$[_B=A8,5:P&\XK"K,8WGCN0?L0
MF(]RQ'XO" ]K$,=>MWT]:!XS>%>7S6FSE'2[V>L;_3P6ZBV%8;38>:G:VR21
MS"8-J8.;U__(LM+4=?PW,O9OB@8)XC(+W_ND*XZ#+<E0'C7ZQ]VADI(J\T)Q
M%N'NEZ])Y2G@HY2M@!5+\NGE.;(=GE+D3E^=1,'X/4W+*LL7PVX\<P,ISRO7
M*B7IAC(X:0GC62FATIYXA635@R/J_:'%I;55$2-\>%M,FJ^-*31W+9E?#3XM
M>BXGEXR_K\,OM*?:U'2+S_/^8R<^K?L;[EHDV:>&"[EC+B7E*N\^*Y'OG;(O
MF,=_S/XBZ^26/%3BWRUI^;HO=^$M-:7;9$GB5EEU4E2Y )J5DF2B!VC _#(]
MB\) QYQ5'6PG^+KA.0EF9%#=+^ZKLG+U][=@@R&028VVJA;&Y/1;=CF-$FV>
MC;*,*^5W?:7B?]24+,LF,Y0>\\]B%7S^]T)))&D)>K/,)Y,S/V51&TQEA\1&
M8BG/E,F[U/+@GNW@,IK)9<N.LZ5F[LZS5;74Z?,ZYU'9WE&C\[O).AO^#.W[
M3,#;:J^)3Y[FY-=AR$J^.72RXL-C88I316:-V=U6\W-'"MU??XO?#NPSK>GX
MK"48?G/XDJ%>F)SKD$!+QE!?1>>F)M;7$J]IDDCVU#7.GK[5,;F\=.CWASS-
M7U9?%(85&[V92&TU!HX9U]\V$ZVJJ(S,-N2-%G&RT(J/S&V",IVJ'27-3XWJ
MTU[016CMZCBX4KW,=%R94\$33]X+9D\K,:S6FR*M.N!8RL?7Y0(MIIF"W?,-
M41,@YOTQW(\WG^$3_Q^6&,;_&"W(_Z?0$/Z7BL+:OY8<YO\;22S2M QH*"TR
MSM.*P]<9^2ZFO2K*\93XLK^PNGYE])J\2>@!\(71^@Y8A30O?4+192.EGZAQ
M<F[W3ME]!L7K*6,<S-J'7V2E\KE939]EW@- Q1'Y.IKW?/'W+:E:-N(37&G]
M'2[BXW2USCLIC>)2( =IT!;-R!LP_TL4.QRSHK4BQN,G'@1A'0TP#C.UJV63
M0()7D3-L5?'+5\Z&<H"T%A/D'I,RS8DFM)5!O6 (13B_9+X9KHB=H63)X4 "
M1(2*@0'3ABL+/_9:E25^-0K-;&ZD,;^FW-%XU9)-95V-SNJ(77 /.6IME(>G
M;[0$X'IGM;.$/P4:1M.<L?Q:JV7Y&D\Z,#K$"*N11!B%HL$M6F<[&,%X<M5;
MJ6U*3FYI+S/S$C5AL4R3.U*Q.<F:]\8 MJN]'<A/8U ,9^P!5B\DTCMF=>.W
ME=<]ZP[;MJ'</HH,D$?#![LY?5L1PI0Y&8%VWVSEN)OC+?*KX;970^31,:*?
M\.B[]E-_)J>'IN*<>(<TX13"_=LK]WYI[ZQJ'HW*_Y[__@!XP3CITUMPF_W9
MQ@1Y<-^[(Q5S!F'L35,:94%]JN8Q*3%/%>+$U N=+$,;FWGJUMKYOOF]^HE0
M2!,N2]'+V/P].^H:*'M*$1V)/;'0":E!G0$T!Z!H[>>&*/\U"8I 5JX',UW.
M.,]G$QWZ >[ K@^ 2T/8M%CBI63+DM&IX/"OXS..B+K]9%CH.;'72P^1$]T"
MZZ+9W65S<]Z77R$=<AP\O+=9V"+'O5)ZS^%!DUT/ &#Q112N1K^UHZTC((A9
MX /#0E%FALU&2AV:$^\PP/6R(%=G9RZE)\7[5:RSU3Q-E,U[K4FJT +=(MCS
MCY./R-^R2@^[VPL45C2+=UT:2B32D3)^N&V"U#_*CQ%Y)0E7RMPK2U_6A?OM
M;;TZM7)D]&82)?4/FOM!G2_@ELKS> )'PAW_U0K3!P#A^3*&&?<[P32/06IN
M)[@2)Q,Z9GT?&F7D'98%=X 7T%20X0$0H*8TY=B8(J655IF4I,?\N=;(XDV,
MF"0Q4B1;\LE[@"L9X5Y#E#_BZ8J.Y7G4RSU@:8;+B 30K+#7&E?H=:PS35_G
M"Q[BXQY7[Y"E%V'MNDR>7'.;I4R;@2R6V=Y-!A;K/.N4?AQ+/KP,?[5ECEP)
MI93,S#3,EDC8!!<]8##$!30KE?DI(3)/+.GK-_^E9K7.VD\#6?SZ3=8?^W^B
M64"KX.]D$Q5_6JXP4)\.8O4"UJO=X@_YF6(%];@R-Z[U2V<GUF**=>:T-?HW
M%SZ.U];MGPOL57LYZA3:F5R+HX-/^S7"4DWW.&14^@NF><K2>O7+*@4PF5$O
M##"F/GZ>SN0I/)[YU;9&(9C[NX'^8Z1U8[+R<X>VPS<EF+C^,J=*O&7U&2'9
MN[<WJ1],3?J^UJ.3O'BOAKQ6U#R ..MV5H,%U#(), X@5.RK%XPG6A*I<V0Y
M-WE2<]5D9$O&V_5J]OW,H@OR/$_QY8&#KUA,*3QE-.F?F62&KACYF-++T$@#
MLCFK@$%L?X<(R$WIIWZ4%GS\KEO=N'HY[]1ZC-&)#)F<,#P]>I5LQSC>9DJ%
M*=7,%>5P,I64+G=EGFU5W>&BI: 3PNV-Y?QL#=P'VC(^SSGDG1A#[!/+=!35
MY19K]39->UTX3?M!$,=<R35\IWUB2MH]X5QP3;70XK:5$EXHZ/3(^L?MC]7T
MW5(EX!H_QN@7?RUN25\-/)OI_<T+"E!4XG!^?GEF=,B>NX(*"+V[N8B-9P4Z
ML<+*WJ7_)@IK9#^:%"W*"FH12C+1%*J42#L%-5S'$A^ICW;&'[:-Z">\86$?
MRP%*9UP1R^ 8BFA'-?,HZB<S#@58N24"%PNJM@]EBLV*9"(>@:O&W^;0Z<$T
M=(61*WRA="4!R/Z*/;]MS!C<SG2(G*:^N9/5!AT!'(D/=2NS&SFE0V&MV#A+
MKT?-+IEQH0.ZGHS3O;KJTFG$*6!Z$[VZD"ICT/<9K;2C&<0$2P=##.LB!':B
M7ABWVTA.QMO_AL2<]@,VHR:(D0CU1RPE(=WGSM"5GID"C24Q^]C8*=EXLH[$
MJ-#O$VQS 9 SFTG;PF+)D84.T1@PF)RP\&+]22]YM<2[83WGX/QMN:7W*\=D
MDD;6"S!MH9 P0NN>1LDD"P\H?ME021WROHX#U2"JL^'^57#JDO$(;Z&E6ED(
M!S#;O+>'6:XZYR0CSBANTGSP'^CQ._(CDF3X!YSZMU4;8G0$51./KHSA.P:]
MN*:42E&H/M-<\J<TS7,]['*&5JFS$.Q9Y5MHAHN90X>?N]K$YFF5(W_XN"Z:
MA?]&?G8([U9);W X;N@7/4@#E=JR<5^!&7/.+Q1<+9N"CX5<%H5BYAI.%3!=
M5$-=Q92?@YHRS5('&RJFFSQ]1?8LX['*7PWY55U4B#D//F$R[I).<8%KDV>R
M8527A"@V!Q:^OGHRLMF$@DICX5":L"!M,%P-=\T\.?@&8[?T2)7N&W/HV?&+
M9:; 7TOQR5^ MG;&1CK@@9P1J=VK3[U+1?B*[PV_7>47;<-4>+,]DPF_*RJ
M;6K^A+T^>,W&ERX/@)AH[CO_G ? V$03Y*];*HDO0/\4$%-@_R664?U+K/-O
MLAJ$_^K_JX.59G7E\I:UEN8>K8W60$47',V\H(^'GUQX7Y@\'N;$[-I"OR\V
M#*)"W:DA$CU\ "BFL/5JS]S[@:)/N+L->NCM+U\4W"5>'@2?N=XFU?<<_G@
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MQX_9?TU/H(V+T;>I61@X22@%$N4\::2?-$GHM^S#4]/*7/SQ^_.-&BDVH^S
M[2!H9W6[;X1?Y9TI_N_S"(4:WSHU.6N[6+I^XC+B7U NU@VH1IZ+#REFVLBO
M7L.J<JE=,X\$#I889XGS-RU!2:'#OZ825 CMI/O&[?5>?^O/P4A0X _*>S4@
M=4 E,SQ1OZBE\Z*(H<(W2A.D8ZCRK)]P6W.DJ'F$"#J^R0MFP+V,?YF7Y=O6
M4-$4O*\Y/Z1N=;RO+;.1JX'^ME1;V]I@6(DUD5^M2%5[7_2 =<H ;*+,.5<U
M,Y*5(ZSLKVNIR:Z9,AYC0$]O*\88T9W9 Y2R5S*/\<:5>!3(OR^B>=18AJPZ
M[,Q0QIPWX,Q0;94BGW3(6$6CR0^,432""^L?P.,,A>Z?(PQ20\><S1IQV.;E
MY3.^R-1>CIM<2H&]PUHSM;])06[E-I"JT;3N%0/:\EV866&; V)O@2]FPP&Q
M/Z(_%4+A5<Q2O1E)7EZ0,)XZTAO%7]\<]0%R06S.91Y_4<H@ARMT-2P\=\8-
MFQIO4\R9*G2U&)]>6 Y @[2WS#CY<:ASNPVR"O&6VATK.-L'O6W85"28SG1S
MT:XY5M)3G$(,3P_+O([NSVTJW4X $8.VU+KLR2\P,&(JD"6E);79IW:093BK
M)M5E'OT@,U&IDWQ03-R$JK7-OY??^Y/;D]82"7&D(:@K2<@D ,9PT[6%AJ9B
M.2K&?JRRU#1[^JQ3=;.T4(SUHH>>=ZV*>=&7%%HB553>KH?UJF NMU""V*T"
M$IIL&&C'-B2NI'B7?@F:!/:F,%'+KCV'A^S1TT[I*TRI 6N+_7GOS(B/PV!U
M]X[>ZF/]G_&C)UK*R(^;&*IG,J.(VPD'^,N2-\9H/_.^K7"<G28E4,W7D5VW
MY0&%=\6J6J793ROI&C$X"YBQ;H9,RN1DES%8+#YEY@H=6">84 !+?Z;YS[MJ
M&/U/UP7_CX[WDP7-N]/9*-TYW33,#CT=CW(HK0E&#Y.&2#&ZE&-C@N7(%KY%
MRJ@1'*C"XA*&$@FN./6G26TD">T$U!\ 'C-8Q* F\WZB01RTL5VQ4N\FTPJS
MQL1CX+8SA9*4]GI!T4WG5T_55RPZ.C^QD0HQ[:5DN.K-INS&=@((5+X_FG3M
M8>TQR]<YG$'U6T$!?WQ;_5?6/ZD">BSFU]EM?PN2ANER)]O*/J3,TX32FTFL
M,4_$KS/JAILV$B_B&OG\3@^U_#H?1FS$&/R!5<;:=,Y7D7UZR%_URX\,9'XU
M'>!01S4AR&"*<]CB37BSB;9Y>AZ.KKFET^!2<4OZO!O4F-_9Y&0[H7MD*[>D
MN/)E)Y3*T66B?INSUOG3@9A9R+[V[W!1-RIHQVJ6#%Y6#&)F.AQCY:LJTS-=
M$1W5%(L/R'+8R;68RE.J <XO3?#3=[4/%[Y0\Y2V'#X+AS)[I/$*7N2X[!@&
M)%DK\4P ;7,AL&W\"5&2:J[DNX+J+17XK,GC#0_]1ZBG(TX10W/_,=#4%)'6
MP0W5KU/TE0YE=.GHJ#MW4NK6\]O];F?.PT6WJ,.6'\.13!#1/27+-P$Z([\(
MS_BVEM?>^[;Z,N(''RXXKUEH*=>SZF::EG22@48!PJ# +.F@E5%8;&<O"3$%
M!4I!@#WT%B@3^&"B4GJ=! *%4"R<CT\4@9J67[C83.DR*PU>3"A"I#JT_A:)
M$%3%58T]9:9A-L7%H)^:DS?/Q/RPEOR4DC.S8266VMFMWNH!\ XDE2V)<<=8
MD5R2@:\&/J,GH\.'%&P_>3^!C@2J98NJ9*[:)C-#YAW59*?G\I=:5Y"(IF9R
M+>A3_#FLP/QKXBY]'47!QL8]D[?E.E]&HI>6LU,[OIH[,N1+[F3$ZS(^DRJN
M4"5)[8,_Y1,+^O_9VUW*2'_A4%RF@F#+(1([CN\? \!HS5_[UCUZI_PN_O<=
M:A0W;$5X_^LZ.+";9*;\?AXK)D-#8"^XPK*^+[:^+PD6='5&<JXM(8DJH2&X
MR[X-#+:VUN2N+>$*]9KQ'NK^^M[=;7R+^_&K0+7<EK>+!O;24M7C#$L"=[.T
MH?N3"K+F9M/'Z30$S=FWOWXUSL]$'#X>E'S"\_?!GS,\GJM^X\;'*)0NQPGI
M/^@@@C0?E9Z#A_M;B:Z$4*/D1[&Z=&_X9X9[SA)W*D>5PBG5-,T21,=&E+XH
M&RT/0>J7<X(!!MTW18N1?=X_/)_2Q0=_41C_T*6BQ5K!3'->,,:,Y<WHI%D$
MUIO9?P"P"8X(? ,:&<0\I7V<RQX:'%)X%:T*#BE=PH]7$=*<".NJM2E]2>?]
MPKNGW*0HDKW)*3HY?S*M*^*GA[0K77LD[CD:PBR@=F(X9:#I1D63OLGJ]3%E
M!- 6+O\ 8+W!D-D>4S(I3G&+<C+]2F\Y%:>@43/?2/2GT<W?VD$T H4/3DC.
MBD><<PS7FPM,[UUSSG#2<Q64BY2UV#3P7//&%+;21!3&52X@K4,O11&=NU(T
M@GY9F8DS#%?/W]@ZJ&4RH^Z.?I%74+DH7!YBD8@A_G'Q)(KS!B,R5$^C"-&Y
M^;C+#MV2)WV<<L,%A7P%Q1:%%'_G#GV<PF&A\_/7\Z,Y)*,Y7*&RQ<OR%:\<
MB;,S\U(_Z6^%3RB(<_PA//_][@+#! HVK]Y&],2$>HS6/:^[F3A^E )"J>R9
M(:;_5T:\YO+.A)I419MZ+W+.**#GN0IR\]/WQE>!T900$81>#H5)XNUR>OY.
MUC^V!C,<2!A]O[">2/IO M:L]P\!.R/Y(T,RF8G5!8C1X^>OG2DTV4WI"K9C
M]]CL'NU!_.]'O9%XTJQWZ6;3BI>-!J^Z%GX M'Q_ $B=AE[(S5[=2YD\ ,KH
MO2%C:-/_W/O:@WO]W34YO\@?\C'JCFCZFY87^Z/&K7=17.+5/0#&(]3C_O=V
M:_H_:*@5>HVVGBJ)W[E*(V::2IN5+CT? #$0H?T!O:TJI N=?[: 6/#!>_&H
M%]Z_I=8? &(@?=7E\-8-%QC:74"IT+F!*LW_]PVE_W\R"/?2*H\1<>,/ %W%
M!P"HC+%,^2[->R,WZN8T\;H$X*GV+]W6_JH<\;5_49__Q=W6_@\>;GD'MX\0
MG=,;&M<Z;#ZP/RUDO'Q-GW7?E'-O+DRA,O[/Y61_40[+ORC/X\.S<K%OO[D*
MRZZ+^C Y!ROI^"D<C6_"V[M$-39ST(KFX8UI.-\9^P)50C+3X!J5>@P-"RSC
M:&YK:$]3O8#7SF]LWLU :"@80 X6_;<72C@][\$%,X0&?87AF3(U:-M4MT,D
M%=##GT@_94(G(MX=M8#2/\ZJ7%U&WT]E:H#,BTXNG:HK#7U'4\&H[U6E5/U4
MSL_>I)@AB1M:\:L=Q1'5AQAL28%NGM6QWM4Z.T%&VC):C:J(M%@;G1SITD]4
MK F@*Y'Q[FRH#0)1'-P9C<TM6N"Y&DZW*"63%E"5Y[EX=VKVAE:C_AIG@AQM
M&K!7,#*LB@!BU'VGHD9\V$V*!K.6:^HX]2KCIV1Z9SV"/V=+-UI-2+9M1U8U
MC$3DNWBK)'V:MH3,79*Z1K.A$0,B12A/Q*4 &6"M2<[!86.EVLDJ.-"],1B=
M0$J8R2O/%SZSE')RVPUL*<LW505JI%[)?:Y58()%,6V$?ZW!H3Q_Z\,+86QZ
M  2RP=#N Z$/@+8?WO"&CAE^PC4*G+T$-ZNBO+N$HS/R#_RPU0JGNY7?I#?1
MPD0$JJG-JX=:G<#HR>HDVJJ&9Q0&+^SR,E#PGMV0]Z1EP W4842-?"K1*4QK
M9Z74+/G1M$4<+]!$E\O/TS$AC'(?3R[+UJ0GC;-VSY9&4#7TM0/)L\^1]S6!
M#P"?)J55]R_VQ3O0ES,;ZR,##<B_7RH*(TR0DS-#H6,>[TK@J1J9XPZ[UKI/
ML2C#H^+(4V0 7Q5TTA ,UN3>8]7.UWEPJ(#SZIUFKS8?]8W'?D&0\BU#Z?9"
MVPL \8@( 5(2V%&SK%./V*3!W@P8Y.M(6,AR]=W2TW_:+T;9TSS^;ZI%&0TZ
M[PFA'DIVES=O?PJL]R#9^3S]=+[0"S!>&$,5("PK@^MIG30/:.V[65PJ2J#+
ML3XI1=-F[1/R+?X+&"ERT_WI7+Q7TV 9KFLY/>5'%TMI^.U"0+#::[_#;3HW
MT;U0VDBPW=!EAF.D(D/EAP$#JYU;I' W0'_\O^K$--5T*:8M'*29C;:&UR:/
M?R;,&5%=!;JM&/-<]3!R_1.PSA,G&68  Q.</Q=F%="FIZ..ZY NH< (^(+*
M#2\)8RR!%(((ZKZ/]+6VO*/\3L2@D?^.JD["'.O5.]5CD2;HZTJG2:84JM1U
M2H;*Q^7GI:5V&&'G$":N4OXN IKNLM'J.AVF0I%85QP:<@.@*>D(YIQ,]FB*
M_9B+OPH^RJQ263KBJNF^^)P=3Z$@3)KS+WJM!C9=\7ZQ3$;&;/&Q8A^=*4'A
MFSQG&+DS'CJ).!IQC[L\VGNP)#^[EK8DRF"->G)6J;T?]K/\G?\^PK)A7BZ(
M'-0R^4JAYN1P?9[O2-&IB/7@ WY=5$>]AGX,>BIQELEF1&@#3R<]F0A:1CJJ
M@HYNVLEHCUMI7$-\8O#11I7C0J13@>WOPABB*!O&1 BQ95X,^KI+SN,^?-\'
MQ%%>N $!AO]BJ_),T\VX&\@N*S$9+"QT>;:BDW%^CA  7&EW)R+<.V_R@ARY
M)JO#1,V=\DE[=+3\QS8E"9!^_MUCT"VX%7P ],M07&R^.],\;?B?!)E(^WIH
MV2X>M+"7ZBDQ'\=_QD^M%. .^N$8Z+I;K[7B:GZJU-J?2[:C[S-L\(:5"</!
M#X WSEW>MT]:[\,2FC)44CH*$XQX )@Q)LA0A#L#'+KZ-G#=/"3:,<S=_XOK
M&SH]D)<%?I1-WKR[*EE49PFCW,E%0N6Z$&X$,>CILJDI8:4,_[>[-;1%,ARO
MK.\N):.OM%H#6E >;6EM>G>A&;>E.Q/:,;4![199%!ML/TVJ +8*E"/8N?KN
MY[![_L.K;SU^[CDI,MP?'@K8]M!:P<TPN83<1Q>!BW=>66[F+-C^F..^W\\8
MF6Q'U".'S@AA(W@S?IMN]Y S67+(M_I:457Y]>>>9ED%]B%<+@7,+H.BK&]Y
M7'X>M:M;.=*!?UAQ\YA<$?[YY\,6&=T6F,5++HA5,$R\_<F1B:6RUE(GG>00
M?^"FG  .#">/$ZD#/MIV)8@_S62YTA2E5#6EKU%L]?D#_Z95VCL>_DAVM] =
M*R]2%_/.%IFTL*:O#5YE#&CFTN9<=2^O-ZP_NZW74H1L5>>>Y 5SXA#!GW<U
M,"\<9II!RQO 3L(NQ#INJ2OX<,L].X;1+AGW]@;K*$<M3_/5@\3$)1/C!KZF
M\>LVWVH_7Q^VR*< U][P)C+GE4,I(IJZH-.1H]<"*0<4>]OAYU1CYWW;^7O/
M0",,B9\+T?5M *2QNC]AM!JQ"B?!@8>)'8H[FA;25+N'-,=I6SWMDLA4-A0.
M9WN,(2=5-2?P1G#"@:]%X@EG=C*6'YCV?!C@5('@/GD !%M:JO6D,@-U\QR)
MXM3GYS@/,5*#/O!16#BM0(:@7A0BJ\WFTO=CT#?>V&92NECZ<ZC14KZI\J1'
M(SS]^U!_)829WQY%Z%RG=E!7BU)7;Y;X9C[1Y4I4/JA\#<7=>G:P\\72D\K!
M0OZ:@04*1KR-.W81!!A@B;"H&5^?/ _4PY--Y+KY]&14YF59Q>ISPK/GQL^<
MMOU'!R,O5JOWA$B%-D"K:;< K0? CIPV3G"5*4)TC5E(HG8TR96O"UMPAS;A
M!BD6+H^6;Z(9GH8EB&]ZTV5@55!FIC!4-)9DHN4D&$P1%^\+2Q3UEX/%[+\D
MXC-JQ%B>KR/%ZWQWD[)\PJ:3UB6'[\%GZ<G)K"0^7=H3_*(B8&Z!02Q#N ]9
M0'R1]@YB57'SJHO"GQM]=5"KSO"D\AM5T&YG_\9W:3OT:]O8!X!%-\ ,_JZ+
MS\K_1*WSU[X\=8-L@;= X*Q72*3A^Q8?WS21V"FU2)?;=J@@.NSCS=> ?K/E
MYJJTJG+RX#T^"MOSTEKM!T"LY<GH7>#F V!NVKU321RFM'H&ESI]U-: 6+'P
MX>RA;5238/5^1/"DZ3V^,(&WR;MK>NE'Z/WB <!5T,1L^\ZG!6?9)?/MZ86.
MT>E[\Y='5!&U;#=XI3CC9GJ10,^>(IC7J&RU#/25ZLQ)3TOQ4)LWWP+<OP0A
M-,GB\ !X9G9C5.#1@-70$6'*WN-34<"[G;!BO,R)U(_0_Q5BWJ 77M64D]IL
MD2@QX+4Q@+IZX+5[LU6,T$1?T\.&Z_5^IQN^J)U]YQ3YTF'T['7O.-CAC1ZV
MAPA<O'!'$%C17)LDW'U8S&U%UD<3]I0RV8\[W"V^U&#UP+_K 8#3I+12@+T?
M$':K)(=6]N/'0M9^($68_!,/<C\R8L<' .D2):M)@D7-:H- ES\&VNKI(P[J
M-O4@A]S*3PJ^'L:%6(JM?W)6>O%6/#[A ]=Z2G<4T;%&"[OMJER@(,E)LK'A
M4LX# -]3&!N;)&3JGJ)09=0/RC%K0B[86!.=F8I%V4\:-JVA^N'9#:XP:=DE
M=]?H#2J\\AZQX!UH?[.@N=F\UU[V-H-L(IV1#&ZS*B=+D:P*13#CD'J/C>9[
M+P^T3U^42.NUW%H5N3-OCHRE6N31(J>GXZA/_!1D@[\P2<2CA'F%)!5O1?^R
M2E\A--@?H_#,:U0UCG(T?X<*=Q0D@WM]/LB6+-'-T]AZ *2ZWN\<"?C<7SI4
M!4:M+/M305DR(A!ZQ6^9#C>);YE(\8;>X_=XGKP'*<%C,]7A1<+^:^+!;[I>
M\<AHSKIRG=D\IRAH$ZQ7O:<2)FU)6N_GU MV]B*9.-RL:FYJP%O8PQT,BJ%D
MVSQA1T-N=;HHK5T%=9^W$,'B(%VGDJMQD]H2E35*HT+.1MYAQ+L+9=5V7B@G
M=##>AFF0='N>B[/L=9GUHPH*RZD*Y8HK"G-YV*[O.(81>7"O#LH=+#^?HU@4
MYG$/HNA]?60_(N#**P#@X:O/V[M)B#FZL<IR_CH!()W_-)Z ##4E+AWL;.CM
ME-9!G2/S[N1+V<IO;+I>K6>(.L.K(^EAK2-[K\98)IVC:WZ%DZXA8YXG,<!\
MN&EYU 00X>7=%K@=0RN (ZM/GUL_W],5@F%7%BQJSFW-RU2FGHI))_FQQ:!O
MX-S3/0"P;'7)X=^\,UV*%&',PPUFP.H-]C=R' ;]3O<@(BH?MBA9QASXP/J'
MZI-1/^:^%Z9.C$SS;ORCWR6O5M+@Q*4DG;JXT_SJCV%"^?/^+Q90=K$CT8;(
M/E8[=X,%>;1,C[<U,)G:;^*A%]^.#A'O-P:9[S;/ \1M B4HW(]3?N_NPBD$
M)AWNJ/1@]56Q\E$2$U96-(SVK$^_1&T9CDB<(^?OZ^!TOGOE L$!FD!T:C)<
M'0WX8?.2!DP1U+J2/!:O^XBTDR-_G ]_]9#\]6OB_LU^@IL^@R;8SNF-3;[$
MTSCL-C8J\BDD_R)-K=_FW#-.M::NUBC'!&ITK)4,Y4B]M'ZH;JG5LG_!3&7J
M,-#0/0&<>97YG6S\X;(6^])2/SZAJ?!\M239K_W>VS=-J<U*O2M[WL]:*/9^
M/1F;!X/BAH0">\:0SD<3II!H@UBL^+5.S+L;=',X%KB^;>II2#):F=Q?;J)<
M=J0*S8$V+O:\<<YR/6C@OH4C&"+V**KRY??<[WV1H>3ZT 1YM&S3UN?%1_SX
M.2Z5BC!J/JN?CEMW.1NU+/H,F[@*(D/AOVG3V]!*-.K@TGD+NPE+E.,>:I9"
M06&L32WU/ETS2;;3'(G4)X#V?K)(TR5&)XK*!X#O&'[5HG:,0%>,P36$22?X
M8+( T(M5!A"OZ1L]2\>\,U[=BO0@ME^SQH GWNK/]8 C3^F9P]^1KP$^HX^P
MBUO]W/97\7BW\EQ'O-,.GM;E-F'2 !S<Z*:-,XQ9O0U0@)^-BO:BS/1V/@"N
MJ;UQO?<C:L_<O,.IN(6>('#M]=$K:Q+6&%.: G[^B&Z<Y+&'WXZA>)\45C4>
M8^[=4X\A5,CN?QI8G.;?TDMZ=!.S-<2>PL*Y><\O3F\NT@(O:\U/H&LTXZHO
MK?.NS;IL1@C[>^M0O/2;(#X"R*OLS)'5A7"("JK <QG(+L?8D-I7<WB"4+R9
M!L?@+?=><5=C:P@2]:DD/9E1[P, [YWOI-!B'8P\]X5WM35@Q/MXM=N) L=#
MQ'35VK=VKGL& O&MA7*@L)/2)7[54K_C%>!;WQ<F?5F]PH-@6Y6V%-6=&BZM
M=.&>-T7'WD7Q7HZNQ4J!MPLT;+]R* N&Z+0&'O*+KN,\.AH#S>7M U78_,_<
MG^*PSPX48Y%B8E8(G?&9F[W)7C?MTT63F[F@A0/U^2%43./)C+8#46P?Y5:B
M+ [3%HS6*I1=N<QN3!2[POVKQ'V_K)/+= S-Y8Y]&>ZVVE3F280X=DY>=G1)
M0>B37/DA@F.436))_L_W9$UKS<:2U8W^EV;0S12-SVG*$2L+@B=81-3N7PU.
M0!M3_S%O*+DRV(II>A,';:&MJ&\-);K2TOQ@4S$8[;-]6S<*)X\?'A<F'X;I
M:7GC(EA.C HO?\U=GRY8^B$%1"@?JE (9ST 2G0Y='/6A:Y?+SV"R-)$O1OB
M,N9T[./V5JS1L":V_'TJU:!N"UKEQ%&Y:(.>[>\U[IBP2,\B79Q H%[(>6-8
MVE-X*;/FVO"X569=C?GGPJ[[DY="#@ YT3;^[5"]Y^]I#Z[7[;+]K Z#R8,D
MVK-6J2I<C-=(Z"DC,#X\N_A]#AB4"Q(DAUJ\6SV!AJ]/7101:3I7<UGB2;W*
M%S,8Y3=.740:MO="/^%?8HFY7'/?J5JDD@N7=/5D[0LG74'JD6Q?%QHC3UQY
MA8AS?HPOT%LO-;V#J+C3*J_"2HI]W?O*UE)7\1-8L7[PG#_5OD?UH1[S(H!;
M]P A[:MIP.<_UOH;)(LAO ;:I'P%5"[,/FX&5+O:QYTR0,;1;S5LVB\L.:]U
MCYRI?+YO5GA6$'B!JD\P9HZLOXT-/ZF-?EI58M-F0U *$#IYTQHONOH @,>X
M4/3JOA9BJI7E=#>Z8.?:%;\[04K'\@;LQ9C;>"A-&XW^=,U>&!$YK).PA1L3
M]N_J/A%=14<HK#%+[/+97EO$]I^];?+^J#C8VWI.7)JWXME=DI,8865=TC)I
MC/U]0@X-<1&.RM0:TH<PTZ,X@$>O:%&0F-*-2^>\FP5A@;0KYDOMR-"^](V@
M??)V&$.C6J5  I>:0%-?SU2;G'L^&4?4U+L,15'!3C,C\Z*OS_G7O7I7Q<+*
M3.=22QZO_A7S5HJ!*?4$:A4]NT060WA 5+R/==)\1I92^.+]")!J]LFN<6'_
MY4K3H;Z>J;4L,1KBF7+KTT.KD91UK6K56^!.1<]A)&8 7M:^SW(*P!7T7R#R
M@%[D][W BP+H_9A#CC[TN>5]N8_BAZB"-H1;Z*6.4M>,+C4<:TTA9_?%KJ9A
M_,8+S?G>_ODM,6G>HZX8N3,!\_;]J2:!!\#;P[7C6_0_\%E!'MD+4Y0P9_D;
M_R=8<<P.1+ER/HCXR8<\M%-5B@A#!#\LLMH2QOBI+DVA/MGLU;>G<X.O#>._
M?LZSX2<UIMK5? "@<7CFP:$?PI)*1,&Q?;(' T2?O5@88^">>:/Y"/#)795"
M)6MKJ#C CI"(@Z*-/AT5(3R>\1AA1%67L,\ZM6,-$B7>YO_^+ 1H\R*D]?$@
M][!=$\T*JS1;-HXQM"5'Q/>@LO-MEYI9AW+#S/3P/41LGZ-&'8JQMFV0^;Q^
M (R99]^E/0 V\FCO7(?OZ) >@6M@*L44"/4$X<5=:XT?:#%'D_7C8RBZ"6)A
M)=J_[YP?&"8+-T@7+Q#-</'O83.]?Y,<\))UGCB&UKJAC/*],VDDNV!UQ$G.
M[#VC"<N0-&B<^F93,T)CMH5KB8TZ#2Z1;+QK8_(D!OY</78-&<Y%$W&!DMRE
M)_1VC-N:MN+PNMD;N+L!MUZ5O'@YYC!*UBD40MA4'2HM)D&3>.]:_).2](1O
M Z9SE K#F;/O*G^E7)\DQS878WN[_):J%X$"<A&+S3-[MU8DP$=DJ/-1E_H#
MO\<@I8?]N=" #\C#=*7WI"QBN5,5*N-)>^0GN7G ,H*$3"PPP@<M-'7&%;\%
MP[U%:S[/-)#Y3F9193!:;$9![5]XQ34<I6%M'S(S+XX] $0G#F,5ZJR/BN6#
MT.YOYK6M.V0^6&JMIT1FV=B#%FKM6V^'"0(> 'R C!PXGC7^OMMECKL;1-7?
MP)9#>X_C[:92W2K!5RN#7L#5!27I P #3@GOU&VIG3SN;HG^&@'JR7(F;R<5
MA8?Z"=.BK M$\:OEFZMQ"1$TL96X.(M6\3EEI2\*=.>$"@VZ$E&S467820J<
MJ-N?X6N7=<(A^ZO<720D(%I%MG8JRMMAO')FWP/D[7WAY]D>[TY:0R\^EI_T
M1@1.E==84:7V9WF_:^R-X5Y9C^39%FRQ+OJ-]4ZK=3(@]7-U70P6O.>P6(WG
M,%G-]$1QYFA]K?3[96'WE[.O/WU6E08_VQ]((N^![>Y9'@#1DSH/@%^!O??A
M9H">_PK-5-0 /G"S*C?V!!7J]%JS#\R<DC(ER3JE&83FJ)W+O%G7G2GA+!+[
M9L6R@2MF:%E4=]Z?CKWT?I3<0QI6M._&I-:WSQ>22J\N:O2>Y0@ L/-T7=FJ
M]9###ENGF -V3 QGUE7'F!@TN=QOC/B_B[*@TVN# JZ6Z$ZP:YVSY_<2(9[=
M.>UXO=;OF:PZLRQWVL(-J+Z;0R_Z#RT$:1'<T#+*R$G5J9(L2TE")X^C#&36
M [L#WOOC:H KM$N.:)\#\6GJB/F"Y =JFM/E91A!X$=I$DL2X96OX6DE)@C#
MVL@C;RR7% 5%2WNI4'>?+,  H9WW6^234KTU\C3!%!A)U\N)GH%A;Z:09WNE
MW7'WKP,=TXB\'Z4<Q401YOPE2\Q8=F>(X//M)A; M33)]/).<6*H9;3J4[1U
MC]/19XZHGF9N%;C:ZNCSO6.#-6N2WJ\3W#<,XD83[U^O2+Y%?\;]]7.J\ C8
M=3G8>\-HPGO_E.(.4^T1+<^VL.Q_^?;Z(\ =YPW'G0Q ;ZJ%P'2)<"I;[Y5+
M*99@]_)+11&K24F'.I2:;MK/Q#VRKB,<[?Q7D4V82R]:?[VLW2W8G8M[XLZ8
M/VG](X_4LG\[^J+O1DT2MCC;))->0.V;H?5=8+!?,Y4F80X+?^4 FOU<O<TT
MC!3+=W4QK9,3*<+^!-K90NXW,]]]SZK#H5X?+GDIP31G:X4CQ^I_3SY+.J,7
MZ47*[><@0"'OJ4JR-:4IT_+!ZUA_)8O1> LSF]R?^%@185+=4 LO*A88J)D=
MLOOP#S8$Q1T3%P[<:;+,WL-#L,+-<P9)GL\'Q?",]PJ]9VF_9A]#Q:Y^Q'%"
M 8+ "?%!P7)7E@*>(UQO9W+/D.V3TL2UUB"0T"L/"S[5>.SKU F\HP5JR4B=
MJ,]"-YVQVFG=[GV&L#/3A)(D > SA]\" >;^CP;W99DM3.Z;@V23J_N*=#ZP
M1\>J6S]6)>*R/BY<+.UHG:H4G:>7>@QMY&8[J+@$H?8J&,%;T%++T??+=?!9
M!%#1MEK0(/H>BGRRU="X'+2$/V']ZN,TORM62XLP#G"V4JMK.Y/SY_J>;>1:
MD0N.1&Q'&JE#\SMM$=(:J"5N?T<EP1<2Y!U)1<',^C3@K.X\_%:KIB%2U %Z
MFI)M=YL<3P6E]!.L0O)>P_'9.,&Z3#(4V*E/W1NVHL%(^F@=@^$?6_>$#W9>
M*MBLMQ[WZB5TB=#O3,@T[..WMZ,Z*]^72\T'_A+:_'/BT57G7_)?)LA[#?]<
MGT8"2T1$D5,^&H+X/X:@JZ25V+L/MH9SBZ[MO=-3+ 780Q"NW\FUE7@Y[$L_
MCV\!1WYMBDAQ"C]Y4G&Q8)\,E7P /!_4"SFJ&D-PF]+M,KUD(O)DWVKJ" 5,
M0$%W2ET-V9"$,E>:Z7F?YRVH@!T *=(!8\[8/:T91#?XY3?OW%VWI9_H0R_,
MG.ZM8^]7^WK7TRS4<,$ AR4FV$C)VIDEX=R\YF]-EGES$AY$W9NKYZFM&_HU
M3"V,9HS9FKL-/=\RS<MG<P=-'1GUV"6@OQ:CH]NNKDI10P'+,+EP1^M72R*"
MF6.]A!6N3C,UX]<V;4TV8?/IB.#TTH3EM?O"QVWFFF\#2X?-&C\W3%GR]\<Y
M#7XU/AVUL]=U!@.L7(JZYUK#'46\BV2+^QK?A(+F2:7OIG4[+XKYZ-)QA"O@
ME06E2>8&Q3MS;YMJPFJ6=&2A0S%LOZU&J2+7:6?J1PE=&E5AD;FU<\7YGTPW
M.U&D:^C4;O.;@_?5E>51KT*;M+S7;HM((CZ0F*0.##.MO]P;P*"GQD_@1_1.
M[DJNXA NPCET98PZ9B;6]GAF7^A0L>>N^G6:TX^P\UV! L$ :4=[T.8"5 U;
MUS3;E-I^^D=R[#5D^<0YHEH(96EQP71<<Z36ANBMWR'QNB,MOT_;=O[^ I3[
M<6VY6UA;FT]T$@-UEZ8Y;]\G-'P;UQI:F*^C+B>Z'K4XWZKDM-2]$IEA=M01
M5")<+/:3F%\>N_%C?W:$I9#I\]Z]+)2O>SO*TN.+0-"/N< J765;HNQ3<4QD
M R_[,_+[^/X]2/Q(>9'.GEHX<.O("/*!S\H@-LK*+(< :<SE?0]?FN]%9:&I
M.?+ ..<[LHX$<25_/R2T?+0RL[ /,/!5,+\*18A#7\E:7:3X_\7>>X=%E6Q[
MPYL@0104022CH"!!<LXH.6>A!51$0@M(SC1!<@8!)4N03$O..4F6V.2<<Q.;
MU/WUG'O.S)SSS=Q[S[USWW/?[YL_ZGE@]ZJJ5;767NNWJE;5=@@ NTAPT'WE
M3JX2V$IU;4OWXG/77 2CP>?6X19%9)!IK+9[E5:!61Z (<G@W0G5 ,LV&XJ-
M7!(\O# ?BR-[<,[[*V7MZK=[44B"L3&W7WML?4Y:QX@"?$Y1P%)L6-ZE0MWH
M<3VC5M4/'FP/SHDE?TI=N4SC4'+ O>*ZCR#-61%S,# .EPTJ9R<##V]1% 3#
MB.>O24C)9*3G,,P307,W+5# ASJG/(20,()UL:RFM#&DNZJL3L8YR;X?"RN)
M6.A(7&$5K3&2^Z?M.T:MGE014F6#]H\+-&1C+/OJHN^RME=?K1)R 4MII!;6
M8?H%/^1O[W?Z:0G%/GQW[W;4U&GLZD<U#,V)&=[8X_I)9N'F!]_SEI@5DN:7
M*DFOD6"4+S:2&"$ZV_@IQM(C'[9U!VM<NT_"['</.V9*U#5&#0%I$TKU.PYT
M,'BTW.QP5T+@NXFHMO>\KYZ]&FY&8X>HRFV12=V .M$L"_[KSRI/'$%OUW*Q
M8T(O5JN)B)SC+EI3'E7"=L980L8-ICURN/-+'VN L.^<!FV-%:^G$2149/&5
M%LQ9Q.-3*+L(3\L58Y)P%[\&&)+>G(\*_</V9$WC=00*T-HO#^M/B#O1#X^U
M=U)^E?-TM0T4\>E&* WNLL"\[F-IP"&%&>&=B_C:,:7$-Z9O%6,Q]>7;MY">
M0/[3P '&F+-4_>7U="_^8R(RHTW#6T/NO#Q\/29?12((TK]%A42K+()P]VB\
MU,E"H(OH(/#.<\NP#[#7\$SF63-W#"\G8UJF'<08>L[J,Q 5*.#9_FYY.NCI
MNY/)FO1ID>#VD?L,EO>]J%75P'7[O-#0LD9,ON(%TXJQ@B)3,VB9/-OE'EN
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M BS3B%)SH&F0A<_Q2/]A=#"^AYR2O>1&B__')&3?  5,F6&M;;*LTR+>FJ"
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M?KVFBN%]TQ+=,L4>. (^6YZOSQ>1;L;5;IV[Q<^&[:3Q=<$J.&NFY8@5F*<
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MKEDEF]"DW(5TV[LLZJ<T6"_WE0&;&L/27'W)Q9O/$+A/D9.#5J^(6XTI6%-
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M%\)OD0C/P&)K84>SE0S),/)2DN7I*PL3-P=K'6S2[\U-)R=I>'5N5\'NKQ;
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M=<_:TFYD+_ \CRB9"VQ(&_#@;.777/5 (5+$?JXYY<L#<CLX58Q5KK*AR+#
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M,1B2JE\'N8Q>L_ J=7?=['KCS3*^5WQ-M''"/S6N-\NJ41RM3";WK/?JQ8$
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M6"9?KWL%+2Y64$KU60 8C_FMMWQ+ZK<.B\4R_)27"9BVHI_EXX9/<\39O]T
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M[O]9C88??[,\\_ZN!!R@],_TN_Z3 ,606!["K];[)4B+#)6Z^W:K14AX4]T
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M*!ZY^/]- %!+ 0(4 Q0    ( #J(?%7X#P6ZG@P  $B    1
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M @ %_!0 #0              @ &DH   930R-3%?,3!K+FAT;5!+ 0(4 Q0
M   ( #J(?%4O$+#)Z0(  . )   0              "  <\& P!E-#(U,5]E
M>#(S+3$N:'1M4$L! A0#%     @ .HA\5>ZO(W;@ @  _@L  !
M     ( !Y@D# &4T,C4Q7V5X,C,M,BYH=&U02P$"% ,4    "  ZB'Q5U0Q:
M""\(  #3/@  $               @ 'T# , 930R-3%?97@S,2TQ+FAT;5!+
M 0(4 Q0    ( #J(?%4&^<61G0@  #A,   0              "  5$5 P!E
M-#(U,5]E>#,Q+3(N:'1M4$L! A0#%     @ .HA\59NT*N)'!@  @AD  !
M             ( !'!X# &4T,C4Q7V5X,S(M,2YH=&U02P$"% ,4    "  Z
MB'Q5(JF6;F08 @!U@0, #0              @ &1) , :6UA9V5?,# Q+FIP
M9U!+ 0(4 Q0    ( #J(?%5"ZL9[00H! '!R 0 -              "  2 ]
E!0!I;6%G95\P,#(N:G!G4$L%!@     -  T ,@,  (Q'!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
